
    <!DOCTYPE html>
    <html lang="zh-CN">
    <head>
        <meta charset="UTF-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <title>PubMed DeepReader - 2026-01-25 10:25</title>
        <script src="https://cdn.tailwindcss.com"></script>
        <script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
        <script src="https://cdn.jsdelivr.net/npm/marked/marked.min.js"></script>
        <style>
            body { height: 100vh; overflow: hidden; }
            .scrollbar-hide::-webkit-scrollbar { display: none; }
            ::-webkit-scrollbar { width: 6px; }
            ::-webkit-scrollbar-thumb { background: #cbd5e1; border-radius: 3px; }
            .prose strong { 
                color: #1e3a8a; font-weight: 800; display: block; 
                margin-top: 1.2em; margin-bottom: 0.4em;
                text-transform: uppercase; font-size: 0.85rem; letter-spacing: 0.05em;
            }
            .prose p { margin-bottom: 0.8em; text-align: justify; line-height: 1.7; }
            .prose p:first-of-type strong { margin-top: 0; }
        </style>
    </head>
    <body class="bg-slate-100 flex flex-col" x-data="app()">
        <header class="bg-white border-b border-gray-200 h-14 flex items-center justify-between px-6 shadow-sm z-10 shrink-0">
            <div class="flex items-center gap-4">
                <div class="font-bold text-xl text-blue-900 tracking-tight">PubMed DeepReader</div>
                <div class="text-xs text-gray-400 mt-1">Updated: 2026-01-25 10:25</div>
            </div>
            <select x-model="currentFeed" @change="selectFeed()" class="bg-gray-50 border border-gray-300 text-gray-900 text-sm rounded-lg p-2 max-w-xs">
                <template x-for="feedName in Object.keys(feeds)" :key="feedName">
                    <option :value="feedName" x-text="feedName"></option>
                </template>
            </select>
        </header>

        <div class="flex flex-1 overflow-hidden">
            <aside class="w-1/3 max-w-md bg-white border-r border-gray-200 flex flex-col overflow-y-auto">
                <template x-for="paper in currentPapers" :key="paper.id">
                    <div @click="currentPaper = paper" 
                         :class="currentPaper.id === paper.id ? 'bg-blue-50 border-l-4 border-blue-600' : 'border-l-4 border-transparent hover:bg-gray-50'"
                         class="p-4 border-b border-gray-100 cursor-pointer transition group">
                        <h3 class="text-sm font-bold text-gray-800 line-clamp-2 leading-snug group-hover:text-blue-700" x-text="paper.title_zh"></h3>
                        <p class="text-xs text-gray-400 mt-1 truncate" x-text="paper.title_en"></p>
                    </div>
                </template>
            </aside>

            <main class="flex-1 bg-slate-50 overflow-y-auto p-6">
                <template x-if="currentPaper">
                    <div class="max-w-6xl mx-auto bg-white rounded-xl shadow-sm p-8 min-h-[90vh]">
                        <div class="border-b border-gray-100 pb-6 mb-6">
                            <h1 class="text-2xl font-bold text-gray-900 mb-2 leading-tight" x-text="currentPaper.title_zh"></h1>
                            <h2 class="text-lg text-gray-500 font-medium mb-4" x-text="currentPaper.title_en"></h2>
                            <div class="flex flex-wrap gap-4 text-xs text-gray-500 bg-gray-50 p-3 rounded-lg border border-gray-100">
                                <span class="flex items-center">ğŸ“… <span class="ml-1" x-text="currentPaper.date"></span></span>
                                <span class="flex items-center">âœï¸ <span class="ml-1" x-text="currentPaper.authors"></span></span>
                                <a :href="currentPaper.link" target="_blank" class="text-blue-600 hover:underline font-bold ml-auto flex items-center">
                                    åŸæ–‡é“¾æ¥ <svg class="w-3 h-3 ml-1" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M10 6H6a2 2 0 00-2 2v10a2 2 0 002 2h10a2 2 0 002-2v-4M14 4h6m0 0v6m0-6L10 14"></path></svg>
                                </a>
                            </div>
                        </div>

                        <template x-if="currentPaper.keywords_zh">
                            <div class="mb-8 p-4 bg-blue-50/50 rounded-lg border border-blue-100">
                                <span class="text-xs font-bold text-blue-800 uppercase tracking-wide block mb-1">Keywords</span>
                                <div class="text-sm text-gray-700 font-medium">
                                    <span x-text="currentPaper.keywords_zh"></span>
                                    <div class="text-xs text-gray-400 mt-1 font-normal" x-text="currentPaper.keywords_en"></div>
                                </div>
                            </div>
                        </template>

                        <div class="grid grid-cols-1 lg:grid-cols-2 gap-10">
                            <div>
                                <div class="flex items-center mb-4">
                                    <span class="w-1 h-6 bg-blue-600 mr-3 rounded-full"></span>
                                    <h3 class="font-bold text-xl text-gray-900">ä¸­æ–‡æ‘˜è¦</h3>
                                </div>
                                <div class="prose prose-sm prose-slate max-w-none text-gray-800" 
                                     x-html="marked.parse(currentPaper.abstract_zh)"></div>
                            </div>
                            <div>
                                <div class="flex items-center mb-4">
                                    <span class="w-1 h-6 bg-gray-300 mr-3 rounded-full"></span>
                                    <h3 class="font-bold text-gray-400 text-xl">Original Abstract</h3>
                                </div>
                                <div class="prose prose-sm prose-slate max-w-none text-gray-500" 
                                     x-html="marked.parse(currentPaper.abstract_en)"></div>
                            </div>
                        </div>
                    </div>
                </template>
                <template x-if="!currentPaper">
                    <div class="flex flex-col items-center justify-center h-full text-gray-400">
                        <p>è¯·é€‰æ‹©å·¦ä¾§æ–‡ç« å¼€å§‹é˜…è¯»</p>
                    </div>
                </template>
            </main>
        </div>
        <script>
            function app() {
                return {
                    feeds: {"è‚›å‘¨è„“è‚¿": [{"id": "41359092", "title_en": "Systematic review: The management of unhealed wounds and persistent perineal sinuses following proctectomy in inflammatory bowel disease", "title_zh": "ç³»ç»Ÿè¯„ä»·ï¼šç‚ç—‡æ€§è‚ ç—…ç›´è‚ åˆ‡é™¤æœ¯åæœªæ„ˆåˆä¼¤å£å’ŒæŒç»­æ€§ä¼šé˜´çª¦çš„å¤„ç†", "authors": "A Hart", "abstract_en": "**Introduction:** Unhealed wounds and persistent perineal sinuses (PPS) may occur in as many as one third of patients after proctectomy for Crohn's disease. The management of these conditions remains a significant challenge, particularly in the context of inflammatory bowel disease (IBD), with existing therapies plagued by high failure rates. This systematic review of the literature assessed the efficacy of medical and surgical therapy for PPS closure in IBD. Secondary aims included review of classification systems used for PPS.\n\n**Methods:** A literature search was conducted using Medline, Embase and Cochrane databases on 17 December 2024. The review was registered on PROSPERO (CRD42024622582). Inclusion criteria were adult patients with IBD and PPS or unhealed wounds following proctectomy. We excluded abstract-only publications, case reports, cancer and paediatric cohorts. Two reviewers independently screened abstracts and full texts and extracted data. The primary outcome was clinical healing rate. Secondary outcomes included classification systems used to describe PPS. Risk of bias was assessed.\n\n**Results:** Of 496 records identified, following removal of duplicates, 489 abstracts were screened, and 60 full text articles assessed for eligibility. Of 25 articles included in the final analysis, 23 were case series or retrospective cohort studies, and all were at high risk of bias. No randomised controlled trials were identified. Five articles (including two of the case series) described classification systems for PPS. Interventions included hyperbaric oxygen therapy, Karydakis flap, cleft closure, omentoplasty, skin grafting, gracilis and rectus abdominis flap, platelet-derived growth factor, curettage, lay open and excision of sinuses. Reported healing rates ranged from 30% to 100%. Heterogeneity in the reporting of outcomes, as well as the interventions performed precluded meta-analysis.\n\n**Conclusion:** The published evidence for treatment of PPS in IBD consists of low-quality evidence case series with high risk of bias. There is a need for standardised outcome reporting and high-quality, prospective studies to establish effective treatment algorithms.", "abstract_zh": "**ä»‹ç»ï¼š** å…‹ç½—æ©ç—…ç›´è‚ åˆ‡é™¤æœ¯åï¼Œå¤šè¾¾ä¸‰åˆ†ä¹‹ä¸€çš„æ‚£è€…å¯èƒ½ä¼šå‡ºç°æœªæ„ˆåˆçš„ä¼¤å£å’ŒæŒç»­æ€§ä¼šé˜´çª¦ (PPS)ã€‚è¿™äº›ç–¾ç—…çš„æ²»ç–—ä»ç„¶æ˜¯ä¸€ä¸ªé‡å¤§æŒ‘æˆ˜ï¼Œç‰¹åˆ«æ˜¯åœ¨ç‚ç—‡æ€§è‚ ç—…ï¼ˆIBDï¼‰çš„èƒŒæ™¯ä¸‹ï¼Œç°æœ‰çš„æ²»ç–—æ–¹æ³•å—åˆ°é«˜å¤±è´¥ç‡çš„å›°æ‰°ã€‚è¿™é¡¹å¯¹æ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾è¯„ä¼°äº† IBD ä¸­ PPS é—­åˆçš„è¯ç‰©å’Œæ‰‹æœ¯æ²»ç–—çš„ç–—æ•ˆã€‚æ¬¡è¦ç›®æ ‡åŒ…æ‹¬å®¡æŸ¥ç”¨äº PPS çš„åˆ†ç±»ç³»ç»Ÿã€‚\n\n**æ–¹æ³•ï¼š** äº2024å¹´12æœˆ17æ—¥ä½¿ç”¨Medlineã€Embaseå’ŒCochraneæ•°æ®åº“è¿›è¡Œäº†æ–‡çŒ®æ£€ç´¢ã€‚è¯¥ç»¼è¿°å·²åœ¨PROSPEROä¸Šæ³¨å†Œï¼ˆCRD42024622582ï¼‰ã€‚çº³å…¥æ ‡å‡†ä¸ºæ‚£æœ‰ IBD å’Œ PPS çš„æˆå¹´æ‚£è€…æˆ–ç›´è‚ åˆ‡é™¤æœ¯åä¼¤å£æœªæ„ˆåˆçš„æ‚£è€…ã€‚æˆ‘ä»¬æ’é™¤äº†ä»…æ‘˜è¦çš„å‡ºç‰ˆç‰©ã€ç—…ä¾‹æŠ¥å‘Šã€ç™Œç—‡å’Œå„¿ç§‘é˜Ÿåˆ—ã€‚ä¸¤åå®¡ç¨¿äººç‹¬ç«‹ç­›é€‰æ‘˜è¦å’Œå…¨æ–‡å¹¶æå–æ•°æ®ã€‚ä¸»è¦ç»“å±€æ˜¯ä¸´åºŠæ²»æ„ˆç‡ã€‚æ¬¡è¦ç»“æœåŒ…æ‹¬ç”¨äºæè¿° PPS çš„åˆ†ç±»ç³»ç»Ÿã€‚è¯„ä¼°äº†åå€šé£é™©ã€‚\n\n**ç»“æœï¼š** åœ¨åˆ é™¤é‡å¤é¡¹åï¼Œåœ¨ç¡®å®šçš„ 496 æ¡è®°å½•ä¸­ï¼Œç­›é€‰äº† 489 æ¡æ‘˜è¦ï¼Œå¹¶è¯„ä¼°äº† 60 ç¯‡å…¨æ–‡æ–‡ç« çš„èµ„æ ¼ã€‚æœ€ç»ˆåˆ†æçº³å…¥çš„ 25 ç¯‡æ–‡ç« ä¸­ï¼Œ23 ç¯‡ä¸ºç—…ä¾‹ç³»åˆ—æˆ–å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œä¸”å‡å­˜åœ¨é«˜åå€šé£é™©ã€‚æ²¡æœ‰å‘ç°éšæœºå¯¹ç…§è¯•éªŒã€‚äº”ç¯‡æ–‡ç« ï¼ˆåŒ…æ‹¬æ¡ˆä¾‹ç³»åˆ—ä¸­çš„ä¸¤ç¯‡ï¼‰æè¿°äº† PPS çš„åˆ†ç±»ç³»ç»Ÿã€‚å¹²é¢„æªæ–½åŒ…æ‹¬é«˜å‹æ°§æ²»ç–—ã€Karydakis çš®ç“£ã€è£‚éš™é—­åˆã€ç½‘è†œæˆå½¢æœ¯ã€æ¤çš®ã€è‚¡è–„è‚Œå’Œè…¹ç›´è‚Œçš®ç“£ã€è¡€å°æ¿è¡ç”Ÿç”Ÿé•¿å› å­ã€åˆ®å®«æœ¯ã€åˆ‡å¼€å’Œåˆ‡é™¤é¼»çª¦ã€‚æ®æŠ¥é“ï¼Œæ²»æ„ˆç‡ä» 30% åˆ° 100% ä¸ç­‰ã€‚ç»“æœæŠ¥å‘Šä»¥åŠæ‰€è¿›è¡Œçš„å¹²é¢„æªæ–½çš„å¼‚è´¨æ€§æ’é™¤äº†èŸèƒåˆ†æã€‚\n\n**ç»“è®ºï¼š** å·²å‘è¡¨çš„ IBD PPS æ²»ç–—è¯æ®ç”±å…·æœ‰é«˜åå€šé£é™©çš„ä½è´¨é‡è¯æ®ç—…ä¾‹ç³»åˆ—ç»„æˆã€‚éœ€è¦æ ‡å‡†åŒ–çš„ç»“æœæŠ¥å‘Šå’Œé«˜è´¨é‡çš„å‰ç»æ€§ç ”ç©¶æ¥å»ºç«‹æœ‰æ•ˆçš„æ²»ç–—ç®—æ³•ã€‚", "keywords_zh": "è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ã€è‚›å‘¨è„“è‚¿", "keywords_en": "Fistulizing perianal Crohnâ€™s disease, Perianal abscess", "link": "https://pubmed.ncbi.nlm.nih.gov/41359092/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Mon, 08 Dec 2025"}, {"id": "41219674", "title_en": "Fistula Outcomes After Seton Removal in Patients with Perianal Fistulizing Crohn's Disease: A Systematic Review and Meta-Analysis", "title_zh": "è‚›å‘¨ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…æ‚£è€…æŒ‚çº¿æ‹”é™¤åçš„ç˜˜ç®¡ç»“æœï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Jeffrey D McCurdy", "abstract_en": "**Background:** While setons are commonly used in the multidisciplinary care of patients with perianal fistulizing Crohn's disease (PFCD), fistula outcomes after their removal are poorly understood. We performed a systematic review with meta-analysis to evaluate fistula outcomes after seton removal in patients with PFCD.\n\n**Methods:** MEDLINE, EMBASE, Web of Science, and Cochrane databases were systematically searched until December 2023. We included studies reporting fistula outcomes after seton removal in PFCD. We used a hierarchy to stratify patients into one of three treatment categories: medical therapy alone, surgical closure, or cell/plasma-based therapy. Fistula outcomes were reported as weighted proportions with 95% confidence intervals (CI).\n\n**Results:** Eighty-two studies (nâ€‰=â€‰2441 patients) were analyzed. Mean/median seton duration varied widely (2 to 70Â weeks). Pooled estimates (95% CI) of fistula outcomes after seton removal for patients treated in the medical therapy alone, surgical closure, or cell/plasma-based therapy categories were, respectively, 64% (54-75), 65% (52-78), and 71% (65-77) for fistula remission; 30% (22-38), 29% (16-42), and 20% (15-25) for recurrence; 15% (8-22), 11% (4-20), and 14% (8-21) for abscess formation; and 26% (18-35), 23% (17-29), and 13% (2-26) for surgical re-intervention. Fistula outcome estimates remained stable in multiple sensitivity analyses. Limited studies directly compared fistula outcomes based on seton duration, yielding inconsistent results.\n\n**Conclusions:** This systematic review provides comprehensive estimates of fistula outcomes after seton removal and demonstrates substantial variability in seton duration. Future research is required to determine the optimal duration of setons.", "abstract_zh": "**èƒŒæ™¯ï¼š** è™½ç„¶æŒ‚çº¿å¸¸ç”¨äºè‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… (PFCD) æ‚£è€…çš„å¤šå­¦ç§‘æŠ¤ç†ï¼Œä½†äººä»¬å¯¹æŒ‚çº¿ç§»é™¤åçš„ç˜˜ç®¡ç»“å±€çŸ¥ä¹‹ç”šå°‘ã€‚æˆ‘ä»¬é€šè¿‡èŸèƒåˆ†æè¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œä»¥è¯„ä¼° PFCD æ‚£è€…æŒ‚çº¿æ‹”é™¤åçš„ç˜˜ç®¡ç»“å±€ã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2023 å¹´ 12 æœˆï¼Œæˆ‘ä»¬å¯¹ MEDLINEã€EMBASEã€Web of Science å’Œ Cochrane æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚æˆ‘ä»¬çº³å…¥äº†æŠ¥å‘Š PFCD æŒ‚çº¿æ‹”é™¤åç˜˜ç®¡ç»“æœçš„ç ”ç©¶ã€‚æˆ‘ä»¬ä½¿ç”¨å±‚æ¬¡ç»“æ„å°†æ‚£è€…åˆ†ä¸ºä¸‰ç§æ²»ç–—ç±»åˆ«ä¹‹ä¸€ï¼šå•çº¯è¯ç‰©æ²»ç–—ã€æ‰‹æœ¯é—­åˆæˆ–åŸºäºç»†èƒ/è¡€æµ†çš„æ²»ç–—ã€‚ç˜˜ç®¡ç»“æœæŠ¥å‘Šä¸ºå…·æœ‰ 95% ç½®ä¿¡åŒºé—´ (CI) çš„åŠ æƒæ¯”ä¾‹ã€‚\n\n**ç»“æœï¼š** åˆ†æäº† 82 é¡¹ç ”ç©¶ï¼ˆn=2441 åæ‚£è€…ï¼‰ã€‚å¹³å‡/ä¸­ä½æŒ‚çº¿æŒç»­æ—¶é—´å·®å¼‚å¾ˆå¤§ï¼ˆ2 è‡³ 70 å‘¨ï¼‰ã€‚å¯¹äºä»…æ¥å—è¯ç‰©æ²»ç–—ã€æ‰‹æœ¯é—­åˆæˆ–åŸºäºç»†èƒ/è¡€æµ†çš„æ²»ç–—ç±»åˆ«çš„æ‚£è€…ï¼ŒæŒ‚çº¿æ‹”é™¤åç˜˜ç®¡ç»“å±€çš„æ±‡æ€»ä¼°è®¡ï¼ˆ95% CIï¼‰ä¸ºç˜˜ç®¡ç¼“è§£åˆ†åˆ«ä¸º 64% (54-75)ã€65% (52-78) å’Œ 71% (65-77)ï¼› 30% (22-38)ã€29% (16-42) å’Œ 20% (15-25) å¤å‘ï¼› 15% (8-22)ã€11% (4-20) å’Œ 14% (8-21) è„“è‚¿å½¢æˆï¼› 26% (18-35)ã€23% (17-29) å’Œ 13% (2-26) éœ€è¦å†æ¬¡æ‰‹æœ¯å¹²é¢„ã€‚åœ¨å¤šé¡¹æ•æ„Ÿæ€§åˆ†æä¸­ï¼Œç˜˜ç®¡ç»“æœä¼°è®¡å€¼ä¿æŒç¨³å®šã€‚æœ‰é™çš„ç ”ç©¶æ ¹æ®æŒ‚çº¿æŒç»­æ—¶é—´ç›´æ¥æ¯”è¾ƒç˜˜ç®¡ç»“å±€ï¼Œäº§ç”Ÿä¸ä¸€è‡´çš„ç»“æœã€‚\n\n**ç»“è®ºï¼š** è¯¥ç³»ç»Ÿè¯„ä»·æä¾›äº†æŒ‚çº¿å»é™¤åç˜˜ç®¡ç»“æœçš„å…¨é¢ä¼°è®¡ï¼Œå¹¶è¯æ˜äº†æŒ‚çº¿æŒç»­æ—¶é—´çš„æ˜¾ç€å·®å¼‚ã€‚éœ€è¦è¿›ä¸€æ­¥çš„ç ”ç©¶æ¥ç¡®å®šæŒ‚çº¿çš„æœ€ä½³æŒç»­æ—¶é—´ã€‚", "keywords_zh": "è‚›ç˜˜ã€ç”Ÿç‰©ç–—æ³•ã€å…‹ç½—æ©ç—…ã€å¼•æµã€é—´å……è´¨å¹²ç»†èƒ", "keywords_en": "Anal fistula, Biologic therapy, Crohnâ€™s disease, Drainage, Mesenchymal stem cells", "link": "https://pubmed.ncbi.nlm.nih.gov/41219674/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Tue, 11 Nov 2025"}, {"id": "41159400", "title_en": "Management of Perianal Sepsis in Neutropenic Patients With Haematological Malignancies-A Systematic Review", "title_zh": "è¡€æ¶²ç³»ç»Ÿæ¶æ€§è‚¿ç˜¤ä¸­æ€§ç²’ç»†èƒå‡å°‘ç—‡æ‚£è€…è‚›å‘¨è„“æ¯’ç—‡çš„æ²»ç–—â€”â€”ç³»ç»Ÿè¯„ä»·", "authors": "Zi Qin Ng", "abstract_en": "**Introduction:** Despite neutropenia being considered a significant risk factor for acute perianal sepsis, there is a lack of consensus on treatment guidelines for perianal abscess in the immunocompromised patient, specifically in patients with neutropenia secondary to a haematological malignancy. The aim of the article is to review the available literature on. Whether surgical intervention produces better outcomes than a non-surgical approach for perianal sepsis in the immunocompromised patient with a haematological malignancy.\n\n**Methods:** Relevant papers were identified through electronic databases including PubMed, Medline and Scopus. Data were extracted independently by two authors on a Microsoft Excel spreadsheet up to July 2024.\n\n**Results:** A total of eight studies were included in the final analysis (124 cases). Perianal or rectal pain (nâ€‰=â€‰81, 65.3%) was the most reported complaint, followed by fever (nâ€‰=â€‰72, 58.1%), swelling and induration (nâ€‰=â€‰54, 43.5%) and erythema was reported in 26 (21.0%) cases. The most common organisms cultured from blood and anorectum were Escherichia coli and Pseudomonas aeruginosa. A total of 12 deaths (18.8%) were reported out of the 64 patients who underwent conservative management, while 10 (16.7%) deaths were reported out of 60 patients who underwent surgical management. Complete wound healing or good wound granulation was achieved for 35 (54.7%) patients in the conservative group and 35 (58.3%) patients in the surgical group.\n\n**Conclusion:** Our review suggests that conservative management is an acceptable treatment in carefully selected patients without an obvious perianal abscess on cross-sectional radiological imaging.", "abstract_zh": "**ä»‹ç»ï¼š** å°½ç®¡ä¸­æ€§ç²’ç»†èƒå‡å°‘ç—‡è¢«è®¤ä¸ºæ˜¯æ€¥æ€§è‚›å‘¨è„“æ¯’ç—‡çš„é‡è¦å±é™©å› ç´ ï¼Œä½†å¯¹äºå…ç–«åŠŸèƒ½ä½ä¸‹æ‚£è€…çš„è‚›å‘¨è„“è‚¿çš„æ²»ç–—æŒ‡å—ç¼ºä¹å…±è¯†ï¼Œç‰¹åˆ«æ˜¯ç»§å‘äºè¡€æ¶²æ¶æ€§è‚¿ç˜¤çš„ä¸­æ€§ç²’ç»†èƒå‡å°‘ç—‡æ‚£è€…ã€‚æœ¬æ–‡çš„ç›®çš„æ˜¯å›é¡¾ç°æœ‰çš„æ–‡çŒ®ã€‚å¯¹äºæ‚£æœ‰è¡€æ¶²ç³»ç»Ÿæ¶æ€§è‚¿ç˜¤çš„å…ç–«åŠŸèƒ½ä½ä¸‹æ‚£è€…çš„è‚›å‘¨è„“æ¯’ç—‡ï¼Œæ‰‹æœ¯å¹²é¢„æ˜¯å¦æ¯”éæ‰‹æœ¯æ–¹æ³•èƒ½äº§ç”Ÿæ›´å¥½çš„ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** ç›¸å…³è®ºæ–‡é€šè¿‡ PubMedã€Medline å’Œ Scopus ç­‰ç”µå­æ•°æ®åº“æ‰¾åˆ°ã€‚æˆªè‡³ 2024 å¹´ 7 æœˆï¼Œä¸¤ä½ä½œè€…åœ¨ Microsoft Excel ç”µå­è¡¨æ ¼ä¸Šç‹¬ç«‹æå–æ•°æ®ã€‚\n\n**ç»“æœï¼š** æœ€ç»ˆåˆ†æå…±çº³å…¥8é¡¹ç ”ç©¶ï¼ˆ124ä¾‹ï¼‰ã€‚è‚›å‘¨æˆ–ç›´è‚ ç–¼ç—› (nâ€‰=â€‰81, 65.3%) æ˜¯æŠ¥å‘Šæœ€å¤šçš„ä¸»è¯‰ï¼Œå…¶æ¬¡æ˜¯å‘çƒ­ (nâ€‰=â€‰72, 58.1%)ã€è‚¿èƒ€å’Œç¡¬ç»“ (nâ€‰=â€‰54, 43.5%)ï¼Œæœ‰ 26 ä¾‹ (21.0%) æŠ¥å‘Šæœ‰çº¢æ–‘ã€‚ä»è¡€æ¶²å’Œè‚›é—¨ç›´è‚ åŸ¹å…»çš„æœ€å¸¸è§çš„å¾®ç”Ÿç‰©æ˜¯å¤§è‚ æ†èŒå’Œé“œç»¿å‡å•èƒèŒã€‚åœ¨æ¥å—ä¿å®ˆæ²»ç–—çš„ 64 ä¾‹æ‚£è€…ä¸­ï¼Œå…±æœ‰ 12 ä¾‹æ­»äº¡ï¼ˆ18.8%ï¼‰ï¼Œè€Œåœ¨æ¥å—æ‰‹æœ¯æ²»ç–—çš„ 60 ä¾‹æ‚£è€…ä¸­ï¼Œå…±æœ‰ 10 ä¾‹ï¼ˆ16.7%ï¼‰æ­»äº¡ã€‚ä¿å®ˆç»„æœ‰35åï¼ˆ54.7%ï¼‰æ‚£è€…ä¼¤å£å®Œå…¨æ„ˆåˆæˆ–ä¼¤å£è‚‰èŠ½è‰¯å¥½ï¼Œæ‰‹æœ¯ç»„æœ‰35åï¼ˆ58.3%ï¼‰æ‚£è€…ã€‚\n\n**ç»“è®ºï¼š** æˆ‘ä»¬çš„ç»¼è¿°è¡¨æ˜ï¼Œå¯¹äºç²¾å¿ƒæŒ‘é€‰çš„æ¨ªæ–­é¢æ”¾å°„å½±åƒå­¦ä¸Šæ²¡æœ‰æ˜æ˜¾è‚›å‘¨è„“è‚¿çš„æ‚£è€…ï¼Œä¿å®ˆæ²»ç–—æ˜¯ä¸€ç§å¯æ¥å—çš„æ²»ç–—æ–¹æ³•ã€‚", "keywords_zh": "è„“è‚¿ä¸­æ€§ç²’ç»†èƒå‡å°‘ç—‡ã€è‚›é—¨ç›´è‚ ã€å…ç–«åŠŸèƒ½ä½ä¸‹ã€è‚›å‘¨", "keywords_en": "abscess neutropenia, anorectal, immunocompromised, perianal", "link": "https://pubmed.ncbi.nlm.nih.gov/41159400/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Wed, 29 Oct 2025"}, {"id": "40983150", "title_en": "Management of Perianal Abscesses in Infants: A Systematic Review From the APSA Outcomes and Evidence-Based Practice Committee", "title_zh": "å©´å„¿è‚›å‘¨è„“è‚¿çš„æ²»ç–—ï¼šAPSA ç»“æœå’Œå¾ªè¯å®è·µå§”å‘˜ä¼šçš„ç³»ç»Ÿå®¡æŸ¥", "authors": "American Pediatric Surgical Association Outcomes and Evidence-Based Practice Committee", "abstract_en": "**Background:** Management of infant perianal disease, including perianal abscess and fistula-in- ano (FIA), remains controversial. There is lack of consensus regarding the risks and benefits of operative and non-operative approaches.\n\n**Methods:** The American Pediatric Surgical Association Outcomes and Evidence Based Practice Committee created a priori consensus-based questions regarding the various approaches to management of perianal abscess and FIA in infants. A comprehensive search strategy was created, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to identify and review relevant articles and answer the established questions.\n\n**Results:** Over 2460 titles and abstracts were screened to identify 31 manuscripts describing the expected course of perianal disease when managed with nonoperative management (NOM) strategies (such as hygiene, sitz baths, and systemic antibiotics), operative intervention for abscess only (incision and drainage (I&D)) or direct surgical management of the FIA (e.g. upfront fistulotomy). Initial failure of NOM is approximately 37.5 %. Recurrence rate after initial success with NOM or I&D is approximately 21 % and 24 %, respectively. The rate of FIA development is approximately 21 % after NOM and 20 % after I&D. Recurrence after operative management of FIA, regardless of approach, is 7 %. Time to complete resolution varies widely and does not appear to differ based on treatment strategy.\n\n**Conclusions:** Both operative and non-operative approaches can be safely used in the management of perianal abscess and FIA but recurrence is common regardless of approach. Risks and benefits of each approach should be considered on a case-by-case basis.\n\n**Type Of Study:** Systematic Review of level 3-4 studies.\n\n**Level Of Evidence:** Level 4.", "abstract_zh": "**èƒŒæ™¯ï¼š** å©´å„¿è‚›å‘¨ç–¾ç—…çš„æ²»ç–—ï¼ŒåŒ…æ‹¬è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜ï¼ˆFIAï¼‰ï¼Œä»ç„¶å­˜åœ¨äº‰è®®ã€‚å…³äºæ‰‹æœ¯å’Œéæ‰‹æœ¯æ–¹æ³•çš„é£é™©å’Œç›Šå¤„ç¼ºä¹å…±è¯†ã€‚\n\n**æ–¹æ³•ï¼š** ç¾å›½å„¿ç§‘å¤–ç§‘åä¼šæˆæœå’Œå¾ªè¯å®è·µå§”å‘˜ä¼šé’ˆå¯¹å©´å„¿è‚›å‘¨è„“è‚¿å’Œ FIA çš„å„ç§æ²»ç–—æ–¹æ³•æå‡ºäº†åŸºäºå…ˆéªŒå…±è¯†çš„é—®é¢˜ã€‚åˆ›å»ºäº†å…¨é¢çš„æœç´¢ç­–ç•¥ï¼Œå¹¶ä½¿ç”¨ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—æ¥è¯†åˆ«å’Œå®¡æŸ¥ç›¸å…³æ–‡ç« å¹¶å›ç­”æ—¢å®šé—®é¢˜ã€‚\n\n**ç»“æœï¼š** ç­›é€‰äº† 2460 å¤šä¸ªæ ‡é¢˜å’Œæ‘˜è¦ï¼Œç¡®å®šäº† 31 ç¯‡æ‰‹ç¨¿ï¼Œæè¿°äº†é‡‡ç”¨éæ‰‹æœ¯æ²»ç–— (NOM) ç­–ç•¥ï¼ˆä¾‹å¦‚å«ç”Ÿã€åæµ´å’Œå…¨èº«æŠ—ç”Ÿç´ ï¼‰ã€ä»…é’ˆå¯¹è„“è‚¿è¿›è¡Œæ‰‹æœ¯å¹²é¢„ï¼ˆåˆ‡å¼€å¼•æµ (I&D)ï¼‰æˆ– FIA ç›´æ¥æ‰‹æœ¯æ²»ç–—ï¼ˆä¾‹å¦‚å‰æœŸç˜˜ç®¡åˆ‡å¼€æœ¯ï¼‰æ—¶è‚›å‘¨ç–¾ç—…çš„é¢„æœŸç—…ç¨‹ã€‚ NOM çš„åˆå§‹æ•…éšœçº¦ä¸º 37.5%ã€‚ NOM æˆ– I&D åˆæ¬¡æˆåŠŸåçš„å¤å‘ç‡åˆ†åˆ«çº¦ä¸º 21% å’Œ 24%ã€‚ NOM åçš„ FIA å¼€å‘ç‡çº¦ä¸º 21%ï¼ŒI&D åçš„ FIA å¼€å‘ç‡çº¦ä¸º 20%ã€‚æ— è®ºé‡‡å–ä½•ç§æ–¹æ³•ï¼ŒFIA æ‰‹æœ¯æ²»ç–—åçš„å¤å‘ç‡ä¸º 7%ã€‚å®Œæˆç¼“è§£çš„æ—¶é—´å·®å¼‚å¾ˆå¤§ï¼Œå¹¶ä¸”æ ¹æ®æ²»ç–—ç­–ç•¥ä¼¼ä¹æ²¡æœ‰å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** æ‰‹æœ¯å’Œéæ‰‹æœ¯æ–¹æ³•éƒ½å¯ä»¥å®‰å…¨åœ°ç”¨äºè‚›å‘¨è„“è‚¿å’Œ FIA çš„æ²»ç–—ï¼Œä½†æ— è®ºé‡‡ç”¨å“ªç§æ–¹æ³•ï¼Œå¤å‘éƒ½å¾ˆå¸¸è§ã€‚åº”æ ¹æ®å…·ä½“æƒ…å†µè€ƒè™‘æ¯ç§æ–¹æ³•çš„é£é™©å’Œæ”¶ç›Šã€‚\n\n**Type of studyï¼š** 3-4 çº§ç ”ç©¶çš„ç³»ç»Ÿå®¡æŸ¥ã€‚\n\n**Level of evidenceï¼š** 4 çº§ã€‚", "keywords_zh": "è‚›ç˜˜ã€ç˜˜ç®¡åˆ‡å¼€æœ¯ã€å©´å„¿ã€è‚›å‘¨è„“è‚¿ã€ç›´è‚ å‘¨å›´è„“è‚¿", "keywords_en": "Fistula-in-ano, Fistulotomy, Infants, Perianal abscess, Perirectal abscess", "link": "https://pubmed.ncbi.nlm.nih.gov/40983150/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Mon, 22 Sep 2025"}, {"id": "40740890", "title_en": "Epidemiology, treatment patterns, and associated risk factors in perianal fistulizing Crohn's disease: A systematic literature review", "title_zh": "è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…çš„æµè¡Œç—…å­¦ã€æ²»ç–—æ¨¡å¼å’Œç›¸å…³å±é™©å› ç´ ï¼šç³»ç»Ÿæ–‡çŒ®ç»¼è¿°", "authors": "Julian PanÃ©s", "abstract_en": "**Background:** Data regarding complex Crohn's perianal fistulas (CPF) epidemiology are limited, and optimal treatment strategies are elusive. An improved understanding of how CPF treatment options are used in the real-world setting and factors associated with CPF development, treatment failure, and reasons for undergoing multiple surgeries may help to inform optimal patient management strategies, reduce treatment burden, and improve outcomes in patients with CPF.\n\n**Aim:** To describe the epidemiology, treatments, outcomes, and associated risk/protective factors for complex CPF.\n\n**Methods:** Electronic databases (MEDLINE, EMBASE, EBM Reviews, EconLit) were searched. Two reviewers independently used populations, interventions, comparators, outcomes, study designs, and time criteria to identify relevant studies. Observational studies published in English from January 1, 2015 to February 17, 2022 with > 50 patients were included, even if complex CPF was not defined. Items of interest included complex CPF definitions, epidemiology, treatment patterns, morbidity, mortality, and risk factors associated with complex CPF development, treatment failure, and undergoing multiple surgeries. Data were reported using descriptive statistics.\n\n**Results:** Overall, 140 studies were included. Complex CPF definitions were heterogeneous and rarely reported (24 studies). Hence, data mostly related to CPF in general. CPF prevalence was variable (range: 1.5%-81.0%). Incidence was wide-ranging and mostly reported cumulatively at 1-year post-Crohn's disease diagnosis (range: 3.5%-50.1%). Overall healing and failure rates after treatment were in the range of 10.5%-80.2% and 3.6%-83.0%, respectively. Abscesses were the most frequently reported morbidity (<i>n =</i> 18). No CPF-related deaths were reported. No consistent risk or protective factors were identified.\n\n**Conclusion:** Epidemiology, treatment patterns, and risk factors for CPF vary, likely due to inconsistent CPF and clinical outcome definitions. Standardization would facilitate comparability, which may inform optimal complex CPF treatment strategies.", "abstract_zh": "**èƒŒæ™¯ï¼š** æœ‰å…³å¤æ‚å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜ (CPF) æµè¡Œç—…å­¦çš„æ•°æ®æœ‰é™ï¼Œæœ€ä½³æ²»ç–—ç­–ç•¥éš¾ä»¥æ‰æ‘¸ã€‚æ›´å¥½åœ°äº†è§£å¦‚ä½•åœ¨ç°å®ç¯å¢ƒä¸­ä½¿ç”¨ CPF æ²»ç–—æ–¹æ¡ˆï¼Œä»¥åŠä¸ CPF å‘å±•ã€æ²»ç–—å¤±è´¥å’Œæ¥å—å¤šæ¬¡æ‰‹æœ¯çš„åŸå› ç›¸å…³çš„å› ç´ ï¼Œå¯èƒ½æœ‰åŠ©äºä¸º CPF æ‚£è€…æä¾›æœ€ä½³çš„æ‚£è€…ç®¡ç†ç­–ç•¥ã€å‡è½»æ²»ç–—è´Ÿæ‹…å¹¶æ”¹å–„é¢„åã€‚\n\n**Aimï¼š** æè¿°å¤æ‚ CPF çš„æµè¡Œç—…å­¦ã€æ²»ç–—ã€ç»“æœå’Œç›¸å…³é£é™©/ä¿æŠ¤å› ç´ ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº†ç”µå­æ•°æ®åº“ï¼ˆMEDLINEã€EMBASEã€EBM Reviewsã€EconLitï¼‰ã€‚ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹ä½¿ç”¨äººç¾¤ã€å¹²é¢„æªæ–½ã€æ¯”è¾ƒå™¨ã€ç»“æœã€ç ”ç©¶è®¾è®¡å’Œæ—¶é—´æ ‡å‡†æ¥ç¡®å®šç›¸å…³ç ”ç©¶ã€‚å³ä½¿æœªå®šä¹‰å¤æ‚ CPFï¼Œä¹Ÿçº³å…¥äº† 2015 å¹´ 1 æœˆ 1 æ—¥è‡³ 2022 å¹´ 2 æœˆ 17 æ—¥æœŸé—´ä»¥è‹±æ–‡å‘è¡¨çš„ã€æ¶‰åŠè¶…è¿‡ 50 åæ‚£è€…çš„è§‚å¯Ÿæ€§ç ”ç©¶ã€‚æ„Ÿå…´è¶£çš„é¡¹ç›®åŒ…æ‹¬å¤æ‚çš„ CPF å®šä¹‰ã€æµè¡Œç—…å­¦ã€æ²»ç–—æ¨¡å¼ã€å‘ç—…ç‡ã€æ­»äº¡ç‡ä»¥åŠä¸å¤æ‚ CPF å‘å±•ã€æ²»ç–—å¤±è´¥å’Œæ¥å—å¤šæ¬¡æ‰‹æœ¯ç›¸å…³çš„é£é™©å› ç´ ã€‚ä½¿ç”¨æè¿°æ€§ç»Ÿè®¡æŠ¥å‘Šæ•°æ®ã€‚\n\n**ç»“æœï¼š** æ€»ä½“è€Œè¨€ï¼Œçº³å…¥äº† 140 é¡¹ç ”ç©¶ã€‚å¤æ‚çš„ CPF å®šä¹‰å¤šç§å¤šæ ·ä¸”å¾ˆå°‘æŠ¥é“ï¼ˆ24 é¡¹ç ”ç©¶ï¼‰ã€‚å› æ­¤ï¼Œæ•°æ®ä¸»è¦ä¸ä¸€èˆ¬å…¬ç§¯é‡‘ç›¸å…³ã€‚ CPF æ‚£ç—…ç‡å„ä¸ç›¸åŒï¼ˆèŒƒå›´ï¼š1.5%-81.0%ï¼‰ã€‚å‘ç—…ç‡èŒƒå›´å¹¿æ³›ï¼Œå¤§å¤šæ•°æ˜¯åœ¨å…‹ç½—æ©ç—…è¯Šæ–­å 1 å¹´ç´¯ç§¯æŠ¥å‘Šçš„ï¼ˆèŒƒå›´ï¼š3.5%-50.1%ï¼‰ã€‚æ²»ç–—åæ€»ä½“æ²»æ„ˆç‡å’Œå¤±è´¥ç‡åˆ†åˆ«ä¸º10.5%-80.2%å’Œ3.6%-83.0%ã€‚è„“è‚¿æ˜¯æœ€å¸¸æŠ¥å‘Šçš„å‘ç—…ç‡ï¼ˆ<i>n =</i> 18ï¼‰ã€‚æ²¡æœ‰ä¸å…¬ç§¯é‡‘ç›¸å…³çš„æ­»äº¡æŠ¥å‘Šã€‚æ²¡æœ‰å‘ç°ä¸€è‡´çš„é£é™©æˆ–ä¿æŠ¤å› ç´ ã€‚\n\n**ç»“è®ºï¼š** CPF çš„æµè¡Œç—…å­¦ã€æ²»ç–—æ¨¡å¼å’Œå±é™©å› ç´ å„ä¸ç›¸åŒï¼Œè¿™å¯èƒ½æ˜¯ç”±äº CPF å’Œä¸´åºŠç»“æœå®šä¹‰ä¸ä¸€è‡´æ‰€è‡´ã€‚æ ‡å‡†åŒ–å°†ä¿ƒè¿›å¯æ¯”æ€§ï¼Œè¿™å¯èƒ½ä¸ºæœ€ä½³çš„å¤æ‚ CPF æ²»ç–—ç­–ç•¥æä¾›ä¿¡æ¯ã€‚", "keywords_zh": "å¤æ‚è‚›å‘¨ç˜˜ã€å…‹ç½—æ©ç—…ã€æµè¡Œç—…å­¦ã€å‘ç—…ç‡ã€å±é™©å› ç´ ã€æ²»ç–—æ¨¡å¼", "keywords_en": "Complex perianal fistula, Crohnâ€™s disease, Epidemiology, Morbidity, Risk factors, Treatment patterns", "link": "https://pubmed.ncbi.nlm.nih.gov/40740890/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 31 Jul 2025"}, {"id": "40585484", "title_en": "Treatment of perianal abscess and anal fistula in infants: a systematic review", "title_zh": "å©´å„¿è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜çš„æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Li Xu", "abstract_en": "**Introduction:** The optimal treatment approach for perianal abscess (PA) and fistula-in-ano (FIA) in infants remains a subject of debate.\n\n**Material And Methods:** A thorough literature search was conducted across multiple databases, including Embase, PubMed, Web of Science, Cochrane Library, ClinicalTrials.gov, and Google Scholar.\n\n**Results:** A total of eighteen retrospective studies, encompassing 1,770 patients, were analyzed. Of the 702 cases (38.7%) that underwent conservative treatment, 528 cases (75.2%) achieved a cure, while 174 cases (24.8%) were unsuccessful, with 93 experiencing PA recurrence and 81 developing FIA. In contrast, among the 1,068 cases (61.3%) that received surgical interventions, 784 cases (73.4%) were cured, whereas 284 cases (26.6%) were not, with 151 experiencing PA recurrence and 133 developing FIA.\n\n**Conclusion:** The available studies indicate minimal differences in the cure and recurrence rates of PA and FIA between the conservative and surgical treatment groups.\n\n**Systematic Review Registration:** https://www.crd.york.ac.uk/PROSPERO/, PROSPERO (CRD42023472249).", "abstract_zh": "**ä»‹ç»ï¼š** å©´å„¿è‚›å‘¨è„“è‚¿ï¼ˆPAï¼‰å’Œè‚›ç˜˜ï¼ˆFIAï¼‰çš„æœ€ä½³æ²»ç–—æ–¹æ³•ä»ç„¶æ˜¯ä¸€ä¸ªäº‰è®ºçš„è¯é¢˜ã€‚\n\n**Material and methodsï¼š** å¯¹å¤šä¸ªæ•°æ®åº“è¿›è¡Œäº†å½»åº•çš„æ–‡çŒ®æ£€ç´¢ï¼ŒåŒ…æ‹¬ Embaseã€PubMedã€Web of Scienceã€Cochrane Libraryã€ClinicalTrials.gov å’Œ Google Scholarã€‚\n\n**ç»“æœï¼š** æ€»å…±åˆ†æäº† 18 é¡¹å›é¡¾æ€§ç ”ç©¶ï¼Œæ¶µç›– 1,770 åæ‚£è€…ã€‚æ¥å—ä¿å®ˆæ²»ç–—çš„702ä¾‹ï¼ˆ38.7%ï¼‰ä¸­ï¼Œæ²»æ„ˆ528ä¾‹ï¼ˆ75.2%ï¼‰ï¼Œæœªæ²»æ„ˆ174ä¾‹ï¼ˆ24.8%ï¼‰ï¼Œå…¶ä¸­93ä¾‹å‡ºç°PAå¤å‘ï¼Œ81ä¾‹å‡ºç°FIAã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼Œåœ¨æ¥å—æ‰‹æœ¯å¹²é¢„çš„1,068ä¾‹ï¼ˆ61.3%ï¼‰ä¸­ï¼Œ784ä¾‹ï¼ˆ73.4%ï¼‰æ²»æ„ˆï¼Œ284ä¾‹ï¼ˆ26.6%ï¼‰æœªæ²»æ„ˆï¼Œå…¶ä¸­151ä¾‹å‡ºç°PAå¤å‘ï¼Œ133ä¾‹å‡ºç°FIAã€‚\n\n**ç»“è®ºï¼š** ç°æœ‰ç ”ç©¶è¡¨æ˜ï¼Œä¿å®ˆæ²»ç–—ç»„å’Œæ‰‹æœ¯æ²»ç–—ç»„ä¹‹é—´ PA å’Œ FIA çš„æ²»æ„ˆç‡å’Œå¤å‘ç‡å·®å¼‚å¾ˆå°ã€‚\n\n**Systematic review registrationï¼š** https://www.crd.york.ac.uk/PROSPERO/ï¼ŒPROSPERO (CRD42023472249)ã€‚", "keywords_zh": "ä¿å®ˆæ²»ç–—, è‚›ç˜˜, å©´å„¿, è‚›å‘¨è„“è‚¿, æ‰‹æœ¯æ²»ç–—", "keywords_en": "conservative treatment, fistula-in-ano, infants, perianal abscess, surgical treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/40585484/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Mon, 30 Jun 2025"}, {"id": "40538531", "title_en": "The Correlation between Hidradenitis Suppurativa and Irritable Bowel Diseases: A Systematic Review", "title_zh": "åŒ–è„“æ€§æ±—è…ºç‚ä¸è‚ æ˜“æ¿€ç–¾ç—…ä¹‹é—´çš„ç›¸å…³æ€§ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Ayezel Munoz Gonzalez", "abstract_en": "**Background:** Hidradenitis suppurativa (HS) is an inflammatory skin condition that presents with nodules or abscesses associated with sinus tracts. Inflammatory bowel diseases (IBD) are inflammatory gastrointestinal (GI) conditions presenting with irregular bowel movements. Although HS and IBDs may have similarities in their clinical presentation and pathophysiology, they can differ in their cutaneous manifestations. Both conditions are potentially caused by genetic changes in the human leukocyte antigen (HLA), cause skin inflammation, and are characterized by abscesses in the GI and sinus tracts.\n\n**Objective:** We sought to determine the extent of coincident IBD and HS and the associated risk factors.\n\n**Methods:** The Ovid Medline database was searched for all current literature on the correlations between HS and IBD. Articles were then included and removed according to specific inclusion and exclusion criteria, and a systematic review was performed on the remaining articles.\n\n**Results:** Thirteen papers that met the inclusion and the exclusion criteria were selected, and after data collection, a significant correlation was found between the development of HS and IBD. Most of the articles reviewed stated that the corresponding association was a causal link between the two diseases. Furthermore, there were various risk factors and comorbidities associated with HS and the development of IBD, including smoking, obesity, perianal disease, and genetic predispositions such as HLA-B27 mutations.\n\n**Discussion:** Studies show that there is a potential correlation with HS and IBDs. Additional research should to determine the genetic correlations between HS and IBDs and the underlying pathophysiological mechanism.", "abstract_zh": "**èƒŒæ™¯ï¼š** åŒ–è„“æ€§æ±—è…ºç‚ (HS) æ˜¯ä¸€ç§ç‚ç—‡æ€§çš®è‚¤ç—…ï¼Œè¡¨ç°ä¸ºä¸çª¦é“ç›¸å…³çš„ç»“èŠ‚æˆ–è„“è‚¿ã€‚ç‚ç—‡æ€§è‚ ç—… (IBD) æ˜¯ä¸€ç§ç‚ç—‡æ€§èƒƒè‚ é“ (GI) ç–¾ç—…ï¼Œè¡¨ç°ä¸ºæ’ä¾¿ä¸è§„åˆ™ã€‚å°½ç®¡ HS å’Œ IBD åœ¨ä¸´åºŠè¡¨ç°å’Œç—…ç†ç”Ÿç†å­¦æ–¹é¢å¯èƒ½æœ‰ç›¸ä¼¼ä¹‹å¤„ï¼Œä½†å®ƒä»¬çš„çš®è‚¤è¡¨ç°å¯èƒ½æœ‰æ‰€ä¸åŒã€‚è¿™ä¸¤ç§æƒ…å†µéƒ½å¯èƒ½ç”±äººç±»ç™½ç»†èƒæŠ—åŸ (HLA) çš„åŸºå› å˜åŒ–å¼•èµ·ï¼Œå¼•èµ·çš®è‚¤ç‚ç—‡ï¼Œå¹¶ä»¥èƒƒè‚ é“å’Œçª¦é“è„“è‚¿ä¸ºç‰¹å¾ã€‚\n\n**ç›®çš„ï¼š** æˆ‘ä»¬è¯•å›¾ç¡®å®š IBD å’Œ HS çš„é‡åˆç¨‹åº¦ä»¥åŠç›¸å…³çš„é£é™©å› ç´ ã€‚\n\n**æ–¹æ³•ï¼š** åœ¨ Ovid Medline æ•°æ®åº“ä¸­æ£€ç´¢äº†æœ‰å…³ HS å’Œ IBD ä¹‹é—´ç›¸å…³æ€§çš„æ‰€æœ‰å½“å‰æ–‡çŒ®ã€‚ç„¶åæ ¹æ®ç‰¹å®šçš„çº³å…¥å’Œæ’é™¤æ ‡å‡†çº³å…¥å’Œåˆ é™¤æ–‡ç« ï¼Œå¹¶å¯¹å‰©ä½™æ–‡ç« è¿›è¡Œç³»ç»Ÿè¯„ä»·ã€‚\n\n**ç»“æœï¼š** ç­›é€‰å‡º13ç¯‡ç¬¦åˆçº³å…¥å’Œæ’é™¤æ ‡å‡†çš„è®ºæ–‡ï¼Œç»è¿‡æ•°æ®æ”¶é›†ï¼Œå‘ç°HSå’ŒIBDçš„å‘å±•ä¹‹é—´å­˜åœ¨æ˜¾ç€ç›¸å…³æ€§ã€‚å¤§å¤šæ•°å®¡æŸ¥çš„æ–‡ç« éƒ½æŒ‡å‡ºï¼Œç›¸åº”çš„å…³è”æ˜¯ä¸¤ç§ç–¾ç—…ä¹‹é—´çš„å› æœå…³ç³»ã€‚æ­¤å¤–ï¼Œå­˜åœ¨ä¸ HS å’Œ IBD å‘å±•ç›¸å…³çš„å„ç§å±é™©å› ç´ å’Œåˆå¹¶ç—‡ï¼ŒåŒ…æ‹¬å¸çƒŸã€è‚¥èƒ–ã€è‚›å‘¨ç–¾ç—…å’Œ HLA-B27 çªå˜ç­‰é—ä¼ å€¾å‘ã€‚\n\n**è®¨è®ºï¼š** ç ”ç©¶è¡¨æ˜ï¼ŒHS å’Œ IBD å­˜åœ¨æ½œåœ¨ç›¸å…³æ€§ã€‚è¿˜åº”å¼€å±•æ›´å¤šç ”ç©¶æ¥ç¡®å®š HS å’Œ IBD ä¹‹é—´çš„é—ä¼ ç›¸å…³æ€§ä»¥åŠæ½œåœ¨çš„ç—…ç†ç”Ÿç†æœºåˆ¶ã€‚", "keywords_zh": "åŒ–è„“æ€§æ±—è…ºç‚ã€è‡ªèº«å…ç–«ã€çš®è‚¤ç§‘ã€èƒƒè‚ ç§‘ã€è‚ æ˜“æ¿€ç—…", "keywords_en": "Hidradenitis suppurativa, autoimmunity, dermatology, gastroenterology, irritable bowel diseases", "link": "https://pubmed.ncbi.nlm.nih.gov/40538531/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Fri, 20 Jun 2025"}, {"id": "40210078", "title_en": "Defining Radiological Healing in Perianal Fistulizing Crohn's Disease: A TOpClass Global Expert Delphi Consensus", "title_zh": "å®šä¹‰è‚›å‘¨ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…çš„æ”¾å°„æ²»ç–—ï¼šé¡¶çº§å…¨çƒä¸“å®¶å¾·å°”è²å…±è¯†", "authors": "TOpClass collaborative authors", "abstract_en": "**Background & Aims:** Perianal fistulising Crohn's disease (pfCD) affects one-fifth of patients with Crohn's disease (CD), significantly affecting their quality of life. Magnetic resonance imaging is the gold standard for evaluating fistula healing in pfCD, but variability in radiological definitions hampers meaningful clinical interpretation and consistent trial design. This study aimed to establish an international consensus on the definition of radiological healing in pfCD.\n\n**Methods:** The study was conducted in 2 phases. Phase 1 involved a systematic review to identify magnetic resonance imaging-based variables and indices used to define healing in pfCD, assessing methodological quality using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) framework. Phase 2 utilized a 2-round online Delphi consensus process with 84 international experts, followed by a stakeholder meeting to achieve consensus (agreement threshold >80%). Results were reported as per Accurate Consensus Reporting Document (ACCORD) guidelines.\n\n**Results:** A radiologically healed fistula can be defined by the absence of T2-weighted hyperintensity, a completely fibrotic fistula tract and, when contrast is used, the absence of contrast enhancement on post-contrast T1-weighted images (95% consensus). Radiological improvement of a fistula can be defined (80% consensus) by the presence of a least one essential criterion: an increasingly fibrotic fistula tract, an unequivocal reduction in one or more of the following: T2-weighted hyperintensity, fistula diameter, fistula length, abscess size, or contrast enhancement of the fistula tract.\n\n**Conclusions:** This international Delphi consensus standardizes radiological endpoints in pfCD, improving consistency in clinical and research settings. Future studies will validate this definition and assess how radiological changes predict long-term clinical outcomes and quality of life improvements.", "abstract_zh": "**Background & aimsï¼š** è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… (pfCD) å½±å“äº”åˆ†ä¹‹ä¸€çš„å…‹ç½—æ©ç—… (CD) æ‚£è€…ï¼Œæ˜¾ç€å½±å“ä»–ä»¬çš„ç”Ÿæ´»è´¨é‡ã€‚ç£å…±æŒ¯æˆåƒæ˜¯è¯„ä¼° pfCD ç˜˜ç®¡æ„ˆåˆçš„é»„é‡‘æ ‡å‡†ï¼Œä½†æ”¾å°„å­¦å®šä¹‰çš„å¯å˜æ€§å¦¨ç¢äº†æœ‰æ„ä¹‰çš„ä¸´åºŠè§£é‡Šå’Œä¸€è‡´çš„è¯•éªŒè®¾è®¡ã€‚æœ¬ç ”ç©¶æ—¨åœ¨å°± pfCD æ”¾å°„æ²»ç–—çš„å®šä¹‰å»ºç«‹å›½é™…å…±è¯†ã€‚\n\n**æ–¹æ³•ï¼š** è¯¥ç ”ç©¶åˆ†ä¸¤ä¸ªé˜¶æ®µè¿›è¡Œã€‚ç¬¬ä¸€é˜¶æ®µæ¶‰åŠç³»ç»Ÿå®¡æŸ¥ï¼Œä»¥ç¡®å®šç”¨äºå®šä¹‰ pfCD æ„ˆåˆçš„åŸºäºç£å…±æŒ¯æˆåƒçš„å˜é‡å’ŒæŒ‡æ•°ï¼Œä½¿ç”¨åŸºäºå…±è¯†çš„å¥åº·æµ‹é‡ä»ªå™¨é€‰æ‹©æ ‡å‡† (COSMIN) æ¡†æ¶è¯„ä¼°æ–¹æ³•å­¦è´¨é‡ã€‚ç¬¬äºŒé˜¶æ®µé‡‡ç”¨äº†ç”±84ä½å›½é™…ä¸“å®¶å‚ä¸çš„ä¸¤è½®åœ¨çº¿å¾·å°”è²å…±è¯†æµç¨‹ï¼Œéšåå¬å¼€åˆ©ç›Šç›¸å…³è€…ä¼šè®®ä»¥è¾¾æˆå…±è¯†ï¼ˆåŒæ„é˜ˆå€¼>80%ï¼‰ã€‚ç»“æœæŒ‰ç…§å‡†ç¡®å…±è¯†æŠ¥å‘Šæ–‡ä»¶ (ACCORD) æŒ‡å—è¿›è¡ŒæŠ¥å‘Šã€‚\n\n**ç»“æœï¼š** æ”¾å°„å­¦æ„ˆåˆçš„ç˜˜ç®¡å¯ä»¥å®šä¹‰ä¸ºä¸å­˜åœ¨ T2 åŠ æƒé«˜ä¿¡å·ã€å®Œå…¨çº¤ç»´åŒ–çš„ç˜˜ç®¡ï¼Œä»¥åŠä½¿ç”¨é€ å½±å‰‚æ—¶ï¼Œé€ å½±å T1 åŠ æƒå›¾åƒä¸Šä¸å­˜åœ¨é€ å½±å‰‚å¢å¼ºï¼ˆ95% å…±è¯†ï¼‰ã€‚ç˜˜ç®¡çš„æ”¾å°„å­¦æ”¹å–„å¯ä»¥é€šè¿‡è‡³å°‘ä¸€ä¸ªåŸºæœ¬æ ‡å‡†çš„å­˜åœ¨æ¥å®šä¹‰ï¼ˆ80%å…±è¯†ï¼‰ï¼šç˜˜ç®¡çº¤ç»´åŒ–ç¨‹åº¦ä¸æ–­å¢åŠ ï¼Œä»¥ä¸‹ä¸€é¡¹æˆ–å¤šé¡¹æŒ‡æ ‡æ˜ç¡®å‡å°‘ï¼šT2åŠ æƒé«˜ä¿¡å·ã€ç˜˜ç®¡ç›´å¾„ã€ç˜˜ç®¡é•¿åº¦ã€è„“è‚¿å¤§å°æˆ–ç˜˜ç®¡é€ å½±å¢å¼ºã€‚\n\n**ç»“è®ºï¼š** è¿™ä¸€å›½é™…å¾·å°”è²å…±è¯†æ ‡å‡†åŒ–äº† pfCD çš„æ”¾å°„å­¦ç»ˆç‚¹ï¼Œæé«˜äº†ä¸´åºŠå’Œç ”ç©¶ç¯å¢ƒçš„ä¸€è‡´æ€§ã€‚æœªæ¥çš„ç ”ç©¶å°†éªŒè¯è¿™ä¸€å®šä¹‰ï¼Œå¹¶è¯„ä¼°æ”¾å°„å­¦å˜åŒ–å¦‚ä½•é¢„æµ‹é•¿æœŸä¸´åºŠç»“æœå’Œç”Ÿæ´»è´¨é‡çš„æ”¹å–„ã€‚", "keywords_zh": "ç»ˆç‚¹ã€ç˜˜ç®¡ã€æ„ˆåˆã€MRIã€è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…", "keywords_en": "Endpoints, Fistula, Healing, MRI, Perianal Fistulising Crohnâ€™s Disease", "link": "https://pubmed.ncbi.nlm.nih.gov/40210078/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 10 Apr 2025"}, {"id": "40155532", "title_en": "Early diagnosis of Crohn's disease in patients presenting with a perianal fistula: systematic review and development of a perianal red flags index", "title_zh": "è‚›å‘¨ç˜˜æ‚£è€…å…‹ç½—æ©ç—…çš„æ—©æœŸè¯Šæ–­ï¼šç³»ç»Ÿå›é¡¾å’Œè‚›å‘¨å±é™©ä¿¡å·æŒ‡æ•°çš„åˆ¶å®š", "authors": "J D W van der Bilt", "abstract_en": "**Background:** Delay in diagnosing Crohn's disease (CD) in patients presenting with perianal abscess (PAA) and/or fistula (PAF) is common. The aim of this study was to identify red flags suggestive of CD.\n\n**Methods:** A systematic literature review was conducted to identify symptoms associated with CD in patients presenting with PAA/PAF. A questionnaire including those symptoms, supplemented with items from the International Organization for the Study of Inflammatory Bowel Diseases (IO-IBD) red flags index for luminal CD, was administered to all adult patients presenting with a PAF and eventually diagnosed with CD and matched patients (1:3) from the same study period with a cryptoglandular PAF (2012-2023) at a single non-academic teaching hospital. All patients were asked to recall symptoms/signs experienced during their first PAF.\n\n**Results:** The systematic review identified 8 articles reporting on 15 clinical characteristics in patients presenting with PAA (nâ€‰=â€‰2)/PAF (nâ€‰=â€‰6), supplemented with 13 items from the IO-IBD red flags index (28 items in total). A total of 25 patients with CD and 75 patients with PAF without CD answered the questionnaire. Univariate analysis identified seven items associated with CD (age, family history,â€‰>â€‰2 perianal interventions, weight loss, abdominal pain, diarrhoea and fatigue), and four items remained significant in multivariate analysis: age (OR 3.4 [1.0-11.5]),â€‰>â€‰2 previous perianal interventions (OR 3.4 [1.0-10.1]), weight loss (OR 14.4 [3.7-55.6]) and abdominal pain (OR 9.8 [1.9-49.8]). Receiver-operating characteristic curve (ROC) analysis showed that a combination of these red flags was associated with good discrimination of CD versus non-CD (AUC 0.83 [0.72-0.94]).\n\n**Conclusions:** The perianal red flags index has a good predictive value for early identification of patients with PAF at risk for underlying CD.", "abstract_zh": "**èƒŒæ™¯ï¼š** å¯¹äºæ‚£æœ‰è‚›å‘¨è„“è‚¿ (PAA) å’Œ/æˆ–ç˜˜ç®¡ (PAF) çš„æ‚£è€…ï¼Œå…‹ç½—æ©ç—… (CD) çš„è¯Šæ–­å»¶è¿Ÿå¾ˆå¸¸è§ã€‚æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯è¯†åˆ«æç¤º CD çš„å±é™©ä¿¡å·ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿæ€§æ–‡çŒ®ç»¼è¿°ï¼Œä»¥ç¡®å®š PAA/PAF æ‚£è€…ä¸­ä¸ CD ç›¸å…³çš„ç—‡çŠ¶ã€‚å¯¹æ‰€æœ‰å‡ºç° PAF å¹¶æœ€ç»ˆè¯Šæ–­ä¸º CD çš„æˆå¹´æ‚£è€…è¿›è¡Œäº†ä¸€ä»½åŒ…å«è¿™äº›ç—‡çŠ¶çš„è°ƒæŸ¥é—®å·ï¼Œå¹¶è¡¥å……äº†å›½é™…ç‚ç—‡æ€§è‚ ç—…ç ”ç©¶ç»„ç»‡ (IO-IBD) ç®¡è…” CD å±é™©ä¿¡å·æŒ‡æ•°çš„é¡¹ç›®ï¼Œå¹¶ä¸æ¥è‡ªåŒä¸€ç ”ç©¶æ—¶æœŸ (2012-2023) åœ¨ä¸€å®¶éå­¦æœ¯æ€§æ•™å­¦åŒ»é™¢çš„éšè…º PAF çš„åŒ¹é…æ‚£è€… (1:3) è¿›è¡Œäº†æ¯”è¾ƒã€‚æ‰€æœ‰æ‚£è€…éƒ½è¢«è¦æ±‚å›å¿†ç¬¬ä¸€æ¬¡ PAF æœŸé—´ç»å†çš„ç—‡çŠ¶/ä½“å¾ã€‚\n\n**ç»“æœï¼š** ç³»ç»Ÿè¯„ä»·ç¡®å®šäº† 8 ç¯‡æ–‡ç« ï¼ŒæŠ¥å‘Šäº† PAA (nâ€‰=â€‰2)/PAF (nâ€‰=â€‰6) æ‚£è€…çš„ 15 é¡¹ä¸´åºŠç‰¹å¾ï¼Œå¹¶è¡¥å……äº† IO-IBD å±é™©ä¿¡å·æŒ‡æ•°ä¸­çš„ 13 é¡¹ï¼ˆæ€»å…± 28 é¡¹ï¼‰ã€‚å…±æœ‰ 25 åæ‚£æœ‰ CD çš„æ‚£è€…å’Œ 75 åæ²¡æœ‰ CD çš„ PAF æ‚£è€…å›ç­”äº†é—®å·ã€‚å•å˜é‡åˆ†æç¡®å®šäº†ä¸ CD ç›¸å…³çš„ 7 ä¸ªé¡¹ç›®ï¼ˆå¹´é¾„ã€å®¶æ—å²ã€â€‰>â€‰2 æ¬¡è‚›å‘¨å¹²é¢„ã€ä½“é‡å‡è½»ã€è…¹ç—›ã€è…¹æ³»å’Œç–²åŠ³ï¼‰ï¼Œ4 ä¸ªé¡¹ç›®åœ¨å¤šå˜é‡åˆ†æä¸­ä»ç„¶æ˜¾ç€ï¼šå¹´é¾„ (OR 3.4 [1.0-11.5])ã€â€‰>â€‰2 æ¬¡æ—¢å¾€è‚›å‘¨å¹²é¢„ (OR 3.4 [1.0-10.1])ã€ä½“é‡å‡è½» (OR 14.4) [3.7-55.6]ï¼‰å’Œè…¹ç—›ï¼ˆOR 9.8 [1.9-49.8]ï¼‰ã€‚å—è¯•è€…å·¥ä½œç‰¹å¾æ›²çº¿ (ROC) åˆ†æè¡¨æ˜ï¼Œè¿™äº›å±é™©ä¿¡å·çš„ç»„åˆä¸ CD ä¸é CD çš„è‰¯å¥½åŒºåˆ†ç›¸å…³ï¼ˆAUC 0.83 [0.72-0.94]ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è‚›å‘¨å±é™©ä¿¡å·æŒ‡æ•°å¯¹äºæ—©æœŸè¯†åˆ«æœ‰æ½œåœ¨ CD é£é™©çš„ PAF æ‚£è€…å…·æœ‰è‰¯å¥½çš„é¢„æµ‹ä»·å€¼ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€å»¶è¿Ÿã€ç‚ç—‡æ€§è‚ ç—…ã€è‚›å‘¨ç˜˜", "keywords_en": "Crohnâ€™s disease, Delay, Inflammatory bowel disease, Perianal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/40155532/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Sat, 29 Mar 2025"}, {"id": "39946821", "title_en": "A systematic review and meta-analysis of the diagnostic test accuracy of diffusion weighted imaging and apparent diffusion coefficient in differentiating active from inactive perianal fistula", "title_zh": "å¯¹å¼¥æ•£åŠ æƒæˆåƒå’Œè¡¨è§‚å¼¥æ•£ç³»æ•°åŒºåˆ†æ´»åŠ¨æ€§å’Œéæ´»åŠ¨æ€§è‚›å‘¨ç˜˜çš„è¯Šæ–­æµ‹è¯•å‡†ç¡®æ€§çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "G S Octavius", "abstract_en": "**Introduction:** This systematic review and meta-analysis evaluated the diagnostic accuracy of MRI-based apparent diffusion coefficient (ADC) and diffusion-weighted imaging (DWI) for differentiating active from inactive perianal fistulas.\n\n**Methods:** The protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024596604). The review included five databases (MEDLINE, Cochrane Library, PubMed, Science Direct, and Google Scholar). Meta-analyses were performed on studies reporting ADC values and other sequences using STATA software with the \"Midas\" command.\n\n**Results:** Of 21 studies included in the review, 12 were meta-analyzed, encompassing 1007 patients (77.5Â % male) with 1092 fistulas and 321 abscesses. Six studies reported ADC values for active vs. inactive fistulas, with a pooled sensitivity of 83Â % (95%CI 68-92), specificity of 75Â % (95%CI 60-85), and AUC of 0.85 (95%CI 0.81-0.87). Pooled ADC cut-offs ranged from 1.105 to 1.109Â Ã—Â 10â»Â³ mm<sup>2</sup>/s. The T2WIÂ +Â DWI sequence demonstrated the highest diagnostic accuracy, with a pooled sensitivity of 99Â % (95%CI 90-100), specificity of 97Â % (95%CI 79-100), and an AUC of 1.\n\n**Conclusion:** ADC alone is inadequate for reliably distinguishing active from inactive fistulas. T2WI combined with DWI offers superior diagnostic performance, surpassing contrast-enhanced T1WI, and is promising for non-invasive evaluation of perianal fistulas. However, several limitations, such as moderate to high risk of bias and heterogeneity, may bias this conclusion.\n\n**Implications For Practice:** T2WIÂ +Â DWI could become the standard for assessing perianal fistulas, avoiding contrast agents, and benefiting patients contraindicated for Gadolinium-based contrast media. Variability and potential bias across studies warrant further research.", "abstract_zh": "**ä»‹ç»ï¼š** è¿™é¡¹ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æè¯„ä¼°äº†åŸºäº MRI çš„è¡¨è§‚æ‰©æ•£ç³»æ•° (ADC) å’Œæ‰©æ•£åŠ æƒæˆåƒ (DWI) åŒºåˆ†æ´»åŠ¨æ€§å’Œéæ´»åŠ¨æ€§è‚›å‘¨ç˜˜çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚\n\n**æ–¹æ³•ï¼š** è¯¥æ–¹æ¡ˆå·²åœ¨å›½é™…ç³»ç»Ÿè¯„ä»·å‰ç»æ€§ç™»è®°å†Œ (PROSPERO) ä¸­æ³¨å†Œ (CRD42024596604)ã€‚è¯¥ç»¼è¿°åŒ…æ‹¬äº”ä¸ªæ•°æ®åº“ï¼ˆMEDLINEã€Cochrane Libraryã€PubMedã€Science Direct å’Œ Google Scholarï¼‰ã€‚ä½¿ç”¨å¸¦æœ‰â€œMidasâ€å‘½ä»¤çš„ STATA è½¯ä»¶å¯¹æŠ¥å‘Š ADC å€¼å’Œå…¶ä»–åºåˆ—çš„ç ”ç©¶è¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** åœ¨è¯¥è¯„ä»·çº³å…¥çš„ 21 é¡¹ç ”ç©¶ä¸­ï¼Œæœ‰ 12 é¡¹è¿›è¡Œäº†èŸèƒåˆ†æï¼Œæ¶‰åŠ 1007 åæ‚£è€…ï¼ˆ77.5% ç”·æ€§ï¼‰ï¼Œæœ‰ 1092 ä¸ªç˜˜ç®¡å’Œ 321 ä¸ªè„“è‚¿ã€‚å…­é¡¹ç ”ç©¶æŠ¥å‘Šäº†æ´»åŠ¨æ€§ç˜˜ç®¡ä¸éæ´»åŠ¨æ€§ç˜˜ç®¡çš„ ADC å€¼ï¼Œæ±‡æ€»æ•æ„Ÿæ€§ä¸º 83% (95%CI 68-92)ï¼Œç‰¹å¼‚æ€§ä¸º 75% (95%CI 60-85)ï¼ŒAUC ä¸º 0.85 (95%CI 0.81-0.87)ã€‚æ±‡é›†çš„ ADC æˆªæ­¢èŒƒå›´ä¸º 1.105 è‡³ 1.109Â Ã—Â 10â»3 mm<sup>2</sup>/sã€‚ T2WI + DWI åºåˆ—æ˜¾ç¤ºå‡ºæœ€é«˜çš„è¯Šæ–­å‡†ç¡®æ€§ï¼Œæ±‡æ€»æ•æ„Ÿæ€§ä¸º 99% (95%CI 90-100)ï¼Œç‰¹å¼‚æ€§ä¸º 97% (95%CI 79-100)ï¼ŒAUC ä¸º 1ã€‚\n\n**ç»“è®ºï¼š** å•ç‹¬ä½¿ç”¨ ADC ä¸è¶³ä»¥å¯é åŒºåˆ†æ´»åŠ¨æ€§ç˜˜ç®¡å’Œéæ´»åŠ¨æ€§ç˜˜ç®¡ã€‚ T2WI ä¸ DWI ç›¸ç»“åˆæä¾›äº†ä¼˜äºå¯¹æ¯”å¢å¼º T1WI çš„è¯Šæ–­æ€§èƒ½ï¼Œå¹¶ä¸”æœ‰æœ›ç”¨äºè‚›å‘¨ç˜˜çš„æ— åˆ›è¯„ä¼°ã€‚ç„¶è€Œï¼Œä¸€äº›é™åˆ¶ï¼Œä¾‹å¦‚ä¸­åº¦è‡³é«˜é£é™©çš„åå€šå’Œå¼‚è´¨æ€§ï¼Œå¯èƒ½ä¼šå¯¼è‡´è¿™ä¸€ç»“è®ºäº§ç”Ÿåå·®ã€‚\n\n**Implications for practiceï¼š** T2WI + DWI å¯ä»¥æˆä¸ºè¯„ä¼°è‚›å‘¨ç˜˜ç®¡ã€é¿å…ä½¿ç”¨é€ å½±å‰‚ä»¥åŠä½¿é’†é€ å½±å‰‚ç¦å¿Œæ‚£è€…å—ç›Šçš„æ ‡å‡†ã€‚ç ”ç©¶ä¹‹é—´çš„å˜å¼‚æ€§å’Œæ½œåœ¨åå·®å€¼å¾—è¿›ä¸€æ­¥ç ”ç©¶ã€‚", "keywords_zh": "è¡¨è§‚æ‰©æ•£ç³»æ•°ã€è¯Šæ–­æµ‹è¯•å‡†ç¡®æ€§ã€æ‰©æ•£åŠ æƒæˆåƒã€ç£å…±æŒ¯æˆåƒã€è‚›å‘¨ç˜˜", "keywords_en": "Apparent diffusion coefficient, Diagnostic test accuracy, Diffusion weighted imaging, Magnetic resonance imaging, Perianal fistula", "link": "https://pubmed.ncbi.nlm.nih.gov/39946821/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 13 Feb 2025"}, {"id": "39422801", "title_en": "Perianal Mucinous Adenocarcinoma: A Case Report and a Systematic Review of the Literature", "title_zh": "è‚›å‘¨ç²˜æ¶²æ€§è…ºç™Œï¼šä¸€ä¾‹æŠ¥å‘Šå’Œæ–‡çŒ®ç³»ç»Ÿå›é¡¾", "authors": "Apostolos P Stamatiadis", "abstract_en": "**Background:** Mucinous adenocarcinoma of anus is an uncommon neoplasm of the gastrointestinal tract. In most of the cases, early diagnosis of this disease is difficult since its symptoms frequently mimic benign inflammatory conditions.\n\n**Methods:** A systematic PubMed and Scopus search was conducted, a propos of a case report.\n\n**Results:** One hundred fifty patients from 93 case reports were included. The mean age of the patients was 60.5Â years (range: 18-81). The majority of them were males (124 out of 150, 82.7%), while the main known risk factor was the history of chronic fistula (109 out of 150, 72.7%). Recurrent perianal sepsis and perianal pain were the principal symptoms at the time of presentation. No symptoms have been reported only in three patients (3 out of 150, 2%). Regarding the prior surgical history of the patients, multiple abscess drainage and perianal fistula's related interventions were present in 62 (41.3%) and 19 (12.7%) patients, respectively. Neoadjuvant chemoradiotherapy was administered in 53 out of 150 patients (35.3%), while the majority of them have been treated with combined treatment of chemotherapy and radiotherapy. APR and its variations were the most applied surgical treatment (68%). Adjuvant chemoradiotherapy was administered almost up to one-third of the included patients (34%). Recurrence of the disease was reported in 41 out of 150 patients (27.3%). Death was reported in 44 out of 150 patients (29.3%).\n\n**Conclusion:** Review of the available published literature suggests that perianal mucinous adenocarcinoma is an extremely rare neoplasia. Î¤here is no consensus as far as the diagnosis and the treatment strategies, due to the rarity of this neoplasm. High degree of clinical suspicion as well as histopathological confirmation is the principal requisites for the diagnosis of mucinous adenocarcinoma, especially in the ground of chronic ulcero-proliferative perianal lesions.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›é—¨ç²˜æ¶²æ€§è…ºç™Œæ˜¯ä¸€ç§ç½•è§çš„èƒƒè‚ é“è‚¿ç˜¤ã€‚åœ¨å¤§å¤šæ•°æƒ…å†µä¸‹ï¼Œè¿™ç§ç–¾ç—…çš„æ—©æœŸè¯Šæ–­å¾ˆå›°éš¾ï¼Œå› ä¸ºå®ƒçš„ç—‡çŠ¶ç»å¸¸æ¨¡ä»¿è‰¯æ€§ç‚ç—‡ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ®ç—…ä¾‹æŠ¥å‘Šçš„å»ºè®®ï¼Œè¿›è¡Œäº†ç³»ç»Ÿçš„ PubMed å’Œ Scopus æ£€ç´¢ã€‚\n\n**ç»“æœï¼š** çº³å…¥ 93 ä»½ç—…ä¾‹æŠ¥å‘Šä¸­çš„ 150 åæ‚£è€…ã€‚æ‚£è€…çš„å¹³å‡å¹´é¾„ä¸º 60.5 å²ï¼ˆèŒƒå›´ï¼š18-81 å²ï¼‰ã€‚å…¶ä¸­å¤§å¤šæ•°ä¸ºç”·æ€§ï¼ˆ150 äººä¸­çš„ 124 äººï¼Œ82.7%ï¼‰ï¼Œè€Œå·²çŸ¥çš„ä¸»è¦å±é™©å› ç´ æ˜¯æ…¢æ€§ç˜˜ç®¡ç—…å²ï¼ˆ150 äººä¸­çš„ 109 äººï¼Œ72.7%ï¼‰ã€‚å¤å‘æ€§è‚›å‘¨è´¥è¡€ç—‡å’Œè‚›å‘¨ç–¼ç—›æ˜¯å°±è¯Šæ—¶çš„ä¸»è¦ç—‡çŠ¶ã€‚ä»… 3 åæ‚£è€…æ²¡æœ‰æŠ¥å‘Šä»»ä½•ç—‡çŠ¶ï¼ˆ150 åæ‚£è€…ä¸­æœ‰ 3 åï¼Œ2%ï¼‰ã€‚å…³äºæ‚£è€…æ—¢å¾€æ‰‹æœ¯å²ï¼Œåˆ†åˆ«æœ‰62ä¾‹ï¼ˆ41.3%ï¼‰å’Œ19ä¾‹ï¼ˆ12.7%ï¼‰æ‚£è€…æ¥å—è¿‡å¤šå¤„è„“è‚¿å¼•æµå’Œè‚›å‘¨ç˜˜ç›¸å…³å¹²é¢„ã€‚ 150ä¾‹æ‚£è€…ä¸­ï¼Œæœ‰53ä¾‹ï¼ˆ35.3%ï¼‰æ¥å—äº†æ–°è¾…åŠ©æ”¾åŒ–ç–—ï¼Œå…¶ä¸­å¤§å¤šæ•°æ‚£è€…æ¥å—äº†åŒ–ç–—å’Œæ”¾ç–—çš„è”åˆæ²»ç–—ã€‚ APR åŠå…¶å˜ä½“æ˜¯æœ€å¸¸ç”¨çš„æ‰‹æœ¯æ²»ç–—æ–¹æ³• (68%)ã€‚å‡ ä¹ä¸‰åˆ†ä¹‹ä¸€çš„çº³å…¥æ‚£è€…ï¼ˆ34%ï¼‰æ¥å—äº†è¾…åŠ©æ”¾åŒ–ç–—ã€‚ 150 åæ‚£è€…ä¸­æœ‰ 41 åï¼ˆ27.3%ï¼‰æŠ¥å‘Šç–¾ç—…å¤å‘ã€‚ 150 åæ‚£è€…ä¸­æœ‰ 44 åæ­»äº¡ï¼ˆ29.3%ï¼‰ã€‚\n\n**ç»“è®ºï¼š** å¯¹ç°æœ‰å·²å‘è¡¨æ–‡çŒ®çš„å›é¡¾è¡¨æ˜ï¼Œè‚›å‘¨ç²˜æ¶²æ€§è…ºç™Œæ˜¯ä¸€ç§æå…¶ç½•è§çš„è‚¿ç˜¤ã€‚ç”±äºè¿™ç§è‚¿ç˜¤çš„ç½•è§æ€§ï¼Œåœ¨è¯Šæ–­å’Œæ²»ç–—ç­–ç•¥æ–¹é¢å°šæœªè¾¾æˆå…±è¯†ã€‚é«˜åº¦çš„ä¸´åºŠæ€€ç–‘å’Œç»„ç»‡ç—…ç†å­¦è¯å®æ˜¯è¯Šæ–­ç²˜æ¶²è…ºç™Œçš„ä¸»è¦å¿…è¦æ¡ä»¶ï¼Œç‰¹åˆ«æ˜¯åœ¨æ…¢æ€§æºƒç–¡å¢æ®–æ€§è‚›å‘¨ç—…å˜çš„æƒ…å†µä¸‹ã€‚", "keywords_zh": "è‚›é—¨ã€è‚›é—¨ã€è‚›é—¨å†…è¶…å£°æ£€æŸ¥ã€ç²˜æ¶²æ€§è…ºç™Œã€è‚›å‘¨", "keywords_en": "Anal, Anus, Endoanal ultrasonography, Mucinous adenocarcinoma, Perianal", "link": "https://pubmed.ncbi.nlm.nih.gov/39422801/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Fri, 18 Oct 2024"}, {"id": "39360706", "title_en": "Darvadstrocel for complex perianal fistulas in Crohn's disease: A systematic review and meta-analysis", "title_zh": "Darvadstrocel æ²»ç–—å…‹ç½—æ©ç—…å¤æ‚è‚›å‘¨ç˜˜ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Cristina Alba", "abstract_en": "**Background:** Local injection of darvadstrocel, a suspension of expanded adipose-derived allogenic mesenchymal stem cells, has been used for treatment-refractory perianal fistulas in Crohn's disease (CD).\n\n**Objective:** This study aimed to investigate efficacy and safety of darvadstrocel for complex perianal fistulas in CD.\n\n**Methods:** A systematic search was conducted through April 2024 in relevant databases for observational studies evaluating darvadstrocel. A random-effects meta-analysis model was used to calculate the pooled effect sizes (proportions or incidence rates [IRs]) with 95% confidence intervals (CIs) of effectiveness and safety outcomes. The risk of bias was evaluated using the Joanna Briggs Institute Critical Appraisal Tool. The I<sup>2</sup> value assessed heterogeneity. Sensitivity and subgroup analyses were also conducted.\n\n**Results:** Twelve studies were included with 595 patients. The pooled rate of patients achieving clinical remission, defined as fistula healing, was 68.1% at month 6 (95% CI 63.4-72.7) and 77.2% (95% CI 70.1-83.8) at month 12. Combined remission, defined as clinical remission and absence of collections >2Â cm confirmed by magnetic resonance imaging, was reported in 60.6% and in 69.7% of patients at months 6 and 12, respectively. The rate of patients with treatment failure, defined as no clinical remission at the last follow-up (mean 18.7Â months; SD 9.9), was 34.5%. Failure rate was independent of follow-up time (pÂ =Â 0.85). For effectiveness outcomes, between-study heterogeneity was negligible. Subgroup analysis indicated that none of the covariates modified the treatment effect. Pooled IRs per 100 patient-years of adverse events (AE), serious AEs, perianal abscesses, and reoperations were 19.6, 3.2, 16.9 and 7.1, respectively.\n\n**Conclusion:** Evidence from observational studies supports the efficacy and safety of darvadstrocel for complex perianal fistulas in CD. Studies have reported high fistula healing rates that can be sustained long-term in most patients, with negligible between-study heterogeneity, as well as a favorable safety profile.", "abstract_zh": "**èƒŒæ™¯ï¼š** å±€éƒ¨æ³¨å°„darvadstrocelï¼ˆä¸€ç§æ‰©å¢çš„è„‚è‚ªæ¥æºåŒç§å¼‚ä½“é—´å……è´¨å¹²ç»†èƒæ‚¬æµ®æ¶²ï¼‰å·²ç”¨äºæ²»ç–—å…‹ç½—æ©ç—…ï¼ˆCDï¼‰éš¾æ²»æ€§è‚›å‘¨ç˜˜ã€‚\n\n**ç›®çš„ï¼š** æœ¬ç ”ç©¶æ—¨åœ¨æ¢è®¨ darvadstrocel æ²»ç–— CD å¤æ‚è‚›å‘¨ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2024 å¹´ 4 æœˆï¼Œæˆ‘ä»¬åœ¨ç›¸å…³æ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ€§æ£€ç´¢ï¼Œä»¥è¯„ä¼° darvadstrocel çš„è§‚å¯Ÿæ€§ç ”ç©¶ã€‚ä½¿ç”¨éšæœºæ•ˆåº”èŸèƒåˆ†ææ¨¡å‹æ¥è®¡ç®—æ±‡æ€»æ•ˆåº”å¤§å°ï¼ˆæ¯”ä¾‹æˆ–å‘ç”Ÿç‡ [IR]ï¼‰ï¼Œæœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ç»“æœçš„ç½®ä¿¡åŒºé—´ (CI) ä¸º 95%ã€‚ä½¿ç”¨ä¹”å®‰å¨œÂ·å¸ƒé‡Œæ ¼æ–¯ç ”ç©¶æ‰€æ‰¹åˆ¤æ€§è¯„ä¼°å·¥å…·è¯„ä¼°åå€šé£é™©ã€‚ I<sup>2</sup> å€¼è¯„ä¼°å¼‚è´¨æ€§ã€‚è¿˜è¿›è¡Œäº†æ•æ„Ÿæ€§å’Œäºšç»„åˆ†æã€‚\n\n**ç»“æœï¼š** 12 é¡¹ç ”ç©¶çº³å…¥äº† 595 åæ‚£è€…ã€‚ç¬¬ 6 ä¸ªæœˆæ—¶è¾¾åˆ°ä¸´åºŠç¼“è§£ï¼ˆå®šä¹‰ä¸ºç˜˜ç®¡æ„ˆåˆï¼‰çš„æ‚£è€…çš„æ±‡æ€»ç‡ä¸º 68.1%ï¼ˆ95% CI 63.4-72.7ï¼‰ï¼Œç¬¬ 12 ä¸ªæœˆæ—¶ä¸º 77.2%ï¼ˆ95% CI 70.1-83.8ï¼‰ã€‚ç»¼åˆç¼“è§£ï¼ˆå®šä¹‰ä¸ºä¸´åºŠç¼“è§£ä¸”ç»ç£å…±æŒ¯æˆåƒè¯å®æ²¡æœ‰ >2 cm çš„ç§¯æ¶²ï¼‰çš„æ‚£è€…æ¯”ä¾‹ä¸º 60.6% å’Œ 69.7%åˆ†åˆ«åœ¨ç¬¬ 6 ä¸ªæœˆå’Œç¬¬ 12 ä¸ªæœˆã€‚æ²»ç–—å¤±è´¥ï¼ˆå®šä¹‰ä¸ºæœ€åä¸€æ¬¡éšè®¿æ—¶æ— ä¸´åºŠç¼“è§£ï¼‰çš„æ‚£è€…æ¯”ä¾‹ï¼ˆå¹³å‡ 18.7 ä¸ªæœˆï¼›SD 9.9ï¼‰ä¸º 34.5%ã€‚å¤±è´¥ç‡ä¸éšè®¿æ—¶é—´æ— å…³ (p = 0.85)ã€‚å¯¹äºæœ‰æ•ˆæ€§ç»“æœï¼Œç ”ç©¶é—´çš„å¼‚è´¨æ€§å¯ä»¥å¿½ç•¥ä¸è®¡ã€‚äºšç»„åˆ†æè¡¨æ˜æ²¡æœ‰ä»»ä½•åå˜é‡æ”¹å˜æ²»ç–—æ•ˆæœã€‚æ¯ 100 æ‚£è€…å¹´ä¸è‰¯äº‹ä»¶ (AE)ã€ä¸¥é‡ AEã€è‚›å‘¨è„“è‚¿å’Œå†æ¬¡æ‰‹æœ¯çš„æ±‡æ€» IR åˆ†åˆ«ä¸º 19.6ã€3.2ã€16.9 å’Œ 7.1ã€‚\n\n**ç»“è®ºï¼š** è§‚å¯Ÿæ€§ç ”ç©¶çš„è¯æ®æ”¯æŒ darvadstrocel å¯¹äº CD å¤æ‚è‚›å‘¨ç˜˜çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚ç ”ç©¶è¡¨æ˜ï¼Œå¤§å¤šæ•°æ‚£è€…çš„ç˜˜ç®¡æ„ˆåˆç‡è¾ƒé«˜ï¼Œå¯ä»¥é•¿æœŸç»´æŒï¼Œç ”ç©¶é—´çš„å¼‚è´¨æ€§å¯ä»¥å¿½ç•¥ä¸è®¡ï¼Œå¹¶ä¸”å®‰å…¨æ€§è‰¯å¥½ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€è„‚è‚ªæ¥æºçš„åŒç§å¼‚ä½“é—´å……è´¨å¹²ç»†èƒã€alofiselã€darvadstrocelã€ç‚ç—‡æ€§è‚ ç—…ã€èŸèƒåˆ†æã€è‚›å‘¨ç˜˜", "keywords_en": "Crohn's disease, adiposeâ€derived allogenic mesenchymal stem cells, alofisel, darvadstrocel, inflammatory bowel disease, metaâ€analysis, perianal fistulas", "link": "https://pubmed.ncbi.nlm.nih.gov/39360706/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 03 Oct 2024"}, {"id": "39298676", "title_en": "Impact of Seton Use on Clinical, Patient-Reported, and Healthcare Resource Utilization Outcomes in Complex Crohn's Perianal Fistulas: A Systematic Literature Review", "title_zh": "ä½¿ç”¨æŒ‚çº¿å¯¹å¤æ‚å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜çš„ä¸´åºŠã€æ‚£è€…æŠ¥å‘Šå’ŒåŒ»ç–—èµ„æºåˆ©ç”¨ç»“æœçš„å½±å“ï¼šç³»ç»Ÿæ–‡çŒ®ç»¼è¿°", "authors": "Phillip Fleshner", "abstract_en": "**Background:** Optimal treatment strategies for seton use in patients with Crohn's perianal fistulas (CPF) remain elusive. This systematic literature review aimed to summarize clinical, patient-reported, and healthcare resource utilization (HCRU) outcomes associated with seton use for symptomatic relief and treatment of complex CPF.\n\n**Methods:** Electronic databases (MEDLINE, Embase, EBM Reviews, EconLit) were searched. Titles, abstracts, and relevant full texts were screened by 2 reviewers for inclusion using prespecified PICOS-T criteria. Articles published in English between January 1, 1980 and September 6, 2021 were included; animal/in vitro studies and case reports with <5 patients were excluded. Outcomes of interest included rates of complete response/remission and fistula recurrence in patients receiving seton with/without infliximab or biologics. Data were summarized using descriptive statistics.\n\n**Results:** Overall, 56 studies were included (full texts: nâ€…=â€…43; congress abstracts: nâ€…=â€…13). CPF and clinical outcome definitions were heterogeneous. Rates (range) of complete response/remission varied widely (seton: 13%-75%; setonâ€…+â€…infliximab: 23%-100%; setonâ€…+â€…biologics: 23%-59%) as did rates for fistula recurrence (seton: 4%-68%; setonâ€…+â€…infliximab: 0%-50%; setonâ€…+â€…biologics: 0%-17%). Rates of fistula-related reintervention, new fistula or abscess formation, and abscess recurrence were also varied; more consistency was observed regarding the use of patient-reported outcomes. Few studies reported outcomes from pediatric/adolescent patients or HCRU.\n\n**Conclusions:** Optimal use of seton in patients with CPF remains unclear. International standardization of definitions for CPF and related clinical outcomes are required to permit data comparability and identify the most effective treatment strategies involving seton use in CPF.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…‹ç½—æ©ç—…è‚›å‘¨ç˜˜ï¼ˆCPFï¼‰æ‚£è€…æŒ‚çº¿çš„æœ€ä½³æ²»ç–—ç­–ç•¥ä»ç„¶éš¾ä»¥æ‰æ‘¸ã€‚æœ¬ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°æ—¨åœ¨æ€»ç»“ä¸ä½¿ç”¨æŒ‚çº¿ç¼“è§£ç—‡çŠ¶å’Œæ²»ç–—å¤æ‚ CPF ç›¸å…³çš„ä¸´åºŠã€æ‚£è€…æŠ¥å‘Šå’ŒåŒ»ç–—èµ„æºåˆ©ç”¨ (HCRU) ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº†ç”µå­æ•°æ®åº“ï¼ˆMEDLINEã€Embaseã€EBM Reviewsã€EconLitï¼‰ã€‚æ ‡é¢˜ã€æ‘˜è¦å’Œç›¸å…³å…¨æ–‡ç”± 2 åå®¡ç¨¿äººç­›é€‰ï¼Œä»¥ä½¿ç”¨é¢„å…ˆæŒ‡å®šçš„ PICOS-T æ ‡å‡†è¿›è¡Œçº³å…¥ã€‚æ”¶å½•äº†1980å¹´1æœˆ1æ—¥è‡³2021å¹´9æœˆ6æ—¥æœŸé—´ä»¥è‹±æ–‡å‘è¡¨çš„æ–‡ç« ï¼›åŠ¨ç‰©/ä½“å¤–ç ”ç©¶å’Œç—…ä¾‹æŠ¥å‘Š<5åæ‚£è€…è¢«æ’é™¤åœ¨å¤–ã€‚æ„Ÿå…´è¶£çš„ç»“æœåŒ…æ‹¬æ¥å—æŒ‚çº¿å¹¶ä½¿ç”¨/ä¸ä½¿ç”¨è‹±å¤«åˆ©æ˜”å•æŠ—æˆ–ç”Ÿç‰©åˆ¶å‰‚çš„æ‚£è€…çš„å®Œå…¨ç¼“è§£/ç¼“è§£ç‡å’Œç˜˜ç®¡å¤å‘ç‡ã€‚ä½¿ç”¨æè¿°æ€§ç»Ÿè®¡æ€»ç»“æ•°æ®ã€‚\n\n**ç»“æœï¼š** æ€»ä½“è€Œè¨€ï¼Œçº³å…¥äº† 56 é¡¹ç ”ç©¶ï¼ˆå…¨æ–‡ï¼šnâ€…=â€…43ï¼›ä¼šè®®æ‘˜è¦ï¼šnâ€…=â€…13ï¼‰ã€‚ CPF å’Œä¸´åºŠç»“æœçš„å®šä¹‰æ˜¯ä¸åŒçš„ã€‚å®Œå…¨ç¼“è§£/ç¼“è§£ç‡ï¼ˆèŒƒå›´ï¼‰å·®å¼‚å¾ˆå¤§ï¼ˆæŒ‚çº¿ï¼š13%-75%ï¼›æŒ‚çº¿â€…+â€…è‹±å¤«åˆ©æ˜”å•æŠ—ï¼š23%-100%ï¼›æŒ‚çº¿â€…+â€…ç”Ÿç‰©åˆ¶å‰‚ï¼š23%-59%ï¼‰ï¼Œç˜˜ç®¡å¤å‘ç‡ä¹Ÿæœ‰å¾ˆå¤§å·®å¼‚ï¼ˆæŒ‚çº¿ï¼š4%-68%ï¼›æŒ‚çº¿â€…+â€…è‹±å¤«åˆ©æ˜”å•æŠ—ï¼š0%-50%ï¼›æŒ‚çº¿â€…+â€…è‹±å¤«åˆ©æ˜”å•æŠ—ï¼š0%-50%ï¼‰ã€‚æŒ‚çº¿â€…+â€…ç”Ÿç‰©åˆ¶å‰‚ï¼š0%-17%ï¼‰ã€‚ä¸ç˜˜ç®¡ç›¸å…³çš„å†å¹²é¢„ã€æ–°ç˜˜ç®¡æˆ–è„“è‚¿å½¢æˆä»¥åŠè„“è‚¿å¤å‘çš„å‘ç”Ÿç‡ä¹Ÿå„ä¸ç›¸åŒï¼›åœ¨ä½¿ç”¨æ‚£è€…æŠ¥å‘Šçš„ç»“æœæ–¹é¢è§‚å¯Ÿåˆ°æ›´åŠ ä¸€è‡´ã€‚å¾ˆå°‘æœ‰ç ”ç©¶æŠ¥å‘Šå„¿ç§‘/é’å°‘å¹´æ‚£è€…æˆ– HCRU çš„ç»“æœã€‚\n\n**ç»“è®ºï¼š** CPF æ‚£è€…æŒ‚çº¿çš„æœ€ä½³ä½¿ç”¨æ–¹å¼ä»ä¸æ¸…æ¥šã€‚éœ€è¦å¯¹ CPF å®šä¹‰å’Œç›¸å…³ä¸´åºŠç»“æœè¿›è¡Œå›½é™…æ ‡å‡†åŒ–ï¼Œä»¥å®ç°æ•°æ®å¯æ¯”æ€§å¹¶ç¡®å®šæ¶‰åŠ CPF æŒ‚çº¿ä½¿ç”¨çš„æœ€æœ‰æ•ˆæ²»ç–—ç­–ç•¥ã€‚", "keywords_zh": "å…‹ç½—æ©ç—…ã€è‚›å‘¨ç˜˜ã€æŒ‚çº¿", "keywords_en": "Crohnâ€™s disease, perianal fistula, seton", "link": "https://pubmed.ncbi.nlm.nih.gov/39298676/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 19 Sep 2024"}, {"id": "38813942", "title_en": "Vaccine-associated paralytic poliomyelitis in oral polio vaccine recipients: disproportionality analysis using VAERS and systematic review", "title_zh": "å£æœè„Šé«“ç°è´¨ç‚ç–«è‹—æ¥ç§è€…ä¸­ä¸ç–«è‹—ç›¸å…³çš„éº»ç—¹æ€§è„Šé«“ç°è´¨ç‚ï¼šä½¿ç”¨ VAERS å’Œç³»ç»Ÿè¯„ä»·è¿›è¡Œä¸æˆæ¯”ä¾‹åˆ†æ", "authors": "Girish Thunga", "abstract_en": "**Background:** Vaccine-associated paralytic poliomyelitis (VAPP) is a rare adverse event of oral poliovirus vaccines (OPV), particularly affecting immunodeficient individuals.\n\n**Research Design And Methods:** This study aimed to (1) Assess the association between OPV and VAPP using Vaccine Adverse Event Reporting System (VAERS) database (2) Outline patient characteristics and risk factors associated with the occurrence of VAPP in OPV recipients through a systematic review of case reports and case series. A disproportionality analysis was conducted using the data from VAERS, encompassing adverse events reported from 1990 till February 2023. Additionally, we conducted a systematic review of case reports and case series using PubMed, Scopus, and Embase databases.\n\n**Results:** The VAERS data revealed 130 VAPP reports among 1,739,903 OPV linked adverse events, with year 2010 reporting the strongest association. The systematic review of 37 studies highlighted VAPP occurrence within 2â€‰months to 4â€‰years post-vaccination, typically with acute flaccid paralysis. Immunodeficiency and perianal abscess emerged as major risk factors. Out of the 37 included studies, 27 showed consistent causal association of VAPP with OPV using WHO-AEFI causality assessment tool.\n\n**Conclusion:** The study emphasized the seriousness of VAPP and highlights its association with OPV, identifying immunodeficiency as a prominent contributor to VAPP manifestation.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç–«è‹—ç›¸å…³éº»ç—¹æ€§è„Šé«“ç°è´¨ç‚ (VAPP) æ˜¯å£æœè„Šé«“ç°è´¨ç‚ç—…æ¯’ç–«è‹— (OPV) çš„ä¸€ç§ç½•è§ä¸è‰¯äº‹ä»¶ï¼Œå°¤å…¶å½±å“å…ç–«ç¼ºé™·ä¸ªä½“ã€‚\n\n**Research design and methodsï¼š** æœ¬ç ”ç©¶æ—¨åœ¨ (1) ä½¿ç”¨ç–«è‹—ä¸è‰¯äº‹ä»¶æŠ¥å‘Šç³»ç»Ÿ (VAERS) æ•°æ®åº“è¯„ä¼° OPV å’Œ VAPP ä¹‹é—´çš„å…³è” (2) é€šè¿‡å¯¹ç—…ä¾‹æŠ¥å‘Šå’Œç—…ä¾‹ç³»åˆ—è¿›è¡Œç³»ç»Ÿå›é¡¾ï¼Œæ¦‚è¿°ä¸ OPV æ¥å—è€…å‘ç”Ÿ VAPP ç›¸å…³çš„æ‚£è€…ç‰¹å¾å’Œå±é™©å› ç´ ã€‚ä½¿ç”¨ VAERS çš„æ•°æ®è¿›è¡Œäº†ä¸æˆæ¯”ä¾‹åˆ†æï¼Œæ¶µç›– 1990 å¹´è‡³ 2023 å¹´ 2 æœˆæŠ¥å‘Šçš„ä¸è‰¯äº‹ä»¶ã€‚æ­¤å¤–ï¼Œæˆ‘ä»¬ä½¿ç”¨ PubMedã€Scopus å’Œ Embase æ•°æ®åº“å¯¹ç—…ä¾‹æŠ¥å‘Šå’Œç—…ä¾‹ç³»åˆ—è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ã€‚\n\n**ç»“æœï¼š** VAERS æ•°æ®æ˜¾ç¤ºï¼Œ1,739,903 èµ· OPV ç›¸å…³ä¸è‰¯äº‹ä»¶ä¸­æœ‰ 130 ä»½ VAPP æŠ¥å‘Šï¼Œå…¶ä¸­ 2010 å¹´æŠ¥å‘Šçš„å…³è”æ€§æœ€å¼ºã€‚å¯¹ 37 é¡¹ç ”ç©¶çš„ç³»ç»Ÿå›é¡¾å¼ºè°ƒäº† VAPP åœ¨ç–«è‹—æ¥ç§å 2 ä¸ªæœˆè‡³ 4 å¹´å†…å‘ç”Ÿï¼Œé€šå¸¸ä¼´æœ‰æ€¥æ€§å¼›ç¼“æ€§éº»ç—¹ã€‚å…ç–«ç¼ºé™·å’Œè‚›å‘¨è„“è‚¿æˆä¸ºä¸»è¦å±é™©å› ç´ ã€‚åœ¨çº³å…¥çš„ 37 é¡¹ç ”ç©¶ä¸­ï¼Œ27 é¡¹ä½¿ç”¨ WHO-AEFI å› æœå…³ç³»è¯„ä¼°å·¥å…·æ˜¾ç¤º VAPP ä¸ OPV ä¹‹é—´å­˜åœ¨ä¸€è‡´çš„å› æœå…³ç³»ã€‚\n\n**ç»“è®ºï¼š** è¯¥ç ”ç©¶å¼ºè°ƒäº† VAPP çš„ä¸¥é‡æ€§ï¼Œå¹¶å¼ºè°ƒäº†å®ƒä¸ OPV çš„å…³è”ï¼Œç¡®å®šå…ç–«ç¼ºé™·æ˜¯ VAPP è¡¨ç°çš„ä¸€ä¸ªé‡è¦å› ç´ ã€‚", "keywords_zh": "ç—…ä¾‹æŠ¥å‘Šã€OPVã€VAPPã€å› æœå…³ç³»ã€å…ç–«ç¼ºé™·ã€è„Šé«“ç°è´¨ç‚", "keywords_en": "Case report, OPV, VAPP, causality, immunodeficiency, polio", "link": "https://pubmed.ncbi.nlm.nih.gov/38813942/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 30 May 2024"}, {"id": "38563064", "title_en": "A systematic review and meta-analysis of the use of packing in the management of perianal abscesses", "title_zh": "è‚›å‘¨è„“è‚¿æ²»ç–—ä¸­å¡«å¡ä½¿ç”¨çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Ome Padfield", "abstract_en": "**Background:** Perianal abscesses are common presentations and reasons for emergency general surgery admissions. Management involves incision and drainage of the abscess and packing the cavity with internal wound dressings. This meta-analysis aimed to assess in adults if packing an abscess or leaving it unpacked leads to a significant difference in the outcomes of pain on wound dressing, time to healing, rate of fistulation and abscess recurrence.\n\n**Methods:** Randomised controlled trials (RCTs) with participants aged 18 years or older that compared packing of perianal abscess cavities with no packing between 2002 and 2022 were searched for in December 2022 on OVID Medline and Embase, the CENTRAL register of trials, PubMed and Google Scholar. Risk of bias was assessed using the Cochrane Risk of Bias tool. Random effects meta-analysis was conducted on the data extracted.\n\n**Results:** Three RCTs involving 490 patients were analysed for the outcomes of abscess recurrence and postoperative fistula formation; the data were not adequate to assess pain on dressing and time to healing. For unpacked versus packed, the pooled relative risk of abscess recurrence was 1.57 (95% confidence interval (CI) 0.764, 3.29, <i>p</i>=0.219) and for fistula formation 0.686 (95% CI 0.430, 1.09, <i>p</i>=0.114). These results suggest there is no significant benefit to packing abscess cavities.\n\n**Conclusions:** Analysis of the outcomes suggests there is no significant difference with regards to rates of abscess recurrence or fistula formation between the packed and unpacked groups; however, appropriately powered RCTs are required in this area to provide more primary evidence to inform best practice and clinical management.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨è„“è‚¿æ˜¯æ€¥è¯Šæ™®é€šå¤–ç§‘æ‰‹æœ¯çš„å¸¸è§è¡¨ç°å’ŒåŸå› ã€‚æ²»ç–—åŒ…æ‹¬åˆ‡å¼€è„“è‚¿å¹¶å¼•æµï¼Œå¹¶ç”¨å†…éƒ¨ä¼¤å£æ•·æ–™å¡«å¡ç©ºè…”ã€‚è¿™é¡¹èŸèƒåˆ†ææ—¨åœ¨è¯„ä¼°æˆäººåŒ…æ‰è„“è‚¿æˆ–ä¸åŒ…æ‰è„“è‚¿æ˜¯å¦ä¼šå¯¼è‡´ä¼¤å£æ•·æ–™ç–¼ç—›ã€æ„ˆåˆæ—¶é—´ã€ç˜˜ç®¡å‘ç”Ÿç‡å’Œè„“è‚¿å¤å‘çš„æ˜¾ç€å·®å¼‚ã€‚\n\n**æ–¹æ³•ï¼š** 2022 å¹´ 12 æœˆï¼Œåœ¨ OVID Medline å’Œ Embaseã€ä¸­å¤®è¯•éªŒæ³¨å†Œåº“ã€PubMed å’Œ Google Scholar ä¸Šæ£€ç´¢äº† 18 å²æˆ–ä»¥ä¸Šå‚ä¸è€…çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ï¼Œè¿™äº›è¯•éªŒæ¯”è¾ƒäº† 2002 å¹´è‡³ 2022 å¹´æœŸé—´è‚›å‘¨è„“è‚¿è…”å¡«å¡ä¸ä¸å¡«å¡çš„æƒ…å†µã€‚ä½¿ç”¨ Cochrane åå€šé£é™©å·¥å…·è¯„ä¼°åå€šé£é™©ã€‚å¯¹æå–çš„æ•°æ®è¿›è¡Œéšæœºæ•ˆåº”èŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** å¯¹æ¶‰åŠ 490 åæ‚£è€…çš„ä¸‰é¡¹éšæœºå¯¹ç…§è¯•éªŒåˆ†æäº†è„“è‚¿å¤å‘å’Œæœ¯åç˜˜ç®¡å½¢æˆçš„ç»“æœï¼›è¿™äº›æ•°æ®ä¸è¶³ä»¥è¯„ä¼°æ•·æ–™æ—¶çš„ç–¼ç—›å’Œæ„ˆåˆæ—¶é—´ã€‚å¯¹äºæœªå¡«å¡ä¸å¡«å¡çš„æƒ…å†µï¼Œè„“è‚¿å¤å‘çš„æ±‡æ€»ç›¸å¯¹é£é™©ä¸º 1.57ï¼ˆ95% ç½®ä¿¡åŒºé—´ (CI) 0.764, 3.29, <i>p</i>=0.219ï¼‰ï¼Œç˜˜ç®¡å½¢æˆçš„æ±‡æ€»ç›¸å¯¹é£é™©ä¸º 0.686ï¼ˆ95% CI 0.430, 1.09ï¼Œ<i>p</i>=0.114ï¼‰ã€‚è¿™äº›ç»“æœè¡¨æ˜ï¼Œå¡«å¡è„“è‚¿ç©ºè…”æ²¡æœ‰æ˜¾ç€çš„å¥½å¤„ã€‚\n\n**ç»“è®ºï¼š** ç»“æœåˆ†æè¡¨æ˜ï¼Œå¡«å¡ç»„å’Œæœªå¡«å¡ç»„ä¹‹é—´è„“è‚¿å¤å‘æˆ–ç˜˜ç®¡å½¢æˆç‡æ²¡æœ‰æ˜¾ç€å·®å¼‚ï¼›ç„¶è€Œï¼Œè¯¥é¢†åŸŸéœ€è¦é€‚å½“çš„éšæœºå¯¹ç…§è¯•éªŒæ¥æä¾›æ›´å¤šä¸»è¦è¯æ®ï¼Œä¸ºæœ€ä½³å®è·µå’Œä¸´åºŠç®¡ç†æä¾›ä¿¡æ¯ã€‚", "keywords_zh": "è„“è‚¿å¡«å¡ã€è‚›å‘¨è„“è‚¿ã€å¤å‘", "keywords_en": "Abscess packing, Perianal abscesses, Recurrence", "link": "https://pubmed.ncbi.nlm.nih.gov/38563064/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Tue, 02 Apr 2024"}, {"id": "38428446", "title_en": "Aluminum potassium sulfate and tannic acid (ALTA) sclerotherapy for hemorrhoidal disease: a systematic review and meta-analysis", "title_zh": "ç¡«é…¸é“é’¾å’Œå•å®é…¸ï¼ˆALTAï¼‰ç¡¬åŒ–ç–—æ³•æ²»ç–—ç—”ç–®ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Kiriakos Ktenidis", "abstract_en": "**Background:** We conducted a systematic review to assess the safety and efficacy of Aluminum potassium sulfate and tannic acid (ALTA) sclerotherapy for the treatment of hemorrhoidal disease.\n\n**Methods:** Our study was conducted in accordance with the PRISMA statement (Preferred Reporting Items for Systematic Reviews and Meta-analyses) 2020. Primary endpoints included overall recurrence and type of recurrence while secondary endpoints included postoperative complications, reintervention, presence of rectal ulcer, rectal stricture, defecation abnormalities and perianal abscess. Î‘ regression analysis, where the percentage of patients with grade II, III and IV hemorrhoidal disease was used as a covariate, was also performed.\n\n**Results:** Twelve studies with 4249 patients met all the inclusion criteria and were eventually included. The crude and pooled estimates of the overall recurrence and complications by the end of follow-up were 10% (95% CI, 6.52%-14.08%) and 5.20% (95% CI, 2.59%-8.52%), respectively. Regression analysis displayed no correlation between recurrence and the grade of hemorrhoid disease II, Î²= -0.0012 (95% CI, -0.0074 to 0.0049) (<i>p</i>â€‰=â€‰.64), grade III Î²= -0.0006 (95% CI, -0.0056 to 0.0045) (<i>p</i>â€‰=â€‰.79) and grade IV Î²â€‰=â€‰0.0025 (95% CI, -0.0075 to 0.0124). However, a trend suggestive of increased recurrence was observed in patient populations with a higher proportion of grade IV disease.\n\n**Conclusion:** ALTA sclerotherapy may be a safe and viable alternative for patients with hemorrhoidal disease. Long-term follow-up and high-quality randomized controlled trials will help define the place of ALTA sclerotherapy in the armamentarium of treatment of hemorrhoids.", "abstract_zh": "**èƒŒæ™¯ï¼š** æˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼Œä»¥è¯„ä¼°ç¡«é…¸é“é’¾å’Œå•å®é…¸ (ALTA) ç¡¬åŒ–ç–—æ³•æ²»ç–—ç—”ç–®ç–¾ç—…çš„å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬çš„ç ”ç©¶æ˜¯æ ¹æ® 2020 å¹´ PRISMA å£°æ˜ï¼ˆç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ï¼‰è¿›è¡Œçš„ã€‚ä¸»è¦ç»ˆç‚¹åŒ…æ‹¬æ€»ä½“å¤å‘å’Œå¤å‘ç±»å‹ï¼Œæ¬¡è¦ç»ˆç‚¹åŒ…æ‹¬æœ¯åå¹¶å‘ç—‡ã€å†æ¬¡å¹²é¢„ã€æ˜¯å¦å­˜åœ¨ç›´è‚ æºƒç–¡ã€ç›´è‚ ç‹­çª„ã€æ’ä¾¿å¼‚å¸¸å’Œè‚›å‘¨è„“è‚¿ã€‚è¿˜è¿›è¡Œäº†Î±å›å½’åˆ†æï¼Œå…¶ä¸­æ‚£æœ‰IIçº§ã€IIIçº§å’ŒIVçº§ç—”ç–®ç–¾ç—…çš„æ‚£è€…çš„ç™¾åˆ†æ¯”è¢«ç”¨ä½œåå˜é‡ã€‚\n\n**ç»“æœï¼š** æ¶‰åŠ 4249 åæ‚£è€…çš„ 12 é¡¹ç ”ç©¶ç¬¦åˆæ‰€æœ‰çº³å…¥æ ‡å‡†å¹¶æœ€ç»ˆè¢«çº³å…¥ã€‚éšè®¿ç»“æŸæ—¶æ€»ä½“å¤å‘å’Œå¹¶å‘ç—‡çš„ç²—ç•¥ä¼°è®¡å’Œæ±‡æ€»ä¼°è®¡åˆ†åˆ«ä¸º 10% (95% CI, 6.52%-14.08%) å’Œ 5.20% (95% CI, 2.59%-8.52%)ã€‚å›å½’åˆ†ææ˜¾ç¤ºå¤å‘ç‡ä¸ç—”ç–®ç–¾ç—…åˆ†çº§ä¹‹é—´æ— ç›¸å…³æ€§ï¼ŒII çº§ï¼ŒÎ²= -0.0012ï¼ˆ95% CIï¼Œ-0.0074 è‡³ 0.0049ï¼‰ï¼ˆ<i>p</i>â€‰=â€‰.64ï¼‰ï¼ŒIII çº§ Î²= -0.0006ï¼ˆ95% CIï¼Œ-0.0056 è‡³ 0.0045ï¼‰ (<i>p</i>â€‰=â€‰.79) å’Œ IV çº§ Î²â€‰=â€‰0.0025 (95% CIï¼Œ-0.0075 è‡³ 0.0124)ã€‚ç„¶è€Œï¼Œåœ¨ IV çº§ç–¾ç—…æ¯”ä¾‹è¾ƒé«˜çš„æ‚£è€…ç¾¤ä½“ä¸­è§‚å¯Ÿåˆ°äº†å¤å‘ç‡å¢åŠ çš„è¶‹åŠ¿ã€‚\n\n**ç»“è®ºï¼š** å¯¹äºç—”ç–®æ‚£è€…æ¥è¯´ï¼ŒALTA ç¡¬åŒ–ç–—æ³•å¯èƒ½æ˜¯ä¸€ç§å®‰å…¨å¯è¡Œçš„æ›¿ä»£æ–¹æ¡ˆã€‚é•¿æœŸéšè®¿å’Œé«˜è´¨é‡éšæœºå¯¹ç…§è¯•éªŒå°†æœ‰åŠ©äºç¡®å®š ALTA ç¡¬åŒ–ç–—æ³•åœ¨ç—”ç–®æ²»ç–—è®¾å¤‡ä¸­çš„åœ°ä½ã€‚", "keywords_zh": "ALTAï¼Œç¡«é…¸é“é’¾ï¼Œç—”ç–®ç–¾ç—…ï¼Œç—”ç–®ï¼Œç¡¬åŒ–ç–—æ³•", "keywords_en": "ALTA, aluminum potassium sulfate, hemorrhoidal disease, hemorrhoids, sclerotherapy", "link": "https://pubmed.ncbi.nlm.nih.gov/38428446/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Fri, 01 Mar 2024"}, {"id": "38223244", "title_en": "Effectiveness and safety of darvadstrocel in patients with complex perianal fistulizing Crohn's disease: a systematic review", "title_zh": "darvadstrocel å¯¹å¤æ‚è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…æ‚£è€…çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Konstantinos H Katsanos", "abstract_en": "**Background:** Managing complex perianal fistulizing Crohn's disease (CD) remains challenging, despite current medical and surgical treatment approaches. Darvadstrocel, a therapy utilizing adipose-derived stem cells, shows promise in promoting tissue regeneration and healing, offering a novel and effective treatment for fistula management.\n\n**Method:** A systematic literature search was conducted on PubMed and Scopus to identify studies involving patients with complex perianal fistulizing CD treated with darvadstrocel.\n\n**Results:** In total, 2 randomized controlled trials (RCT), 5 observational studies with retrospective data collection and 2 observational studies with prospective design were included in the final review. Data from the European ADMIRE-CD RCT demonstrated that darvadstrocel is superior to placebo in terms of clinical and imaging improvement over both the short and long term. These findings align with the prospective studies analyzed in this systematic review. The rate of treatment-emergent adverse events in the ADMIRE-CD trial's RCTs was similar in both the darvadstrocel and control groups, with perianal abscess being the most common adverse event up to 52 weeks after drug administration. Retrospective studies indicated no side-effects beyond 52 weeks.\n\n**Conclusions:** Darvadstrocel appears to be a new, potentially effective and safe treatment option for the management of complex perianal fistulas. However, more randomized clinical trials are needed to evaluate the efficacy and safety profile of the drug.", "abstract_zh": "**èƒŒæ™¯ï¼š** å°½ç®¡ç›®å‰æœ‰è¯ç‰©å’Œæ‰‹æœ¯æ²»ç–—æ–¹æ³•ï¼Œä½†æ²»ç–—å¤æ‚çš„è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—… (CD) ä»ç„¶å…·æœ‰æŒ‘æˆ˜æ€§ã€‚ Darvadstrocel æ˜¯ä¸€ç§åˆ©ç”¨è„‚è‚ªå¹²ç»†èƒçš„ç–—æ³•ï¼Œåœ¨ä¿ƒè¿›ç»„ç»‡å†ç”Ÿå’Œæ„ˆåˆæ–¹é¢æ˜¾ç¤ºå‡ºå‰æ™¯ï¼Œä¸ºç˜˜ç®¡æ²»ç–—æä¾›äº†ä¸€ç§æ–°é¢–æœ‰æ•ˆçš„æ²»ç–—æ–¹æ³•ã€‚\n\n**Methodï¼š** åœ¨ PubMed å’Œ Scopus ä¸Šè¿›è¡Œäº†ç³»ç»Ÿçš„æ–‡çŒ®æ£€ç´¢ï¼Œä»¥ç¡®å®šæ¶‰åŠæ¥å— darvadstrocel æ²»ç–—çš„å¤æ‚è‚›å‘¨ç˜˜ç®¡æ€§ CD æ‚£è€…çš„ç ”ç©¶ã€‚\n\n**ç»“æœï¼š** æœ€ç»ˆè¯„ä»·æ€»å…±çº³å…¥äº† 2 é¡¹éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€5 é¡¹å›é¡¾æ€§æ•°æ®æ”¶é›†è§‚å¯Ÿæ€§ç ”ç©¶å’Œ 2 é¡¹å‰ç»æ€§è®¾è®¡è§‚å¯Ÿæ€§ç ”ç©¶ã€‚æ¥è‡ªæ¬§æ´² ADMIRE-CD RCT çš„æ•°æ®è¡¨æ˜ï¼Œdarvadstrocel åœ¨çŸ­æœŸå’Œé•¿æœŸçš„ä¸´åºŠå’Œå½±åƒå­¦æ”¹å–„æ–¹é¢å‡ä¼˜äºå®‰æ…°å‰‚ã€‚è¿™äº›å‘ç°ä¸æœ¬ç³»ç»Ÿç»¼è¿°ä¸­åˆ†æçš„å‰ç»æ€§ç ”ç©¶ä¸€è‡´ã€‚åœ¨ ADMIRE-CD è¯•éªŒçš„éšæœºå¯¹ç…§è¯•éªŒä¸­ï¼Œdarvadstrocel ç»„å’Œå¯¹ç…§ç»„ä¸­æ²»ç–—å¼•èµ·çš„ä¸è‰¯äº‹ä»¶å‘ç”Ÿç‡ç›¸ä¼¼ï¼Œå…¶ä¸­è‚›å‘¨è„“è‚¿æ˜¯ç»™è¯å 52 å‘¨å†…æœ€å¸¸è§çš„ä¸è‰¯äº‹ä»¶ã€‚å›é¡¾æ€§ç ”ç©¶è¡¨æ˜è¶…è¿‡ 52 å‘¨æ²¡æœ‰å‰¯ä½œç”¨ã€‚\n\n**ç»“è®ºï¼š** Darvadstrocel ä¼¼ä¹æ˜¯æ²»ç–—å¤æ‚è‚›å‘¨ç˜˜çš„ä¸€ç§æ–°çš„ã€æ½œåœ¨æœ‰æ•ˆä¸”å®‰å…¨çš„æ²»ç–—é€‰æ‹©ã€‚ç„¶è€Œï¼Œéœ€è¦æ›´å¤šçš„éšæœºä¸´åºŠè¯•éªŒæ¥è¯„ä¼°è¯¥è¯ç‰©çš„åŠŸæ•ˆå’Œå®‰å…¨æ€§ã€‚", "keywords_zh": "ç˜˜ç®¡æ€§å…‹ç½—æ©ç—…ã€è„‚è‚ªå¹²ç»†èƒã€darvadstrocelã€æ²»ç–—", "keywords_en": "Fistulizing Crohnâ€™s disease, adipose-derived stem-cells, darvadstrocel, treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/38223244/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Mon, 15 Jan 2024"}, {"id": "37545826", "title_en": "Hidradenitis suppurativa and squamous cell carcinoma: a systematic review of the literature", "title_zh": "åŒ–è„“æ€§æ±—è…ºç‚å’Œé³çŠ¶ç»†èƒç™Œï¼šæ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾", "authors": "Beata Bergler-Czop", "abstract_en": "Hidradenitis suppurativa (HS) is a chronic disease which is often recurrent and occurs as abscesses of the apocrine gland. The most common locations of HS are gluteal/perianal, axillary or inguinal. It is reasonable to assume that squamous cell carcinoma may arise from HS. As researchers in the field of dermatology, HS surgery and conventional surgical oncology, we studied whether there is any correlation between HS and neoplasms. Evidence shows a correlation between HS and squamous cell carcinoma. The aim of the study was to find literature about HS and SCC and analyse potential risk factors. This is a systemic review concerning squamous cell carcinoma and hidradenitis suppurativa.", "abstract_zh": "åŒ–è„“æ€§æ±—è…ºç‚ï¼ˆHSï¼‰æ˜¯ä¸€ç§æ…¢æ€§ç–¾ç—…ï¼Œç»å¸¸å¤å‘ï¼Œå¹¶ä»¥é¡¶æµ†è…ºè„“è‚¿çš„å½¢å¼å‡ºç°ã€‚ HS æœ€å¸¸è§çš„ä½ç½®æ˜¯è‡€è‚Œ/è‚›å‘¨ã€è…‹çªæˆ–è…¹è‚¡æ²Ÿã€‚é³çŠ¶ç»†èƒç™Œå¯èƒ½ç”± HS å¼•èµ·çš„å‡è®¾æ˜¯åˆç†çš„ã€‚ä½œä¸ºçš®è‚¤ç§‘ã€çƒ­å°„ç—…å¤–ç§‘å’Œä¼ ç»Ÿè‚¿ç˜¤å¤–ç§‘é¢†åŸŸçš„ç ”ç©¶äººå‘˜ï¼Œæˆ‘ä»¬ç ”ç©¶äº†çƒ­å°„ç—…å’Œè‚¿ç˜¤ä¹‹é—´æ˜¯å¦å­˜åœ¨ç›¸å…³æ€§ã€‚æœ‰è¯æ®è¡¨æ˜ HS ä¸é³çŠ¶ç»†èƒç™Œä¹‹é—´å­˜åœ¨ç›¸å…³æ€§ã€‚è¯¥ç ”ç©¶çš„ç›®çš„æ˜¯æŸ¥æ‰¾æœ‰å…³ HS å’Œ SCC çš„æ–‡çŒ®å¹¶åˆ†ææ½œåœ¨çš„å±é™©å› ç´ ã€‚è¿™æ˜¯å…³äºé³çŠ¶ç»†èƒç™Œå’ŒåŒ–è„“æ€§æ±—è…ºç‚çš„ç³»ç»Ÿç»¼è¿°ã€‚", "keywords_zh": "åŒ–è„“æ€§æ±—è…ºç‚ï¼Œé³çŠ¶ç»†èƒç™Œï¼Œæ‰‹æœ¯æ²»ç–—", "keywords_en": "hidradenitis suppurativa, squamous cell carcinoma, surgical treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/37545826/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Mon, 07 Aug 2023"}, {"id": "37023788", "title_en": "A Systematic Review and Meta-Analysis of Comparing Drainage Alone versus Drainage with Primary Fistula Treatment for the Perianal Abscess in Children", "title_zh": "å•ç‹¬å¼•æµä¸å¼•æµè”åˆç˜˜ç®¡æ²»ç–—å„¿ç«¥è‚›å‘¨è„“è‚¿çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Chen Wang", "abstract_en": "This systematic review and meta-analysis of nonrandomized studies (NRSs) aimed to evaluate the clinical efficacy and safety of two types of surgical interventions (respectively drainage alone and drainage with primary fistula treatment) for perianal abscesses (PAs) in children. Studies from 1992 to July 2022 were searched in 10 electronic databases. All relevant NRSs with available data which compared surgical drainage with or without primary fistula treatment were included. Patients with underlying diseases which led to abscess formation were excluded. The Newcastle-Ottawa Scale was used to assess the risk of bias and quality of the included studies. The outcomes were the healing rate, fistula formation rate, fecal incontinence, and wound healing duration. A total of 16 articles with 1,262 patients were considered suitable for the final meta-analysis. Primary fistula treatment was associated with a significantly higher healing rate when compared with incision and drainage alone (odds ratio [OR]: 5.76, 95% confidence interval [CI]: 4.04-8.22). This aggressive procedure for PA resulted in an 86% reduction in the fistula formation rate (OR: 0.14, 95% CI: 0.06-0.32). Limited data showed patients who underwent primary fistula treatment have a minor effect on postoperative fecal incontinence. Primary fistula treatment demonstrates a better clinical efficacy in promoting the healing rate and decreasing the formation of fistulas in PAs in children. The available evidence for a minor impact on anal function after this intervention is less strong.", "abstract_zh": "è¿™é¡¹ééšæœºç ”ç©¶ï¼ˆNRSï¼‰çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ—¨åœ¨è¯„ä¼°ä¸¤ç§ç±»å‹çš„æ‰‹æœ¯å¹²é¢„ï¼ˆåˆ†åˆ«å•ç‹¬å¼•æµå’Œå¼•æµè”åˆåˆæ¬¡ç˜˜ç®¡æ²»ç–—ï¼‰æ²»ç–—å„¿ç«¥è‚›å‘¨è„“è‚¿ï¼ˆPAï¼‰çš„ä¸´åºŠç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚åœ¨ 10 ä¸ªç”µå­æ•°æ®åº“ä¸­æ£€ç´¢äº† 1992 å¹´è‡³ 2022 å¹´ 7 æœˆçš„ç ”ç©¶ã€‚åŒ…æ‹¬æ‰€æœ‰å…·æœ‰å¯ç”¨æ•°æ®çš„ç›¸å…³ NRSï¼Œè¿™äº› NRS æ¯”è¾ƒäº†æ‰‹æœ¯å¼•æµä¸æˆ–ä¸è¿›è¡Œåˆæ¬¡ç˜˜ç®¡æ²»ç–—çš„æƒ…å†µã€‚æ’é™¤æ‚£æœ‰å¯¼è‡´è„“è‚¿å½¢æˆçš„åŸºç¡€ç–¾ç—…çš„æ‚£è€…ã€‚çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨ç”¨äºè¯„ä¼°çº³å…¥ç ”ç©¶çš„åå€šé£é™©å’Œè´¨é‡ã€‚ç»“æœæ˜¯æ„ˆåˆç‡ã€ç˜˜ç®¡å½¢æˆç‡ã€å¤§ä¾¿å¤±ç¦å’Œä¼¤å£æ„ˆåˆæŒç»­æ—¶é—´ã€‚å…±æœ‰ 16 ç¯‡æ–‡ç« ã€1,262 åæ‚£è€…è¢«è®¤ä¸ºé€‚åˆæœ€ç»ˆçš„èŸèƒåˆ†æã€‚ä¸å•ç‹¬åˆ‡å¼€å¼•æµç›¸æ¯”ï¼ŒåŸå‘æ€§ç˜˜ç®¡æ²»ç–—å…·æœ‰æ˜¾ç€æ›´é«˜çš„æ²»æ„ˆç‡ï¼ˆæ¯”å€¼æ¯” [OR]ï¼š5.76ï¼Œ95% ç½®ä¿¡åŒºé—´ [CI]ï¼š4.04-8.22ï¼‰ã€‚è¿™ç§ç§¯æçš„ PA æ‰‹æœ¯ä½¿ç˜˜ç®¡å½¢æˆç‡é™ä½äº† 86%ï¼ˆORï¼š0.14ï¼Œ95% CIï¼š0.06-0.32ï¼‰ã€‚æœ‰é™çš„æ•°æ®æ˜¾ç¤ºï¼Œæ¥å—åŸå‘æ€§ç˜˜ç®¡æ²»ç–—çš„æ‚£è€…å¯¹æœ¯åå¤§ä¾¿å¤±ç¦çš„å½±å“è¾ƒå°ã€‚åŸå‘æ€§ç˜˜ç®¡æ²»ç–—åœ¨ä¿ƒè¿›å„¿ç«¥PAsçš„æ„ˆåˆç‡å’Œå‡å°‘ç˜˜ç®¡å½¢æˆæ–¹é¢æ˜¾ç¤ºå‡ºæ›´å¥½çš„ä¸´åºŠç–—æ•ˆã€‚ç°æœ‰è¯æ®è¡¨æ˜è¿™ç§å¹²é¢„åå¯¹è‚›é—¨åŠŸèƒ½æœ‰è½»å¾®å½±å“ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/37023788/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 06 Apr 2023"}, {"id": "36894443", "title_en": "The Optimal Primary Treatment for Pediatric Perianal Abscess and Anal Fistula: A Systemic Review and Meta-Analysis", "title_zh": "å°å„¿è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜çš„æœ€ä½³åˆæ­¥æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Hou-Chuan Chen", "abstract_en": "**Background:** Perianal abscesses and anal fistulas are common. The principle of intention-to-treat has not been considered in previous systemic reviews. Thus, the comparison between primary and post-recurrence management was confused, and the recommendation of primary treatment is obscure. The current study aims to identify the optimal initial treatment for pediatric patients.\n\n**Methods:** Using PRISMA guidelines, studies were identified from MEDLINE, EMBASE, PubMed, Cochrane Library, and Google Scholar without any language or study design restriction. The inclusion criteria include original articles or articles with original data, studies of management for a perianal abscess with or without anal fistula, and patient age of <18 years. Patients with local malignancy, Crohn's disease, or other underlying predisposing conditions were excluded. Studies without analyzing recurrence, case series of <5, and irrelevant articles were excluded in the screening stage. Of the 124 screened articles, 14 articles had no full texts or detailed information. Articles written in a language other than English or Mandarin were translated by Google Translation first and confirmed with native speakers. After the eligibility process, studies that compared identified primary managements were then included in the qualitative synthesis.\n\n**Results:** Thirty-one studies involving 2507 pediatric patients met the inclusion criteria. The study design consisted of two prospective case series of 47 patients and retrospective cohort studies. No randomized control trials were identified. Meta-analyses for recurrence after initial management were performed with a random-effects model. Conservative treatment and drainage revealed no difference (Odds ratio [OR], 1.222; 95% Confidential interval [CI]: 0.615-2.427, pÂ =Â 0.567). Conservative management had a higher risk of recurrence than surgery without statistical significance (OR 0.278, 95% CI: 0.109-0.707, pÂ =Â 0.007). Compared with incision/drainage, surgery can prevent recurrence remarkably (OR 4.360, 95% CI: 1.761-10.792, pÂ =Â 0.001). Subgroup analysis of different approaches within conservative treatment and operation was not performed for lacking information.\n\n**Conclusion:** Strong recommendations cannot be made due to the lack of prospective or randomized controlled studies. However, the current study based on real primary management supports initial surgical intervention for pediatric patients with perianal abscesses and anal fistula to prevent recurrence.\n\n**Level Of Evidence:** Type of study: Systemic review; Evidence level: Level II.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜å¾ˆå¸¸è§ã€‚ä»¥å¾€çš„ç³»ç»Ÿè¯„ä»·å¹¶æœªè€ƒè™‘æ„å‘æ²»ç–—åŸåˆ™ã€‚å› æ­¤ï¼Œåˆçº§æ²»ç–—å’Œå¤å‘åæ²»ç–—ä¹‹é—´çš„æ¯”è¾ƒæ˜¯æ··ä¹±çš„ï¼Œåˆçº§æ²»ç–—çš„å»ºè®®ä¹Ÿå«ç³Šä¸æ¸…ã€‚ç›®å‰çš„ç ”ç©¶æ—¨åœ¨ç¡®å®šå„¿ç§‘æ‚£è€…çš„æœ€ä½³åˆå§‹æ²»ç–—ã€‚\n\n**æ–¹æ³•ï¼š** ä½¿ç”¨ PRISMA æŒ‡å—ï¼Œä» MEDLINEã€EMBASEã€PubMedã€Cochrane å›¾ä¹¦é¦†å’Œ Google Scholar ä¸­è¯†åˆ«ç ”ç©¶ï¼Œæ²¡æœ‰ä»»ä½•è¯­è¨€æˆ–ç ”ç©¶è®¾è®¡é™åˆ¶ã€‚çº³å…¥æ ‡å‡†åŒ…æ‹¬åŸåˆ›æ–‡ç« æˆ–å¸¦æœ‰åŸå§‹æ•°æ®çš„æ–‡ç« ã€ä¼´æˆ–ä¸ä¼´è‚›ç˜˜çš„è‚›å‘¨è„“è‚¿çš„æ²»ç–—ç ”ç©¶ä»¥åŠæ‚£è€…å¹´é¾„<18å²ã€‚æ‚£æœ‰å±€éƒ¨æ¶æ€§è‚¿ç˜¤ã€å…‹ç½—æ©ç—…æˆ–å…¶ä»–æ½œåœ¨è¯±å‘å› ç´ çš„æ‚£è€…è¢«æ’é™¤åœ¨å¤–ã€‚æœªåˆ†æå¤å‘çš„ç ”ç©¶ã€ç—…ä¾‹ç³»åˆ—<5å’Œä¸ç›¸å…³çš„æ–‡ç« åœ¨ç­›é€‰é˜¶æ®µè¢«æ’é™¤ã€‚åœ¨ç­›é€‰çš„ 124 ç¯‡æ–‡ç« ä¸­ï¼Œæœ‰ 14 ç¯‡æ–‡ç« æ²¡æœ‰å…¨æ–‡æˆ–è¯¦ç»†ä¿¡æ¯ã€‚ç”¨è‹±è¯­æˆ–æ™®é€šè¯ä»¥å¤–çš„è¯­è¨€æ’°å†™çš„æ–‡ç« é¦–å…ˆé€šè¿‡è°·æ­Œç¿»è¯‘è¿›è¡Œç¿»è¯‘ï¼Œå¹¶ä¸æ¯è¯­äººå£«ç¡®è®¤ã€‚èµ„æ ¼å®¡æŸ¥ç»“æŸåï¼Œå¯¹å·²ç¡®å®šçš„ä¸»è¦ç®¡ç†æªæ–½è¿›è¡Œæ¯”è¾ƒçš„ç ”ç©¶éšåè¢«çº³å…¥å®šæ€§ç»¼åˆã€‚\n\n**ç»“æœï¼š** æ¶‰åŠ 2507 åå„¿ç§‘æ‚£è€…çš„ 31 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚ç ”ç©¶è®¾è®¡åŒ…æ‹¬ä¸¤ä¸ªåŒ…å« 47 åæ‚£è€…çš„å‰ç»æ€§ç—…ä¾‹ç³»åˆ—å’Œå›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ã€‚æ²¡æœ‰å‘ç°éšæœºå¯¹ç…§è¯•éªŒã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹å¯¹åˆå§‹æ²»ç–—åçš„å¤å‘è¿›è¡ŒèŸèƒåˆ†æã€‚ä¿å®ˆæ²»ç–—å’Œå¼•æµæ˜¾ç¤ºæ²¡æœ‰å·®å¼‚ï¼ˆä¼˜åŠ¿æ¯” [OR]ï¼Œ1.222ï¼›95% ç½®ä¿¡åŒºé—´ [CI]ï¼š0.615-2.427ï¼Œp = 0.567ï¼‰ã€‚ä¿å®ˆæ²»ç–—çš„å¤å‘é£é™©é«˜äºæ‰‹æœ¯ï¼Œä½†æ— ç»Ÿè®¡å­¦æ„ä¹‰ï¼ˆOR 0.278ï¼Œ95% CIï¼š0.109-0.707ï¼Œp = 0.007ï¼‰ã€‚ä¸åˆ‡å¼€/å¼•æµç›¸æ¯”ï¼Œæ‰‹æœ¯å¯ä»¥æ˜¾ç€é¢„é˜²å¤å‘ï¼ˆOR 4.360ï¼Œ95% CIï¼š1.761-10.792ï¼Œp = 0.001ï¼‰ã€‚ç”±äºç¼ºä¹ä¿¡æ¯ï¼Œæœªå¯¹ä¿å®ˆæ²»ç–—å’Œæ‰‹æœ¯ä¸­çš„ä¸åŒæ–¹æ³•è¿›è¡Œäºšç»„åˆ†æã€‚\n\n**ç»“è®ºï¼š** ç”±äºç¼ºä¹å‰ç»æ€§æˆ–éšæœºå¯¹ç…§ç ”ç©¶ï¼Œæ— æ³•æå‡ºå¼ºçƒˆå»ºè®®ã€‚ç„¶è€Œï¼Œç›®å‰åŸºäºçœŸå®åˆçº§ç®¡ç†çš„ç ”ç©¶æ”¯æŒå¯¹è‚›å‘¨è„“è‚¿å’Œè‚›ç˜˜çš„å„¿ç§‘æ‚£è€…è¿›è¡Œåˆæ­¥æ‰‹æœ¯å¹²é¢„ä»¥é¢„é˜²å¤å‘ã€‚\n\n**Level of evidenceï¼š** ç ”ç©¶ç±»å‹ï¼šç³»ç»Ÿè¯„ä»·ï¼›è¯æ®çº§åˆ«ï¼šIIçº§ã€‚", "keywords_zh": "è‚›ç˜˜ï¼Œå„¿ç§‘ï¼Œè‚›å‘¨è„“è‚¿ï¼Œåˆçº§æ²»ç–—", "keywords_en": "Anal fistula, Pediatric, Perianal abscess, Primary management", "link": "https://pubmed.ncbi.nlm.nih.gov/36894443/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 09 Mar 2023"}, {"id": "36794974", "title_en": "Mesenchymal Stem Cells Versus Placebo for Perianal Fistulizing Crohn's Disease: A Systemic Review and Meta-Analysis", "title_zh": "é—´å……è´¨å¹²ç»†èƒä¸å®‰æ…°å‰‚æ²»ç–—è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Minhao Yu", "abstract_en": "**Background:** Mesenchymal stem cells (MSCs)-based therapy for perianal fistulizing Crohn's disease (pfCD) has been extensively studies in the past decade. Its efficacy and safety had been preliminarily confirmed in some phase 2 or phase 3 clinical trials. This meta-analysis is performed to evaluate the efficacy and safety of MSCs-based therapy for pfCD.\n\n**Methods:** Electronic databases (Pubmed, Cochrane Library, Embase) were searched for studies that reported the efficacy and safety of MSCs. And RevMan were used to assess the efficacy and safety.\n\n**Results:** After screening, 5 randomized controlled trials (RCTs) were included in this meta-analysis. RevMan 5.4 for meta-analysis showed that: [Efficacy] Patients had definite remission after MSCs treatment, with an odds ratio (OR) of 2.06 (<i>P</i> < .0001, 95%CI 1.46, 2.89) vs controls. [Safety] The incidence of the most frequently reported TEAEs (treatment-emergent adverse events, TEAEs), perianal abscess and proctalgia, did not significantly increase due to the use of MSCs, with an OR of 1.07 in perianal abscess (<i>P</i> = .87, 95%CI 0.67, 1.72) vs controls, and an OR of 1.10 in proctalgia (<i>P</i> = .47, 95%CI 0.63, 1.92) vs controls.\n\n**Conclusions:** MSCs seem to be an effective and safe therapy for pfCD. MSCs based therapy has the potential to be used in combination with traditional therapies.", "abstract_zh": "**èƒŒæ™¯ï¼š** åœ¨è¿‡å»çš„åå¹´ä¸­ï¼ŒåŸºäºé—´å……è´¨å¹²ç»†èƒï¼ˆMSCï¼‰çš„è‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…ï¼ˆpfCDï¼‰ç–—æ³•å¾—åˆ°äº†å¹¿æ³›çš„ç ”ç©¶ã€‚å…¶æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§å·²åœ¨ä¸€äº›2æœŸæˆ–3æœŸä¸´åºŠè¯•éªŒä¸­å¾—åˆ°åˆæ­¥è¯å®ã€‚è¿›è¡Œè¿™é¡¹èŸèƒåˆ†ææ˜¯ä¸ºäº†è¯„ä¼°åŸºäº MSC çš„ pfCD ç–—æ³•çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** åœ¨ç”µå­æ•°æ®åº“ï¼ˆPubmedã€Cochrane Libraryã€Embaseï¼‰ä¸­æ£€ç´¢äº†æŠ¥å‘Š MSC åŠŸæ•ˆå’Œå®‰å…¨æ€§çš„ç ”ç©¶ã€‚å¹¶ç”¨RevManè¯„ä¼°ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\n**ç»“æœï¼š** ç­›é€‰åï¼Œ5 é¡¹éšæœºå¯¹ç…§è¯•éªŒ (RCT) çº³å…¥æœ¬èŸèƒåˆ†æã€‚ RevMan 5.4èŸèƒåˆ†ææ˜¾ç¤ºï¼šã€ç–—æ•ˆã€‘MSCsæ²»ç–—åæ‚£è€…è·å¾—æ˜ç¡®ç¼“è§£ï¼Œä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œä¼˜åŠ¿æ¯”ï¼ˆORï¼‰ä¸º2.06ï¼ˆ<i>P</i> < .0001ï¼Œ95%CI 1.46ï¼Œ2.89ï¼‰ã€‚ [å®‰å…¨æ€§] æœ€å¸¸æŠ¥å‘Šçš„ TEAEï¼ˆæ²»ç–—å¼•èµ·çš„ä¸è‰¯äº‹ä»¶ï¼ŒTEAEï¼‰ã€è‚›å‘¨è„“è‚¿å’Œç›´è‚ ç—›çš„å‘ç”Ÿç‡å¹¶æœªå› ä½¿ç”¨ MSC è€Œæ˜¾ç€å¢åŠ ï¼Œä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œè‚›å‘¨è„“è‚¿çš„ OR ä¸º 1.07ï¼ˆ<i>P</i> = .87, 95%CI 0.67, 1.72ï¼‰ï¼Œç›´è‚ ç—›çš„ OR ä¸º 1.10 (<i>P</i> = .47, 95%CI 0.63, 1.92) ä¸å¯¹ç…§ç»„ç›¸æ¯”ã€‚\n\n**ç»“è®ºï¼š** MSC ä¼¼ä¹æ˜¯æ²»ç–— pfCD çš„æœ‰æ•ˆä¸”å®‰å…¨çš„ç–—æ³•ã€‚åŸºäºé—´å……è´¨å¹²ç»†èƒçš„ç–—æ³•æœ‰å¯èƒ½ä¸ä¼ ç»Ÿç–—æ³•ç»“åˆä½¿ç”¨ã€‚", "keywords_zh": "é—´å……è´¨å¹²ç»†èƒï¼ŒèŸèƒåˆ†æï¼Œè‚›å‘¨ç˜˜ç®¡å…‹ç½—æ©ç—…", "keywords_en": "mesenchymal stem cells, meta-analysis, perianal fistulizing Crohnâ€™s disease", "link": "https://pubmed.ncbi.nlm.nih.gov/36794974/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 16 Feb 2023"}, {"id": "34792604", "title_en": "Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts", "title_zh": "è‚›å‘¨å…‹ç½—æ©ç—…çš„æµè¡Œç—…å­¦å’Œè‡ªç„¶å²ï¼šåŸºäºäººç¾¤çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Siddharth Singh", "abstract_en": "**Background And Aims:** Perianal Crohn's disease (pCD) is a potentially severe phenotype of CD. We conducted a systematic review with meta-analysis to estimate cumulative incidence, risk factors, and outcomes of pCD in population-based cohort studies.\n\n**Methods:** Through a systematic literature review through March 1, 2021, we identified population-based inception cohort studies reporting cumulative incidence of perianal disease (primarily abscess and/or fistula) in patients with CD. We estimated the cumulative incidence of pCD at presentation and 1-, 5-, and 10-year follow-up, and risk factors for perianal disease and outcomes including risk of major (bowel resection, proctectomy, ostomy) and minor perianal (incision and drainage, seton placement, etc.) surgery.\n\n**Results:** In 12 population-based studies, prevalence of pCD was 18.7% (95% confidence interval [CI], 12.5%-27.0%) with 1-, 5-, and 10-year risk of perianal disease being 14.3% (95% CI, 7.9%-24.6%), 17.6% (95% CI, 11.3%-26.5%), and 18.9% (95% CI, 15.0%-23.4%), respectively. Approximately 11.5% of patients (95% CI, 6.7%-19.0%) had perianal disease at or before CD diagnosis. Colonic disease location and rectal involvement were associated with higher risk of pCD. Overall, 63.3% of patients (95% CI, 53.3-72.3) required minor perianal surgery and 6.4% of patients (95% CI, 1.8%-20.6%) required major abdominal surgery for pCD. Use of biologic therapy for pCD is common and has steadily increased throughout the years.\n\n**Conclusions:** Approximately 1 in 5 patients with CD develops perianal disease within 10 years of CD diagnosis, including 11.5% who have perianal disease at presentation. Approximately two-thirds of patients require perianal surgery, with a smaller fraction requiring major abdominal surgery.", "abstract_zh": "**Background and aimsï¼š** è‚›å‘¨å…‹ç½—æ©ç—… (pCD) æ˜¯ä¸€ç§æ½œåœ¨çš„ä¸¥é‡å…‹ç½—æ©ç—…è¡¨å‹ã€‚æˆ‘ä»¬é€šè¿‡èŸèƒåˆ†æè¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œä»¥ä¼°è®¡åŸºäºäººç¾¤çš„é˜Ÿåˆ—ç ”ç©¶ä¸­ pCD çš„ç´¯ç§¯å‘ç—…ç‡ã€å±é™©å› ç´ å’Œç»“æœã€‚\n\n**æ–¹æ³•ï¼š** é€šè¿‡æˆªè‡³ 2021 å¹´ 3 æœˆ 1 æ—¥çš„ç³»ç»Ÿæ–‡çŒ®å›é¡¾ï¼Œæˆ‘ä»¬ç¡®å®šäº†åŸºäºäººç¾¤çš„åˆå§‹é˜Ÿåˆ—ç ”ç©¶ï¼ŒæŠ¥å‘Šäº† CD æ‚£è€…è‚›å‘¨ç–¾ç—…ï¼ˆä¸»è¦æ˜¯è„“è‚¿å’Œ/æˆ–ç˜˜ç®¡ï¼‰çš„ç´¯ç§¯å‘ç—…ç‡ã€‚æˆ‘ä»¬ä¼°è®¡äº†å°±è¯Šæ—¶ä»¥åŠ 1 å¹´ã€5 å¹´å’Œ 10 å¹´éšè®¿æ—¶çš„ pCD ç´¯ç§¯å‘ç”Ÿç‡ï¼Œä»¥åŠè‚›å‘¨ç–¾ç—…å’Œç»“å±€çš„å±é™©å› ç´ ï¼ŒåŒ…æ‹¬å¤§æ‰‹æœ¯ï¼ˆè‚ åˆ‡é™¤ã€ç›´è‚ åˆ‡é™¤æœ¯ã€é€ å£æœ¯ï¼‰å’Œå°è‚›å‘¨æ‰‹æœ¯ï¼ˆåˆ‡å¼€å¼•æµã€æŒ‚çº¿æ”¾ç½®ç­‰ï¼‰çš„é£é™©ã€‚\n\n**ç»“æœï¼š** åœ¨ 12 é¡¹åŸºäºäººç¾¤çš„ç ”ç©¶ä¸­ï¼ŒpCD æ‚£ç—…ç‡ä¸º 18.7%ï¼ˆ95% ç½®ä¿¡åŒºé—´ [CI]ï¼Œ12.5%-27.0%ï¼‰ï¼Œ1 å¹´ã€5 å¹´å’Œ 10 å¹´è‚›å‘¨ç–¾ç—…é£é™©åˆ†åˆ«ä¸º 14.3%ï¼ˆ95% CIï¼Œ7.9%-24.6%ï¼‰ã€17.6%ï¼ˆ95% CIï¼Œ11.3%-26.5%ï¼‰å’Œåˆ†åˆ«ä¸º 18.9%ï¼ˆ95% CIï¼Œ15.0%-23.4%ï¼‰ã€‚å¤§çº¦ 11.5% çš„æ‚£è€… (95% CI, 6.7%-19.0%) åœ¨ CD è¯Šæ–­æ—¶æˆ–ä¹‹å‰æ‚£æœ‰è‚›å‘¨ç–¾ç—…ã€‚ç»“è‚ ç–¾ç—…éƒ¨ä½å’Œç›´è‚ å—ç´¯ä¸è¾ƒé«˜çš„ pCD é£é™©ç›¸å…³ã€‚æ€»ä½“è€Œè¨€ï¼Œ63.3% çš„æ‚£è€… (95% CI, 53.3-72.3) éœ€è¦è¿›è¡Œå°å‹è‚›å‘¨æ‰‹æœ¯ï¼Œ6.4% çš„æ‚£è€… (95% CI, 1.8%-20.6%) éœ€è¦é’ˆå¯¹ pCD è¿›è¡Œè…¹éƒ¨å¤§æ‰‹æœ¯ã€‚ä½¿ç”¨ç”Ÿç‰©ç–—æ³•æ²»ç–— pCD å¾ˆå¸¸è§ï¼Œå¹¶ä¸”å¤šå¹´æ¥ä¸€ç›´åœ¨ç¨³æ­¥å¢åŠ ã€‚\n\n**ç»“è®ºï¼š** å¤§çº¦äº”åˆ†ä¹‹ä¸€çš„ CD æ‚£è€…åœ¨ CD è¯Šæ–­å 10 å¹´å†…å‡ºç°è‚›å‘¨ç–¾ç—…ï¼Œå…¶ä¸­ 11.5% å°±è¯Šæ—¶æ‚£æœ‰è‚›å‘¨ç–¾ç—…ã€‚å¤§çº¦ä¸‰åˆ†ä¹‹äºŒçš„æ‚£è€…éœ€è¦è¿›è¡Œè‚›å‘¨æ‰‹æœ¯ï¼Œä¸€å°éƒ¨åˆ†æ‚£è€…éœ€è¦è¿›è¡Œè…¹éƒ¨å¤§æ‰‹æœ¯ã€‚", "keywords_zh": "è’™ç‰¹åˆ©å°”åˆ†ç±»ï¼ŒæŠ— TNFï¼Œæµè¡Œç—…å­¦ï¼Œç˜˜ç®¡ï¼Œè‡ªç„¶å²", "keywords_en": "Montreal classification, anti-TNF, epidemiology, fistula, natural history", "link": "https://pubmed.ncbi.nlm.nih.gov/34792604/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 18 Nov 2021"}, {"id": "34792583", "title_en": "Strategies to Distinguish Perianal Fistulas Related to Crohn's Disease From Cryptoglandular Disease: Systematic Review With Meta-Analysis", "title_zh": "åŒºåˆ†ä¸å…‹ç½—æ©ç—…ç›¸å…³çš„è‚›å‘¨ç˜˜å’Œéšè…ºç–¾ç—…çš„ç­–ç•¥ï¼šèŸèƒåˆ†æçš„ç³»ç»Ÿè¯„ä»·", "authors": "Jeffrey D McCurdy", "abstract_en": "**Background:** Management of perianal fistulas differs based on fistula type. We aimed to assess the ability of diagnostic strategies to differentiate between Crohn's disease (CD) and cryptoglandular disease (CGD) in patients with perianal fistulas.\n\n**Methods:** We performed a diagnostic accuracy systematic review and meta-analysis. A systematic search of electronic databases was performed from inception through February 2021 for studies assessing a diagnostic test's ability to distinguish fistula types. We calculated weighted summary estimates with 95% confidence intervals for sensitivity and specificity by bivariate analysis, using fixed effects models when data were available from 2 or more studies. The Quality Assessment of Diagnostic Accuracy Studies tool was used to assess study quality.\n\n**Results:** Twenty-one studies were identified and included clinical symptoms (2 studies; n=154), magnetic resonance imaging (MRI) characteristics (3 studies; n=296), ultrasound characteristics (7 studies; n=1003), video capsule endoscopy (2 studies; n=44), fecal calprotectin (1 study; n=56), and various biomarkers (8 studies; n=440). MRI and ultrasound characteristics had the most robust data. Rectal inflammation, multiple-branched fistula tracts, and abscesses on pelvic MRI and the Crohn's ultrasound fistula sign, fistula debris, and bifurcated fistulas on pelvic ultrasonography had high specificity (range, 80%-95% vs 89%-96%) but poor sensitivity (range, 17%-37% vs 31%-63%), respectively. Fourteen of 21 studies had risk of bias on at least 1 of the Quality Assessment of Diagnostic Accuracy Studies domains.\n\n**Conclusions:** Limited high-quality evidence suggest that imaging characteristics may help discriminate CD from CGD in patients with perianal fistulas. Larger, prospective studies are needed to confirm these findings and to evaluate if combining multiple diagnostic tests can improve diagnostic sensitivity.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›å‘¨ç˜˜çš„æ²»ç–—æ ¹æ®ç˜˜ç®¡ç±»å‹çš„ä¸åŒè€Œæœ‰æ‰€ä¸åŒã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯è¯„ä¼°è¯Šæ–­ç­–ç•¥åŒºåˆ†è‚›å‘¨ç˜˜æ‚£è€…å…‹ç½—æ©ç—…ï¼ˆCDï¼‰å’Œéšè…ºç—…ï¼ˆCGDï¼‰çš„èƒ½åŠ›ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬è¿›è¡Œäº†è¯Šæ–­å‡†ç¡®æ€§ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚ä»ä¸€å¼€å§‹åˆ° 2021 å¹´ 2 æœˆï¼Œæˆ‘ä»¬å¯¹ç”µå­æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæœç´¢ï¼Œä»¥è¯„ä¼°è¯Šæ–­æµ‹è¯•åŒºåˆ†ç˜˜ç®¡ç±»å‹çš„èƒ½åŠ›ã€‚å½“æ•°æ®æ¥è‡ª 2 é¡¹æˆ–æ›´å¤šç ”ç©¶æ—¶ï¼Œæˆ‘ä»¬ä½¿ç”¨å›ºå®šæ•ˆåº”æ¨¡å‹ï¼Œé€šè¿‡åŒå˜é‡åˆ†æè®¡ç®—äº†çµæ•åº¦å’Œç‰¹å¼‚æ€§çš„ 95% ç½®ä¿¡åŒºé—´çš„åŠ æƒæ±‡æ€»ä¼°è®¡å€¼ã€‚è¯Šæ–­å‡†ç¡®æ€§ç ”ç©¶è´¨é‡è¯„ä¼°å·¥å…·ç”¨äºè¯„ä¼°ç ”ç©¶è´¨é‡ã€‚\n\n**ç»“æœï¼š** ç¡®å®šäº† 21 é¡¹ç ”ç©¶ï¼ŒåŒ…æ‹¬ä¸´åºŠç—‡çŠ¶ï¼ˆ2 é¡¹ç ”ç©¶ï¼›n=154ï¼‰ã€ç£å…±æŒ¯æˆåƒ (MRI) ç‰¹å¾ï¼ˆ3 é¡¹ç ”ç©¶ï¼›n=296ï¼‰ã€è¶…å£°ç‰¹å¾ï¼ˆ7 é¡¹ç ”ç©¶ï¼›n=1003ï¼‰ã€è§†é¢‘èƒ¶å›Šå†…çª¥é•œæ£€æŸ¥ï¼ˆ2 é¡¹ç ”ç©¶ï¼›n=44ï¼‰ã€ç²ªä¾¿é’™å«è›‹ç™½ï¼ˆ1 é¡¹ç ”ç©¶ï¼›n=56ï¼‰å’Œå„ç§ç”Ÿç‰©æ ‡å¿—ç‰©ï¼ˆ8 é¡¹ç ”ç©¶ï¼›n=440ï¼‰ã€‚ MRI å’Œè¶…å£°ç‰¹å¾æ‹¥æœ‰æœ€å¯é çš„æ•°æ®ã€‚ç›†è…” MRI ä¸Šçš„ç›´è‚ ç‚ç—‡ã€å¤šåˆ†æ”¯ç˜˜ç®¡å’Œè„“è‚¿ä»¥åŠç›†è…”è¶…å£°æ£€æŸ¥ä¸Šçš„å…‹ç½—æ©æ°è¶…å£°ç˜˜å¾ã€ç˜˜ç®¡ç¢ç‰‡å’Œåˆ†å‰ç˜˜çš„ç‰¹å¼‚æ€§è¾ƒé«˜ï¼ˆèŒƒå›´ï¼Œ80%-95% vs 89%-96%ï¼‰ï¼Œä½†æ•æ„Ÿæ€§è¾ƒå·®ï¼ˆèŒƒå›´ï¼Œ17%-37% vs 31%-63%ï¼‰ã€‚ 21 é¡¹ç ”ç©¶ä¸­æœ‰ 14 é¡¹åœ¨è‡³å°‘ 1 ä¸ªè¯Šæ–­å‡†ç¡®æ€§ç ”ç©¶è´¨é‡è¯„ä¼°é¢†åŸŸå­˜åœ¨åå€šé£é™©ã€‚\n\n**ç»“è®ºï¼š** æœ‰é™çš„é«˜è´¨é‡è¯æ®è¡¨æ˜ï¼Œå½±åƒå­¦ç‰¹å¾å¯èƒ½æœ‰åŠ©äºåŒºåˆ†è‚›å‘¨ç˜˜æ‚£è€…çš„ CD å’Œ CGDã€‚éœ€è¦æ›´å¤§è§„æ¨¡çš„å‰ç»æ€§ç ”ç©¶æ¥è¯å®è¿™äº›å‘ç°ï¼Œå¹¶è¯„ä¼°ç»“åˆå¤šç§è¯Šæ–­æµ‹è¯•æ˜¯å¦å¯ä»¥æé«˜è¯Šæ–­çµæ•åº¦ã€‚", "keywords_zh": "éšè…ºç–¾ç—…ã€è‚›ç˜˜ã€è‚›å‘¨ç–¾ç—…", "keywords_en": "cryptoglandular disease, fistula-in-ano, perianal disease", "link": "https://pubmed.ncbi.nlm.nih.gov/34792583/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Thu, 18 Nov 2021"}, {"id": "34628909", "title_en": "A systematic review and meta-analysis of incision and seton drainage in the treatment of high perianal abscess", "title_zh": "åˆ‡å¼€æŒ‚çº¿å¼•æµæ²»ç–—é«˜ä½è‚›å‘¨è„“è‚¿çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Lihua Zheng", "abstract_en": "**Background:** Surgery is the clinically preferred treatment for high perianal abscesses. Incision and seton drainage improve the cure rate and reduce recurrence. We aimed to systematically evaluate the clinical effect and safety of incision and seton drainage in the treatment of high perianal abscess.\n\n**Methods:** China Knowledge Network (CNKI), WanFang database, VIP database, PubMed, and Cochrane Library were searched and all relevant Chinese and English language documents until July 2021were retrieved. All records that described randomized clinical trials (RCTs) of incision and seton drainage for the treatment of high perianal abscess were eligible. Documents that met the inclusion criteria were evaluated for bias using the Cochrane Collaboration Risk Evaluation Standard, and Revman5.4 software was used to analyze the data.\n\n**Results:** Fourteen RCTs were included. The results of nine studies showed that the clinical cure rate of the incision-seton group was higher than that of the incision-drainage group (P<0.05). Seven studies showed that the wound healing time of the incision-seton group was shorter than that of the incision-drainage group (P<0.05). Four studies showed that the visual analogue scale (VAS) score of the incision-seton group was lower than that of the incision-drainage group (P<0.05). Five studies showed that the Wexner score of the incision-seton group was lower than that of the incision-drainage group (P<0.05). Six studies showed that the formation rate of anal fistula in the incision-seton group was lower than that in the incision-drainage group (P<0.05). Six studies demonstrated that the recurrence rate of abscess in the incision-seton group was lower than that in the incision-drainage group (P<0.05). Seven studies showed that the incidence of adverse events in the incision-seton group was lower than that in the incision-drainage group (P<0.05). Five studies demonstrated that the length of stay in the incision-seton group was shorter than that of the incision-drainage group (P<0.05).\n\n**Discussion:** The choice of surgical methods in clinical research has always been controversial. The incision-seton method can effectively and safely treat high perianal abscess. However, the results of this meta-analysis still leave some gaps in the evidence. More large-sample, high-quality, and multi-center RCTs are needed.", "abstract_zh": "**èƒŒæ™¯ï¼š** æ‰‹æœ¯æ˜¯ä¸´åºŠä¸Šæ²»ç–—é«˜ä½è‚›å‘¨è„“è‚¿çš„é¦–é€‰æ²»ç–—æ–¹æ³•ã€‚åˆ‡å¼€æŒ‚çº¿å¼•æµæé«˜æ²»æ„ˆç‡ï¼Œå‡å°‘å¤å‘ã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯ç³»ç»Ÿè¯„ä»·åˆ‡å¼€æŒ‚çº¿å¼•æµæ²»ç–—é«˜ä½è‚›å‘¨è„“è‚¿çš„ä¸´åºŠæ•ˆæœå’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢ä¸­å›½çŸ¥ç½‘ï¼ˆCNKIï¼‰ã€ä¸‡æ–¹æ•°æ®åº“ã€ç»´æ™®æ•°æ®åº“ã€PubMedã€Cochraneå›¾ä¹¦é¦†ï¼Œæ£€ç´¢åˆ°2021å¹´7æœˆä¸ºæ­¢çš„æ‰€æœ‰ç›¸å…³ä¸­è‹±æ–‡æ–‡çŒ®ã€‚æ‰€æœ‰æè¿°åˆ‡å¼€æŒ‚çº¿å¼•æµæ²»ç–—é«˜ä½è‚›å‘¨è„“è‚¿çš„éšæœºä¸´åºŠè¯•éªŒ (RCT) çš„è®°å½•å‡ç¬¦åˆèµ„æ ¼ã€‚ä½¿ç”¨Cochraneåä½œé£é™©è¯„ä¼°æ ‡å‡†å¯¹ç¬¦åˆçº³å…¥æ ‡å‡†çš„æ–‡çŒ®è¿›è¡Œåå€šè¯„ä¼°ï¼Œå¹¶ä½¿ç”¨Revman5.4è½¯ä»¶å¯¹æ•°æ®è¿›è¡Œåˆ†æã€‚\n\n**ç»“æœï¼š** å…¶ä¸­åŒ…æ‹¬ 14 é¡¹éšæœºå¯¹ç…§è¯•éªŒã€‚ 9é¡¹ç ”ç©¶ç»“æœæ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„ä¸´åºŠæ²»æ„ˆç‡é«˜äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 7é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„ä¼¤å£æ„ˆåˆæ—¶é—´çŸ­äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 4é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„è§†è§‰æ¨¡æ‹Ÿè¯„åˆ†ï¼ˆVASï¼‰ä½äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 5é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„Wexnerè¯„åˆ†ä½äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 6é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„è‚›ç˜˜å½¢æˆç‡ä½äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 6é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„è„“è‚¿å¤å‘ç‡ä½äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 7é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„ä¸è‰¯äº‹ä»¶å‘ç”Ÿç‡ä½äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚ 5é¡¹ç ”ç©¶æ˜¾ç¤ºåˆ‡å¼€æŒ‚çº¿ç»„çš„ä½é™¢æ—¶é—´çŸ­äºåˆ‡å¼€å¼•æµç»„ï¼ˆP<0.05ï¼‰ã€‚\n\n**è®¨è®ºï¼š** ä¸´åºŠç ”ç©¶ä¸­æ‰‹æœ¯æ–¹å¼çš„é€‰æ‹©ä¸€ç›´å­˜åœ¨äº‰è®®ã€‚åˆ‡å¼€æŒ‚çº¿æ³•å¯ä»¥æœ‰æ•ˆã€å®‰å…¨åœ°æ²»ç–—é«˜ä½è‚›å‘¨è„“è‚¿ã€‚ç„¶è€Œï¼Œè¿™é¡¹èŸèƒåˆ†æçš„ç»“æœä»ç„¶åœ¨è¯æ®ä¸Šç•™ä¸‹äº†ä¸€äº›ç©ºç™½ã€‚éœ€è¦æ›´å¤šå¤§æ ·æœ¬ã€é«˜è´¨é‡ã€å¤šä¸­å¿ƒçš„éšæœºå¯¹ç…§è¯•éªŒã€‚", "keywords_zh": "åˆ‡å¼€æŒ‚çº¿æ²»ç–—ï¼Œé«˜ä½è‚›å‘¨è„“è‚¿ï¼Œåˆ‡å¼€å¼•æµæ²»ç–—ï¼ŒMetaåˆ†æ", "keywords_en": "Incision-seton therapy, high perianal abscess, incision-drainage therapy, meta-analysis", "link": "https://pubmed.ncbi.nlm.nih.gov/34628909/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=14OzJS8GjXZKNRRzPCpEeeWNsNMgy1WIuhFrUouU5lu4ZC2kX-&fc=20260103014642&ff=20260124211229&v=2.18.0.post22+67771e2", "date": "Mon, 11 Oct 2021"}], "æœªå‘½å": [], "ç—”ç–®": [{"id": "41535511", "title_en": "Long-term outcomes of stapled haemorrhoidopexy versus conventional haemorrhoidectomy: An updated systematic review, meta-analysis and trial-sequential analysis of randomized controlled trials", "title_zh": "å»åˆå™¨ç—”ç–®å›ºå®šæœ¯ä¸ä¼ ç»Ÿç—”ç–®åˆ‡é™¤æœ¯çš„é•¿æœŸç»“æœï¼šéšæœºå¯¹ç…§è¯•éªŒçš„æœ€æ–°ç³»ç»Ÿè¯„ä»·ã€èŸèƒåˆ†æå’Œè¯•éªŒåºè´¯åˆ†æ", "authors": "Roberto Cirocchi", "abstract_en": "**Purpose:** Stapled haemorrhoidopexy (SH) offers well-established short-term advantages over conventional haemorrhoidectomy (CH), but its long-term effectiveness remains controversial. This systematic review and meta-analysis aimed to compare long-term outcomes of SH versus CH in adult patients with grade II-IV haemorrhoids, incorporating Trial Sequential Analysis (TSA).\n\n**Methods:** MEDLINE, EMBASE and CENTRAL were searched from January 2001 to October 2025 for randomized controlled trials (RCTs) comparing SH and CH with a minimum follow-up of 12Â months. Two reviewers independently performed study selection, data extraction and risk-of-bias assessment (RoB-2). Primary outcomes included recurrence, reintervention, anal function, and quality of life (QoL). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. TSA was applied to overall recurrence.\n\n**Results:** Seventeen RCTs including 1,041 SH and 1,031 CH patients were analysed. SH was associated with a higher risk of overall recurrence compared with CH (RRâ€‰=â€‰1.56,95%CIâ€‰=â€‰1.00-2.44;I<sup>2</sup>â€‰=â€‰48%). TSA showed that the accrued information size (1,913 patients) did not reach the required information size (2,608 patients), indicating that current evidence remains underpowered. Prolapse-related recurrence was significantly more frequent after SH (RRâ€‰=â€‰3.28,95%CIâ€‰=â€‰1.49-7.25;I<sup>2</sup>â€‰=â€‰12%), whereas bleeding-related recurrence did not differ between groups (RRâ€‰=â€‰1.20,95%CIâ€‰=â€‰0.63-2.26;I<sup>2</sup>â€‰=â€‰23%). No significant differences were found for reintervention, persistent anal pain, functional impairment or QoL.\n\n**Conclusion:** SH is associated with a higher risk of long-term recurrence, particularly prolapse-related recurrence, compared with CH, while long-term pain, functional outcomes and QoL appear broadly comparable. These findings suggest that, although SH may remain an option for selected patients, CH provides more durable anatomical correction, and procedural choice should balance early recovery against long-term durability.", "abstract_zh": "**Purposeï¼š** ä¸ä¼ ç»Ÿç—”ç–®åˆ‡é™¤æœ¯ (CH) ç›¸æ¯”ï¼Œå»åˆå™¨ç—”ç–®å›ºå®šæœ¯ (SH) å…·æœ‰æ˜æ˜¾çš„çŸ­æœŸä¼˜åŠ¿ï¼Œä½†å…¶é•¿æœŸæœ‰æ•ˆæ€§ä»å­˜åœ¨äº‰è®®ã€‚è¿™é¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææ—¨åœ¨æ¯”è¾ƒ SH ä¸ CH åœ¨ II-IV çº§ç—”ç–®æˆå¹´æ‚£è€…ä¸­çš„é•¿æœŸç»“å±€ï¼Œå¹¶ç»“åˆè¯•éªŒåºè´¯åˆ†æ (TSA)ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº† 2001 å¹´ 1 æœˆè‡³ 2025 å¹´ 10 æœˆæœŸé—´ MEDLINEã€EMBASE å’Œ CENTRAL ä¸­æ¯”è¾ƒ SH å’Œ CH çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ï¼Œéšè®¿æ—¶é—´è‡³å°‘ä¸º 12 ä¸ªæœˆã€‚ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹è¿›è¡Œç ”ç©¶é€‰æ‹©ã€æ•°æ®æå–å’Œåå€šé£é™©è¯„ä¼°ï¼ˆRoB-2ï¼‰ã€‚ä¸»è¦ç»“å±€åŒ…æ‹¬å¤å‘ã€å†æ¬¡å¹²é¢„ã€è‚›é—¨åŠŸèƒ½å’Œç”Ÿæ´»è´¨é‡ (QoL)ã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹è®¡ç®—å…·æœ‰ 95% ç½®ä¿¡åŒºé—´ (CI) çš„åˆå¹¶é£é™©æ¯” (RR)ã€‚ TSA åº”ç”¨äºæ€»ä½“å¤å‘æƒ…å†µã€‚\n\n**ç»“æœï¼š** åˆ†æäº† 17 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼ŒåŒ…æ‹¬ 1,041 å SH å’Œ 1,031 å CH æ‚£è€…ã€‚ä¸CHç›¸æ¯”ï¼ŒSHä¸è¾ƒé«˜çš„æ€»ä½“å¤å‘é£é™©ç›¸å…³ï¼ˆRRâ€‰=â€‰1.56ï¼Œ95%CIâ€‰=â€‰1.00-2.44ï¼›I<sup>2</sup>â€‰=â€‰48%ï¼‰ã€‚ TSA æ˜¾ç¤ºï¼Œç´¯ç§¯çš„ä¿¡æ¯é‡ï¼ˆ1,913 åæ‚£è€…ï¼‰æœªè¾¾åˆ°æ‰€éœ€çš„ä¿¡æ¯é‡ï¼ˆ2,608 åæ‚£è€…ï¼‰ï¼Œè¡¨æ˜å½“å‰è¯æ®ä»ç„¶ä¸è¶³ã€‚ SH åè„±å‚ç›¸å…³å¤å‘æ˜¾ç€å¢åŠ  (RRâ€‰=â€‰3.28,95%CIâ€‰=â€‰1.49-7.25;I<sup>2</sup>â€‰=â€‰12%)ï¼Œè€Œå‡ºè¡€ç›¸å…³å¤å‘åœ¨ç»„é—´æ²¡æœ‰å·®å¼‚(RRâ€‰=â€‰1.20,95%CIâ€‰=â€‰0.63-2.26;I<sup>2</sup>â€‰=â€‰23%)ã€‚åœ¨é‡æ–°å¹²é¢„ã€æŒç»­æ€§è‚›é—¨ç–¼ç—›ã€åŠŸèƒ½éšœç¢æˆ–ç”Ÿæ´»è´¨é‡æ–¹é¢æ²¡æœ‰å‘ç°æ˜¾ç€å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** ä¸ CH ç›¸æ¯”ï¼ŒSH ä¸è¾ƒé«˜çš„é•¿æœŸå¤å‘é£é™©ç›¸å…³ï¼Œç‰¹åˆ«æ˜¯ä¸è„±å‚ç›¸å…³çš„å¤å‘ï¼Œè€Œé•¿æœŸç–¼ç—›ã€åŠŸèƒ½ç»“æœå’Œç”Ÿæ´»è´¨é‡ä¼¼ä¹å¤§è‡´ç›¸å½“ã€‚è¿™äº›ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œå°½ç®¡ SH å¯èƒ½ä»ç„¶æ˜¯é€‰å®šæ‚£è€…çš„ä¸€ç§é€‰æ‹©ï¼Œä½† CH æä¾›äº†æ›´æŒä¹…çš„è§£å‰–çŸ«æ­£ï¼Œå¹¶ä¸”æ‰‹æœ¯é€‰æ‹©åº”å¹³è¡¡æ—©æœŸæ¢å¤ä¸é•¿æœŸè€ä¹…æ€§ã€‚", "keywords_zh": "åœ†å½¢å»åˆå™¨ã€å¼—æ ¼æ£®ã€ç—”åˆ‡é™¤æœ¯ã€ç—”ç–®ã€è°æ³¢æ‰‹æœ¯åˆ€ã€LigaSureã€Milligan-Morganã€PPHã€å»åˆå™¨ç—”ç–®å›ºå®šæœ¯", "keywords_en": "Circular stapler, Ferguson, Haemorrhoidectomy, Haemorrhoids, Harmonic scalpel, LigaSure, Milligan-Morgan, PPH, Stapled haemorrhoidopexy", "link": "https://pubmed.ncbi.nlm.nih.gov/41535511/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 14 Jan 2026"}, {"id": "41503542", "title_en": "Arterial Embolization for the Internal Hemorrhoids Management: A Systematic Review", "title_zh": "åŠ¨è„‰æ “å¡æ²»ç–—å†…ç—”ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Hadi Rokni Yazdi", "abstract_en": "**Background And Aims:** Hemorrhoids are common vascular structures that can become symptomatic when prolapsed, representing the most prevalent benign anorectal condition worldwide. Despite affecting up to 11% of the population with symptoms including pain, bleeding, and discomfort, hemorrhoids remain underdiagnosed and often inappropriately managed. This systematic review aimed to evaluate the efficacy, clinical outcomes, and morbidity of endovascular artery embolization in hemorrhoids.\n\n**Method:** Up to August 2022, PubMed, Scopus, Web of Science, and Embase were searched comprehensively. All studies had eligible criteria included, except review articles, articles published in a language other than English, and case reports or series of cases. Two independent reviewers performed a literature review and data extraction. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 checklist was used for quality assessment.\n\n**Results:** The systematic review included 15 studies. The patient's age ranged from 40.5â€‰Â±â€‰9.51 to 72.2â€‰Â±â€‰10.9. Eleven studies mentioned the sample size as gender-specific, with 57.89% (<i>n</i>â€‰=â€‰187/323) male patients. The embolic site involved in embolization, according to the frequency, was 424 patients for the superior rectal artery in all studies, and coils and micro coils were utilized as Embolic material in most cases. No major complication or death was noted in 12 studies. The most frequent complications were postoperative pain and tenesmus, bleeding, ulceration and fibrotic scars, and low-grade fever. In 11.79% (<i>n</i>â€‰=â€‰27/229) of patients re-embolization and after-treatment surgery were due to surgical failure and symptom recurrence, such as bleeding.\n\n**Conclusion:** Rectal artery embolization using microcoils, embolic particles, or a combination is a new method for managing internal hemorrhoids with proper clinical efficacy without significant complications. QoL score has improved after emborrhoid, and most cases had a lower bleeding score.", "abstract_zh": "**Background and aimsï¼š** ç—”ç–®æ˜¯å¸¸è§çš„è¡€ç®¡ç»“æ„ï¼Œè„±å‚æ—¶å¯èƒ½ä¼šå‡ºç°ç—‡çŠ¶ï¼Œæ˜¯å…¨ä¸–ç•Œæœ€å¸¸è§çš„è‰¯æ€§è‚›é—¨ç›´è‚ ç–¾ç—…ã€‚å°½ç®¡æœ‰å¤šè¾¾ 11% çš„äººå£å‡ºç°ç–¼ç—›ã€å‡ºè¡€å’Œä¸é€‚ç­‰ç—‡çŠ¶ï¼Œä½†ç—”ç–®çš„è¯Šæ–­ç‡ä»ç„¶è¾ƒä½ï¼Œè€Œä¸”å¾€å¾€æ²»ç–—ä¸å½“ã€‚æœ¬ç³»ç»Ÿè¯„ä»·æ—¨åœ¨è¯„ä¼°è¡€ç®¡å†…åŠ¨è„‰æ “å¡æ²»ç–—ç—”ç–®çš„ç–—æ•ˆã€ä¸´åºŠç»“æœå’Œå‘ç—…ç‡ã€‚\n\n**Methodï¼š** æˆªè‡³2022å¹´8æœˆï¼ŒPubMedã€Scopusã€Web of Scienceã€Embaseå‡è¢«å…¨é¢æ£€ç´¢ã€‚æ‰€æœ‰ç ”ç©¶å‡åŒ…å«åˆæ ¼æ ‡å‡†ï¼Œä½†è¯„è®ºæ–‡ç« ã€ä»¥è‹±è¯­ä»¥å¤–çš„è¯­è¨€å‘è¡¨çš„æ–‡ç« ä»¥åŠç—…ä¾‹æŠ¥å‘Šæˆ–ç³»åˆ—ç—…ä¾‹é™¤å¤–ã€‚ä¸¤åç‹¬ç«‹è¯„å®¡å‘˜è¿›è¡Œäº†æ–‡çŒ®è¯„å®¡å’Œæ•°æ®æå–ã€‚ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) 2020 æ£€æŸ¥è¡¨ç”¨äºè´¨é‡è¯„ä¼°ã€‚\n\n**ç»“æœï¼š** ç³»ç»Ÿè¯„ä»·åŒ…æ‹¬ 15 é¡¹ç ”ç©¶ã€‚æ‚£è€…å¹´é¾„ä¸º40.5Â±9.51å²è‡³72.2Â±10.9å²ã€‚ 11 é¡¹ç ”ç©¶æåˆ°æ ·æœ¬é‡å…·æœ‰æ€§åˆ«ç‰¹å¼‚æ€§ï¼Œå…¶ä¸­ 57.89% (<i>n</i>â€‰=â€‰187/323) ä¸ºç”·æ€§æ‚£è€…ã€‚æ‰€æœ‰ç ”ç©¶ä¸­æ¶‰åŠæ “å¡çš„éƒ¨ä½ä¸ºç›´è‚ ä¸ŠåŠ¨è„‰424ä¾‹ï¼Œæ “å¡éƒ¨ä½å¤šé‡‡ç”¨å¼¹ç°§åœˆå’Œå¾®å¼¹ç°§åœˆä½œä¸ºæ “å¡ææ–™ã€‚ 12 é¡¹ç ”ç©¶ä¸­æœªå‘ç°é‡å¤§å¹¶å‘ç—‡æˆ–æ­»äº¡ã€‚æœ€å¸¸è§çš„å¹¶å‘ç—‡æ˜¯æœ¯åç–¼ç—›å’Œé‡Œæ€¥åé‡ã€å‡ºè¡€ã€æºƒç–¡å’Œçº¤ç»´åŒ–ç–¤ç—•ä»¥åŠä½çƒ§ã€‚ 11.79%ï¼ˆ<i>n</i>â€‰=â€‰27/229ï¼‰çš„æ‚£è€…å†æ¬¡æ “å¡å’Œæ²»ç–—åæ‰‹æœ¯æ˜¯ç”±äºæ‰‹æœ¯å¤±è´¥å’Œå‡ºè¡€ç­‰ç—‡çŠ¶å¤å‘ã€‚\n\n**ç»“è®ºï¼š** ä½¿ç”¨å¾®å¼¹ç°§åœˆã€æ “å¡é¢—ç²’æˆ–å…¶ç»„åˆè¿›è¡Œç›´è‚ åŠ¨è„‰æ “å¡æ˜¯ä¸€ç§æ²»ç–—å†…ç—”çš„æ–°æ–¹æ³•ï¼Œå…·æœ‰è‰¯å¥½çš„ä¸´åºŠç–—æ•ˆï¼Œä¸”æ— æ˜æ˜¾å¹¶å‘ç—‡ã€‚ç—”ç–®æœ¯åç”Ÿæ´»è´¨é‡è¯„åˆ†æœ‰æ‰€æ”¹å–„ï¼Œå¤§å¤šæ•°ç—…ä¾‹çš„å‡ºè¡€è¯„åˆ†è¾ƒä½ã€‚", "keywords_zh": "æ “å¡, ç—”ç–®, ç—”ç–®, ç—”åŠ¨è„‰, ç›´è‚ åŠ¨è„‰", "keywords_en": "embolization, emborrhoid, hemorrhoid, hemorrhoidal artery, rectal artery", "link": "https://pubmed.ncbi.nlm.nih.gov/41503542/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 08 Jan 2026"}, {"id": "41450176", "title_en": "Worldwide prevalence of haemorrhoids: a systematic review and meta-analysis", "title_zh": "å…¨çƒç—”ç–®æ‚£ç—…ç‡ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Pouyan Ebrahimi", "abstract_en": "**Background:** Haemorrhoidal disease (HD) is one of the most common anorectal disorders globally, significantly impacting individuals' quality of life and productivity. Despite its importance, global prevalence remains unclear due to limited population-specific studies. This study aimed to systematically assess the global prevalence of HD through a systematic review and meta-analysis.\n\n**Methods:** We conducted a systematic review and meta-analysis by searching PubMed, Scopus, Embase, Web of Science, and Google Scholar up to March 31, 2025, without language restrictions. Studies reporting prevalence of haemorrhoids in general, clinical, or high-risk populations were included. Exclusion criteria comprised studies lacking total sample size, focusing on other anorectal conditions, or using duplicate or insufficient data. Four independent reviewers extracted and appraised study quality using the Joanna Briggs Institute tool. The primary outcome was pooled point prevalence of HD, analyzed using a random-effects model with 95% confidence intervals (CIs). The study was registered in PROSPERO (CRD420251045600).\n\n**Results:** From 6,312 records, 150 studies (210 datasets) comprising 8,960,338 individuals were included. The global pooled point prevalence was 25.92% (95% CI: 22.62-29.22). Lifetime prevalence was 27.19% (95% CI: 14.77-39.60), and one-year prevalence was 21.65% (95% CI: 14.33-28.97). Prevalence was higher in women (27.33%, 95% CI: 21.84-32.82) than in men, and highest in the African region 28.07% (95% CI: 15.34-40.79). Invasive diagnostic methods (28.05%, 95% CI: 23.86-32.26) yielded higher prevalence estimates than non-invasive methods. Also, factors showing associations with HD in unadjusted analyses include older age, obesity, pregnancy, diabetes, family history, constipation, and hypertension.\n\n**Conclusion:** HD remains a prevalent condition globally, with minor variation across regions. The burden is consistent regardless of socioeconomic context. Diagnostic method and population characteristics influence prevalence estimates. These findings underscore the importance of targeted prevention and early intervention strategies, especially for at-risk groups.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç—”ç–®ç–¾ç—…ï¼ˆHDï¼‰æ˜¯å…¨çƒæœ€å¸¸è§çš„è‚›é—¨ç›´è‚ ç–¾ç—…ä¹‹ä¸€ï¼Œæ˜¾ç€å½±å“ä¸ªäººçš„ç”Ÿæ´»è´¨é‡å’Œç”Ÿäº§åŠ›ã€‚å°½ç®¡å…¶é‡è¦æ€§ï¼Œä½†ç”±äºé’ˆå¯¹ç‰¹å®šäººç¾¤çš„ç ”ç©¶æœ‰é™ï¼Œå…¨çƒæ‚£ç—…ç‡ä»ä¸æ¸…æ¥šã€‚æœ¬ç ”ç©¶æ—¨åœ¨é€šè¿‡ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ¥ç³»ç»Ÿè¯„ä¼° HD çš„å…¨çƒæ‚£ç—…ç‡ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬é€šè¿‡æ£€ç´¢æˆªè‡³ 2025 å¹´ 3 æœˆ 31 æ—¥çš„ PubMedã€Scopusã€Embaseã€Web of Science å’Œ Google Scholarï¼Œè¿›è¡Œäº†ç³»ç»Ÿç»¼è¿°å’ŒèŸèƒåˆ†æï¼Œæ²¡æœ‰è¯­è¨€é™åˆ¶ã€‚æŠ¥å‘ŠåŒ…æ‹¬ä¸€èˆ¬äººç¾¤ã€ä¸´åºŠäººç¾¤æˆ–é«˜å±äººç¾¤ä¸­ç—”ç–®æ‚£ç—…ç‡çš„ç ”ç©¶ã€‚æ’é™¤æ ‡å‡†åŒ…æ‹¬ç¼ºä¹æ€»æ ·æœ¬é‡ã€å…³æ³¨å…¶ä»–è‚›é—¨ç›´è‚ ç–¾ç—…æˆ–ä½¿ç”¨é‡å¤æˆ–ä¸è¶³æ•°æ®çš„ç ”ç©¶ã€‚å››ä½ç‹¬ç«‹è¯„å®¡å‘˜ä½¿ç”¨ä¹”å®‰å¨œå¸ƒé‡Œæ ¼æ–¯ç ”ç©¶æ‰€å·¥å…·æå–å¹¶è¯„ä¼°ç ”ç©¶è´¨é‡ã€‚ä¸»è¦ç»“æœæ˜¯ HD çš„æ±‡æ€»ç‚¹æ‚£ç—…ç‡ï¼Œä½¿ç”¨å…·æœ‰ 95% ç½®ä¿¡åŒºé—´ (CI) çš„éšæœºæ•ˆåº”æ¨¡å‹è¿›è¡Œåˆ†æã€‚è¯¥ç ”ç©¶å·²åœ¨ PROSPERO ä¸­æ³¨å†Œï¼ˆCRD420251045600ï¼‰ã€‚\n\n**ç»“æœï¼š** ä» 6,312 æ¡è®°å½•ä¸­ï¼Œçº³å…¥äº† 150 é¡¹ç ”ç©¶ï¼ˆ210 ä¸ªæ•°æ®é›†ï¼‰ï¼Œæ¶‰åŠ 8,960,338 åä¸ªä½“ã€‚å…¨çƒæ±‡æ€»ç‚¹æ‚£ç—…ç‡ä¸º 25.92%ï¼ˆ95% CIï¼š22.62-29.22ï¼‰ã€‚ç»ˆç”Ÿæ‚£ç—…ç‡ä¸º 27.19%ï¼ˆ95% CIï¼š14.77-39.60ï¼‰ï¼Œä¸€å¹´æ‚£ç—…ç‡ä¸º 21.65%ï¼ˆ95% CIï¼š14.33-28.97ï¼‰ã€‚å¥³æ€§æ‚£ç—…ç‡ï¼ˆ27.33%ï¼Œ95% CIï¼š21.84-32.82ï¼‰é«˜äºç”·æ€§ï¼Œéæ´²åœ°åŒºæ‚£ç—…ç‡æœ€é«˜ï¼Œä¸º 28.07%ï¼ˆ95% CIï¼š15.34-40.79ï¼‰ã€‚ä¾µå…¥æ€§è¯Šæ–­æ–¹æ³•ï¼ˆ28.05%ï¼Œ95% CIï¼š23.86-32.26ï¼‰æ¯”éä¾µå…¥æ€§æ–¹æ³•äº§ç”Ÿæ›´é«˜çš„æ‚£ç—…ç‡ä¼°è®¡å€¼ã€‚æ­¤å¤–ï¼Œæœªç»è°ƒæ•´çš„åˆ†ææ˜¾ç¤ºä¸ HD ç›¸å…³çš„å› ç´ åŒ…æ‹¬å¹´é¾„è¾ƒå¤§ã€è‚¥èƒ–ã€æ€€å­•ã€ç³–å°¿ç—…ã€å®¶æ—å²ã€ä¾¿ç§˜å’Œé«˜è¡€å‹ã€‚\n\n**ç»“è®ºï¼š** HD åœ¨å…¨çƒèŒƒå›´å†…ä»ç„¶æ˜¯ä¸€ç§æµè¡Œç—…ï¼Œå„åœ°åŒºä¹‹é—´å·®å¼‚è¾ƒå°ã€‚æ— è®ºç¤¾ä¼šç»æµèƒŒæ™¯å¦‚ä½•ï¼Œè´Ÿæ‹…éƒ½æ˜¯ä¸€è‡´çš„ã€‚è¯Šæ–­æ–¹æ³•å’Œäººç¾¤ç‰¹å¾å½±å“æ‚£ç—…ç‡ä¼°è®¡ã€‚è¿™äº›å‘ç°å¼ºè°ƒäº†æœ‰é’ˆå¯¹æ€§çš„é¢„é˜²å’Œæ—©æœŸå¹²é¢„ç­–ç•¥çš„é‡è¦æ€§ï¼Œç‰¹åˆ«æ˜¯å¯¹äºé«˜å±äººç¾¤ã€‚", "keywords_zh": "ç—”ç–®ã€æµè¡Œç—…å­¦ã€ç—”ç–®ã€èŸèƒåˆ†æã€æ‚£ç—…ç‡", "keywords_en": "Haemorrhoids, epidemiology, haemorrhoid, meta-analysis, prevalence", "link": "https://pubmed.ncbi.nlm.nih.gov/41450176/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 26 Dec 2025"}, {"id": "41444098", "title_en": "Clinical factors affecting the therapeutic dose window in cervical cancer brachytherapy: A systematic review and meta-regression", "title_zh": "å½±å“å®«é¢ˆç™Œè¿‘è·ç¦»æ”¾å°„æ²»ç–—æ²»ç–—å‰‚é‡çª—çš„ä¸´åºŠå› ç´ ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒå›å½’", "authors": "Nick J van de Berg", "abstract_en": "**Background And Purpose:** Although dose planning aims in cervical cancer brachytherapy are well-defined, variability in clinical practices makes it difficult to draw generalizable conclusions on achievable dosimetry. This review and meta-regression aim to assess clinical practices in terms of their therapeutic dose window, that is, the balance between target and organs-at-risk (OAR) doses.\n\n**Materials And Methods:** A search of the literature was performed in Scopus, PubMed, and Web of Science databases. Peer-reviewed articles were included that described planning constraints and reported high-risk clinical target volume (CTV<sub>HR</sub>) D<sub>90%</sub> and OAR [Formula: see text] for intracavitary (IC) tandem and ring (T&R) / tandem and ovoid (T&O) / mold (M) applicators, possibly supplemented with interstitial (IS) needles (+N). To determine factors associated with target volume coverage (D<sub>90%</sub>) and OAR sparing ( [Formula: see text] ), multivariate meta-regressions were performed.\n\n**Results:** Out of 1590 articles, 34 met the full inclusion criteria. In most studies, the CTV<sub>HR</sub>D<sub>90%</sub> aimed at â‰¥84-86 Gy EQD2<sub>Î±/Î²â€¯=â€¯10Gy</sub>, and constraints for the OARs were 80-90 Gy, 65-75 Gy and 70-75 Gy EQD2<sub>Î±/Î²â€¯=â€¯3Gy</sub> for the bladder, rectum and sigmoid [Formula: see text] , respectively. Studies using IC/IS applicators were associated with a âˆ¼4 Gy increase in CTV<sub>HR</sub>D<sub>90%</sub> compared to IC only, with no effect on OAR dose. T&R studies achieved improvements of 3.2 Gy and 2.8-3.4 Gy at typical planning aims in comparison with T&O applicators in target and OAR doses. In 100% (15/15) of patient groups treated with T&Râ€¯+â€¯N both CTV<sub>HR</sub> and OAR objectives were met for the population average. For T&R, T&O, and T&Oâ€¯+â€¯N groups, this was the case in 89% (8/9), 43% (6/14), and 50% (4/8), respectively.\n\n**Conclusion:** Studies using interstitial needles with T&R applicators in MR-guided brachytherapy for cervical cancer seem to be associated with a favorable therapeutic target dose/OAR sparing ratio.", "abstract_zh": "**èƒŒæ™¯ä¸ç›®çš„ï¼š** å°½ç®¡å®«é¢ˆç™Œè¿‘è·ç¦»æ”¾å°„æ²»ç–—çš„å‰‚é‡è®¡åˆ’ç›®æ ‡æ˜¯æ˜ç¡®å®šä¹‰çš„ï¼Œä½†ä¸´åºŠå®è·µçš„å¯å˜æ€§ä½¿å¾—å¾ˆéš¾å°±å¯å®ç°çš„å‰‚é‡æµ‹å®šå¾—å‡ºæ™®éçš„ç»“è®ºã€‚æœ¬ç»¼è¿°å’ŒèŸèƒå›å½’æ—¨åœ¨è¯„ä¼°ä¸´åºŠå®è·µçš„æ²»ç–—å‰‚é‡çª—å£ï¼Œå³ç›®æ ‡å‰‚é‡å’Œå±åŠå™¨å®˜ï¼ˆOARï¼‰å‰‚é‡ä¹‹é—´çš„å¹³è¡¡ã€‚\n\n**ææ–™ä¸æ–¹æ³•ï¼š** åœ¨ Scopusã€PubMed å’Œ Web of Science æ•°æ®åº“ä¸­è¿›è¡Œäº†æ–‡çŒ®æ£€ç´¢ã€‚å…¶ä¸­åŒ…æ‹¬åŒè¡Œè¯„å®¡çš„æ–‡ç« ï¼Œæè¿°äº†è®¡åˆ’é™åˆ¶å¹¶æŠ¥å‘Šäº†è…”å†… (IC) ä¸²è”å’Œç¯å½¢ (T&R) / ä¸²è”å’Œåµå½¢ (T&O) / æ¨¡å…· (M) æ–½è¯å™¨çš„é«˜é£é™©ä¸´åºŠé¶åŒº (CTV<sub>HR</sub>) D<sub>90%</sub> å’Œ OAR [å…¬å¼ï¼šå‚è§æ–‡æœ¬]ï¼Œå¯èƒ½è¾…ä»¥é—´è´¨ (IS) é’ˆ (+N)ã€‚ä¸ºäº†ç¡®å®šä¸ç›®æ ‡ä½“ç§¯è¦†ç›– (D<sub>90%</sub>) å’Œ OAR ä¿ç•™ï¼ˆ[å…¬å¼ï¼šè§æ–‡æœ¬]ï¼‰ç›¸å…³çš„å› ç´ ï¼Œè¿›è¡Œäº†å¤šå˜é‡å…ƒå›å½’ã€‚\n\n**ç»“æœï¼š** åœ¨ 1590 ç¯‡æ–‡ç« ä¸­ï¼Œæœ‰ 34 ç¯‡ç¬¦åˆå®Œå…¨çº³å…¥æ ‡å‡†ã€‚åœ¨å¤§å¤šæ•°ç ”ç©¶ä¸­ï¼ŒCTV<sub>HR</sub>D<sub>90%</sub>çš„ç›®æ ‡æ˜¯â‰¥84-86 Gy EQD2<sub>Î±/Î²=10Gy</sub>ï¼ŒOARçš„é™åˆ¶ä¸ºè†€èƒ±ã€ç›´è‚ å’Œä¹™çŠ¶ç»“è‚ 80-90 Gyã€65-75 Gyå’Œ70-75 Gy EQD2<sub>Î±/Î²=3Gy</sub> [å¼ï¼šè§æ­£æ–‡] åˆ†åˆ«ã€‚ä¸ä»…ä½¿ç”¨ IC ç›¸æ¯”ï¼Œä½¿ç”¨ IC/IS æ–½è¯å™¨çš„ç ”ç©¶å‘ç° CTV<sub>HR</sub>D<sub>90%</sub> å¢åŠ çº¦ 4 Gyï¼Œä½†å¯¹ OAR å‰‚é‡æ²¡æœ‰å½±å“ã€‚ä¸ T&O æ–½æ”¾å™¨çš„ç›®æ ‡å‰‚é‡å’Œ OAR å‰‚é‡ç›¸æ¯”ï¼ŒT&R ç ”ç©¶åœ¨å…¸å‹è®¡åˆ’ç›®æ ‡ä¸‹å®ç°äº† 3.2 Gy å’Œ 2.8-3.4 Gy çš„æ”¹è¿›ã€‚åœ¨ 100% (15/15) æ¥å— T&R+N æ²»ç–—çš„æ‚£è€…ç»„ä¸­ï¼ŒCTV<sub>HR</sub> å’Œ OAR ç›®æ ‡å‡è¾¾åˆ°æ€»ä½“å¹³å‡æ°´å¹³ã€‚å¯¹äº T&Rã€T&O å’Œ T&O+N ç»„ï¼Œè¿™ç§æƒ…å†µçš„æ¯”ä¾‹åˆ†åˆ«ä¸º 89% (8/9)ã€43% (6/14) å’Œ 50% (4/8)ã€‚\n\n**ç»“è®ºï¼š** åœ¨ MR å¼•å¯¼çš„å®«é¢ˆç™Œè¿‘è·ç¦»æ”¾å°„æ²»ç–—ä¸­ä½¿ç”¨é—´è´¨é’ˆå’Œ T&R æ–½æºå™¨çš„ç ”ç©¶ä¼¼ä¹ä¸æœ‰åˆ©çš„æ²»ç–—ç›®æ ‡å‰‚é‡/OAR ä¿ç•™æ¯”ç›¸å…³ã€‚", "keywords_zh": "æ–½æºå™¨ä½¿ç”¨ã€å›¾åƒå¼•å¯¼é€‚åº”æ€§è¿‘è·ç¦»æ”¾å°„æ²»ç–—ã€å±€éƒ¨æ™šæœŸå®«é¢ˆç™Œã€æ²»ç–—å‰‚é‡çª—", "keywords_en": "Applicator use, Image-guided adaptive brachytherapy, Locally advanced cervical cancer, Therapeutic dose window", "link": "https://pubmed.ncbi.nlm.nih.gov/41444098/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 24 Dec 2025"}, {"id": "41413743", "title_en": "Altered molecular signature of the intestinal microbiota in irritable bowel syndrome patients versus healthy controls: An updated systematic review", "title_zh": "è‚ æ˜“æ¿€ç»¼åˆå¾æ‚£è€…ä¸å¥åº·å¯¹ç…§è€…è‚ é“å¾®ç”Ÿç‰©ç¾¤åˆ†å­ç‰¹å¾çš„æ”¹å˜ï¼šæ›´æ–°çš„ç³»ç»Ÿè¯„ä»·", "authors": "Hui Zheng", "abstract_en": "**Background And Aims:** Irritable bowel syndrome (IBS), a prevalent functional gastrointestinal disorder, poses significant challenges for both patients and medical practitioners. Recent investigations have indicated the gut microbiome as a potential therapeutic target for IBS. Nevertheless, the exact association between these microorganisms and IBS symptoms remains incompletely elucidated. This updated systematic analysis aims to assess the extant research correlating the gut microbial community with IBS.\n\n**Methods:** A systematic search was performed in major electronic databases including PubMed, EMBASE and Web of Science, spanning from their inception to December 2024. The objective was to identify case-control studies that examined and compared the composition of the fecal or colonic microbiota in individuals diagnosed with IBS against healthy controls.\n\n**Results:** Our systematic search included 44 articles, which collectively revealed that IBS patients exhibit lower intestinal microbiome diversity compared to healthy controls. Fecal microbiome analysis demonstrated an imbalance in the phyla Firmicutes and Bacteroidetes among IBS patients. Specifically, IBS with diarrhea (IBS-D) patients showed reduced levels of Butyricimonas and Proteobacteria, while IBS with constipation (IBS-C) patients exhibited decreased Firmicutes and Actinobacteria, along with increased Verrucomicrobiota and Proteobacteria. Additionally, disruptions in the gut microbiome were noted, particularly in the duodenum and jejunum, as well as changes in key bacterial populations within the colon and rectum.\n\n**Conclusion:** Our review confirms significant gut microbiota dysbiosis in IBS patients, characterized by reduced microbial diversity and altered abundances of Firmicutes and Bacteroidetes. These findings support the potential for microbiota-targeted therapies in IBS management, though further research is needed to establish causal mechanisms and clinical applications.", "abstract_zh": "**Background and aimsï¼š** è‚ æ˜“æ¿€ç»¼åˆç—‡ï¼ˆIBSï¼‰æ˜¯ä¸€ç§å¸¸è§çš„åŠŸèƒ½æ€§èƒƒè‚ é“ç–¾ç—…ï¼Œç»™æ‚£è€…å’ŒåŒ»ç”Ÿå¸¦æ¥äº†å·¨å¤§çš„æŒ‘æˆ˜ã€‚æœ€è¿‘çš„ç ”ç©¶è¡¨æ˜è‚ é“å¾®ç”Ÿç‰©ç»„æ˜¯ IBS çš„æ½œåœ¨æ²»ç–—é¶ç‚¹ã€‚ç„¶è€Œï¼Œè¿™äº›å¾®ç”Ÿç‰©ä¸ IBS ç—‡çŠ¶ä¹‹é—´çš„ç¡®åˆ‡å…³è”ä»æœªå®Œå…¨é˜æ˜ã€‚è¿™é¡¹æ›´æ–°çš„ç³»ç»Ÿåˆ†ææ—¨åœ¨è¯„ä¼°ç°æœ‰çš„è‚ é“å¾®ç”Ÿç‰©ç¾¤è½ä¸è‚ æ˜“æ¿€ç»¼åˆç—‡ç›¸å…³çš„ç ”ç©¶ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬åœ¨åŒ…æ‹¬ PubMedã€EMBASE å’Œ Web of Science åœ¨å†…çš„ä¸»è¦ç”µå­æ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼Œæ£€ç´¢æ—¶é—´ä»æ•°æ®åº“æˆç«‹åˆ° 2024 å¹´ 12 æœˆã€‚ç›®çš„æ˜¯ç¡®å®šç—…ä¾‹å¯¹ç…§ç ”ç©¶ï¼Œè¿™äº›ç ”ç©¶æ£€æŸ¥å¹¶æ¯”è¾ƒäº†è¯Šæ–­ä¸º IBS çš„ä¸ªä½“ä¸å¥åº·å¯¹ç…§è€…çš„ç²ªä¾¿æˆ–ç»“è‚ å¾®ç”Ÿç‰©ç¾¤çš„ç»„æˆã€‚\n\n**ç»“æœï¼š** æˆ‘ä»¬çš„ç³»ç»Ÿæœç´¢åŒ…æ‹¬ 44 ç¯‡æ–‡ç« ï¼Œè¿™äº›æ–‡ç« å…±åŒæ­ç¤ºäº†ä¸å¥åº·å¯¹ç…§ç›¸æ¯”ï¼ŒIBS æ‚£è€…çš„è‚ é“å¾®ç”Ÿç‰©ç»„å¤šæ ·æ€§è¾ƒä½ã€‚ç²ªä¾¿å¾®ç”Ÿç‰©ç»„åˆ†æè¡¨æ˜ IBS æ‚£è€…çš„åšå£èŒé—¨å’Œæ‹Ÿæ†èŒé—¨ä¸å¹³è¡¡ã€‚å…·ä½“è€Œè¨€ï¼Œè…¹æ³»å‹IBSï¼ˆIBS-Dï¼‰æ‚£è€…çš„ä¸é…¸å•èƒèŒå’Œå˜å½¢èŒæ°´å¹³é™ä½ï¼Œè€Œä¾¿ç§˜å‹IBSï¼ˆIBS-Cï¼‰æ‚£è€…çš„åšå£èŒé—¨å’Œæ”¾çº¿èŒå‡å°‘ï¼Œç–£å¾®ç”Ÿç‰©ç¾¤å’Œå˜å½¢èŒå¢åŠ ã€‚æ­¤å¤–ï¼Œè¿˜æ³¨æ„åˆ°è‚ é“å¾®ç”Ÿç‰©ç»„çš„ç ´åï¼Œç‰¹åˆ«æ˜¯åœ¨åäºŒæŒ‡è‚ å’Œç©ºè‚ ä¸­ï¼Œä»¥åŠç»“è‚ å’Œç›´è‚ å†…å…³é”®ç»†èŒç§ç¾¤çš„å˜åŒ–ã€‚\n\n**ç»“è®ºï¼š** æˆ‘ä»¬çš„ç»¼è¿°è¯å®äº† IBS æ‚£è€…å­˜åœ¨æ˜¾ç€çš„è‚ é“å¾®ç”Ÿç‰©ç¾¤å¤±è°ƒï¼Œå…¶ç‰¹å¾æ˜¯å¾®ç”Ÿç‰©å¤šæ ·æ€§å‡å°‘ä»¥åŠåšå£èŒé—¨å’Œæ‹Ÿæ†èŒé—¨çš„ä¸°åº¦æ”¹å˜ã€‚è¿™äº›å‘ç°æ”¯æŒäº†å¾®ç”Ÿç‰©ç¾¤é¶å‘æ²»ç–—åœ¨ IBS æ²»ç–—ä¸­çš„æ½œåŠ›ï¼Œå°½ç®¡è¿˜éœ€è¦è¿›ä¸€æ­¥ç ”ç©¶æ¥ç¡®å®šå› æœæœºåˆ¶å’Œä¸´åºŠåº”ç”¨ã€‚", "keywords_zh": "IBS è‚ æ˜“æ¿€ç»¼åˆå¾ã€IBS-CÂ IBS ä¾¿ç§˜ã€IBS-DÂ IBS è…¹æ³»ã€èŒç¾¤å¤±è°ƒã€è‚ é“èŒç¾¤ã€è‚ æ˜“æ¿€ç»¼åˆå¾ã€å¾®ç”Ÿç‰©ç»„ã€ç³»ç»Ÿè¯„ä»·", "keywords_en": "IBS irritable bowel syndrome, IBS-CÂ IBS with constipation, IBS-DÂ IBS with diarrhea, Dysbiosis, Gut microbiota, Irritable bowel syndrome, Microbiome, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/41413743/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 18 Dec 2025"}, {"id": "41399305", "title_en": "Diagnostic accuracy and safety of image-guided transperineal versus transrectal prostate biopsy for clinically significant prostate cancer: a GRADE-assessed systematic review and meta-analysis", "title_zh": "å›¾åƒå¼•å¯¼ç»ä¼šé˜´å‰åˆ—è…ºæ´»æ£€ä¸ç»ç›´è‚ å‰åˆ—è…ºæ´»æ£€å¯¹æœ‰ä¸´åºŠæ„ä¹‰çš„å‰åˆ—è…ºç™Œçš„è¯Šæ–­å‡†ç¡®æ€§å’Œå®‰å…¨æ€§ï¼šGRADE è¯„ä¼°çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Muhammad Salih", "abstract_en": "**Introduction:** This systematic review and meta-analysis compared the diagnostic performance and complication profiles of transperineal biopsy (TPBx) versus transrectal biopsy (TRBx) for prostate cancer, incorporating recent randomized and large observational studies.\n\n**Methods:** Following PRISMA 2020 guidelines, PubMed, Scopus, Embase, and Cochrane Library were searched till April 2025. Studies directly comparing TPBx and TRBx were included. Risk of bias was assessed using RoB 2.0 for randomized trials and the Newcastle - Ottawa Scale for observational studies. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses and a GRADE assessment were performed to evaluate the certainty of evidence.\n\n**Results:** Twenty-nine studies (<i>n</i>â€‰=â€‰90,621) were included. TPBx showed higher PCa detection (RR 1.08; 95% CI 1.01-1.15; <i>p</i>â€‰=â€‰0.02) and csPCa detection (RR 1.14; 95% CI 1.05-1.24; <i>p</i>â€‰=â€‰0.001), though the certainty of evidence was low to moderate. Heterogeneity was moderate to high. TPBx also showed lower infection-related complications and comparable overall events, though procedure-related pain was slightly higher.\n\n**Conclusion:** TPBx offers improved diagnostic yield and lower infection risk compared with TRBx, with comparable safety. However, given the moderate heterogeneity and limited high-quality RCTs, further confirmatory trials are necessary.\n\n**Protocol Registration:** https://www.crd.york.ac.uk/PROSPERO identifier is CRD420251035763.", "abstract_zh": "**ä»‹ç»ï¼š** è¿™é¡¹ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ¯”è¾ƒäº†å‰åˆ—è…ºç™Œç»ä¼šé˜´æ´»æ£€ (TPBx) ä¸ç»ç›´è‚ æ´»æ£€ (TRBx) çš„è¯Šæ–­æ€§èƒ½å’Œå¹¶å‘ç—‡æƒ…å†µï¼Œçº³å…¥äº†æœ€è¿‘çš„éšæœºå’Œå¤§å‹è§‚å¯Ÿæ€§ç ”ç©¶ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ® PRISMA 2020 æŒ‡å—ï¼Œæ£€ç´¢äº† PubMedã€Scopusã€Embase å’Œ Cochrane å›¾ä¹¦é¦†ï¼Œç›´è‡³ 2025 å¹´ 4 æœˆã€‚å…¶ä¸­åŒ…æ‹¬ç›´æ¥æ¯”è¾ƒ TPBx å’Œ TRBx çš„ç ”ç©¶ã€‚ä½¿ç”¨ RoB 2.0 è¿›è¡Œéšæœºè¯•éªŒè¯„ä¼°åå€šé£é™©ï¼Œä½¿ç”¨çº½å¡æ–¯å°” - æ¸¥å¤ªåé‡è¡¨è¿›è¡Œè§‚å¯Ÿæ€§ç ”ç©¶ã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹è®¡ç®—å…·æœ‰ 95% ç½®ä¿¡åŒºé—´ (CI) çš„æ±‡æ€»ç›¸å¯¹é£é™© (RR)ã€‚è¿›è¡Œäºšç»„åˆ†æå’Œ GRADE è¯„ä¼°ä»¥è¯„ä¼°è¯æ®çš„ç¡®å®šæ€§ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 29 é¡¹ç ”ç©¶ (<i>n</i>â€‰=â€‰90,621)ã€‚ TPBx æ˜¾ç¤ºå‡ºè¾ƒé«˜çš„ PCa æ£€å‡ºç‡ï¼ˆRR 1.08ï¼›95% CI 1.01-1.15ï¼›<i>p</i>â€‰=â€‰0.02ï¼‰å’Œ csPCa æ£€å‡ºç‡ï¼ˆRR 1.14ï¼›95% CI 1.05-1.24ï¼›<i>p</i>â€‰=â€‰0.001ï¼‰ï¼Œä½†è¯æ®è´¨é‡ä¸ºä½è‡³ä¸­ç­‰ã€‚å¼‚è´¨æ€§ä¸ºä¸­åº¦è‡³é«˜åº¦ã€‚ TPBx è¿˜è¡¨ç°å‡ºè¾ƒä½çš„æ„ŸæŸ“ç›¸å…³å¹¶å‘ç—‡å’Œå¯æ¯”è¾ƒçš„æ€»ä½“äº‹ä»¶ï¼Œå°½ç®¡æ‰‹æœ¯ç›¸å…³çš„ç–¼ç—›ç•¥é«˜ã€‚\n\n**ç»“è®ºï¼š** ä¸ TRBx ç›¸æ¯”ï¼ŒTPBx å…·æœ‰æ›´é«˜çš„è¯Šæ–­ç‡å’Œæ›´ä½çš„æ„ŸæŸ“é£é™©ï¼Œä¸”å®‰å…¨æ€§ç›¸å½“ã€‚ç„¶è€Œï¼Œé‰´äºä¸­ç­‰å¼‚è´¨æ€§å’Œæœ‰é™çš„é«˜è´¨é‡éšæœºå¯¹ç…§è¯•éªŒï¼Œè¿›ä¸€æ­¥çš„éªŒè¯æ€§è¯•éªŒæ˜¯å¿…è¦çš„ã€‚\n\n**Protocol registrationï¼š** https://www.crd.york.ac.uk/PROSPERO æ ‡è¯†ç¬¦ä¸º CRD420251035763ã€‚", "keywords_zh": "å‰åˆ—è…ºæ´»æ£€ã€æœ‰ä¸´åºŠæ„ä¹‰çš„å‰åˆ—è…ºç™Œã€å‰åˆ—è…ºç™Œã€ç»ä¼šé˜´ã€ç»ç›´è‚ ", "keywords_en": "Prostate biopsy, clinically significant prostate cancer, prostate cancer, transperineal, transrectal", "link": "https://pubmed.ncbi.nlm.nih.gov/41399305/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 16 Dec 2025"}, {"id": "41385931", "title_en": "Transperineal versus Transrectal Prostate Biopsy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "title_zh": "ç»ä¼šé˜´å‰åˆ—è…ºæ´»æ£€ä¸ç»ç›´è‚ å‰åˆ—è…ºæ´»æ£€ï¼šéšæœºå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Leopoldo Alves Ribeiro-Filho", "abstract_en": "To compare the safety and diagnostic performance of transperineal (TP) versus transrectal (TR) ultrasound-guided prostate biopsies using only data from randomized controlled trials (RCTs). A systematic search was performed in multiple databases up to May 2025. We included only RCTs comparing TP and TR approaches in men undergoing MRI-targeted prostate biopsies. Meta-analysis was conducted using odds ratios (OR) and 95% confidence intervals (CI) for categorical outcomes. The primary endpoints were cancer detection rate and postbiopsy infection rate. Secondary outcomes included urinary retention, bleeding, pain, and complications stratified by the Clavien-Dindo system. Study quality and certainty of evidence were assessed using the Cochrane ROB2 and GRADE tools. Four RCTs encompassing 2682 patients (TP: 1323; TR: 1359) were included. No significant differences were observed in overall prostate cancer detection rates (OR 1.03, 95% CI, 0.79-1.36) or detection of anterior lesions (OR 1.01, 95% CI, 0.41-2.45). Similarly, no differences were found in bleeding (OR 1.14, 95% CI, 0.66-1.95), urinary retention (OR 1.01, 95% CI, 0.50-2.04), total infections (OR 1.02, 95% CI, 0.77-1.35), or severe infections (OR 2.17, 95% CI, 0.97-4.88). Mild pain was more frequent in the TP group (OR 1.56, 95% CI, 1.20-2.03), while moderate to severe pain did not differ significantly (OR 0.65, 95% CI, 0.39-1.07). Transperineal and transrectal MRI-fusion-guided biopsy approaches demonstrated equivalent diagnostic accuracy and safety profiles. While the transperineal route was associated with slightly greater mild discomfort, cancer detection and complication rates were comparable. The selection of approach should be guided by principles of antimicrobial stewardship, patient preference, and institutional expertise.", "abstract_zh": "ä»…ä½¿ç”¨éšæœºå¯¹ç…§è¯•éªŒ (RCT) çš„æ•°æ®æ¥æ¯”è¾ƒç»ä¼šé˜´ (TP) ä¸ç»ç›´è‚  (TR) è¶…å£°å¼•å¯¼å‰åˆ—è…ºæ´»æ£€çš„å®‰å…¨æ€§å’Œè¯Šæ–­æ€§èƒ½ã€‚æˆªè‡³ 2025 å¹´ 5 æœˆï¼Œæˆ‘ä»¬åœ¨å¤šä¸ªæ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ€§æ£€ç´¢ã€‚æˆ‘ä»¬ä»…çº³å…¥äº†æ¯”è¾ƒ TP å’Œ TR æ–¹æ³•åœ¨æ¥å— MRI é¶å‘å‰åˆ—è…ºæ´»æ£€çš„ç”·æ€§ä¸­çš„éšæœºå¯¹ç…§è¯•éªŒã€‚ä½¿ç”¨ä¼˜åŠ¿æ¯” (OR) å’Œ 95% ç½®ä¿¡åŒºé—´ (CI) è¿›è¡Œåˆ†ç±»ç»“æœçš„èŸèƒåˆ†æã€‚ä¸»è¦ç»ˆç‚¹æ˜¯ç™Œç—‡æ£€å‡ºç‡å’Œæ´»æ£€åæ„ŸæŸ“ç‡ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬æŒ‰ Clavien-Dindo ç³»ç»Ÿåˆ†å±‚çš„å°¿æ½´ç•™ã€å‡ºè¡€ã€ç–¼ç—›å’Œå¹¶å‘ç—‡ã€‚ä½¿ç”¨ Cochrane ROB2 å’Œ GRADE å·¥å…·è¯„ä¼°ç ”ç©¶è´¨é‡å’Œè¯æ®çš„ç¡®å®šæ€§ã€‚çº³å…¥äº†å››é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼Œæ¶‰åŠ 2682 åæ‚£è€…ï¼ˆTPï¼š1323ï¼›TRï¼š1359ï¼‰ã€‚æ€»ä½“å‰åˆ—è…ºç™Œæ£€å‡ºç‡ï¼ˆOR 1.03ï¼Œ95% CIï¼Œ0.79-1.36ï¼‰æˆ–å‰éƒ¨ç—…å˜æ£€å‡ºç‡ï¼ˆOR 1.01ï¼Œ95% CIï¼Œ0.41-2.45ï¼‰æ²¡æœ‰è§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ã€‚åŒæ ·ï¼Œå‡ºè¡€ï¼ˆOR 1.14ï¼Œ95% CIï¼Œ0.66-1.95ï¼‰ã€å°¿æ½´ç•™ï¼ˆOR 1.01ï¼Œ95% CIï¼Œ0.50-2.04ï¼‰ã€æ€»æ„ŸæŸ“ï¼ˆOR 1.02ï¼Œ95% CIï¼Œ0.77-1.35ï¼‰æˆ–ä¸¥é‡æ„ŸæŸ“ï¼ˆOR 2.17ï¼Œ95% CIï¼Œ 0.97-4.88ï¼‰ã€‚ TP ç»„è½»åº¦ç–¼ç—›æ›´ä¸ºå¸¸è§ï¼ˆOR 1.56ï¼Œ95% CIï¼Œ1.20-2.03ï¼‰ï¼Œè€Œä¸­åº¦è‡³é‡åº¦ç–¼ç—›æ²¡æœ‰æ˜¾ç€å·®å¼‚ï¼ˆOR 0.65ï¼Œ95% CIï¼Œ0.39-1.07ï¼‰ã€‚ç»ä¼šé˜´å’Œç»ç›´è‚  MRI èåˆå¼•å¯¼æ´»æ£€æ–¹æ³•è¡¨ç°å‡ºç›¸åŒçš„è¯Šæ–­å‡†ç¡®æ€§å’Œå®‰å…¨æ€§ã€‚è™½ç„¶ç»ä¼šé˜´é€”å¾„ä¼šå¸¦æ¥ç¨å¤§çš„è½»å¾®ä¸é€‚ï¼Œä½†ç™Œç—‡æ£€å‡ºç‡å’Œå¹¶å‘ç—‡å‘ç”Ÿç‡ç›¸å½“ã€‚æ–¹æ³•çš„é€‰æ‹©åº”éµå¾ªæŠ—èŒè¯ç‰©ç®¡ç†ã€æ‚£è€…åå¥½å’Œæœºæ„ä¸“ä¸šçŸ¥è¯†çš„åŸåˆ™ã€‚", "keywords_zh": "è¯Šæ–­, å‰åˆ—è…ºç™Œ, éšæœºè¯•éªŒ, ç»ä¼šé˜´æ´»æ£€, ç»ä¼šé˜´å‰åˆ—è…ºæ´»æ£€", "keywords_en": "Diagnosis, Prostate cancer, Randomized trial, Transperineal Biopsy, Transperineal prostate biopsy", "link": "https://pubmed.ncbi.nlm.nih.gov/41385931/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 12 Dec 2025"}, {"id": "41372917", "title_en": "The impact of primary tumor location of colorectal cancer on the survival outcome of patients with brain metastasis: a systematic review and meta-analysis", "title_zh": "ç»“ç›´è‚ ç™ŒåŸå‘è‚¿ç˜¤éƒ¨ä½å¯¹è„‘è½¬ç§»æ‚£è€…ç”Ÿå­˜ç»“å±€çš„å½±å“ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Abhishek Kumar", "abstract_en": "**Objectives:** Several prior studies have shown that in metastasized colorectal cancer, the primary cancer's location influences patients' survival rates, with left-sided colorectal cancer being associated with longer survival than right-sided colorectal cancer. This study aimed to explore the influence of the primary location of colorectal cancer on survival following brain metastasis.\n\n**Methods:** To address this clinical question, we conducted a systematic review and meta-analysis. We included studies focused on patients diagnosed with brain metastasis from colorectal cancer. These studies reported survival outcomes based on different primary tumor sites (right versus left and colon versus rectum). The primary outcome was to aggregate the hazard ratio (HR) of left-sided colorectal cancer when metastasized to the brain compared with right-sided colorectal cancer. The secondary outcome was to aggregate the HR of rectal cancer when it metastasized to the brain compared with colon cancer.\n\n**Results:** Ten studies with a total of 1792 patients were included in the meta-analysis, and combined HR was calculated. Left-sided colon cancer showed higher overall survival compared with right-sided colon cancer when metastasized to the brain (HR: 0.71, 95% CI: 0.54-0.94, I<sup>2</sup>â€‰=â€‰0%). Rectal cancer did not show a statistically significant difference in overall survival compared with colon cancer (HR: 0.75, 95% CI: 0.40-1.41, I<sup>2</sup>â€‰=â€‰81%).\n\n**Conclusions:** Concordant with lung and liver metastases, the primary location of colorectal cancer influenced overall survival when metastasized to the brain. Left-sided colon cancer demonstrated higher overall survival than right-sided colon cancer.", "abstract_zh": "**Objectivesï¼š** å…ˆå‰çš„å‡ é¡¹ç ”ç©¶è¡¨æ˜ï¼Œåœ¨è½¬ç§»æ€§ç»“ç›´è‚ ç™Œä¸­ï¼ŒåŸå‘ç™Œç—‡çš„ä½ç½®ä¼šå½±å“æ‚£è€…çš„ç”Ÿå­˜ç‡ï¼Œå·¦ä¾§ç»“ç›´è‚ ç™Œæ¯”å³ä¾§ç»“ç›´è‚ ç™Œçš„ç”Ÿå­˜æœŸæ›´é•¿ã€‚æœ¬ç ”ç©¶æ—¨åœ¨æ¢è®¨ç»“ç›´è‚ ç™Œçš„åŸå‘éƒ¨ä½å¯¹è„‘è½¬ç§»åç”Ÿå­˜çš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** ä¸ºäº†è§£å†³è¿™ä¸ªä¸´åºŠé—®é¢˜ï¼Œæˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æã€‚æˆ‘ä»¬çº³å…¥çš„ç ”ç©¶é‡ç‚¹æ˜¯è¯Šæ–­ä¸ºç»“ç›´è‚ ç™Œè„‘è½¬ç§»çš„æ‚£è€…ã€‚è¿™äº›ç ”ç©¶æŠ¥å‘Šäº†åŸºäºä¸åŒåŸå‘è‚¿ç˜¤éƒ¨ä½ï¼ˆå³ä¸å·¦ã€ç»“è‚ ä¸ç›´è‚ ï¼‰çš„ç”Ÿå­˜ç»“æœã€‚ä¸»è¦ç»“æœæ˜¯æ±‡æ€»å·¦ä¾§ç»“ç›´è‚ ç™Œä¸å³ä¾§ç»“ç›´è‚ ç™Œè½¬ç§»è‡³å¤§è„‘æ—¶çš„é£é™©æ¯”ï¼ˆHRï¼‰ã€‚æ¬¡è¦ç»“æœæ˜¯ä¸ç»“è‚ ç™Œç›¸æ¯”ï¼Œæ±‡æ€»ç›´è‚ ç™Œè½¬ç§»è‡³å¤§è„‘æ—¶çš„ HRã€‚\n\n**ç»“æœï¼š** èŸèƒåˆ†æçº³å…¥ 10 é¡¹ç ”ç©¶ï¼Œå…± 1792 åæ‚£è€…ï¼Œå¹¶è®¡ç®—äº†åˆå¹¶ HRã€‚å½“è½¬ç§»è‡³è„‘éƒ¨æ—¶ï¼Œå·¦ä¾§ç»“è‚ ç™Œæ¯”å³ä¾§ç»“è‚ ç™Œè¡¨ç°å‡ºæ›´é«˜çš„æ€»ç”Ÿå­˜ç‡ï¼ˆHRï¼š0.71ï¼Œ95% CIï¼š0.54-0.94ï¼ŒI<sup>2</sup>â€‰=â€‰0%ï¼‰ã€‚ä¸ç»“è‚ ç™Œç›¸æ¯”ï¼Œç›´è‚ ç™Œçš„æ€»ç”Ÿå­˜ç‡æ²¡æœ‰è¡¨ç°å‡ºç»Ÿè®¡å­¦ä¸Šçš„æ˜¾ç€å·®å¼‚ï¼ˆHRï¼š0.75ï¼Œ95% CIï¼š0.40-1.41ï¼ŒI<sup>2</sup>â€‰=â€‰81%ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ä¸è‚ºå’Œè‚è½¬ç§»ä¸€è‡´ï¼Œç»“ç›´è‚ ç™Œè½¬ç§»åˆ°å¤§è„‘æ—¶çš„ä¸»è¦ä½ç½®ä¼šå½±å“æ€»ä½“ç”Ÿå­˜ç‡ã€‚å·¦ä¾§ç»“è‚ ç™Œçš„æ€»ä½“ç”Ÿå­˜ç‡é«˜äºå³ä¾§ç»“è‚ ç™Œã€‚", "keywords_zh": "è„‘è½¬ç§»ã€ç»“ç›´è‚ ç™Œã€å·¦ç»“è‚ ç™Œã€ç›´è‚ ç™Œã€å³ç»“è‚ ç™Œ", "keywords_en": "Brain metastasis, Colorectal cancer, Left colon cancer, Rectal cancer, Right colon cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/41372917/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 10 Dec 2025"}, {"id": "41359190", "title_en": "Anatomical and functional outcomes of combined ventral rectopexy and sacrocolpo/hysteropexy for multicompartment pelvic organ prolapse: a systematic review and meta-analysis", "title_zh": "è…¹ä¾§ç›´è‚ å›ºå®šæœ¯å’Œéª¶é˜´é“/å­å®«å›ºå®šæœ¯è”åˆæ²»ç–—å¤šå®¤ç›†è…”å™¨å®˜è„±å‚çš„è§£å‰–å’ŒåŠŸèƒ½ç»“æœï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Marine Lallemant", "abstract_en": "**Introduction:** Limited data exists in literature regarding concomitant ventral rectopexy (VRP) and sacrocolpo/hysteropexy (SCP/SHP), with existing studies being predominantly retrospective. The aim of this meta-analysis is to assess the anatomical and functional outcomes of combined VRP and SCP/SHP for the treatment of multicompartmental pelvic organ prolapse (POP).\n\n**Methods:** We performed systematic research and meta-analysis from PubMed/MEDLINE and EMBASE, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, until 15 January 2025. Women submitted to VRP with SCP/SHP were included. Improvement of anorectal symptoms were evaluated. Postoperative anatomical relapse was reported. Re-operation rates were evaluated.\n\n**Results:** Six articles were included. Constipation/obstructed defecation syndrome (ODS) [odds ratio (OR) 0.26, 95% CI 0.10-0.68; pâ€‰=â€‰0.006 (I<sup>2</sup> test 81%, pâ€‰=â€‰0.56)] and of anal/fecal incontinence (AI/FI) rates [OR 0.09, 95% CI 0.03-0.30; pâ€‰<â€‰0.0001 (I<sup>2</sup> test 70%, pâ€‰=â€‰0.04)] significantly improved after combined VRP and SCP/SHP. The proportion metanalysis of four included studies reported a subjective POP recurrence rate of 7% (95% CI 1-13%; I<sup>2</sup> test 82.9%, pâ€‰<â€‰0.001). The proportion metanalysis of five included studies for objective POP recurrence was 5% (95% CI 1-9%; I<sup>2</sup> test 56.9%, pâ€‰=â€‰0.041). No serious adverse events were reported.\n\n**Conclusions:** VRP combined with SCP/SHP has been shown to be safe and effective for women with multicompartment POP, providing optimal anatomical and functional outcomes. Larger, long-term, prospective-controlled studies are needed to confirm these results.", "abstract_zh": "**ä»‹ç»ï¼š** æ–‡çŒ®ä¸­å…³äºä¼´éšè…¹ä¾§ç›´è‚ å›ºå®šæœ¯ï¼ˆVRPï¼‰å’Œéª¶é˜´é“/å­å®«å›ºå®šæœ¯ï¼ˆSCP/SHPï¼‰çš„æ•°æ®æœ‰é™ï¼Œç°æœ‰ç ”ç©¶ä¸»è¦æ˜¯å›é¡¾æ€§çš„ã€‚æœ¬èŸèƒåˆ†æçš„ç›®çš„æ˜¯è¯„ä¼° VRP å’Œ SCP/SHP è”åˆæ²»ç–—å¤šå®¤ç›†è…”å™¨å®˜è„±å‚ (POP) çš„è§£å‰–å­¦å’ŒåŠŸèƒ½ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2025 å¹´ 1 æœˆ 15 æ—¥ï¼Œæˆ‘ä»¬æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) 2020 æŒ‡å—ï¼Œä» PubMed/MEDLINE å’Œ EMBASE è¿›è¡Œäº†ç³»ç»Ÿç ”ç©¶å’ŒèŸèƒåˆ†æã€‚çº³å…¥äº†é€šè¿‡ SCP/SHP æäº¤ VRP çš„å¥³æ€§ã€‚è¯„ä¼°è‚›é—¨ç›´è‚ ç—‡çŠ¶çš„æ”¹å–„æƒ…å†µã€‚æ®æŠ¥é“æœ¯åè§£å‰–å­¦å¤å‘ã€‚è¯„ä¼°äº†å†æ‰‹æœ¯ç‡ã€‚\n\n**ç»“æœï¼š** æ”¶å½•äº†å…­ç¯‡æ–‡ç« ã€‚ä¾¿ç§˜/æ’ä¾¿é˜»å¡ç»¼åˆå¾ (ODS) [æ¯”å€¼æ¯” (OR) 0.26ï¼Œ95% CI 0.10-0.68ï¼› pâ€‰=â€‰0.006ï¼ˆI<sup>2</sup> æµ‹è¯• 81%ï¼Œpâ€‰=â€‰0.56ï¼‰] å’Œè‚›é—¨/å¤§ä¾¿å¤±ç¦ (AI/FI) ç‡ [OR 0.09ï¼Œ95% CI 0.03-0.30ï¼› pâ€‰<â€‰0.0001ï¼ˆI<sup>2</sup>æµ‹è¯•70%ï¼Œpâ€‰=â€‰0.04ï¼‰]åœ¨VRPå’ŒSCP/SHPç»“åˆåæ˜¾ç€æ”¹å–„ã€‚å››é¡¹çº³å…¥ç ”ç©¶çš„æ¯”ä¾‹èŸèƒåˆ†ææŠ¥å‘Šä¸»è§‚ POP å¤å‘ç‡ä¸º 7%ï¼ˆ95% CI 1-13%ï¼›I<sup>2</sup> æ£€éªŒ 82.9%ï¼Œp<0.001ï¼‰ã€‚äº”é¡¹çº³å…¥å®¢è§‚ POP å¤å‘ç ”ç©¶çš„èŸèƒåˆ†ææ¯”ä¾‹ä¸º 5%ï¼ˆ95% CI 1-9%ï¼›I<sup>2</sup> æ£€éªŒ 56.9%ï¼Œpâ€‰=â€‰0.041ï¼‰ã€‚æ²¡æœ‰æŠ¥å‘Šä¸¥é‡ä¸è‰¯äº‹ä»¶ã€‚\n\n**ç»“è®ºï¼š** VRP ä¸ SCP/SHP ç›¸ç»“åˆå·²è¢«è¯æ˜å¯¹æ‚£æœ‰å¤šå®¤ POP çš„å¥³æ€§å®‰å…¨æœ‰æ•ˆï¼Œå¯æä¾›æœ€ä½³çš„è§£å‰–å’ŒåŠŸèƒ½ç»“æœã€‚éœ€è¦æ›´å¤§è§„æ¨¡ã€é•¿æœŸã€å‰ç»æ€§å¯¹ç…§ç ”ç©¶æ¥è¯å®è¿™äº›ç»“æœã€‚", "keywords_zh": "è‚›é—¨å¤±ç¦ã€æ’ä¾¿é˜»å¡ç»¼åˆå¾ã€ç›†è…”å™¨å®˜è„±å‚ã€ç›´è‚ è„±å‚ã€éª¶éª¨é˜´é“å›ºå®šæœ¯ã€éª¶å­å®«å›ºå®šæœ¯ã€è…¹ä¾§ç›´è‚ å›ºå®šæœ¯", "keywords_en": "Anal incontinence, Obstructed defecation syndrome, Pelvic organ prolapse, Rectal prolapse, Sacrocolpopexy, Sacrohysteropexy, Ventral rectopexy", "link": "https://pubmed.ncbi.nlm.nih.gov/41359190/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 08 Dec 2025"}, {"id": "41316735", "title_en": "Colorectal polyp distribution in relation to age: meta-analysis", "title_zh": "ç»“ç›´è‚ æ¯è‚‰åˆ†å¸ƒä¸å¹´é¾„çš„å…³ç³»ï¼šèŸèƒåˆ†æ", "authors": "Frank Frizelle", "abstract_en": "**Background:** An increase in early-onset colorectal cancer has been observed globally, despite a decline in colorectal cancer incidence rates in many Western countries. Screening strategies for younger individuals are particularly challenging, as there are limited data on polyps in young individuals to guide clinicians. This study aimed to systematically review the current evidence surrounding polyp distribution in different age groups.\n\n**Methods:** A literature search was performed in PubMed, Scopus, MEDLINE, Embase (OVID), Web of Science, and Cochrane Review databases using the keywords 'age' and 'polyp', and Medical Subject Heading terms 'age of onset', 'age factors', 'age distribution', and 'age groups', with no restrictions on publication year. Articles published in English that described the distribution of polyps (adenomatous, advanced adenomatous polyps, and sessile serrated lesions) or individuals with polyps according to different age groups were considered for inclusion. Younger patients were defined as those aged < 50 years. The outcomes of interest were the number of patients with polyps in the left and/or right colon, or the number of polyps per side of the colorectum in different age groups.\n\n**Results:** From 12 470 articles, 24 met the eligibility criteria for the systematic review, and 12 were suitable for meta-analysis. Among younger people, 46.5% had right-sided and 75.9% had left-sided polyps. In comparison, 70.8% of the older group had right-sided and 61.9% had left-sided polyps. Meta-analyses of studies showed a greater proportion of younger people than older people with at least one left-sided polyp (mean difference 0.06, 95% confidence interval (c.i.) 0.03 to 0.09; P < 0.001). There was also a greater proportion of left-sided polyps in younger people (odds ratio 0.77, 95% c.i. 0.59 to 1.01; P < 0.001).\n\n**Conclusion:** Patients aged < 50 years have a greater tendency towards having polyps in the left colon, compared with people â‰¥ 50 years of age, similar to the distribution of early-onset colorectal cancer. This has implications for the methodology of screening and investigation of symptoms in those aged < 50 years.", "abstract_zh": "**èƒŒæ™¯ï¼š** å°½ç®¡è®¸å¤šè¥¿æ–¹å›½å®¶çš„ç»“ç›´è‚ ç™Œå‘ç—…ç‡æœ‰æ‰€ä¸‹é™ï¼Œä½†å…¨çƒèŒƒå›´å†…æ—©å‘æ€§ç»“ç›´è‚ ç™Œçš„å‘ç—…ç‡æœ‰æ‰€å¢åŠ ã€‚é’ˆå¯¹å¹´è½»äººçš„ç­›æŸ¥ç­–ç•¥å°¤å…¶å…·æœ‰æŒ‘æˆ˜æ€§ï¼Œå› ä¸ºæŒ‡å¯¼ä¸´åºŠåŒ»ç”Ÿçš„å¹´è½»äººæ¯è‚‰æ•°æ®æœ‰é™ã€‚æœ¬ç ”ç©¶æ—¨åœ¨ç³»ç»Ÿåœ°å›é¡¾æœ‰å…³ä¸åŒå¹´é¾„ç»„æ¯è‚‰åˆ†å¸ƒçš„å½“å‰è¯æ®ã€‚\n\n**æ–¹æ³•ï¼š** ä½¿ç”¨å…³é”®è¯â€œå¹´é¾„â€å’Œâ€œæ¯è‚‰â€ä»¥åŠåŒ»å­¦ä¸»é¢˜è¯â€œå‘ç—…å¹´é¾„â€ã€â€œå¹´é¾„å› ç´ â€ã€â€œå¹´é¾„åˆ†å¸ƒâ€å’Œâ€œå¹´é¾„ç»„â€åœ¨ PubMedã€Scopusã€MEDLINEã€Embase (OVID)ã€Web of Science å’Œ Cochrane Review æ•°æ®åº“ä¸­è¿›è¡Œæ–‡çŒ®æ£€ç´¢ï¼Œå¯¹å‘è¡¨å¹´ä»½æ²¡æœ‰é™åˆ¶ã€‚ä»¥è‹±æ–‡å‘è¡¨çš„æè¿°æ¯è‚‰ï¼ˆè…ºç˜¤æ€§ã€æ™šæœŸè…ºç˜¤æ€§æ¯è‚‰å’Œæ— è’‚é”¯é½¿çŠ¶ç—…å˜ï¼‰æˆ–æ¯è‚‰ä¸ªä½“æ ¹æ®ä¸åŒå¹´é¾„ç»„çš„åˆ†å¸ƒçš„æ–‡ç« è¢«è€ƒè™‘çº³å…¥ã€‚å¹´è½»æ‚£è€…è¢«å®šä¹‰ä¸ºå¹´é¾„ < 50 å²çš„æ‚£è€…ã€‚æ„Ÿå…´è¶£çš„ç»“æœæ˜¯å·¦å’Œ/æˆ–å³ç»“è‚ æ¯è‚‰æ‚£è€…çš„æ•°é‡ï¼Œæˆ–ä¸åŒå¹´é¾„ç»„æ¯ä¾§ç»“è‚ ç›´è‚ æ¯è‚‰çš„æ•°é‡ã€‚\n\n**ç»“æœï¼š** åœ¨ 12 470 ç¯‡æ–‡ç« ä¸­ï¼Œ24 ç¯‡ç¬¦åˆç³»ç»Ÿè¯„ä»·çš„èµ„æ ¼æ ‡å‡†ï¼Œ12 ç¯‡é€‚åˆèŸèƒåˆ†æã€‚åœ¨å¹´è½»äººä¸­ï¼Œ46.5% æ‚£æœ‰å³ä¾§æ¯è‚‰ï¼Œ75.9% æ‚£æœ‰å·¦ä¾§æ¯è‚‰ã€‚ç›¸æ¯”ä¹‹ä¸‹ï¼Œ70.8% çš„è€å¹´äººæ‚£æœ‰å³ä¾§æ¯è‚‰ï¼Œ61.9% çš„è€å¹´äººæ‚£æœ‰å·¦ä¾§æ¯è‚‰ã€‚ç ”ç©¶èŸèƒåˆ†ææ˜¾ç¤ºï¼Œæ‚£æœ‰è‡³å°‘ä¸€é¢—å·¦ä¾§æ¯è‚‰çš„å¹´è½»äººæ¯”ä¾‹é«˜äºè€å¹´äººï¼ˆå¹³å‡å·® 0.06ï¼Œ95% ç½®ä¿¡åŒºé—´ (c.i.) 0.03 è‡³ 0.09ï¼›P < 0.001ï¼‰ã€‚å¹´è½»äººä¸­å·¦ä¾§æ¯è‚‰çš„æ¯”ä¾‹ä¹Ÿè¾ƒé«˜ï¼ˆæ¯”å€¼æ¯” 0.77ï¼Œ95% c.i. 0.59 è‡³ 1.01ï¼›P < 0.001ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ä¸å¹´é¾„â‰¥50å²çš„äººç›¸æ¯”ï¼Œå¹´é¾„<50å²çš„æ‚£è€…å·¦åŠç»“è‚ æ¯è‚‰çš„å€¾å‘æ›´å¤§ï¼Œä¸æ—©å‘æ€§ç»“ç›´è‚ ç™Œçš„åˆ†å¸ƒç›¸ä¼¼ã€‚è¿™å¯¹äº 50 å²ä»¥ä¸‹äººç¾¤çš„ç—‡çŠ¶ç­›æŸ¥å’Œè°ƒæŸ¥æ–¹æ³•å…·æœ‰é‡è¦æ„ä¹‰ã€‚", "keywords_zh": "è…ºç˜¤ã€ç»“è‚ ã€ç›´è‚ ã€æ— è’‚é”¯é½¿çŠ¶ç—…å˜", "keywords_en": "adenoma, colon, rectum, sessile serrated lesions", "link": "https://pubmed.ncbi.nlm.nih.gov/41316735/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sat, 29 Nov 2025"}, {"id": "41290553", "title_en": "Preemptive Versus Postoperative Analgesia in Colorectal Surgery: A Systematic Review and Meta-Analysis", "title_zh": "ç»“ç›´è‚ æ‰‹æœ¯ä¸­çš„å…ˆå‘æ€§é•‡ç—›ä¸æœ¯åé•‡ç—›ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Muhammed Elhadi", "abstract_en": "**Background:** Preemptive and preventative methods have been suggested to decrease pain by blocking nociceptive inputs to tissues. Preemptive analgesia has the potential to enhance postoperative recovery in patients undergoing colorectal surgery. This study aimed to evaluate the efficacy and safety of preemptive versus postoperative analgesia in this population.\n\n**Methods:** We systematically searched PubMed, Scopus, Web of Science, and the Cochrane Library from inception to December 2024, and updated the search in May 2025, to identify randomized controlled trials (RCTs) comparing preemptive analgesia with postoperative analgesia in adult patients undergoing colorectal surgery. The primary outcomes were opioid consumption within 24Â h, visual analog scale (VAS) pain score at rest at 24 and 48Â h postoperatively. Secondary outcomes included adverse events, length of hospital stay, surgery duration (minutes), and postoperative nausea and vomiting (PONV). The Cochrane Risk of Bias 2.0 tool was used to assess risk of bias, and the strength of evidence was graded using the GRADE approach.\n\n**Results:** We identified a total of 2739 records. Seven studies involving 625 patients (312 preemptive and 313 postoperative) met the inclusion criteria. Preemptive analgesia decreased VAS scores at 24Â h compared to postoperative analgesia (MD -0.45, 95% CI: -0.89 to -0.01, pÂ =Â 0.04). However, significant heterogeneity was observed among included studies. Additionally, there was no difference between the two groups regarding VAS at 48Â h (MD -0.17, 95% CI -0.43 to 0.09, pÂ =Â 0.21) and opioid consumption at 24Â h (MD -21.17, 95% CI 48.18-5.85, pÂ =Â 0.12).\n\n**Conclusion:** The findings indicate that preemptive analgesia did not decrease opioid consumption at 24Â h; however, it decreased VAS score at 24Â h without any difference in VAS at 48Â h, length of hospital stay, incidence of PONV, or other adverse events when compared to postoperative analgesia alone in colorectal surgery.\n\n**Trial Registration:** The study is registered in PROSPERO under the registration number CRD420250636020.", "abstract_zh": "**èƒŒæ™¯ï¼š** å·²æå‡ºå…ˆå‘åˆ¶äººå’Œé¢„é˜²æ€§æ–¹æ³•ï¼Œé€šè¿‡é˜»æ­¢å¯¹ç»„ç»‡çš„ä¼¤å®³æ€§è¾“å…¥æ¥å‡è½»ç–¼ç—›ã€‚è¶…å‰é•‡ç—›æœ‰å¯èƒ½ä¿ƒè¿›ç»“ç›´è‚ æ‰‹æœ¯æ‚£è€…çš„æœ¯åæ¢å¤ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼°å…ˆå‘æ€§é•‡ç—›ä¸æœ¯åé•‡ç—›åœ¨è¿™ä¸€äººç¾¤ä¸­çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬ç³»ç»Ÿåœ°æ£€ç´¢äº† PubMedã€Scopusã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†ï¼Œä»å¼€å§‹åˆ° 2024 å¹´ 12 æœˆï¼Œå¹¶äº 2025 å¹´ 5 æœˆæ›´æ–°äº†æ£€ç´¢ï¼Œä»¥è¯†åˆ«åœ¨æ¥å—ç»“ç›´è‚ æ‰‹æœ¯çš„æˆå¹´æ‚£è€…ä¸­æ¯”è¾ƒè¶…å‰é•‡ç—›ä¸æœ¯åé•‡ç—›çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€‚ä¸»è¦ç»“æœæ˜¯ 24 å°æ—¶å†…é˜¿ç‰‡ç±»è¯ç‰©çš„æ¶ˆè€—é‡ã€æœ¯å 24 å°æ—¶å’Œ 48 å°æ—¶çš„è§†è§‰æ¨¡æ‹Ÿé‡è¡¨ (VAS) é™æ¯ç–¼ç—›è¯„åˆ†ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬ä¸è‰¯äº‹ä»¶ã€ä½é™¢æ—¶é—´ã€æ‰‹æœ¯æŒç»­æ—¶é—´ï¼ˆåˆ†é’Ÿï¼‰å’Œæœ¯åæ¶å¿ƒå’Œå‘•åï¼ˆPONVï¼‰ã€‚ Cochrane åå€šé£é™© 2.0 å·¥å…·ç”¨äºè¯„ä¼°åå€šé£é™©ï¼Œå¹¶ä½¿ç”¨ GRADE æ–¹æ³•å¯¹è¯æ®å¼ºåº¦è¿›è¡Œåˆ†çº§ã€‚\n\n**ç»“æœï¼š** æˆ‘ä»¬æ€»å…±è¯†åˆ«å‡º 2739 æ¡è®°å½•ã€‚æ¶‰åŠ 625 åæ‚£è€…ï¼ˆ312 åå…ˆå‘æ€§æ‚£è€…å’Œ 313 åæœ¯åæ‚£è€…ï¼‰çš„ 7 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚ä¸æœ¯åé•‡ç—›ç›¸æ¯”ï¼Œè¶…å‰é•‡ç—›åœ¨ 24 å°æ—¶é™ä½äº† VAS è¯„åˆ†ï¼ˆMD -0.45ï¼Œ95% CIï¼š-0.89 è‡³ -0.01ï¼Œp = 0.04ï¼‰ã€‚ç„¶è€Œï¼Œçº³å…¥çš„ç ”ç©¶ä¹‹é—´è§‚å¯Ÿåˆ°æ˜¾ç€çš„å¼‚è´¨æ€§ã€‚æ­¤å¤–ï¼Œä¸¤ç»„ä¹‹é—´ 48 å°æ—¶ VASï¼ˆMD -0.17ï¼Œ95% CI -0.43 è‡³ 0.09ï¼Œp = 0.21ï¼‰å’Œ 24 å°æ—¶é˜¿ç‰‡ç±»è¯ç‰©æ¶ˆè€—é‡ï¼ˆMD -21.17ï¼Œ95% CI 48.18-5.85ï¼Œp = 0.12ï¼‰ä¹‹é—´æ²¡æœ‰å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œè¶…å‰é•‡ç—›å¹¶æ²¡æœ‰å‡å°‘ 24 å°æ—¶é˜¿ç‰‡ç±»è¯ç‰©çš„æ¶ˆè€—é‡ï¼›ç„¶è€Œï¼Œä¸ç»“ç›´è‚ æ‰‹æœ¯ä¸­å•ç‹¬ä½¿ç”¨æœ¯åé•‡ç—›ç›¸æ¯”ï¼Œå®ƒé™ä½äº† 24 å°æ—¶ VAS è¯„åˆ†ï¼Œä½† 48 å°æ—¶ VASã€ä½é™¢æ—¶é—´ã€PONV å‘ç”Ÿç‡æˆ–å…¶ä»–ä¸è‰¯äº‹ä»¶æ²¡æœ‰ä»»ä½•å·®å¼‚ã€‚\n\n**Trial registrationï¼š** è¯¥ç ”ç©¶å·²åœ¨ PROSPERO ä¸­æ³¨å†Œï¼Œæ³¨å†Œå·ä¸º CRD420250636020ã€‚", "keywords_zh": "ç»“ç›´è‚ æ‰‹æœ¯ã€æœ¯åé•‡ç—›ã€è¶…å‰é•‡ç—›", "keywords_en": "colorectal surgery, postoperative analgesia, preemptive analgesia", "link": "https://pubmed.ncbi.nlm.nih.gov/41290553/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 25 Nov 2025"}, {"id": "41263625", "title_en": "Regarding: \"Efficacy and safety of methylene blue for postoperative pain of haemorrhoids: a systematic review and meta-analysis\"", "title_zh": "å…³äºï¼šâ€œäºšç”²è“æ²»ç–—ç—”ç–®æœ¯åç–¼ç—›çš„åŠŸæ•ˆå’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æâ€", "authors": "Fahmi H Kakamad", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/41263625/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 20 Nov 2025"}, {"id": "41223393", "title_en": "Systematic Review of Hyperbaric Oxygen for Late Radiation Tissue Injury (Bowel, Bladder)", "title_zh": "é«˜å‹æ°§æ²»ç–—æ™šæœŸæ”¾å°„æ€§ç»„ç»‡æŸä¼¤ï¼ˆè‚ ã€è†€èƒ±ï¼‰çš„ç³»ç»Ÿè¯„ä»·", "authors": "Marissa Janine Carter", "abstract_en": "**Background:** This systematic review evaluated comparative studies to determine if hyperbaric oxygen therapy (HBOâ‚‚) is beneficial to late radiation tissue injury (LRTI) of the bowel/bladder.\n\n**Methods:** We included adequately powered, comparative studies evaluating the effect of HBOâ‚‚ on patients with LRTI (â‰¥3 months duration and/or â‰¥6 months after radiation therapy) to the bowel/bladder compared to no HBOâ‚‚ or placebo/sham; complete outcomes data must have corresponded to the tools used to measure change in LRTI symptoms. Medline was searched through May 4, 2023, Embase through May 29, 2023, and Google Scholar through May 5, 2023. The Cochrane risk-of-bias tool and GRADE approach were used with a certainty of outcomes assessment.\n\n**Results:** Three RCTs were included with 273 subjects. Two double-blinded studies evaluated rectal symptoms; one open study evaluated cystitis. One study had a low risk of bias; two had some concerns. All had moderate certainty of outcomes. There is moderate certainty with a weak recommendation for using HBOâ‚‚ for rectal complications or cystitis, which (in context of GRADE terminology) means the decision to treat depends on a case-by-case basis.\n\n**Discussion:** The highly heterogeneous design of the trials made meta-analysis impossible, but moderate certainty of the beneficial effect of HBOâ‚‚ on LRTI to the rectum and bladder was confirmed. With the weak recommendation, a discussion should take place between the patient and their physician as to whether or not the patient is likely to benefit from HBOâ‚‚.", "abstract_zh": "**èƒŒæ™¯ï¼š** æœ¬ç³»ç»Ÿç»¼è¿°è¯„ä¼°äº†æ¯”è¾ƒç ”ç©¶ï¼Œä»¥ç¡®å®šé«˜å‹æ°§æ²»ç–— (HBO 2) æ˜¯å¦æœ‰ç›Šäºè‚ /è†€èƒ±çš„æ™šæœŸæ”¾å°„æ€§ç»„ç»‡æŸä¼¤ (LRTI)ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬çº³å…¥äº†å……åˆ†æœ‰åŠ›çš„æ¯”è¾ƒç ”ç©¶ï¼Œè¯„ä¼°ä¸ä¸ä½¿ç”¨ HBO æˆ–å®‰æ…°å‰‚/å‡æ‰‹æœ¯ç›¸æ¯”ï¼ŒHBO 2 å¯¹ LRTIï¼ˆæŒç»­æ—¶é—´â‰¥3 ä¸ªæœˆå’Œ/æˆ–æ”¾å°„æ²»ç–—åâ‰¥6 ä¸ªæœˆï¼‰æ‚£è€…å¯¹è‚ /è†€èƒ±çš„å½±å“ï¼›å®Œæ•´çš„ç»“æœæ•°æ®å¿…é¡»ä¸ç”¨äºæµ‹é‡ LRTI ç—‡çŠ¶å˜åŒ–çš„å·¥å…·ç›¸å¯¹åº”ã€‚ Medline çš„æ£€ç´¢æˆªæ­¢æ—¥æœŸä¸º 2023 å¹´ 5 æœˆ 4 æ—¥ï¼ŒEmbase çš„æ£€ç´¢æˆªæ­¢æ—¥æœŸä¸º 2023 å¹´ 5 æœˆ 29 æ—¥ï¼ŒGoogle Scholar çš„æ£€ç´¢æˆªæ­¢æ—¥æœŸä¸º 2023 å¹´ 5 æœˆ 5 æ—¥ã€‚ä½¿ç”¨ Cochrane åå€šé£é™©å·¥å…·å’Œ GRADE æ–¹æ³•å¯¹ç»“æœè¿›è¡Œç¡®å®šæ€§è¯„ä¼°ã€‚\n\n**ç»“æœï¼š** ä¸‰é¡¹éšæœºå¯¹ç…§è¯•éªŒçº³å…¥äº† 273 åå—è¯•è€…ã€‚ä¸¤é¡¹åŒç›²ç ”ç©¶è¯„ä¼°äº†ç›´è‚ ç—‡çŠ¶ï¼›ä¸€é¡¹å¼€æ”¾ç ”ç©¶è¯„ä¼°äº†è†€èƒ±ç‚ã€‚ä¸€é¡¹ç ”ç©¶çš„åå€šé£é™©è¾ƒä½ï¼›ä¸¤ä¸ªäººæœ‰ä¸€äº›æ‹…å¿§ã€‚æ‰€æœ‰ç»“æœçš„ç¡®å®šæ€§å‡ä¸ºä¸­ç­‰ã€‚å¯¹äºä½¿ç”¨ HBO æ¥æ²»ç–—ç›´è‚ å¹¶å‘ç—‡æˆ–è†€èƒ±ç‚æœ‰ä¸­ç­‰ç¨‹åº¦çš„ç¡®å®šæ€§å’Œå¼±æ¨èï¼Œè¿™ï¼ˆåœ¨ GRADE æœ¯è¯­çš„èƒŒæ™¯ä¸‹ï¼‰æ„å‘³ç€æ²»ç–—å†³å®šå–å†³äºå…·ä½“æƒ…å†µã€‚\n\n**è®¨è®ºï¼š** è¯•éªŒè®¾è®¡çš„é«˜åº¦å¼‚è´¨æ€§ä½¿å¾—èŸèƒåˆ†æå˜å¾—ä¸å¯èƒ½ï¼Œä½† HBO2 å¯¹ç›´è‚ å’Œè†€èƒ± LRTI çš„æœ‰ç›Šä½œç”¨çš„ä¸­ç­‰ç¡®å®šæ€§å¾—åˆ°äº†è¯å®ã€‚å¯¹äºå¼±å»ºè®®ï¼Œæ‚£è€…å’ŒåŒ»ç”Ÿåº”å°±æ‚£è€…æ˜¯å¦å¯èƒ½ä» HBO2 ä¸­å—ç›Šè¿›è¡Œè®¨è®ºã€‚", "keywords_zh": "LRTIã€ç™Œç—‡ã€æ…¢æ€§ä¼¤å£ã€æ¯”è¾ƒç ”ç©¶ã€è†€èƒ±ç‚ã€é«˜å‹æ°§æ²»ç–—ã€ç›´è‚ ç‚", "keywords_en": "LRTI, cancer, chronic wounds, comparative studies, cystitis, hyperbaric oxygen therapy, proctitis", "link": "https://pubmed.ncbi.nlm.nih.gov/41223393/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 12 Nov 2025"}, {"id": "41075390", "title_en": "Quality of Life and Functional Outcomes After Watch-and-Wait for Locally Advanced Rectal Cancer: A Meta-analysis", "title_zh": "å±€éƒ¨æ™šæœŸç›´è‚ ç™Œè§‚å¯Ÿç­‰å¾…åçš„ç”Ÿæ´»è´¨é‡å’ŒåŠŸèƒ½ç»“æœï¼šèŸèƒåˆ†æ", "authors": "Jonathan S Abelson", "abstract_en": "**Introduction:** Watch-and-wait (W&W), which involves total neoadjuvant therapy followed by close observation, has emerged as an alternative to total mesorectal excision for patients with locally advanced rectal cancer who achieve a clinical or near-complete response. This approach aims to preserve bowel function and avoid the morbidity associated with radical surgery.\n\n**Methods:** This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Cochrane guidelines. Eligible studies included randomized trials and observational studies of patients with locally advanced rectal cancer treated with total neoadjuvant therapy, followed by either W&W or total mesorectal excision. The primary outcome was quality of life (QoL), assessed using validated instruments (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, Quality of Life Questionnaire-CR29, Fecal Incontinence Quality of Life). Secondary outcomes included bowel function among patients without an ostomy, using validated measures such as Cleveland Clinic Florida Fecal Incontinence Scores, Vaizey, Memorial Sloan Kettering Cancer Center, and low anterior resection syndrome scores. A comprehensive search of PubMed, EMBASE, Medline, and Web of Science (Sept 2023-May 2025) was performed without language or date restrictions. Abstract/full-text screening, data extraction, and risk of bias assessments were conducted independently by two reviewers. Meta-analyses used inverse-variance weighting under a random-effects model. Data unsuitable for meta-analysis were synthesized narratively.\n\n**Results:** Of 617 screened studies, 28 were reviewed in full and 9 met inclusion criteria (total 923 patients). Meta-analysis of five studies (n = 601) with no statistically significant difference in overall QoL between groups (pooled mean difference = 0.10, 95% confidence interval: -0.19 to 0.39, P = 0.49). However, pooled analysis of fecal incontinence scores from four studies (n = 384) showed a significant advantage for W&W (pooled mean difference = -1.10, 95% confidence interval: -1.50 to -0.73, P < 0.001). Qualitative synthesis of low anterior resections syndrome scores outcomes favored W&W.\n\n**Conclusions:** W&W, offers a functional advantage without compromising QoL. The decision to pursue W&W should be individualized, considering both the potential functional benefits and the oncological risks.", "abstract_zh": "**ä»‹ç»ï¼š** è§‚å¯Ÿç­‰å¾…ï¼ˆWï¼†Wï¼‰æ¶‰åŠå…¨é¢æ–°è¾…åŠ©æ²»ç–—ï¼Œç„¶åè¿›è¡Œå¯†åˆ‡è§‚å¯Ÿï¼Œå·²æˆä¸ºå±€éƒ¨æ™šæœŸç›´è‚ ç™Œæ‚£è€…è¾¾åˆ°ä¸´åºŠæˆ–æ¥è¿‘å®Œå…¨ç¼“è§£çš„å…¨ç›´è‚ ç³»è†œåˆ‡é™¤çš„æ›¿ä»£æ–¹æ¡ˆã€‚è¿™ç§æ–¹æ³•æ—¨åœ¨ä¿æŠ¤è‚ é“åŠŸèƒ½å¹¶é¿å…ä¸æ ¹æ²»æ€§æ‰‹æœ¯ç›¸å…³çš„å‘ç—…ç‡ã€‚\n\n**æ–¹æ³•ï¼š** æœ¬ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æéµå¾ªç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ä»¥åŠ Cochrane æŒ‡å—ã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶åŒ…æ‹¬å¯¹æ¥å—å…¨æ–°è¾…åŠ©æ²»ç–—ã€éšåè¿›è¡Œ W&W æˆ–å…¨ç›´è‚ ç³»è†œåˆ‡é™¤çš„å±€éƒ¨æ™šæœŸç›´è‚ ç™Œæ‚£è€…è¿›è¡Œçš„éšæœºè¯•éªŒå’Œè§‚å¯Ÿæ€§ç ”ç©¶ã€‚ä¸»è¦ç»“å±€æ˜¯ç”Ÿæ´»è´¨é‡ï¼ˆQoLï¼‰ï¼Œä½¿ç”¨ç»è¿‡éªŒè¯çš„ä»ªå™¨ï¼ˆæ¬§æ´²ç™Œç—‡ç ”ç©¶å’Œæ²»ç–—ç»„ç»‡ç”Ÿæ´»è´¨é‡é—®å·-C30ã€ç”Ÿæ´»è´¨é‡é—®å·-CR29ã€å¤§ä¾¿å¤±ç¦ç”Ÿæ´»è´¨é‡ï¼‰è¿›è¡Œè¯„ä¼°ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬æœªè¿›è¡Œé€ å£æœ¯çš„æ‚£è€…çš„è‚ é“åŠŸèƒ½ï¼Œä½¿ç”¨ç»è¿‡éªŒè¯çš„æªæ–½ï¼Œå¦‚å…‹åˆ©å¤«å…°è¯Šæ‰€ä½›ç½—é‡Œè¾¾å¤§ä¾¿å¤±ç¦è¯„åˆ†ã€Vaizeyã€çºªå¿µæ–¯éš†å‡¯ç‰¹ç³ç™Œç—‡ä¸­å¿ƒå’Œä½å‰åˆ‡é™¤ç»¼åˆå¾è¯„åˆ†ã€‚å¯¹ PubMedã€EMBASEã€Medline å’Œ Web of Scienceï¼ˆ2023 å¹´ 9 æœˆè‡³ 2025 å¹´ 5 æœˆï¼‰è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œæ²¡æœ‰è¯­è¨€æˆ–æ—¥æœŸé™åˆ¶ã€‚æ‘˜è¦/å…¨æ–‡ç­›é€‰ã€æ•°æ®æå–å’Œåå€šé£é™©è¯„ä¼°ç”±ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹è¿›è¡Œã€‚èŸèƒåˆ†æåœ¨éšæœºæ•ˆåº”æ¨¡å‹ä¸‹ä½¿ç”¨é€†æ–¹å·®åŠ æƒã€‚ä¸é€‚åˆèŸèƒåˆ†æçš„æ•°æ®ä»¥å™è¿°æ–¹å¼åˆæˆã€‚\n\n**ç»“æœï¼š** åœ¨ 617 é¡¹ç­›é€‰ç ”ç©¶ä¸­ï¼Œ28 é¡¹ç»è¿‡å…¨é¢å®¡æŸ¥ï¼Œ9 é¡¹ç¬¦åˆçº³å…¥æ ‡å‡†ï¼ˆæ€»å…± 923 åæ‚£è€…ï¼‰ã€‚å¯¹äº”é¡¹ç ”ç©¶ (n = 601) è¿›è¡ŒèŸèƒåˆ†æï¼Œç»„é—´æ€»ä½“ç”Ÿæ´»è´¨é‡æ— ç»Ÿè®¡å­¦æ˜¾ç€å·®å¼‚ï¼ˆæ±‡æ€»å¹³å‡å·® = 0.10ï¼Œ95% ç½®ä¿¡åŒºé—´ï¼š-0.19 è‡³ 0.39ï¼ŒP = 0.49ï¼‰ã€‚ç„¶è€Œï¼Œå››é¡¹ç ”ç©¶ (n = 384) çš„å¤§ä¾¿å¤±ç¦è¯„åˆ†æ±‡æ€»åˆ†ææ˜¾ç¤º W&W å…·æœ‰æ˜¾ç€ä¼˜åŠ¿ï¼ˆæ±‡æ€»å¹³å‡å·® = -1.10ï¼Œ95% ç½®ä¿¡åŒºé—´ï¼š-1.50 è‡³ -0.73ï¼ŒP < 0.001ï¼‰ã€‚ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾è¯„åˆ†ç»“æœçš„å®šæ€§ç»¼åˆæœ‰åˆ©äº W&Wã€‚\n\n**ç»“è®ºï¼š** W&W åœ¨ä¸å½±å“ç”Ÿæ´»è´¨é‡çš„æƒ…å†µä¸‹æä¾›åŠŸèƒ½ä¼˜åŠ¿ã€‚è¿½æ±‚ W&W çš„å†³å®šåº”è¯¥å› äººè€Œå¼‚ï¼ŒåŒæ—¶è€ƒè™‘æ½œåœ¨çš„åŠŸèƒ½ç›Šå¤„å’Œè‚¿ç˜¤é£é™©ã€‚", "keywords_zh": "å±€éƒ¨æ™šæœŸç›´è‚ ç™Œï¼ŒèŸèƒåˆ†æï¼Œç”Ÿæ´»è´¨é‡ï¼Œç³»ç»Ÿè¯„ä»·ï¼Œè§‚å¯Ÿç­‰å¾…", "keywords_en": "Locally advanced rectal cancer, Meta-analysis, Quality of life, Systematic review, Watch-and-wait", "link": "https://pubmed.ncbi.nlm.nih.gov/41075390/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sat, 11 Oct 2025"}, {"id": "41023221", "title_en": "Single-incision laparoscopic endorectal pull-through for Hirschsprung disease: a prospective institutional study and systematic review with meta-analysis", "title_zh": "å•åˆ‡å£è…¹è…”é•œç›´è‚ å†…ç‰µå¼•æ²»ç–—å…ˆå¤©æ€§å·¨ç»“è‚ ï¼šå‰ç»æ€§æœºæ„ç ”ç©¶å’ŒèŸèƒåˆ†æç³»ç»Ÿè¯„ä»·", "authors": "Quang Thanh Nguyen", "abstract_en": "**Background:** Single-incision laparoscopic endorectal pull-through (SILEP) has emerged as an alternative to conventional laparoscopic surgery for Hirschsprung disease (HSCR), offering improved cosmetic outcomes with comparable efficacy. However, its adoption remains limited, and evidence supporting its long-term safety and functional outcomes is sparse. This study presents our institutional experience with SILEP, alongside a systematic review and meta-analysis evaluating perioperative outcomes, postoperative complications, bowel function, and cosmesis.\n\n**Patients And Methods:** A prospective study was conducted at our institution involving 93 pediatric patients diagnosed with HSCR, who underwent SILEP between 2020 and 2021. Demographic data, perioperative details, and postoperative outcomes, including bowel function score (Rintala) and cosmetic results (Manchester Scar Scale), were prospectively collected and analyzed. Additionally, a systematic review and meta-analysis were performed following PRISMA guidelines, pooling data from nine studies comprising 420 patients.\n\n**Results:** The mean operative time was 70.0â€‰Â±â€‰30.3Â min, significantly shorter than the pooled estimate from the meta-analysis (166.44Â min; 95% CI 137.74-195.14, pâ€‰<â€‰0.001). No intraoperative complications or conversions were recorded. The mean hospital stay was 5.23â€‰Â±â€‰2.69Â days, consistent with prior reports. Enterocolitis occurred in 16.1% of cases, comparable to the pooled estimate (12%; 95% CI 7-21%). Among patients agedâ€‰â‰¥â€‰4Â years (nâ€‰=â€‰64), 84% achieved good to excellent bowel function scores. The mean Manchester Scar Score was 5.73â€‰Â±â€‰1.38.\n\n**Conclusion:** SILEP is a safe, effective, and cosmetically superior approach for HSCR, with favorable perioperative outcomes and functional results. Our findings, supported by meta-analysis data, reinforce the feasibility of SILEP as a viable alternative for HSCR management.", "abstract_zh": "**èƒŒæ™¯ï¼š** å•åˆ‡å£è…¹è…”é•œç›´è‚ å†…æ‹‰ç©¿æœ¯ (SILEP) å·²æˆä¸ºæ²»ç–—å…ˆå¤©æ€§å·¨ç»“è‚  (HSCR) çš„ä¼ ç»Ÿè…¹è…”é•œæ‰‹æœ¯çš„æ›¿ä»£æ–¹æ¡ˆï¼Œå¯æä¾›æ”¹å–„çš„ç¾å®¹æ•ˆæœä¸”ç–—æ•ˆç›¸å½“ã€‚ç„¶è€Œï¼Œå®ƒçš„é‡‡ç”¨ä»ç„¶æœ‰é™ï¼Œå¹¶ä¸”æ”¯æŒå…¶é•¿æœŸå®‰å…¨æ€§å’ŒåŠŸèƒ½ç»“æœçš„è¯æ®å¾ˆå°‘ã€‚æœ¬ç ”ç©¶ä»‹ç»äº†æˆ‘ä»¬åœ¨ SILEP æ–¹é¢çš„æœºæ„ç»éªŒï¼Œä»¥åŠè¯„ä¼°å›´æ‰‹æœ¯æœŸç»“æœã€æœ¯åå¹¶å‘ç—‡ã€è‚ é“åŠŸèƒ½å’Œç¾å®¹çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æã€‚\n\n**Patients and methodsï¼š** æˆ‘ä»¬çš„æœºæ„è¿›è¡Œäº†ä¸€é¡¹å‰ç»æ€§ç ”ç©¶ï¼Œæ¶‰åŠ 93 åè¯Šæ–­ä¸º HSCR çš„å„¿ç«¥æ‚£è€…ï¼Œè¿™äº›æ‚£è€…åœ¨ 2020 å¹´è‡³ 2021 å¹´é—´æ¥å—äº† SILEPã€‚å‰ç»æ€§æ”¶é›†å’Œåˆ†æäº†äººå£ç»Ÿè®¡æ•°æ®ã€å›´æ‰‹æœ¯æœŸè¯¦ç»†ä¿¡æ¯å’Œæœ¯åç»“æœï¼ŒåŒ…æ‹¬è‚ åŠŸèƒ½è¯„åˆ† (Rintala) å’Œç¾å®¹ç»“æœï¼ˆæ›¼å½»æ–¯ç‰¹ç–¤ç—•é‡è¡¨ï¼‰ã€‚æ­¤å¤–ï¼Œè¿˜æŒ‰ç…§ PRISMA æŒ‡å—è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æï¼Œæ±‡é›†äº†æ¶‰åŠ 420 åæ‚£è€…çš„ 9 é¡¹ç ”ç©¶çš„æ•°æ®ã€‚\n\n**ç»“æœï¼š** å¹³å‡æ‰‹æœ¯æ—¶é—´ä¸º 70.0Â±30.3 åˆ†é’Ÿï¼Œæ˜æ˜¾çŸ­äºèŸèƒåˆ†æçš„æ±‡æ€»ä¼°è®¡æ—¶é—´ï¼ˆ166.44 åˆ†é’Ÿï¼›95% CI 137.74-195.14ï¼Œp<0.001ï¼‰ã€‚æ²¡æœ‰è®°å½•æœ¯ä¸­å¹¶å‘ç—‡æˆ–è½¬åŒ–ã€‚å¹³å‡ä½é™¢æ—¶é—´ä¸º 5.23Â±2.69 å¤©ï¼Œä¸ä¹‹å‰çš„æŠ¥å‘Šä¸€è‡´ã€‚ 16.1% çš„ç—…ä¾‹å‘ç”Ÿå°è‚ ç»“è‚ ç‚ï¼Œä¸æ±‡æ€»ä¼°è®¡å€¼ç›¸å½“ï¼ˆ12%ï¼›95% CI 7-21%ï¼‰ã€‚åœ¨å¹´é¾„â€‰â‰¥â€‰4å²çš„æ‚£è€…ä¸­ï¼ˆnâ€‰=â€‰64ï¼‰ï¼Œ84%çš„äººå–å¾—äº†è‰¯å¥½è‡³ä¼˜ç§€çš„è‚ é“åŠŸèƒ½è¯„åˆ†ã€‚å¹³å‡æ›¼å½»æ–¯ç‰¹ç–¤ç—•è¯„åˆ†ä¸º 5.73Â±1.38ã€‚\n\n**ç»“è®ºï¼š** SILEP æ˜¯ä¸€ç§å®‰å…¨ã€æœ‰æ•ˆä¸”ç¾è§‚çš„ HSCR æ–¹æ³•ï¼Œå…·æœ‰è‰¯å¥½çš„å›´æ‰‹æœ¯æœŸç»“æœå’ŒåŠŸèƒ½ç»“æœã€‚æˆ‘ä»¬çš„ç ”ç©¶ç»“æœå¾—åˆ°èŸèƒåˆ†ææ•°æ®çš„æ”¯æŒï¼Œå¼ºåŒ–äº† SILEP ä½œä¸º HSCR ç®¡ç†çš„å¯è¡Œæ›¿ä»£æ–¹æ¡ˆçš„å¯è¡Œæ€§ã€‚", "keywords_zh": "è‚ é“åŠŸèƒ½ï¼Œå…ˆå¤©æ€§å·¨ç»“è‚ ï¼Œè…¹è…”é•œï¼ŒèŸèƒåˆ†æï¼Œå•åˆ‡å£ï¼ŒSoave æ‰‹æœ¯", "keywords_en": "Bowel function, Hirschsprungâ€™s disease, Laparoscopic, Meta-analysis, Single-incision, Soave procedure", "link": "https://pubmed.ncbi.nlm.nih.gov/41023221/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 29 Sep 2025"}, {"id": "40972340", "title_en": "Postoperative physiotherapy in enhanced recovery pathways: A general surgery evidence update, dominated by colorectal studies", "title_zh": "åŠ é€Ÿåº·å¤è·¯å¾„ä¸­çš„æœ¯åç‰©ç†æ²»ç–—ï¼šä»¥ç»“ç›´è‚ ç ”ç©¶ä¸ºä¸»çš„æ™®å¤–ç§‘è¯æ®æ›´æ–°", "authors": "Thomas W Wainwright", "abstract_en": "**Introduction:** Physiotherapy is a pivotal component of enhanced recovery protocols, particularly in initiating early mobilisation and supporting the return to functional independence. Despite this, there is a lack of guidance on optimal post-mobilisation physiotherapy strategies. This systematic review aims to synthesise and critically appraise the most recent evidence on postoperative physiotherapy interventions within enhanced recovery pathways for general surgical patients. This review seeks to advance scientific understanding and provide guidance for the optimisation of physiotherapy practice within enhanced recovery pathways.\n\n**Materials And Methods:** A systematic review of the literature between 2000 and 2024 was conducted to identify studies of physiotherapy interventions in general surgical populations following an enhanced recovery protocol.\n\n**Results:** Ten studies met the inclusion criteria. Six studies were conducted in colorectal patients, one study (plus a secondary analysis) was conducted in radical cystectomy patients, one in head and neck patients undergoing oncologic resection, and one included a mixed patient sample (colon, rectum, stomach, pancreas and liver surgery). Interventions involving early physiotherapy were found to benefit postoperative walking distance, achievement of activities of daily living and length of stay in hospital. There was mixed evidence for influence on readiness for discharge, quality of recovery measures and health-related quality of life. No consistent effects were observed for inpatient satisfaction or functional outcome.\n\n**Conclusion:** This review supports the feasibility and potential benefits of a structured physiotherapy interventions within enhanced recovery protocols. These results highlight the potential for structured mobilisation interventions to enhance recovery, particularly when supported by education and technology-based strategies.", "abstract_zh": "**ä»‹ç»ï¼š** ç‰©ç†æ²»ç–—æ˜¯åŠ é€Ÿåº·å¤æ–¹æ¡ˆçš„å…³é”®ç»„æˆéƒ¨åˆ†ï¼Œç‰¹åˆ«æ˜¯åœ¨å¯åŠ¨æ—©æœŸæ´»åŠ¨å’Œæ”¯æŒæ¢å¤åŠŸèƒ½ç‹¬ç«‹æ–¹é¢ã€‚å°½ç®¡å¦‚æ­¤ï¼Œä»ç¼ºä¹æœ€ä½³åŠ¨å‘˜åç‰©ç†æ²»ç–—ç­–ç•¥çš„æŒ‡å¯¼ã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨ç»¼åˆå¹¶ä¸¥æ ¼è¯„ä¼°æ™®é€šå¤–ç§‘æ‚£è€…åŠ é€Ÿåº·å¤é€”å¾„æœ¯åç‰©ç†æ²»ç–—å¹²é¢„çš„æœ€æ–°è¯æ®ã€‚æœ¬ç»¼è¿°æ—¨åœ¨å¢è¿›ç§‘å­¦ç†è§£ï¼Œå¹¶ä¸ºåŠ é€Ÿåº·å¤é€”å¾„ä¸­ç‰©ç†æ²»ç–—å®è·µçš„ä¼˜åŒ–æä¾›æŒ‡å¯¼ã€‚\n\n**ææ–™ä¸æ–¹æ³•ï¼š** å¯¹ 2000 å¹´è‡³ 2024 å¹´æœŸé—´çš„æ–‡çŒ®è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œä»¥ç¡®å®šåœ¨åŠ é€Ÿåº·å¤æ–¹æ¡ˆåå¯¹æ™®é€šæ‰‹æœ¯äººç¾¤è¿›è¡Œç‰©ç†æ²»ç–—å¹²é¢„çš„ç ”ç©¶ã€‚\n\n**ç»“æœï¼š** åé¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚å…­é¡¹ç ”ç©¶åœ¨ç»“ç›´è‚ æ‚£è€…ä¸­è¿›è¡Œï¼Œä¸€é¡¹ç ”ç©¶ï¼ˆåŠ ä¸ŠäºŒæ¬¡åˆ†æï¼‰æ˜¯åœ¨æ ¹æ²»æ€§è†€èƒ±åˆ‡é™¤æœ¯æ‚£è€…ä¸­è¿›è¡Œçš„ï¼Œä¸€é¡¹ç ”ç©¶æ˜¯åœ¨æ¥å—è‚¿ç˜¤åˆ‡é™¤æœ¯çš„å¤´é¢ˆéƒ¨æ‚£è€…ä¸­è¿›è¡Œçš„ï¼Œä¸€é¡¹ç ”ç©¶åŒ…æ‹¬æ··åˆæ‚£è€…æ ·æœ¬ï¼ˆç»“è‚ ã€ç›´è‚ ã€èƒƒã€èƒ°è…ºå’Œè‚è„æ‰‹æœ¯ï¼‰ã€‚ç ”ç©¶å‘ç°ï¼Œæ¶‰åŠæ—©æœŸç‰©ç†æ²»ç–—çš„å¹²é¢„æªæ–½æœ‰åˆ©äºæœ¯åæ­¥è¡Œè·ç¦»ã€æ—¥å¸¸ç”Ÿæ´»æ´»åŠ¨çš„å®Œæˆåº¦å’Œä½é™¢æ—¶é—´ã€‚å¯¹äºå‡ºé™¢å‡†å¤‡ã€åº·å¤æªæ–½è´¨é‡å’Œå¥åº·ç›¸å…³ç”Ÿæ´»è´¨é‡çš„å½±å“ï¼Œè¯æ®ä¸ä¸€ã€‚å¯¹äºä½é™¢æ‚£è€…æ»¡æ„åº¦æˆ–åŠŸèƒ½ç»“æœæ²¡æœ‰è§‚å¯Ÿåˆ°ä¸€è‡´çš„æ•ˆæœã€‚\n\n**ç»“è®ºï¼š** è¿™ç¯‡ç»¼è¿°æ”¯æŒäº†å¼ºåŒ–åº·å¤æ–¹æ¡ˆä¸­ç»“æ„åŒ–ç‰©ç†æ²»ç–—å¹²é¢„æªæ–½çš„å¯è¡Œæ€§å’Œæ½œåœ¨ç›Šå¤„ã€‚è¿™äº›ç»“æœå‡¸æ˜¾äº†ç»“æ„åŒ–åŠ¨å‘˜å¹²é¢„æªæ–½åœ¨ä¿ƒè¿›åº·å¤æ–¹é¢çš„æ½œåŠ›ï¼Œç‰¹åˆ«æ˜¯åœ¨æ•™è‚²å’ŒæŠ€æœ¯æˆ˜ç•¥çš„æ”¯æŒä¸‹ã€‚", "keywords_zh": "åŠ é€Ÿåº·å¤å¤–ç§‘ (ERAS)ã€æ´»åŠ¨ã€ç‰©ç†æ²»ç–—ã€æ¢å¤ã€åº·å¤ã€æ‰‹æœ¯", "keywords_en": "Enhanced recovery after surgery (ERAS), Mobilisation, Physiotherapy, Recovery, Rehabilitation, Surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40972340/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 19 Sep 2025"}, {"id": "40968352", "title_en": "Stroke risk in cancer survivors: A meta-analysis and meta regression", "title_zh": "ç™Œç—‡å¹¸å­˜è€…çš„ä¸­é£é£é™©ï¼šèŸèƒåˆ†æå’ŒèŸèƒå›å½’", "authors": "Rommel Mario RodrÃ­guez Burbano", "abstract_en": "**Introduction:** It is suggested that survivors of different types of cancer may have an increased risk of stroke. Our study aims to evaluate cancer patients and non-cancer controls by analyzing stroke events in each group. Previous studies concluded that certain types of cancer increased stroke risk, however, their results had significant heterogeneity and statistical concerns.\n\n**Methods:** Medline, Embase, and Cochrane databases were systematically searched until February 18th, 2024, assessing stroke in cancer survivor patients compared to the global population. Data were examined using the Mantel-Haenszel method and 95% CIs. Heterogeneity was assessed using IÂ² statistics. Rstudio software, version 4.2.3., was used for statistical analysis.\n\n**Results:** A total of 18 studies were included, and stroke was reported in both cancer and non-cancer groups. Breast cancer (HR 1.09; 95% CI 1.02-1.17; pâ€‰=â€‰0.01; IÂ²= 0%), Central Nervous System cancers (HR 2.47; 95% CI 1.01-6.01; pâ€‰=â€‰0.047; IÂ²= 78%), cervical cancers (HR 1.58; 95% CI 1.19-2.09; pâ€‰=â€‰0.001; IÂ²= 0%), head and neck cancers (HR 1.4439; 95% CI 1.3095-1.5922; pâ€‰<â€‰0.001; IÂ²=31.5%), lung cancers (HR 1.60; 95% CI 1.40-1.83; pâ€‰<â€‰0.001; IÂ²=67%), multiple myeloma (HR 1.58; 95% CI 1.32-1.89; pâ€‰<â€‰0.001; IÂ²= 49%), nasopharyngeal cancers (HR 1.9178; 95% CI 1.3358-2.7533; pâ€‰<â€‰0.001; IÂ²=89.7%), oesophageal cancers (HR 1.33; 95% CI 1.07-1.65; pâ€‰=â€‰0.009; IÂ²= 0%), ovarian cancers (HR 1.33; 95% CI 1.07-1.65; pâ€‰=â€‰0.01; IÂ²= 38%), pancreatic cancers (HR 2,70; 95% CI 2.34-3.11; pâ€‰<â€‰0.001; IÂ²= 0%) and rectum cancers (HR 1.29; 95% CI 1.01-1.63; pâ€‰=â€‰0.04; IÂ²= 0%) showed statistically significant differences between groups in favor of non-cancer controls.\n\n**Conclusions:** In this meta-analysis, the stroke risk was increased in all cancers that reached statistical significance. Furthermore, our study brings relevant data to the body of literature concerning this long-term clinical uncertainty.", "abstract_zh": "**ä»‹ç»ï¼š** ç ”ç©¶è¡¨æ˜ï¼Œä¸åŒç±»å‹ç™Œç—‡çš„å¹¸å­˜è€…æ‚£ä¸­é£çš„é£é™©å¯èƒ½ä¼šå¢åŠ ã€‚æˆ‘ä»¬çš„ç ”ç©¶æ—¨åœ¨é€šè¿‡åˆ†ææ¯ç»„çš„ä¸­é£äº‹ä»¶æ¥è¯„ä¼°ç™Œç—‡æ‚£è€…å’Œéç™Œç—‡å¯¹ç…§ã€‚å…ˆå‰çš„ç ”ç©¶å¾—å‡ºçš„ç»“è®ºæ˜¯ï¼ŒæŸäº›ç±»å‹çš„ç™Œç—‡ä¼šå¢åŠ ä¸­é£é£é™©ï¼Œç„¶è€Œï¼Œä»–ä»¬çš„ç»“æœå­˜åœ¨æ˜¾ç€çš„å¼‚è´¨æ€§å’Œç»Ÿè®¡é—®é¢˜ã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³ 2024 å¹´ 2 æœˆ 18 æ—¥ï¼Œå¯¹ Medlineã€Embase å’Œ Cochrane æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼Œè¯„ä¼°äº†ç™Œç—‡å¹¸å­˜è€…æ‚£è€…ä¸­é£ä¸å…¨çƒäººå£çš„æƒ…å†µã€‚ä½¿ç”¨ Mantel-Haenszel æ–¹æ³•å’Œ 95% CI æ£€æŸ¥æ•°æ®ã€‚ä½¿ç”¨ IÂ² ç»Ÿè®¡æ•°æ®è¯„ä¼°å¼‚è´¨æ€§ã€‚ä½¿ç”¨Rstudioè½¯ä»¶4.2.3ç‰ˆè¿›è¡Œç»Ÿè®¡åˆ†æã€‚\n\n**ç»“æœï¼š** æ€»å…±çº³å…¥äº† 18 é¡¹ç ”ç©¶ï¼Œç™Œç—‡ç»„å’Œéç™Œç—‡ç»„å‡æŠ¥å‘Šäº†ä¸­é£ã€‚ä¹³è…ºç™Œï¼ˆHR 1.09ï¼›95% CI 1.02-1.17ï¼›pâ€‰=â€‰0.01ï¼›IÂ²= 0%ï¼‰ã€ä¸­æ¢ç¥ç»ç³»ç»Ÿç™Œç—‡ï¼ˆHR 2.47ï¼›95% CI 1.01-6.01ï¼›pâ€‰=â€‰0.047ï¼›IÂ²= 78%ï¼‰ã€å®«é¢ˆç™Œï¼ˆHR 1.58ï¼›95% CI 1.19-2.09ï¼›pâ€‰=â€‰0.001ï¼›IÂ²= 0%ï¼‰ã€å¤´é¢ˆç™Œï¼ˆHR 1.4439ï¼›95% CI 1.3095-1.5922ï¼›pâ€‰<â€‰0.001ï¼›IÂ²=31.5%ï¼‰ã€è‚ºç™Œï¼ˆHR 1.60ï¼›95% CI 1.40-1.83ï¼›p<â€‰0.001ï¼›IÂ²=67%ï¼‰ã€å¤šå‘æ€§éª¨é«“ç˜¤ï¼ˆHR 1.58ï¼›95% CI 1.32-1.89ï¼›p<â€‰0.001ï¼›IÂ²= 49%ï¼‰ã€é¼»å’½ç™Œï¼ˆHR 1.9178ï¼›95% CI 1.3358-2.7533ï¼›pâ€‰<â€‰0.001ï¼›IÂ²=89.7%ï¼‰ã€é£Ÿé“ç™Œï¼ˆHR 1.33ï¼›95% CI 1.07-1.65ï¼›pâ€‰=â€‰0.009ï¼›IÂ²= 0%ï¼‰ã€åµå·¢ç™Œï¼ˆHR 1.33ï¼›95% CI 1.07-1.65ï¼›pâ€‰=â€‰0.01ï¼›IÂ²= 38%ï¼‰ã€èƒ°è…ºç™Œï¼ˆHR 2.70ï¼›95% CI 2.34-3.11ï¼›pâ€‰<â€‰0.001ï¼›IÂ²= 0%ï¼‰å’Œç›´è‚ ç™Œï¼ˆHR 1.29ï¼›95% CI 1.01-1.63ï¼› pâ€‰=â€‰0.04ï¼›IÂ²= 0%ï¼‰æ˜¾ç¤ºç»„é—´å­˜åœ¨ç»Ÿè®¡å­¦æ˜¾ç€å·®å¼‚ï¼Œæœ‰åˆ©äºéç™Œç—‡å¯¹ç…§ã€‚\n\n**ç»“è®ºï¼š** åœ¨è¿™é¡¹èŸèƒåˆ†æä¸­ï¼Œæ‰€æœ‰ç™Œç—‡çš„ä¸­é£é£é™©å‡å¢åŠ ï¼Œå¹¶è¾¾åˆ°ç»Ÿè®¡å­¦æ˜¾ç€æ€§ã€‚æ­¤å¤–ï¼Œæˆ‘ä»¬çš„ç ”ç©¶ä¸ºæœ‰å…³è¿™ç§é•¿æœŸä¸´åºŠä¸ç¡®å®šæ€§çš„æ–‡çŒ®æä¾›äº†ç›¸å…³æ•°æ®ã€‚", "keywords_zh": "ç™Œç—‡å¹¸å­˜è€…ã€èŸèƒåˆ†æã€ä¸­é£é£é™©", "keywords_en": "Cancer survivors, Meta-Analysis, Stroke risk", "link": "https://pubmed.ncbi.nlm.nih.gov/40968352/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 19 Sep 2025"}, {"id": "40956186", "title_en": "Clinicopathological characteristics and biomarker alterations in early-onset vs. late-onset colorectal cancer: a systematic review and meta-analysis", "title_zh": "æ—©å‘æ€§ç»“ç›´è‚ ç™Œä¸æ™šå‘æ€§ç»“ç›´è‚ ç™Œçš„ä¸´åºŠç—…ç†å­¦ç‰¹å¾å’Œç”Ÿç‰©æ ‡å¿—ç‰©å˜åŒ–ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Lie Yang", "abstract_en": "**Background:** The clinicopathological and molecular characteristics of early-onset colorectal cancer (EOCRC) are unclear. In this study, we compared the clinicopathological features, biomarkers, and prognoses between EOCRC and late-onset colorectal cancer (LOCRC).\n\n**Methods:** A search was conducted on PubMed, Web of Science, Embase, and Cochrane Library from inception to May 2024. The key outcomes were clinicopathological features, prevalence of molecular biomarker alterations, and 5-year overall survival (OS), with pooled odds ratios (ORs) and hazard ratios (HRs), along with their corresponding 95% confidence intervals (CIs), calculated for each outcome.\n\n**Results:** Forty studies were included in the final analysis. EOCRC exhibited distal colon and rectum localization (OR: 0.59; 95% CI: 0.55-0.62; P < 0.001), was poorly differentiated (OR: 0.56; 95% CI: 0.52-0.60; P = 0.01), tended to be more mucinous or signet-ring cell carcinoma (OR: 0.56; 95% CI: 0.52-0.60; P < 0.001), and was associated with advanced stages (OR: 1.49; 95% CI: 1.30-1.71; P < 0.001), lymph node metastasis (LNM) (OR: 0.56; 95% CI: 0.53-0.60; P < 0.001), and distant metastasis (OR: 1.29; 95% CI: 1.04-1.60; P = 0.02). EOCRC exhibited higher TP53 mutation rates (OR: 1.33; 95% CI: 1.13-1.58; P < 0.001), MSI-H status (OR: 1.45; 95% CI: 1.10-1.92; P = 0.01), but lower PIK3CA mutation rates (OR: 0.93; 95% CI: 0.88-0.99; P = 0.03). EOCRC and LOCRC had similar 5-year OS rates (HR: 1.01; 95% CI: 0.79-1.30; P = 0.92). Although no significant difference was observed in the APC, BRAF, KRAS, NRAS, SM4D4, and MMR, subgroup analyses revealed that BRAF ( P = 0.01), KRAS mutations ( P < 0.001), and DNA hypermethylation ( P = 0.01) were less prevalent among westerners.\n\n**Conclusion:** EOCRC often presents with more aggressive and metastatic features due to its frequent diagnosis at advanced stages. TP53 mutations and the MSI-H status are prevalent in EOCRC. EOCRC's prognosis is often comparable to LOCRC. Radical and tailored treatment strategies should be developed to improve the survival outcomes in advanced and metastatic EOCRC.", "abstract_zh": "**èƒŒæ™¯ï¼š** æ—©å‘æ€§ç»“ç›´è‚ ç™Œï¼ˆEOCRCï¼‰çš„ä¸´åºŠç—…ç†å­¦å’Œåˆ†å­ç‰¹å¾å°šä¸æ¸…æ¥šã€‚åœ¨è¿™é¡¹ç ”ç©¶ä¸­ï¼Œæˆ‘ä»¬æ¯”è¾ƒäº† EOCRC å’Œæ™šå‘ç»“ç›´è‚ ç™Œ (LOCRC) çš„ä¸´åºŠç—…ç†ç‰¹å¾ã€ç”Ÿç‰©æ ‡å¿—ç‰©å’Œé¢„åã€‚\n\n**æ–¹æ³•ï¼š** ä»å¼€å§‹åˆ° 2024 å¹´ 5 æœˆï¼Œæˆ‘ä»¬åœ¨ PubMedã€Web of Scienceã€Embase å’Œ Cochrane å›¾ä¹¦é¦†ä¸Šè¿›è¡Œäº†æ£€ç´¢ã€‚ä¸»è¦ç»“æœæ˜¯ä¸´åºŠç—…ç†å­¦ç‰¹å¾ã€åˆ†å­ç”Ÿç‰©æ ‡è®°ç‰©æ”¹å˜çš„å‘ç”Ÿç‡å’Œ 5 å¹´æ€»ç”Ÿå­˜ç‡ (OS)ï¼Œä»¥åŠé’ˆå¯¹æ¯ä¸ªç»“æœè®¡ç®—çš„æ±‡æ€»æ¯”å€¼æ¯” (OR) å’Œé£é™©æ¯” (HR) åŠå…¶ç›¸åº”çš„ 95% ç½®ä¿¡åŒºé—´ (CI)ã€‚\n\n**ç»“æœï¼š** æœ€ç»ˆåˆ†æä¸­çº³å…¥äº†å››åé¡¹ç ”ç©¶ã€‚ EOCRC è¡¨ç°å‡ºè¿œç«¯ç»“è‚ å’Œç›´è‚ å®šä½ï¼ˆORï¼š0.59ï¼›95% CIï¼š0.55-0.62ï¼›P < 0.001ï¼‰ï¼Œåˆ†åŒ–ä¸è‰¯ï¼ˆORï¼š0.56ï¼›95% CIï¼š0.52-0.60ï¼›P = 0.01ï¼‰ï¼Œå€¾å‘äºæ›´å¤šç²˜æ¶²æ€§æˆ–å°æˆ’ç»†èƒç™Œï¼ˆORï¼š0.56ï¼›95% CIï¼š 0.52-0.60ï¼›P < 0.001ï¼‰ï¼Œå¹¶ä¸”ä¸æ™šæœŸï¼ˆORï¼š1.49ï¼›95% CIï¼š1.30-1.71ï¼›P < 0.001ï¼‰ã€æ·‹å·´ç»“è½¬ç§»ï¼ˆLNMï¼‰ï¼ˆORï¼š0.56ï¼›95% CIï¼š0.53-0.60ï¼›P < 0.001ï¼‰å’Œè¿œå¤„è½¬ç§»ï¼ˆORï¼š 1.29ï¼›95% CIï¼š1.04-1.60ï¼›P = 0.02ï¼‰ã€‚ EOCRC è¡¨ç°å‡ºè¾ƒé«˜çš„ TP53 çªå˜ç‡ï¼ˆORï¼š1.33ï¼›95% CIï¼š1.13-1.58ï¼›P < 0.001ï¼‰ã€MSI-H çŠ¶æ€ï¼ˆORï¼š1.45ï¼›95% CIï¼š1.10-1.92ï¼›P = 0.01ï¼‰ï¼Œä½† PIK3CA çªå˜ç‡è¾ƒä½ï¼ˆORï¼š0.93ï¼›95% CIï¼š 0.88-0.99ï¼›P = 0.03ï¼‰ã€‚ EOCRC å’Œ LOCRC çš„ 5 å¹´ OS ç‡ç›¸ä¼¼ï¼ˆHRï¼š1.01ï¼›95% CIï¼š0.79-1.30ï¼›P = 0.92ï¼‰ã€‚å°½ç®¡APCã€BRAFã€KRASã€NRASã€SM4D4å’ŒMMRæ²¡æœ‰è§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ï¼Œä½†äºšç»„åˆ†ææ˜¾ç¤ºBRAFï¼ˆP=0.01ï¼‰ã€KRASçªå˜ï¼ˆP<0.001ï¼‰å’ŒDNAé«˜ç”²åŸºåŒ–ï¼ˆP=0.01ï¼‰åœ¨è¥¿æ–¹äººä¸­è¾ƒå°‘è§ã€‚\n\n**ç»“è®ºï¼š** ç”±äº EOCRC ç»å¸¸åœ¨æ™šæœŸè¯Šæ–­ï¼Œå› æ­¤é€šå¸¸è¡¨ç°å‡ºæ›´å…·ä¾µè¢­æ€§å’Œè½¬ç§»æ€§çš„ç‰¹å¾ã€‚ TP53 çªå˜å’Œ MSI-H çŠ¶æ€åœ¨ EOCRC ä¸­æ™®éå­˜åœ¨ã€‚ EOCRC çš„é¢„åé€šå¸¸ä¸ LOCRC ç›¸å½“ã€‚åº”åˆ¶å®šæ ¹æ²»æ€§å’Œé‡èº«å®šåˆ¶çš„æ²»ç–—ç­–ç•¥ï¼Œä»¥æ”¹å–„æ™šæœŸå’Œè½¬ç§»æ€§ EOCRC çš„ç”Ÿå­˜ç»“æœã€‚", "keywords_zh": "ä¸´åºŠç—…ç†ç‰¹å¾, ç»“ç›´è‚ ç™Œ, æ—©å‘å‹, åˆ†å­ç”Ÿç‰©æ ‡å¿—ç‰©, ç”Ÿå­˜", "keywords_en": "clinicopathological features, colorectal cancer, early-onset, molecular biomarker, survival", "link": "https://pubmed.ncbi.nlm.nih.gov/40956186/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 16 Sep 2025"}, {"id": "40944330", "title_en": "Efficacy and safety of methylene blue for postoperative pain of haemorrhoids: a systematic review and meta-analysis", "title_zh": "äºšç”²è“æ²»ç–—ç—”ç–®æœ¯åç–¼ç—›çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Li Xu", "abstract_en": "**Objectives:** Pain is a common complication after haemorrhoid surgery. In addition to anaesthetic methods, surgical techniques and postoperative interventions, surgeons also use intraoperative adjuncts to alleviate postoperative pain. This study aims to evaluate the effectiveness and safety of methylene blue in reducing postoperative pain in haemorrhoid patients.\n\n**Methods:** A search was conducted in PubMed, Embase, Cochrane Library and Web of Science for randomized controlled trials (RCTs) up until 9 December 2024, involving methylene blue use for pain relief after haemorrhoid surgery. Two reviewers independently assessed the study eligibility, extracted data and evaluated the risk of bias. Data analysis was performed using Stata 18 software. The primary outcome was the visual analogue scale (VAS) pain scores at different time points within 14â€‰days postoperatively. Secondary outcomes included the number of patients requiring analgesics and the occurrence of complications.\n\n**Results:** 358 articles were retrieved and six studies involving 598 patients were included after screening. Compared with the control group, the use of methylene blue reduced pain within 12â€‰h postoperatively(WMD -1.582, 95% CI -2.834 to -0.330, <i>p</i>â€‰=â€‰.013), as well as on day 2 (WMD -1.441, 95% CI - 1.874 to -1.008, <i>p</i>â€‰<â€‰.0001), day 3 (WMD -0.975, 95% CI -1.309 to -0.641, <i>p</i>â€‰<â€‰.0001), day 5(WMD -0.786, 95% CI -1.094 to -0.478, <i>p</i>â€‰=â€‰.028) and day 7 (WMD -0.679, 95% CI -1.257 to -0.101, <i>p</i>â€‰=â€‰.021), decreased the number of patients using analgesics(RR 0.293, 95% CI 0.203 to 0.422, <i>p</i>â€‰<â€‰.0001) and did not increase the incidence of complications(RR 0.65, 95% CI 0.39-1.10, <i>p</i>â€‰=â€‰.111) such as urinary retention, secondary haemorrhage, pruritus, temporary incontinence, wound infection, or local skin reactions.\n\n**Conclusions:** This study shows that methylene blue can reduce postoperative pain, decrease analgesic use and does not increase complications after haemorrhoid surgery.", "abstract_zh": "**Objectivesï¼š** ç–¼ç—›æ˜¯ç—”ç–®æ‰‹æœ¯åå¸¸è§çš„å¹¶å‘ç—‡ã€‚é™¤äº†éº»é†‰æ–¹æ³•ã€æ‰‹æœ¯æŠ€æœ¯å’Œæœ¯åå¹²é¢„å¤–ï¼Œå¤–ç§‘åŒ»ç”Ÿè¿˜ä½¿ç”¨æœ¯ä¸­è¾…åŠ©æ‰‹æ®µæ¥å‡è½»æœ¯åç–¼ç—›ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼°äºšç”²è“å‡è½»ç—”ç–®æ‚£è€…æœ¯åç–¼ç—›çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** åœ¨ PubMedã€Embaseã€Cochrane å›¾ä¹¦é¦†å’Œ Web of Science ä¸­æ£€ç´¢äº†æˆªè‡³ 2024 å¹´ 12 æœˆ 9 æ—¥çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ï¼Œæ¶‰åŠäºšç”²è“ç”¨äºç¼“è§£ç—”ç–®æ‰‹æœ¯åçš„ç–¼ç—›ã€‚ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹è¯„ä¼°ç ”ç©¶èµ„æ ¼ã€æå–æ•°æ®å¹¶è¯„ä¼°åå€šé£é™©ã€‚ä½¿ç”¨Stata 18è½¯ä»¶è¿›è¡Œæ•°æ®åˆ†æã€‚ä¸»è¦ç»“æœæ˜¯æœ¯å14å¤©å†…ä¸åŒæ—¶é—´ç‚¹çš„è§†è§‰æ¨¡æ‹Ÿè¯„åˆ†ï¼ˆVASï¼‰ç–¼ç—›è¯„åˆ†ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬éœ€è¦é•‡ç—›è¯çš„æ‚£è€…æ•°é‡å’Œå¹¶å‘ç—‡çš„å‘ç”Ÿç‡ã€‚\n\n**ç»“æœï¼š** ç­›é€‰åå…±æ£€ç´¢åˆ° 358 ç¯‡æ–‡ç« ï¼Œçº³å…¥ 6 é¡¹æ¶‰åŠ 598 åæ‚£è€…çš„ç ”ç©¶ã€‚ä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œä½¿ç”¨äºšç”²åŸºè“å¯å‡è½»æœ¯å 12 å°æ—¶å†…çš„ç–¼ç—›ï¼ˆWMD -1.582ï¼Œ95% CI -2.834 è‡³ -0.330ï¼Œ<i>p</i>â€‰=â€‰.013ï¼‰ä»¥åŠç¬¬ 2 å¤©ï¼ˆWMD -1.441ï¼Œ95% CI -1.874 è‡³ -1.008ï¼Œ <i>p</i>â€‰<â€‰.0001ï¼‰ï¼Œç¬¬ 3 å¤©ï¼ˆWMD -0.975ï¼Œ95% CI -1.309 è‡³ -0.641ï¼Œ<i>p</i>â€‰<â€‰.0001ï¼‰ï¼Œç¬¬ 5 å¤©ï¼ˆWMD -0.786ï¼Œ95% CI -1.094 è‡³ -0.478ï¼Œ <i>p</i>â€‰=â€‰.028ï¼‰å’Œç¬¬7å¤©ï¼ˆWMD -0.679ï¼Œ95% CI -1.257è‡³-0.101ï¼Œ<i>p</i>â€‰=â€‰.021ï¼‰ï¼Œä½¿ç”¨é•‡ç—›è¯çš„æ‚£è€…æ•°é‡å‡å°‘ï¼ˆRR 0.293ï¼Œ95% CI 0.203è‡³0.422ï¼Œ <i>p</i>â€‰<â€‰.0001ï¼‰ï¼Œå¹¶ä¸”ä¸ä¼šå¢åŠ å°¿æ½´ç•™ã€ç»§å‘æ€§å‡ºè¡€ã€ç˜™ç—’ã€æš‚æ—¶å¤±ç¦ã€ä¼¤å£æ„ŸæŸ“æˆ–å±€éƒ¨çš®è‚¤ååº”ç­‰å¹¶å‘ç—‡çš„å‘ç”Ÿç‡ï¼ˆRR 0.65ï¼Œ95% CI 0.39-1.10ï¼Œ<i>p</i>â€‰=â€‰.111ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹ç ”ç©¶è¡¨æ˜ï¼Œäºšç”²è“å¯ä»¥å‡è½»æœ¯åç–¼ç—›ï¼Œå‡å°‘é•‡ç—›è¯çš„ä½¿ç”¨ï¼Œå¹¶ä¸”ä¸ä¼šå¢åŠ ç—”ç–®æ‰‹æœ¯åçš„å¹¶å‘ç—‡ã€‚", "keywords_zh": "é•‡ç—›ï¼Œç—”ç–®åˆ‡é™¤æœ¯ï¼Œäºšç”²è“ï¼Œæœ¯åç–¼ç—›", "keywords_en": "Analgesia, haemorrhoidectomy, methylene blue, postoperative pain", "link": "https://pubmed.ncbi.nlm.nih.gov/40944330/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sat, 13 Sep 2025"}, {"id": "40914745", "title_en": "Robotic versus laparoscopic total mesorectal excision for mid-low rectal cancer after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis of oncological, perioperative, and survival-related outcomes", "title_zh": "æ–°è¾…åŠ©æ”¾åŒ–ç–—åæœºå™¨äººä¸è…¹è…”é•œå…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯æ²»ç–—ä¸­ä½ä½ç›´è‚ ç™Œï¼šè‚¿ç˜¤å­¦ã€å›´æ‰‹æœ¯æœŸå’Œç”Ÿå­˜ç›¸å…³ç»“æœçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Shukai Wang", "abstract_en": "A major cause of cancer death, colorectal cancer is becoming more common in younger people. The comparative effectiveness of robotic versus laparoscopic total mesorectal excision (TME) as surgical interventions for mid-low rectal cancer following neoadjuvant chemoradiotherapy (nCRT) remains uncertain. To systematically evaluate oncological, perioperative, and survival outcomes of robotic versus laparoscopic surgery for mid-low rectal cancer following nCRT. A PRISMA-compliant systematic review and meta-analysis included 20 non-randomized studies (13,212 patients) from Web of Science, PubMed, and Embase up to July 2025. Outcomes encompassed pathological completeness (circumferential resection margin, TME quality), perioperative metrics (operative duration, conversion rates), complications, and survival (5-year OS/DFS). Risk of bias was assessed via ROBINS-I; statistical synthesis utilized RevMan5.4 and hazard ratios derived from Kaplan-Meier curves. This meta-analysis of 20 non-randomized studies (13,212 patients) found no significant differences in 5-year overall survival (HR: 1.07, 95% CI 0.20-5.66, pâ€‰=â€‰0.94, I<sup>2</sup>â€‰=â€‰98%) or disease-free survival (HR: 1.16, 95% CI 0.72-1.89, pâ€‰=â€‰0.54, I<sup>2</sup>â€‰=â€‰0%) between robotic and laparoscopic TME after nCRT. Robotic surgery demonstrated superior technical outcomes, including higher rates of complete TME (OR: 1.97, pâ€‰=â€‰0.02) and reduced conversion to open surgery (OR: 0.46, pâ€‰<â€‰0.001), but required significantly longer operative time (WMD:â€‰+â€‰42.09Â min, pâ€‰<â€‰0.001). Perioperative metrics showed equivalence in intraoperative blood loss (pâ€‰=â€‰0.20), hospitalization duration (pâ€‰=â€‰0.78), and postoperative complications, including anastomotic leakage (5.4% vs. 6.5%, pâ€‰=â€‰0.28) and Clavien-Dindo III-IV events (OR: 1.11, pâ€‰=â€‰0.54). Pathological outcomes were comparable, with no differences in circumferential resection margin positivity (OR: 1.0, pâ€‰=â€‰1), distal margin length (pâ€‰=â€‰0.92), or lymph-node yield (pâ€‰=â€‰0.55). Local (OR: 0.85, pâ€‰=â€‰0.34) and distant recurrence rates (pâ€‰=â€‰0.99) were statistically indistinguishable. Risk-of-bias assessment revealed confounding risks in non-randomized designs, underscoring the need for RCT validation. Robotic and laparoscopic TME achieve equivalent long-term survival and oncological control after nCRT, with robotic advantages in technical precision counterbalanced by prolonged operative duration. The equivalence underscores nCRT's dominant role in tumor control, while procedural differences highlight context-dependent surgical feasibility. High heterogeneity in survival data and reliance on non-randomized evidence necessitate validation through rigorously designed RCTs incorporating standardized protocols and patient-reported functional outcomes.", "abstract_zh": "ä½œä¸ºç™Œç—‡æ­»äº¡çš„ä¸»è¦åŸå› ï¼Œç»“ç›´è‚ ç™Œåœ¨å¹´è½»äººä¸­å˜å¾—è¶Šæ¥è¶Šå¸¸è§ã€‚æœºå™¨äººä¸è…¹è…”é•œå…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯ï¼ˆTMEï¼‰ä½œä¸ºæ–°è¾…åŠ©æ”¾åŒ–ç–—ï¼ˆnCRTï¼‰åä¸­ä½ä½ç›´è‚ ç™Œæ‰‹æœ¯å¹²é¢„çš„æ•ˆæœä»ä¸ç¡®å®šã€‚ç³»ç»Ÿè¯„ä¼° nCRT åæœºå™¨äººä¸è…¹è…”é•œæ‰‹æœ¯æ²»ç–—ä¸­ä½ä½ç›´è‚ ç™Œçš„è‚¿ç˜¤å­¦ã€å›´æ‰‹æœ¯æœŸå’Œç”Ÿå­˜ç»“æœã€‚ç¬¦åˆ PRISMA æ ‡å‡†çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æåŒ…æ‹¬æˆªè‡³ 2025 å¹´ 7 æœˆæ¥è‡ª Web of Scienceã€PubMed å’Œ Embase çš„ 20 é¡¹ééšæœºç ”ç©¶ï¼ˆ13,212 åæ‚£è€…ï¼‰ã€‚ç»“æœåŒ…æ‹¬ç—…ç†å®Œæ•´æ€§ï¼ˆåœ†å‘¨åˆ‡é™¤è¾¹ç¼˜ã€TME è´¨é‡ï¼‰ã€å›´æ‰‹æœ¯æœŸæŒ‡æ ‡ï¼ˆæ‰‹æœ¯æŒç»­æ—¶é—´ã€è½¬æ¢ç‡ï¼‰ã€å¹¶å‘ç—‡å’Œç”Ÿå­˜ç‡ï¼ˆ5 å¹´ OS/DFSï¼‰ã€‚é€šè¿‡ ROBINS-I è¯„ä¼°åå€šé£é™©ï¼›ç»Ÿè®¡ç»¼åˆåˆ©ç”¨ RevMan5.4 å’Œæºè‡ª Kaplan-Meier æ›²çº¿çš„é£é™©æ¯”ã€‚è¿™é¡¹å¯¹ 20 é¡¹ééšæœºç ”ç©¶ï¼ˆ13,212 åæ‚£è€…ï¼‰çš„èŸèƒåˆ†æå‘ç°ï¼Œ5 å¹´æ€»ç”Ÿå­˜ç‡ï¼ˆHRï¼š1.07ï¼Œ95% CI 0.20-5.66ï¼Œpâ€‰=â€‰0.94ï¼ŒI<sup>2</sup>â€‰=â€‰98%ï¼‰æˆ–æ— ç—…ç”Ÿå­˜ç‡ï¼ˆHRï¼š1.16ï¼Œ95% CIï¼‰æ²¡æœ‰æ˜¾ç€å·®å¼‚nCRT åæœºå™¨äºº TME ä¸è…¹è…”é•œ TME ä¹‹é—´çš„å·®å¼‚ä¸º 0.72-1.89ï¼Œpâ€‰=â€‰0.54ï¼ŒI<sup>2</sup>â€‰=â€‰0%ï¼‰ã€‚æœºå™¨äººæ‰‹æœ¯è¡¨ç°å‡ºä¼˜è¶Šçš„æŠ€æœ¯æˆæœï¼ŒåŒ…æ‹¬æ›´é«˜çš„å®Œå…¨ TME ç‡ï¼ˆORï¼š1.97ï¼Œpâ€‰=â€‰0.02ï¼‰å’Œå‡å°‘ä¸­è½¬å¼€æ”¾æ‰‹æœ¯ï¼ˆORï¼š0.46ï¼Œpâ€‰<â€‰0.001ï¼‰ï¼Œä½†éœ€è¦æ˜æ˜¾æ›´é•¿çš„æ‰‹æœ¯æ—¶é—´ï¼ˆWMDï¼šâ€‰+â€‰42.09 åˆ†é’Ÿï¼Œpâ€‰<â€‰0.001ï¼‰ã€‚å›´æ‰‹æœ¯æœŸæŒ‡æ ‡æ˜¾ç¤ºæœ¯ä¸­å¤±è¡€é‡ (pâ€‰=â€‰0.20)ã€ä½é™¢æ—¶é—´ (pâ€‰=â€‰0.78) å’Œæœ¯åå¹¶å‘ç—‡ï¼ŒåŒ…æ‹¬å»åˆå£ç˜˜ï¼ˆ5.4% vs. 6.5%ï¼Œpâ€‰=â€‰0.28ï¼‰å’Œ Clavien-Dindo III-IV äº‹ä»¶ï¼ˆORï¼š1.11ï¼Œpâ€‰=â€‰0.54ï¼‰ç­‰æ–¹é¢çš„ç­‰æ•ˆæ€§ã€‚ç—…ç†ç»“æœå…·æœ‰å¯æ¯”æ€§ï¼Œç¯å‘¨åˆ‡ç¼˜é˜³æ€§ç‡ï¼ˆORï¼š1.0ï¼Œpâ€‰=â€‰1ï¼‰ã€è¿œç«¯åˆ‡ç¼˜é•¿åº¦ï¼ˆpâ€‰=â€‰0.92ï¼‰æˆ–æ·‹å·´ç»“äº§é‡ï¼ˆpâ€‰=â€‰0.55ï¼‰æ²¡æœ‰å·®å¼‚ã€‚å±€éƒ¨å¤å‘ç‡ï¼ˆORï¼š0.85ï¼Œpâ€‰=â€‰0.34ï¼‰å’Œè¿œå¤„å¤å‘ç‡ï¼ˆpâ€‰=â€‰0.99ï¼‰åœ¨ç»Ÿè®¡å­¦ä¸Šæ— æ³•åŒºåˆ†ã€‚åå€šé£é™©è¯„ä¼°æ­ç¤ºäº†ééšæœºè®¾è®¡ä¸­çš„æ··æ‚é£é™©ï¼Œå¼ºè°ƒäº† RCT éªŒè¯çš„å¿…è¦æ€§ã€‚æœºå™¨äººå’Œè…¹è…”é•œ TME åœ¨ nCRT åå®ç°äº†åŒç­‰çš„é•¿æœŸç”Ÿå­˜å’Œè‚¿ç˜¤æ§åˆ¶ï¼Œæœºå™¨äººåœ¨æŠ€æœ¯ç²¾åº¦æ–¹é¢çš„ä¼˜åŠ¿è¢«å»¶é•¿çš„æ‰‹æœ¯æ—¶é—´æ‰€æŠµæ¶ˆã€‚è¿™ç§ç­‰åŒæ€§å¼ºè°ƒäº† nCRT åœ¨è‚¿ç˜¤æ§åˆ¶ä¸­çš„ä¸»å¯¼ä½œç”¨ï¼Œè€Œç¨‹åºå·®å¼‚åˆ™å¼ºè°ƒäº†æ‰‹æœ¯å¯è¡Œæ€§ã€‚ç”Ÿå­˜æ•°æ®çš„é«˜åº¦å¼‚è´¨æ€§å’Œå¯¹ééšæœºè¯æ®çš„ä¾èµ–éœ€è¦é€šè¿‡ä¸¥æ ¼è®¾è®¡çš„éšæœºå¯¹ç…§è¯•éªŒï¼ˆç»“åˆæ ‡å‡†åŒ–æ–¹æ¡ˆå’Œæ‚£è€…æŠ¥å‘Šçš„åŠŸèƒ½ç»“æœï¼‰è¿›è¡ŒéªŒè¯ã€‚", "keywords_zh": "è…¹è…”é•œæ‰‹æœ¯ã€Metaåˆ†æã€ä¸­ä½ä½ç›´è‚ ç™Œã€æ–°è¾…åŠ©æ”¾åŒ–ç–—ã€æœºå™¨äººæ‰‹æœ¯ã€å…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯", "keywords_en": "Laparoscopic surgery, Meta-analysis, Midâ€“low rectal cancer, Neoadjuvant chemoradiotherapy, Robotic surgery, Total mesorectal excision", "link": "https://pubmed.ncbi.nlm.nih.gov/40914745/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sat, 06 Sep 2025"}, {"id": "40907429", "title_en": "ICG-FA for Anastomotic Leak Prevention During Minimally Invasive Colorectal Surgery: A Meta-analysis", "title_zh": "ICG-FA åœ¨å¾®åˆ›ç»“ç›´è‚ æ‰‹æœ¯æœŸé—´é¢„é˜²å»åˆå£æ¼ï¼šèŸèƒåˆ†æ", "authors": "Muhammad Shehryar Hussain", "abstract_en": "**Introduction:** Anastomotic leakage is a serious complication after colorectal surgery. Indocyanine green fluorescence angiography (ICG-FA) allows real-time perfusion assessment and may reduce leak rates; however, recent larger randomized clinical trials reported conflicting results. This meta-analysis aimed to clarify the effectiveness of ICG-FA in reducing anastomotic leakage and related complications following minimally invasive colorectal surgery.\n\n**Methods:** We conducted a comprehensive search across the databases to identify relevant studies. The search results were imported into Covidence for article eligibility screening, and all relevant outcomes data were synthesized using risk ratios (RRs) or mean differences with 95% confidence intervals (CIs) in meta-analysis models using RevMan 5.4. CRD420251031138.\n\n**Results:** Six randomized clinical trials involving 3264 participants were included. ICG-FA significantly reduced the risk of overall anastomotic leakage (RR: 0.66, 95% CI [0.53-0.83], P = 0.0005) and complications (RR: 0.88, 95% CI [0.78-0.99], P = 0.03). Subgroup analysis showed a significant reduction in leakage for left-sided anastomoses (RR: 0.57, 95% CI [0.44-0.75], P < 0.0001) but not for right-sided ones (RR: 0.90, 95% CI [0.53-1.51], P = 0.68). No significant differences were found in Clavien-Dindo â‰¥3 complications, reoperation rates, or hospital stay. However, the ICG-FA group had a longer operation time (mean difference: 5.57, 95% CI [1.56-9.58], P = 0.006).\n\n**Conclusions:** ICG-FA significantly reduces anastomotic leakage and overall complications in minimally invasive colorectal surgery, especially for left-sided anastomoses. However, its use is associated with a slightly longer operative time. Further research is needed to confirm its role in right-sided procedures and long-term outcomes.", "abstract_zh": "**ä»‹ç»ï¼š** å»åˆå£æ¼æ˜¯ç»“ç›´è‚ æ‰‹æœ¯åçš„ä¸¥é‡å¹¶å‘ç—‡ã€‚å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½±ï¼ˆICG-FAï¼‰å¯è¿›è¡Œå®æ—¶çŒæ³¨è¯„ä¼°ï¼Œå¹¶å¯é™ä½æ¸—æ¼ç‡ï¼›ç„¶è€Œï¼Œæœ€è¿‘æ›´å¤§è§„æ¨¡çš„éšæœºä¸´åºŠè¯•éªŒæŠ¥å‘Šäº†ç›¸äº’çŸ›ç›¾çš„ç»“æœã€‚è¿™é¡¹èŸèƒåˆ†ææ—¨åœ¨é˜æ˜ ICG-FA åœ¨å‡å°‘å¾®åˆ›ç»“ç›´è‚ æ‰‹æœ¯åå»åˆå£ç˜˜å’Œç›¸å…³å¹¶å‘ç—‡æ–¹é¢çš„æœ‰æ•ˆæ€§ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬å¯¹æ•°æ®åº“è¿›è¡Œäº†å…¨é¢æœç´¢ï¼Œä»¥ç¡®å®šç›¸å…³ç ”ç©¶ã€‚å°†æœç´¢ç»“æœå¯¼å…¥ Covidence è¿›è¡Œæ–‡ç« èµ„æ ¼ç­›é€‰ï¼Œå¹¶ä½¿ç”¨ RevMan 5.4 åœ¨èŸèƒåˆ†ææ¨¡å‹ä¸­ä½¿ç”¨é£é™©æ¯” (RR) æˆ–å¹³å‡å·®ä¸ 95% ç½®ä¿¡åŒºé—´ (CI) åˆæˆæ‰€æœ‰ç›¸å…³ç»“æœæ•°æ®ã€‚ CRD420251031138ã€‚\n\n**ç»“æœï¼š** å…¶ä¸­åŒ…æ‹¬ 6 é¡¹éšæœºä¸´åºŠè¯•éªŒï¼Œæ¶‰åŠ 3264 åå‚ä¸è€…ã€‚ ICG-FA æ˜¾ç€é™ä½äº†æ€»ä½“å»åˆå£ç˜˜ï¼ˆRRï¼š0.66ï¼Œ95% CI [0.53-0.83]ï¼ŒP = 0.0005ï¼‰å’Œå¹¶å‘ç—‡ï¼ˆRRï¼š0.88ï¼Œ95% CI [0.78-0.99]ï¼ŒP = 0.03ï¼‰çš„é£é™©ã€‚äºšç»„åˆ†ææ˜¾ç¤ºå·¦ä¾§å»åˆæœ¯çš„æ¸—æ¼æ˜¾ç€å‡å°‘ï¼ˆRRï¼š0.57ï¼Œ95% CI [0.44-0.75]ï¼ŒP < 0.0001ï¼‰ï¼Œä½†å³ä¾§å»åˆæœ¯çš„æ¸—æ¼æ²¡æœ‰æ˜¾ç€å‡å°‘ï¼ˆRRï¼š0.90ï¼Œ95% CI [0.53-1.51]ï¼ŒP = 0.68ï¼‰ã€‚ Clavien-Dindo â‰¥3 ç§å¹¶å‘ç—‡ã€å†æ‰‹æœ¯ç‡æˆ–ä½é™¢æ—¶é—´æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚ç„¶è€Œï¼ŒICG-FAç»„çš„æ‰‹æœ¯æ—¶é—´è¾ƒé•¿ï¼ˆå¹³å‡å·®ï¼š5.57ï¼Œ95% CI [1.56-9.58]ï¼ŒP = 0.006ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ICG-FA æ˜¾ç€å‡å°‘å¾®åˆ›ç»“ç›´è‚ æ‰‹æœ¯ä¸­çš„å»åˆå£ç˜˜å’Œæ€»ä½“å¹¶å‘ç—‡ï¼Œå°¤å…¶æ˜¯å·¦ä¾§å»åˆæœ¯ã€‚ç„¶è€Œï¼Œå…¶ä½¿ç”¨ä¼šå¯¼è‡´æ‰‹æœ¯æ—¶é—´ç¨é•¿ã€‚éœ€è¦è¿›ä¸€æ­¥çš„ç ”ç©¶æ¥ç¡®è®¤å…¶åœ¨æ­£ç¡®ç¨‹åºå’Œé•¿æœŸç»“æœä¸­çš„ä½œç”¨ã€‚", "keywords_zh": "å»åˆå£æ¼ã€ç»“ç›´è‚ æ‰‹æœ¯ã€è§å…‰è¡€ç®¡é€ å½±ã€ICGã€å²å“šèç»¿ã€Metaåˆ†æã€å¾®åˆ›æ‰‹æœ¯", "keywords_en": "Anastomotic leakage, Colorectal surgery, Fluorescence angiography, ICG, Indocyanine green, Meta-analysis, Minimally invasive surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40907429/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 04 Sep 2025"}, {"id": "40905480", "title_en": "Neoadjuvant Chemotherapy Without Radiation for Locally Advanced Rectal Cancer: A Meta-analysis of Surgical Outcomes After Total Mesorectal Excision", "title_zh": "å±€éƒ¨æ™šæœŸç›´è‚ ç™Œæ— æ”¾å°„æ–°è¾…åŠ©åŒ–ç–—ï¼šå…¨ç›´è‚ ç³»è†œåˆ‡é™¤åæ‰‹æœ¯ç»“æœçš„èŸèƒåˆ†æ", "authors": "Dean A Fergusson", "abstract_en": "**Background:** Neoadjuvant chemotherapy alone (with radiation omission) for locally advanced rectal cancer has been evaluated in several randomized controlled trials. Although oncologic outcomes have been well described, the impact of this treatment strategy on surgical outcomes is unknown.\n\n**Objective:** To evaluate how important surgical outcomes were reported in previous trials comparing neoadjuvant chemotherapy to chemoradiation therapy for locally advanced rectal cancer and to perform a meta-analysis of available data.\n\n**Data Sources:** A systematic review was conducted using MEDLINE, Embase, and the Cochrane Library Databases.\n\n**Study Selection:** All published randomized controlled trials that compared neoadjuvant chemotherapy to chemoradiation for MRI-staged rectal adenocarcinoma.\n\n**Interventions:** Neoadjuvant chemotherapy alone (with radiation omission).\n\n**Main Outcome Measures:** Postoperative surgical outcomes, including anastomotic leak, diverting ostomy use, ostomy nonreversal, 30-day postoperative morbidity, and postoperative bowel function.\n\n**Results:** Four randomized controlled trials met eligibility criteria and were included for data analysis. Oncologic outcomes demonstrated that neoadjuvant chemotherapy was equivalent or noninferior to chemoradiation therapy. Anastomotic leak and use of diverting ostomy were reported in 3 of the 4 trials, whereas 30-day postoperative morbidity and ostomy nonreversal were reported in only 2 trials. Bowel function was measured in 3 trials but was measured and reported differently in each trial. On meta-analysis, neoadjuvant chemotherapy was associated with a significant reduction in anastomotic leak (relative risk [RR] 0.54; 95% CI, 0.35-0.81), use of diverting ostomy (RR 0.79; 95% CI, 0.70-0.88), and ostomy nonreversal (RR 0.37; 95% CI, 0.15-0.93). There was no association between neoadjuvant chemotherapy and 30-day postoperative morbidity (RR 0.88; 95% CI, 0.53-1.45).\n\n**Limitations:** A small number of included trials with heterogeneity in outcome definitions was the limitation.\n\n**Conclusions:** Important surgical outcomes were not reported in trials comparing neoadjuvant chemotherapy alone to chemoradiation therapy for locally advanced rectal cancer. Based on the limited data available, chemotherapy alone was associated with reduced risk of anastomotic leak, diverting ostomy use, and ostomy nonreversal. See Video Abstract .", "abstract_zh": "**èƒŒæ™¯ï¼š** å¤šé¡¹éšæœºå¯¹ç…§è¯•éªŒå·²å¯¹å•ç‹¬æ–°è¾…åŠ©åŒ–ç–—ï¼ˆçœç•¥æ”¾ç–—ï¼‰æ²»ç–—å±€éƒ¨æ™šæœŸç›´è‚ ç™Œè¿›è¡Œäº†è¯„ä¼°ã€‚å°½ç®¡è‚¿ç˜¤å­¦ç»“æœå·²å¾—åˆ°å¾ˆå¥½çš„æè¿°ï¼Œä½†è¿™ç§æ²»ç–—ç­–ç•¥å¯¹æ‰‹æœ¯ç»“æœçš„å½±å“å°šä¸æ¸…æ¥šã€‚\n\n**ç›®çš„ï¼š** è¯„ä¼°å…ˆå‰æ¯”è¾ƒæ–°è¾…åŠ©åŒ–ç–—ä¸æ”¾åŒ–ç–—æ²»ç–—å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„è¯•éªŒä¸­æŠ¥å‘Šçš„æ‰‹æœ¯ç»“æœçš„é‡è¦æ€§ï¼Œå¹¶å¯¹ç°æœ‰æ•°æ®è¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**Data sourcesï¼š** ä½¿ç”¨ MEDLINEã€Embase å’Œ Cochrane å›¾ä¹¦é¦†æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ã€‚\n\n**Study selectionï¼š** æ‰€æœ‰å·²å‘è¡¨çš„éšæœºå¯¹ç…§è¯•éªŒéƒ½å¯¹ MRI åˆ†æœŸç›´è‚ è…ºç™Œçš„æ–°è¾…åŠ©åŒ–ç–—ä¸æ”¾åŒ–ç–—è¿›è¡Œäº†æ¯”è¾ƒã€‚\n\n**Interventionsï¼š** å•ç‹¬æ–°è¾…åŠ©åŒ–ç–—ï¼ˆçœç•¥æ”¾å°„æ²»ç–—ï¼‰ã€‚\n\n**Main outcome measuresï¼š** æœ¯åæ‰‹æœ¯ç»“æœï¼ŒåŒ…æ‹¬å»åˆå£ç˜˜ã€åˆ†æµé€ å£æœ¯çš„ä½¿ç”¨ã€é€ å£æœ¯ä¸å¯é€†è½¬ã€æœ¯å 30 å¤©çš„å‘ç—…ç‡å’Œæœ¯åè‚ åŠŸèƒ½ã€‚\n\n**ç»“æœï¼š** å››é¡¹éšæœºå¯¹ç…§è¯•éªŒç¬¦åˆèµ„æ ¼æ ‡å‡†å¹¶è¢«çº³å…¥æ•°æ®åˆ†æã€‚è‚¿ç˜¤å­¦ç»“æœè¡¨æ˜ï¼Œæ–°è¾…åŠ©åŒ–ç–—ç›¸å½“äºæˆ–ä¸åŠ£äºæ”¾åŒ–ç–—ã€‚ 4 é¡¹è¯•éªŒä¸­æœ‰ 3 é¡¹æŠ¥å‘Šäº†å»åˆå£ç˜˜å’Œæ”¹é“é€ å£æœ¯çš„ä½¿ç”¨ï¼Œè€Œä»… 2 é¡¹è¯•éªŒæŠ¥å‘Šäº†æœ¯å 30 å¤©çš„å‘ç—…ç‡å’Œé€ å£æœ¯ä¸å¯é€†è½¬ã€‚åœ¨ 3 é¡¹è¯•éªŒä¸­æµ‹é‡äº†è‚ åŠŸèƒ½ï¼Œä½†æ¯é¡¹è¯•éªŒçš„æµ‹é‡å’ŒæŠ¥å‘Šéƒ½ä¸åŒã€‚èŸèƒåˆ†æè¡¨æ˜ï¼Œæ–°è¾…åŠ©åŒ–ç–—ä¸å»åˆå£ç˜˜æ˜¾ç€å‡å°‘ï¼ˆç›¸å¯¹é£é™© [RR] 0.54ï¼›95% CIï¼Œ0.35-0.81ï¼‰ã€æ”¹é“é€ å£æœ¯çš„ä½¿ç”¨ï¼ˆRR 0.79ï¼›95% CIï¼Œ0.70-0.88ï¼‰å’Œé€ å£éé€†è½¬ï¼ˆRR 0.37ï¼›95% CIï¼Œ 0.15-0.93ï¼‰ã€‚æ–°è¾…åŠ©åŒ–ç–—ä¸æœ¯å 30 å¤©å‘ç—…ç‡ä¹‹é—´æ²¡æœ‰å…³è”ï¼ˆRR 0.88ï¼›95% CIï¼Œ0.53-1.45ï¼‰ã€‚\n\n**Limitationsï¼š** å°‘æ•°çº³å…¥çš„è¯•éªŒåœ¨ç»“æœå®šä¹‰ä¸Šå­˜åœ¨å¼‚è´¨æ€§æ˜¯é™åˆ¶å› ç´ ã€‚\n\n**ç»“è®ºï¼š** åœ¨æ¯”è¾ƒå•ç‹¬æ–°è¾…åŠ©åŒ–ç–—ä¸æ”¾åŒ–ç–—æ²»ç–—å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„è¯•éªŒä¸­ï¼Œæ²¡æœ‰æŠ¥å‘Šé‡è¦çš„æ‰‹æœ¯ç»“æœã€‚æ ¹æ®ç°æœ‰çš„æœ‰é™æ•°æ®ï¼Œå•ç‹¬åŒ–ç–—ä¸é™ä½å»åˆå£ç˜˜ã€è½¬ç§»é€ å£æœ¯ä½¿ç”¨å’Œé€ å£æœ¯ä¸å¯é€†è½¬çš„é£é™©ç›¸å…³ã€‚å‚è§è§†é¢‘æ‘˜è¦ã€‚", "keywords_zh": "åŒ–ç–—ã€æ–°è¾…åŠ©æ²»ç–—ã€é—æ¼æ”¾å°„æ²»ç–—ã€ç›´è‚ ç™Œã€æ‰‹æœ¯ç»“æœ", "keywords_en": "Chemotherapy, Neoadjuvant therapy, Radiation omission, Rectal cancer, Surgical outcomes", "link": "https://pubmed.ncbi.nlm.nih.gov/40905480/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 04 Sep 2025"}, {"id": "40894328", "title_en": "Systematic meta-review: diagnostic accuracy of colon capsule endoscopy for colonic neoplasia with umbrella meta-analysis", "title_zh": "ç³»ç»ŸèŸèƒå›é¡¾ï¼šç»“è‚ èƒ¶å›Šå†…é•œæ£€æŸ¥å¯¹ç»“è‚ è‚¿ç˜¤çš„ä¼å½¢èŸèƒåˆ†æè¯Šæ–­å‡†ç¡®æ€§", "authors": "Anastasios Koulaouzidis", "abstract_en": "**Background:** Colorectal cancer (CRC) incidence is rising globally, intensifying pressure on endoscopy services. Colon capsule endoscopy (CCE) offers a non-invasive alternative. Despite several systematic reviews showing reasonable polyp detection rates, clinical scepticism remains.\n\n**Objectives:** This meta-review and umbrella meta-analysis aim to synthesise evidence on CCE's diagnostic accuracy in polyp and CRC detection, using CT colonography or colonoscopy as the reference standard.\n\n**Methods:** We conducted a systematic search of EMBASE, MEDLINE and PubMed for systematic reviews evaluating the diagnostic accuracy of CCE in detecting polyps and CRC. A qualitative thematic review and synthesis were conducted following PRISMA guidelines. A bivariate generalised linear mixed model with random effects was used for pooled diagnostic accuracy estimates, and meta-regression was performed using restricted maximum likelihood estimation.\n\n**Results:** Nine systematic reviews encompassing 28 unique studies (3472 participants) were included. For polyps of any size, the pooled per-patient sensitivity was 0.79 (95% CI: 0.69-0.86), specificity was 0.77 (95% CI: 0.71-0.82), and the area under the curve (AUC) was 0.81. For polyps â©¾6â€‰mm, sensitivity and specificity were 0.80 and 0.87 (AUC 0.81), and for polyps â©¾10â€‰mm, 0.88 and 0.95 (AUC 0.95), respectively. Second-generation CCE (CCE2) improved diagnostic accuracy across all polyp sizes. For polyps of any size, CCE2 achieved a sensitivity of 0.90, specificity of 0.81 and AUC of 0.82. For polypsâ€‰â©¾â€‰6â€‰mm and â©¾10â€‰mm, AUCs were 0.92 and 0.94, respectively. CCE2 showed high sensitivity for detecting any polyp size and polyps â©¾6â€‰mm, with low heterogeneity (<i>p</i>â€‰>â€‰0.05, <i>I</i> <sup>2</sup>â€‰<â€‰25%). CRC detection sensitivity was 0.96 (95% CI: 0.73-1.00) after excluding cases where the capsule failed to reach the rectum due to battery exhaustion.\n\n**Conclusion:** CCE2 has high diagnostic accuracy for polyps and colorectal cancer detection. While technical challenges persist, CCE2 shows promise as a complementary diagnostic tool to help address the increasing demands for endoscopy services.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…¨çƒç»“ç›´è‚ ç™Œï¼ˆCRCï¼‰å‘ç—…ç‡ä¸æ–­ä¸Šå‡ï¼ŒåŠ å¤§äº†å†…çª¥é•œæ£€æŸ¥æœåŠ¡çš„å‹åŠ›ã€‚ç»“è‚ èƒ¶å›Šå†…çª¥é•œæ£€æŸ¥ (CCE) æä¾›äº†ä¸€ç§éä¾µå…¥æ€§æ›¿ä»£æ–¹æ¡ˆã€‚å°½ç®¡å¤šé¡¹ç³»ç»Ÿè¯„ä»·æ˜¾ç¤ºæ¯è‚‰æ£€å‡ºç‡åˆç†ï¼Œä½†ä¸´åºŠä»æŒæ€€ç–‘æ€åº¦ã€‚\n\n**Objectivesï¼š** è¿™é¡¹èŸèƒå®¡æŸ¥å’Œä¼å¼èŸèƒåˆ†ææ—¨åœ¨ä»¥ CT ç»“è‚ æˆåƒæˆ–ç»“è‚ é•œæ£€æŸ¥ä½œä¸ºå‚è€ƒæ ‡å‡†ï¼Œç»¼åˆè¯æ˜ CCE åœ¨æ¯è‚‰å’Œ CRC æ£€æµ‹ä¸­è¯Šæ–­å‡†ç¡®æ€§çš„è¯æ®ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬å¯¹ EMBASEã€MEDLINE å’Œ PubMed è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼Œä»¥è¿›è¡Œç³»ç»Ÿè¯„ä»·ï¼Œè¯„ä¼° CCE åœ¨æ£€æµ‹æ¯è‚‰å’Œ CRC æ–¹é¢çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚æŒ‰ç…§ PRISMA æŒ‡å—è¿›è¡Œäº†å®šæ€§ä¸»é¢˜å®¡æŸ¥å’Œç»¼åˆã€‚å…·æœ‰éšæœºæ•ˆåº”çš„äºŒå…ƒå¹¿ä¹‰çº¿æ€§æ··åˆæ¨¡å‹ç”¨äºæ±‡æ€»è¯Šæ–­å‡†ç¡®æ€§ä¼°è®¡ï¼Œå¹¶ä½¿ç”¨é™åˆ¶æœ€å¤§ä¼¼ç„¶ä¼°è®¡è¿›è¡Œå…ƒå›å½’ã€‚\n\n**ç»“æœï¼š** å…¶ä¸­åŒ…æ‹¬ 9 é¡¹ç³»ç»Ÿè¯„ä»·ï¼Œæ¶µç›– 28 é¡¹ç‹¬ç‰¹ç ”ç©¶ï¼ˆ3472 åå‚ä¸è€…ï¼‰ã€‚å¯¹äºä»»ä½•å¤§å°çš„æ¯è‚‰ï¼Œæ¯ä½æ‚£è€…çš„æ±‡æ€»æ•æ„Ÿæ€§ä¸º 0.79ï¼ˆ95% CIï¼š0.69-0.86ï¼‰ï¼Œç‰¹å¼‚æ€§ä¸º 0.77ï¼ˆ95% CIï¼š0.71-0.82ï¼‰ï¼Œæ›²çº¿ä¸‹é¢ç§¯ (AUC) ä¸º 0.81ã€‚å¯¹äºâ‰¥6mmçš„æ¯è‚‰ï¼Œæ•æ„Ÿæ€§å’Œç‰¹å¼‚æ€§åˆ†åˆ«ä¸º0.80å’Œ0.87ï¼ˆAUC 0.81ï¼‰ï¼Œå¯¹äºâ‰¥10mmçš„æ¯è‚‰ï¼Œæ•æ„Ÿæ€§å’Œç‰¹å¼‚æ€§åˆ†åˆ«ä¸º0.88å’Œ0.95ï¼ˆAUC 0.95ï¼‰ã€‚ç¬¬äºŒä»£ CCE (CCE2) æé«˜äº†æ‰€æœ‰æ¯è‚‰å°ºå¯¸çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚å¯¹äºä»»ä½•å¤§å°çš„æ¯è‚‰ï¼ŒCCE2 çš„æ•æ„Ÿæ€§ä¸º 0.90ï¼Œç‰¹å¼‚æ€§ä¸º 0.81ï¼ŒAUC ä¸º 0.82ã€‚å¯¹äºâ€‰â©¾â€‰6â€‰mmå’Œâ©¾10â€‰mmçš„æ¯è‚‰ï¼ŒAUCåˆ†åˆ«ä¸º0.92å’Œ0.94ã€‚ CCE2 å¯¹æ£€æµ‹ä»»ä½•æ¯è‚‰å¤§å°å’Œæ¯è‚‰ â©¾6â€‰mm è¡¨ç°å‡ºé«˜çµæ•åº¦ï¼Œå¼‚è´¨æ€§ä½ï¼ˆ<i>p</i>â€‰>â€‰0.05ï¼Œ<i>I</i> <sup>2</sup>â€‰<â€‰25%ï¼‰ã€‚æ’é™¤èƒ¶å›Šå› ç”µæ± è€—å°½è€Œæœªèƒ½åˆ°è¾¾ç›´è‚ çš„æƒ…å†µåï¼ŒCRC æ£€æµ‹çµæ•åº¦ä¸º 0.96ï¼ˆ95% CIï¼š0.73-1.00ï¼‰ã€‚\n\n**ç»“è®ºï¼š** CCE2å¯¹äºæ¯è‚‰å’Œç»“ç›´è‚ ç™Œæ£€æµ‹å…·æœ‰è¾ƒé«˜çš„è¯Šæ–­å‡†ç¡®æ€§ã€‚å°½ç®¡æŠ€æœ¯æŒ‘æˆ˜ä»ç„¶å­˜åœ¨ï¼Œä½† CCE2 ä½œä¸ºä¸€ç§è¡¥å……è¯Šæ–­å·¥å…·æœ‰æœ›å¸®åŠ©æ»¡è¶³æ—¥ç›Šå¢é•¿çš„å†…çª¥é•œæœåŠ¡éœ€æ±‚ã€‚", "keywords_zh": "CCEã€CRCæ£€æµ‹ã€CTç»“è‚ é•œæ£€æŸ¥ã€èƒ¶å›Šå†…é•œæ£€æŸ¥ã€ç»“è‚ èƒ¶å›Šå†…é•œæ£€æŸ¥ã€ç»“è‚ é•œæ£€æŸ¥ã€å…¨è‚ èƒ¶å›Šå†…é•œæ£€æŸ¥ã€æ¯è‚‰ã€æ¯è‚‰æ£€æµ‹ã€æ¯è‚‰æ ·ç—…å˜", "keywords_en": "CCE, CRC detection, CT colonoscopy, capsule endoscopy, colon capsule endoscopy, colonoscopy, panenteric capsule endoscopy, polyp, polyp detection, polypoidal lesion", "link": "https://pubmed.ncbi.nlm.nih.gov/40894328/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 02 Sep 2025"}, {"id": "40877526", "title_en": "Outcomes of embolization therapy of superior rectal arteries for the management of grade 1 to 3 internal hemorrhoids: a systematic Review of clinical studies", "title_zh": "ç›´è‚ ä¸ŠåŠ¨è„‰æ “å¡æ²»ç–— 1 è‡³ 3 çº§å†…ç—”çš„ç»“æœï¼šä¸´åºŠç ”ç©¶çš„ç³»ç»Ÿè¯„ä»·", "authors": "Jana Al Jnainati", "abstract_en": "**Background:** Superior rectal artery embolization (\"Emborrhoid\") offers a catheter-based alternative for grade I-III internal hemorrhoids when office therapies fail or surgery is undesirable.\n\n**Methods:** Following PRISMA 2020, PubMed and Embase were searched (Jan 2014-Jan 2024). Two reviewers independently screened records, extracted data, and applied RoB 2, ROBINS-I, or an adapted Newcastle-Ottawa Scale. Prespecified outcomes were technical success, clinical success (â‰¥â€‰2-point fall in bleeding score or equivalent), adverse events, and recurrence. Substantial heterogeneity blocked meta-analysis; results were narratively synthesized.\n\n**Results:** Twenty-two studies encompassing 810 procedures qualified. Technical success reached 93-100%. Clinical success ranged from 63 to 94%, yielding marked bleeding control and symptom relief. Reported complications were mild and self-limited (pelvic discomfort, nausea, and low-grade fever); no ischemic injury, continence disturbance, or mortality occurred. Recurrence necessitating repeat treatment affected 8-20% of patients, usually when collateral arterial supply persisted. Patient-reported satisfaction exceeded 80% in every series. Only two small, heterogeneous comparative studies versus rubber-band ligation or sclerotherapy were available, precluding a pooled analysis.\n\n**Conclusions:** Current evidence suggests Emborrhoid is a safe, effective bridge between office procedures and surgery-particularly valuable for frail or anticoagulated patients. Yet small single-center cohorts, disparate techniques, and scarce head-to-head trials limit external validity. Multicenter randomized studies with harmonized outcomes andâ€‰â‰¥â€‰24-month follow-up are required to confirm long-term efficacy, cost-effectiveness, and optimal patient selection.", "abstract_zh": "**èƒŒæ™¯ï¼š** å½“åŠå…¬å®¤æ²»ç–—å¤±è´¥æˆ–ä¸å®œè¿›è¡Œæ‰‹æœ¯æ—¶ï¼Œç›´è‚ ä¸ŠåŠ¨è„‰æ “å¡æœ¯ï¼ˆâ€œæ “å¡æœ¯â€ï¼‰ä¸º I-III çº§å†…ç—”æä¾›äº†ä¸€ç§åŸºäºå¯¼ç®¡çš„æ›¿ä»£æ–¹æ¡ˆã€‚\n\n**æ–¹æ³•ï¼š** ç»§ PRISMA 2020 ä¹‹åï¼Œå¯¹ PubMed å’Œ Embase è¿›è¡Œäº†æ£€ç´¢ï¼ˆ2014 å¹´ 1 æœˆ-2024 å¹´ 1 æœˆï¼‰ã€‚ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹ç­›é€‰è®°å½•ã€æå–æ•°æ®å¹¶åº”ç”¨ RoB 2ã€ROBINS-I æˆ–æ”¹ç¼–çš„çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨ã€‚é¢„å…ˆè®¾å®šçš„ç»“æœæ˜¯æŠ€æœ¯æˆåŠŸã€ä¸´åºŠæˆåŠŸï¼ˆå‡ºè¡€è¯„åˆ†ä¸‹é™â‰¥2åˆ†æˆ–åŒç­‰æ°´å¹³ï¼‰ã€ä¸è‰¯äº‹ä»¶å’Œå¤å‘ã€‚æ˜¾ç€çš„å¼‚è´¨æ€§é˜»ç¢äº†èŸèƒåˆ†æï¼›ç»“æœæ˜¯å™è¿°æ€§ç»¼åˆçš„ã€‚\n\n**ç»“æœï¼š** æ¶µç›– 810 é¡¹ç¨‹åºçš„ 22 é¡¹ç ”ç©¶åˆæ ¼ã€‚æŠ€æœ¯æˆåŠŸç‡è¾¾åˆ°93-100%ã€‚ä¸´åºŠæˆåŠŸç‡ä¸º 63% è‡³ 94%ï¼Œæ˜¾ç€æ§åˆ¶å‡ºè¡€å¹¶ç¼“è§£ç—‡çŠ¶ã€‚æŠ¥å‘Šçš„å¹¶å‘ç—‡è½»å¾®ä¸”å…·æœ‰è‡ªé™æ€§ï¼ˆéª¨ç›†ä¸é€‚ã€æ¶å¿ƒå’Œä½çƒ§ï¼‰ï¼›æ²¡æœ‰å‘ç”Ÿç¼ºè¡€æ€§æŸä¼¤ã€å¤±ç¦éšœç¢æˆ–æ­»äº¡ã€‚éœ€è¦é‡å¤æ²»ç–—çš„å¤å‘å½±å“äº† 8-20% çš„æ‚£è€…ï¼Œé€šå¸¸æ˜¯åœ¨ä¾§æ”¯åŠ¨è„‰ä¾›åº”æŒç»­å­˜åœ¨çš„æƒ…å†µä¸‹ã€‚æ¯ä¸ªç³»åˆ—ä¸­æ‚£è€…æŠ¥å‘Šçš„æ»¡æ„åº¦å‡è¶…è¿‡ 80%ã€‚åªæœ‰ä¸¤é¡¹å°å‹ã€å¼‚è´¨æ€§ä¸æ©¡çš®ç­‹ç»“æ‰æˆ–ç¡¬åŒ–ç–—æ³•çš„æ¯”è¾ƒç ”ç©¶å¯ç”¨ï¼Œæ’é™¤äº†æ±‡æ€»åˆ†æã€‚\n\n**ç»“è®ºï¼š** ç›®å‰çš„è¯æ®è¡¨æ˜ï¼ŒEmborroid æ˜¯åŠå…¬å®¤ç¨‹åºå’Œæ‰‹æœ¯ä¹‹é—´çš„å®‰å…¨ã€æœ‰æ•ˆçš„æ¡¥æ¢ï¼Œå¯¹äºä½“å¼±æˆ–æ¥å—æŠ—å‡æ²»ç–—çš„æ‚£è€…å°¤å…¶æœ‰ä»·å€¼ã€‚ç„¶è€Œï¼Œå°å‹å•ä¸­å¿ƒé˜Ÿåˆ—ã€ä¸åŒçš„æŠ€æœ¯å’Œç¨€ç¼ºçš„å¤´å¯¹å¤´è¯•éªŒé™åˆ¶äº†å¤–éƒ¨æœ‰æ•ˆæ€§ã€‚éœ€è¦å…·æœ‰ä¸€è‡´ç»“æœçš„å¤šä¸­å¿ƒéšæœºç ”ç©¶å’Œâ‰¥24ä¸ªæœˆçš„éšè®¿æ¥ç¡®è®¤é•¿æœŸç–—æ•ˆã€æˆæœ¬æ•ˆç›Šå’Œæœ€ä½³æ‚£è€…é€‰æ‹©ã€‚", "keywords_zh": "æ “å¡ææ–™ã€ç—”ç–®æ “å¡ã€å¾®åˆ›æ²»ç–—ã€æ‚£è€…æ»¡æ„åº¦ã€å¤å‘ç‡ã€ç›´è‚ ä¸ŠåŠ¨è„‰ã€ç³»ç»Ÿè¯„ä»·", "keywords_en": "Embolic materials, Hemorrhoidal embolization, Minimally invasive therapy, Patient satisfaction, Recurrence rates, Superior rectal artery, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40877526/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 28 Aug 2025"}, {"id": "40876363", "title_en": "Local excision versus total mesorectal excision following neoadjuvant chemoradiotherapy for rectal cancer: A systematic review and meta-analysis", "title_zh": "ç›´è‚ ç™Œæ–°è¾…åŠ©æ”¾åŒ–ç–—åå±€éƒ¨åˆ‡é™¤ä¸å…¨ç›´è‚ ç³»è†œåˆ‡é™¤ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Neary Peter", "abstract_en": "**Background:** Total mesorectal excision (TME) with or without neoadjuvant chemoradiotherapy remains the gold standard treatment for rectal cancer. However, newer organ sparing methods, including Local Excision (LE) have been introduced in conjunction with neoadjuvant therapy to improve morbidity and functional outcomes while not impacting on oncological outcomes.\n\n**Methods:** A systematic review and meta-analysis was performed using the PRISMA guidelines. All studies comparing neoadjuvant chemoradiotherapy and local excision versus TME were included from 2000 to 2024. Primary endpoint included local recurrence rates. Secondary outcomes included distant recurrence, disease free survival (DFS), overall survival (OS), and morbidity. Subgroup analysis was performed on randomised control trials (RCT).\n\n**Results:** Sixteen studies (nÂ =Â 2121; LEÂ =Â 616, TMEÂ =Â 1505) were included. LE was associated with higher local recurrence (8.3Â % vs 5.5Â %; OR 1.82, 95Â % CI 1.19-2.77, pÂ =Â 0.006). However, in RCTs (nÂ =Â 245), this difference was not significant (7.3Â % vs 6.6Â %; OR 1.10, 95Â % CI 0.41-2.97, pÂ =Â 0.84). No significant differences were observed in distant recurrence, DFS, or OS. LE was associated with significantly reduced morbidity (OR 0.30, 95Â % CI 0.18-0.50, pÂ <Â 0.0001).\n\n**Conclusion:** Local recurrence was not statistically significant in the RCT subgroup analysis. Despite, higher local recurrence rates in the overall pooled analysis, no significant differences were observed for secondary outcomes. Neoadjuvant chemoradiotherapy and local excision appears oncologically safe, defined by DFS and OS, in select patient cohorts with a clinical complete or near-complete response to neoadjuvant therapy.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯ï¼ˆTMEï¼‰è”åˆæˆ–ä¸è”åˆæ–°è¾…åŠ©æ”¾åŒ–ç–—ä»ç„¶æ˜¯ç›´è‚ ç™Œçš„é‡‘æ ‡å‡†æ²»ç–—ã€‚ç„¶è€Œï¼Œæ–°çš„å™¨å®˜ä¿ç•™æ–¹æ³•ï¼ŒåŒ…æ‹¬å±€éƒ¨åˆ‡é™¤ï¼ˆLEï¼‰ï¼Œå·²ä¸æ–°è¾…åŠ©æ²»ç–—ç»“åˆä½¿ç”¨ï¼Œä»¥æ”¹å–„å‘ç—…ç‡å’ŒåŠŸèƒ½ç»“æœï¼ŒåŒæ—¶ä¸å½±å“è‚¿ç˜¤ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** ä½¿ç”¨ PRISMA æŒ‡å—è¿›è¡Œç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚ 2000 å¹´è‡³ 2024 å¹´æœŸé—´æ‰€æœ‰æ¯”è¾ƒæ–°è¾…åŠ©æ”¾åŒ–ç–—å’Œå±€éƒ¨åˆ‡é™¤ä¸ TME çš„ç ”ç©¶å‡çº³å…¥å…¶ä¸­ã€‚ä¸»è¦ç»ˆç‚¹åŒ…æ‹¬å±€éƒ¨å¤å‘ç‡ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬è¿œå¤„å¤å‘ã€æ— ç—…ç”Ÿå­˜æœŸï¼ˆDFSï¼‰ã€æ€»ç”Ÿå­˜æœŸï¼ˆOSï¼‰å’Œå‘ç—…ç‡ã€‚åœ¨éšæœºå¯¹ç…§è¯•éªŒï¼ˆRCTï¼‰ä¸­è¿›è¡Œäºšç»„åˆ†æã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 16 é¡¹ç ”ç©¶ï¼ˆn = 2121ï¼›LE = 616ï¼ŒTME = 1505ï¼‰ã€‚ LE ä¸è¾ƒé«˜çš„å±€éƒ¨å¤å‘ç‡ç›¸å…³ï¼ˆ8.3% vs 5.5%ï¼›OR 1.82ï¼Œ95% CI 1.19-2.77ï¼Œp = 0.006ï¼‰ã€‚ç„¶è€Œï¼Œåœ¨éšæœºå¯¹ç…§è¯•éªŒ (n = 245) ä¸­ï¼Œè¿™ç§å·®å¼‚å¹¶ä¸æ˜¾ç€ï¼ˆ7.3% vs 6.6%ï¼›OR 1.10ï¼Œ95% CI 0.41-2.97ï¼Œp = 0.84ï¼‰ã€‚åœ¨è¿œå¤„å¤å‘ã€DFS æˆ– OS æ–¹é¢æœªè§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ã€‚ LE ä¸å‘ç—…ç‡æ˜¾ç€é™ä½ç›¸å…³ï¼ˆOR 0.30ï¼Œ95% CI 0.18-0.50ï¼Œp < 0.0001ï¼‰ã€‚\n\n**ç»“è®ºï¼š** åœ¨ RCT äºšç»„åˆ†æä¸­ï¼Œå±€éƒ¨å¤å‘æ²¡æœ‰ç»Ÿè®¡å­¦æ„ä¹‰ã€‚å°½ç®¡åœ¨æ€»ä½“æ±‡æ€»åˆ†æä¸­å±€éƒ¨å¤å‘ç‡è¾ƒé«˜ï¼Œä½†æ¬¡è¦ç»“å±€æ²¡æœ‰è§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ã€‚åœ¨å¯¹æ–°è¾…åŠ©æ²»ç–—å…·æœ‰ä¸´åºŠå®Œå…¨æˆ–æ¥è¿‘å®Œå…¨ååº”çš„é€‰å®šæ‚£è€…é˜Ÿåˆ—ä¸­ï¼Œæ–°è¾…åŠ©æ”¾åŒ–ç–—å’Œå±€éƒ¨åˆ‡é™¤ä¼¼ä¹åœ¨è‚¿ç˜¤å­¦ä¸Šæ˜¯å®‰å…¨çš„ï¼ˆç”± DFS å’Œ OS å®šä¹‰ï¼‰ã€‚", "keywords_zh": "å±€éƒ¨åˆ‡é™¤ã€æ ¹æ²»æ€§æ‰‹æœ¯ã€ç›´è‚ ç™Œã€å…¨ç›´è‚ ç³»è†œåˆ‡é™¤", "keywords_en": "Local excision, Radical surgery, Rectal cancer, Total mesorectal excision", "link": "https://pubmed.ncbi.nlm.nih.gov/40876363/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 28 Aug 2025"}, {"id": "40845608", "title_en": "Transparency in Externally Validated Models: A systematic review of machine learning vs. logistic regression for predicting colorectal anastomotic leakage", "title_zh": "å¤–éƒ¨éªŒè¯æ¨¡å‹çš„é€æ˜åº¦ï¼šå¯¹æœºå™¨å­¦ä¹ ä¸é€»è¾‘å›å½’é¢„æµ‹ç»“ç›´è‚ å»åˆå£æ¼çš„ç³»ç»Ÿè¯„ä»·", "authors": "Freek Daams", "abstract_en": "**Introduction:** Colorectal resection carries a 2.8Â %-30Â % risk of anastomotic leakage. Machine learning can estimate risks and guide decisions, but clinical implementation remains inadequate due to transparency issues. This review assesses the performance and transparency of machine learning models compared to logistic regression.\n\n**Methods:** A systematic review followed PRISMA guidelines. Medline, Embase, Web of Science, and Cochrane databases were searched for studies using Logistic Regression or Machine Learning with external validation for colorectal anastomotic leakage prediction. Data were extracted using CHARMS, risk of bias assessed with PROBAST, and transparency with TRIPODÂ +Â AI.\n\n**Results:** Ten studies were included. Machine learning models were validated on smaller cohorts than logistic regression. Transparency scores ranged from 29Â % to 63Â %, averaging 45Â % for logistic regression and 43Â % for machine learning. Reporting of missing data was inconsistent, and external validation was limited. Most studies had a high risk of bias due to small sample sizes and low event counts.\n\n**Conclusion:** In comparison to Logistic regression studies, machine learning studies are limited by small cohorts, low outcome numbers, and a lower level of transparency. Future research should prioritise transparency, adhere to TRIPODÂ +Â AI standards, and develop LR and ML models in parallel using the same datasets while ensuring separate models for colon and rectal surgery. Currently, these models are not yet suitable for clinical implementation; more robust and transparent models must be developed based on these recommendations before they can be applied in clinical practice.", "abstract_zh": "**ä»‹ç»ï¼š** ç»“ç›´è‚ åˆ‡é™¤æœ¯æœ‰ 2.8%-30% çš„å»åˆå£ç˜˜é£é™©ã€‚æœºå™¨å­¦ä¹ å¯ä»¥ä¼°è®¡é£é™©å¹¶æŒ‡å¯¼å†³ç­–ï¼Œä½†ç”±äºé€æ˜åº¦é—®é¢˜ï¼Œä¸´åºŠå®æ–½ä»ç„¶ä¸è¶³ã€‚è¿™ç¯‡ç»¼è¿°è¯„ä¼°äº†æœºå™¨å­¦ä¹ æ¨¡å‹ä¸é€»è¾‘å›å½’ç›¸æ¯”çš„æ€§èƒ½å’Œé€æ˜åº¦ã€‚\n\n**æ–¹æ³•ï¼š** ç³»ç»Ÿè¯„ä»·éµå¾ª PRISMA æŒ‡å—ã€‚åœ¨ Medlineã€Embaseã€Web of Science å’Œ Cochrane æ•°æ®åº“ä¸­æœç´¢äº†ä½¿ç”¨ Logistic å›å½’æˆ–æœºå™¨å­¦ä¹ å¹¶è¿›è¡Œç»“ç›´è‚ å»åˆå£æ¼é¢„æµ‹å¤–éƒ¨éªŒè¯çš„ç ”ç©¶ã€‚ä½¿ç”¨ CHARMS æå–æ•°æ®ï¼Œä½¿ç”¨ PROBAST è¯„ä¼°åå€šé£é™©ï¼Œå¹¶ä½¿ç”¨ TRIPOD + AI è¯„ä¼°é€æ˜åº¦ã€‚\n\n**ç»“æœï¼š** å…¶ä¸­åŒ…æ‹¬åé¡¹ç ”ç©¶ã€‚æœºå™¨å­¦ä¹ æ¨¡å‹åœ¨æ¯”é€»è¾‘å›å½’æ›´å°çš„é˜Ÿåˆ—ä¸Šè¿›è¡Œäº†éªŒè¯ã€‚é€æ˜åº¦å¾—åˆ†èŒƒå›´ä¸º 29% åˆ° 63%ï¼Œé€»è¾‘å›å½’å¹³å‡ä¸º 45%ï¼Œæœºå™¨å­¦ä¹ å¹³å‡ä¸º 43%ã€‚ç¼ºå¤±æ•°æ®çš„æŠ¥å‘Šä¸ä¸€è‡´ï¼Œå¤–éƒ¨éªŒè¯ä¹Ÿæœ‰é™ã€‚ç”±äºæ ·æœ¬é‡å°å’Œäº‹ä»¶è®¡æ•°ä½ï¼Œå¤§å¤šæ•°ç ”ç©¶å­˜åœ¨è¾ƒé«˜çš„åå€šé£é™©ã€‚\n\n**ç»“è®ºï¼š** ä¸é€»è¾‘å›å½’ç ”ç©¶ç›¸æ¯”ï¼Œæœºå™¨å­¦ä¹ ç ”ç©¶å—åˆ°å°ç¾¤ä½“ã€ä½ç»“æœæ•°é‡å’Œè¾ƒä½é€æ˜åº¦çš„é™åˆ¶ã€‚æœªæ¥çš„ç ”ç©¶åº”ä¼˜å…ˆè€ƒè™‘é€æ˜åº¦ï¼Œéµå®ˆ TRIPOD + AI æ ‡å‡†ï¼Œå¹¶ä½¿ç”¨ç›¸åŒçš„æ•°æ®é›†å¹¶è¡Œå¼€å‘ LR å’Œ ML æ¨¡å‹ï¼ŒåŒæ—¶ç¡®ä¿ç»“è‚ å’Œç›´è‚ æ‰‹æœ¯çš„æ¨¡å‹ä¸åŒã€‚ç›®å‰ï¼Œè¿™äº›æ¨¡å‹å°šä¸é€‚åˆä¸´åºŠå®æ–½ï¼›å¿…é¡»æ ¹æ®è¿™äº›å»ºè®®å¼€å‘æ›´ç¨³å¥å’Œé€æ˜çš„æ¨¡å‹ï¼Œç„¶åæ‰èƒ½åº”ç”¨äºä¸´åºŠå®è·µã€‚", "keywords_zh": "å»åˆå£æ¼ã€ç»“ç›´è‚ æ‰‹æœ¯ã€Logistic å›å½’ã€æœºå™¨å­¦ä¹ ã€é¢„æµ‹", "keywords_en": "Anastomotic leakage, Colorectal surgery, Logistic regression, Machine learning, Prediction", "link": "https://pubmed.ncbi.nlm.nih.gov/40845608/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 22 Aug 2025"}, {"id": "40824311", "title_en": "Abdominoperineal pull-through with delayed coloanal anastomosis for pelvic anastomotic failure-a systematic review", "title_zh": "è…¹ä¼šé˜´ç‰µå¼•å»¶è¿Ÿç»“è‚ è‚›ç®¡å»åˆæœ¯æ²»ç–—ç›†è…”å»åˆå¤±è´¥çš„ç³»ç»Ÿè¯„ä»·", "authors": "I Seow-En", "abstract_en": "**Aim:** Despite theÂ potential benefits of abdominoperineal pull-through with delayed coloanal anastomosis (DCAA), it is still infrequently performed as a salvage procedure for pelvic anastomotic failure. We aimed to perform a systematic review on the subject to guide practice.\n\n**Method:** PubMed, Embase and Cochrane were used to identify studies evaluating DCAA for salvage after pelvic surgery from inception to August 2024. Risk of bias assessment was performed using the Newcastle-Ottawa scale. The primary outcome was overall stoma-free survival. Secondary outcomes included hospital length of stay, high-grade postoperative complication rates, 30-day postoperative mortality rates, incidence of redo surgical intervention after DCAA, and postoperative anorectal function.\n\n**Results:** Five retrospective cohort studies evaluating a total of 97 patientsÂ who underwent salvage abdominoperineal pull-through and DCAA were included in this review. All patients had previous pelvic surgery, predominantly proctectomy (nâ€‰=â€‰84, 86.6%). The most common indication forÂ redo surgery was chronic fistula (nâ€‰=â€‰62, 63.9%) followed by anastomotic leak or chronic pelvic sepsis (nâ€‰=â€‰34, 35.1%). The pooled overall stoma-free survival rate across all five studies was 81.4% over a mean 24-month postoperative follow-up duration. The overall incidence of high-grade complicationsÂ after DCAA was 39.1% (nâ€‰=â€‰38). Pooled mean length of stay was 17 days. There were no cases of early postoperative death. Pooled rate of repeat surgery across four studies was 11.6% (nâ€‰=â€‰8). Pooled mean functional scores across three studies indicated minor low anterior resection syndrome at 26 months.\n\n**Conclusion:** Abdominoperineal pull-through with delayed coloanal anastomosis is a viable option for salvage surgery following pelvic anastomotic complications, with low rates of permanent stoma and acceptable long-term anorectal function.", "abstract_zh": "**Aimï¼š** å°½ç®¡è…¹ä¼šé˜´æ‹‰ç©¿å»¶è¿Ÿç»“è‚ è‚›é—¨å»åˆæœ¯ (DCAA) å…·æœ‰æ½œåœ¨ç›Šå¤„ï¼Œä½†å®ƒä»ç„¶å¾ˆå°‘ä½œä¸ºéª¨ç›†å»åˆå¤±è´¥çš„æŒ½æ•‘æ‰‹æœ¯è¿›è¡Œã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯å¯¹è¯¥ä¸»é¢˜è¿›è¡Œç³»ç»Ÿå›é¡¾ä»¥æŒ‡å¯¼å®è·µã€‚\n\n**Methodï¼š** PubMedã€Embase å’Œ Cochrane è¢«ç”¨æ¥è¯†åˆ«ä»å¼€å§‹åˆ° 2024 å¹´ 8 æœˆè¯„ä¼° DCAA åœ¨ç›†è…”æ‰‹æœ¯åæŒ½æ•‘æ•ˆæœçš„ç ”ç©¶ã€‚ä½¿ç”¨çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨è¿›è¡Œåå€šé£é™©è¯„ä¼°ã€‚ä¸»è¦ç»“æœæ˜¯æ€»ä½“æ— é€ å£ç”Ÿå­˜ç‡ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬ä½é™¢æ—¶é—´ã€æœ¯åé«˜çº§å¹¶å‘ç—‡å‘ç”Ÿç‡ã€æœ¯å 30 å¤©æ­»äº¡ç‡ã€DCAA åé‡åšæ‰‹æœ¯å¹²é¢„çš„å‘ç”Ÿç‡ä»¥åŠæœ¯åè‚›é—¨ç›´è‚ åŠŸèƒ½ã€‚\n\n**ç»“æœï¼š** æœ¬ç»¼è¿°çº³å…¥äº†äº”é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œè¯„ä¼°äº†æ€»å…± 97 åæ¥å—æŒ½æ•‘æ€§è…¹ä¼šé˜´ç‰µå¼•æœ¯å’Œ DCAA çš„æ‚£è€…ã€‚æ‰€æœ‰æ‚£è€…å‡æ›¾æ¥å—è¿‡ç›†è…”æ‰‹æœ¯ï¼Œä¸»è¦æ˜¯ç›´è‚ åˆ‡é™¤æœ¯ï¼ˆnâ€‰=â€‰84ï¼Œ86.6%ï¼‰ã€‚é‡åšæ‰‹æœ¯æœ€å¸¸è§çš„é€‚åº”ç—‡æ˜¯æ…¢æ€§ç˜˜ï¼ˆnâ€‰=â€‰62ï¼Œ63.9%ï¼‰ï¼Œå…¶æ¬¡æ˜¯å»åˆå£ç˜˜æˆ–æ…¢æ€§ç›†è…”è„“æ¯’ç—‡ï¼ˆnâ€‰=â€‰34ï¼Œ35.1%ï¼‰ã€‚åœ¨å¹³å‡ 24 ä¸ªæœˆçš„æœ¯åéšè®¿æœŸé—´ï¼Œæ‰€æœ‰äº”é¡¹ç ”ç©¶çš„æ±‡æ€»æ€»ä½“æ— é€ å£ç”Ÿå­˜ç‡ä¸º 81.4%ã€‚ DCAA åé«˜çº§å¹¶å‘ç—‡çš„æ€»ä½“å‘ç”Ÿç‡ä¸º 39.1% (nâ€‰=â€‰38)ã€‚åˆå¹¶å¹³å‡ä½é™¢æ—¶é—´ä¸º 17 å¤©ã€‚æ— æœ¯åæ—©æœŸæ­»äº¡ç—…ä¾‹ã€‚å››é¡¹ç ”ç©¶çš„é‡å¤æ‰‹æœ¯æ±‡æ€»ç‡ä¸º 11.6% (nâ€‰=â€‰8)ã€‚ä¸‰é¡¹ç ”ç©¶çš„æ±‡æ€»å¹³å‡åŠŸèƒ½è¯„åˆ†è¡¨æ˜ 26 ä¸ªæœˆæ—¶æœ‰è½»å¾®çš„ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ã€‚\n\n**ç»“è®ºï¼š** è…¹ä¼šé˜´ç‰µå¼•è”åˆå»¶è¿Ÿç»“è‚ è‚›ç®¡å»åˆæœ¯æ˜¯ç›†è…”å»åˆå¹¶å‘ç—‡åæŒ½æ•‘æ‰‹æœ¯çš„å¯è¡Œé€‰æ‹©ï¼Œå…·æœ‰è¾ƒä½çš„æ°¸ä¹…æ€§é€ å£ç‡å’Œå¯æ¥å—çš„é•¿æœŸè‚›é—¨ç›´è‚ åŠŸèƒ½ã€‚", "keywords_zh": "è…¹ä¼šé˜´ç‰µå¼•ã€ç»“ç›´è‚ æ‰‹æœ¯ã€å»¶è¿Ÿç»“è‚ è‚›é—¨å»åˆæœ¯ã€é‡åšæ‰‹æœ¯", "keywords_en": "Abdominoperineal pull-through, Colorectal surgery, Delayed coloanal anastomosis, Redo surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40824311/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 18 Aug 2025"}, {"id": "40819153", "title_en": "Comprehensive evaluation of reinforcement strategies for anastomotic leak prevention in rectal cancer surgery: an umbrella review of meta-analyses", "title_zh": "ç›´è‚ ç™Œæ‰‹æœ¯ä¸­é¢„é˜²å»åˆå£ç˜˜çš„å¼ºåŒ–ç­–ç•¥çš„ç»¼åˆè¯„ä»·ï¼šèŸèƒåˆ†æçš„æ€»ä½“è¯„ä»·", "authors": "Leonardo Vincenti", "abstract_en": "Anastomotic leakage remains a serious complication following colorectal surgery. Various reinforcement techniques have been explored in literature, with multiple systematic reviews and meta-analyses addressing their effectiveness. However, no umbrella review has yet comprehensively synthesized this evidence. We aimed to summarize and critically appraise the available systematic reviews and meta-analyses investigating the effectiveness of anastomotic reinforcement techniques in colorectal surgery. A comprehensive literature search was conducted in PubMed, Embase, Scopus, and Cochrane Library up to June 2025. Eligible studies were systematic reviews or meta-analyses evaluating any reinforcement technique (biological, mechanical, or chemical) in colorectal anastomoses. Data extraction included review characteristics, reinforcement strategies, primary outcomes (anastomotic leak), and methodological quality assessed using AMSTAR 2. Twenty-one systematic reviews and meta-analyses were included. The reinforcement strategies evaluated comprised transanal tube (TAT) placement, suture reinforcement, and omentoplasty. Most reviews showed a reduction in anastomotic leak rates, particularly with TAT (43-70%) and sutures (59-75%), with the most pronounced effect observed in patients without a diverting stoma. TAT was also associated with a reduction in reintervention rates (62-84%). Findings on hospital stay were inconsistent, while no significant effects were reported for anastomotic bleeding, infections, stenosis, or mortality. The overall methodological quality of the included studies was rated as critically low. TAT and reinforcement sutures show potential in reducing anastomotic leakage in colorectal surgery. However, significant heterogeneity and variable methodological quality across reviews limit definitive conclusions. High-quality, targeted studies and standardized outcome definitions are warranted.", "abstract_zh": "å»åˆå£æ¼ä»ç„¶æ˜¯ç»“ç›´è‚ æ‰‹æœ¯åçš„ä¸¥é‡å¹¶å‘ç—‡ã€‚æ–‡çŒ®ä¸­å·²ç»æ¢è®¨äº†å„ç§å¼ºåŒ–æŠ€æœ¯ï¼Œå¹¶è¿›è¡Œäº†å¤šé¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææ¥æ¢è®¨å…¶æœ‰æ•ˆæ€§ã€‚ç„¶è€Œï¼Œè¿˜æ²¡æœ‰æ€»ä½“å®¡æŸ¥å…¨é¢ç»¼åˆè¿™äº›è¯æ®ã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯æ€»ç»“å’Œæ‰¹åˆ¤æ€§è¯„ä»·ç°æœ‰çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æï¼Œç ”ç©¶ç»“ç›´è‚ æ‰‹æœ¯ä¸­å»åˆåŠ å›ºæŠ€æœ¯çš„æœ‰æ•ˆæ€§ã€‚æˆªè‡³ 2025 å¹´ 6 æœˆï¼Œåœ¨ PubMedã€Embaseã€Scopus å’Œ Cochrane å›¾ä¹¦é¦†è¿›è¡Œäº†å…¨é¢çš„æ–‡çŒ®æ£€ç´¢ã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶æ˜¯è¯„ä¼°ç»“ç›´è‚ å»åˆæœ¯ä¸­ä»»ä½•å¼ºåŒ–æŠ€æœ¯ï¼ˆç”Ÿç‰©ã€æœºæ¢°æˆ–åŒ–å­¦ï¼‰çš„ç³»ç»Ÿè¯„ä»·æˆ–èŸèƒåˆ†æã€‚æ•°æ®æå–åŒ…æ‹¬ç»¼è¿°ç‰¹å¾ã€å¼ºåŒ–ç­–ç•¥ã€ä¸»è¦ç»“å±€ï¼ˆå»åˆå£ç˜˜ï¼‰ä»¥åŠä½¿ç”¨ AMSTAR 2 è¯„ä¼°çš„æ–¹æ³•å­¦è´¨é‡ã€‚å…¶ä¸­åŒ…æ‹¬ 21 é¡¹ç³»ç»Ÿç»¼è¿°å’ŒèŸèƒåˆ†æã€‚è¯„ä¼°çš„åŠ å›ºç­–ç•¥åŒ…æ‹¬ç»è‚›ç®¡ï¼ˆTATï¼‰æ”¾ç½®ã€ç¼åˆåŠ å›ºå’Œç½‘è†œæˆå½¢æœ¯ã€‚å¤§å¤šæ•°è¯„è®ºæ˜¾ç¤ºå»åˆå£æ¼ç‡é™ä½ï¼Œç‰¹åˆ«æ˜¯ TATï¼ˆ43-70%ï¼‰å’Œç¼åˆï¼ˆ59-75%ï¼‰ï¼Œåœ¨æ²¡æœ‰åˆ†æµé€ å£çš„æ‚£è€…ä¸­è§‚å¯Ÿåˆ°æœ€æ˜æ˜¾çš„æ•ˆæœã€‚ TAT è¿˜ä¸å†å¹²é¢„ç‡çš„é™ä½æœ‰å…³ (62-84%)ã€‚å…³äºä½é™¢æ—¶é—´çš„ç ”ç©¶ç»“æœä¸ä¸€è‡´ï¼Œè€Œå¯¹äºå»åˆå£å‡ºè¡€ã€æ„ŸæŸ“ã€ç‹­çª„æˆ–æ­»äº¡ç‡æ²¡æœ‰æ˜¾ç€å½±å“ã€‚çº³å…¥ç ”ç©¶çš„æ€»ä½“æ–¹æ³•å­¦è´¨é‡è¢«è¯„ä¸ºæä½ã€‚ TAT å’ŒåŠ å›ºç¼åˆçº¿æ˜¾ç¤ºå‡ºå‡å°‘ç»“ç›´è‚ æ‰‹æœ¯ä¸­å»åˆå£æ¸—æ¼çš„æ½œåŠ›ã€‚ç„¶è€Œï¼Œä¸åŒè¯„è®ºé—´æ˜¾ç€çš„å¼‚è´¨æ€§å’Œå¯å˜çš„æ–¹æ³•å­¦è´¨é‡é™åˆ¶äº†æ˜ç¡®çš„ç»“è®ºã€‚é«˜è´¨é‡ã€æœ‰é’ˆå¯¹æ€§çš„ç ”ç©¶å’Œæ ‡å‡†åŒ–çš„ç»“æœå®šä¹‰æ˜¯å¿…è¦çš„ã€‚", "keywords_zh": "å»åˆå£æ¼ã€å»åˆå£åŠ å›ºã€ç›´è‚ ç™Œã€ç»è‚›ç®¡", "keywords_en": "Anastomotic leak, Anastomotic reinforcement, Rectal cancer, Transanal tube", "link": "https://pubmed.ncbi.nlm.nih.gov/40819153/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sat, 16 Aug 2025"}, {"id": "40808658", "title_en": "Association between anastomotic leak after rectal resection and bowel dysfunction, a systematic review, meta-analysis and meta-regression", "title_zh": "ç›´è‚ åˆ‡é™¤æœ¯åå»åˆå£ç˜˜ä¸è‚ åŠŸèƒ½éšœç¢ä¹‹é—´çš„å…³è”ã€ç³»ç»Ÿè¯„ä»·ã€èŸèƒåˆ†æå’ŒèŸèƒå›å½’", "authors": "Marylise Boutros", "abstract_en": "**Background:** Anastomotic leak (AL) after colorectal anastomosis can be a risk factor for bowel dysfunction, namely low anterior resection syndrome (LARS). The present study aimed to assess bowel dysfunction in patients who developed AL after anterior resection compared to patients without AL.\n\n**Methods:** We conducted a PRISMA-compliant systematic review of PubMed, Scopus and Cochrane Library for randomized and observational studies investigating the association between AL after anterior resection and bowel dysfunction. The main outcomes were LARS, faecal incontinence and urgency. Pairwise meta-analyses were conducted to calculate the relative risk (RR) of the study outcomes and their 95% confidence intervals (CI).\n\n**Results:** This review included 20 retrospective studies comprising 4764 patients (61.6% male, median age 63â€‰years). AL was detected in 14% of patients and those who experienced AL had a higher risk of LARS (six studies; 1329 patients, RR: 1.27 95%CI: 1.02, 1.58, pâ€‰=â€‰0.035), major LARS (seven studies; 1395 patients, RR: 1.38, 95%CI: 1.07, 1.79, pâ€‰=â€‰0.012), urgency (five studies; 955 patients, RR: 1.15, 95%CI: 1.04, 1.27, pâ€‰=â€‰0.005) and had higher LARS scores (seven studies; 1450 patients, WMD: 6.64, 95%CI: 3.76, 9.52, pâ€‰<â€‰0.001) and Wexner incontinence scores (seven studies; 1045 patients, WMD: 1.72, 95%CI: 0.16, 3.28, pâ€‰=â€‰0.031).\n\n**Conclusion:** Based on low to moderate certainty evidence, AL after colorectal and coloanal anastomoses was significantly associated with an increased risk of LARS, particularly major LARS, urgency and higher LARS and Wexner/Cleveland Clinic Florida-Fecal Incontinence Scores.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ å»åˆæœ¯åå»åˆå£æ¼ï¼ˆALï¼‰å¯èƒ½æ˜¯è‚ åŠŸèƒ½éšœç¢çš„å±é™©å› ç´ ï¼Œå³ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ˆLARSï¼‰ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼°å‰åˆ‡é™¤æœ¯åå‘ç”Ÿ AL çš„æ‚£è€…ä¸æœªå‘ç”Ÿ AL çš„æ‚£è€…ç›¸æ¯”çš„è‚ åŠŸèƒ½éšœç¢ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬å¯¹ PubMedã€Scopus å’Œ Cochrane å›¾ä¹¦é¦†è¿›è¡Œäº†ç¬¦åˆ PRISMA æ ‡å‡†çš„ç³»ç»Ÿè¯„ä»·ï¼Œä»¥è¿›è¡Œéšæœºå’Œè§‚å¯Ÿæ€§ç ”ç©¶ï¼Œè°ƒæŸ¥å‰åˆ‡é™¤æœ¯å AL ä¸è‚ åŠŸèƒ½éšœç¢ä¹‹é—´çš„å…³è”ã€‚ä¸»è¦ç»“å±€æ˜¯ LARSã€å¤§ä¾¿å¤±ç¦å’Œå°¿æ€¥ã€‚è¿›è¡Œé…å¯¹èŸèƒåˆ†æä»¥è®¡ç®—ç ”ç©¶ç»“æœçš„ç›¸å¯¹é£é™©ï¼ˆRRï¼‰åŠå…¶95%ç½®ä¿¡åŒºé—´ï¼ˆCIï¼‰ã€‚\n\n**ç»“æœï¼š** è¯¥ç»¼è¿°åŒ…æ‹¬ 20 é¡¹å›é¡¾æ€§ç ”ç©¶ï¼Œæ¶‰åŠ 4764 åæ‚£è€…ï¼ˆ61.6% ä¸ºç”·æ€§ï¼Œä¸­ä½å¹´é¾„ 63 å²ï¼‰ã€‚ 14% çš„æ‚£è€…æ£€æµ‹åˆ° ALï¼Œç»å†è¿‡ AL çš„æ‚£è€…å‘ç”Ÿ LARS çš„é£é™©è¾ƒé«˜ï¼ˆå…­é¡¹ç ”ç©¶ï¼›1329 åæ‚£è€…ï¼ŒRRï¼š1.27 95%CIï¼š1.02, 1.58ï¼Œpâ€‰=â€‰0.035ï¼‰ï¼Œä¸»è¦ LARSï¼ˆä¸ƒé¡¹ç ”ç©¶ï¼›1395 åæ‚£è€…ï¼ŒRRï¼š1.38ï¼Œ95%CIï¼š1.07ï¼Œ 1.79ï¼Œpâ€‰=â€‰0.012ï¼‰ï¼Œç´§è¿«æ€§ï¼ˆäº”é¡¹ç ”ç©¶ï¼›955 åæ‚£è€…ï¼ŒRRï¼š1.15ï¼Œ95%CIï¼š1.04ï¼Œ1.27ï¼Œpâ€‰=â€‰0.005ï¼‰å¹¶ä¸”å…·æœ‰è¾ƒé«˜çš„ LARS è¯„åˆ†ï¼ˆä¸ƒé¡¹ç ”ç©¶ï¼›1450 åæ‚£è€…ï¼ŒWMDï¼š6.64ï¼Œ95%CIï¼š3.76ï¼Œ 9.52ï¼Œp<â€‰0.001ï¼‰å’Œ Wexner å¤±ç¦è¯„åˆ†ï¼ˆä¸ƒé¡¹ç ”ç©¶ï¼›1045 åæ‚£è€…ï¼ŒWMDï¼š1.72ï¼Œ95%CIï¼š0.16ã€3.28ï¼Œp=â€‰0.031ï¼‰ã€‚\n\n**ç»“è®ºï¼š** æ ¹æ®ä½åˆ°ä¸­ç­‰ç¡®å®šæ€§çš„è¯æ®ï¼Œç»“ç›´è‚ å’Œç»“è‚ è‚›ç®¡å»åˆæœ¯åçš„ AL ä¸ LARS é£é™©å¢åŠ æ˜¾ç€ç›¸å…³ï¼Œç‰¹åˆ«æ˜¯ä¸»è¦ LARSã€å°¿æ€¥å’Œè¾ƒé«˜çš„ LARS ä»¥åŠ Wexner/Cleveland Clinic ä½›ç½—é‡Œè¾¾å¤§ä¾¿å¤±ç¦è¯„åˆ†ã€‚", "keywords_zh": "LARSï¼Œå»åˆå£ç˜˜ï¼Œå‰åˆ‡é™¤æœ¯ï¼Œè‚ åŠŸèƒ½éšœç¢ï¼Œç»“ç›´è‚ ï¼Œç³»ç»Ÿè¯„ä»·", "keywords_en": "LARS, anastomotic leak, anterior resection, bowel dysfunction, colorectal, systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40808658/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 14 Aug 2025"}, {"id": "40793873", "title_en": "Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies", "title_zh": "ç³»ç»Ÿç»¼è¿°ï¼šé¸Ÿæªæ³•å®åŸºå› ç»„ç ”ç©¶ä¸­ç²ªä¾¿å¾®ç”Ÿç‰©ç»„ä¸ç»“ç›´è‚ è‚¿ç˜¤ä¹‹é—´çš„å…³ç³»", "authors": "Colin Rees", "abstract_en": "**Background:** The human gut microbiome is of academic and clinical interest. Associations between certain organisms and colorectal neoplasia have been reported, but findings have limited reproducibility in different populations.\n\n**Methods:** We performed a systematic review of whole metagenome shotgun sequencing studies using faecal samples from patients with colorectal neoplasia and control populations. Searches were performed on 30th June 2023. We identified 26 studies, reporting on 22 study populations (13 from Asia, five from Europe and four from North America). Study size ranged from 14 to 971 individuals (mean 170).\n\n**Results:** Some reproducible data were identified, such as the significant enrichment of Fusobacterium nucleatum and Parvimonas micra in colorectal cancer patients compared to controls (in 10 and nine studies, respectively). However, 21 out of 26 studies scored poorly on quality appraisal, specifically surrounding selection of cases and controls. Definitions of controls varied; some studies used individuals with normal endoscopic investigations, some used 'healthy' individuals where no colonoscopy was performed, and one used those with non-neoplastic findings (haemorrhoids). There was even less reproducibility of data in studies where individuals with colorectal polyps were compared to controls, possibly because of heterogeneity in these patient groupings as a variety of definitions for 'polyp cases' were used.\n\n**Conclusions:** Heterogeneity and potential for bias indicates that findings should be interpreted with caution. Standardised protocols to ensure robust methodology and allow pooling of large-scale data are required before these findings can be used in clinical practice (PROSPERO: CRD42023431977).", "abstract_zh": "**èƒŒæ™¯ï¼š** äººç±»è‚ é“å¾®ç”Ÿç‰©ç»„å…·æœ‰å­¦æœ¯å’Œä¸´åºŠæ„ä¹‰ã€‚æŸäº›å¾®ç”Ÿç‰©ä¸ç»“ç›´è‚ è‚¿ç˜¤ä¹‹é—´çš„å…³è”å·²æœ‰æŠ¥é“ï¼Œä½†ç ”ç©¶ç»“æœåœ¨ä¸åŒäººç¾¤ä¸­çš„é‡å¤æ€§æœ‰é™ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬ä½¿ç”¨ç»“ç›´è‚ è‚¿ç˜¤æ‚£è€…å’Œå¯¹ç…§äººç¾¤çš„ç²ªä¾¿æ ·æœ¬å¯¹æ•´ä¸ªå®åŸºå› ç»„é¸Ÿæªæ³•æµ‹åºç ”ç©¶è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ã€‚æ£€ç´¢äº 2023 å¹´ 6 æœˆ 30 æ—¥è¿›è¡Œã€‚æˆ‘ä»¬ç¡®å®šäº† 26 é¡¹ç ”ç©¶ï¼ŒæŠ¥å‘Šäº† 22 ä¸ªç ”ç©¶äººç¾¤ï¼ˆ13 é¡¹æ¥è‡ªäºšæ´²ï¼Œ5 é¡¹æ¥è‡ªæ¬§æ´²ï¼Œ4 é¡¹æ¥è‡ªåŒ—ç¾ï¼‰ã€‚ç ”ç©¶è§„æ¨¡ä» 14 äººåˆ° 971 äººä¸ç­‰ï¼ˆå¹³å‡ 170 äººï¼‰ã€‚\n\n**ç»“æœï¼š** ç¡®å®šäº†ä¸€äº›å¯é‡å¤çš„æ•°æ®ï¼Œä¾‹å¦‚ä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼Œç»“ç›´è‚ ç™Œæ‚£è€…ä¸­å…·æ ¸æ¢­æ†èŒå’Œå¾®å°å•èƒèŒæ˜¾ç€å¯Œé›†ï¼ˆåˆ†åˆ«åœ¨ 10 é¡¹å’Œ 9 é¡¹ç ”ç©¶ä¸­ï¼‰ã€‚ç„¶è€Œï¼Œ26 é¡¹ç ”ç©¶ä¸­æœ‰ 21 é¡¹åœ¨è´¨é‡è¯„ä¼°æ–¹é¢å¾—åˆ†è¾ƒä½ï¼Œç‰¹åˆ«æ˜¯åœ¨ç—…ä¾‹å’Œå¯¹ç…§çš„é€‰æ‹©æ–¹é¢ã€‚æ§åˆ¶çš„å®šä¹‰å„ä¸ç›¸åŒï¼›ä¸€äº›ç ”ç©¶ä½¿ç”¨äº†æ­£å¸¸å†…çª¥é•œæ£€æŸ¥çš„ä¸ªä½“ï¼Œä¸€äº›ç ”ç©¶ä½¿ç”¨äº†æœªè¿›è¡Œç»“è‚ é•œæ£€æŸ¥çš„â€œå¥åº·â€ä¸ªä½“ï¼Œè¿˜æœ‰ä¸€é¡¹ç ”ç©¶ä½¿ç”¨äº†éè‚¿ç˜¤å‘ç°ï¼ˆç—”ç–®ï¼‰çš„ä¸ªä½“ã€‚åœ¨å°†ç»“ç›´è‚ æ¯è‚‰æ‚£è€…ä¸å¯¹ç…§ç»„è¿›è¡Œæ¯”è¾ƒçš„ç ”ç©¶ä¸­ï¼Œæ•°æ®çš„é‡å¤æ€§ç”šè‡³æ›´ä½ï¼Œè¿™å¯èƒ½æ˜¯å› ä¸ºè¿™äº›æ‚£è€…åˆ†ç»„çš„å¼‚è´¨æ€§ï¼Œå› ä¸ºä½¿ç”¨äº†å¤šç§â€œæ¯è‚‰ç—…ä¾‹â€å®šä¹‰ã€‚\n\n**ç»“è®ºï¼š** å¼‚è´¨æ€§å’Œæ½œåœ¨åå·®è¡¨æ˜åº”è°¨æ…è§£é‡Šç ”ç©¶ç»“æœã€‚åœ¨å°†è¿™äº›å‘ç°ç”¨äºä¸´åºŠå®è·µä¹‹å‰ï¼Œéœ€è¦åˆ¶å®šæ ‡å‡†åŒ–æ–¹æ¡ˆä»¥ç¡®ä¿ç¨³å¥çš„æ–¹æ³•å¹¶å…è®¸æ±‡é›†å¤§è§„æ¨¡æ•°æ®ï¼ˆPROSPEROï¼šCRD42023431977ï¼‰ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40793873/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 12 Aug 2025"}, {"id": "40788642", "title_en": "Role of Neoadjuvant Immune Checkpoint Inhibitors in Locally Advanced Rectal Cancer: A Systematic Review of Currently Available Studies", "title_zh": "æ–°è¾…åŠ©å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚åœ¨å±€éƒ¨æ™šæœŸç›´è‚ ç™Œä¸­çš„ä½œç”¨ï¼šå¯¹ç°æœ‰ç ”ç©¶çš„ç³»ç»Ÿå›é¡¾", "authors": "Alexander G Heriot", "abstract_en": "**Background:** During the past few decades, the standard of care for locally advanced rectal cancer, involving neoadjuvant chemoradiation followed by surgery, has been associated with a pathological complete response rate of only 10% to 20%. Combination therapy with immune checkpoint inhibitors may improve treatment response.\n\n**Objective:** This systematic review examines the current evidence regarding neoadjuvant immune checkpoint inhibitors in locally advanced rectal cancer in terms of treatment efficacy, impact on surgical outcomes, and potential adverse events.\n\n**Data Sources:** A literature search was conducted using the Ovid MEDLINE, Embase, Web of Science, and Cochrane Library databases from the start of database records to October 31, 2024.\n\n**Study Selection:** All studies that reported outcomes in patients with locally advanced rectal cancer who received immune checkpoint inhibitors as part of their neoadjuvant treatment were included for examination.\n\n**Main Outcome Measures:** Primary outcome was pathological complete response rate. Secondary outcomes were major pathological response rate, clinical complete response rate, complete response rate, R0 resection rate, and sphincter preservation rate. Safety data were included where available. Potential biomarkers of treatment response were identified.\n\n**Results:** Twelve studies were reviewed. All were prospective phase I/II clinical trials. The overall pathological complete response rate ranged from 25% to 62.5% (50% for deficient mismatch repair/high microsatellite instability; 25%-62.5% for proficient mismatch repair/microsatellite stable). The clinical complete response rate ranged from 10.9% to 100% (56%-100% for deficient mismatch repair/high microsatellite instability; 16.4%-48% for proficient mismatch repair/microsatellite stable). The complete response rate ranged from 44% to 75% (75% for deficient mismatch repair/high microsatellite instability; 44%-56.5% for proficient mismatch repair/microsatellite stable). The R0 resection rate ranged from 94% to 100% and the sphincter preservation rate ranged from 59.4% to 100%. The majority of adverse events were of grades 1 and 2.\n\n**Limitations:** Our review was limited by a small number of mostly single-arm studies with a lack of long-term survival outcomes, as well as marked clinical and methodological heterogeneity among included studies.\n\n**Conclusions:** Combination therapy with immune checkpoint inhibitors in locally advanced rectal cancer appears to improve treatment response, but high-level evidence and long-term data are still lacking.", "abstract_zh": "**èƒŒæ™¯ï¼š** åœ¨è¿‡å»çš„å‡ åå¹´é‡Œï¼Œå±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„æŠ¤ç†æ ‡å‡†ï¼ˆåŒ…æ‹¬æ–°è¾…åŠ©æ”¾åŒ–ç–—å’Œæ‰‹æœ¯ï¼‰çš„ç—…ç†å®Œå…¨ç¼“è§£ç‡ä»…ä¸º 10% è‡³ 20%ã€‚ä¸å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚çš„è”åˆæ²»ç–—å¯èƒ½ä¼šæ”¹å–„æ²»ç–—ååº”ã€‚\n\n**ç›®çš„ï¼š** æœ¬ç³»ç»Ÿç»¼è¿°ä»æ²»ç–—æ•ˆæœã€å¯¹æ‰‹æœ¯ç»“æœçš„å½±å“å’Œæ½œåœ¨ä¸è‰¯äº‹ä»¶æ–¹é¢æ¢è®¨äº†æœ‰å…³æ–°è¾…åŠ©å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚æ²»ç–—å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„å½“å‰è¯æ®ã€‚\n\n**Data sourcesï¼š** ä½¿ç”¨ Ovid MEDLINEã€Embaseã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†æ•°æ®åº“è¿›è¡Œäº†ä»æ•°æ®åº“è®°å½•å¼€å§‹åˆ° 2024 å¹´ 10 æœˆ 31 æ—¥çš„æ–‡çŒ®æ£€ç´¢ã€‚\n\n**Study selectionï¼š** æ‰€æœ‰æŠ¥å‘Šæ¥å—å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ä½œä¸ºæ–°è¾…åŠ©æ²»ç–—ä¸€éƒ¨åˆ†çš„å±€éƒ¨æ™šæœŸç›´è‚ ç™Œæ‚£è€…ç»“å±€çš„ç ”ç©¶å‡è¢«çº³å…¥æ£€æŸ¥ã€‚\n\n**Main outcome measuresï¼š** ä¸»è¦ç»“æœæ˜¯ç—…ç†å®Œå…¨ç¼“è§£ç‡ã€‚æ¬¡è¦ç»“å±€ä¸ºä¸»è¦ç—…ç†ç¼“è§£ç‡ã€ä¸´åºŠå®Œå…¨ç¼“è§£ç‡ã€å®Œå…¨ç¼“è§£ç‡ã€R0åˆ‡é™¤ç‡å’Œæ‹¬çº¦è‚Œä¿ç•™ç‡ã€‚å¦‚æœ‰å¯ç”¨çš„å®‰å…¨æ•°æ®ä¹ŸåŒ…æ‹¬åœ¨å†…ã€‚ç¡®å®šäº†æ²»ç–—ååº”çš„æ½œåœ¨ç”Ÿç‰©æ ‡å¿—ç‰©ã€‚\n\n**ç»“æœï¼š** å®¡æŸ¥äº†åäºŒé¡¹ç ”ç©¶ã€‚æ‰€æœ‰å‡ä¸ºå‰ç»æ€§ I/II æœŸä¸´åºŠè¯•éªŒã€‚æ€»ä½“ç—…ç†å®Œå…¨ç¼“è§£ç‡èŒƒå›´ä¸º 25% è‡³ 62.5%ï¼ˆé”™é…ä¿®å¤ç¼ºé™·/å¾®å«æ˜Ÿé«˜åº¦ä¸ç¨³å®šä¸º 50%ï¼›é”™é…ä¿®å¤ç†Ÿç»ƒ/å¾®å«æ˜Ÿç¨³å®šä¸º 25%-62.5%ï¼‰ã€‚ä¸´åºŠå®Œå…¨ç¼“è§£ç‡ä¸º10.9%è‡³100%ï¼ˆé”™é…ä¿®å¤ç¼ºé™·/å¾®å«æ˜Ÿé«˜åº¦ä¸ç¨³å®šæ€§ä¸º56%-100%ï¼›é”™é…ä¿®å¤ç†Ÿç»ƒ/å¾®å«æ˜Ÿç¨³å®šä¸º16.4%-48%ï¼‰ã€‚å®Œå…¨ç¼“è§£ç‡èŒƒå›´ä¸º 44% è‡³ 75%ï¼ˆé”™é…ä¿®å¤ç¼ºé™·/å¾®å«æ˜Ÿä¸ç¨³å®šæ€§é«˜ä¸º 75%ï¼›é”™é…ä¿®å¤ç†Ÿç»ƒ/å¾®å«æ˜Ÿç¨³å®šä¸º 44%-56.5%ï¼‰ã€‚ R0åˆ‡é™¤ç‡ä¸º94%ï½100%ï¼Œæ‹¬çº¦è‚Œä¿ç•™ç‡ä¸º59.4%ï½100%ã€‚å¤§å¤šæ•°ä¸è‰¯äº‹ä»¶ä¸º 1 çº§å’Œ 2 çº§ã€‚\n\n**Limitationsï¼š** æˆ‘ä»¬çš„ç»¼è¿°å—åˆ°å°‘æ•°ä¸»è¦æ˜¯å•è‡‚ç ”ç©¶çš„é™åˆ¶ï¼Œç¼ºä¹é•¿æœŸç”Ÿå­˜ç»“æœï¼Œä»¥åŠçº³å…¥çš„ç ”ç©¶ä¹‹é—´å­˜åœ¨æ˜æ˜¾çš„ä¸´åºŠå’Œæ–¹æ³•å­¦å¼‚è´¨æ€§ã€‚\n\n**ç»“è®ºï¼š** å±€éƒ¨æ™šæœŸç›´è‚ ç™Œä¸å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚çš„è”åˆæ²»ç–—ä¼¼ä¹å¯ä»¥æ”¹å–„æ²»ç–—ååº”ï¼Œä½†ä»ç¼ºä¹é«˜æ°´å¹³çš„è¯æ®å’Œé•¿æœŸæ•°æ®ã€‚", "keywords_zh": "å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ã€å…ç–«æ²»ç–—ã€ç—…ç†å®Œå…¨ç¼“è§£ã€ç›´è‚ ç™Œ", "keywords_en": "Immune checkpoint inhibitors, Immunotherapy, Pathologic complete response, Rectal cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/40788642/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 11 Aug 2025"}, {"id": "40788606", "title_en": "Research Perspective on Role of Neoadjuvant Immune Checkpoint Inhibitors in Locally Advanced Rectal Cancer: A Systematic Review of Currently Available Studies", "title_zh": "æ–°è¾…åŠ©å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚åœ¨å±€éƒ¨æ™šæœŸç›´è‚ ç™Œä¸­ä½œç”¨çš„ç ”ç©¶è§†è§’ï¼šå¯¹ç°æœ‰ç ”ç©¶çš„ç³»ç»Ÿå›é¡¾", "authors": "William C Chapman", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40788606/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 11 Aug 2025"}, {"id": "40760310", "title_en": "Correction: Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations", "title_zh": "çº æ­£ï¼šèšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–—ç—”ç–®ç–¾ç—…çš„çœŸå®åº”ç”¨ï¼šå›½é™…è°ƒæŸ¥å’Œç³»ç»Ÿè¯„ä»·ä»¥åŠä¸´åºŠå®è·µå»ºè®®çš„è§è§£", "authors": "Gianpiero Gravante", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40760310/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 05 Aug 2025"}, {"id": "40723194", "title_en": "Quality of Life in Rectal Cancer Treatments: An Updated Systematic Review of Randomized Controlled Trials (2013-2023)", "title_zh": "ç›´è‚ ç™Œæ²»ç–—çš„ç”Ÿæ´»è´¨é‡ï¼šéšæœºå¯¹ç…§è¯•éªŒçš„æœ€æ–°ç³»ç»Ÿè¯„ä»·ï¼ˆ2013-2023ï¼‰", "authors": "Emanuele Damiano Luca Urso", "abstract_en": "**Background:** Rectal cancer management involves surgery, chemotherapy (CT), radiotherapy (RT), and patient care strategies, all of which significantly affect health-related quality of life (HRQoL). Understanding these effects is critical for optimizing treatment protocols. This review aimed to systematically analyze the impact of rectal cancer treatment on HRQoL.\n\n**Methods:** Four databases, Scopus, EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials, were searched for randomized controlled trials (RCTs) published between January 2013 and December 2023. RCTs specifically focusing on rectal cancer treatments (surgical interventions, pre- and/or post-CT and/or RT, and patient care strategies) were included. An abstract review, data extraction, and a risk-of-bias assessment were independently conducted by two reviewers.\n\n**Results:** The 41 included studies comprised 9240 patients: 16 evaluated surgical interventions (3507 patients), 15 evaluated pre- and/or post-CT and/or RT protocols (5114 patients), and 10 focused on patient-care strategies (619 patients). Sphincter-sparing procedures were associated with better HRQoL than abdominoperineal resection, and rectal-sparing techniques were associated with better overall HRQoL than rectal resection. RT was associated with a poorer HRQoL. Continuity-of-care interventions improved HRQoL in ostomy patients, whereas transanal irrigation improved HRQoL after ostomy closure.\n\n**Conclusions:** This systematic review of RCTs underscores the importance of organ-sparing strategies, such as rectum-sparing approaches and continuity-of-care packages, in improving HRQoL in patients with rectal cancer. Although RT negatively affects HRQoL, treatment regimens should be individualized. Tailored organ-preservation approaches and structured follow-up care are essential for optimizing HRQoL in patients with rectal cancer.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç›´è‚ ç™Œç®¡ç†æ¶‰åŠæ‰‹æœ¯ã€åŒ–ç–— (CT)ã€æ”¾ç–— (RT) å’Œæ‚£è€…æŠ¤ç†ç­–ç•¥ï¼Œæ‰€æœ‰è¿™äº›éƒ½ä¼šæ˜¾ç€å½±å“å¥åº·ç›¸å…³çš„ç”Ÿæ´»è´¨é‡ (HRQoL)ã€‚äº†è§£è¿™äº›å½±å“å¯¹äºä¼˜åŒ–æ²»ç–—æ–¹æ¡ˆè‡³å…³é‡è¦ã€‚æœ¬ç»¼è¿°æ—¨åœ¨ç³»ç»Ÿåˆ†æç›´è‚ ç™Œæ²»ç–—å¯¹ HRQoL çš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº† Scopusã€EMBASEã€MEDLINE å’Œ Cochrane å¯¹ç…§è¯•éªŒä¸­å¤®æ³¨å†Œåº“è¿™å››ä¸ªæ•°æ®åº“ï¼Œä»¥æŸ¥æ‰¾ 2013 å¹´ 1 æœˆè‡³ 2023 å¹´ 12 æœˆæœŸé—´å‘è¡¨çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€‚å…¶ä¸­åŒ…æ‹¬ä¸“é—¨é’ˆå¯¹ç›´è‚ ç™Œæ²»ç–—ï¼ˆæ‰‹æœ¯å¹²é¢„ã€CT å’Œ/æˆ– RT ä¹‹å‰å’Œ/æˆ–ä¹‹åä»¥åŠæ‚£è€…æŠ¤ç†ç­–ç•¥ï¼‰çš„ RCTã€‚æ‘˜è¦å®¡æŸ¥ã€æ•°æ®æå–å’Œåå€šé£é™©è¯„ä¼°ç”±ä¸¤åå®¡æŸ¥å‘˜ç‹¬ç«‹è¿›è¡Œã€‚\n\n**ç»“æœï¼š** è¿™ 41 é¡¹ç ”ç©¶æ¶‰åŠ 9240 åæ‚£è€…ï¼š16 é¡¹è¯„ä¼°æ‰‹æœ¯å¹²é¢„ï¼ˆ3507 åæ‚£è€…ï¼‰ï¼Œ15 é¡¹è¯„ä¼° CT å’Œ/æˆ– RT æ–¹æ¡ˆä¹‹å‰å’Œ/æˆ–ä¹‹åï¼ˆ5114 åæ‚£è€…ï¼‰ï¼Œ10 é¡¹é‡ç‚¹å…³æ³¨æ‚£è€…æŠ¤ç†ç­–ç•¥ï¼ˆ619 åæ‚£è€…ï¼‰ã€‚ä¸è…¹ä¼šé˜´åˆ‡é™¤æœ¯ç›¸æ¯”ï¼Œä¿ç•™æ‹¬çº¦è‚Œçš„æ‰‹æœ¯ä¸æ›´å¥½çš„ HRQoL ç›¸å…³ï¼Œè€Œä¸ç›´è‚ åˆ‡é™¤æœ¯ç›¸æ¯”ï¼Œç›´è‚ ä¿ç•™æŠ€æœ¯ä¸æ›´å¥½çš„æ€»ä½“ HRQoL ç›¸å…³ã€‚ RT ä¸è¾ƒå·®çš„ HRQoL ç›¸å…³ã€‚è¿ç»­æŠ¤ç†å¹²é¢„æªæ–½æ”¹å–„äº†é€ å£æ‚£è€…çš„ HRQoLï¼Œè€Œç»è‚›é—¨å†²æ´—åˆ™æ”¹å–„äº†é€ å£é—­åˆåçš„ HRQoLã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹éšæœºå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿè¯„ä»·å¼ºè°ƒäº†å™¨å®˜ä¿ç•™ç­–ç•¥ï¼ˆä¾‹å¦‚ä¿ç•™ç›´è‚ æ–¹æ³•å’Œè¿ç»­æ€§æŠ¤ç†åŒ…ï¼‰åœ¨æ”¹å–„ç›´è‚ ç™Œæ‚£è€… HRQoL æ–¹é¢çš„é‡è¦æ€§ã€‚å°½ç®¡æ”¾ç–—ä¼šå¯¹ HRQoL äº§ç”Ÿè´Ÿé¢å½±å“ï¼Œä½†æ²»ç–—æ–¹æ¡ˆåº”ä¸ªä½“åŒ–ã€‚å®šåˆ¶çš„å™¨å®˜ä¿å­˜æ–¹æ³•å’Œç»“æ„åŒ–çš„éšè®¿æŠ¤ç†å¯¹äºä¼˜åŒ–ç›´è‚ ç™Œæ‚£è€…çš„ HRQoL è‡³å…³é‡è¦ã€‚", "keywords_zh": "å¥åº·ç›¸å…³çš„ç”Ÿæ´»è´¨é‡ã€å™¨å®˜ä¿å­˜ç­–ç•¥ã€æ”¾å°„æ²»ç–—ã€ç›´è‚ ç™Œ", "keywords_en": "health-related quality of life, organ-preserving strategies, radiotherapy, rectal cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/40723194/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 29 Jul 2025"}, {"id": "40719429", "title_en": "Mechanical bowel preparation to prevent infective complications after colon and rectal surgery: a systematic review and meta-analysis of randomized controlled trials", "title_zh": "æœºæ¢°è‚ é“å‡†å¤‡é¢„é˜²ç»“è‚ å’Œç›´è‚ æ‰‹æœ¯åæ„ŸæŸ“å¹¶å‘ç—‡ï¼šéšæœºå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Eloy EspÃ­n-Basany", "abstract_en": "**Introduction:** Surgical site infections (SSI) represent a global health challenge, particularly in colorectal surgery, when rates can reach up to 20%. The role of mechanical bowel preparation (MBP) is still debated. A systematic review is proposed to evaluate MBP effectiveness in reducing SSI and complications after colorectal surgery.\n\n**Evidence Acquisition:** This systematic review and meta-analysis was conducted following the PRISMA guidelines. Only randomized studies comparing two or more methods for preventing infectious complications in patients undergoing colorectal surgery were included. The primary endpoint was the occurrence of SSIs, while secondary endpoints included anastomotic leak (AL) and intra-abdominal septic complications (IASC) other than AL.\n\n**Evidence Synthesis:** Eighteen studies met the inclusion criteria, including a total of 6,302 patients in the analysis. The meta-analysis showed similar SSI rates between the MBP and no-treatment groups (OR 1.015, 95% CI 0.855-1.206, I<sup>2</sup>=22.33%, P=0.863) as well as between the MBP and enema groups (OR 1.100, 95% CI 0.616-1.965, I<sup>2</sup>=35.96%, P=0.748). The risk of anastomotic leak (AL) was also similar when comparing no treatment to MBP (OR 0.904, 95% CI 0.661-1.237, I<sup>2</sup>=0%, P=0.528), and MBP to enema (OR 0.727, 95% CI 0.286-1.845, I<sup>2</sup>=25.98%, P=0.502). IASC rates were lower with MBP compared to no treatment (OR 0.526, 95% CI 0.326-0.848, I<sup>2</sup>=3.50%, P=0.008).\n\n**Conclusions:** This meta-analysis found no significant reduction in SSI or AL rates with MBP alone compared to no preparation or enema use. However, MBP significantly lowered IASC. Further research is warranted to evaluate the effectiveness of MBP combined with antibiotics in reducing postoperative complications.", "abstract_zh": "**ä»‹ç»ï¼š** æ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ (SSI) æ˜¯ä¸€é¡¹å…¨çƒå¥åº·æŒ‘æˆ˜ï¼Œç‰¹åˆ«æ˜¯åœ¨ç»“ç›´è‚ æ‰‹æœ¯ä¸­ï¼Œæ„ŸæŸ“ç‡é«˜è¾¾ 20%ã€‚æœºæ¢°è‚ é“å‡†å¤‡ï¼ˆMBPï¼‰çš„ä½œç”¨ä»ç„¶å­˜åœ¨äº‰è®®ã€‚å»ºè®®è¿›è¡Œç³»ç»Ÿè¯„ä»·æ¥è¯„ä¼° MBP åœ¨å‡å°‘ç»“ç›´è‚ æ‰‹æœ¯å SSI å’Œå¹¶å‘ç—‡æ–¹é¢çš„æœ‰æ•ˆæ€§ã€‚\n\n**Evidence acquisitionï¼š** æœ¬ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææ˜¯æŒ‰ç…§ PRISMA æŒ‡å—è¿›è¡Œçš„ã€‚ä»…çº³å…¥æ¯”è¾ƒä¸¤ç§æˆ–å¤šç§é¢„é˜²ç»“ç›´è‚ æ‰‹æœ¯æ‚£è€…æ„ŸæŸ“å¹¶å‘ç—‡çš„æ–¹æ³•çš„éšæœºç ”ç©¶ã€‚ä¸»è¦ç»ˆç‚¹æ˜¯ SSI çš„å‘ç”Ÿï¼Œæ¬¡è¦ç»ˆç‚¹åŒ…æ‹¬ AL ä»¥å¤–çš„å»åˆå£ç˜˜ (AL) å’Œè…¹è…”å†…è„“æ¯’ç—‡å¹¶å‘ç—‡ (IASC)ã€‚\n\n**Evidence synthesisï¼š** 18 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ï¼Œåˆ†æä¸­å…±æœ‰ 6,302 åæ‚£è€…ã€‚èŸèƒåˆ†ææ˜¾ç¤ºï¼ŒMBP ç»„å’Œæœªæ²»ç–—ç»„ä¹‹é—´ï¼ˆOR 1.015ï¼Œ95% CI 0.855-1.206ï¼ŒI<sup>2</sup>=22.33%ï¼ŒP=0.863ï¼‰ä»¥åŠ MBP å’ŒçŒè‚ ç»„ä¹‹é—´ï¼ˆOR 1.100ï¼Œ95% CI 0.616-1.965ï¼Œ I<sup>2</sup>=35.96%ï¼ŒP=0.748ï¼‰ã€‚å°†ä¸æ²»ç–—ä¸ MBP è¿›è¡Œæ¯”è¾ƒï¼ˆOR 0.904ï¼Œ95% CI 0.661-1.237ï¼ŒI<sup>2</sup>=0%ï¼ŒP=0.528ï¼‰ï¼Œä»¥åŠå°† MBP ä¸çŒè‚ è¿›è¡Œæ¯”è¾ƒï¼ˆOR 0.727ï¼Œ95% CI 0.286-1.845ï¼Œ I<sup>2</sup>=25.98%ï¼ŒP=0.502ï¼‰ã€‚ä¸æœªæ²»ç–—ç›¸æ¯”ï¼ŒMBP æ²»ç–—ç»„çš„ IASC ç‡è¾ƒä½ï¼ˆOR 0.526ï¼Œ95% CI 0.326-0.848ï¼ŒI<sup>2</sup>=3.50%ï¼ŒP=0.008ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹èŸèƒåˆ†æå‘ç°ï¼Œä¸ä¸ä½¿ç”¨åˆ¶å‰‚æˆ–çŒè‚ å‰‚ç›¸æ¯”ï¼Œå•ç‹¬ä½¿ç”¨ MBP çš„ SSI æˆ– AL ç‡æ²¡æœ‰æ˜¾ç€é™ä½ã€‚ç„¶è€Œï¼ŒMBP æ˜¾ç€é™ä½äº† IASCã€‚éœ€è¦è¿›ä¸€æ­¥çš„ç ”ç©¶æ¥è¯„ä¼° MBP è”åˆæŠ—ç”Ÿç´ åœ¨å‡å°‘æœ¯åå¹¶å‘ç—‡æ–¹é¢çš„æœ‰æ•ˆæ€§ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40719429/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 28 Jul 2025"}, {"id": "40714623", "title_en": "Closing the gap: addressing delayed healthcare-seeking and improving quality of life for Ethiopian women with pelvic organ prolapse", "title_zh": "ç¼©å°å·®è·ï¼šè§£å†³æ‚£æœ‰ç›†è…”å™¨å®˜è„±å‚çš„åŸƒå¡ä¿„æ¯”äºšå¦‡å¥³å»¶è¿Ÿå°±åŒ»çš„é—®é¢˜å¹¶æé«˜ç”Ÿæ´»è´¨é‡", "authors": "Lencho Kajela", "abstract_en": "**Background:** Pelvic organs prolapse (POP) involves the herniation of pelvic organs, such as the uterus, cervix, vaginal wall, bladder, and rectum, into the vagina. While it is a common gynecologic problem, its impact on quality of life and timely healthcare-seeking remains poorly understood in developing countries. This systematic review and meta-analysis aimed to assess the quality of life, delays in healthcare-seeking, and associated factors among women diagnosed with POP in Ethiopia.\n\n**Methods:** A systematic review and meta-analysis were conducted following PRISMA guidelines. Extensive literature searches were performed in PubMed, CINAHL, Google Scholar, ScienceDirect, and Scopus. A restricted maximum likelihood random-effects model was used to estimate pooled proportions. Heterogeneity among studies was assessed using the Cochrane Q-test and I2 statistics. Publication bias was evaluated using funnel plots and Egger's test. Stata 17 software was used for all analyses.\n\n**Results:** From an initial pool of 421 articles, 10 met the inclusion criteria, encompassing data from 1489 women diagnosed with POP. The pooled proportion of poor quality of life among women with POP in Ethiopia was 52.07Â % [95Â % C.I.: 48.04Â %, 56.09Â %]. Moderate heterogeneity was observed across studies. The mean delay between symptom onset and seeking medical care was 50.64Â months [95Â % C.I: 32.50, 68.79], with an estimated 78.22Â % [95Â % C.I.: 70.72Â %, 85.72Â %] of women experiencing delays in seeking healthcare. Postmenopausal status (OR = 2.05, 95Â % CI: 1.22-3.45), living with POP for more than 2Â years (OR = 4.17, 95Â % CI: 1.23-14.10), and having Stage III/IV POP (OR = 4.48, 95Â % CI: 1.61-12.44) associated with poor quality of life. In addition, factors associated with delayed healthcare seeking include: fear of disclosure (OR = 4.60, 95Â % CI: 4.65-45.71), lack of social support (OR = 4.09, 95Â % CI: 1.91-8.74), low income (OR = 4.80, 95Â % CI: 2.12-10.86), and experiencing stigma (OR = 5.78, 95Â % CI: 1.07-31.36).\n\n**Conclusion:** This review highlights a high prevalence of poor quality of life and significant delays in healthcare-seeking among Ethiopian women with POP, with an average delay of over four years after symptom onset. Stigma, fear of disclosure, low income, and lack of social support were significantly associated with delays in seeking health care. Additionally, longer prolapse duration, menopause, and stage III or IV pelvic organ prolapse (POP) were significantly associated with a reduced quality of life.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç›†è…”å™¨å®˜è„±å‚ï¼ˆPOPï¼‰æ¶‰åŠç›†è…”å™¨å®˜ï¼ˆå¦‚å­å®«ã€å­å®«é¢ˆã€é˜´é“å£ã€è†€èƒ±å’Œç›´è‚ ï¼‰ç–å…¥é˜´é“ã€‚è™½ç„¶è¿™æ˜¯ä¸€ä¸ªå¸¸è§çš„å¦‡ç§‘é—®é¢˜ï¼Œä½†åœ¨å‘å±•ä¸­å›½å®¶ï¼Œå®ƒå¯¹ç”Ÿæ´»è´¨é‡å’ŒåŠæ—¶å°±åŒ»çš„å½±å“ä»ç„¶çŸ¥ä¹‹ç”šå°‘ã€‚è¿™é¡¹ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ—¨åœ¨è¯„ä¼°åŸƒå¡ä¿„æ¯”äºšè¯Šæ–­æ‚£æœ‰ POP çš„å¥³æ€§çš„ç”Ÿæ´»è´¨é‡ã€å°±åŒ»å»¶è¿Ÿä»¥åŠç›¸å…³å› ç´ ã€‚\n\n**æ–¹æ³•ï¼š** æŒ‰ç…§ PRISMA æŒ‡å—è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚åœ¨ PubMedã€CINAHLã€Google Scholarã€ScienceDirect å’Œ Scopus ä¸­è¿›è¡Œäº†å¹¿æ³›çš„æ–‡çŒ®æ£€ç´¢ã€‚ä½¿ç”¨é™åˆ¶æœ€å¤§ä¼¼ç„¶éšæœºæ•ˆåº”æ¨¡å‹æ¥ä¼°è®¡åˆå¹¶æ¯”ä¾‹ã€‚ä½¿ç”¨ Cochrane Q æ£€éªŒå’Œ I2 ç»Ÿè®¡æ¥è¯„ä¼°ç ”ç©¶ä¹‹é—´çš„å¼‚è´¨æ€§ã€‚ä½¿ç”¨æ¼æ–—å›¾å’Œè‰¾æ ¼æ£€éªŒè¯„ä¼°å‘è¡¨åå€šã€‚ Stata 17 è½¯ä»¶ç”¨äºæ‰€æœ‰åˆ†æã€‚\n\n**ç»“æœï¼š** ä»æœ€åˆçš„ 421 ç¯‡æ–‡ç« ä¸­ï¼Œæœ‰ 10 ç¯‡ç¬¦åˆçº³å…¥æ ‡å‡†ï¼Œæ¶µç›–äº† 1489 åè¢«è¯Šæ–­æ‚£æœ‰ POP çš„å¥³æ€§çš„æ•°æ®ã€‚åŸƒå¡ä¿„æ¯”äºš POP å¥³æ€§ä¸­ç”Ÿæ´»è´¨é‡è¾ƒå·®çš„æ€»ä½“æ¯”ä¾‹ä¸º 52.07% [95% C.I.: 48.04%, 56.09%]ã€‚å„é¡¹ç ”ç©¶ä¸­è§‚å¯Ÿåˆ°ä¸­ç­‰ç¨‹åº¦çš„å¼‚è´¨æ€§ã€‚ç—‡çŠ¶å‡ºç°å’Œå°±åŒ»ä¹‹é—´çš„å¹³å‡å»¶è¿Ÿæ—¶é—´ä¸º 50.64 ä¸ªæœˆ [95% C.I.: 32.50, 68.79]ï¼Œä¼°è®¡æœ‰ 78.22% [95% C.I.: 70.72%, 85.72%] çš„å¥³æ€§åœ¨å¯»æ±‚åŒ»ç–—ä¿å¥æ–¹é¢å‡ºç°å»¶è¿Ÿã€‚ç»ç»åçŠ¶æ€ï¼ˆOR = 2.05ï¼Œ95% CIï¼š1.22-3.45ï¼‰ã€æ‚£æœ‰ POP è¶…è¿‡ 2 å¹´ï¼ˆOR = 4.17ï¼Œ95% CIï¼š1.23-14.10ï¼‰ä»¥åŠæ‚£æœ‰ III/IV æœŸ POPï¼ˆOR = 4.48ï¼Œ95% CIï¼š1.61-12.44ï¼‰ä¸ä¸è‰¯è´¨é‡ç›¸å…³ç”Ÿæ´»ã€‚æ­¤å¤–ï¼Œä¸å»¶è¿Ÿå°±åŒ»ç›¸å…³çš„å› ç´ åŒ…æ‹¬ï¼šå®³æ€•æŠ«éœ²ï¼ˆOR = 4.60ï¼Œ95% CIï¼š4.65-45.71ï¼‰ã€ç¼ºä¹ç¤¾ä¼šæ”¯æŒï¼ˆOR = 4.09ï¼Œ95% CIï¼š1.91-8.74ï¼‰ã€ä½æ”¶å…¥ï¼ˆOR = 4.80ï¼Œ95% CIï¼š2.12-10.86ï¼‰å’Œç»å†è€»è¾±ï¼ˆOR = 5.78ï¼Œ95% CIï¼š1.07-31.36ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™ç¯‡ç»¼è¿°å¼ºè°ƒäº†æ‚£æœ‰ POP çš„åŸƒå¡ä¿„æ¯”äºšå¥³æ€§æ™®éå­˜åœ¨ç”Ÿæ´»è´¨é‡å·®å’Œå°±åŒ»ä¸¥é‡å»¶è¿Ÿçš„æƒ…å†µï¼Œç—‡çŠ¶å‡ºç°åå¹³å‡å»¶è¿Ÿå››å¹´ä»¥ä¸Šã€‚è€»è¾±ã€å®³æ€•æŠ«éœ²ã€ä½æ”¶å…¥å’Œç¼ºä¹ç¤¾ä¼šæ”¯æŒä¸å»¶è¿Ÿå¯»æ±‚åŒ»ç–—ä¿å¥å¯†åˆ‡ç›¸å…³ã€‚æ­¤å¤–ï¼Œè¾ƒé•¿çš„è„±å‚æŒç»­æ—¶é—´ã€æ›´å¹´æœŸå’Œ III æœŸæˆ– IV æœŸç›†è…”å™¨å®˜è„±å‚ (POP) ä¸ç”Ÿæ´»è´¨é‡ä¸‹é™æ˜¾ç€ç›¸å…³ã€‚", "keywords_zh": "åŸƒå¡ä¿„æ¯”äºš, å¯»æ±‚åŒ»ç–—ä¿å¥, ç›†åº•åŠŸèƒ½éšœç¢, ç›†è…”å™¨å®˜è„±å‚, ç”Ÿæ´»è´¨é‡", "keywords_en": "Ethiopia, Healthcare-seeking, Pelvic floor dysfunction, Pelvic organs prolapse, Quality of life", "link": "https://pubmed.ncbi.nlm.nih.gov/40714623/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sun, 27 Jul 2025"}, {"id": "40703667", "title_en": "Radiotherapy boost to the primary tumour in locally advanced rectal cancer: Systematic review of practices and meta-analysis", "title_zh": "æ”¾å°„æ²»ç–—å¯¹å±€éƒ¨æ™šæœŸç›´è‚ ç™ŒåŸå‘è‚¿ç˜¤çš„å¢å¼ºä½œç”¨ï¼šå®è·µå’ŒèŸèƒåˆ†æçš„ç³»ç»Ÿå›é¡¾", "authors": "GeneviÃ¨ve Van Ooteghem", "abstract_en": "**Introduction:** In locally advanced rectal cancer (LARC), increasing the complete response (CR) rate after total neo-adjuvant treatment may increase the patient eligibility for non-operative management (\"watch and wait\", W&W). Although a radiotherapy (RT) boost to the primary tumour may enhance CR rates, clear guidelines are currently lacking. This systematic review and <i>meta</i>-analysis investigate the technical parameters used for rectal boost RT and assess their impact on oncological outcomes.\n\n**Methods:** Following PRISMA guidelines, the terms \"rectum,\" \"radiotherapy,\" and \"boost\" were searched in PubMed and EMBASE (PROSPERO: CRD42023444685). Studies reporting on external beam RT boost to the primary tumour in LARC and meeting quality criteria were included. Descriptive analyses extracted data on RT technique, preparation, boost delineation, dose, chemotherapy, and follow-up. A mixed-effects <i>meta</i>-analysis model evaluated the impact of selected parameters on CR and local recurrence rate (LRR). Studies were analysed separately based on treatment intent: planned surgery or W&W.\n\n**Results:** Out of 3904 references, 83 were included in the descriptive analysis and 78 in the <i>meta</i>-analysis. Substantial variability in RT parameters was observed across studies. Pathologic CR rates were significantly higher with intensity-modulated/volumetric-modulated arc RT (IMRT/VMAT, pÂ =Â 0.007), simultaneous boost (pÂ =Â 0.020), dose escalation (Biological equivalent doseÂ >Â 74Â Gy, pÂ =Â 0.035), and the combination of induction and consolidation chemotherapy (pÂ =Â 0.023). No significant associations were found for clinical CR or LRR.\n\n**Conclusion:** While rectal RT boost is already part of real-world practices, the wide heterogeneity in techniques highlights the urgent need for standardisation. Our <i>meta</i>-analysis suggests that IMRT/VMAT, simultaneous boost, and dose escalation are associated with higher pathological CR rates and should be considered in future rectal boost guidelines. These findings, however, warrant careful interpretation due to the absence of adjustments for clinical, tumoral, or patient-related parameters that may also influence response rate and oncological outcomes.", "abstract_zh": "**ä»‹ç»ï¼š** åœ¨å±€éƒ¨æ™šæœŸç›´è‚ ç™Œ (LARC) ä¸­ï¼Œæé«˜æ–°è¾…åŠ©æ²»ç–—åçš„å®Œå…¨ç¼“è§£ (CR) ç‡å¯èƒ½ä¼šå¢åŠ æ‚£è€…æ¥å—éæ‰‹æœ¯æ²»ç–—çš„èµ„æ ¼ï¼ˆâ€œè§‚å¯Ÿå¹¶ç­‰å¾…â€ï¼ŒW&Wï¼‰ã€‚å°½ç®¡å¯¹åŸå‘è‚¿ç˜¤è¿›è¡Œæ”¾å°„æ²»ç–—ï¼ˆRTï¼‰å¯èƒ½ä¼šæé«˜ CR ç‡ï¼Œä½†ç›®å‰ç¼ºä¹æ˜ç¡®çš„æŒ‡å—ã€‚è¿™é¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æè°ƒæŸ¥äº†ç›´è‚ å¢å¼ºæ”¾ç–—æ‰€ç”¨çš„æŠ€æœ¯å‚æ•°ï¼Œå¹¶è¯„ä¼°äº†å®ƒä»¬å¯¹è‚¿ç˜¤å­¦ç»“æœçš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ® PRISMA æŒ‡å—ï¼Œåœ¨ PubMed å’Œ EMBASE ä¸­æ£€ç´¢äº†æœ¯è¯­â€œç›´è‚ â€ã€â€œæ”¾å°„æ²»ç–—â€å’Œâ€œå¢å¼ºâ€ï¼ˆPROSPEROï¼šCRD42023444685ï¼‰ã€‚æŠ¥å‘Šäº†å¤–ç…§å°„æ”¾ç–—å¯¹ LARC åŸå‘è‚¿ç˜¤çš„å¢å¼ºä½œç”¨å¹¶ç¬¦åˆè´¨é‡æ ‡å‡†çš„ç ”ç©¶ä¹Ÿè¢«çº³å…¥å…¶ä¸­ã€‚æè¿°æ€§åˆ†ææå–äº†æœ‰å…³ RT æŠ€æœ¯ã€å‡†å¤‡ã€åŠ å¼ºèŒƒå›´ã€å‰‚é‡ã€åŒ–ç–—å’Œéšè®¿çš„æ•°æ®ã€‚æ··åˆæ•ˆåº”å…ƒåˆ†ææ¨¡å‹è¯„ä¼°äº†æ‰€é€‰å‚æ•°å¯¹ CR å’Œå±€éƒ¨å¤å‘ç‡ (LRR) çš„å½±å“ã€‚æ ¹æ®æ²»ç–—ç›®çš„åˆ†åˆ«åˆ†æç ”ç©¶ï¼šè®¡åˆ’æ‰‹æœ¯æˆ– W&Wã€‚\n\n**ç»“æœï¼š** åœ¨ 3904 ç¯‡å‚è€ƒæ–‡çŒ®ä¸­ï¼Œ83 ç¯‡çº³å…¥æè¿°æ€§åˆ†æï¼Œ78 ç¯‡çº³å…¥å…ƒåˆ†æã€‚ä¸åŒç ”ç©¶ä¸­è§‚å¯Ÿåˆ° RT å‚æ•°å­˜åœ¨æ˜¾ç€å·®å¼‚ã€‚å¼ºåº¦è°ƒåˆ¶/ä½“ç§¯è°ƒåˆ¶å¼§å½¢æ”¾ç–—ï¼ˆIMRT/VMATï¼Œp = 0.007ï¼‰ã€åŒæ—¶åŠ å¼ºåŒ–ç–—ï¼ˆp = 0.020ï¼‰ã€å‰‚é‡é€’å¢ï¼ˆç”Ÿç‰©ç­‰æ•ˆå‰‚é‡> 74 Gyï¼Œp = 0.035ï¼‰ä»¥åŠè¯±å¯¼å’Œå·©å›ºåŒ–ç–—ç›¸ç»“åˆï¼ˆp = 0.023ï¼‰çš„ç—…ç† CR ç‡æ˜¾ç€æ›´é«˜ã€‚æœªå‘ç°ä¸ä¸´åºŠ CR æˆ– LRR æ˜¾ç€ç›¸å…³ã€‚\n\n**ç»“è®ºï¼š** è™½ç„¶ç›´è‚ æ”¾ç–—å¢å¼ºå·²ç»æˆä¸ºç°å®ä¸–ç•Œå®è·µçš„ä¸€éƒ¨åˆ†ï¼Œä½†æŠ€æœ¯ä¸Šçš„å¹¿æ³›å¼‚è´¨æ€§å‡¸æ˜¾äº†æ ‡å‡†åŒ–çš„è¿«åˆ‡éœ€è¦ã€‚æˆ‘ä»¬çš„èŸèƒåˆ†æè¡¨æ˜ IMRT/VMATã€åŒæ­¥åŠ å¼ºå’Œå‰‚é‡é€’å¢ä¸è¾ƒé«˜çš„ç—…ç† CR ç‡ç›¸å…³ï¼Œåº”åœ¨æœªæ¥çš„ç›´è‚ åŠ å¼ºæŒ‡å—ä¸­äºˆä»¥è€ƒè™‘ã€‚ç„¶è€Œï¼Œç”±äºæ²¡æœ‰å¯¹ä¹Ÿå¯èƒ½å½±å“ç¼“è§£ç‡å’Œè‚¿ç˜¤å­¦ç»“æœçš„ä¸´åºŠã€è‚¿ç˜¤æˆ–æ‚£è€…ç›¸å…³å‚æ•°è¿›è¡Œè°ƒæ•´ï¼Œè¿™äº›å‘ç°éœ€è¦ä»”ç»†è§£é‡Šã€‚", "keywords_zh": "å®Œå…¨ç¼“è§£ã€å‰‚é‡é€’å¢ã€å±€éƒ¨æ™šæœŸç›´è‚ ç™Œã€èŸèƒåˆ†æã€æ–°è¾…åŠ©æ²»ç–—ã€ç›´è‚ åŠ å¼ºæ²»ç–—", "keywords_en": "Complete response, Dose escalation, Locally advanced rectal cancer, Meta-analysis, Neo-adjuvant therapy, Rectal boost", "link": "https://pubmed.ncbi.nlm.nih.gov/40703667/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 24 Jul 2025"}, {"id": "40697442", "title_en": "Early-onset colorectal cancer in patients younger than 50 years: a systematic review of the literature", "title_zh": "50 å²ä»¥ä¸‹æ‚£è€…çš„æ—©å‘ç»“ç›´è‚ ç™Œï¼šæ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾", "authors": "Konstantinos Vlachos", "abstract_en": "Early-onset colorectal cancer (EO-CRC) refers to CRC diagnosed before the age of 50. Its incidence has risen in recent years, turning researchers' attention to its oncologic behavior and potentially modifiable risk factors. In this review, PubMed/MEDLINE database was searched for all original research articles concerning EO-CRC. The inclusion criteria were CRC patients under 50, without a known predisposing factor for malignancy or an inherited CRC syndrome, presenting oncological characteristics and outcomes. All studies were assessed for bias, based on the ROBINS-E 2022 tool, and were synthesized in a qualitative analysis. Twenty-nine articles, reporting on 64,376 EO-CRC patients, were included in the qualitative synthesis. Results were classified into 3 categories: a) demographics; b) histopathologic characteristics; and c) treatment outcomes. Of these publications, 21 studies agreed that rectum (45%) and left-sided (47.1%) cancers are most common in younger patients, and 5 indicated that the highest prevalence of CRC concerns the 40-49 years age group. Seventeen of 29 studies reported a higher stage (III and IV) on diagnosis, with lymphovascular and perineural invasion. Our review has some limitations: as it was based on a single database, not all studies provided information on the variables; and patients were not categorized in all studies in the same age groups, although all were under 50 years. As EO-CRC is on the rise, the need for closer monitoring and possibly earlier screening becomes apparent. Further research should focus on finding novel screening biomarkers and modifiable risk factors that would decrease mortality and improve patient outcomes.", "abstract_zh": "æ—©å‘æ€§ç»“ç›´è‚ ç™Œï¼ˆEO-CRCï¼‰æ˜¯æŒ‡50å²ä¹‹å‰è¯Šæ–­å‡ºçš„ç»“ç›´è‚ ç™Œã€‚è¿‘å¹´æ¥å…¶å‘ç—…ç‡æœ‰æ‰€ä¸Šå‡ï¼Œè¿™ä½¿å¾—ç ”ç©¶äººå‘˜å¼€å§‹å…³æ³¨å…¶è‚¿ç˜¤è¡Œä¸ºå’Œæ½œåœ¨å¯æ”¹å˜çš„å±é™©å› ç´ ã€‚åœ¨è¿™ç¯‡ç»¼è¿°ä¸­ï¼Œæ£€ç´¢äº† PubMed/MEDLINE æ•°æ®åº“ä¸­æœ‰å…³ EO-CRC çš„æ‰€æœ‰åŸå§‹ç ”ç©¶æ–‡ç« ã€‚çº³å…¥æ ‡å‡†æ˜¯ 50 å²ä»¥ä¸‹çš„ CRC æ‚£è€…ï¼Œæ²¡æœ‰å·²çŸ¥çš„æ¶æ€§è‚¿ç˜¤è¯±å‘å› ç´ æˆ–é—ä¼ æ€§ CRC ç»¼åˆå¾ï¼Œä¸”å…·æœ‰è‚¿ç˜¤å­¦ç‰¹å¾å’Œç»“æœã€‚æ‰€æœ‰ç ”ç©¶å‡æ ¹æ® ROBINS-E 2022 å·¥å…·è¿›è¡Œåå€šè¯„ä¼°ï¼Œå¹¶è¿›è¡Œå®šæ€§åˆ†æç»¼åˆã€‚å®šæ€§ç»¼åˆä¸­çº³å…¥äº† 29 ç¯‡æ–‡ç« ï¼ŒæŠ¥å‘Šäº† 64,376 å EO-CRC æ‚£è€…ã€‚ç»“æœåˆ†ä¸º 3 ç±»ï¼ša) äººå£ç»Ÿè®¡ï¼› b) ç»„ç»‡ç—…ç†å­¦ç‰¹å¾ï¼› c) æ²»ç–—ç»“æœã€‚åœ¨è¿™äº›å‡ºç‰ˆç‰©ä¸­ï¼Œ21 é¡¹ç ”ç©¶ä¸€è‡´è®¤ä¸ºï¼Œç›´è‚ ç™Œ (45%) å’Œå·¦ä¾§ç™Œç—‡ (47.1%) åœ¨å¹´è½»æ‚£è€…ä¸­æœ€å¸¸è§ï¼Œ5 é¡¹ç ”ç©¶è¡¨æ˜ CRC æ‚£ç—…ç‡æœ€é«˜çš„æ˜¯ 40-49 å²å¹´é¾„ç»„ã€‚ 29 é¡¹ç ”ç©¶ä¸­æœ‰ 17 é¡¹æŠ¥å‘Šäº†è¾ƒé«˜çš„è¯Šæ–­é˜¶æ®µï¼ˆIII å’Œ IVï¼‰ï¼Œä¼´æœ‰æ·‹å·´è¡€ç®¡å’Œç¥ç»å‘¨å›´ä¾µçŠ¯ã€‚æˆ‘ä»¬çš„å®¡æŸ¥æœ‰ä¸€äº›å±€é™æ€§ï¼šç”±äºå®ƒåŸºäºå•ä¸€æ•°æ®åº“ï¼Œå¹¶éæ‰€æœ‰ç ”ç©¶éƒ½æä¾›æœ‰å…³å˜é‡çš„ä¿¡æ¯ï¼›å°½ç®¡æ‰€æœ‰ç ”ç©¶çš„æ‚£è€…å¹´é¾„éƒ½åœ¨ 50 å²ä»¥ä¸‹ï¼Œä½†å¹¶éæ‰€æœ‰ç ”ç©¶ä¸­çš„æ‚£è€…éƒ½è¢«å½’ä¸ºåŒä¸€å¹´é¾„ç»„ã€‚éšç€ EO-CRC çš„å¢åŠ ï¼Œæ›´å¯†åˆ‡çš„ç›‘æµ‹ä»¥åŠå¯èƒ½æ›´æ—©çš„ç­›æŸ¥çš„å¿…è¦æ€§å˜å¾—æ˜¾è€Œæ˜“è§ã€‚è¿›ä¸€æ­¥çš„ç ”ç©¶åº”é›†ä¸­äºå¯»æ‰¾æ–°çš„ç­›æŸ¥ç”Ÿç‰©æ ‡å¿—ç‰©å’Œå¯æ”¹å˜çš„é£é™©å› ç´ ï¼Œä»¥é™ä½æ­»äº¡ç‡å¹¶æ”¹å–„æ‚£è€…çš„æ²»ç–—ç»“æœã€‚", "keywords_zh": "50å²ï¼Œæ—©å‘æ€§ç»“ç›´è‚ ç™Œï¼ŒæŒ‡å—ï¼Œå¹´è½»äºº", "keywords_en": "50 years old, Early-onset colorectal cancer, guidelines, young adults", "link": "https://pubmed.ncbi.nlm.nih.gov/40697442/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 23 Jul 2025"}, {"id": "40672439", "title_en": "Diagnosis and treatment for anal fistula: a systematic review of clinical practice guidelines and consensus statements", "title_zh": "è‚›ç˜˜çš„è¯Šæ–­å’Œæ²»ç–—ï¼šä¸´åºŠå®è·µæŒ‡å—å’Œå…±è¯†å£°æ˜çš„ç³»ç»Ÿå›é¡¾", "authors": "Rong Shi", "abstract_en": "**Background:** Anal fistula constitutes a pathological channel originating either from the anal canal or rectum to the skin surrounding the anus, primarily characterized by recurrent pain, purulent discharge, and pruritus. This study aims to compare and standardize the recommendations for the diagnosis and treatment of anal fistula, drawing on contemporary clinical practice guidelines.\n\n**Methods:** A comprehensive search was conducted across multiple databases including PubMed, EMBASE, China National Knowledge Infrastructure, Wanfang Database, Chinese Science and Technology Periodical Database, and Chinese Biological Medicine Database, from their inception through April 1, 2024. The objective was to collate all published guidelines on anal fistula. The quality of the eligible guidelines was appraised by two reviewers using the Appraisal of Guidelines for Research and Evaluation II instrument.\n\n**Results:** The search yielded fifteen guidance documents -comprising nine guidelines and six consensus statements -each offering specific recommendations. Twelve of these documents address screening and diagnosis of anal fistula, while all fifteen discuss various treatment and management strategies. Document analysis highlighted MRI as the predominant diagnostic recommendation. Treatment and management strategies were categorized into four categories: preoperative management, surgical method selection, pharmacological interventions, and postoperative management. Regarding surgical interventions, all guidelines address incision and drainage of fistulas. Most guidelines offer a low recommendation for cutting setons, mainly attributed to the presence of incontinence. For high-positioned anal fistula, a push-pull flap procedure is recommended, whereas the LIFT procedure is advocated for newly identified, high, and sphincter-penetrating fistulas. Among the 15 guidelines and consensus statements evaluated in this study, more than half demonstrated methodological limitations, with particularly deficient performance in the applicability domain. As a critical determinant of implementation effectiveness, these deficiencies may undermine guidelines' capacity to optimize health outcomes.\n\n**Conclusion:** There is a pressing need for an updated search of potential evidence on the diagnosis and treatment of anal fistula. Effective diagnoses and therapeutic approaches, whether conventional or complementary and alternative medicine, should be thoroughly evaluated and incorporated based on robust evidence.", "abstract_zh": "**èƒŒæ™¯ï¼š** è‚›ç˜˜æ˜¯ä»è‚›ç®¡æˆ–ç›´è‚ åˆ°è‚›é—¨å‘¨å›´çš®è‚¤çš„ç—…ç†é€šé“ï¼Œä¸»è¦è¡¨ç°ä¸ºåå¤ç–¼ç—›ã€è„“æ€§åˆ†æ³Œç‰©å’Œç˜™ç—’ã€‚æœ¬ç ”ç©¶æ—¨åœ¨å€Ÿé‰´å½“ä»£ä¸´åºŠå®è·µæŒ‡å—ï¼Œå¯¹è‚›ç˜˜çš„è¯Šæ–­å’Œæ²»ç–—å»ºè®®è¿›è¡Œæ¯”è¾ƒå’Œæ ‡å‡†åŒ–ã€‚\n\n**æ–¹æ³•ï¼š** å¯¹PubMedã€EMBASEã€ä¸­å›½å›½å®¶çŸ¥è¯†åŸºç¡€è®¾æ–½ã€ä¸‡æ–¹æ•°æ®åº“ã€ä¸­å›½ç§‘æŠ€æœŸåˆŠæ•°æ®åº“å’Œä¸­å›½ç”Ÿç‰©åŒ»å­¦æ•°æ®åº“ç­‰å¤šä¸ªæ•°æ®åº“è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œä»å»ºåº“åˆ°2024å¹´4æœˆ1æ—¥ã€‚ç›®çš„æ˜¯æ•´ç†æ‰€æœ‰å·²å‘å¸ƒçš„è‚›ç˜˜æŒ‡å—ã€‚åˆæ ¼æŒ‡å—çš„è´¨é‡ç”±ä¸¤åè¯„å®¡å‘˜ä½¿ç”¨â€œç ”ç©¶å’Œè¯„ä¼°æŒ‡å— II è¯„ä¼°â€å·¥å…·è¿›è¡Œè¯„ä¼°ã€‚\n\n**ç»“æœï¼š** æœç´¢äº§ç”Ÿäº†åäº”ä»½æŒ‡å¯¼æ–‡ä»¶ï¼Œå…¶ä¸­åŒ…æ‹¬ä¹ä»½æŒ‡å—å’Œå…­ä»½å…±è¯†å£°æ˜ï¼Œæ¯ä»½æ–‡ä»¶éƒ½æä¾›äº†å…·ä½“å»ºè®®ã€‚å…¶ä¸­åäºŒä»½æ–‡ä»¶æ¶‰åŠè‚›ç˜˜çš„ç­›æŸ¥å’Œè¯Šæ–­ï¼Œæ‰€æœ‰åäº”ä»½æ–‡ä»¶éƒ½è®¨è®ºäº†å„ç§æ²»ç–—å’Œç®¡ç†ç­–ç•¥ã€‚æ–‡æ¡£åˆ†æå¼ºè°ƒ MRI æ˜¯ä¸»è¦çš„è¯Šæ–­å»ºè®®ã€‚æ²»ç–—å’Œç®¡ç†ç­–ç•¥åˆ†ä¸ºå››ç±»ï¼šæœ¯å‰ç®¡ç†ã€æ‰‹æœ¯æ–¹æ³•é€‰æ‹©ã€è¯ç‰©å¹²é¢„å’Œæœ¯åç®¡ç†ã€‚å…³äºæ‰‹æœ¯å¹²é¢„ï¼Œæ‰€æœ‰æŒ‡å—å‡æ¶‰åŠç˜˜ç®¡åˆ‡å¼€å’Œå¼•æµã€‚å¤§å¤šæ•°æŒ‡å—å¯¹åˆ‡æŒ‚çº¿çš„å»ºè®®è¾ƒä½ï¼Œè¿™ä¸»è¦æ˜¯ç”±äºå­˜åœ¨å¤±ç¦ã€‚å¯¹äºé«˜ä½è‚›ç˜˜ï¼Œå»ºè®®é‡‡ç”¨æ¨æ‹‰çš®ç“£æ‰‹æœ¯ï¼Œè€Œå¯¹äºæ–°å‘ç°çš„é«˜ä½è‚›ç˜˜å’Œæ‹¬çº¦è‚Œç©¿é€æ€§è‚›ç˜˜åˆ™æå€¡é‡‡ç”¨ LIFT æ‰‹æœ¯ã€‚åœ¨æœ¬ç ”ç©¶è¯„ä¼°çš„ 15 æ¡æŒ‡å—å’Œå…±è¯†å£°æ˜ä¸­ï¼Œè¶…è¿‡ä¸€åŠè¡¨ç°å‡ºæ–¹æ³•å­¦å±€é™æ€§ï¼Œå°¤å…¶æ˜¯åœ¨é€‚ç”¨æ€§é¢†åŸŸè¡¨ç°ä¸è¶³ã€‚ä½œä¸ºå®æ–½æœ‰æ•ˆæ€§çš„å…³é”®å†³å®šå› ç´ ï¼Œè¿™äº›ç¼ºé™·å¯èƒ½ä¼šå‰Šå¼±æŒ‡å—ä¼˜åŒ–å¥åº·ç»“æœçš„èƒ½åŠ›ã€‚\n\n**ç»“è®ºï¼š** è¿«åˆ‡éœ€è¦æ›´æ–°æœ‰å…³è‚›ç˜˜è¯Šæ–­å’Œæ²»ç–—çš„æ½œåœ¨è¯æ®ã€‚æœ‰æ•ˆçš„è¯Šæ–­å’Œæ²»ç–—æ–¹æ³•ï¼Œæ— è®ºæ˜¯ä¼ ç»ŸåŒ»å­¦è¿˜æ˜¯è¡¥å……å’Œæ›¿ä»£åŒ»å­¦ï¼Œéƒ½åº”åŸºäºå¼ºæœ‰åŠ›çš„è¯æ®è¿›è¡Œå½»åº•è¯„ä¼°å’Œæ•´åˆã€‚", "keywords_zh": "è‚›ç˜˜, è¯Šæ–­, æŒ‡å—, ç³»ç»Ÿè¯„ä»·, æ²»ç–—", "keywords_en": "anal fistula, diagnosis, guidelines, systematic review, therapeutic", "link": "https://pubmed.ncbi.nlm.nih.gov/40672439/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 17 Jul 2025"}, {"id": "40670732", "title_en": "Robotic Beyond Total Mesorectal Excision (bTME) for locally advanced and recurrent anorectal cancer: a systematic review", "title_zh": "æœºå™¨äººè¶…è¶Šå…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯ï¼ˆbTMEï¼‰æ²»ç–—å±€éƒ¨æ™šæœŸå’Œå¤å‘æ€§è‚›é—¨ç›´è‚ ç™Œï¼šç³»ç»Ÿè¯„ä»·", "authors": "Muhammad Rafaih Iqbal", "abstract_en": "Robotic surgery is increasingly utilized for rectal cancer resection, particularly in cases requiring beyond total mesorectal excision (bTME) to achieve oncological clearance. Despite longer operative times, robotic bTME has been associated with reduced morbidity and blood loss, making it an emerging approach in specialized centers. A systematic review following PRISMA guidelines was conducted in Web of Science, PubMed, and Scopus. Studies reporting robotic bTME for recurrent or locally advanced anorectal cancer were included. Outcomes assessed included study characteristics, demographics, operative outcomes, oncological data, and follow-up. Nineteen studies comprising 1027 patients met the inclusion criteria (13 case series-68% and 6 cohort studies-32%). The median patient age ranged from 51 to 68Â years with 73.7% males. Most patients had an ASA score of 2 (53.1%), and BMI ranged from 21.1 to 28.6. Tumor locations were predominantly near the anal verge (median: 3-6Â cm), and the most common clinical staging was cT3, cN1, and cM0. Surgical complications included urinary issues (22.6%), anastomotic leakage (11.4%), ileus (10.4%), and bleeding (5.3%). Follow-up data indicated a recurrence rate of 24.9%, and the 1-year survival rate was >â€‰90%. These studies reported an overall complication rate of 49.7%, with a median follow-up of 12-36Â months. Oncological outcomes were favorable, although there was significant variability in survival data between studies. The heterogenicity of the studies makes it challenging to conclusively establish robotic bTME as a feasible alternative to the gold standard. Further prospective studies, with measurable outcomes and consistent terminology, are needed to ensure homogeneity.", "abstract_zh": "æœºå™¨äººæ‰‹æœ¯è¶Šæ¥è¶Šå¤šåœ°ç”¨äºç›´è‚ ç™Œåˆ‡é™¤ï¼Œç‰¹åˆ«æ˜¯åœ¨éœ€è¦å®Œå…¨ç›´è‚ ç³»è†œåˆ‡é™¤ï¼ˆbTMEï¼‰ä»¥å¤–æ‰èƒ½å®ç°è‚¿ç˜¤æ¸…é™¤çš„ç—…ä¾‹ã€‚å°½ç®¡æ‰‹æœ¯æ—¶é—´è¾ƒé•¿ï¼Œä½†æœºå™¨äºº bTME ä¸é™ä½å‘ç—…ç‡å’Œå¤±è¡€é‡æœ‰å…³ï¼Œä½¿å…¶æˆä¸ºä¸“ä¸šä¸­å¿ƒçš„æ–°å…´æ–¹æ³•ã€‚ Web of Scienceã€PubMed å’Œ Scopus éµå¾ª PRISMA æŒ‡å—è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ã€‚æŠ¥å‘Šæœºå™¨äºº bTME ç”¨äºæ²»ç–—å¤å‘æ€§æˆ–å±€éƒ¨æ™šæœŸè‚›é—¨ç›´è‚ ç™Œçš„ç ”ç©¶ä¹Ÿè¢«çº³å…¥å…¶ä¸­ã€‚è¯„ä¼°çš„ç»“æœåŒ…æ‹¬ç ”ç©¶ç‰¹å¾ã€äººå£ç»Ÿè®¡ã€æ‰‹æœ¯ç»“æœã€è‚¿ç˜¤æ•°æ®å’Œéšè®¿ã€‚åŒ…å« 1027 åæ‚£è€…çš„ 19 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ï¼ˆ13 é¡¹ç—…ä¾‹ç³»åˆ—ç ”ç©¶ - 68% å’Œ 6 é¡¹é˜Ÿåˆ—ç ”ç©¶ - 32%ï¼‰ã€‚æ‚£è€…ä¸­ä½å¹´é¾„èŒƒå›´ä¸º 51 å²è‡³ 68 å²ï¼Œå…¶ä¸­ 73.7% ä¸ºç”·æ€§ã€‚å¤§å¤šæ•°æ‚£è€…çš„ ASA è¯„åˆ†ä¸º 2 åˆ†ï¼ˆ53.1%ï¼‰ï¼ŒBMI èŒƒå›´ä¸º 21.1 è‡³ 28.6ã€‚è‚¿ç˜¤ä½ç½®ä¸»è¦ä½äºè‚›ç¼˜é™„è¿‘ï¼ˆä¸­ä½ï¼š3-6 cmï¼‰ï¼Œæœ€å¸¸è§çš„ä¸´åºŠåˆ†æœŸæ˜¯ cT3ã€cN1 å’Œ cM0ã€‚æ‰‹æœ¯å¹¶å‘ç—‡åŒ…æ‹¬æ³Œå°¿é—®é¢˜ï¼ˆ22.6%ï¼‰ã€å»åˆå£æ¼ï¼ˆ11.4%ï¼‰ã€è‚ æ¢—é˜»ï¼ˆ10.4%ï¼‰å’Œå‡ºè¡€ï¼ˆ5.3%ï¼‰ã€‚éšè®¿æ•°æ®æ˜¾ç¤ºå¤å‘ç‡ä¸º24.9%ï¼Œ1å¹´ç”Ÿå­˜ç‡>90%ã€‚è¿™äº›ç ”ç©¶æŠ¥å‘Šçš„æ€»ä½“å¹¶å‘ç—‡ç‡ä¸º 49.7%ï¼Œä¸­ä½éšè®¿æ—¶é—´ä¸º 12-36 ä¸ªæœˆã€‚å°½ç®¡ç ”ç©¶ä¹‹é—´çš„ç”Ÿå­˜æ•°æ®å­˜åœ¨æ˜¾ç€å·®å¼‚ï¼Œä½†è‚¿ç˜¤å­¦ç»“æœè‰¯å¥½ã€‚ç ”ç©¶çš„å¼‚è´¨æ€§ä½¿å¾—æœ€ç»ˆç¡®å®šæœºå™¨äºº bTME ä½œä¸ºé»„é‡‘æ ‡å‡†çš„å¯è¡Œæ›¿ä»£æ–¹æ¡ˆå…·æœ‰æŒ‘æˆ˜æ€§ã€‚éœ€è¦è¿›ä¸€æ­¥çš„å‰ç»æ€§ç ”ç©¶ï¼Œå…·æœ‰å¯æµ‹é‡çš„ç»“æœå’Œä¸€è‡´çš„æœ¯è¯­ï¼Œä»¥ç¡®ä¿åŒè´¨æ€§ã€‚", "keywords_zh": "è‚›é—¨ç›´è‚ ç™Œã€å…¨ç›´è‚ ç³»è†œåˆ‡é™¤ä¹‹å¤–ã€å¾®åˆ›æ‰‹æœ¯ã€ç›†è…”å»“æ¸…æœ¯ã€æœºå™¨äººæ‰‹æœ¯", "keywords_en": "Anorectal cancer, Beyond total mesorectal excision, Minimally invasive surgery, Pelvic exenteration, Robotic surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40670732/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 16 Jul 2025"}, {"id": "40665575", "title_en": "Haemorrhoidal artery ligation: Is Doppler guidance useful? A systematic review and meta-analysis of randomized controlled trials", "title_zh": "ç—”åŠ¨è„‰ç»“æ‰ï¼šå¤šæ™®å‹’å¼•å¯¼æœ‰ç”¨å—ï¼Ÿéšæœºå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Gaetano Gallo", "abstract_en": "**Aim:** Haemorrhoidal arterial ligation (HAL) with or without mucopexy (recto-anal repair, RAR) is a minimally invasive technique for the treatment of haemorrhoidal disease. It is still debated if it should be performed with Doppler guidance (DG-HAL) or without. The primary aim of this study was to find evidence that the use of Doppler guidance reduces the risk of recurrence. The secondary aim was to evaluate the benefit of Doppler guidance on postoperative complications.\n\n**Methods:** A comprehensive literature search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (2020). The population, intervention, comparison, outcomes and study design (PICOS) framework was used for eligibility criteria. Data were extracted independently by two reviewers for initial screening and for eligibility to be included in the meta-analysis of randomized controlled trials. Random effects meta-analysis, leave-one-out meta-analysis and meta-regression were performed to assess the main outcomes.\n\n**Results:** Seven randomized controlled trials, published between 2008 and 2023, were selected. They included 514 patients (mean age 49.13â€‰years, 46% men) with different haemorrhoidal degrees. The HAL technique was performed in 255 patients and DG-HAL in 259 patients. The meta-analysis revealed that the DG-HAL procedure was associated with a significant risk of recurrence (Pâ€‰=â€‰0.007) and similar postoperative pain (Pâ€‰=â€‰0.623) compared to the HAL procedure. In a subgroup analysis of patients treated with a combined RAR procedure, no differences were found between the DG-HAL-RAR and HAL-RAR regarding the risk of recurrence (Pâ€‰=â€‰0.36) and postoperative pain (Pâ€‰=â€‰0.31).\n\n**Conclusion:** In conclusion, this meta-analysis did not find superiority of DG-HAL over HAL with or without RAR in reducing postoperative complications and recurrence.", "abstract_zh": "**Aimï¼š** ç—”åŠ¨è„‰ç»“æ‰ (HAL) è”åˆæˆ–ä¸è”åˆç²˜æ¶²å›ºå®šæœ¯ï¼ˆç›´è‚ è‚›é—¨ä¿®å¤æœ¯ï¼ŒRARï¼‰æ˜¯ä¸€ç§æ²»ç–—ç—”ç–®ç–¾ç—…çš„å¾®åˆ›æŠ€æœ¯ã€‚æ˜¯å¦åº”è¯¥ä½¿ç”¨å¤šæ™®å‹’å¼•å¯¼ (DG-HAL) æˆ–ä¸ä½¿ç”¨å¤šæ™®å‹’å¼•å¯¼è¿›è¡Œä»æœ‰äº‰è®®ã€‚æœ¬ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯å¯»æ‰¾è¯æ®è¯æ˜ä½¿ç”¨å¤šæ™®å‹’å¼•å¯¼å¯é™ä½å¤å‘é£é™©ã€‚ç¬¬äºŒä¸ªç›®çš„æ˜¯è¯„ä¼°å¤šæ™®å‹’å¼•å¯¼å¯¹æœ¯åå¹¶å‘ç—‡çš„ç›Šå¤„ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å— (2020) è¿›è¡Œäº†å…¨é¢çš„æ–‡çŒ®æ£€ç´¢ã€‚äººå£ã€å¹²é¢„ã€æ¯”è¾ƒã€ç»“æœå’Œç ”ç©¶è®¾è®¡ï¼ˆPICOSï¼‰æ¡†æ¶ç”¨äºèµ„æ ¼æ ‡å‡†ã€‚æ•°æ®ç”±ä¸¤åè¯„å®¡å‘˜ç‹¬ç«‹æå–ï¼Œç”¨äºåˆæ­¥ç­›é€‰å’Œçº³å…¥éšæœºå¯¹ç…§è¯•éªŒèŸèƒåˆ†æçš„èµ„æ ¼ã€‚è¿›è¡Œéšæœºæ•ˆåº”èŸèƒåˆ†æã€ç•™ä¸€èŸèƒåˆ†æå’ŒèŸèƒå›å½’æ¥è¯„ä¼°ä¸»è¦ç»“æœã€‚\n\n**ç»“æœï¼š** é€‰æ‹©äº† 2008 å¹´è‡³ 2023 å¹´é—´å‘è¡¨çš„ä¸ƒé¡¹éšæœºå¯¹ç…§è¯•éªŒã€‚ä»–ä»¬åŒ…æ‹¬ 514 åæ‚£æœ‰ä¸åŒç—”ç–®ç¨‹åº¦çš„æ‚£è€…ï¼ˆå¹³å‡å¹´é¾„ 49.13 å²ï¼Œ46% ä¸ºç”·æ€§ï¼‰ã€‚ 255 åæ‚£è€…æ¥å—äº† HAL æŠ€æœ¯ï¼Œ259 åæ‚£è€…æ¥å—äº† DG-HAL æŠ€æœ¯ã€‚èŸèƒåˆ†ææ˜¾ç¤ºï¼Œä¸ HAL æ‰‹æœ¯ç›¸æ¯”ï¼ŒDG-HAL æ‰‹æœ¯å…·æœ‰æ˜¾ç€çš„å¤å‘é£é™© (Pâ€‰=â€‰0.007) å’Œç›¸ä¼¼çš„æœ¯åç–¼ç—› (Pâ€‰=â€‰0.623)ã€‚åœ¨å¯¹è”åˆ RAR æ‰‹æœ¯æ²»ç–—çš„æ‚£è€…è¿›è¡Œçš„äºšç»„åˆ†æä¸­ï¼ŒDG-HAL-RAR å’Œ HAL-RAR åœ¨å¤å‘é£é™© (Pâ€‰=â€‰0.36) å’Œæœ¯åç–¼ç—› (Pâ€‰=â€‰0.31) æ–¹é¢æ²¡æœ‰å‘ç°å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** æ€»ä¹‹ï¼Œè¿™é¡¹èŸèƒåˆ†ææ²¡æœ‰å‘ç° DG-HAL åœ¨å‡å°‘æœ¯åå¹¶å‘ç—‡å’Œå¤å‘æ–¹é¢æ¯”æœ‰æˆ–æ²¡æœ‰ RAR çš„ HAL å…·æœ‰ä¼˜è¶Šæ€§ã€‚", "keywords_zh": "å¤šæ™®å‹’ã€ç—”ç–®ã€ç—”åŠ¨è„‰ç»“æ‰ã€ç—”è¡€ç®¡åŒ–ã€ç²˜æ¶²å›ºå®šæœ¯", "keywords_en": "Doppler, haemorrhoid, haemorrhoidal artery ligation, haemorrhoidal vascularization, mucopexy", "link": "https://pubmed.ncbi.nlm.nih.gov/40665575/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 16 Jul 2025"}, {"id": "40632066", "title_en": "Negative pressure wound therapy for colorectal incisions: a systematic review and meta-analysis of controlled trials", "title_zh": "ç»“ç›´è‚ åˆ‡å£è´Ÿå‹ä¼¤å£æ²»ç–—ï¼šå¯¹ç…§è¯•éªŒçš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Chiehfeng Chen", "abstract_en": "**Objective:** Negative pressure wound therapy (NPWT) has demonstrated promising results in reducing surgical site infection (SSI) rates following orthopaedic, vascular, cardiothoracic, plastic and abdominal surgery. The literature on use of NPWT on colorectal incisions is growing, with several randomised controlled trials (RCTs); however, findings have been inconsistent. This review evaluated the effectiveness and safety of NPWT for colorectal incisions in elective and emergency surgery.\n\n**Method:** The Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Cumulative Index to Nursing and Allied Health Literature, and ClinicalTrials.gov databases were searched for RCTs and non-RCTs comparing NPWT with standard of care.\n\n**Results:** A total of five RCTs and six non-RCTs were included (with a total number of patients 2193). NPWT significantly reduced the rate of infection in colorectal incisions (odds ratio (OR): 0.57; 95% confidence interval (CI): 0.41, 0.78; I<sup>2</sup>=14%; p<0.0005) and wound complications of the colorectal surgical incisions (OR: 0.33; 95% CI: 0.13, 0.88; I<sup>2</sup>=59%; p=0.03). NPWT also shortened the wound healing time by three days (mean difference: -2.98; 95% CI: -4.99, -0.97; I<sup>2</sup>=0%; p=0.004). Subgroup analysis revealed that NPWT conferred greater benefits on wounds resulting from life-threatening emergency surgery, and contaminated or dirty-infected wounds.\n\n**Conclusion:** The findings of this review showed that NPWT is an effective intervention for the closure of wounds in patients following colorectal surgery, and lead to a significant reduction in SSIs, overall wound complications, and mean complete wound healing time. It was particularly effective in emergency cases and in contaminated to dirty-infected wounds. Treatment options should be considered in terms of cost-benefits and adequate patient selection during shared decision-making.", "abstract_zh": "**ç›®çš„ï¼š** è´Ÿå‹ä¼¤å£æ²»ç–— (NPWT) åœ¨é™ä½éª¨ç§‘ã€è¡€ç®¡ã€å¿ƒèƒ¸ã€æ•´å½¢å’Œè…¹éƒ¨æ‰‹æœ¯åæ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ (SSI) ç‡æ–¹é¢å·²æ˜¾ç¤ºå‡ºè‰¯å¥½çš„æ•ˆæœã€‚å…³äºåœ¨ç»“ç›´è‚ åˆ‡å£ä¸Šä½¿ç”¨ NPWT çš„æ–‡çŒ®è¶Šæ¥è¶Šå¤šï¼Œå…¶ä¸­æœ‰å‡ é¡¹éšæœºå¯¹ç…§è¯•éªŒ (RCT)ï¼›ç„¶è€Œï¼Œè°ƒæŸ¥ç»“æœå¹¶ä¸ä¸€è‡´ã€‚æœ¬ç»¼è¿°è¯„ä¼°äº† NPWT åœ¨æ‹©æœŸå’Œæ€¥è¯Šæ‰‹æœ¯ä¸­ç»“ç›´è‚ åˆ‡å£çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**Methodï¼š** æ£€ç´¢äº† Cochrane å¯¹ç…§è¯•éªŒä¸­å¤®æ³¨å†Œåº“ã€PubMedã€EMBASEã€æŠ¤ç†å’Œè”åˆå¥åº·æ–‡çŒ®ç´¯ç§¯ç´¢å¼•ä»¥åŠ ClinicalTrials.gov æ•°æ®åº“ï¼Œä»¥æŸ¥æ‰¾æ¯”è¾ƒ NPWT ä¸æ ‡å‡†æŠ¤ç†çš„éšæœºå¯¹ç…§è¯•éªŒå’Œééšæœºå¯¹ç…§è¯•éªŒã€‚\n\n**ç»“æœï¼š** å…±çº³å…¥ 5 é¡¹éšæœºå¯¹ç…§è¯•éªŒå’Œ 6 é¡¹ééšæœºå¯¹ç…§è¯•éªŒï¼ˆæ‚£è€…æ€»æ•° 2193 ä¾‹ï¼‰ã€‚ NPWTæ˜¾ç€é™ä½ç»“ç›´è‚ åˆ‡å£æ„ŸæŸ“ç‡ï¼ˆæ¯”å€¼æ¯”ï¼ˆORï¼‰ï¼š0.57ï¼›95%ç½®ä¿¡åŒºé—´ï¼ˆCIï¼‰ï¼š0.41ï¼Œ0.78ï¼›I<sup>2</sup>=14%ï¼›p<0.0005ï¼‰å’Œç»“ç›´è‚ æ‰‹æœ¯åˆ‡å£ä¼¤å£å¹¶å‘ç—‡ï¼ˆORï¼š0.33ï¼›95% CIï¼š0.13ï¼Œ0.88ï¼›95% CIï¼š0.13ï¼Œ0.88ï¼›p<0.0005ï¼‰ã€‚ I<sup>2</sup>=59%ï¼›p=0.03ï¼‰ã€‚ NPWT è¿˜å°†ä¼¤å£æ„ˆåˆæ—¶é—´ç¼©çŸ­äº†ä¸‰å¤©ï¼ˆå¹³å‡å·®ï¼š-2.98ï¼›95% CIï¼š-4.99ï¼Œ-0.97ï¼›I<sup>2</sup>=0%ï¼›p=0.004ï¼‰ã€‚äºšç»„åˆ†ææ˜¾ç¤ºï¼ŒNPWT å¯¹å±åŠç”Ÿå‘½çš„ç´§æ€¥æ‰‹æœ¯é€ æˆçš„ä¼¤å£ä»¥åŠæ±¡æŸ“æˆ–è„æ„ŸæŸ“çš„ä¼¤å£å…·æœ‰æ›´å¤§çš„ç›Šå¤„ã€‚\n\n**ç»“è®ºï¼š** æœ¬æ¬¡ç»¼è¿°çš„ç»“æœè¡¨æ˜ï¼ŒNPWT æ˜¯ç»“ç›´è‚ æ‰‹æœ¯åæ‚£è€…ä¼¤å£é—­åˆçš„æœ‰æ•ˆå¹²é¢„æªæ–½ï¼Œå¯æ˜¾ç€å‡å°‘ SSIã€æ€»ä½“ä¼¤å£å¹¶å‘ç—‡å’Œå¹³å‡ä¼¤å£å®Œå…¨æ„ˆåˆæ—¶é—´ã€‚å®ƒåœ¨ç´§æ€¥æƒ…å†µå’Œæ±¡æŸ“åˆ°è„æ„ŸæŸ“çš„ä¼¤å£ä¸­ç‰¹åˆ«æœ‰æ•ˆã€‚åœ¨å…±åŒå†³ç­–è¿‡ç¨‹ä¸­ï¼Œåº”æ ¹æ®æˆæœ¬æ•ˆç›Šå’Œå……åˆ†çš„æ‚£è€…é€‰æ‹©æ¥è€ƒè™‘æ²»ç–—æ–¹æ¡ˆã€‚", "keywords_zh": "ç»“ç›´è‚ æ‰‹æœ¯ã€èŸèƒåˆ†æã€è´Ÿå‹ä¼¤å£æ²»ç–—ã€æ‰‹æœ¯åˆ‡å£ã€æ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ã€ç³»ç»Ÿè¯„ä»·ã€ä¼¤å£ã€ä¼¤å£æŠ¤ç†ã€ä¼¤å£æ•·æ–™ã€ä¼¤å£æ„ˆåˆ", "keywords_en": "colorectal surgery, meta-analysis, negative pressure wound therapy, surgical incision, surgical site infection, systematic review, wound, wound care, wound dressing, wound healing", "link": "https://pubmed.ncbi.nlm.nih.gov/40632066/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 09 Jul 2025"}, {"id": "40624403", "title_en": "Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations", "title_zh": "èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–—ç—”ç–®ç–¾ç—…çš„çœŸå®åº”ç”¨ï¼šå›½é™…è°ƒæŸ¥å’Œç³»ç»Ÿè¯„ä»·ä»¥åŠä¸´åºŠå®è·µå»ºè®®çš„è§è§£", "authors": "Azka Mustaan", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40624403/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 07 Jul 2025"}, {"id": "40596934", "title_en": "Comparison of efficacy and safety between surgical and conservative treatments for hemorrhoids: a meta-analysis", "title_zh": "æ‰‹æœ¯æ²»ç–—å’Œä¿å®ˆæ²»ç–—ç—”ç–®çš„ç–—æ•ˆå’Œå®‰å…¨æ€§æ¯”è¾ƒï¼šä¸€é¡¹èŸèƒåˆ†æ", "authors": "Xiaoqiang Jia", "abstract_en": "**Objectives:** Hemorrhoids, a common anorectal condition, can be managed through surgical or conservative treatments. The aim of this meta-analysis is to compare the efficacy and safety of surgical and conservative treatments for hemorrhoids.\n\n**Methods:** A systematic search was conducted from of PubMed, Embase, the Cochrane Library, and Web of Science from their inception to September 25, 2024. Eligible studies compared surgical treatments with non-invasive conservative treatments in hemorrhoids. Statistical analyses included pooled odds ratios (ORs) and mean differences (MDs)/standard mean differences (SMDs) with 95% confidence intervals (CIs).\n\n**Results:** Seven studies, including 760 patients, were analyzed. Surgery achieved higher rates of complete symptom resolution than conservative therapy (ORâ€‰=â€‰2.96, 95% CI: 1.66-5.28, pâ€‰<â€‰0.001). Overall pain scores favored surgery (SMD = -0.93, 95% CI: 1.73 to -0.13, pâ€‰=â€‰0.02). Subgroup analysis showed clear superiority within four days (SMD = -1.26, 95% CI -1.84 to -0.68) but parity beyond ten days (SMDâ€‰=â€‰0.00, 95% CI -0.44 to 0.44; pâ€‰=â€‰0.99). Comparable patterns were observed in pregnant women with thrombosed external hemorrhoids. Rates of postoperative bleeding (OR: 1.09; 95% CI: 0.42 to 2.82, pâ€‰=â€‰0.86; I2â€‰=â€‰41%, pâ€‰=â€‰0.15) and urinary retention (OR: 1.75; 95% CI: 0.30 to 10.31, pâ€‰=â€‰0.54; I2â€‰=â€‰45%, pâ€‰=â€‰0.18) did not differ significantly between groups. Surgical-specific adverse events were infrequent (incontinence 3%, persistent pain 5%, watery discharge 6%). Surgery shortened recovery in pregnant thrombosed cases by approximately seven days (MD: -6.80; 95% CI: -7.64 to -5.96, pâ€‰<â€‰0.001; I2â€‰=â€‰55%, pâ€‰=â€‰0.14) and reduced overall recurrence (95% CI: 0.10 to 0.37, pâ€‰<â€‰0.001; I2â€‰=â€‰0%, pâ€‰=â€‰0.97).\n\n**Conclusion:** Surgical treatments provide superior symptom relief, faster recovery, and lower recurrence but with some specific post-treatment complications, while conservative treatments are safer and less invasive but with provides slower symptom relief and higher recurrence rates. Individualized treatment should consider symptom severity, patient preferences, and risk tolerance.", "abstract_zh": "**Objectivesï¼š** ç—”ç–®æ˜¯ä¸€ç§å¸¸è§çš„è‚›é—¨ç›´è‚ ç–¾ç—…ï¼Œå¯ä»¥é€šè¿‡æ‰‹æœ¯æˆ–ä¿å®ˆæ²»ç–—æ¥æ²»ç–—ã€‚è¿™é¡¹èŸèƒåˆ†æçš„ç›®çš„æ˜¯æ¯”è¾ƒæ‰‹æœ¯æ²»ç–—å’Œä¿å®ˆæ²»ç–—ç—”ç–®çš„ç–—æ•ˆå’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** å¯¹ PubMedã€Embaseã€Cochrane å›¾ä¹¦é¦†å’Œ Web of Science ä»æˆç«‹åˆ° 2024 å¹´ 9 æœˆ 25 æ—¥æœŸé—´è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶æ¯”è¾ƒäº†ç—”ç–®çš„æ‰‹æœ¯æ²»ç–—ä¸éä¾µå…¥æ€§ä¿å®ˆæ²»ç–—ã€‚ç»Ÿè®¡åˆ†æåŒ…æ‹¬åˆå¹¶ä¼˜åŠ¿æ¯” (OR) å’Œå¹³å‡å·® (MD)/æ ‡å‡†å¹³å‡å·® (SMD)ï¼Œç½®ä¿¡åŒºé—´ (CI) ä¸º 95%ã€‚\n\n**ç»“æœï¼š** å¯¹ä¸ƒé¡¹ç ”ç©¶ï¼ˆåŒ…æ‹¬ 760 åæ‚£è€…ï¼‰è¿›è¡Œäº†åˆ†æã€‚æ‰‹æœ¯çš„ç—‡çŠ¶å®Œå…¨ç¼“è§£ç‡é«˜äºä¿å®ˆæ²»ç–—ï¼ˆORâ€‰=â€‰2.96ï¼Œ95% CIï¼š1.66-5.28ï¼Œpâ€‰<â€‰0.001ï¼‰ã€‚æ€»ä½“ç–¼ç—›è¯„åˆ†å€¾å‘äºæ‰‹æœ¯ï¼ˆSMD = -0.93ï¼Œ95% CIï¼š1.73 è‡³ -0.13ï¼Œpâ€‰=â€‰0.02ï¼‰ã€‚äºšç»„åˆ†ææ˜¾ç¤ºå››å¤©å†…å…·æœ‰æ˜æ˜¾ä¼˜åŠ¿ï¼ˆSMD = -1.26ï¼Œ95% CI -1.84 è‡³ -0.68ï¼‰ï¼Œä½†åå¤©ååˆ™å…·æœ‰åŒç­‰æ€§ï¼ˆSMDâ€‰=â€‰0.00ï¼Œ95% CI -0.44 è‡³ 0.44ï¼›pâ€‰=â€‰0.99ï¼‰ã€‚åœ¨æ‚£æœ‰è¡€æ “æ€§å¤–ç—”çš„å­•å¦‡ä¸­è§‚å¯Ÿåˆ°äº†ç±»ä¼¼çš„æ¨¡å¼ã€‚æœ¯åå‡ºè¡€ç‡ï¼ˆORï¼š1.09ï¼›95% CIï¼š0.42è‡³2.82ï¼Œpâ€‰=â€‰0.86ï¼›I2â€‰=â€‰41%ï¼Œpâ€‰=â€‰0.15ï¼‰å’Œå°¿æ½´ç•™ç‡ï¼ˆORï¼š1.75ï¼›95% CIï¼š0.30è‡³10.31ï¼Œpâ€‰=â€‰0.54ï¼› I2â€‰=â€‰45%ï¼Œpâ€‰=â€‰0.18ï¼‰ç»„é—´æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚æ‰‹æœ¯ç‰¹å¼‚æ€§ä¸è‰¯äº‹ä»¶å¹¶ä¸å¸¸è§ï¼ˆå¤±ç¦ 3%ã€æŒç»­æ€§ç–¼ç—› 5%ã€æ°´æ ·åˆ†æ³Œç‰© 6%ï¼‰ã€‚æ‰‹æœ¯ä½¿å¦Šå¨ è¡€æ “ç—…ä¾‹çš„æ¢å¤æ—¶é—´ç¼©çŸ­çº¦ 7 å¤©ï¼ˆMDï¼š-6.80ï¼›95% CIï¼š-7.64 è‡³ -5.96ï¼Œp<â€‰0.001ï¼›I2â€‰=â€‰55%ï¼Œpâ€‰=â€‰0.14ï¼‰ï¼Œå¹¶å‡å°‘æ€»ä½“å¤å‘ï¼ˆ95% CIï¼š0.10 è‡³ 0.37ï¼Œp<â€‰0.001ï¼›I2=â€‰55%ï¼Œpâ€‰=â€‰0.14ï¼‰ã€‚ I2â€‰=â€‰0%ï¼Œpâ€‰=â€‰0.97ï¼‰ã€‚\n\n**ç»“è®ºï¼š** æ‰‹æœ¯æ²»ç–—å¯æ˜¾ç€ç¼“è§£ç—‡çŠ¶ã€åŠ å¿«æ¢å¤é€Ÿåº¦å¹¶é™ä½å¤å‘ç‡ï¼Œä½†ä¼šå‡ºç°ä¸€äº›ç‰¹å®šçš„æ²»ç–—åå¹¶å‘ç—‡ï¼Œè€Œä¿å®ˆæ²»ç–—æ›´å®‰å…¨ä¸”ä¾µå…¥æ€§è¾ƒå°ï¼Œä½†ç—‡çŠ¶ç¼“è§£è¾ƒæ…¢ä¸”å¤å‘ç‡è¾ƒé«˜ã€‚ä¸ªä½“åŒ–æ²»ç–—åº”è€ƒè™‘ç—‡çŠ¶ä¸¥é‡ç¨‹åº¦ã€æ‚£è€…åå¥½å’Œé£é™©æ‰¿å—èƒ½åŠ›ã€‚", "keywords_zh": "ä¿å®ˆæ²»ç–—ã€ç—”ç–®ã€èŸèƒåˆ†æã€æ‰‹æœ¯æ²»ç–—", "keywords_en": "Conservative treatment, Hemorrhoids, Meta-Analysis, Surgical treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/40596934/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 02 Jul 2025"}, {"id": "40590873", "title_en": "Endoscopic Submucosal Dissection and Transanal Endoscopic Microsurgery in the Treatment of Rectal Neuroendocrine Tumors: Systematic Review and Meta-Analysis of the Observational Studies", "title_zh": "å†…é•œç²˜è†œä¸‹å‰¥ç¦»æœ¯å’Œç»è‚›é—¨å†…é•œæ˜¾å¾®æ‰‹æœ¯æ²»ç–—ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ï¼šè§‚å¯Ÿæ€§ç ”ç©¶çš„ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Andrzej BiaÅ‚ek", "abstract_en": "**Introduction:** Rectal neuroendocrine tumors (rNETs) are subepithelial lesions with potential of malignancy. Despite the guidelines recommending that rNETs measuring 10-20 mm should be removed either endoscopic submucosal dissection (ESD) or transanal endoscopic microsurgery (TEM), the management with these entities is still a clinical dilemma. We performed a meta-analysis to compare ESD and TEM regarding method effectiveness and safety in the treatment of rNETs.\n\n**Methods:** PubMed/MEDLINE/Embase/EBSCO/CINAHL was searched up for observational studies analyzing the efficacy and safety of both methods in the treatment of rNETs.\n\n**Results:** A total of 59 observational studies with a total of n = 2,804 participants were included. In a subgroup analysis, we demonstrated that the R0 resection rate was significantly ( P = 0.002) lower for ESD (rate: 0.854) than for TEM (0.924). The recurrence rate differed significantly ( P = 0.008); the lowest (event rate [ER] = 0.015) was found for ESD and the highest for TEM (ER = 0.035). The overall bleeding rate was 0.046 and perforation rate was 0.023 and no significant differences ( P = 0.274 for bleeding, P = 0.808 for perforation) were found by intervention type. The rate of other complications (wound dehiscence, soilage, incontinence, rectovaginal fistula, pelvic pain, retroperitoneal emphysema, coagulation syndrome) was significantly ( P = 0.000) higher for TEM (ER = 0.107) than ESD (ER = 0.013). We also included 4 comparative studies with 490 patients. Using random-effects analysis, we found that the risk ratio for R0 resection was approximately 10% lower for ESD. Our analysis showed significantly greater size ( P = 0.01) and follow-up ( P = 0.03) in the group treated with TEM.\n\n**Discussion:** The efficacy of TEM is higher than ESD with a higher risk of complications in this method. Lesions with a greater size are treated with TEM, and recurrence rate is greater for this procedure. Long follow-up is needed after the treatment of rNETs to detect the recurrence early.", "abstract_zh": "**ä»‹ç»ï¼š** ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ï¼ˆrNETï¼‰æ˜¯å…·æœ‰æ¶æ€§æ½œåŠ›çš„ä¸Šçš®ä¸‹ç—…å˜ã€‚å°½ç®¡æŒ‡å—å»ºè®®åº”é€šè¿‡å†…é•œç²˜è†œä¸‹å‰¥ç¦»æœ¯ (ESD) æˆ–ç»è‚›é—¨å†…é•œæ˜¾å¾®æ‰‹æœ¯ (TEM) åˆ‡é™¤ 10-20 æ¯«ç±³çš„ rNETï¼Œä½†è¿™äº›å®ä½“çš„æ²»ç–—ä»ç„¶æ˜¯ä¸€ä¸ªä¸´åºŠå›°å¢ƒã€‚æˆ‘ä»¬è¿›è¡Œäº†ä¸€é¡¹èŸèƒåˆ†æï¼Œä»¥æ¯”è¾ƒ ESD å’Œ TEM æ²»ç–— rNET çš„æ–¹æ³•æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº† PubMed/MEDLINE/Embase/EBSCO/CINAHL çš„è§‚å¯Ÿæ€§ç ”ç©¶ï¼Œåˆ†æè¿™ä¸¤ç§æ–¹æ³•æ²»ç–— rNET çš„æœ‰æ•ˆæ€§å’Œå®‰å…¨æ€§ã€‚\n\n**ç»“æœï¼š** å…±çº³å…¥ 59 é¡¹è§‚å¯Ÿæ€§ç ”ç©¶ï¼Œå…±æœ‰ 2,804 åå‚ä¸è€…ã€‚åœ¨äºšç»„åˆ†æä¸­ï¼Œæˆ‘ä»¬è¯æ˜ ESD çš„ R0 åˆ‡é™¤ç‡ï¼ˆæ¯”ç‡ï¼š0.854ï¼‰æ˜¾ç€ä½äº TEMï¼ˆ0.924ï¼‰ï¼ˆP = 0.002ï¼‰ã€‚å¤å‘ç‡å·®å¼‚æ˜¾ç€ï¼ˆP=0.008ï¼‰ï¼› ESD æœ€ä½ï¼ˆäº‹ä»¶ç‡ [ER] = 0.015ï¼‰ï¼ŒTEM æœ€é«˜ï¼ˆER = 0.035ï¼‰ã€‚æ€»å‡ºè¡€ç‡ä¸º0.046ï¼Œç©¿å­”ç‡ä¸º0.023ï¼Œä¸åŒå¹²é¢„ç±»å‹å·®å¼‚æ— ç»Ÿè®¡å­¦æ„ä¹‰ï¼ˆå‡ºè¡€P=0.274ï¼Œç©¿å­”P=0.808ï¼‰ã€‚ TEM (ER = 0.107) çš„å…¶ä»–å¹¶å‘ç—‡ï¼ˆä¼¤å£è£‚å¼€ã€æ±¡æ¸ã€å¤±ç¦ã€ç›´è‚ é˜´é“ç˜˜ã€éª¨ç›†ç–¼ç—›ã€è…¹è†œåæ°”è‚¿ã€å‡è¡€ç»¼åˆå¾ï¼‰å‘ç”Ÿç‡æ˜¾ç€é«˜äº ESD (ER = 0.013) (P = 0.000)ã€‚æˆ‘ä»¬è¿˜çº³å…¥äº† 4 é¡¹æ¯”è¾ƒç ”ç©¶ï¼Œæ¶‰åŠ 490 åæ‚£è€…ã€‚é€šè¿‡éšæœºæ•ˆåº”åˆ†æï¼Œæˆ‘ä»¬å‘ç° R0 åˆ‡é™¤çš„é£é™©æ¯” ESD å¤§çº¦ä½ 10%ã€‚æˆ‘ä»¬çš„åˆ†ææ˜¾ç¤ºï¼ŒTEM æ²»ç–—ç»„çš„ä½“å‹æ˜¾ç€å¢å¤§ (P = 0.01)ï¼Œéšè®¿æ—¶é—´ä¹Ÿæ˜æ˜¾å¢å¤§ (P = 0.03)ã€‚\n\n**è®¨è®ºï¼š** TEM çš„ç–—æ•ˆé«˜äº ESDï¼Œä½†è¯¥æ–¹æ³•å‡ºç°å¹¶å‘ç—‡çš„é£é™©è¾ƒé«˜ã€‚ç—…å˜å°ºå¯¸è¶Šå¤§ï¼Œåˆ™é‡‡ç”¨ TEM æ²»ç–—ï¼Œå¤å‘ç‡è¶Šé«˜ã€‚ rNET æ²»ç–—åéœ€è¦é•¿æœŸéšè®¿ï¼Œä»¥ä¾¿åŠæ—©å‘ç°å¤å‘æƒ…å†µã€‚", "keywords_zh": "ESDã€TEMã€rNETã€ç›´è‚ ç¥ç»å†…åˆ†æ³Œè‚¿ç˜¤ã€æ²»ç–—", "keywords_en": "ESD, TEM, rNETs, rectal neuroendocrine tumors, treatment", "link": "https://pubmed.ncbi.nlm.nih.gov/40590873/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 01 Jul 2025"}, {"id": "40576944", "title_en": "Operative versus nonoperative treatment of thrombosed external hemorrhoids: a systematic review and meta-analysis", "title_zh": "è¡€æ “æ€§å¤–ç—”çš„æ‰‹æœ¯ä¸éæ‰‹æœ¯æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Rachid Eduardo Noleto da Nobrega Oliveira", "abstract_en": "Thrombosed external hemorrhoids are a complication of hemorrhoids characterized by severe pain, swelling, and lump formation due to acute venous engorgement. Treatment options remain controversial, with limited evidence guiding the choice between surgical and conservative approaches. PubMed, Embase, and Cochrane Library databases were searched from inception to December 2024 to identify clinical trials comparing surgery with conservative treatment in thrombosed external hemorrhoids. Statistical analyses were performed using Review Manager 5.4.1 with a random-effects model. Heterogeneity was assessed using the I<sup>2</sup> test. We included six studies with a total of 851 patients, of whom 390 (45.8%) underwent surgical treatment. Surgical treatment was associated with a lower risk of recurrence compared to conservative management (RR 0.49; 95% CI 0.26-0.91; Pâ€‰<â€‰0.05; I<sup>2</sup>â€‰=â€‰54%). However, there were no significant differences in the risk of bleeding between the groups (RR 0.96; 95% CI 0.27-3.44; Pâ€‰=â€‰0.95; I<sup>2</sup>â€‰=â€‰60%). Subgroup analyses of the excision surgery group revealed no differences between approaches. Our main findings indicated no significant difference in bleeding between surgery and conservative treatment groups. However, operative management is associated with significantly lower recurrences, which should be the preferred choice.", "abstract_zh": "è¡€æ “æ€§å¤–ç—”æ˜¯ç—”ç–®çš„ä¸€ç§å¹¶å‘ç—‡ï¼Œå…¶ç‰¹å¾æ˜¯ç”±äºæ€¥æ€§é™è„‰å……è¡€è€Œå¯¼è‡´å‰§çƒˆç–¼ç—›ã€è‚¿èƒ€å’Œè‚¿å—å½¢æˆã€‚æ²»ç–—é€‰æ‹©ä»ç„¶å­˜åœ¨äº‰è®®ï¼ŒæŒ‡å¯¼æ‰‹æœ¯å’Œä¿å®ˆæ²»ç–—ä¹‹é—´é€‰æ‹©çš„è¯æ®æœ‰é™ã€‚å¯¹ PubMedã€Embase å’Œ Cochrane å›¾ä¹¦é¦†æ•°æ®åº“è¿›è¡Œäº†æ£€ç´¢ï¼Œä»æœ€åˆåˆ° 2024 å¹´ 12 æœˆï¼Œä»¥è¯†åˆ«æ¯”è¾ƒæ‰‹æœ¯ä¸ä¿å®ˆæ²»ç–—è¡€æ “æ€§å¤–ç—”çš„ä¸´åºŠè¯•éªŒã€‚ä½¿ç”¨ Review Manager 5.4.1 å’Œéšæœºæ•ˆåº”æ¨¡å‹è¿›è¡Œç»Ÿè®¡åˆ†æã€‚ä½¿ç”¨ I<sup>2</sup> æ£€éªŒè¯„ä¼°å¼‚è´¨æ€§ã€‚æˆ‘ä»¬çº³å…¥äº† 6 é¡¹ç ”ç©¶ï¼Œå…± 851 åæ‚£è€…ï¼Œå…¶ä¸­ 390 å (45.8%) æ¥å—äº†æ‰‹æœ¯æ²»ç–—ã€‚ä¸ä¿å®ˆæ²»ç–—ç›¸æ¯”ï¼Œæ‰‹æœ¯æ²»ç–—çš„å¤å‘é£é™©è¾ƒä½ï¼ˆRR 0.49ï¼›95% CI 0.26-0.91ï¼›Pâ€‰<â€‰0.05ï¼›I<sup>2</sup>â€‰=â€‰54%ï¼‰ã€‚ç„¶è€Œï¼Œå„ç»„ä¹‹é—´çš„å‡ºè¡€é£é™©æ²¡æœ‰æ˜¾ç€å·®å¼‚ï¼ˆRR 0.96ï¼›95% CI 0.27-3.44ï¼›Pâ€‰=â€‰0.95ï¼›I<sup>2</sup>â€‰=â€‰60%ï¼‰ã€‚åˆ‡é™¤æ‰‹æœ¯ç»„çš„äºšç»„åˆ†ææ˜¾ç¤ºæ–¹æ³•ä¹‹é—´æ²¡æœ‰å·®å¼‚ã€‚æˆ‘ä»¬çš„ä¸»è¦å‘ç°è¡¨æ˜æ‰‹æœ¯æ²»ç–—ç»„å’Œä¿å®ˆæ²»ç–—ç»„ä¹‹é—´çš„å‡ºè¡€æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚ç„¶è€Œï¼Œæ‰‹æœ¯æ²»ç–—å¯æ˜¾ç€é™ä½å¤å‘ç‡ï¼Œè¿™åº”è¯¥æ˜¯é¦–é€‰ã€‚", "keywords_zh": "ç—”ç–®ï¼Œéæ‰‹æœ¯æ€§ï¼Œæ‰‹æœ¯æ€§ï¼Œå¤å‘", "keywords_en": "Hemorrhoids, Nonoperative, Operative, Recurrence", "link": "https://pubmed.ncbi.nlm.nih.gov/40576944/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 27 Jun 2025"}, {"id": "40548987", "title_en": "Robotic surgery in anorectal malformations: Where are we? A systematic review", "title_zh": "è‚›é—¨ç›´è‚ ç•¸å½¢çš„æœºå™¨äººæ‰‹æœ¯ï¼šæˆ‘ä»¬åœ¨å“ªé‡Œï¼Ÿç³»ç»Ÿå›é¡¾", "authors": "Giovanna Riccipetitoni", "abstract_en": "Robotic surgery has emerged as a promising technique in pediatric colorectal surgery, offering enhanced precision, superior ergonomics, and potentially improved outcomes compared to conventional laparoscopic and open approaches. This systematic review aimed to evaluate the current literature on robotic-assisted surgery for anorectal malformations (ARMs) in pediatric patients. A comprehensive search of PubMed, Web of Science, and the Cochrane Library was conducted for studies published between 2000 and 2025, focusing on robotic procedures in infants with ARMs. Eight studies met the inclusion criteria, reporting on a total of 39 patients (male-to-female ratio 15:0.5), with a median age at surgery of 6.9Â months. The most frequent ARM types were recto-prostatic, recto-bulbar, and recto-vesical fistulas. Median operative time was 226.3Â min, and median length of hospital stay was 5.5Â days. No intraoperative or early postoperative complications were observed, while late complications occurred in 18% of cases. Only one study included a comparative analysis with laparoscopic-assisted PSARP, precluding meta-analysis. Robotic-assisted anorectoplasty appears to be a safe and feasible approach, particularly advantageous for nerve-sparing pelvic dissection. However, further high-quality studies are necessary to define indications, evaluate long-term functional outcomes, and compare this technique with conventional surgical approaches.", "abstract_zh": "æœºå™¨äººæ‰‹æœ¯å·²æˆä¸ºå„¿ç§‘ç»“ç›´è‚ æ‰‹æœ¯ä¸­ä¸€é¡¹æœ‰å‰æ™¯çš„æŠ€æœ¯ï¼Œä¸ä¼ ç»Ÿçš„è…¹è…”é•œå’Œå¼€æ”¾æ‰‹æœ¯ç›¸æ¯”ï¼Œå®ƒå…·æœ‰æ›´é«˜çš„ç²¾ç¡®åº¦ã€å“è¶Šçš„äººä½“å·¥ç¨‹å­¦è®¾è®¡ä»¥åŠæ½œåœ¨çš„æ”¹å–„ç»“æœã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨è¯„ä¼°ç›®å‰å…³äºå„¿ç«¥æ‚£è€…è‚›é—¨ç›´è‚ ç•¸å½¢ (ARM) æœºå™¨äººè¾…åŠ©æ‰‹æœ¯çš„æ–‡çŒ®ã€‚å¯¹ PubMedã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†å¯¹ 2000 å¹´è‡³ 2025 å¹´é—´å‘è¡¨çš„ç ”ç©¶è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œé‡ç‚¹å…³æ³¨ ARM å©´å„¿çš„æœºå™¨äººæ‰‹æœ¯ã€‚å…«é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ï¼Œå…±æŠ¥å‘Šäº† 39 åæ‚£è€…ï¼ˆç”·å¥³æ¯”ä¾‹ 15:0.5ï¼‰ï¼Œæ‰‹æœ¯æ—¶çš„ä¸­ä½å¹´é¾„ä¸º 6.9 ä¸ªæœˆã€‚æœ€å¸¸è§çš„ ARM ç±»å‹æ˜¯ç›´è‚ å‰åˆ—è…ºç˜˜ã€ç›´è‚ çƒç˜˜å’Œç›´è‚ è†€èƒ±ç˜˜ã€‚ä¸­ä½æ‰‹æœ¯æ—¶é—´ä¸º 226.3 åˆ†é’Ÿï¼Œä¸­ä½ä½é™¢æ—¶é—´ä¸º 5.5 å¤©ã€‚æœªè§‚å¯Ÿåˆ°æœ¯ä¸­æˆ–æœ¯åæ—©æœŸå¹¶å‘ç—‡ï¼Œè€Œ18%çš„ç—…ä¾‹å‡ºç°æ™šæœŸå¹¶å‘ç—‡ã€‚åªæœ‰ä¸€é¡¹ç ”ç©¶åŒ…æ‹¬ä¸è…¹è…”é•œè¾…åŠ© PSARP çš„æ¯”è¾ƒåˆ†æï¼Œæ’é™¤äº†èŸèƒåˆ†æã€‚æœºå™¨äººè¾…åŠ©è‚›é—¨ç›´è‚ æˆå½¢æœ¯ä¼¼ä¹æ˜¯ä¸€ç§å®‰å…¨å¯è¡Œçš„æ–¹æ³•ï¼Œç‰¹åˆ«æœ‰åˆ©äºä¿ç•™ç¥ç»çš„ç›†è…”è§£å‰–ã€‚ç„¶è€Œï¼Œéœ€è¦è¿›ä¸€æ­¥çš„é«˜è´¨é‡ç ”ç©¶æ¥å®šä¹‰é€‚åº”ç—‡ã€è¯„ä¼°é•¿æœŸåŠŸèƒ½ç»“æœå¹¶å°†è¯¥æŠ€æœ¯ä¸ä¼ ç»Ÿæ‰‹æœ¯æ–¹æ³•è¿›è¡Œæ¯”è¾ƒã€‚", "keywords_zh": "è‚›é—¨ç›´è‚ ç•¸å½¢ã€è‚›é—¨ç›´è‚ æˆå½¢æœ¯ã€æœºå™¨äººè¾…åŠ©æ‰‹æœ¯", "keywords_en": "Anorectal malformation, Anorectoplasty, Robotic-assisted surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40548987/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 23 Jun 2025"}, {"id": "40508850", "title_en": "Biopsychosocial Strategies for Alleviating Low Back Pain in Late Mothers: A Systematic Review", "title_zh": "ç¼“è§£å·²æ•…æ¯äº²è…°ç—›çš„ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šç­–ç•¥ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Mariola Bidzan", "abstract_en": "<b>Background:</b> Low back pain (LBP) in older mothers is a prevalent and multifaceted condition influenced by a range of biopsychosocial factors. As the trend of late motherhood increases globally, it is essential to understand how LBP affects this population from a biopsychosocial perspective. <b>Objective:</b> This systematic review aims to examine the biopsychosocial determinants of LBP in older mothers by synthesizing findings from quantitative studies published between January 2010 and May 2024. Specifically, it explores the biological, psychological, and social factors contributing to LBP in this population and how it affects their daily lives and well-being. <b>Methods:</b> A comprehensive literature search was conducted across PubMed, PsychInfo, Web of Science, EMBASE, DARE, and the Cochrane Library. Studies were screened for eligibility based on predefined criteria. Five quantitative studies with a combined sample of 118,964 participants were included. The methodological quality was assessed, and data were extracted for analysis. <b>Results:</b> All five studies addressed biological aspects of LBP, including pelvic girdle pain, hemorrhoids, and varicose veins. Three studies also explored psychological factors such as depression and stress. Two studies incorporated social dimensions, including inadequate support systems, occupational burdens, and healthcare access barriers. Age and parity were consistently reported as exacerbating physical and psychological symptoms. <b>Conclusions:</b> This review highlights the importance of considering biopsychosocial factors when managing LBP in older mothers. Tailored interventions, such as exercise programs, family support, and workplace accommodations, are essential for improving outcomes. Further research using longitudinal studies is needed to explore these factors in greater depth.", "abstract_zh": "<b>èƒŒæ™¯ï¼š</b>é«˜é¾„æ¯äº²çš„è…°ç—› (LBP) æ˜¯ä¸€ç§æ™®éå­˜åœ¨çš„å¤šæ–¹é¢ç–¾ç—…ï¼Œå—ä¸€ç³»åˆ—ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šå› ç´ çš„å½±å“ã€‚éšç€å…¨çƒæ™šå­•è¶‹åŠ¿çš„å¢åŠ ï¼Œæœ‰å¿…è¦ä»ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šè§’åº¦äº†è§£å…‰ä½“ç—›å¦‚ä½•å½±å“è¿™ä¸€äººç¾¤ã€‚ <b>ç›®çš„ï¼š</b>æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨é€šè¿‡ç»¼åˆ 2010 å¹´ 1 æœˆè‡³ 2024 å¹´ 5 æœˆæœŸé—´å‘è¡¨çš„å®šé‡ç ”ç©¶ç»“æœï¼Œæ¢è®¨è€å¹´æ¯äº² LBP çš„ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šå†³å®šå› ç´ ã€‚å…·ä½“è€Œè¨€ï¼Œå®ƒæ¢è®¨äº†å¯¼è‡´è¯¥äººç¾¤ LBP çš„ç”Ÿç‰©ã€å¿ƒç†å’Œç¤¾ä¼šå› ç´ ï¼Œä»¥åŠå®ƒå¦‚ä½•å½±å“å¥¹ä»¬çš„æ—¥å¸¸ç”Ÿæ´»å’Œç¦ç¥‰ã€‚ <b>æ–¹æ³•ï¼š</b>åœ¨ PubMedã€PsychInfoã€Web of Scienceã€EMBASEã€DARE å’Œ Cochrane å›¾ä¹¦é¦†è¿›è¡Œäº†å…¨é¢çš„æ–‡çŒ®æ£€ç´¢ã€‚æ ¹æ®é¢„å…ˆå®šä¹‰çš„æ ‡å‡†ç­›é€‰ç ”ç©¶èµ„æ ¼ã€‚å…¶ä¸­åŒ…æ‹¬äº”é¡¹å®šé‡ç ”ç©¶ï¼Œåˆå¹¶æ ·æœ¬ä¸º 118,964 åå‚ä¸è€…ã€‚è¯„ä¼°æ–¹æ³•å­¦è´¨é‡ï¼Œå¹¶æå–æ•°æ®è¿›è¡Œåˆ†æã€‚ <b>ç»“æœï¼š</b>æ‰€æœ‰äº”é¡¹ç ”ç©¶éƒ½æ¶‰åŠ LBP çš„ç”Ÿç‰©å­¦æ–¹é¢ï¼ŒåŒ…æ‹¬éª¨ç›†å¸¦ç–¼ç—›ã€ç—”ç–®å’Œé™è„‰æ›²å¼ ã€‚ä¸‰é¡¹ç ”ç©¶è¿˜æ¢è®¨äº†æŠ‘éƒå’Œå‹åŠ›ç­‰å¿ƒç†å› ç´ ã€‚ä¸¤é¡¹ç ”ç©¶çº³å…¥äº†ç¤¾ä¼šå±‚é¢ï¼ŒåŒ…æ‹¬æ”¯æŒç³»ç»Ÿä¸è¶³ã€èŒä¸šè´Ÿæ‹…å’ŒåŒ»ç–—ä¿å¥è·å–éšœç¢ã€‚æ®ä¸€è‡´æŠ¥é“ï¼Œå¹´é¾„å’Œèƒæ¬¡ä¼šåŠ å‰§èº«ä½“å’Œå¿ƒç†ç—‡çŠ¶ã€‚ <b>ç»“è®ºï¼š</b>æœ¬ç»¼è¿°å¼ºè°ƒäº†åœ¨ç®¡ç†é«˜é¾„æ¯äº²è…°ç—›æ—¶è€ƒè™‘ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šå› ç´ çš„é‡è¦æ€§ã€‚é‡èº«å®šåˆ¶çš„å¹²é¢„æªæ–½ï¼Œä¾‹å¦‚é”»ç‚¼è®¡åˆ’ã€å®¶åº­æ”¯æŒå’Œå·¥ä½œåœºæ‰€ä½å®¿ï¼Œå¯¹äºæ”¹å–„ç»“æœè‡³å…³é‡è¦ã€‚éœ€è¦ä½¿ç”¨çºµå‘ç ”ç©¶è¿›è¡Œè¿›ä¸€æ­¥ç ”ç©¶ï¼Œä»¥æ›´æ·±å…¥åœ°æ¢è®¨è¿™äº›å› ç´ ã€‚", "keywords_zh": "ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šå› ç´ ã€ç”Ÿç‰©å¿ƒç†ç¤¾ä¼šæ¨¡å‹ã€è…°ç—›ã€é«˜é¾„æ¯äº²", "keywords_en": "biopsychosocial factors, biopsychosocial model, low back pain, older mothers", "link": "https://pubmed.ncbi.nlm.nih.gov/40508850/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 13 Jun 2025"}, {"id": "40501157", "title_en": "The median sacral artery and its surgical anatomy in pelvic and spinal surgery: a systematic review and meta-analysis", "title_zh": "éª¶æ­£ä¸­åŠ¨è„‰åŠå…¶åœ¨ç›†è…”å’Œè„ŠæŸ±æ‰‹æœ¯ä¸­çš„æ‰‹æœ¯è§£å‰–ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "PrzemysÅ‚aw PÄ™kala", "abstract_en": "**Background:** The median sacral artery (MSA) is a small but clinically significant artery arising from the aortic bifurcation and traveling along the anterior sacrum. It supplies the lumbar and sacral vertebrae and, in some cases, parts of the rectum. Despite its size, the MSA is crucial in regional circulation and is particularly relevant in spinal, pelvic, and vascular surgeries. This meta-analysis aims to provide a comprehensive synthesis of anatomical evidence regarding the MSA's origin, variations, and surgical relevance.\n\n**Materials And Methods:** A systematic search was conducted in major databases (PubMed, Embase, ScienceDirect, Scopus, Web of Science, and SciELO) until January 2025. Studies reporting anatomical data on the MSA, including its origin, variations, and clinical significance, were included. A total of 13 studies (n = 1,007 arteries) met the criteria.\n\n**Results:** The MSA originated directly from the aorta in 89.98% (95% CI: 84.05%-95.92%) of cases. In 8.27% (95% CI: 3.29%-13.25%), it shared a common origin with a lumbar artery, typically the 4th lumbar artery (97.86%). The 5th lumbar artery variation was rare (0.66%). Regarding its position relative to the sacral midline, the MSA was found on the left (48.80%), right (31.32%), or directly along the midline (13.35%). The mean distance from the midline was 3.54 mm.\n\n**Conclusions:** Recognizing MSA variations is essential for surgical planning to prevent vascular injury during spinal and gynecological procedures. Further cadaveric and imaging studies are needed to enhance procedural safety.", "abstract_zh": "**èƒŒæ™¯ï¼š** éª¶æ­£ä¸­åŠ¨è„‰ (MSA) æ˜¯ä¸€æ¡å°ä½†å…·æœ‰ä¸´åºŠæ„ä¹‰çš„åŠ¨è„‰ï¼Œèµ·æºäºä¸»åŠ¨è„‰åˆ†å‰å¹¶æ²¿éª¶å‰éƒ¨è¡Œè¿›ã€‚å®ƒä¾›åº”è…°æ¤å’Œéª¶æ¤ï¼Œåœ¨æŸäº›æƒ…å†µä¸‹ï¼Œä¾›åº”éƒ¨åˆ†ç›´è‚ ã€‚å°½ç®¡ MSA å¾ˆå¤§ï¼Œä½†å®ƒå¯¹å±€éƒ¨å¾ªç¯è‡³å…³é‡è¦ï¼Œå°¤å…¶ä¸è„ŠæŸ±ã€éª¨ç›†å’Œè¡€ç®¡æ‰‹æœ¯ç›¸å…³ã€‚è¿™é¡¹èŸèƒåˆ†ææ—¨åœ¨æä¾›æœ‰å…³ MSA èµ·æºã€å˜å¼‚å’Œæ‰‹æœ¯ç›¸å…³æ€§çš„è§£å‰–å­¦è¯æ®çš„å…¨é¢ç»¼åˆã€‚\n\n**ææ–™ä¸æ–¹æ³•ï¼š** æˆªè‡³ 2025 å¹´ 1 æœˆï¼Œæˆ‘ä»¬åœ¨ä¸»è¦æ•°æ®åº“ï¼ˆPubMedã€Embaseã€ScienceDirectã€Scopusã€Web of Science å’Œ SciELOï¼‰ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚å…¶ä¸­åŒ…æ‹¬æŠ¥å‘Š MSA è§£å‰–æ•°æ®çš„ç ”ç©¶ï¼ŒåŒ…æ‹¬å…¶èµ·æºã€å˜å¼‚å’Œä¸´åºŠæ„ä¹‰ã€‚å…±æœ‰ 13 é¡¹ç ”ç©¶ï¼ˆn = 1,007 æ¡åŠ¨è„‰ï¼‰ç¬¦åˆæ ‡å‡†ã€‚\n\n**ç»“æœï¼š** 89.98% (95% CI: 84.05%-95.92%) çš„ç—…ä¾‹ä¸­ MSA ç›´æ¥èµ·æºäºä¸»åŠ¨è„‰ã€‚ 8.27%ï¼ˆ95% CIï¼š3.29%-13.25%ï¼‰çš„æ‚£è€…ä¸è…°åŠ¨è„‰æœ‰å…±åŒèµ·æºï¼Œé€šå¸¸æ˜¯ç¬¬å››è…°åŠ¨è„‰ï¼ˆ97.86%ï¼‰ã€‚ç¬¬5è…°åŠ¨è„‰å˜å¼‚ç½•è§ï¼ˆ0.66%ï¼‰ã€‚å°±å…¶ç›¸å¯¹äºéª¶éª¨ä¸­çº¿çš„ä½ç½®è€Œè¨€ï¼ŒMSAä½äºå·¦ä¾§ï¼ˆ48.80%ï¼‰ã€å³ä¾§ï¼ˆ31.32%ï¼‰æˆ–ç›´æ¥æ²¿ç€ä¸­çº¿ï¼ˆ13.35%ï¼‰ã€‚è·ä¸­çº¿çš„å¹³å‡è·ç¦»ä¸º 3.54 æ¯«ç±³ã€‚\n\n**ç»“è®ºï¼š** è®¤è¯† MSA å˜åŒ–å¯¹äºæ‰‹æœ¯è§„åˆ’è‡³å…³é‡è¦ï¼Œä»¥é˜²æ­¢è„ŠæŸ±å’Œå¦‡ç§‘æ‰‹æœ¯æœŸé—´å‘ç”Ÿè¡€ç®¡æŸä¼¤ã€‚éœ€è¦è¿›ä¸€æ­¥çš„å°¸ä½“å’Œæˆåƒç ”ç©¶ä»¥æé«˜æ‰‹æœ¯å®‰å…¨æ€§ã€‚", "keywords_zh": "è§£å‰–å˜å¼‚ã€ä¸´åºŠè§£å‰–å­¦ã€éª¶æ­£ä¸­åŠ¨è„‰ã€èŸèƒåˆ†æã€ç›†è…”è¡€ç®¡åŒ–ã€éª¶éª¨", "keywords_en": "anatomic variations, clinical anatomy, median sacral artery, meta-analysis, pelvic vascularization, sacrum", "link": "https://pubmed.ncbi.nlm.nih.gov/40501157/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 12 Jun 2025"}, {"id": "40500490", "title_en": "Indocyanine green and height of anastomosis in colorectal surgery- a network meta-analysis", "title_zh": "å²å“šèç»¿ä¸ç»“ç›´è‚ æ‰‹æœ¯å»åˆé«˜åº¦çš„ç½‘ç»œèŸèƒåˆ†æ", "authors": "James Wei-Tatt Toh", "abstract_en": "**Purpose:** Anastomotic leak is a potentially life-threatening complication of colorectal surgery, with perfusion and height of anastomoses considered important risk factors. Indocyanine green (ICG) is commonly used in fluorescence angiography (FA) for perfusion assessment though techniques vary. This is a network meta-analysis comparing use of ICG-FA and height of anastomosis for left sided colorectal anastomoses and rates of anastomotic leak.\n\n**Methods:** A systematic review was performed including all adult clinical studies using ICG-FA in colorectal anastomoses. A network meta-analysis was performed to compare high and low anterior resections and the use of ICG for the outcome of anastomotic leak.\n\n**Results:** Of some 333 studies retrieved during review, 31 studies were included, totalling 6431 patients. In a meta-analysis to compare high and low anterior resection, with and without ICG, odds of anastomotic leak were greater in low compared to high anastomoses, and ICG is protective in both, OR of 0.38 (0.20-0.73) for high and OR of 0.41 (0.30-0.54) in low anastomoses, with ICG compared to without.\n\n**Conclusion:** There is benefit of ICG for both HAR and LAR in reducing anastomotic leak. While there is no consensus on the application, dosage and timing of ICG during anterior resection, pooled results and most studies have shown that the use of ICG to check for tissue perfusion of anastomosis reduces leak. ICG should be considered as part of a surgeon's armamentarium for intraoperative anastomotic check to reduce the risk of postoperative anastomotic leak.", "abstract_zh": "**Purposeï¼š** å»åˆå£ç˜˜æ˜¯ç»“ç›´è‚ æ‰‹æœ¯çš„ä¸€ç§æ½œåœ¨å±åŠç”Ÿå‘½çš„å¹¶å‘ç—‡ï¼ŒçŒæ³¨å’Œå»åˆå£é«˜åº¦è¢«è®¤ä¸ºæ˜¯é‡è¦çš„å±é™©å› ç´ ã€‚å°½ç®¡æŠ€æœ¯å„å¼‚ï¼Œå²å“šèç»¿ (ICG) é€šå¸¸ç”¨äºè§å…‰è¡€ç®¡é€ å½± (FA) ä¸­è¿›è¡ŒçŒæ³¨è¯„ä¼°ã€‚è¿™æ˜¯ä¸€é¡¹ç½‘ç»œèŸèƒåˆ†æï¼Œæ¯”è¾ƒäº†å·¦ä¾§ç»“ç›´è‚ å»åˆæœ¯ä¸­ ICG-FA çš„ä½¿ç”¨å’Œå»åˆé«˜åº¦ä»¥åŠå»åˆå£æ¼ç‡ã€‚\n\n**æ–¹æ³•ï¼š** è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼ŒåŒ…æ‹¬åœ¨ç»“ç›´è‚ å»åˆæœ¯ä¸­ä½¿ç”¨ ICG-FA çš„æ‰€æœ‰æˆäººä¸´åºŠç ”ç©¶ã€‚è¿›è¡Œäº†ç½‘ç»œèŸèƒåˆ†ææ¥æ¯”è¾ƒé«˜ä½å’Œä½ä½å‰åˆ‡é™¤æœ¯ä»¥åŠ ICG å¯¹å»åˆå£ç˜˜ç»“æœçš„ä½¿ç”¨ã€‚\n\n**ç»“æœï¼š** åœ¨å®¡æŸ¥è¿‡ç¨‹ä¸­æ£€ç´¢åˆ°çš„çº¦ 333 é¡¹ç ”ç©¶ä¸­ï¼Œçº³å…¥äº† 31 é¡¹ç ”ç©¶ï¼Œå…±è®¡ 6431 åæ‚£è€…ã€‚åœ¨ä¸€é¡¹æ¯”è¾ƒé«˜ä½å’Œä½ä½å‰åˆ‡é™¤æœ¯ï¼ˆæœ‰å’Œæ²¡æœ‰ ICGï¼‰çš„èŸèƒåˆ†æä¸­ï¼Œä¸é«˜ä½å»åˆç›¸æ¯”ï¼Œä½ä½å»åˆæœ¯å‘ç”Ÿå»åˆå£æ¼çš„å‡ ç‡æ›´å¤§ï¼Œå¹¶ä¸” ICG å¯¹ä¸¤ç§æƒ…å†µéƒ½æœ‰ä¿æŠ¤ä½œç”¨ï¼Œæœ‰ ICG ä¸æ—  ICG ç›¸æ¯”ï¼Œé«˜ä½å»åˆçš„ OR ä¸º 0.38ï¼ˆ0.20-0.73ï¼‰ï¼Œä½ä½å»åˆçš„ OR ä¸º 0.41ï¼ˆ0.30-0.54ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ICG å¯¹äº HAR å’Œ LAR éƒ½æœ‰åˆ©äºå‡å°‘å»åˆå£ç˜˜ã€‚è™½ç„¶å¯¹äºå‰åˆ‡é™¤æœ¯ä¸­ ICG çš„åº”ç”¨ã€å‰‚é‡å’Œæ—¶æœºå°šæœªè¾¾æˆå…±è¯†ï¼Œä½†æ±‡æ€»ç»“æœå’Œå¤§å¤šæ•°ç ”ç©¶è¡¨æ˜ï¼Œä½¿ç”¨ ICG æ£€æŸ¥å»åˆå£çš„ç»„ç»‡çŒæ³¨å¯å‡å°‘æ¸—æ¼ã€‚ ICG åº”è¢«è§†ä¸ºå¤–ç§‘åŒ»ç”Ÿæœ¯ä¸­å»åˆå£æ£€æŸ¥è£…å¤‡çš„ä¸€éƒ¨åˆ†ï¼Œä»¥é™ä½æœ¯åå»åˆå£ç˜˜çš„é£é™©ã€‚", "keywords_zh": "å»åˆå£æ¼ã€ç»“ç›´è‚ å»åˆæœ¯ã€é«˜ä½å‰åˆ‡é™¤æœ¯ã€å²å“šé’ç»¿ã€ä½ä½å‰åˆ‡é™¤æœ¯", "keywords_en": "Anastomotic leak, Colorectal anastomosis, High anterior resection, Indocyanine green, Low anterior resection", "link": "https://pubmed.ncbi.nlm.nih.gov/40500490/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 11 Jun 2025"}, {"id": "40493094", "title_en": "Limitations of the Goligher classification in randomized trials for hemorrhoidal disease: a qualitative systematic review of selection criteria", "title_zh": "ç—”ç–®ç–¾ç—…éšæœºè¯•éªŒä¸­ Goligher åˆ†ç±»çš„å±€é™æ€§ï¼šé€‰æ‹©æ ‡å‡†çš„å®šæ€§ç³»ç»Ÿè¯„ä»·", "authors": "G Gallo", "abstract_en": "**Background:** The diverse range of therapeutic options for hemorrhoidal disease (HD) highlights the need for precise classification systems to guide treatment. Although the Goligher classification remains the most widely used, it has been criticized for its simplicity and limited ability to capture symptom severity or guide treatment decisions. This study aims to evaluate the patient selection criteria and classification systems employed in randomized controlled trials (RCTs) for HD.\n\n**Methods:** A systematic review was conducted following the 2020 PRISMA guidelines. A comprehensive search of databases identified randomized controlled trials (RCTs) comparing treatments for HD, focusing on classification systems used for patient enrollment. Eligible studies included adult patients and at least one arm involving surgical treatment.\n\n**Results:** Out of 6692 records, 162 studies met the inclusion criteria, with a median cohort size of 84 patients and 55.4% male. Most studies (86.4%) used the Goligher system, though the majority did not fully describe or cite the system. Only 13.6% of studies employed more recent alternative classification systems. The most common outcome measures across studies were postoperative pain (147 studies) and complications (133 studies). Recurrence rates were reported in 42% of studies, yet 70% of these did not provide adequate inclusion criteria or references to Goligher's classification.\n\n**Conclusions:** The inconsistent application of the Goligher classification and the variability in patient selection criteria across RCTs highlight the need for more nuanced and standardized systems. Future research should focus on refining classification methods and incorporating patient-reported outcomes to improve the reliability and relevance of HD trials.\n\n**Prospero Registration:** CRD42023387339.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç—”ç–®ç–¾ç—… (HD) çš„æ²»ç–—é€‰æ‹©å¤šç§å¤šæ ·ï¼Œå‡¸æ˜¾äº†éœ€è¦ç²¾ç¡®çš„åˆ†ç±»ç³»ç»Ÿæ¥æŒ‡å¯¼æ²»ç–—ã€‚å°½ç®¡ Goligher åˆ†ç±»ä»ç„¶æ˜¯ä½¿ç”¨æœ€å¹¿æ³›çš„åˆ†ç±»ï¼Œä½†å®ƒå› å…¶ç®€å•æ€§å’Œæ•æ‰ç—‡çŠ¶ä¸¥é‡ç¨‹åº¦æˆ–æŒ‡å¯¼æ²»ç–—å†³ç­–çš„èƒ½åŠ›æœ‰é™è€Œå—åˆ°æ‰¹è¯„ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼° HD éšæœºå¯¹ç…§è¯•éªŒ (RCT) ä¸­é‡‡ç”¨çš„æ‚£è€…é€‰æ‹©æ ‡å‡†å’Œåˆ†ç±»ç³»ç»Ÿã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ® 2020 å¹´ PRISMA æŒ‡å—è¿›è¡Œäº†ç³»ç»Ÿå®¡æŸ¥ã€‚å¯¹æ•°æ®åº“çš„å…¨é¢æ£€ç´¢ç¡®å®šäº†æ¯”è¾ƒ HD æ²»ç–—æ–¹æ³•çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ï¼Œé‡ç‚¹å…³æ³¨ç”¨äºæ‚£è€…å…¥ç»„çš„åˆ†ç±»ç³»ç»Ÿã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶åŒ…æ‹¬æˆå¹´æ‚£è€…å’Œè‡³å°‘ä¸€åªæ¶‰åŠæ‰‹æœ¯æ²»ç–—çš„æ‰‹è‡‚ã€‚\n\n**ç»“æœï¼š** åœ¨ 6692 é¡¹è®°å½•ä¸­ï¼Œæœ‰ 162 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ï¼Œé˜Ÿåˆ—è§„æ¨¡ä¸­ä½æ•°ä¸º 84 åæ‚£è€…ï¼Œå…¶ä¸­ 55.4% ä¸ºç”·æ€§ã€‚å¤§å¤šæ•°ç ”ç©¶ (86.4%) ä½¿ç”¨ Goligher ç³»ç»Ÿï¼Œå°½ç®¡å¤§å¤šæ•°ç ”ç©¶æ²¡æœ‰å®Œå…¨æè¿°æˆ–å¼•ç”¨è¯¥ç³»ç»Ÿã€‚åªæœ‰ 13.6% çš„ç ”ç©¶é‡‡ç”¨äº†æ›´æ–°çš„æ›¿ä»£åˆ†ç±»ç³»ç»Ÿã€‚ç ”ç©¶ä¸­æœ€å¸¸è§çš„ç»“æœæŒ‡æ ‡æ˜¯æœ¯åç–¼ç—›ï¼ˆ147 é¡¹ç ”ç©¶ï¼‰å’Œå¹¶å‘ç—‡ï¼ˆ133 é¡¹ç ”ç©¶ï¼‰ã€‚ 42% çš„ç ”ç©¶æŠ¥å‘Šäº†å¤å‘ç‡ï¼Œä½†å…¶ä¸­ 70% çš„ç ”ç©¶æ²¡æœ‰æä¾›è¶³å¤Ÿçš„çº³å…¥æ ‡å‡†æˆ–å¯¹ Goligher åˆ†ç±»çš„å‚è€ƒã€‚\n\n**ç»“è®ºï¼š** Goligher åˆ†ç±»çš„åº”ç”¨ä¸ä¸€è‡´ä»¥åŠéšæœºå¯¹ç…§è¯•éªŒä¸­æ‚£è€…é€‰æ‹©æ ‡å‡†çš„å¯å˜æ€§çªå‡ºè¡¨æ˜éœ€è¦æ›´ç»†è‡´å’Œæ ‡å‡†åŒ–çš„ç³»ç»Ÿã€‚æœªæ¥çš„ç ”ç©¶åº”ä¾§é‡äºå®Œå–„åˆ†ç±»æ–¹æ³•å¹¶çº³å…¥æ‚£è€…æŠ¥å‘Šçš„ç»“æœï¼Œä»¥æé«˜ HD è¯•éªŒçš„å¯é æ€§å’Œç›¸å…³æ€§ã€‚\n\n**Prospero registrationï¼š** CRD42023387339ã€‚", "keywords_zh": "åˆ†ç±»ç³»ç»Ÿã€Goligher åˆ†ç±»ã€ç—”ç–®ç–¾ç—…ã€ç—”ç–®ã€æ‚£è€…é€‰æ‹©ã€éšæœºå¯¹ç…§è¯•éªŒ", "keywords_en": "Classification systems, Goligher classification, Hemorrhoidal disease, Hemorrhoids, Patient selection, Randomized controlled trials", "link": "https://pubmed.ncbi.nlm.nih.gov/40493094/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 10 Jun 2025"}, {"id": "40481245", "title_en": "Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations", "title_zh": "èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–—ç—”ç–®ç–¾ç—…çš„çœŸå®åº”ç”¨ï¼šå›½é™…è°ƒæŸ¥å’Œç³»ç»Ÿè¯„ä»·ä»¥åŠä¸´åºŠå®è·µå»ºè®®çš„è§è§£", "authors": "Gianpiero Gravante", "abstract_en": "Polidocanol foam sclerotherapy has gained increasing attention as a minimally invasive treatment for hemorrhoidal disease (HD). However, significant variability exists in its clinical application regarding patient selection, procedural techniques, and postoperative management. This study aimed to assess real-world practice patterns among international experts, summarize existing evidence through a systematic literature review, and develop evidence-based clinical practice recommendations. A systematic review was conducted in MEDLINE, EMBASE, and CENTRAL to identify studies evaluating polidocanol foam sclerotherapy for HD. A total of 20 studies met the inclusion criteria. Additionally, an international survey was distributed to 30 experts in proctology and colorectal surgery to explore variations in indications, perioperative management, technique, and follow-up. Survey responses were analyzed descriptively to identify common trends and areas of divergence. Subsequently, based on both the experts' opinions and the results of the survey, a Delphi method was employed to produce clinical practice recommendations. The questions for the Delphi process were developed by the authors leading the project, followed by a detailed discussion with the whole panel of experts. Most experts (90%) reported using polidocanol foam sclerotherapy primarily for Goligher grade II HD, with 67% extending its use to grade III cases. Preoperative bowel preparation and anesthesia use varied widely. The preferred concentration was 3% polidocanol, with 2Â mL injected per hemorrhoidal pile in most cases. Post-procedural care lacked standardization, though stool softeners and flavonoids were commonly recommended. Compared to rubber band ligation, polidocanol foam was perceived as having higher success rates (88.3% vs. 66.7%) and lower recurrence rates (16.1% vs. 41.2%). Adverse events were infrequent. The present article offers a comprehensive suite of clinical practice expert-based recommendations concerning the use of polidocanol foam sclerotherapy for HD. However, there is still significant variation in its application. These findings highlight the need for standardized guidelines and further research to optimize procedural strategies and long-term outcomes.", "abstract_zh": "èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•ä½œä¸ºç—”ç–®ç–¾ç—…ï¼ˆHDï¼‰çš„å¾®åˆ›æ²»ç–—æ–¹æ³•è¶Šæ¥è¶Šå—åˆ°å…³æ³¨ã€‚ç„¶è€Œï¼Œå…¶ä¸´åºŠåº”ç”¨åœ¨æ‚£è€…é€‰æ‹©ã€æ‰‹æœ¯æŠ€æœ¯å’Œæœ¯åç®¡ç†æ–¹é¢å­˜åœ¨æ˜¾ç€å·®å¼‚ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¯„ä¼°å›½é™…ä¸“å®¶çš„çœŸå®å®è·µæ¨¡å¼ï¼Œé€šè¿‡ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°æ€»ç»“ç°æœ‰è¯æ®ï¼Œå¹¶åˆ¶å®šåŸºäºè¯æ®çš„ä¸´åºŠå®è·µå»ºè®®ã€‚ MEDLINEã€EMBASE å’Œ CENTRAL è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼Œä»¥ç¡®å®šè¯„ä¼°èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–— HD çš„ç ”ç©¶ã€‚å…±æœ‰ 20 é¡¹ç ”ç©¶ç¬¦åˆçº³å…¥æ ‡å‡†ã€‚æ­¤å¤–ï¼Œè¿˜å‘ 30 åç›´è‚ ç—…å­¦å’Œç»“ç›´è‚ å¤–ç§‘ä¸“å®¶è¿›è¡Œäº†ä¸€é¡¹å›½é™…è°ƒæŸ¥ï¼Œä»¥æ¢è®¨é€‚åº”ç—‡ã€å›´æ‰‹æœ¯æœŸç®¡ç†ã€æŠ€æœ¯å’Œéšè®¿æ–¹é¢çš„å·®å¼‚ã€‚å¯¹è°ƒæŸ¥å›å¤è¿›è¡Œæè¿°æ€§åˆ†æï¼Œä»¥ç¡®å®šå…±åŒè¶‹åŠ¿å’Œåˆ†æ­§é¢†åŸŸã€‚éšåï¼Œæ ¹æ®ä¸“å®¶æ„è§å’Œè°ƒæŸ¥ç»“æœï¼Œé‡‡ç”¨å¾·å°”è²æ³•æå‡ºä¸´åºŠå®è·µå»ºè®®ã€‚å¾·å°”è²æµç¨‹çš„é—®é¢˜æ˜¯ç”±é¢†å¯¼è¯¥é¡¹ç›®çš„ä½œè€…æå‡ºçš„ï¼Œç„¶åä¸æ•´ä¸ªä¸“å®¶å°ç»„è¿›è¡Œäº†è¯¦ç»†è®¨è®ºã€‚å¤§å¤šæ•°ä¸“å®¶ (90%) æŠ¥å‘Šä¸»è¦ä½¿ç”¨èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–— Goligher II çº§ HDï¼Œå…¶ä¸­ 67% å°†å…¶ä½¿ç”¨èŒƒå›´æ‰©å¤§åˆ° III çº§ç—…ä¾‹ã€‚æœ¯å‰è‚ é“å‡†å¤‡å’Œéº»é†‰ä½¿ç”¨å·®å¼‚å¾ˆå¤§ã€‚é¦–é€‰æµ“åº¦æ˜¯ 3% èšå¤šå¡é†‡ï¼Œå¤§å¤šæ•°æƒ…å†µä¸‹æ¯ä¸ªç—”ç–®æ³¨å°„ 2 mLã€‚å°½ç®¡é€šå¸¸æ¨èä½¿ç”¨å¤§ä¾¿è½¯åŒ–å‰‚å’Œç±»é»„é…®ï¼Œä½†æœ¯åæŠ¤ç†ç¼ºä¹æ ‡å‡†åŒ–ã€‚ä¸æ©¡çš®ç­‹ç»“æ‰ç›¸æ¯”ï¼Œèšå¤šå¡é†‡æ³¡æ²«è¢«è®¤ä¸ºå…·æœ‰æ›´é«˜çš„æˆåŠŸç‡ï¼ˆ88.3% vs. 66.7%ï¼‰å’Œè¾ƒä½çš„å¤å‘ç‡ï¼ˆ16.1% vs. 41.2%ï¼‰ã€‚ä¸è‰¯äº‹ä»¶å¾ˆå°‘å‘ç”Ÿã€‚æœ¬æ–‡æä¾›äº†ä¸€å¥—åŸºäºä¸´åºŠå®è·µä¸“å®¶çš„å…¨é¢å»ºè®®ï¼Œæ¶‰åŠä½¿ç”¨èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•æ²»ç–— HDã€‚ç„¶è€Œï¼Œå…¶åº”ç”¨ä»ç„¶å­˜åœ¨æ˜¾ç€å·®å¼‚ã€‚è¿™äº›å‘ç°å¼ºè°ƒéœ€è¦æ ‡å‡†åŒ–æŒ‡å—å’Œè¿›ä¸€æ­¥ç ”ç©¶æ¥ä¼˜åŒ–ç¨‹åºç­–ç•¥å’Œé•¿æœŸç»“æœã€‚", "keywords_zh": "ä¸“å®¶è°ƒæŸ¥ã€ç—”ç–®ç–¾ç—…ã€èšå¤šå¡é†‡æ³¡æ²«ã€ç¡¬åŒ–ç–—æ³•ã€ç³»ç»Ÿè¯„ä»·", "keywords_en": "Expert survey, Hemorrhoidal disease, Polidocanol foam, Sclerotherapy, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40481245/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 06 Jun 2025"}, {"id": "40461025", "title_en": "Comparison of endoscopic vacuum therapy with standard care for colorectal anastomotic leakage: a systematic review and meta-analysis", "title_zh": "å†…é•œè´Ÿå‹æ²»ç–—ä¸ç»“ç›´è‚ å»åˆå£ç˜˜æ ‡å‡†æŠ¤ç†çš„æ¯”è¾ƒï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Yunhong Tian", "abstract_en": "This systematic review and meta-analysis aimed to evaluate the effectiveness of endoscopic vacuum therapy (EVT) compared with standard care in managing colorectal anastomotic leakage, a serious complication following colorectal surgery.We conducted a literature search across PubMed, Embase, and the Cochrane Library for clinical studies published before October 2024 that compared the outcomes of EVT and standard care for anastomotic leakage, including leakage resolution rates, treatment duration, hospital stay duration, or postoperative complications. The pooled estimates of risk ratio (RR) or mean difference were primarily derived using a fixed-effects model, with a random-effects model used when high heterogeneity was detected.The analysis included six observational studies (273 patients). EVT was associated with a significantly higher resolution rate compared with standard care (RR 1.18, 95%CI 1.03 to 1.35; <i>P</i> = 0.02). Treatment duration was significantly shorter in the EVT group (mean difference -30.6 days, 95%CI -43.5 to -17.7; <i>P</i> < 0.001), while hospital stay duration showed no significant difference between EVT and standard care (mean difference 1.7 days, 95%CI -4.2 to 7.7; <i>P</i> = 0.57). No statistically significant difference was found in the rate of treatment-related complications between EVT and standard care (RR 1.17, 95%CI 0.52 to 2.80; <i>P</i> = 0.71).This meta-analysis suggests that EVT has superior effectiveness in terms of leakage resolution rates, as well as a shorter treatment duration compared with standard care for colorectal anastomotic leakage. This study is however constrained by the lack of prospective data, the risk of selection bias, and heterogeneity, requiring cautious interpretation of the findings.PROSPERO registration: CRD 4873455814.", "abstract_zh": "è¿™é¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†ææ—¨åœ¨è¯„ä¼°å†…é•œçœŸç©ºæ²»ç–— (EVT) ä¸æ ‡å‡†æŠ¤ç†ç›¸æ¯”åœ¨å¤„ç†ç»“ç›´è‚ å»åˆå£ç˜˜ï¼ˆç»“ç›´è‚ æ‰‹æœ¯åçš„ä¸¥é‡å¹¶å‘ç—‡ï¼‰æ–¹é¢çš„æœ‰æ•ˆæ€§ã€‚æˆ‘ä»¬å¯¹ PubMedã€Embase å’Œ Cochrane å›¾ä¹¦é¦†è¿›è¡Œäº†æ–‡çŒ®æ£€ç´¢ï¼ŒæŸ¥æ‰¾ 2024 å¹´ 10 æœˆä¹‹å‰å‘è¡¨çš„ä¸´åºŠç ”ç©¶ï¼Œæ¯”è¾ƒ EVT å’Œæ ‡å‡†æŠ¤ç†å¯¹å»åˆå£ç˜˜çš„ç»“æœï¼ŒåŒ…æ‹¬æ³„æ¼è§£å†³ç‡ã€æ²»ç–—æŒç»­æ—¶é—´ã€ä½é™¢æ—¶é—´æˆ–æœ¯åå¹¶å‘ç—‡ã€‚é£é™©æ¯” (RR) æˆ–å¹³å‡å·®çš„æ±‡æ€»ä¼°è®¡å€¼ä¸»è¦ä½¿ç”¨å›ºå®šæ•ˆåº”æ¨¡å‹å¾—å‡ºï¼Œå½“æ£€æµ‹åˆ°é«˜åº¦å¼‚è´¨æ€§æ—¶ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹ã€‚è¯¥åˆ†æåŒ…æ‹¬å…­é¡¹è§‚å¯Ÿæ€§ç ”ç©¶ï¼ˆ273 åæ‚£è€…ï¼‰ã€‚ä¸æ ‡å‡†æŠ¤ç†ç›¸æ¯”ï¼ŒEVT çš„ç¼“è§£ç‡æ˜æ˜¾æ›´é«˜ï¼ˆRR 1.18ï¼Œ95% CI 1.03 è‡³ 1.35ï¼›<i>P</i> = 0.02ï¼‰ã€‚ EVT ç»„çš„æ²»ç–—æ—¶é—´æ˜¾ç€ç¼©çŸ­ï¼ˆå¹³å‡å·® -30.6 å¤©ï¼Œ95%CI -43.5 è‡³ -17.7ï¼›<i>P</i> < 0.001ï¼‰ï¼Œè€Œ EVT å’Œæ ‡å‡†æ²»ç–—ä¹‹é—´çš„ä½é™¢æ—¶é—´æ— æ˜¾ç€å·®å¼‚ï¼ˆå¹³å‡å·® 1.7 å¤©ï¼Œ95%CI -4.2 è‡³ -17.7ï¼›<i>P</i> = 0.57ï¼‰ã€‚ EVT å’Œæ ‡å‡†æŠ¤ç†ä¹‹é—´çš„æ²»ç–—ç›¸å…³å¹¶å‘ç—‡å‘ç”Ÿç‡æ²¡æœ‰æ˜¾ç€å·®å¼‚ï¼ˆRR 1.17ï¼Œ95%CI 0.52 è‡³ 2.80ï¼›<i>P</i> = 0.71ï¼‰ã€‚è¯¥èŸèƒåˆ†æè¡¨æ˜ï¼Œä¸ç»“ç›´è‚ å»åˆå£ç˜˜æ ‡å‡†æŠ¤ç†ç›¸æ¯”ï¼ŒEVT åœ¨æ¸—æ¼è§£å†³ç‡æ–¹é¢å…·æœ‰æ›´é«˜çš„æœ‰æ•ˆæ€§ï¼Œå¹¶ä¸”æ²»ç–—æŒç»­æ—¶é—´æ›´çŸ­ã€‚ç„¶è€Œï¼Œè¿™é¡¹ç ”ç©¶å—åˆ°ç¼ºä¹å‰ç»æ€§æ•°æ®ã€é€‰æ‹©åå€šé£é™©å’Œå¼‚è´¨æ€§çš„é™åˆ¶ï¼Œéœ€è¦å¯¹ç ”ç©¶ç»“æœè¿›è¡Œè°¨æ…è§£é‡Šã€‚PROSPERO æ³¨å†Œï¼šCRD 4873455814ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40461025/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 03 Jun 2025"}, {"id": "40456210", "title_en": "Transmission of gonorrhea from the oral cavity to the rectal tract: A systematic review", "title_zh": "æ·‹ç—…ä»å£è…”ä¼ æ’­åˆ°ç›´è‚ ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Mabel Miluska Suca Salas", "abstract_en": "BackgroundThe antimicrobial resistance of Neisseria gonorrhoeae and the high prevalence of asymptomatic extragenital infections are a worldwide concern. This research investigated whether gonorrhea can be transmitted from the oral cavity to the anorectal tract among men who have sex with men.<b>Purpose</b>The aim of this research is to find plausible relationships regarding the probability of gonococcal transmission from the oral cavity to the anorectal tract among MSM.<b>Research Design</b>A research question was defined using the P.I.C.O. strategy (population, intervention or exposure, comparison and outcome), where the target population is MSM, the intervention is exposure to contaminated oral cavity/saliva, the control is the absence of exposure, and the outcome is the acquisition of GC. The eligibility criteria included observational studies involving men who have sex with men, regardless of sexual orientation, aged 16 or older, screened for oropharyngeal and rectal gonorrhea, and examining the role of oral fluids in transmission. Studies involving partners previously diagnosed with urogenital gonorrhea or reporting consistent condom use during receptive penoanal sex were excluded to avoid urethral-to-anorectal transmission bias.<b>Study Sample</b>The databases employed were PubMed, Scopus, Web of Science, EBSCO, SciELO, and the Virtual Health Library (VHL). A total of 383 studies were identified, however, only 6 were included.<b>Data Collection and/or Analysis</b>According to the Newcastle-Ottawa Scale (NOS), two studies were \"very good,\" two \"good,\" and two \"satisfactory\". Most studies described a complete methodology according to Strengthening the Reporting of Observational studies in Epidemiology (STROBE).<b>Results</b>Differences in diagnostic methods, methodologies, and variables limited the findings. While the results do not confirm transmission from the oral cavity to the anorectal tract, they suggest its possibility. Further research is needed to better understand this transmission route.<b>Conclusions</b>Transmissibility of gonorrhea from oropharyngeal via to the anorectal tract cannot be totally establish. However, evidence suggested the existence of this gonorrhea transmission. The fact that men with rectal gonorrhea continue to appear, even in contexts of condom use or the absence of receptive penoanal sex, brings the importance of cases monitoring and the establishment of preventive strategies.", "abstract_zh": "èƒŒæ™¯æ·‹ç—…å¥ˆç‘ŸèŒçš„æŠ—èŒè¯ç‰©è€è¯æ€§å’Œæ— ç—‡çŠ¶ç”Ÿæ®–å™¨å¤–æ„ŸæŸ“çš„é«˜æ‚£ç—…ç‡æ˜¯å…¨ä¸–ç•Œå…³æ³¨çš„é—®é¢˜ã€‚æœ¬ç ”ç©¶è°ƒæŸ¥äº†ç”·ç”·æ€§è¡Œä¸ºè€…ä¸­æ·‹ç—…æ˜¯å¦å¯ä»¥ä»å£è…”ä¼ æ’­åˆ°è‚›é—¨ç›´è‚ ã€‚<b>ç›®çš„</b>æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯å¯»æ‰¾ MSM ä¸­æ·‹çƒèŒä»å£è…”ä¼ æ’­åˆ°è‚›é—¨ç›´è‚ çš„æ¦‚ç‡ä¹‹é—´çš„åˆç†å…³ç³»ã€‚<b>ç ”ç©¶è®¾è®¡</b>ä½¿ç”¨ P.I.C.O. å®šä¹‰äº†ä¸€ä¸ªç ”ç©¶é—®é¢˜ã€‚ç­–ç•¥ï¼ˆäººç¾¤ã€å¹²é¢„æˆ–æš´éœ²ã€æ¯”è¾ƒå’Œç»“æœï¼‰ï¼Œå…¶ä¸­ç›®æ ‡äººç¾¤æ˜¯ MSMï¼Œå¹²é¢„æ˜¯æš´éœ²äºå—æ±¡æŸ“çš„å£è…”/å”¾æ¶²ï¼Œå¯¹ç…§æ˜¯ä¸å­˜åœ¨æš´éœ²ï¼Œç»“æœæ˜¯ GC çš„è·å¾—ã€‚èµ„æ ¼æ ‡å‡†åŒ…æ‹¬å¯¹å¹´é¾„åœ¨ 16 å²æˆ–ä»¥ä¸Šçš„ç”·ç”·æ€§è¡Œä¸ºè€…ï¼ˆæ— è®ºæ€§å–å‘å¦‚ä½•ï¼‰è¿›è¡Œè§‚å¯Ÿæ€§ç ”ç©¶ï¼Œç­›æŸ¥å£å’½å’Œç›´è‚ æ·‹ç—…ï¼Œå¹¶æ£€æŸ¥å£è…”æ¶²ä½“åœ¨ä¼ æ’­ä¸­çš„ä½œç”¨ã€‚æ¶‰åŠå…ˆå‰è¯Šæ–­ä¸ºæ³Œå°¿ç”Ÿæ®–æ·‹ç—…æˆ–æŠ¥å‘Šåœ¨æ¥å—æ€§è‚›äº¤æœŸé—´æŒç»­ä½¿ç”¨å®‰å…¨å¥—çš„ç ”ç©¶è¢«æ’é™¤ï¼Œä»¥é¿å…å°¿é“åˆ°è‚›é—¨ç›´è‚ ä¼ æ’­åå·®ã€‚<b>ç ”ç©¶æ ·æœ¬</b>ä½¿ç”¨çš„æ•°æ®åº“åŒ…æ‹¬ PubMedã€Scopusã€Web of Scienceã€EBSCOã€SciELO å’Œè™šæ‹Ÿå¥åº·å›¾ä¹¦é¦† (VHL)ã€‚æ€»å…±ç¡®å®šäº† 383 é¡¹ç ”ç©¶ï¼Œä½†ä»…çº³å…¥ 6 é¡¹ã€‚<b>æ•°æ®æ”¶é›†å’Œ/æˆ–åˆ†æ</b>æ ¹æ®çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨ (NOS)ï¼Œä¸¤é¡¹ç ”ç©¶ä¸ºâ€œéå¸¸å¥½â€ï¼Œä¸¤é¡¹ä¸ºâ€œè‰¯å¥½â€ï¼Œä¸¤é¡¹ä¸ºâ€œä»¤äººæ»¡æ„â€ã€‚å¤§å¤šæ•°ç ”ç©¶æ ¹æ®åŠ å¼ºæµè¡Œç—…å­¦è§‚å¯Ÿç ”ç©¶æŠ¥å‘Š (STROBE) æè¿°äº†å®Œæ•´çš„æ–¹æ³•ã€‚<b>ç»“æœ</b>è¯Šæ–­æ–¹æ³•ã€æ–¹æ³•å’Œå˜é‡çš„å·®å¼‚é™åˆ¶äº†ç ”ç©¶ç»“æœã€‚è™½ç„¶ç»“æœå¹¶æœªè¯å®ä»å£è…”ä¼ æ’­åˆ°è‚›é—¨ç›´è‚ ï¼Œä½†è¡¨æ˜äº†å…¶å¯èƒ½æ€§ã€‚éœ€è¦è¿›ä¸€æ­¥ç ”ç©¶ä»¥æ›´å¥½åœ°äº†è§£è¿™ç§ä¼ æ’­é€”å¾„ã€‚<b>ç»“è®º</b>æ·‹ç—…ä»å£å’½åˆ°è‚›é—¨ç›´è‚ çš„ä¼ æ’­èƒ½åŠ›å°šä¸èƒ½å®Œå…¨ç¡®å®šã€‚ç„¶è€Œï¼Œæœ‰è¯æ®è¡¨æ˜å­˜åœ¨è¿™ç§æ·‹ç—…ä¼ æ’­ã€‚å³ä½¿åœ¨ä½¿ç”¨å®‰å…¨å¥—æˆ–ç¼ºä¹æ¥å—æ€§äº¤çš„æƒ…å†µä¸‹ï¼Œæ‚£æœ‰ç›´è‚ æ·‹ç—…çš„ç”·æ€§ä»ç„¶ä¸æ–­å‡ºç°ï¼Œè¿™ä¸€äº‹å®å‡¸æ˜¾äº†ç—…ä¾‹ç›‘æµ‹å’Œåˆ¶å®šé¢„é˜²ç­–ç•¥çš„é‡è¦æ€§ã€‚", "keywords_zh": "å£è…”ã€æ·‹ç—…ã€ç›´è‚ ã€æ€§å°‘æ•°å’Œæ€§åˆ«å°‘æ•°ã€æ€§ä¼ æ’­ç–¾ç—…", "keywords_en": "Mouth, gonorrhoea, rectum, sexual and gender minorities, sexually transmitted diseases", "link": "https://pubmed.ncbi.nlm.nih.gov/40456210/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 02 Jun 2025"}, {"id": "40434549", "title_en": "A rare combination of hypogonadotropic hypogonadism, GH deficiency and rectal atresia in a female with an FGFR1 variant: a case report and systematic review of the literature", "title_zh": "å…·æœ‰ FGFR1 å˜å¼‚çš„å¥³æ€§ç½•è§åœ°å‡ºç°ä¿ƒæ€§è…ºæ¿€ç´ ä½ä¸‹æ€§æ€§è…ºåŠŸèƒ½å‡é€€ç—‡ã€ç”Ÿé•¿æ¿€ç´ ç¼ºä¹ç—‡å’Œç›´è‚ é—­é”ï¼šç—…ä¾‹æŠ¥å‘Šå’Œæ–‡çŒ®ç³»ç»Ÿå›é¡¾", "authors": "George Mastorakos", "abstract_en": "**Purpose:** To report a case with combined pituitary hormone deficiency (CPHD) and Fibroblast growth factor receptor 1 (FGFR1) gene defect, and summarize the clinical characteristics of similar cases by reviewing the current reports from the literature.\n\n**Methods:** A 24-year-old woman was admitted to the outpatient endocrinology unit with a diagnosis of primary amenorrhea, history of Growth Hormone deficiency and multiple congenital anomalies including rectal atresia. The subsequent hormonal investigation led to the diagnosis of hypogonadotropic hypogonadism and persistent GH deficiency. Abdominal and pelvic ultrasounds were normal whereas the brain MRI revealed a hypoplastic sella turcica with a hypoplastic anterior pituitary lobe, an ectopic posterior pituitary lobe and a thin pituitary stalk. The genetic analysis revealed a novel pathogenic missense heterozygous variant (c.1958Gâ€‰>â€‰A, p.Agr635Gln) in exon 15 of FGFR1 gene. PubMed, Scopus, and Web of Science were searched for the identification of studies reporting cases of CPHD with FGFR1 gene defects.\n\n**Results:** Of the 648 records retrieved, 10 were included in this review. A comprehensive overview of the cases was summarized, and their clinical and genetic characteristics were presented.\n\n**Conclusion:** Although FGFR1 variants have been associated with Kallmann syndrome and isolated hypogonadotropic hypogonadism and recently with CPHD, the patient's phenotype includes phenotypic alterations not previously described, to the best of our knowledge, within the spectrum of non-reproductive features of either of these entities. Isolated GH deficiency combined with other non-common abnormalities exerts a great possibility for subsequent CPHD manifestation.", "abstract_zh": "**Purposeï¼š** æŠ¥å‘Š1ä¾‹åˆå¹¶å‚ä½“æ¿€ç´ ç¼ºä¹ç—‡ï¼ˆCPHDï¼‰å’Œæˆçº¤ç»´ç»†èƒç”Ÿé•¿å› å­å—ä½“1ï¼ˆFGFR1ï¼‰åŸºå› ç¼ºé™·çš„ç—…ä¾‹ï¼Œé€šè¿‡å›é¡¾ç°æœ‰æ–‡çŒ®æŠ¥é“ï¼Œæ€»ç»“åŒç±»ç—…ä¾‹çš„ä¸´åºŠç‰¹ç‚¹ã€‚\n\n**æ–¹æ³•ï¼š** ä¸€å 24 å²å¥³æ€§è¢«é€å¾€å†…åˆ†æ³Œç§‘é—¨è¯Šï¼Œè¯Šæ–­ä¸ºåŸå‘æ€§é—­ç»ã€ç”Ÿé•¿æ¿€ç´ ç¼ºä¹ç—…å²ä»¥åŠåŒ…æ‹¬ç›´è‚ é—­é”åœ¨å†…çš„å¤šç§å…ˆå¤©æ€§å¼‚å¸¸ã€‚éšåçš„æ¿€ç´ æ£€æŸ¥è¯Šæ–­ä¸ºä½ä¿ƒæ€§è…ºæ¿€ç´ æ€§æ€§è…ºåŠŸèƒ½å‡é€€ç—‡å’ŒæŒç»­æ€§ GH ç¼ºä¹ã€‚è…¹éƒ¨å’Œç›†è…”è¶…å£°æ£€æŸ¥æ­£å¸¸ï¼Œè€Œè„‘éƒ¨ MRI æ˜¾ç¤ºè¶éå‘è‚²ä¸è‰¯ï¼Œå‚ä½“å‰å¶å‘è‚²ä¸è‰¯ã€å¼‚ä½å‚ä½“åå¶å’Œç»†å‚ä½“æŸ„ã€‚é—ä¼ åˆ†ææ­ç¤ºäº† FGFR1 åŸºå› ç¬¬ 15 å·å¤–æ˜¾å­ä¸­å­˜åœ¨ä¸€ç§æ–°çš„è‡´ç—…æ€§é”™ä¹‰æ‚åˆå˜å¼‚ä½“ï¼ˆc.1958Gâ€‰>â€‰Aï¼Œp.Agr635Glnï¼‰ã€‚å¯¹ PubMedã€Scopus å’Œ Web of Science è¿›è¡Œäº†æœç´¢ï¼Œä»¥ç¡®å®šæŠ¥å‘Š FGFR1 åŸºå› ç¼ºé™·çš„ CPHD ç—…ä¾‹çš„ç ”ç©¶ã€‚\n\n**ç»“æœï¼š** åœ¨æ£€ç´¢åˆ°çš„ 648 æ¡è®°å½•ä¸­ï¼Œæœ¬æ¬¡å®¡æŸ¥çº³å…¥äº† 10 æ¡è®°å½•ã€‚å¯¹ç—…ä¾‹è¿›è¡Œäº†å…¨é¢çš„æ¦‚è¿°ï¼Œå¹¶ä»‹ç»äº†å®ƒä»¬çš„ä¸´åºŠå’Œé—ä¼ ç‰¹å¾ã€‚\n\n**ç»“è®ºï¼š** å°½ç®¡ FGFR1 å˜å¼‚ä¸å¡å°”æ›¼ç»¼åˆå¾å’Œå­¤ç«‹æ€§ä½ä¿ƒæ€§è…ºæ¿€ç´ æ€§æ€§è…ºåŠŸèƒ½å‡é€€ç—‡ä»¥åŠæœ€è¿‘çš„ CPHD ç›¸å…³ï¼Œä½†æ®æˆ‘ä»¬æ‰€çŸ¥ï¼Œæ‚£è€…çš„è¡¨å‹åŒ…æ‹¬ä»¥å‰æœªæè¿°è¿‡çš„è¡¨å‹æ”¹å˜ï¼Œå±äºè¿™äº›å®ä½“çš„éç”Ÿæ®–ç‰¹å¾èŒƒå›´ã€‚å­¤ç«‹çš„ GH ç¼ºä¹åˆå¹¶å…¶ä»–ä¸å¸¸è§çš„å¼‚å¸¸å¾ˆå¯èƒ½å¯¼è‡´éšåçš„ CPHD è¡¨ç°ã€‚", "keywords_zh": "CPHDã€FGFR1ã€GHDã€å‚ä½“åŠŸèƒ½å‡é€€ç—‡ã€è¯„è®º", "keywords_en": "CPHD, FGFR1, GHD, Hypopituitarism, Review", "link": "https://pubmed.ncbi.nlm.nih.gov/40434549/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 28 May 2025"}, {"id": "40413456", "title_en": "MicroRNAs involved in colorectal cancer, a rapid mini-systematic review", "title_zh": "ä¸ç»“ç›´è‚ ç™Œæœ‰å…³çš„ MicroRNAï¼Œå¿«é€Ÿå°å‹ç³»ç»Ÿè¯„ä»·", "authors": "Mahdi Barazesh", "abstract_en": "**Introduction:** Colorectal cancer (CRC) involves the uncontrolled proliferation of glandular epithelial cells in the colon or rectum. The high mortality rate associated with CRC has driven extensive research into innovative diagnostic and therapeutic strategies. Among these, microRNAs (miRNA) have gained attention for their crucial role in regulating various cellular processes that contribute to the initiation, progression, and metastasis of CRC.\n\n**Method:** This systematic review aimed to assess the roles of various miRNAs in CRC by analyzing multiple studies. The PICO framework was followed to structure the study regarding miRNA involved in CRC development and progression compared to normal cases. The outcomes were measured according miRNAs impact on CRC progression, survival rates, and treatment response. Systematic review of studies published from 2000 to November 2023 were included. Data were collected from prominent databases, including Google Scholar, PubMed, ScienceDirect, Irandoc, SID, and Magiran, covering studies from 2000 to November 2023. Studies were managed using EndNote for citation management, and duplicates were removed. The remaining studies were evaluated based on predefined inclusion and exclusion criteria.\n\n**Results:** In our review, we categorized 28 miRNAs based on their potential tumor suppressor or oncogenic effects in CRC progression. Among them, 14 miRNAs were highlighted as important based on the assessment using TCGA data, with miR-200a also showing a significant effect on patient survival.\n\n**Conclusion:** This study compiled and analyzed validated miRNAs associated with CRC progression. The findings suggest the potential of these miRNAs as non-invasive biomarkers, which may be used alone or in combination with traditional tumor markers for improved diagnostic and prognostic applications in CRC. This review contributes novel insights by updating the current understanding and offering a comprehensive evaluation of miRNAs in CRC.", "abstract_zh": "**ä»‹ç»ï¼š** ç»“ç›´è‚ ç™Œ (CRC) æ¶‰åŠç»“è‚ æˆ–ç›´è‚ ä¸­è…ºä¸Šçš®ç»†èƒä¸å—æ§åˆ¶çš„å¢æ®–ã€‚ç»“ç›´è‚ ç™Œç›¸å…³çš„é«˜æ­»äº¡ç‡æ¨åŠ¨äº†å¯¹åˆ›æ–°è¯Šæ–­å’Œæ²»ç–—ç­–ç•¥çš„å¹¿æ³›ç ”ç©¶ã€‚å…¶ä¸­ï¼ŒmicroRNA (miRNA) å› å…¶åœ¨è°ƒèŠ‚å„ç§ç»†èƒè¿‡ç¨‹ä¸­çš„å…³é”®ä½œç”¨è€Œå—åˆ°å…³æ³¨ï¼Œè¿™äº›ç»†èƒè¿‡ç¨‹æœ‰åŠ©äº CRC çš„èµ·å§‹ã€è¿›å±•å’Œè½¬ç§»ã€‚\n\n**Methodï¼š** æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨é€šè¿‡åˆ†æå¤šé¡¹ç ”ç©¶æ¥è¯„ä¼°å„ç§ miRNA åœ¨ CRC ä¸­çš„ä½œç”¨ã€‚éµå¾ª PICO æ¡†æ¶æ¥æ„å»ºä¸æ­£å¸¸ç—…ä¾‹ç›¸æ¯”å‚ä¸ CRC å‘ç”Ÿå’Œè¿›å±•çš„ miRNA çš„ç ”ç©¶ã€‚ç»“æœæ˜¯æ ¹æ® miRNA å¯¹ CRC è¿›å±•ã€ç”Ÿå­˜ç‡å’Œæ²»ç–—ååº”çš„å½±å“æ¥è¡¡é‡çš„ã€‚å¯¹ 2000 å¹´è‡³ 2023 å¹´ 11 æœˆå‘è¡¨çš„ç ”ç©¶è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ã€‚æ•°æ®æ”¶é›†è‡ªè‘—åæ•°æ®åº“ï¼ŒåŒ…æ‹¬ Google Scholarã€PubMedã€ScienceDirectã€Irandocã€SID å’Œ Magiranï¼Œæ¶µç›– 2000 å¹´è‡³ 2023 å¹´ 11 æœˆçš„ç ”ç©¶ã€‚ç ”ç©¶ä½¿ç”¨ EndNote è¿›è¡Œå¼•æ–‡ç®¡ç†ï¼Œå¹¶åˆ é™¤é‡å¤é¡¹ã€‚å…¶ä½™ç ”ç©¶æ ¹æ®é¢„å…ˆç¡®å®šçš„çº³å…¥å’Œæ’é™¤æ ‡å‡†è¿›è¡Œè¯„ä¼°ã€‚\n\n**ç»“æœï¼š** åœ¨æˆ‘ä»¬çš„ç»¼è¿°ä¸­ï¼Œæˆ‘ä»¬æ ¹æ® 28 ç§ miRNA åœ¨ CRC è¿›å±•ä¸­çš„æ½œåœ¨æŠ‘ç™Œæˆ–è‡´ç™Œä½œç”¨å¯¹å…¶è¿›è¡Œäº†åˆ†ç±»ã€‚å…¶ä¸­ï¼Œæ ¹æ® TCGA æ•°æ®çš„è¯„ä¼°ï¼Œ14 ä¸ª miRNA è¢«å¼ºè°ƒä¸ºé‡è¦ï¼Œå…¶ä¸­ miR-200a ä¹Ÿæ˜¾ç¤ºå‡ºå¯¹æ‚£è€…ç”Ÿå­˜çš„æ˜¾ç€å½±å“ã€‚\n\n**ç»“è®ºï¼š** æœ¬ç ”ç©¶ç¼–è¯‘å¹¶åˆ†æäº†ä¸ CRC è¿›å±•ç›¸å…³çš„ç»è¿‡éªŒè¯çš„ miRNAã€‚è¿™äº›å‘ç°è¡¨æ˜è¿™äº› miRNA ä½œä¸ºéä¾µå…¥æ€§ç”Ÿç‰©æ ‡å¿—ç‰©çš„æ½œåŠ›ï¼Œå¯ä»¥å•ç‹¬ä½¿ç”¨æˆ–ä¸ä¼ ç»Ÿè‚¿ç˜¤æ ‡å¿—ç‰©ç»“åˆä½¿ç”¨ï¼Œä»¥æ”¹å–„ CRC çš„è¯Šæ–­å’Œé¢„ååº”ç”¨ã€‚è¿™ç¯‡ç»¼è¿°é€šè¿‡æ›´æ–°å½“å‰çš„ç†è§£å¹¶å¯¹ CRC ä¸­çš„ miRNA è¿›è¡Œå…¨é¢è¯„ä¼°ï¼Œæä¾›äº†æ–°é¢–çš„è§è§£ã€‚", "keywords_zh": "ç”Ÿç‰©æ ‡å¿—ç‰©ã€ç»“ç›´è‚ ç™Œã€MicroRNA", "keywords_en": "Biomarker, Colorectal cancer, MicroRNAs", "link": "https://pubmed.ncbi.nlm.nih.gov/40413456/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sat, 24 May 2025"}, {"id": "40410673", "title_en": "The efficacy of retrograde and antegrade enemas in the management of low anterior resection syndrome in patients undergoing rectal resection: a systematic review and meta-analysis", "title_zh": "é€†è¡Œå’Œé¡ºè¡ŒçŒè‚ æ²»ç–—ç›´è‚ åˆ‡é™¤æœ¯æ‚£è€…ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾çš„ç–—æ•ˆï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Hui Yang", "abstract_en": "**Background:** Rectal resection could potentially cause low anterior resection syndrome (LARS). Although recent studies have reported the efficacy of enema against LARS, no systematic review and meta-analysis has been conducted.\n\n**Methods:** A systematic search was conducted in PubMed, EMBASE, MEDLINE, CINAHL Complete, Cochrane library and Web of Science. Eligible studies that quantified the effect of enema vs. other approaches on LARS following rectal resection were selected. Meta-analysis was conducted by using RevMan 5.4 software and StataMP 17. Where meta-analysis was not possible, vote counting was performed.\n\n**Results:** This study comprised five RCTs with 159 participants and meta-analysis was performed in 4 studies. Compared with the control group, enema reduced LARS score with mean differences of -10.84 (95% CI: -16.71 to -4.98, Pâ€‰=â€‰0.0003). Subgroup analysis based on the type of enema were performed, with three European studies using retrograde enema and one Asian study using antegrade enema, with mean differences of -13.77 (95% CI: -17.97 to -9.57, Pâ€‰<â€‰0.00001) and -4.86 (95% CI: -9.26 to -0.46, Pâ€‰=â€‰0.03), respectively. According to follow-up period, two trials reported short-term effects and the other two investigated medium/long-term effects with mean differences of -14.22 (95% CI: -20.05 to -8.38, Pâ€‰=â€‰0.23) and -7.59 (95% CI: -14.47 to -0.71, Pâ€‰=â€‰0.13), respectively. One study that used antegrade enema was key contributor to the substantial interstudy heterogeneity by the leave-one-out sensitivity analysis. After exclusion of this study, no heterogeneity was found (t<sup>2</sup>â€‰=â€‰0.00; Ï‡<sup>2</sup>â€‰=â€‰1.63, dfâ€‰=â€‰2, pâ€‰=â€‰0.44; I<sup>2</sup>â€‰=â€‰0%). Vote counting also showed positive effects of enema on LARS.\n\n**Conclusions:** Enema, particularly retrograde enema, is effective in managing LARS. However, the effectiveness of antegrade enema deserves further investigation. The short-term effects of enema are more pronounced compared to long-term outcomes. Due to the limited number of included studies, these findings should be taken cautiously. More RCTs on other continents are needed to validate the impact of enema on LARS, as well as to develop standardised protocols to facilitate clinical practice.\n\n**Prospero Registration:** CRD42024539973.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç›´è‚ åˆ‡é™¤æœ¯å¯èƒ½ä¼šå¯¼è‡´ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ˆLARSï¼‰ã€‚å°½ç®¡æœ€è¿‘çš„ç ”ç©¶æŠ¥å‘Šäº†çŒè‚ å¯¹ LARS çš„åŠŸæ•ˆï¼Œä½†å°šæœªè¿›è¡Œç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚\n\n**æ–¹æ³•ï¼š** åœ¨ PubMedã€EMBASEã€MEDLINEã€CINAHL Completeã€Cochrane å›¾ä¹¦é¦†å’Œ Web of Science ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚é€‰æ‹©äº†é‡åŒ–çŒè‚ ä¸å…¶ä»–æ–¹æ³•å¯¹ç›´è‚ åˆ‡é™¤æœ¯å LARS æ•ˆæœçš„åˆæ ¼ç ”ç©¶ã€‚ä½¿ç”¨ RevMan 5.4 è½¯ä»¶å’Œ StataMP 17 è¿›è¡ŒèŸèƒåˆ†æã€‚åœ¨æ— æ³•è¿›è¡ŒèŸèƒåˆ†æçš„æƒ…å†µä¸‹ï¼Œè¿›è¡Œè®¡ç¥¨ã€‚\n\n**ç»“æœï¼š** è¿™é¡¹ç ”ç©¶åŒ…æ‹¬ 5 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼Œå…±æœ‰ 159 åå‚ä¸è€…ï¼Œå¹¶å¯¹ 4 é¡¹ç ”ç©¶è¿›è¡Œäº†èŸèƒåˆ†æã€‚ä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼ŒçŒè‚ é™ä½LARSè¯„åˆ†ï¼Œå¹³å‡å·®å¼‚ä¸º-10.84ï¼ˆ95% CIï¼š-16.71è‡³-4.98ï¼ŒPâ€‰=â€‰0.0003ï¼‰ã€‚æ ¹æ®çŒè‚ ç±»å‹è¿›è¡Œäºšç»„åˆ†æï¼Œå…¶ä¸­ä¸‰é¡¹æ¬§æ´²ç ”ç©¶ä½¿ç”¨é€†è¡ŒçŒè‚ ï¼Œä¸€é¡¹äºšæ´²ç ”ç©¶ä½¿ç”¨é¡ºè¡ŒçŒè‚ ï¼Œå¹³å‡å·®å¼‚ä¸º-13.77ï¼ˆ95ï¼…CIï¼š-17.97è‡³-9.57ï¼ŒPâ€‰<â€‰0.00001ï¼‰å’Œ-4.86ï¼ˆ95ï¼…CIï¼š-9.26è‡³-0.46ï¼ŒPâ€‰=â€‰0.03ï¼‰ï¼Œåˆ†åˆ«ã€‚æ ¹æ®éšè®¿æ—¶é—´ï¼Œä¸¤é¡¹è¯•éªŒæŠ¥å‘Šäº†çŸ­æœŸæ•ˆåº”ï¼Œå¦å¤–ä¸¤é¡¹ç ”ç©¶äº†ä¸­/é•¿æœŸæ•ˆåº”ï¼Œå¹³å‡å·®å¼‚åˆ†åˆ«ä¸º-14.22ï¼ˆ95% CIï¼š-20.05è‡³-8.38ï¼ŒPâ€‰=â€‰0.23ï¼‰å’Œ-7.59ï¼ˆ95% CIï¼š-14.47è‡³-0.71ï¼ŒPâ€‰=â€‰0.13ï¼‰ã€‚ä¸€é¡¹ä½¿ç”¨é¡ºè¡ŒçŒè‚ çš„ç ”ç©¶æ˜¯ç•™ä¸€æ•æ„Ÿæ€§åˆ†æå¯¼è‡´ç ”ç©¶é—´æ˜¾ç€å¼‚è´¨æ€§çš„å…³é”®å› ç´ ã€‚æ’é™¤æœ¬ç ”ç©¶åï¼Œæœªå‘ç°å¼‚è´¨æ€§ï¼ˆt<sup>2</sup>â€‰=â€‰0.00ï¼›Ï‡<sup>2</sup>â€‰=â€‰1.63ï¼Œdfâ€‰=â€‰2ï¼Œpâ€‰=â€‰0.44ï¼›I<sup>2</sup>â€‰=â€‰0%ï¼‰ã€‚è®¡ç¥¨ä¹Ÿæ˜¾ç¤ºçŒè‚ å¯¹ LARS å…·æœ‰ç§¯æä½œç”¨ã€‚\n\n**ç»“è®ºï¼š** çŒè‚ ï¼Œç‰¹åˆ«æ˜¯é€†è¡ŒçŒè‚ ï¼Œå¯¹äºæ²»ç–— LARS æ˜¯æœ‰æ•ˆçš„ã€‚ç„¶è€Œï¼Œé¡ºè¡ŒçŒè‚ çš„æœ‰æ•ˆæ€§å€¼å¾—è¿›ä¸€æ­¥ç ”ç©¶ã€‚ä¸é•¿æœŸç»“æœç›¸æ¯”ï¼ŒçŒè‚ çš„çŸ­æœŸæ•ˆæœæ›´ä¸ºæ˜æ˜¾ã€‚ç”±äºçº³å…¥çš„ç ”ç©¶æ•°é‡æœ‰é™ï¼Œè¿™äº›ç ”ç©¶ç»“æœåº”è°¨æ…å¯¹å¾…ã€‚éœ€è¦åœ¨å…¶ä»–å¤§é™†è¿›è¡Œæ›´å¤šéšæœºå¯¹ç…§è¯•éªŒæ¥éªŒè¯çŒè‚ å¯¹ LARS çš„å½±å“ï¼Œå¹¶åˆ¶å®šæ ‡å‡†åŒ–æ–¹æ¡ˆä»¥ä¿ƒè¿›ä¸´åºŠå®è·µã€‚\n\n**Prospero registrationï¼š** CRD42024539973ã€‚", "keywords_zh": "çŒè‚ ï¼Œä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ŒèŸèƒåˆ†æï¼Œç›´è‚ åˆ‡é™¤æœ¯", "keywords_en": "Enema, Low anterior resection syndrome, Meta-analysis, Rectal resection", "link": "https://pubmed.ncbi.nlm.nih.gov/40410673/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 23 May 2025"}, {"id": "40407946", "title_en": "Simultaneous robotic-assisted prostatectomy and rectal resection: a systematic review", "title_zh": "æœºå™¨äººè¾…åŠ©å‰åˆ—è…ºåˆ‡é™¤æœ¯å’Œç›´è‚ åˆ‡é™¤æœ¯åŒæ—¶è¿›è¡Œï¼šç³»ç»Ÿè¯„ä»·", "authors": "Matthew J Roberts", "abstract_en": "Prostate cancer (PC) and rectal cancer (RC) are common and can require complex management, especially when presenting synchronously or with invasive characteristics. Robotic surgery has emerged as a viable option for managing these challenging cases; however, the outcomes are yet to be summarised or compared to traditional approaches. This systematic review aims to evaluate the feasibility, oncological outcomes, and functional results of simultaneous robotic-assisted resections of the prostate and rectum. Following prior protocol registration (PROSPERO: CRD42023449872) and according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, we conducted a systematic search across multiple databases, selecting studies that involved simultaneous bladder-sparing robotic-assisted prostatectomy and rectal resection. The Joanna Briggs Institute tool was used for risk of bias assessment. Data on patient demographics, treatment details, post-operative course, and functional and oncological outcomes were extracted and analysed. From 1357 identified records, 25 studies met our inclusion criteria resulting in 45 cases/patients. The median patient age was 62Â years. Diverse treatment backgrounds and outcome definitions were recorded. Median operative time was 548Â min and median estimated blood loss was 450Â mL. The overall complication rate was 44.4%, with major complications (Clavien-Dindo III) occurring in 17.8% of cases. Surgical margins were negative in 92.6% of cases. Continence recovery occurred for most (78.6%) of the cases reporting on urinary function. Simultaneous robotic-assisted prostatectomy and rectal resection appears to be a feasible, safe and oncologically effective approach with satisfactory oncological and functional outcomes for managing patients with synchronous or invasive PC and RC.", "abstract_zh": "å‰åˆ—è…ºç™Œ (PC) å’Œç›´è‚ ç™Œ (RC) å¾ˆå¸¸è§ï¼Œå¯èƒ½éœ€è¦å¤æ‚çš„æ²»ç–—ï¼Œç‰¹åˆ«æ˜¯åœ¨åŒæ—¶å‡ºç°æˆ–å…·æœ‰ä¾µè¢­æ€§ç‰¹å¾æ—¶ã€‚æœºå™¨äººæ‰‹æœ¯å·²æˆä¸ºå¤„ç†è¿™äº›å…·æœ‰æŒ‘æˆ˜æ€§çš„ç—…ä¾‹çš„å¯è¡Œé€‰æ‹©ï¼›ç„¶è€Œï¼Œç»“æœå°šæœªæ€»ç»“æˆ–ä¸ä¼ ç»Ÿæ–¹æ³•è¿›è¡Œæ¯”è¾ƒã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨è¯„ä¼°æœºå™¨äººè¾…åŠ©åŒæ­¥å‰åˆ—è…ºå’Œç›´è‚ åˆ‡é™¤æœ¯çš„å¯è¡Œæ€§ã€è‚¿ç˜¤å­¦ç»“æœå’ŒåŠŸèƒ½ç»“æœã€‚åœ¨å…ˆå‰çš„æ–¹æ¡ˆæ³¨å†Œï¼ˆPROSPEROï¼šCRD42023449872ï¼‰ä¹‹åå¹¶æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ï¼ˆPRISMAï¼‰æŒ‡å—ï¼Œæˆ‘ä»¬åœ¨å¤šä¸ªæ•°æ®åº“ä¸­è¿›è¡Œäº†ç³»ç»Ÿæœç´¢ï¼Œé€‰æ‹©æ¶‰åŠåŒæ—¶ä¿ç•™è†€èƒ±çš„æœºå™¨äººè¾…åŠ©å‰åˆ—è…ºåˆ‡é™¤æœ¯å’Œç›´è‚ åˆ‡é™¤æœ¯çš„ç ”ç©¶ã€‚ä¹”å®‰å¨œÂ·å¸ƒé‡Œæ ¼æ–¯ç ”ç©¶æ‰€å·¥å…·ç”¨äºè¯„ä¼°åå·®é£é™©ã€‚æå–å¹¶åˆ†æäº†æ‚£è€…äººå£ç»Ÿè®¡ã€æ²»ç–—ç»†èŠ‚ã€æœ¯åç—…ç¨‹ä»¥åŠåŠŸèƒ½å’Œè‚¿ç˜¤ç»“æœçš„æ•°æ®ã€‚ä» 1357 ä»½å·²ç¡®å®šçš„è®°å½•ä¸­ï¼Œæœ‰ 25 é¡¹ç ”ç©¶ç¬¦åˆæˆ‘ä»¬çš„çº³å…¥æ ‡å‡†ï¼Œå…± 45 ä¾‹/æ‚£è€…ã€‚æ‚£è€…å¹´é¾„ä¸­ä½æ•°ä¸º 62 å²ã€‚è®°å½•äº†ä¸åŒçš„æ²»ç–—èƒŒæ™¯å’Œç»“æœå®šä¹‰ã€‚ä¸­ä½æ‰‹æœ¯æ—¶é—´ä¸º 548 åˆ†é’Ÿï¼Œä¸­ä½ä¼°è®¡å¤±è¡€é‡ä¸º 450 mLã€‚æ€»ä½“å¹¶å‘ç—‡å‘ç”Ÿç‡ä¸º44.4%ï¼Œå…¶ä¸­ä¸»è¦å¹¶å‘ç—‡ï¼ˆClavien-Dindo IIIï¼‰å‘ç”Ÿç‡ä¸º17.8%ã€‚ 92.6% çš„ç—…ä¾‹æ‰‹æœ¯åˆ‡ç¼˜å‘ˆé˜´æ€§ã€‚å¤§å¤šæ•°ï¼ˆ78.6%ï¼‰æŠ¥å‘Šæ³Œå°¿åŠŸèƒ½çš„ç—…ä¾‹å‡æ¢å¤äº†å¤±ç¦ã€‚åŒæ­¥æœºå™¨äººè¾…åŠ©å‰åˆ—è…ºåˆ‡é™¤æœ¯å’Œç›´è‚ åˆ‡é™¤æœ¯ä¼¼ä¹æ˜¯ä¸€ç§å¯è¡Œã€å®‰å…¨ä¸”è‚¿ç˜¤å­¦æœ‰æ•ˆçš„æ–¹æ³•ï¼Œå¯¹äºæ²»ç–—åŒæ­¥æˆ–ä¾µå…¥æ€§ PC å’Œ RC æ‚£è€…å…·æœ‰ä»¤äººæ»¡æ„çš„è‚¿ç˜¤å­¦å’ŒåŠŸèƒ½ç»“æœã€‚", "keywords_zh": "è…¹ä¼šé˜´åˆ‡é™¤æœ¯ï¼ˆAPRï¼‰ã€å‰åˆ‡é™¤æœ¯ï¼ˆARï¼‰ã€å‰åˆ—è…ºç™Œã€å‰åˆ—è…ºåˆ‡é™¤æœ¯ã€ç›´è‚ ç™Œã€æœºå™¨äººæ‰‹æœ¯", "keywords_en": "Abdominoperineal resection (APR), Anterior resection (AR), Prostate cancer, Prostatectomy, Rectal cancer, Robotic surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/40407946/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 23 May 2025"}, {"id": "40371426", "title_en": "Prostate biopsy in patients without rectal access: a systematic review and proportional meta-analysis", "title_zh": "æ— ç›´è‚ å…¥è·¯æ‚£è€…çš„å‰åˆ—è…ºæ´»æ£€ï¼šç³»ç»Ÿè¯„ä»·å’Œæ¯”ä¾‹èŸèƒåˆ†æ", "authors": "Dionysios Mitropoulos", "abstract_en": "**Introduction:** Historically, the anal canal plays a substantial role in both screening and diagnosis of pro-state cancer with digital rectal examination (DRE) and transrectal ultrasound (TRUS) guided biopsy, respectively. However, in patients with a prior history of abdominoperineal resection the transrectal route towards the prostate capsule cannot be utilized and thus alternative approaches have to be employed. The aim of this systematic review and proportional meta-analysis is to evaluate the available alternative prostate biopsy techniques in patients without rectal access.\n\n**Material And Methods:** The systematic literature review was performed using MEDLINE, Scopus, EMBASE, and the CENTRAL register for randomized controlled trials (RCTs). The following search algorithm was used: \"resection of rectum\" OR \"abdominoperineal resection\" OR \"without rectal access\" AND \"prostate biopsy\" (PROSPERO 2023 CRD42023459080).\n\n**Results:** A total of 21 studies and 203 patients were included in this systematic review and meta-analysis, while 6 different prostate biopsy techniques were detected in the current literature. The transperineal approach under transperineal US (TPUS) and the transgluteal approach guided by computed tomography (CT) were associated with 0.74 [0.48; 0.94] and 0.70 [0.49; 0.89] pooled diagnostic yield estimates as well as 0.01 [0.00; 0.01] and 0 [0.00; 0.01] pooled complication rate estimates. The performance of multiparametric magnetic resonance imaging (mpMRI) prior to transgluteal CT-guided prostate biopsy seemed to significantly affect the biopsy result (p = 0.0002).\n\n**Conclusions:** Based on current data, the TPUS-guided prostate biopsy has the highest pooled diagnostic yield estimate. However, this conclusion is based on poor evidence and more reliable and well-organized studies are needed to thoroughly explore this problem.", "abstract_zh": "**ä»‹ç»ï¼š** ä»å†å²ä¸Šçœ‹ï¼Œè‚›ç®¡åˆ†åˆ«åœ¨ç›´è‚ æŒ‡æ£€ï¼ˆDREï¼‰å’Œç»ç›´è‚ è¶…å£°ï¼ˆTRUSï¼‰å¼•å¯¼æ´»æ£€çš„å‰åˆ—è…ºç™Œç­›æŸ¥å’Œè¯Šæ–­ä¸­å‘æŒ¥ç€é‡è¦ä½œç”¨ã€‚ç„¶è€Œï¼Œå¯¹äºæ—¢å¾€æœ‰è…¹ä¼šé˜´åˆ‡é™¤å²çš„æ‚£è€…ï¼Œæ— æ³•åˆ©ç”¨ç»ç›´è‚ é€”å¾„åˆ°è¾¾å‰åˆ—è…ºå›Šï¼Œå› æ­¤å¿…é¡»é‡‡ç”¨æ›¿ä»£æ–¹æ³•ã€‚æœ¬ç³»ç»Ÿè¯„ä»·å’Œæ¯”ä¾‹èŸèƒåˆ†æçš„ç›®çš„æ˜¯è¯„ä¼°å¯¹äºæ²¡æœ‰ç›´è‚ é€šè·¯çš„æ‚£è€…å¯ç”¨çš„æ›¿ä»£å‰åˆ—è…ºæ´»æ£€æŠ€æœ¯ã€‚\n\n**Material and methodsï¼š** ä½¿ç”¨ MEDLINEã€Scopusã€EMBASE å’Œ CENTRAL æ³¨å†Œåº“è¿›è¡Œç³»ç»Ÿæ–‡çŒ®ç»¼è¿°ä»¥è¿›è¡Œéšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€‚ä½¿ç”¨ä»¥ä¸‹æœç´¢ç®—æ³•ï¼šâ€œç›´è‚ åˆ‡é™¤æœ¯â€æˆ–â€œè…¹ä¼šé˜´åˆ‡é™¤æœ¯â€æˆ–â€œæ— ç›´è‚ é€šè·¯â€å’Œâ€œå‰åˆ—è…ºæ´»æ£€â€(PROSPERO 2023 CRD42023459080)ã€‚\n\n**ç»“æœï¼š** æœ¬æ¬¡ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æå…±çº³å…¥ 21 é¡¹ç ”ç©¶å’Œ 203 åæ‚£è€…ï¼ŒåŒæ—¶åœ¨å½“å‰æ–‡çŒ®ä¸­æ£€æµ‹åˆ° 6 ç§ä¸åŒçš„å‰åˆ—è…ºæ´»æ£€æŠ€æœ¯ã€‚ç»ä¼šé˜´è¶…å£° (TPUS) ä¸‹çš„ç»ä¼šé˜´å…¥è·¯å’Œè®¡ç®—æœºæ–­å±‚æ‰«æ (CT) å¼•å¯¼ä¸‹çš„ç»è‡€å…¥è·¯ä¸ 0.74 [0.48ï¼›0.74] ç›¸å…³ã€‚ 0.94]å’Œ0.70[0.49ï¼› 0.89] æ±‡æ€»è¯Šæ–­äº§é‡ä¼°è®¡å€¼ä»¥åŠ 0.01 [0.00ï¼›0.00ï¼› 0.01] å’Œ 0 [0.00ï¼› 0.01]åˆå¹¶å¹¶å‘ç—‡å‘ç”Ÿç‡ä¼°è®¡å€¼ã€‚ç»è‡€ CT å¼•å¯¼çš„å‰åˆ—è…ºæ´»æ£€ä¹‹å‰çš„å¤šå‚æ•°ç£å…±æŒ¯æˆåƒ (mpMRI) çš„è¡¨ç°ä¼¼ä¹æ˜¾ç€å½±å“æ´»æ£€ç»“æœ (p = 0.0002)ã€‚\n\n**ç»“è®ºï¼š** æ ¹æ®å½“å‰æ•°æ®ï¼ŒTPUS å¼•å¯¼çš„å‰åˆ—è…ºæ´»æ£€å…·æœ‰æœ€é«˜çš„æ±‡æ€»è¯Šæ–­ç‡ä¼°è®¡ã€‚ç„¶è€Œï¼Œè¿™ä¸€ç»“è®ºçš„è¯æ®ä¸è¶³ï¼Œéœ€è¦æ›´å¯é å’Œç»„ç»‡è‰¯å¥½çš„ç ”ç©¶æ¥å½»åº•æ¢è®¨è¿™ä¸ªé—®é¢˜ã€‚", "keywords_zh": "æ´»æ£€, å‰åˆ—è…º, å‰åˆ—è…ºç™Œ, ç»ä¼šé˜´, è¶…å£°æ³¢", "keywords_en": "biopsy, prostate, prostate cancer, transperineal, ultrasound", "link": "https://pubmed.ncbi.nlm.nih.gov/40371426/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 15 May 2025"}, {"id": "40347378", "title_en": "Effects of low anterior resection syndrome after colorectal cancer resections on health-related quality of life: a systematic review and meta-analysis", "title_zh": "ç»“ç›´è‚ ç™Œåˆ‡é™¤æœ¯åä½ä½å‰åˆ‡é™¤ç»¼åˆå¾å¯¹å¥åº·ç›¸å…³ç”Ÿæ´»è´¨é‡çš„å½±å“ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "S V Hosseini", "abstract_en": "**Background:** Low anterior resection syndrome (LARS) is a term that encompasses multidimensional bowel dysfunction that typically occurs following resections of rectum and distal parts of the colon. We aimed to systematically assess the available literature on the effects of bowel dysfunction after colorectal cancer (CRC) surgeries on health-related quality of life (HRQOL) and conduct a meta-analysis.\n\n**Methods:** Studies were included if they assessed patients who had undergone sphincter-preservation surgeries for CRC. Studies were eligible if they assessed bowel dysfunction using the LARS score and HRQOL using the European Organization for Research and Treatment Core Quality-of-Life Questionnaire (EORTC QLQ-C30).\n\n**Results:** Of 1410 reports, 28 studies were included. According to the analyses, patients with major LARS had lower global health status [weighted mean differences (WMD)â€‰=â€‰-â€‰10.98; 95% confidence interval (CI) -â€‰13.18, -â€‰8.79], physical functioning (WMDâ€‰=â€‰- 5.96; 95%Â CI - 7.40, - 4.52), role functioning (WMDâ€‰=â€‰- 10.59; 95%Â CI - 12.54, - 8.63), emotional functioning (WMDâ€‰=â€‰- 11.09; 95%Â CI - 14.34, 7.84), cognitive functioning (WMDâ€‰=â€‰- 9.27; 95%Â CI - 12.22, - 6.32), and social functioning (WMDâ€‰=â€‰- 15.73; 95%Â CI - 18.82, - 12.63) and higher scores of symptoms compared to patients with minor/no LARS.\n\n**Conclusions:** The study findings suggest that patients with major LARS experience worse HRQOL compared to those with minor/no LARS.\n\n**Registration:** PROSPERO, CRD42023479657.", "abstract_zh": "**èƒŒæ™¯ï¼š** ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ˆLARSï¼‰æ˜¯ä¸€ä¸ªæ¶µç›–å¤šç»´è‚ åŠŸèƒ½éšœç¢çš„æœ¯è¯­ï¼Œé€šå¸¸å‘ç”Ÿåœ¨ç›´è‚ å’Œç»“è‚ è¿œç«¯åˆ‡é™¤æœ¯åã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯ç³»ç»Ÿè¯„ä¼°å…³äºç»“ç›´è‚ ç™Œï¼ˆCRCï¼‰æ‰‹æœ¯åè‚ åŠŸèƒ½éšœç¢å¯¹å¥åº·ç›¸å…³ç”Ÿæ´»è´¨é‡ï¼ˆHRQOLï¼‰å½±å“çš„ç°æœ‰æ–‡çŒ®ï¼Œå¹¶è¿›è¡ŒèŸèƒåˆ†æã€‚\n\n**æ–¹æ³•ï¼š** å¦‚æœä»–ä»¬è¯„ä¼°å› ç»“ç›´è‚ ç™Œæ¥å—æ‹¬çº¦è‚Œä¿ç•™æ‰‹æœ¯çš„æ‚£è€…ï¼Œåˆ™çº³å…¥ç ”ç©¶ã€‚å¦‚æœç ”ç©¶ä½¿ç”¨ LARS è¯„åˆ†å’Œ HRQOL ä½¿ç”¨æ¬§æ´²ç ”ç©¶å’Œæ²»ç–—ç»„ç»‡æ ¸å¿ƒç”Ÿæ´»è´¨é‡é—®å· (EORTC QLQ-C30) è¯„ä¼°è‚ é“åŠŸèƒ½éšœç¢ï¼Œåˆ™ç ”ç©¶åˆæ ¼ã€‚\n\n**ç»“æœï¼š** 1410 ä»½æŠ¥å‘Šä¸­çº³å…¥äº† 28 é¡¹ç ”ç©¶ã€‚æ ¹æ®åˆ†æï¼Œé‡åº¦ LARS æ‚£è€…çš„æ•´ä½“å¥åº·çŠ¶å†µè¾ƒä½[åŠ æƒå¹³å‡å·® (WMD)â€‰=â€‰-â€‰10.98ï¼› 95% ç½®ä¿¡åŒºé—´ (CI) -â€‰13.18, -â€‰8.79]ã€èº«ä½“åŠŸèƒ½ (WMDâ€‰=â€‰- 5.96; 95% CI - 7.40, - 4.52)ã€è§’è‰²åŠŸèƒ½ (WMDâ€‰=â€‰- 10.59; 95% CI - 12.54, - 8.63)ã€æƒ…ç»ªåŠŸèƒ½(WMDâ€‰=â€‰- 11.09; 95% CI - 14.34, 7.84)ã€è®¤çŸ¥åŠŸèƒ½ (WMDâ€‰=â€‰- 9.27; 95% CI - 12.22, - 6.32) å’Œç¤¾äº¤åŠŸèƒ½ (WMDâ€‰=â€‰- 15.73; 95% CI - 18.82, - 12.63ï¼‰ï¼Œä¸è½»å¾®/æ—  LARS çš„æ‚£è€…ç›¸æ¯”ï¼Œç—‡çŠ¶å¾—åˆ†æ›´é«˜ã€‚\n\n**ç»“è®ºï¼š** ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œä¸æ‚£æœ‰è½»å¾®/æ—  LARS çš„æ‚£è€…ç›¸æ¯”ï¼Œæ‚£æœ‰ä¸¥é‡ LARS çš„æ‚£è€…çš„ HRQOL è¾ƒå·®ã€‚\n\n**Registrationï¼š** æ™®æ´›æ–¯å½¼ç½—ï¼ŒCRD42023479657ã€‚", "keywords_zh": "ç»“ç›´è‚ è‚¿ç˜¤, ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾, èŸèƒåˆ†æ, ç”Ÿæ´»è´¨é‡, ç³»ç»Ÿè¯„ä»·", "keywords_en": "Colorectal neoplasms, Low anterior resection syndrome, Meta-analysis, Quality of life, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40347378/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sat, 10 May 2025"}, {"id": "40330445", "title_en": "Perirectal spacers in radiotherapy for prostate cancer - a systematic review and meta-analysis", "title_zh": "ç›´è‚ å‘¨å›´é—´éš”å™¨åœ¨å‰åˆ—è…ºç™Œæ”¾å°„æ²»ç–—ä¸­çš„åº”ç”¨â€”â€”ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Shahrokh F Shariat", "abstract_en": "**Introduction:** Perirectal spacers reduce the radiotherapy (RT) dose delivered to the rectum, but their impact on treatment toxicity remains debated. We conducted a systematic review and meta-analysis to synthesise emerging data (PROSPERO: CRD42024506380).\n\n**Material And Methods:** MEDLINE, Embase, Scopus, and Google Scholar were searched through 2024/08/18 for prospective randomised (RCT) and non-randomised trials evaluating the clinical outcomes of perirectal spacing in prostate cancer (PCa) patients. Random effects generalised linear mixed models were used to pool odds ratios (OR) for rectal adverse events (AEs) from RCTs. Non-randomised trials were summarised qualitatively. The risk of bias was assessed using the RoB2 and ROBINS-I tools.\n\n**Results:** Three RCTs (<i>n</i> = 645) were identified. The rates of grade â‰¥ 2 (G â‰¥ 2) rectal AEs in control groups were low, ranging 4.2-13.8% for early AEs and 0-1.4% for late AEs. Perirectal spacers were associated with decreased incidence of early G â‰¥ 2 rectal AEs (OR: 0.43; 95% CI: 0.19-0.96), but not of late G â‰¥ 2 rectal AEs (OR: 0.26; 95% CI: 0.02-2.91). Assuming a comparator risk of 7.1% and 1%, this corresponded to a number needed to treat of 26 patients to avoid one early AE, and 135 pa- tients to avoid one late G â‰¥ 2 AE, respectively. Randomised clinical trial were at moderate risk of bias due to concerns regarding the concealment of allocation.\n\n**Conclusions:** There is evidence that perirectal spacers result in a small decrease in acute rectal toxicity. However, modern RT for clinically localised PCa is generally well-tolerated, and severe AEs are rare. Greater scrutiny of the risks and benefits associated with perirectal spacers is necessary.", "abstract_zh": "**ä»‹ç»ï¼š** ç›´è‚ å‘¨å›´é—´éš”å™¨å¯å‡å°‘ç›´è‚ çš„æ”¾å°„æ²»ç–— (RT) å‰‚é‡ï¼Œä½†å…¶å¯¹æ²»ç–—æ¯’æ€§çš„å½±å“ä»å­˜åœ¨äº‰è®®ã€‚æˆ‘ä»¬è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†ææ¥ç»¼åˆæ–°å…´æ•°æ®ï¼ˆPROSPEROï¼šCRD42024506380ï¼‰ã€‚\n\n**Material and methodsï¼š** æˆªè‡³ 2024 å¹´ 8 æœˆ 18 æ—¥ï¼ŒMEDLINEã€Embaseã€Scopus å’Œ Google Scholar å‡æœç´¢äº†è¯„ä¼°å‰åˆ—è…ºç™Œ (PCa) æ‚£è€…ç›´è‚ å‘¨å›´é—´éš”ä¸´åºŠç»“æœçš„å‰ç»æ€§éšæœº (RCT) å’Œééšæœºè¯•éªŒã€‚ä½¿ç”¨éšæœºæ•ˆåº”å¹¿ä¹‰çº¿æ€§æ··åˆæ¨¡å‹æ¥æ±‡æ€»éšæœºå¯¹ç…§è¯•éªŒä¸­ç›´è‚ ä¸è‰¯äº‹ä»¶ (AE) çš„æ¯”å€¼æ¯” (OR)ã€‚å¯¹ééšæœºè¯•éªŒè¿›è¡Œäº†å®šæ€§æ€»ç»“ã€‚ä½¿ç”¨ RoB2 å’Œ ROBINS-I å·¥å…·è¯„ä¼°åå€šé£é™©ã€‚\n\n**ç»“æœï¼š** ç¡®å®šäº†ä¸‰é¡¹éšæœºå¯¹ç…§è¯•éªŒ (<i>n</i> = 645)ã€‚å¯¹ç…§ç»„ä¸­ â‰¥ 2 çº§ (G â‰¥ 2) ç›´è‚  AE å‘ç”Ÿç‡è¾ƒä½ï¼Œæ—©æœŸ AE ä¸º 4.2-13.8%ï¼Œæ™šæœŸ AE ä¸º 0-1.4%ã€‚ç›´è‚ å‘¨å›´é—´éš”ç‰©ä¸æ—©æœŸ G â‰¥ 2 ç›´è‚  AE å‘ç”Ÿç‡é™ä½ç›¸å…³ï¼ˆORï¼š0.43ï¼›95% CIï¼š0.19-0.96ï¼‰ï¼Œä½†ä¸æ™šæœŸ G â‰¥ 2 ç›´è‚  AE å‘ç”Ÿç‡é™ä½æ— å…³ï¼ˆORï¼š0.26ï¼›95% CIï¼š0.02-2.91ï¼‰ã€‚å‡è®¾æ¯”è¾ƒé£é™©ä¸º 7.1% å’Œ 1%ï¼Œè¿™åˆ†åˆ«ç›¸å½“äºéœ€è¦æ²»ç–— 26 åæ‚£è€…ä»¥é¿å…ä¸€ç§æ—©æœŸ AE å’Œ 135 åæ‚£è€…ä»¥é¿å…ä¸€ç§æ™šæœŸ G â‰¥ 2 AEã€‚ç”±äºæ‹…å¿ƒåˆ†é…çš„éšè—ï¼Œéšæœºä¸´åºŠè¯•éªŒå­˜åœ¨ä¸­ç­‰åå€šé£é™©ã€‚\n\n**ç»“è®ºï¼š** æœ‰è¯æ®è¡¨æ˜ï¼Œç›´è‚ å‘¨å›´å«ç‰‡å¯ä½¿æ€¥æ€§ç›´è‚ æ¯’æ€§å°å¹…é™ä½ã€‚ç„¶è€Œï¼Œç°ä»£æ”¾ç–—æ²»ç–—ä¸´åºŠå±€é™æ€§å‰åˆ—è…ºç™Œé€šå¸¸è€å—æ€§è‰¯å¥½ï¼Œä¸¥é‡çš„ AE å¾ˆå°‘è§ã€‚æœ‰å¿…è¦å¯¹ç›´è‚ å‘¨å›´é—´éš”ç‰©ç›¸å…³çš„é£é™©å’Œç›Šå¤„è¿›è¡Œæ›´ä¸¥æ ¼çš„å®¡æŸ¥ã€‚", "keywords_zh": "Barrigelã€ProSpaceã€SpaceOARã€æ€¥æ€§æ¯’æ€§ã€æ…¢æ€§æ¯’æ€§ã€èƒƒè‚ é“æ¯’æ€§", "keywords_en": "Barrigel, ProSpace, SpaceOAR, acute toxicity, chronic toxicity, gastrointestinal toxicity", "link": "https://pubmed.ncbi.nlm.nih.gov/40330445/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 07 May 2025"}, {"id": "40327435", "title_en": "Research Perspective on \"Social Determinants of Health in Diverticulitis: A Systematic Review\"", "title_zh": "â€œæ†©å®¤ç‚å¥åº·çš„ç¤¾ä¼šå†³å®šå› ç´ ï¼šç³»ç»Ÿå›é¡¾â€çš„ç ”ç©¶è§†è§’", "authors": "Ira L Leeds", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40327435/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 06 May 2025"}, {"id": "40269754", "title_en": "Risk factors for unplanned 31-day readmission after surgery for colorectal cancer patients: a meta-analysis", "title_zh": "ç»“ç›´è‚ ç™Œæ‚£è€…æœ¯å 31 å¤©éè®¡åˆ’å†å…¥é™¢çš„å±é™©å› ç´ ï¼šä¸€é¡¹èŸèƒåˆ†æ", "authors": "Liping Cui", "abstract_en": "**Background:** The high incidence of unplanned readmissions within 31Â days after colorectal cancer surgery remains a significant challenge. However, the identified risk factors for these readmissions are inconsistent across the literature. This study aims to perform a comprehensive meta-analysis to estimate the incidence of unplanned readmissions and systematically identify the factors associated with this risk, providing robust evidence for targeted interventions to reduce readmission rates.\n\n**Methods:** This study was conducted in accordance with the PRISMA guidelines. All study steps, including study selection, data extraction, and quality assessment, were independently performed by two authors, with any disagreements resolved through consultation with a third author. A comprehensive search for published studies was conducted across the following databases up to January 2025: VIP Journal Database, Wanfang Data, CNKI, SinoMed, PubMed, Embase, Web of Science, and the Cochrane Library. Statistical analyses were performed using RevMan 5.4 and Stata 17.0, with a p-value of less than 0.05 considered statistically significant.\n\n**Results:** This meta-analysis identified several significant risk factors associated with unplanned readmission during this period (Pâ€‰<â€‰0.05), including age (ORâ€‰=â€‰1.13), postoperative complications (ORâ€‰=â€‰1.87), tumor stage (TNMâ€‰â‰¥â€‰III) (ORâ€‰=â€‰2.01), tumor site in the rectum (ORâ€‰=â€‰1.64), stoma creation (ORâ€‰=â€‰1.70), Complicated diabetes (ORâ€‰=â€‰1.56), Charlson Comorbidity Index (CCI) (ORâ€‰=â€‰1.27), blood transfusion (BT) (ORâ€‰=â€‰1.24), Length of hospital stay (LOS) (ORâ€‰=â€‰1.65), and surgical approach (ORâ€‰=â€‰1.22). Notably, female (ORâ€‰=â€‰0.85) was identified as a protective factor against unplanned readmission.\n\n**Conclusion:** The unplanned readmission rate within 31Â days after colorectal cancer surgery was 11.73%. Current evidence suggests that age, postoperative complications, TNMâ€‰â‰¥â€‰III, tumor site in the rectum, stoma creation, complicated diabetes, Charlson Comorbidity Index (CCI), blood transfusion (BT), length of hospital stay (LOS), and surgical approach are significant risk factors for unplanned readmission. Conversely, female has been identified as a protective factor. To mitigate these risks and reduce readmission rates, healthcare professionals should implement targeted educational and clinical interventions.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ ç™Œæ‰‹æœ¯å 31 å¤©å†…æ„å¤–å†å…¥é™¢çš„é«˜å‘ç”Ÿç‡ä»ç„¶æ˜¯ä¸€ä¸ªé‡å¤§æŒ‘æˆ˜ã€‚ç„¶è€Œï¼Œæ–‡çŒ®ä¸­ç¡®å®šçš„è¿™äº›å†å…¥é™¢çš„é£é™©å› ç´ å¹¶ä¸ä¸€è‡´ã€‚æœ¬ç ”ç©¶æ—¨åœ¨è¿›è¡Œå…¨é¢çš„èŸèƒåˆ†æï¼Œä»¥ä¼°è®¡éè®¡åˆ’å†å…¥é™¢çš„å‘ç”Ÿç‡ï¼Œå¹¶ç³»ç»Ÿåœ°è¯†åˆ«ä¸è¯¥é£é™©ç›¸å…³çš„å› ç´ ï¼Œä¸ºé™ä½å†å…¥é™¢ç‡çš„é’ˆå¯¹æ€§å¹²é¢„æªæ–½æä¾›æœ‰åŠ›çš„è¯æ®ã€‚\n\n**æ–¹æ³•ï¼š** æœ¬ç ”ç©¶æ˜¯æ ¹æ® PRISMA æŒ‡å—è¿›è¡Œçš„ã€‚æ‰€æœ‰ç ”ç©¶æ­¥éª¤ï¼ŒåŒ…æ‹¬ç ”ç©¶é€‰æ‹©ã€æ•°æ®æå–å’Œè´¨é‡è¯„ä¼°ï¼Œå‡ç”±ä¸¤ä½ä½œè€…ç‹¬ç«‹æ‰§è¡Œï¼Œä»»ä½•åˆ†æ­§å‡é€šè¿‡ä¸ç¬¬ä¸‰ä½ä½œè€…åå•†è§£å†³ã€‚å¯¹æˆªè‡³ 2025 å¹´ 1 æœˆçš„ä»¥ä¸‹æ•°æ®åº“ä¸­å·²å‘è¡¨çš„ç ”ç©¶è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼šVIP æœŸåˆŠæ•°æ®åº“ã€ä¸‡æ–¹æ•°æ®ã€CNKIã€SinoMedã€PubMedã€Embaseã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†ã€‚ä½¿ç”¨ RevMan 5.4 å’Œ Stata 17.0 è¿›è¡Œç»Ÿè®¡åˆ†æï¼Œp å€¼å°äº 0.05 è¢«è®¤ä¸ºå…·æœ‰ç»Ÿè®¡æ˜¾ç€æ€§ã€‚\n\n**ç»“æœï¼š** è¿™é¡¹èŸèƒåˆ†æç¡®å®šäº†åœ¨æ­¤æœŸé—´ä¸éè®¡åˆ’å†å…¥é™¢ç›¸å…³çš„å‡ ä¸ªé‡è¦å±é™©å› ç´ ï¼ˆPâ€‰<â€‰0.05ï¼‰ï¼ŒåŒ…æ‹¬å¹´é¾„ï¼ˆORâ€‰=â€‰1.13ï¼‰ã€æœ¯åå¹¶å‘ç—‡ï¼ˆORâ€‰=â€‰1.87ï¼‰ã€è‚¿ç˜¤åˆ†æœŸï¼ˆTNMâ€‰â‰¥â€‰IIIï¼‰ï¼ˆORâ€‰=â€‰2.01ï¼‰ã€ç›´è‚ è‚¿ç˜¤éƒ¨ä½(ORâ€‰=â€‰1.64)ã€é€ å£æœ¯ (ORâ€‰=â€‰1.70)ã€å¤æ‚æ€§ç³–å°¿ç—… (ORâ€‰=â€‰1.56)ã€æŸ¥å°”æ£®åˆå¹¶ç—‡æŒ‡æ•° (CCI) (ORâ€‰=â€‰1.27)ã€è¾“è¡€ (BT) (ORâ€‰=â€‰1.24)ã€ä½é™¢æ—¶é—´ (LOS) ï¼ˆORâ€‰=â€‰1.65ï¼‰å’Œæ‰‹æœ¯æ–¹æ³•ï¼ˆORâ€‰=â€‰1.22ï¼‰ã€‚å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œå¥³æ€§ï¼ˆORâ€‰=â€‰0.85ï¼‰è¢«è®¤ä¸ºæ˜¯é˜²æ­¢æ„å¤–å†å…¥é™¢çš„ä¿æŠ¤å› ç´ ã€‚\n\n**ç»“è®ºï¼š** ç»“ç›´è‚ ç™Œæœ¯å31å¤©å†…éè®¡åˆ’å†å…¥é™¢ç‡ä¸º11.73%ã€‚ç›®å‰çš„è¯æ®è¡¨æ˜ï¼Œå¹´é¾„ã€æœ¯åå¹¶å‘ç—‡ã€TNMâ€‰â‰¥â€‰IIIã€ç›´è‚ è‚¿ç˜¤éƒ¨ä½ã€é€ å£åˆ›å»ºã€å¹¶å‘ç³–å°¿ç—…ã€æŸ¥å°”æ£®åˆå¹¶ç—‡æŒ‡æ•°ï¼ˆCCIï¼‰ã€è¾“è¡€ï¼ˆBTï¼‰ã€ä½é™¢æ—¶é—´ï¼ˆLOSï¼‰å’Œæ‰‹æœ¯æ–¹å¼æ˜¯éè®¡åˆ’å†å…¥é™¢çš„é‡è¦å±é™©å› ç´ ã€‚ç›¸åï¼Œå¥³æ€§è¢«è®¤ä¸ºæ˜¯ä¸€ä¸ªä¿æŠ¤å› ç´ ã€‚ä¸ºäº†å‡è½»è¿™äº›é£é™©å¹¶é™ä½å†å…¥é™¢ç‡ï¼ŒåŒ»ç–—ä¿å¥ä¸“ä¸šäººå‘˜åº”å®æ–½æœ‰é’ˆå¯¹æ€§çš„æ•™è‚²å’Œä¸´åºŠå¹²é¢„æªæ–½ã€‚", "keywords_zh": "ç»“ç›´è‚ ç™Œã€èŸèƒåˆ†æã€å±é™©å› ç´ ã€éè®¡åˆ’å†å…¥é™¢", "keywords_en": "Colorectal cancer, Meta-analysis, Risk factors, Unplanned readmission", "link": "https://pubmed.ncbi.nlm.nih.gov/40269754/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 24 Apr 2025"}, {"id": "40260850", "title_en": "Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer", "title_zh": "åœ¨å®¶ä¸­ä¸åœ¨åŒ»é™¢æˆ–ç¤¾åŒºç¯å¢ƒä¸­ä¸ºæˆäººç™Œç—‡æ‚£è€…æä¾›é™è„‰æŠ—ç™Œæ²»ç–—", "authors": "Rachelle Buchbinder", "abstract_en": "**Background:** Intravenous (IV) chemotherapy and immunotherapy are administered at frequent, regular intervals (weekly to four-weekly) for 4 to 24 months, with treatment sessions lasting between 20 minutes and several hours for adults with cancer. These treatments are usually given in chemotherapy day units in hospitals as same-day treatments. However, less complex anti-cancer therapy regimens may be administered in the participant's home.\n\n**Objectives:** To assess the safety, patient preference for, and cost of IV (including subcutaneous) anti-cancer therapy (chemotherapy or immunotherapy) delivered at home as an alternative to the same IV anti-cancer therapy regimen delivered in a hospital or community setting in adults with cancer.\n\n**Search Methods:** We searched CENTRAL, Cochrane Database of Systematic Reviews, MEDLINE, Embase, CINAHL, NHS Economic Evaluation Database, Cost-Effectiveness Analysis Registry and trial registries (ClinicalTrials.gov and WHO-ICTRP) from inception until 16 October 2024. We also searched PDQ Evidence and Epistemonikos for related systematic reviews. We screened reference lists of included studies and relevant systematic reviews.\n\n**Selection Criteria:** We included randomised parallel and cross-over trials, conducted in adults (aged 18 years and over) diagnosed with any type and stage of cancer requiring IV anti-cancer chemotherapy or immunotherapy. Eligible studies compared delivery of IV anti-cancer therapy at home with delivery of the same therapy in a hospital setting (as an inpatient or outpatient), or in the community setting (e.g. GP practice, community clinic). We included economic evaluation studies (i.e. cost-effectiveness analyses, cost-utility analyses, cost-benefit analyses) conducted alongside eligible effectiveness studies. Primary outcomes were adverse events, hospital inpatient admission and additional hospital attendance (e.g. emergency department visit) within 48 hours of administration of anti-cancer therapy, IV line complications, participant preference, and cost of delivering IV anti-cancer therapy from a healthcare system perspective.\n\n**Data Collection And Analysis:** Two review authors selected studies for inclusion, extracted trial characteristics and numerical data, assessed risk of bias, and judged the certainty of evidence using the GRADE approach. The main comparison was delivery of IV anti-cancer therapy at home versus in a hospital outpatient clinic. The primary time points of interest for outcomes related to serious adverse events, complications and cost were those collected at the longest follow-up postintervention. For outcomes such as participant preference, participant quality of life, participant and caregiver satisfaction, and non-adherence to the treatment regimen, data collected at time points as soon as possible after the intervention were of primary interest.\n\n**Main Results:** We identified seven eligible trials (three parallel RCTs, four randomised cross-over trials; 401 randomised participants, with 272 participants included in the final analyses) and five ongoing trials. Five included trials were performed prior to the 2000s and two were performed between 2007 and 2011. Trial participants' mean age ranged from 60 to 70 years. Four trials recruited a mix of cancer patients, including breast, colon, rectum, pancreatic, pancreaticobiliary, non-Hodgkin's lymphoma, lung, and head and neck cancer. Three trials focused on specific cancers (i.e. colorectal cancer, breast cancer, colon cancer). Seven trials compared delivery of IV anti-cancer therapy at home versus in a hospital outpatient clinic. One trial compared delivery of IV anti-cancer therapy in the participant's home, in the hospital outpatient clinic, and in local general practice surgery. All participants were assessed either by a physician or trained chemotherapy nurse prior to receiving each treatment cycle, and trained chemotherapy nurses administered the therapy, as per standard clinical practice, in all settings in all trials. We judged three trials as having low overall risk of bias. In four trials, the overall risk of bias was unclear due to poorly reported study methods, failing to report assessed data points and inaccessible study protocols. Due to the very low certainty of the evidence, we are uncertain of the effect of delivering IV anti-cancer therapy at home versus in the hospital outpatient clinic on the response to and management of adverse events, on both hospital inpatient admission and additional hospital attendance within 48 hours of administration of anti-cancer therapy, and on IV line complications (including infection and thrombosis). Based on low-certainty evidence, participants receiving therapy at home may be more likely to prefer future treatments at home, after receiving treatment in this setting (35 more per 100, 10 to 70 more; data from 1 RCT with 65 participants). Based on low-certainty evidence, delivering IV anti-cancer therapy at home may make little or no difference to the cost of the treatment from the healthcare system perspective in comparison to delivering it in the hospital outpatient clinic (mean cost (in 2022 Australian dollars (AUD)) per treatment at home: 126 AUD less; 1798 AUD less to 1546 AUD more; data from 2 RCTs with 80 participants). We are uncertain of the effect of delivering IV anti-cancer therapy at home, versus a local GP surgery, on the response to and management of adverse events. No studies reported on hospital inpatient admission. Evidence on additional hospital attendance within 48 hours of administration of anti-cancer therapy is of very low certainty. Low-certainty evidence suggests that compared to receiving treatment in a local GP surgery, participants may or may not be more likely to prefer future treatments at home, and delivering anti-cancer therapy at home may make little or no difference to the cost of the treatment.\n\n**Authors' Conclusions:** Evidence on the safety and cost-effectiveness of IV anti-cancer therapy at home is scarce and outdated. IV anti-cancer regimens have evolved; the findings of studies performed more than a decade ago may lack applicability to current practice. However, key considerations when considering suitability for home treatment remain unchanged: safety, duration of treatment and geographic catchment area. The finding that patients may prefer future treatments at home after receiving treatment in this setting, albeit based upon low-certainty evidence, is consistent with the widespread current practice of delivering IV anti-cancer therapy, including immunotherapies, at home when judged safe and preferred by the patient. Appropriate selection of patients and regimens is a key consideration for ensuring the safety of delivering IV anti-cancer therapy at home.", "abstract_zh": "**èƒŒæ™¯ï¼š** é™è„‰ (IV) åŒ–ç–—å’Œå…ç–«ç–—æ³•ä»¥é¢‘ç¹ã€æœ‰è§„å¾‹çš„é—´éš”ï¼ˆæ¯å‘¨è‡³æ¯å››å‘¨ï¼‰è¿›è¡Œï¼ŒæŒç»­ 4 è‡³ 24 ä¸ªæœˆï¼Œå¯¹äºæˆäººç™Œç—‡æ‚£è€…ï¼Œæ²»ç–—æŒç»­ 20 åˆ†é’Ÿè‡³å‡ ä¸ªå°æ—¶ã€‚è¿™äº›æ²»ç–—é€šå¸¸åœ¨åŒ»é™¢çš„åŒ–ç–—æ—¥é—´å•ä½ä½œä¸ºå½“å¤©æ²»ç–—è¿›è¡Œã€‚ç„¶è€Œï¼Œä¸å¤ªå¤æ‚çš„æŠ—ç™Œæ²»ç–—æ–¹æ¡ˆå¯ä»¥åœ¨å‚ä¸è€…çš„å®¶ä¸­è¿›è¡Œã€‚\n\n**Objectivesï¼š** è¯„ä¼°åœ¨å®¶ä¸­è¿›è¡Œçš„é™è„‰æ³¨å°„ï¼ˆåŒ…æ‹¬çš®ä¸‹ï¼‰æŠ—ç™Œæ²»ç–—ï¼ˆåŒ–ç–—æˆ–å…ç–«æ²»ç–—ï¼‰çš„å®‰å…¨æ€§ã€æ‚£è€…åå¥½å’Œè´¹ç”¨ï¼Œä½œä¸ºæˆäººç™Œç—‡æ‚£è€…åœ¨åŒ»é™¢æˆ–ç¤¾åŒºç¯å¢ƒä¸­è¿›è¡Œçš„ç›¸åŒé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—æ–¹æ¡ˆçš„æ›¿ä»£æ–¹æ¡ˆã€‚\n\n**Search methodsï¼š** æˆ‘ä»¬æ£€ç´¢äº† CENTRALã€Cochrane ç³»ç»Ÿè¯„ä»·æ•°æ®åº“ã€MEDLINEã€Embaseã€CINAHLã€NHS ç»æµè¯„ä¼°æ•°æ®åº“ã€æˆæœ¬æ•ˆç›Šåˆ†æç™»è®°å¤„å’Œè¯•éªŒç™»è®°å¤„ï¼ˆClinicalTrials.gov å’Œ WHO-ICTRPï¼‰ï¼Œä»å¼€å§‹åˆ° 2024 å¹´ 10 æœˆ 16 æ—¥ã€‚æˆ‘ä»¬è¿˜æ£€ç´¢äº† PDQ Evidence å’Œ Epistemonikos ä»¥è·å–ç›¸å…³çš„ç³»ç»Ÿè¯„ä»·ã€‚æˆ‘ä»¬ç­›é€‰äº†çº³å…¥ç ”ç©¶çš„å‚è€ƒæ–‡çŒ®åˆ—è¡¨å’Œç›¸å…³çš„ç³»ç»Ÿè¯„ä»·ã€‚\n\n**Selection criteriaï¼š** æˆ‘ä»¬çº³å…¥äº†éšæœºå¹³è¡Œå’Œäº¤å‰è¯•éªŒï¼Œè¿™äº›è¯•éªŒåœ¨è¯Šæ–­ä¸ºä»»ä½•ç±»å‹å’Œé˜¶æ®µçš„ç™Œç—‡ä¸”éœ€è¦é™è„‰æ³¨å°„æŠ—ç™ŒåŒ–ç–—æˆ–å…ç–«æ²»ç–—çš„æˆäººï¼ˆ18 å²åŠä»¥ä¸Šï¼‰ä¸­è¿›è¡Œã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶å°†åœ¨å®¶ä¸­è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ä¸åœ¨åŒ»é™¢ç¯å¢ƒï¼ˆä½é™¢æ‚£è€…æˆ–é—¨è¯Šæ‚£è€…ï¼‰æˆ–ç¤¾åŒºç¯å¢ƒï¼ˆä¾‹å¦‚å…¨ç§‘åŒ»ç”Ÿè¯Šæ‰€ã€ç¤¾åŒºè¯Šæ‰€ï¼‰ä¸­è¿›è¡Œç›¸åŒçš„æ²»ç–—è¿›è¡Œäº†æ¯”è¾ƒã€‚æˆ‘ä»¬çº³å…¥äº†ä¸åˆæ ¼æœ‰æ•ˆæ€§ç ”ç©¶ä¸€èµ·è¿›è¡Œçš„ç»æµè¯„ä¼°ç ”ç©¶ï¼ˆå³æˆæœ¬æ•ˆç›Šåˆ†æã€æˆæœ¬æ•ˆç”¨åˆ†æã€æˆæœ¬æ•ˆç›Šåˆ†æï¼‰ã€‚ä¸»è¦ç»“å±€æ˜¯æŠ—ç™Œæ²»ç–—å 48 å°æ—¶å†…çš„ä¸è‰¯äº‹ä»¶ã€ä½é™¢æ‚£è€…å…¥é™¢å’Œé¢å¤–å°±è¯Šï¼ˆä¾‹å¦‚æ€¥è¯Šç§‘å°±è¯Šï¼‰ã€IV çº¿å¹¶å‘ç—‡ã€å‚ä¸è€…åå¥½ä»¥åŠä»åŒ»ç–—ä¿å¥ç³»ç»Ÿè§’åº¦æä¾› IV æŠ—ç™Œæ²»ç–—çš„æˆæœ¬ã€‚\n\n**Data collection and analysisï¼š** ä¸¤ä½ç»¼è¿°ä½œè€…é€‰æ‹©çº³å…¥ç ”ç©¶ï¼Œæå–è¯•éªŒç‰¹å¾å’Œæ•°å€¼æ•°æ®ï¼Œè¯„ä¼°åå€šé£é™©ï¼Œå¹¶ä½¿ç”¨ GRADE æ–¹æ³•åˆ¤æ–­è¯æ®çš„ç¡®å®šæ€§ã€‚ä¸»è¦æ¯”è¾ƒæ˜¯åœ¨å®¶ä¸­ä¸åœ¨åŒ»é™¢é—¨è¯Šè¯Šæ‰€è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ã€‚ä¸ä¸¥é‡ä¸è‰¯äº‹ä»¶ã€å¹¶å‘ç—‡å’Œè´¹ç”¨ç›¸å…³çš„ç»“æœçš„ä¸»è¦å…³æ³¨æ—¶é—´ç‚¹æ˜¯åœ¨å¹²é¢„åæœ€é•¿çš„éšè®¿ä¸­æ”¶é›†çš„æ—¶é—´ç‚¹ã€‚å¯¹äºå‚ä¸è€…åå¥½ã€å‚ä¸è€…ç”Ÿæ´»è´¨é‡ã€å‚ä¸è€…å’ŒæŠ¤ç†äººå‘˜æ»¡æ„åº¦ä»¥åŠä¸éµå®ˆæ²»ç–—æ–¹æ¡ˆç­‰ç»“æœï¼Œå¹²é¢„åå°½å¿«åœ¨æ—¶é—´ç‚¹æ”¶é›†çš„æ•°æ®æ˜¯ä¸»è¦å…³æ³¨ç‚¹ã€‚\n\n**Main resultsï¼š** æˆ‘ä»¬ç¡®å®šäº† 7 é¡¹ç¬¦åˆæ¡ä»¶çš„è¯•éªŒï¼ˆ3 é¡¹å¹³è¡Œéšæœºå¯¹ç…§è¯•éªŒã€4 é¡¹éšæœºäº¤å‰è¯•éªŒï¼›401 åéšæœºå—è¯•è€…ï¼Œå…¶ä¸­ 272 åå—è¯•è€…çº³å…¥æœ€ç»ˆåˆ†æï¼‰å’Œ 5 é¡¹æ­£åœ¨è¿›è¡Œçš„è¯•éªŒã€‚å…¶ä¸­äº”é¡¹è¯•éªŒæ˜¯åœ¨ 2000 å¹´ä»£ä¹‹å‰è¿›è¡Œçš„ï¼Œä¸¤é¡¹è¯•éªŒæ˜¯åœ¨ 2007 å¹´è‡³ 2011 å¹´ä¹‹é—´è¿›è¡Œçš„ã€‚è¯•éªŒå‚ä¸è€…çš„å¹³å‡å¹´é¾„ä¸º 60 å²è‡³ 70 å²ã€‚å››é¡¹è¯•éªŒæ‹›å‹Ÿäº†å¤šç§ç™Œç—‡æ‚£è€…ï¼ŒåŒ…æ‹¬ä¹³è…ºç™Œã€ç»“è‚ ç™Œã€ç›´è‚ ç™Œã€èƒ°è…ºç™Œã€èƒ°èƒ†ç™Œã€ééœå¥‡é‡‘æ·‹å·´ç˜¤ã€è‚ºç™Œå’Œå¤´é¢ˆç™Œã€‚ä¸‰é¡¹è¯•éªŒä¾§é‡äºç‰¹å®šç™Œç—‡ï¼ˆå³ç»“ç›´è‚ ç™Œã€ä¹³è…ºç™Œã€ç»“è‚ ç™Œï¼‰ã€‚ä¸ƒé¡¹è¯•éªŒæ¯”è¾ƒäº†åœ¨å®¶å’ŒåŒ»é™¢é—¨è¯Šè¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ã€‚ä¸€é¡¹è¯•éªŒæ¯”è¾ƒäº†åœ¨å‚ä¸è€…å®¶ä¸­ã€åŒ»é™¢é—¨è¯Šè¯Šæ‰€å’Œå½“åœ°å…¨ç§‘æ‰‹æœ¯ä¸­è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—çš„æƒ…å†µã€‚åœ¨æ¥å—æ¯ä¸ªæ²»ç–—å‘¨æœŸä¹‹å‰ï¼Œæ‰€æœ‰å‚ä¸è€…å‡ç”±åŒ»ç”Ÿæˆ–ç»è¿‡åŸ¹è®­çš„åŒ–ç–—æŠ¤å£«è¿›è¡Œè¯„ä¼°ï¼Œå¹¶ç”±ç»è¿‡åŸ¹è®­çš„åŒ–ç–—æŠ¤å£«æŒ‰ç…§æ ‡å‡†ä¸´åºŠå®è·µåœ¨æ‰€æœ‰è¯•éªŒçš„æ‰€æœ‰ç¯å¢ƒä¸­è¿›è¡Œæ²»ç–—ã€‚æˆ‘ä»¬åˆ¤æ–­ä¸‰é¡¹è¯•éªŒæ€»ä½“åå€šé£é™©è¾ƒä½ã€‚åœ¨å››é¡¹è¯•éªŒä¸­ï¼Œç”±äºç ”ç©¶æ–¹æ³•æŠ¥å‘Šä¸å……åˆ†ã€æœªèƒ½æŠ¥å‘Šè¯„ä¼°çš„æ•°æ®ç‚¹ä»¥åŠæ— æ³•è·å–çš„ç ”ç©¶æ–¹æ¡ˆï¼Œæ€»ä½“åå€šé£é™©å°šä¸æ¸…æ¥šã€‚ç”±äºè¯æ®çš„è´¨é‡éå¸¸ä½ï¼Œæˆ‘ä»¬ä¸ç¡®å®šåœ¨å®¶è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ä¸åœ¨åŒ»é™¢é—¨è¯Šè¿›è¡Œæ²»ç–—ç›¸æ¯”ï¼Œå¯¹ä¸è‰¯äº‹ä»¶çš„ååº”å’Œç®¡ç†ã€æŠ—ç™Œæ²»ç–—å 48 å°æ—¶å†…ä½é™¢æ‚£è€…å…¥é™¢å’Œé¢å¤–å°±è¯Šä»¥åŠé™è„‰æ³¨å°„å¹¶å‘ç—‡ï¼ˆåŒ…æ‹¬æ„ŸæŸ“å’Œè¡€æ “å½¢æˆï¼‰çš„å½±å“ã€‚æ ¹æ®ä½ç¡®å®šæ€§è¯æ®ï¼Œåœ¨å®¶æ¥å—æ²»ç–—çš„å‚ä¸è€…åœ¨è¿™ç§ç¯å¢ƒä¸‹æ¥å—æ²»ç–—åï¼Œå¯èƒ½æ›´å–œæ¬¢æœªæ¥åœ¨å®¶æ¥å—æ²»ç–—ï¼ˆæ¯ 100 äººä¸­å¤šå‡º 35 äººï¼Œå¤šå‡º 10 åˆ° 70 äººï¼›æ•°æ®æ¥è‡ª 1 é¡¹åŒ…å« 65 åå‚ä¸è€…çš„éšæœºå¯¹ç…§è¯•éªŒï¼‰ã€‚æ ¹æ®ä½ç¡®å®šæ€§è¯æ®ï¼Œä»åŒ»ç–—ä¿å¥ç³»ç»Ÿçš„è§’åº¦æ¥çœ‹ï¼Œä¸åœ¨åŒ»é™¢é—¨è¯Šè¿›è¡Œæ²»ç–—ç›¸æ¯”ï¼Œåœ¨å®¶è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—å¯èƒ½å¯¹æ²»ç–—æˆæœ¬å‡ ä¹æ²¡æœ‰å½±å“æˆ–æ²¡æœ‰å½±å“ï¼ˆåœ¨å®¶æ¯æ¬¡æ²»ç–—çš„å¹³å‡æˆæœ¬ï¼ˆä»¥ 2022 å¹´æ¾³å…ƒ (AUD) è®¡ç®—ï¼‰ï¼šå°‘ 126 æ¾³å…ƒï¼›å°‘ 1798 æ¾³å…ƒè‡³å¤š 1546 æ¾³å…ƒï¼›æ•°æ®æ¥è‡ª 80 åå—è¯•è€…çš„ 2 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼‰ã€‚æˆ‘ä»¬ä¸ç¡®å®šåœ¨å®¶è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ä¸å½“åœ°å…¨ç§‘åŒ»ç”Ÿæ‰‹æœ¯ç›¸æ¯”ï¼Œå¯¹ä¸è‰¯äº‹ä»¶çš„ååº”å’Œç®¡ç†çš„å½±å“ã€‚æ²¡æœ‰ç ”ç©¶æŠ¥å‘Šä½é™¢æ‚£è€…çš„å…¥é™¢æƒ…å†µã€‚æŠ—ç™Œæ²»ç–—å 48 å°æ—¶å†…é¢å¤–ä½é™¢çš„è¯æ®çš„ç¡®å®šæ€§éå¸¸ä½ã€‚ä½è´¨é‡è¯æ®è¡¨æ˜ï¼Œä¸åœ¨å½“åœ°å…¨ç§‘åŒ»ç”Ÿæ‰‹æœ¯ä¸­æ¥å—æ²»ç–—ç›¸æ¯”ï¼Œå‚ä¸è€…å¯èƒ½ä¼šæˆ–å¯èƒ½ä¸ä¼šæ›´å–œæ¬¢æœªæ¥åœ¨å®¶ä¸­çš„æ²»ç–—ï¼Œå¹¶ä¸”åœ¨å®¶æä¾›æŠ—ç™Œæ²»ç–—å¯èƒ½å¯¹æ‚£è€…æ¥è¯´å‡ ä¹æ²¡æœ‰å½±å“æˆ–æ²¡æœ‰å½±å“ã€‚\n\n**Authors' conclusionsï¼š** å…³äºå®¶åº­é™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—çš„å®‰å…¨æ€§å’Œæˆæœ¬æ•ˆç›Šçš„è¯æ®å¾ˆå°‘ä¸”å·²ç»è¿‡æ—¶ã€‚é™è„‰æ³¨å°„æŠ—ç™Œç–—æ³•å·²ç»å‘å±•ï¼›åå¤šå¹´å‰è¿›è¡Œçš„ç ”ç©¶ç»“æœå¯èƒ½ä¸é€‚ç”¨äºå½“å‰çš„å®è·µã€‚ç„¶è€Œï¼Œåœ¨è€ƒè™‘æ˜¯å¦é€‚åˆå®¶åº­æ²»ç–—æ—¶ï¼Œå…³é”®è€ƒè™‘å› ç´ ä¿æŒä¸å˜ï¼šå®‰å…¨æ€§ã€æ²»ç–—æŒç»­æ—¶é—´å’Œåœ°ç†è¦†ç›–åŒºåŸŸã€‚å°½ç®¡åŸºäºä½ç¡®å®šæ€§è¯æ®ï¼Œä½†æ‚£è€…åœ¨è¿™ç§æƒ…å†µä¸‹æ¥å—æ²»ç–—åå¯èƒ½æ›´å–œæ¬¢æœªæ¥åœ¨å®¶æ¥å—æ²»ç–—çš„å‘ç°ä¸å½“å‰å¹¿æ³›çš„åœ¨å®¶ä¸­è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ï¼ˆåŒ…æ‹¬å…ç–«æ²»ç–—ï¼‰çš„åšæ³•æ˜¯ä¸€è‡´çš„ï¼Œå½“æ‚£è€…è®¤ä¸ºå®‰å…¨ä¸”é¦–é€‰æ—¶ï¼Œåœ¨å®¶ä¸­è¿›è¡Œé™è„‰æ³¨å°„æŠ—ç™Œæ²»ç–—ï¼ˆåŒ…æ‹¬å…ç–«æ²»ç–—ï¼‰ã€‚é€‚å½“é€‰æ‹©æ‚£è€…å’Œæ–¹æ¡ˆæ˜¯ç¡®ä¿åœ¨å®¶è¿›è¡Œé™è„‰æŠ—ç™Œæ²»ç–—å®‰å…¨çš„å…³é”®è€ƒè™‘å› ç´ ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40260850/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 22 Apr 2025"}, {"id": "40246613", "title_en": "Carbon Ion Radiotherapy Reirradiation for Recurrent Malignancy: A Systematic Assessment", "title_zh": "ç¢³ç¦»å­æ”¾å°„æ²»ç–—å†ç…§å°„æ²»ç–—å¤å‘æ€§æ¶æ€§è‚¿ç˜¤ï¼šç³»ç»Ÿè¯„ä¼°", "authors": "S Chen", "abstract_en": "Reirradiation presents a significant challenge despite recent advances in modern radiation therapy. Carbon ion radiotherapy has garnered increasing attention among radiation oncologists due to its potentially superior physical dosimetric distribution and radiobiological advantages. This systematic review comprehensively evaluated clinical outcomes from 27 original studies on the use of carbon ion reirradiation for locoregional recurrent malignancies, including those affecting the central nervous system, lung, head and neck, pancreas, liver, rectum, and gynecological sites. The findings suggest that carbon ion reirradiation for locoregional recurrent malignancies yields favorable clinical outcomes with a relatively low incidence of high-grade toxicities. For recurrent nasopharyngeal carcinoma, the reported 2-year overall survival, local control, regional control, and metastasis-free survival rates were 83.7%, 58.0%, 87.3%, and 94.7%, respectively. Grade â‰¥3 late nasopharyngeal necrosis occurred in 16% (33/206) of cases. In the case of recurrent glioblastoma, median overall survival and local control survival were reported at 13 and 7 months, respectively, with minimal high-grade complications; observed low-grade toxicities included acute involuntary movements, incomplete hemiparesis, and late-onset dysphasia. For recurrent lung cancer, 2-year local control and overall survival rates were reported as 54.0% and 61.9%, respectively. Grade â‰¥3 toxicities included two cases of radiation pneumonitis and one case of bronchopleural fistula. In recurrent pancreatic cancer, 1-year local control, progression-free survival, and overall survival rates were 53.5%, 24.5%, and 48.7%, respectively. A high-grade complication of Grade 3 acute duodenal stenosis was observed in one patient. Additionally, concurrent chemotherapy with carbon ion reirradiation was associated with minimal high-grade additive toxicities. Overall, carbon ion reirradiation appears to be a potentially safe and effective reirradiation modality for treating locoregional recurrent malignancies, though data remains limited.", "abstract_zh": "å°½ç®¡ç°ä»£æ”¾å°„æ²»ç–—æœ€è¿‘å–å¾—äº†è¿›å±•ï¼Œä½†å†æ”¾å°„ä»ç„¶æ˜¯ä¸€ä¸ªé‡å¤§æŒ‘æˆ˜ã€‚ç¢³ç¦»å­æ”¾å°„æ²»ç–—ç”±äºå…¶æ½œåœ¨çš„ä¼˜è¶Šçš„ç‰©ç†å‰‚é‡åˆ†å¸ƒå’Œæ”¾å°„ç”Ÿç‰©å­¦ä¼˜åŠ¿è€Œè¶Šæ¥è¶Šå—åˆ°æ”¾å°„è‚¿ç˜¤å­¦å®¶çš„å…³æ³¨ã€‚æœ¬ç³»ç»Ÿç»¼è¿°å…¨é¢è¯„ä¼°äº† 27 é¡¹å…³äºä½¿ç”¨ç¢³ç¦»å­å†ç…§å°„æ²»ç–—å±€éƒ¨å¤å‘æ€§æ¶æ€§è‚¿ç˜¤çš„åŸå§‹ç ”ç©¶çš„ä¸´åºŠç»“æœï¼ŒåŒ…æ‹¬å½±å“ä¸­æ¢ç¥ç»ç³»ç»Ÿã€è‚ºã€å¤´é¢ˆã€èƒ°è…ºã€è‚è„ã€ç›´è‚ å’Œå¦‡ç§‘éƒ¨ä½çš„æ¶æ€§è‚¿ç˜¤ã€‚ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œç¢³ç¦»å­å†ç…§å°„æ²»ç–—å±€éƒ¨å¤å‘æ€§æ¶æ€§è‚¿ç˜¤å¯äº§ç”Ÿè‰¯å¥½çš„ä¸´åºŠç»“æœï¼Œä¸”é«˜çº§åˆ«æ¯’æ€§çš„å‘ç”Ÿç‡ç›¸å¯¹è¾ƒä½ã€‚å¯¹äºå¤å‘é¼»å’½ç™Œï¼ŒæŠ¥å‘Šçš„2å¹´æ€»ç”Ÿå­˜ç‡ã€å±€éƒ¨æ§åˆ¶ç‡ã€åŒºåŸŸæ§åˆ¶ç‡å’Œæ— è½¬ç§»ç”Ÿå­˜ç‡åˆ†åˆ«ä¸º83.7%ã€58.0%ã€87.3%å’Œ94.7%ã€‚ 16%ï¼ˆ33/206ï¼‰çš„ç—…ä¾‹å‘ç”Ÿâ‰¥3çº§æ™šæœŸé¼»å’½åæ­»ã€‚å¯¹äºå¤å‘æ€§èƒ¶è´¨æ¯ç»†èƒç˜¤ï¼Œä¸­ä½æ€»ç”Ÿå­˜æœŸå’Œå±€éƒ¨å¯¹ç…§ç”Ÿå­˜æœŸåˆ†åˆ«æŠ¥å‘Šä¸º 13 ä¸ªæœˆå’Œ 7 ä¸ªæœˆï¼Œä¸”é«˜åº¦å¹¶å‘ç—‡æå°‘ï¼›è§‚å¯Ÿåˆ°çš„ä½åº¦æ¯’æ€§åŒ…æ‹¬æ€¥æ€§ä¸è‡ªä¸»è¿åŠ¨ã€ä¸å®Œå…¨æ€§åç˜«å’Œè¿Ÿå‘æ€§è¯­è¨€éšœç¢ã€‚å¯¹äºå¤å‘æ€§è‚ºç™Œï¼Œ2 å¹´å±€éƒ¨æ§åˆ¶ç‡å’Œæ€»ç”Ÿå­˜ç‡åˆ†åˆ«ä¸º 54.0% å’Œ 61.9%ã€‚ â‰¥3çº§æ¯’æ€§åŒ…æ‹¬2ä¾‹æ”¾å°„æ€§è‚ºç‚å’Œ1ä¾‹æ”¯æ°”ç®¡èƒ¸è†œç˜˜ã€‚åœ¨å¤å‘æ€§èƒ°è…ºç™Œä¸­ï¼Œ1 å¹´å±€éƒ¨æ§åˆ¶ç‡ã€æ— è¿›å±•ç”Ÿå­˜ç‡å’Œæ€»ç”Ÿå­˜ç‡åˆ†åˆ«ä¸º 53.5%ã€24.5% å’Œ 48.7%ã€‚åœ¨ä¸€åæ‚£è€…ä¸­è§‚å¯Ÿåˆ° 3 çº§æ€¥æ€§åäºŒæŒ‡è‚ ç‹­çª„çš„é«˜çº§å¹¶å‘ç—‡ã€‚æ­¤å¤–ï¼ŒåŒæ­¥åŒ–ç–—ä¸ç¢³ç¦»å­å†ç…§å°„ä¸æœ€å°çš„é«˜çº§é™„åŠ æ¯’æ€§ç›¸å…³ã€‚æ€»ä½“è€Œè¨€ï¼Œç¢³ç¦»å­å†ç…§å°„ä¼¼ä¹æ˜¯æ²»ç–—å±€éƒ¨å¤å‘æ€§æ¶æ€§è‚¿ç˜¤çš„ä¸€ç§æ½œåœ¨å®‰å…¨æœ‰æ•ˆçš„å†ç…§å°„æ–¹å¼ï¼Œå°½ç®¡æ•°æ®ä»ç„¶æœ‰é™ã€‚", "keywords_zh": "ç¢³ç¦»å­ã€ä¸´åºŠç»“æœã€å±€éƒ¨å¤å‘ã€æ¶æ€§è‚¿ç˜¤ã€å†ç…§å°„ã€æ¯’æ€§", "keywords_en": "Carbon ion, Clinical outcomes, Locoregional recurrence, Malignancy, Reirradiation, Toxicities", "link": "https://pubmed.ncbi.nlm.nih.gov/40246613/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 17 Apr 2025"}, {"id": "40246071", "title_en": "Implantable Rectal Spacers in Prostate Cancer Radiation Therapy: A Systematic Review", "title_zh": "å‰åˆ—è…ºç™Œæ”¾å°„æ²»ç–—ä¸­æ¤å…¥å¼ç›´è‚ é—´éš”å™¨ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Ben G L Vanneste", "abstract_en": "**Purpose:** This systematic review provides an overview of the available literature regarding the efficacy and safety of implantable rectal spacers (IRSs) in reducing rectal dose and gastrointestinal toxicity during prostate cancer radiation therapy.\n\n**Methods And Materials:** A comprehensive literature search was conducted in December 2024. Results included prospective research in humans and were limited to the English language. The 30 included studies, all published between 2007 and 2024, were randomized controlled trials or clinical trials that focused on adverse events, rectal dose reduction, gastrointestinal toxicity, or bowel quality of life. Next, IRS implantation technique, safety, and spacing distance were assessed.\n\n**Results:** Randomized controlled trial data were available for hydrogel, hyaluronic acid, and rectal balloon implant spacers, whereas only one pilot study is available for human collagen. Prospective clinical research on IRS in brachytherapy is limited. One centimeter of spacing between the rectum and prostate sufficed to spare the rectum, the primary dose-limiting organ. Findings indicate a favorable safety profile, with an overall complication rate of 0,96% when using hydrogel spacers. There was no grade 4 to 5 gastrointestinal toxicity reported in clinical trials. The use of an IRS was associated with improved long-term bowel quality of life.\n\n**Conclusions:** The integration of IRS into clinical practice offers the potential to enhance the therapeutic landscape for patients with prostate cancer. However, its use should be guided by careful consideration of individual patient needs to determine those who benefit most from the IRS because not all patients may benefit equally.", "abstract_zh": "**Purposeï¼š** æœ¬ç³»ç»Ÿç»¼è¿°æ¦‚è¿°äº†æœ‰å…³æ¤å…¥å¼ç›´è‚ é—´éš”å™¨ (IRS) åœ¨å‡å°‘å‰åˆ—è…ºç™Œæ”¾å°„æ²»ç–—æœŸé—´ç›´è‚ å‰‚é‡å’Œèƒƒè‚ é“æ¯’æ€§æ–¹é¢çš„åŠŸæ•ˆå’Œå®‰å…¨æ€§çš„ç°æœ‰æ–‡çŒ®ã€‚\n\n**Methods and materialsï¼š** 2024 å¹´ 12 æœˆè¿›è¡Œäº†å…¨é¢çš„æ–‡çŒ®æ£€ç´¢ã€‚ç»“æœåŒ…æ‹¬é’ˆå¯¹äººç±»çš„å‰ç»æ€§ç ”ç©¶ï¼Œä¸”ä»…é™äºè‹±è¯­ã€‚è¿™ 30 é¡¹çº³å…¥ç ”ç©¶å‡äº 2007 å¹´è‡³ 2024 å¹´æœŸé—´å‘è¡¨ï¼Œå‡ä¸ºéšæœºå¯¹ç…§è¯•éªŒæˆ–ä¸´åºŠè¯•éªŒï¼Œé‡ç‚¹å…³æ³¨ä¸è‰¯äº‹ä»¶ã€ç›´è‚ å‰‚é‡å‡å°‘ã€èƒƒè‚ é“æ¯’æ€§æˆ–è‚ é“ç”Ÿæ´»è´¨é‡ã€‚æ¥ä¸‹æ¥ï¼Œè¯„ä¼°äº† IRS æ¤å…¥æŠ€æœ¯ã€å®‰å…¨æ€§å’Œé—´è·ã€‚\n\n**ç»“æœï¼š** æ°´å‡èƒ¶ã€é€æ˜è´¨é…¸å’Œç›´è‚ çƒå›Šæ¤å…¥å«ç‰‡æœ‰éšæœºå¯¹ç…§è¯•éªŒæ•°æ®ï¼Œè€Œäººç±»èƒ¶åŸè›‹ç™½åªæœ‰ä¸€é¡¹åˆæ­¥ç ”ç©¶ã€‚ IRS åœ¨è¿‘è·ç¦»æ”¾å°„æ²»ç–—ä¸­çš„å‰ç»æ€§ä¸´åºŠç ”ç©¶æœ‰é™ã€‚ç›´è‚ å’Œå‰åˆ—è…ºä¹‹é—´ä¸€å˜ç±³çš„é—´è·è¶³ä»¥ä¿æŠ¤ç›´è‚ ï¼Œå³ä¸»è¦çš„å‰‚é‡é™åˆ¶å™¨å®˜ã€‚ç ”ç©¶ç»“æœè¡¨æ˜ï¼Œä½¿ç”¨æ°´å‡èƒ¶å«ç‰‡æ—¶çš„æ€»ä½“å¹¶å‘ç—‡ç‡ä¸º 0.96%ï¼Œå…·æœ‰è‰¯å¥½çš„å®‰å…¨æ€§ã€‚ä¸´åºŠè¯•éªŒä¸­æœªæŠ¥å‘Š4è‡³5çº§èƒƒè‚ é“æ¯’æ€§ã€‚ IRS çš„ä½¿ç”¨ä¸é•¿æœŸè‚ é“ç”Ÿæ´»è´¨é‡çš„æ”¹å–„ç›¸å…³ã€‚\n\n**ç»“è®ºï¼š** IRS èå…¥ä¸´åºŠå®è·µæœ‰å¯èƒ½æ”¹å–„å‰åˆ—è…ºç™Œæ‚£è€…çš„æ²»ç–—å‰æ™¯ã€‚ç„¶è€Œï¼Œå…¶ä½¿ç”¨åº”ä»”ç»†è€ƒè™‘ä¸ªä½“æ‚£è€…çš„éœ€æ±‚ï¼Œä»¥ç¡®å®šå“ªäº›äººä» IRS ä¸­å—ç›Šæœ€å¤§ï¼Œå› ä¸ºå¹¶éæ‰€æœ‰æ‚£è€…éƒ½å¯ä»¥å¹³ç­‰å—ç›Šã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40246071/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 17 Apr 2025"}, {"id": "40234278", "title_en": "Inflammatory myofibroblastic tumors of the colon in pediatrics: clinical presentation, management, and outcomes-A case report and systematic review of literature", "title_zh": "å„¿ç§‘ç»“è‚ ç‚æ€§è‚Œçº¤ç»´æ¯ç»†èƒç˜¤ï¼šä¸´åºŠè¡¨ç°ã€æ²»ç–—å’Œç»“æœâ€”â€”ç—…ä¾‹æŠ¥å‘Šå’Œæ–‡çŒ®ç³»ç»Ÿå›é¡¾", "authors": "Essam Elhalaby", "abstract_en": "**Purpose:** Inflammatory myofibroblastic tumors (IMTs) of the colon represent an exceptionally rare entity in the pediatric population. This systematic review aims to comprehensively analyze the clinical presentation, diagnostic workup, management strategies, and outcomes of colorectal IMTs in children.\n\n**Methods:** A systematic literature review was conducted across multiple electronic databases (inception to January 2025), including MEDLINE (via PubMed), Embase, Cochrane, Web of Science, and Google Scholar. Two independent reviewers screened abstracts, reviewed studies, and extracted data on all reported cases of colorectal IMTs in the pediatric population, including one previously unreported case from our institution.\n\n**Results:** Including our case, 53 pediatric patients with colorectal IMTs were identified from 39 studies. The mean age at diagnosis was 7 years (range: 5 months-17 years) with a slight female preponderance. The IMTs comprised a wide range of anatomic locations with rectum (27%) and ascending colon (24%) being the most common. Abdominal pain (54%), gastrointestinal bleeding (29%), and fever (21%) were the predominant symptoms. Anemia was the most common laboratory abnormality (62%). Surgical resection was the primary treatment modality in 98% of cases. After a mean follow-up of 38 months ( range: 3-181 months), the local recurrence rate was 11%, with no distant metastases reported.\n\n**Conclusion:** Colorectal IMTs in children present diagnostic and therapeutic challenges. While complete surgical resection remains the gold standard treatment, emerging therapies such as ALK inhibitors and NSAIDs warrant further investigation. The potential for late recurrence mandates long term follow-up.", "abstract_zh": "**Purposeï¼š** ç»“è‚ ç‚æ€§è‚Œçº¤ç»´æ¯ç»†èƒè‚¿ç˜¤ (IMT) åœ¨å„¿ç§‘äººç¾¤ä¸­æ˜¯ä¸€ç§æå…¶ç½•è§çš„å®ä½“ã€‚æœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨å…¨é¢åˆ†æå„¿ç«¥ç»“ç›´è‚  IMT çš„ä¸´åºŠè¡¨ç°ã€è¯Šæ–­æ£€æŸ¥ã€ç®¡ç†ç­–ç•¥å’Œç»“æœã€‚\n\n**æ–¹æ³•ï¼š** å¯¹å¤šä¸ªç”µå­æ•°æ®åº“ï¼ˆæˆç«‹è‡³ 2025 å¹´ 1 æœˆï¼‰è¿›è¡Œäº†ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°ï¼ŒåŒ…æ‹¬ MEDLINEï¼ˆé€šè¿‡ PubMedï¼‰ã€Embaseã€Cochraneã€Web of Science å’Œ Google Scholarã€‚ä¸¤åç‹¬ç«‹è¯„å®¡å‘˜ç­›é€‰äº†æ‘˜è¦ã€è¯„å®¡äº†ç ”ç©¶å¹¶æå–äº†å„¿ç§‘äººç¾¤ä¸­æ‰€æœ‰æŠ¥å‘Šçš„ç»“ç›´è‚  IMT ç—…ä¾‹çš„æ•°æ®ï¼Œå…¶ä¸­åŒ…æ‹¬æˆ‘ä»¬æœºæ„ä»¥å‰æœªæŠ¥å‘Šçš„ä¸€ä¾‹ç—…ä¾‹ã€‚\n\n**ç»“æœï¼š** åŒ…æ‹¬æˆ‘ä»¬çš„ç—…ä¾‹åœ¨å†…ï¼Œæˆ‘ä»¬ä» 39 é¡¹ç ”ç©¶ä¸­é‰´å®šå‡º 53 åæ‚£æœ‰ç»“ç›´è‚  IMT çš„å„¿ç«¥æ‚£è€…ã€‚è¯Šæ–­æ—¶çš„å¹³å‡å¹´é¾„ä¸º 7 å²ï¼ˆèŒƒå›´ï¼š5 ä¸ªæœˆè‡³ 17 å²ï¼‰ï¼Œå…¶ä¸­å¥³æ€§ç•¥å¤šã€‚ IMT åŒ…æ‹¬å¹¿æ³›çš„è§£å‰–ä½ç½®ï¼Œå…¶ä¸­æœ€å¸¸è§çš„æ˜¯ç›´è‚  (27%) å’Œå‡ç»“è‚  (24%)ã€‚è…¹ç—›ï¼ˆ54%ï¼‰ã€èƒƒè‚ é“å‡ºè¡€ï¼ˆ29%ï¼‰å’Œå‘çƒ§ï¼ˆ21%ï¼‰æ˜¯ä¸»è¦ç—‡çŠ¶ã€‚è´«è¡€æ˜¯æœ€å¸¸è§çš„å®éªŒå®¤å¼‚å¸¸ï¼ˆ62%ï¼‰ã€‚æ‰‹æœ¯åˆ‡é™¤æ˜¯ 98% ç—…ä¾‹çš„ä¸»è¦æ²»ç–—æ–¹å¼ã€‚å¹³å‡éšè®¿38ä¸ªæœˆï¼ˆèŒƒå›´ï¼š3-181ä¸ªæœˆï¼‰åï¼Œå±€éƒ¨å¤å‘ç‡ä¸º11%ï¼Œæ— è¿œå¤„è½¬ç§»æŠ¥é“ã€‚\n\n**ç»“è®ºï¼š** å„¿ç«¥ç»“ç›´è‚  IMT æå‡ºäº†è¯Šæ–­å’Œæ²»ç–—æŒ‘æˆ˜ã€‚è™½ç„¶å®Œå…¨æ‰‹æœ¯åˆ‡é™¤ä»ç„¶æ˜¯é‡‘æ ‡å‡†æ²»ç–—ï¼Œä½† ALK æŠ‘åˆ¶å‰‚å’Œ NSAID ç­‰æ–°å…´ç–—æ³•å€¼å¾—è¿›ä¸€æ­¥ç ”ç©¶ã€‚æ™šæœŸå¤å‘çš„å¯èƒ½æ€§éœ€è¦é•¿æœŸéšè®¿ã€‚", "keywords_zh": "ç—…ä¾‹æŠ¥å‘Šã€ç»“ç›´è‚ ã€IMTã€ç‚æ€§è‚Œçº¤ç»´æ¯ç»†èƒè‚¿ç˜¤ã€è‚¿ç˜¤ã€å„¿ç§‘", "keywords_en": "Case report, Colorectal, IMT, Inflammatory myofibroblastic tumor, Neoplasm, Pediatric", "link": "https://pubmed.ncbi.nlm.nih.gov/40234278/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 15 Apr 2025"}, {"id": "40229635", "title_en": "Microbiome landscapes of the bladder, intestine, and vagina in bladder cancer: a systematic review", "title_zh": "è†€èƒ±ç™Œä¸­è†€èƒ±ã€è‚ é“å’Œé˜´é“çš„å¾®ç”Ÿç‰©ç»„æ™¯è§‚ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Uwe Bieri", "abstract_en": "**Background:** Microbiomes have been linked to oncogenesis, e.g. the intestinal microbiome and colon cancer or HPV-associated cervical cancer. A connection between microbiomes of different body cavities and tumor oncogenesis was shown. The gut microbiome's influence on bladder cancer was established, raising the question whether nearby microbiomes (rectum, vagina) also influence bladder cancer due to their proximity.\n\n**Objective:** Considering the influence of various body cavities and the broader microbial components, this systematic review aims to investigate differences in the bladder, vaginal, and intestinal microbiota-including bacterial, viral, fungal and archaea-between patients with bladder cancer and healthy controls.\n\n**Methods:** Databases (PubMed, Scopus, Embase) were searched until April 2022. Three types of studies were included: \"(1) studies using bladder cancer and control groups (case-controlled studies) (2) studies that provided information on the presence or abundance of microbial taxa (3) studies that provided information on increased or decreased taxa in bladder cancer and/or control groups.\". Risk of bias was assessed using the Newcastle Ottawa Scale.\n\n**Results:** Fourteen studies (695 samples: 403 bladder cancer, 292 controls) were analyzed. Bacterial taxa that have been detected in at least two studies, the genera Geobacillus and Rubrobacter were more frequently in bladder cancer patients; while Streptococcus and Roseomonas were more prevalent in controls. No consistent taxa were identified across stool or bladder tissue samples.\n\n**Conclusion:** The microbiota in bladder cancer patients show significant variation across studies. Standardized methods and expanded investigations into viral and fungal components are needed to clarify the role of microbiota in bladder cancer.", "abstract_zh": "**èƒŒæ™¯ï¼š** å¾®ç”Ÿç‰©ç»„ä¸è‚¿ç˜¤å‘ç”Ÿæœ‰å…³ï¼Œä¾‹å¦‚è‚ é“å¾®ç”Ÿç‰©ç¾¤ä¸ç»“è‚ ç™Œæˆ– HPV ç›¸å…³å®«é¢ˆç™Œã€‚æ˜¾ç¤ºäº†ä¸åŒä½“è…”çš„å¾®ç”Ÿç‰©ç»„ä¸è‚¿ç˜¤å‘ç”Ÿä¹‹é—´çš„è”ç³»ã€‚è‚ é“å¾®ç”Ÿç‰©ç»„å¯¹è†€èƒ±ç™Œçš„å½±å“å·²ç»ç¡®å®šï¼Œè¿™å°±æå‡ºäº†ä¸€ä¸ªé—®é¢˜ï¼šé™„è¿‘çš„å¾®ç”Ÿç‰©ç»„ï¼ˆç›´è‚ ã€é˜´é“ï¼‰æ˜¯å¦ä¹Ÿä¼šå› ä¸ºè·ç¦»è¾ƒè¿‘è€Œå½±å“è†€èƒ±ç™Œã€‚\n\n**ç›®çš„ï¼š** è€ƒè™‘åˆ°å„ç§ä½“è…”å’Œæ›´å¹¿æ³›çš„å¾®ç”Ÿç‰©æˆåˆ†çš„å½±å“ï¼Œæœ¬ç³»ç»Ÿç»¼è¿°æ—¨åœ¨ç ”ç©¶è†€èƒ±ç™Œæ‚£è€…å’Œå¥åº·å¯¹ç…§è€…ä¹‹é—´è†€èƒ±ã€é˜´é“å’Œè‚ é“å¾®ç”Ÿç‰©ç¾¤ï¼ˆåŒ…æ‹¬ç»†èŒã€ç—…æ¯’ã€çœŸèŒå’Œå¤ç»†èŒï¼‰çš„å·®å¼‚ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢æ•°æ®åº“ï¼ˆPubMedã€Scopusã€Embaseï¼‰ç›´è‡³ 2022 å¹´ 4 æœˆã€‚å…¶ä¸­åŒ…æ‹¬ä¸‰ç§ç±»å‹çš„ç ”ç©¶ï¼šâ€œ(1) ä½¿ç”¨è†€èƒ±ç™Œå’Œå¯¹ç…§ç»„çš„ç ”ç©¶ï¼ˆç—…ä¾‹å¯¹ç…§ç ”ç©¶ï¼‰(2) æä¾›æœ‰å…³å¾®ç”Ÿç‰©ç±»ç¾¤å­˜åœ¨æˆ–ä¸°åº¦çš„ä¿¡æ¯çš„ç ”ç©¶ (3) æä¾›æœ‰å…³è†€èƒ±ç™Œå’Œ/æˆ–å¯¹ç…§ç»„ä¸­ç±»ç¾¤å¢åŠ æˆ–å‡å°‘çš„ä¿¡æ¯çš„ç ”ç©¶ã€‚â€ã€‚ä½¿ç”¨çº½å¡æ–¯å°”æ¸¥å¤ªåé‡è¡¨è¯„ä¼°åå€šé£é™©ã€‚\n\n**ç»“æœï¼š** åˆ†æäº† 14 é¡¹ç ”ç©¶ï¼ˆ695 ä¸ªæ ·æœ¬ï¼š403 ä¸ªè†€èƒ±ç™Œï¼Œ292 ä¸ªå¯¹ç…§ï¼‰ã€‚è‡³å°‘åœ¨ä¸¤é¡¹ç ”ç©¶ä¸­æ£€æµ‹åˆ°çš„ç»†èŒç±»ç¾¤ï¼ŒåœŸèŠ½å­¢æ†èŒå±å’Œçº¢æ†èŒå±åœ¨è†€èƒ±ç™Œæ‚£è€…ä¸­æ›´ä¸ºå¸¸è§ï¼›è€Œé“¾çƒèŒå’Œç«ç‘°å•èƒèŒåœ¨å¯¹ç…§ç»„ä¸­æ›´ä¸ºæ™®éã€‚åœ¨ç²ªä¾¿æˆ–è†€èƒ±ç»„ç»‡æ ·æœ¬ä¸­æ²¡æœ‰å‘ç°ä¸€è‡´çš„åˆ†ç±»å•å…ƒã€‚\n\n**ç»“è®ºï¼š** è†€èƒ±ç™Œæ‚£è€…çš„å¾®ç”Ÿç‰©ç¾¤åœ¨ä¸åŒç ”ç©¶ä¸­æ˜¾â€‹â€‹ç¤ºå‡ºæ˜¾ç€å·®å¼‚ã€‚éœ€è¦æ ‡å‡†åŒ–æ–¹æ³•å’Œå¯¹ç—…æ¯’å’ŒçœŸèŒæˆåˆ†çš„æ‰©å±•ç ”ç©¶æ¥é˜æ˜å¾®ç”Ÿç‰©ç¾¤åœ¨è†€èƒ±ç™Œä¸­çš„ä½œç”¨ã€‚", "keywords_zh": "ç»†èŒã€è†€èƒ±ç™Œã€è†€èƒ±å¾®ç”Ÿç‰©ç¾¤ã€çœŸèŒã€è‚ é“å¾®ç”Ÿç‰©ç¾¤ã€å¾®ç”Ÿç‰©ç¾¤ã€é˜´é“å¾®ç”Ÿç‰©ç¾¤ã€ç—…æ¯’", "keywords_en": "Bacteria, Bladder cancer, Bladder microbiota, Fungi, Intestinal microbiota, Microbiome, Vaginal microbiota, Viruses", "link": "https://pubmed.ncbi.nlm.nih.gov/40229635/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 14 Apr 2025"}, {"id": "40225020", "title_en": "Gastrointestinal Tract Perineuriomas and Benign Fibroblastic Polyps: Case Report and Comprehensive Systematic Review", "title_zh": "èƒƒè‚ é“ç¥ç»æŸè†œç˜¤å’Œè‰¯æ€§çº¤ç»´æ¯ç»†èƒæ¯è‚‰ï¼šç—…ä¾‹æŠ¥å‘Šå’Œç»¼åˆç³»ç»Ÿè¯„ä»·", "authors": "Talat Bessissow", "abstract_en": "<b>Background:</b> Perineurioma is a rare benign peripheral nerve sheath tumor that can arise in various body locations. In the gastrointestinal (GI) tract, perineuriomas are uncommon and have only been reported in case reports and case series. In addition, a new classification suggests reclassifying benign fibroblastic polyps as perineurioma when they show positive markers of perineurial differentiation. <b>Objective:</b> This study aims to enhance understanding of GI tract perineuriomas by presenting a new case and conducting a systematic literature review. <b>Methods:</b> We described a new case of colonic perineurioma and systematically reviewed all case reports and case series on GI perineuriomas and benign fibroblastic polyps with perineurial markers. We searched ScienceDirect, PubMed/MEDLINE, and Web of Science up to May 2024. <b>Results:</b> A total of 148 cases were analyzed, and most of the cases were published in the last decade (2014-2024). The majority were females (59.46%), with a mean age of 51â€‰years (standard deviation [SD] Â±14.87). Most GI perineuriomas (87.5%) were in the distal colon, predominantly in the sigmoid/rectosigmoid (56%) and rectum (14%). Outside the colon, the stomach was the most affected site (7 of 10 cases), with fewer cases in the small intestine and esophagus. The two most commonly performed stains were for epithelial membrane antigen (EMA) and glucose transporter 1 (GLUT-1), at 75% and 56% of cases, respectively. Noncolonic perineuriomas were generally larger and more symptomatic than colonic ones. Submucosal polyps were more likely symptomatic than mucosal polyps. <b>Conclusion:</b> Perineurioma in the GI tract is a rare benign polyp mainly identified in the distal colon. Its rarity and limited follow-up data restrict our understanding of recurrence rates. We recommend reporting uncommon polyp locations, detailing polyp morphologies, and using at least two markers for classification.", "abstract_zh": "<b>èƒŒæ™¯ï¼š</b>ç¥ç»æŸè†œç˜¤æ˜¯ä¸€ç§ç½•è§çš„è‰¯æ€§å‘¨å›´ç¥ç»é˜è‚¿ç˜¤ï¼Œå¯å‘ç”Ÿåœ¨èº«ä½“çš„å„ä¸ªéƒ¨ä½ã€‚åœ¨èƒƒè‚ é“ï¼ˆGIï¼‰ä¸­ï¼Œç¥ç»æŸè†œç˜¤å¹¶ä¸å¸¸è§ï¼Œä»…åœ¨ç—…ä¾‹æŠ¥å‘Šå’Œç—…ä¾‹ç³»åˆ—ä¸­æŠ¥é“è¿‡ã€‚æ­¤å¤–ï¼Œä¸€ç§æ–°çš„åˆ†ç±»å»ºè®®ï¼Œå½“è‰¯æ€§æˆçº¤ç»´ç»†èƒæ¯è‚‰æ˜¾ç¤ºå‡ºç¥ç»æŸè†œåˆ†åŒ–çš„é˜³æ€§æ ‡è®°æ—¶ï¼Œå°†å…¶é‡æ–°åˆ†ç±»ä¸ºç¥ç»æŸè†œç˜¤ã€‚ <b>ç›®çš„ï¼š</b>æœ¬ç ”ç©¶æ—¨åœ¨é€šè¿‡æå‡ºæ–°ç—…ä¾‹å¹¶è¿›è¡Œç³»ç»Ÿæ–‡çŒ®ç»¼è¿°æ¥å¢å¼ºå¯¹èƒƒè‚ é“ç¥ç»æŸè†œç˜¤çš„äº†è§£ã€‚ <b>æ–¹æ³•ï¼š</b>æˆ‘ä»¬æè¿°äº†ä¸€ä¸ªæ–°çš„ç»“è‚ ç¥ç»æŸè†œç—…ä¾‹ï¼Œå¹¶ç³»ç»Ÿåœ°å›é¡¾äº†æœ‰å…³èƒƒè‚ é“ç¥ç»æŸè†œç˜¤å’Œå…·æœ‰ç¥ç»æŸè†œæ ‡è®°çš„è‰¯æ€§æˆçº¤ç»´ç»†èƒæ¯è‚‰çš„æ‰€æœ‰ç—…ä¾‹æŠ¥å‘Šå’Œç—…ä¾‹ç³»åˆ—ã€‚æˆ‘ä»¬æ£€ç´¢äº†æˆªè‡³ 2024 å¹´ 5 æœˆçš„ ScienceDirectã€PubMed/MEDLINE å’Œ Web of Scienceã€‚<b>ç»“æœï¼š</b>å…±åˆ†æäº† 148 ä¸ªç—…ä¾‹ï¼Œå¤§å¤šæ•°ç—…ä¾‹å‘è¡¨äºè¿‡å»åå¹´ï¼ˆ2014-2024 å¹´ï¼‰ã€‚å¤§å¤šæ•°ä¸ºå¥³æ€§ (59.46%)ï¼Œå¹³å‡å¹´é¾„ä¸º 51 å²ï¼ˆæ ‡å‡†å·® [SD] Â±14.87ï¼‰ã€‚å¤§å¤šæ•°èƒƒè‚ é“ç¥ç»æŸè†œç˜¤ï¼ˆ87.5%ï¼‰ä½äºè¿œç«¯ç»“è‚ ï¼Œä¸»è¦ä½äºä¹™çŠ¶ç»“è‚ /ç›´è‚ ä¹™çŠ¶ç»“è‚ ï¼ˆ56%ï¼‰å’Œç›´è‚ ï¼ˆ14%ï¼‰ã€‚åœ¨ç»“è‚ ä»¥å¤–ï¼Œèƒƒæ˜¯å—å½±å“æœ€ä¸¥é‡çš„éƒ¨ä½ï¼ˆ10ä¾‹ä¸­æœ‰7ä¾‹ï¼‰ï¼Œå°è‚ å’Œé£Ÿé“çš„ç—…ä¾‹è¾ƒå°‘ã€‚æœ€å¸¸è¿›è¡Œçš„ä¸¤ç§æŸ“è‰²æ˜¯ä¸Šçš®è†œæŠ—åŸ (EMA) å’Œè‘¡è„ç³–è½¬è¿è›‹ç™½ 1 (GLUT-1)ï¼Œåˆ†åˆ«å  75% å’Œ 56% çš„ç—…ä¾‹ã€‚éç»“è‚ ç¥ç»æŸè†œç˜¤é€šå¸¸æ¯”ç»“è‚ ç¥ç»æŸè†œç˜¤æ›´å¤§ä¸”ç—‡çŠ¶æ›´ä¸¥é‡ã€‚ç²˜è†œä¸‹æ¯è‚‰æ¯”ç²˜è†œæ¯è‚‰æ›´æœ‰å¯èƒ½å‡ºç°ç—‡çŠ¶ã€‚ <b>ç»“è®ºï¼š</b> èƒƒè‚ é“ç¥ç»æŸè†œç˜¤æ˜¯ä¸€ç§ç½•è§çš„è‰¯æ€§æ¯è‚‰ï¼Œä¸»è¦å‘ç”Ÿåœ¨è¿œç«¯ç»“è‚ ã€‚å®ƒçš„ç¨€æœ‰æ€§å’Œæœ‰é™çš„éšè®¿æ•°æ®é™åˆ¶äº†æˆ‘ä»¬å¯¹å¤å‘ç‡çš„ç†è§£ã€‚æˆ‘ä»¬å»ºè®®æŠ¥å‘Šä¸å¸¸è§çš„æ¯è‚‰ä½ç½®ï¼Œè¯¦ç»†è¯´æ˜æ¯è‚‰å½¢æ€ï¼Œå¹¶ä½¿ç”¨è‡³å°‘ä¸¤ä¸ªæ ‡è®°è¿›è¡Œåˆ†ç±»ã€‚", "keywords_zh": "è‰¯æ€§æˆçº¤ç»´ç»†èƒæ¯è‚‰, ç—…ä¾‹æŠ¥å‘Š, ç—…ä¾‹ç³»åˆ—, èƒƒè‚ é“, ç¥ç»æŸè†œç˜¤, ç³»ç»Ÿè¯„ä»·", "keywords_en": "benign fibroblastic polyps, case report, case series, gastrointestinal tract, perineurioma, systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40225020/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 14 Apr 2025"}, {"id": "40192825", "title_en": "Botulinum toxin injection for management of post-haemorrhoidectomy pain: an updated systematic review and meta-analysis of randomised clinical trials", "title_zh": "è‚‰æ¯’æ¯’ç´ æ³¨å°„æ²»ç–—ç—”ç–®åˆ‡é™¤æœ¯åç–¼ç—›ï¼šéšæœºä¸´åºŠè¯•éªŒçš„æœ€æ–°ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "S Albayati", "abstract_en": "**Introduction:** Excisional haemorrhoidectomy remains the gold-standard treatment for grade III-IV haemorrhoids owing to the high success rate. However, post-operative pain management is an ongoing challenge. Botulinum toxin injection is thought to improve pain by targeting the internal anal sphincter spasm which occurs following haemorrhoidectomy. This systematic review and meta-analysis examines the effects of concurrent botulinum toxin injection on post-haemorrhoidectomy pain.\n\n**Methods:** A search of MEDLINE, EMBASE and Cochrane Databases for randomised controlled trials (RCTs) of botulinum toxin injection compared with placebo for management of post-haemorrhoidectomy pain was conducted following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Outcomes assessed included daily post-operative pain scores assessed using an analogue scale (0-10), pain at first defecation, analgesia use, complication rates and time to return to work.\n\n**Results:** A total of seven RCTs assessing 340 patients who underwent an excisional haemorrhoidectomy were included. In total, seven studies (nâ€‰=â€‰340) found significant reduction in pain post-procedure with botulinum toxin use on day 1 (mean difference, MD -1.53; 95% confidence intervals, CI -2.12, -0.94; pâ€‰<â€‰0.00001), with similar findings on day 2 and 4 (MD -1.84, 95% CI -3.28, -0.41; pâ€‰=â€‰0.01 and MD -1.63, 95% CI -2.15, -1.09; pâ€‰<â€‰0.00001, respectively). However, the analgesic effects were not seen on subsequent analyses up to day 14. Botulinum toxin was seen to be safe, with no significant difference in faecal incontinence (MD 1.05, 95% CI 0.40, 2.75; pâ€‰=â€‰0.93) or urinary retention (MD 0.37, 95% CI 0.09, 1.53; pâ€‰=â€‰0.17).\n\n**Conclusions:** Botulinum toxin use for pain relief post-excisional haemorrhoidectomy is safe and effective in the initial peri-operative period; however, the results were short-lived. Further, more robust randomised controlled trials are needed to strengthen these findings and determine the utility of botulinum toxin in this setting.\n\n**Trial Registration:** PROSPERO Register for Systematic Reviews Registration Number - CRD42024541351 on April 29 2024.", "abstract_zh": "**ä»‹ç»ï¼š** ç”±äºæˆåŠŸç‡é«˜ï¼Œç—”åˆ‡é™¤æœ¯ä»ç„¶æ˜¯æ²»ç–— III-IV çº§ç—”ç–®çš„é‡‘æ ‡å‡†ã€‚ç„¶è€Œï¼Œæœ¯åç–¼ç—›ç®¡ç†æ˜¯ä¸€ä¸ªæŒç»­çš„æŒ‘æˆ˜ã€‚è‚‰æ¯’æ†èŒæ¯’ç´ æ³¨å°„è¢«è®¤ä¸ºå¯ä»¥é€šè¿‡é’ˆå¯¹ç—”ç–®åˆ‡é™¤æœ¯åå‘ç”Ÿçš„è‚›é—¨å†…æ‹¬çº¦è‚Œç—‰æŒ›æ¥æ”¹å–„ç–¼ç—›ã€‚è¿™é¡¹ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æç ”ç©¶äº†åŒæ—¶æ³¨å°„è‚‰æ¯’æ¯’ç´ å¯¹ç—”ç–®åˆ‡é™¤æœ¯åç–¼ç—›çš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ®ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—ï¼Œåœ¨ MEDLINEã€EMBASE å’Œ Cochrane æ•°æ®åº“ä¸­æ£€ç´¢äº†è‚‰æ¯’æ¯’ç´ æ³¨å°„ä¸å®‰æ…°å‰‚æ²»ç–—ç—”ç–®åˆ‡é™¤æœ¯åç–¼ç—›çš„éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€‚è¯„ä¼°çš„ç»“æœåŒ…æ‹¬ä½¿ç”¨æ¨¡æ‹Ÿé‡è¡¨ï¼ˆ0-10ï¼‰è¯„ä¼°çš„æ¯æ—¥æœ¯åç–¼ç—›è¯„åˆ†ã€ç¬¬ä¸€æ¬¡æ’ä¾¿æ—¶çš„ç–¼ç—›ã€é•‡ç—›å‰‚çš„ä½¿ç”¨ã€å¹¶å‘ç—‡å‘ç”Ÿç‡å’Œé‡è¿”å·¥ä½œå²—ä½çš„æ—¶é—´ã€‚\n\n**ç»“æœï¼š** æ€»å…±çº³å…¥äº† 7 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼Œè¯„ä¼°äº† 340 åæ¥å—ç—”åˆ‡é™¤æœ¯çš„æ‚£è€…ã€‚æ€»å…±æœ‰ä¸ƒé¡¹ç ”ç©¶ (nâ€‰=â€‰340) å‘ç°ï¼Œåœ¨ç¬¬ 1 å¤©ä½¿ç”¨è‚‰æ¯’æ†èŒæ¯’ç´ å¯æ˜¾ç€å‡è½»æœ¯åç–¼ç—›ï¼ˆå¹³å‡å·®ï¼ŒMD -1.53ï¼›95% ç½®ä¿¡åŒºé—´ï¼ŒCI -2.12, -0.94ï¼›p<â€‰0.00001ï¼‰ï¼Œç¬¬ 2 å¤©å’Œç¬¬ 4 å¤©ä¹Ÿæœ‰ç±»ä¼¼çš„ç»“æœï¼ˆMD -1.84ï¼Œ95% CI -3.28ï¼Œ -0.41ï¼›pâ€‰=â€‰0.01ï¼ŒMD -1.63ï¼Œ95% CI -2.15ï¼Œ-1.09ï¼›pâ€‰<â€‰0.00001ï¼‰ã€‚ç„¶è€Œï¼Œåœ¨éšåçš„ç¬¬ 14 å¤©åˆ†æä¸­å¹¶æœªå‘ç°é•‡ç—›ä½œç”¨ã€‚è‚‰æ¯’æ†èŒæ¯’ç´ è¢«è®¤ä¸ºæ˜¯å®‰å…¨çš„ï¼Œåœ¨å¤§ä¾¿å¤±ç¦ï¼ˆMD 1.05ï¼Œ95% CI 0.40ï¼Œ2.75ï¼›pâ€‰=â€‰0.93ï¼‰æˆ–å°¿æ½´ç•™ï¼ˆMD 0.37ï¼Œ95% CI 0.09ï¼Œ1.53ï¼›pâ€‰=â€‰0.93ï¼‰æ–¹é¢æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚ pâ€‰=â€‰0.17ï¼‰ã€‚\n\n**ç»“è®ºï¼š** åœ¨å›´æ‰‹æœ¯æœŸåˆæœŸï¼Œä½¿ç”¨è‚‰æ¯’æ†èŒæ¯’ç´ ç¼“è§£ç—”ç–®åˆ‡é™¤æœ¯åçš„ç–¼ç—›æ˜¯å®‰å…¨æœ‰æ•ˆçš„ï¼›ç„¶è€Œï¼Œç»“æœæ˜¯çŸ­æš‚çš„ã€‚æ­¤å¤–ï¼Œéœ€è¦æ›´å¼ºæœ‰åŠ›çš„éšæœºå¯¹ç…§è¯•éªŒæ¥åŠ å¼ºè¿™äº›å‘ç°å¹¶ç¡®å®šè‚‰æ¯’æ†èŒæ¯’ç´ åœ¨è¿™ç§æƒ…å†µä¸‹çš„æ•ˆç”¨ã€‚\n\n**Trial registrationï¼š** PROSPERO äº 2024 å¹´ 4 æœˆ 29 æ—¥æ³¨å†Œç³»ç»Ÿè¯„ä»·æ³¨å†Œå· - CRD42024541351ã€‚", "keywords_zh": "é•‡ç—›ã€è‚‰æ¯’æ†èŒæ¯’ç´ ã€ç—”ç–®åˆ‡é™¤æœ¯ã€ç–¼ç—›ã€æœ¯å", "keywords_en": "Analgesia, Botulinum Toxins, Hemorrhoidectomy, Pain, Post-operative", "link": "https://pubmed.ncbi.nlm.nih.gov/40192825/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 07 Apr 2025"}, {"id": "40186734", "title_en": "A systematic review of preoperative radiological factors associated with the development of low anterior resection syndrome (LARS)", "title_zh": "ä¸ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ˆLARSï¼‰å‘ç”Ÿç›¸å…³çš„æœ¯å‰æ”¾å°„å­¦å› ç´ çš„ç³»ç»Ÿè¯„ä»·", "authors": "Giuseppe CurrÃ²", "abstract_en": "The aim of this systematic review is to summarise the available evidence for radiological changes associated with postoperative low anterior resection syndrome (LARS). A literature search was undertaken for all studies focusing on preoperative radiological predictors of postoperative LARS. Articles were selected from MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) databases up to October 2024. Eighty-four articles were screened: eighty-one were excluded and three were included in the analysis. All included studies focused on preoperative Magnetic Resonance Imaging (MRI) already performed as part of the oncological assessments, no study examined ultrasound or defecography. Authors retrospectively selected patients that underwent LAR, screened them with the LARS score, and reviewed preoperative MRI images with specific softwares in order to find radiological characteristics associated with LARS. Results showed that particular anatomical characteristics were present in patients that subsequently developed major LARS: the volume of the pubococcygealâ€‰+â€‰iliococcygeus muscles in 27 LARS patients out of 46 LAR (odds ratio-OR 14.7, 95% CI 1.7-128.3; pâ€‰=â€‰0.02), the thickness of the anorectal joint in 136 LARS out of 255 LAR preceded by neoadjuvant chemoradiotherapy (OR 0.653, 95% CI 0.565-0.756; pâ€‰=â€‰0.001) and the mesorectal/pelvic volumes in 135 LARS out of 236 LAR (Cox Regression analysis, pâ€‰=â€‰0.0017 and pâ€‰=â€‰0.0001 respectively). Pelvic floor musculature is a factor, among the others, that contributes to LARS. Future prospective studies need to validate these retrospective results, further delineate its influence, and investigate the potential contribution of other radiologic investigations (ultrasound and defecography) in this setting.", "abstract_zh": "æœ¬ç³»ç»Ÿè¯„ä»·çš„ç›®çš„æ˜¯æ€»ç»“ä¸æœ¯åä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ï¼ˆLARSï¼‰ç›¸å…³çš„æ”¾å°„å­¦å˜åŒ–çš„ç°æœ‰è¯æ®ã€‚å¯¹æ‰€æœ‰å…³æ³¨æœ¯å LARS æœ¯å‰æ”¾å°„å­¦é¢„æµ‹å› ç´ çš„ç ”ç©¶è¿›è¡Œäº†æ–‡çŒ®æ£€ç´¢ã€‚æˆªè‡³ 2024 å¹´ 10 æœˆï¼Œæ–‡ç« é€‰è‡ª MEDLINEã€EMBASE å’Œ Cochrane å¯¹ç…§è¯•éªŒä¸­å¤®æ³¨å†Œåº“ (CENTRAL) æ•°æ®åº“ã€‚ç­›é€‰äº† 84 ç¯‡æ–‡ç« ï¼š81 ç¯‡è¢«æ’é™¤ï¼Œ3 ç¯‡çº³å…¥åˆ†æã€‚æ‰€æœ‰çº³å…¥çš„ç ”ç©¶éƒ½é›†ä¸­åœ¨ä½œä¸ºè‚¿ç˜¤å­¦è¯„ä¼°ä¸€éƒ¨åˆ†è¿›è¡Œçš„æœ¯å‰ç£å…±æŒ¯æˆåƒ (MRI)ï¼Œæ²¡æœ‰ç ”ç©¶æ£€æŸ¥è¶…å£°æˆ–æ’ç²ªé€ å½±ã€‚ä½œè€…å›é¡¾æ€§é€‰æ‹©æ¥å— LAR çš„æ‚£è€…ï¼Œé€šè¿‡ LARS è¯„åˆ†å¯¹å…¶è¿›è¡Œç­›æŸ¥ï¼Œå¹¶ä½¿ç”¨ç‰¹å®šè½¯ä»¶æŸ¥çœ‹æœ¯å‰ MRI å›¾åƒï¼Œä»¥å‘ç°ä¸ LARS ç›¸å…³çš„æ”¾å°„å­¦ç‰¹å¾ã€‚ç»“æœæ˜¾ç¤ºï¼Œéšåå‘ç”Ÿä¸¥é‡ LARS çš„æ‚£è€…å­˜åœ¨ç‰¹å®šçš„è§£å‰–å­¦ç‰¹å¾ï¼š46 ä¾‹ LAR æ‚£è€…ä¸­ï¼Œ27 ä¾‹æ‚£è€…çš„è€»éª¨å°¾éª¨â€‰+â€‰é«‚å°¾éª¨è‚Œè‚‰ä½“ç§¯ï¼ˆæ¯”å€¼æ¯” OR 14.7ï¼Œ95% CI 1.7-128.3ï¼›pâ€‰=â€‰0.02ï¼‰ï¼Œ136 ä¾‹ LARS ä¸­è‚›é—¨ç›´è‚ å…³èŠ‚çš„åšåº¦255 ä¾‹ LAR ä¸­å…ˆè¡Œæ–°è¾…åŠ©æ”¾åŒ–ç–—ï¼ˆOR 0.653ï¼Œ95% CI 0.565-0.756ï¼›pâ€‰=â€‰0.001ï¼‰ï¼Œ236 ä¾‹ LAR ä¸­ 135 ä¾‹ LARS çš„ç›´è‚ ç³»è†œ/ç›†è…”ä½“ç§¯ï¼ˆCox å›å½’åˆ†æï¼Œpâ€‰=â€‰0.0017 å’Œpâ€‰=â€‰0.0001ï¼‰ã€‚ç›†åº•è‚Œè‚‰ç»„ç»‡æ˜¯å¯¼è‡´ LARS çš„ä¸€ä¸ªå› ç´ ã€‚æœªæ¥çš„å‰ç»æ€§ç ”ç©¶éœ€è¦éªŒè¯è¿™äº›å›é¡¾æ€§ç»“æœï¼Œè¿›ä¸€æ­¥æè¿°å…¶å½±å“ï¼Œå¹¶è°ƒæŸ¥å…¶ä»–æ”¾å°„å­¦æ£€æŸ¥ï¼ˆè¶…å£°å’Œæ’ç²ªé€ å½±ï¼‰åœ¨æ­¤æƒ…å†µä¸‹çš„æ½œåœ¨è´¡çŒ®ã€‚", "keywords_zh": "ä½ä½å‰åˆ‡é™¤ç»¼åˆå¾ã€ç£å…±æŒ¯æˆåƒã€ç›†åº•ç–¾ç—…ã€æ”¾å°„å­¦ã€è¶…å£°", "keywords_en": "Low anterior resection syndrome, Magnetic resonance imaging, Pelvic floor diseases, Radiology, Ultrasound", "link": "https://pubmed.ncbi.nlm.nih.gov/40186734/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sat, 05 Apr 2025"}, {"id": "40171091", "title_en": "Treatment of Hemorrhoidal Disease in Patients with Liver Cirrhosis: A Systematic Review", "title_zh": "è‚ç¡¬åŒ–æ‚£è€…ç—”ç–®çš„æ²»ç–—ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Paulo Salgueiro", "abstract_en": "**Introduction:** The incidence of hemorrhoidal disease (HD) in cirrhotic patients is similar to that of general population, varying between 21% and 79%. Managing this clinical condition in these patients is challenging, due to the need to differentiate between bleeding originating from hemorrhoids or anorectal varices, and the unique hemostatic balance of each patient, which can lead to a decompensation of liver function and subsequently increase the anesthetic risk. To date, there are no systematic reviews specifically addressing this topic.\n\n**Methods:** This was a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were retrieved from three electronic databases. Efficacy (symptomatic improvement, patient satisfaction, quality of life improvement, disease recurrence/need for surgery and/or hemorrhoidal prolapse reduction in anoscopy) and safety (reported adverse events) outcomes were evaluated. Data from each study were initially described individually, followed by a comparative analysis for procedures applied in multiple studies.\n\n**Results:** Six studies were included - 1 randomized clinical trial (RCT), 2 prospective cohort studies, 1 retrospective cohort study, and 2 case series. The considered techniques encompassed rubber band ligation (RBL), injection sclerotherapy (IS) using 3 agents - aluminum potassium sulfate and tannic acid (ALTA), ethanolamine oleate 5% (EAO), or N-butyl-cyanoacrylate, hemorrhoidopexy, and emborrhoid technique. RBL showed great symptomatic improvement and patient satisfaction in 63% and 73% of patients, respectively, and in 90% was associated with one-grade prolapse reduction after only one session. The most frequently reported adverse events included pain (16%) and ulceration/fissure (1-17%). Concerning IS, symptomatic improvement was observed in all patients. Recurrence rates varied with the agent used (EAO: 13% at 12 months; N-butyl-cyanoacrylate: 40% at 12 months; ALTA: 18% at 5 years), and 86.7% of patients exhibited more than one-grade reduction after the initial session. The most frequent adverse event was pain (EAO: 63%; N-butyl-cyanoacrylate: 60%). Stapled hemorrhoidopexy resulted in symptomatic improvement in all patients, although associated with a recurrence rate of 25% within 4 months. With an emborrhoid technique, 80% of the patients showed clinical improvement at a 3-month follow-up, without significant adverse events, at the cost of a 40% recurrence rate.\n\n**Conclusions:** All the treatment methods assessed in the included studies appear to be effective and safe in cirrhotic patients. This assumption challenges previous concerns regarding significant bleeding after office-based procedures like RBL in this population. Future research should prioritize RCT to thoroughly assess the management of HD in these patients, particularly addressing polidocanol foam sclerotherapy, a minimally invasive technique that has previously been shown to be more effective than RBL in the general population and in patients with bleeding disorders.", "abstract_zh": "**ä»‹ç»ï¼š** è‚ç¡¬åŒ–æ‚£è€…ä¸­ç—”ç–®ç–¾ç—… (HD) çš„å‘ç—…ç‡ä¸ä¸€èˆ¬äººç¾¤ç›¸ä¼¼ï¼Œåœ¨ 21% è‡³ 79% ä¹‹é—´å˜åŒ–ã€‚å¤„ç†è¿™äº›æ‚£è€…çš„è¿™ç§ä¸´åºŠçŠ¶å†µå…·æœ‰æŒ‘æˆ˜æ€§ï¼Œå› ä¸ºéœ€è¦åŒºåˆ†æºè‡ªç—”ç–®æˆ–è‚›é—¨ç›´è‚ é™è„‰æ›²å¼ çš„å‡ºè¡€ï¼Œä»¥åŠæ¯ä¸ªæ‚£è€…ç‹¬ç‰¹çš„æ­¢è¡€å¹³è¡¡ï¼Œè¿™å¯èƒ½å¯¼è‡´è‚åŠŸèƒ½å¤±ä»£å¿ï¼Œä»è€Œå¢åŠ éº»é†‰é£é™©ã€‚è¿„ä»Šä¸ºæ­¢ï¼Œè¿˜æ²¡æœ‰ä¸“é—¨é’ˆå¯¹è¯¥ä¸»é¢˜çš„ç³»ç»Ÿç»¼è¿°ã€‚\n\n**æ–¹æ³•ï¼š** è¿™æ˜¯éµå¾ªç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æé¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—çš„ç³»ç»Ÿè¯„ä»·ã€‚ç ”ç©¶æ˜¯ä»ä¸‰ä¸ªç”µå­æ•°æ®åº“ä¸­æ£€ç´¢çš„ã€‚è¯„ä¼°ç–—æ•ˆï¼ˆç—‡çŠ¶æ”¹å–„ã€æ‚£è€…æ»¡æ„åº¦ã€ç”Ÿæ´»è´¨é‡æ”¹å–„ã€ç–¾ç—…å¤å‘/æ‰‹æœ¯éœ€è¦å’Œ/æˆ–è‚›é—¨é•œæ£€æŸ¥ä¸­ç—”ç–®è„±å‚å‡å°‘ï¼‰å’Œå®‰å…¨æ€§ï¼ˆæŠ¥å‘Šçš„ä¸è‰¯äº‹ä»¶ï¼‰ç»“æœã€‚æ¯é¡¹ç ”ç©¶çš„æ•°æ®æœ€åˆéƒ½æ˜¯å•ç‹¬æè¿°çš„ï¼Œç„¶åå¯¹å¤šé¡¹ç ”ç©¶ä¸­åº”ç”¨çš„ç¨‹åºè¿›è¡Œæ¯”è¾ƒåˆ†æã€‚\n\n**ç»“æœï¼š** çº³å…¥å…­é¡¹ç ”ç©¶ - 1 é¡¹éšæœºä¸´åºŠè¯•éªŒ (RCT)ã€2 é¡¹å‰ç»æ€§é˜Ÿåˆ—ç ”ç©¶ã€1 é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶å’Œ 2 é¡¹ç—…ä¾‹ç³»åˆ—ç ”ç©¶ã€‚è€ƒè™‘çš„æŠ€æœ¯åŒ…æ‹¬æ©¡çš®ç­‹ç»“æ‰ (RBL)ã€ä½¿ç”¨ 3 ç§è¯ç‰©çš„æ³¨å°„ç¡¬åŒ–ç–—æ³• (IS) - ç¡«é…¸é“é’¾å’Œå•å®é…¸ (ALTA)ã€æ²¹é…¸ä¹™é†‡èƒº 5% (EAO) æˆ–æ°°åŸºä¸™çƒ¯é…¸æ­£ä¸é…¯ã€ç—”ç–®å›ºå®šæœ¯å’Œç—”ç–®æŠ€æœ¯ã€‚ RBL åˆ†åˆ«åœ¨ 63% å’Œ 73% çš„æ‚£è€…ä¸­æ˜¾ç¤ºå‡ºæå¤§çš„ç—‡çŠ¶æ”¹å–„å’Œæ‚£è€…æ»¡æ„åº¦ï¼Œå¹¶ä¸” 90% çš„æ‚£è€…ä»…åœ¨ä¸€æ¬¡ç–—ç¨‹åå°±å®ç°äº†ä¸€çº§è„±å‚å‡å°‘ã€‚æœ€å¸¸æŠ¥å‘Šçš„ä¸è‰¯äº‹ä»¶åŒ…æ‹¬ç–¼ç—›ï¼ˆ16%ï¼‰å’Œæºƒç–¡/è£‚éš™ï¼ˆ1-17%ï¼‰ã€‚å…³äº ISï¼Œæ‰€æœ‰æ‚£è€…å‡è§‚å¯Ÿåˆ°ç—‡çŠ¶æ”¹å–„ã€‚å¤å‘ç‡éšæ‰€ç”¨è¯ç‰©çš„ä¸åŒè€Œå˜åŒ–ï¼ˆEAOï¼š12 ä¸ªæœˆæ—¶ä¸º 13%ï¼›æ°°åŸºä¸™çƒ¯é…¸æ­£ä¸é…¯ï¼š12 ä¸ªæœˆæ—¶ä¸º 40%ï¼›ALTAï¼š5 å¹´æ—¶ä¸º 18%ï¼‰ï¼Œ86.7% çš„æ‚£è€…åœ¨åˆæ¬¡æ²»ç–—åè¡¨ç°å‡ºè¶…è¿‡ä¸€çº§çš„å¤å‘ç‡ã€‚æœ€å¸¸è§çš„ä¸è‰¯äº‹ä»¶æ˜¯ç–¼ç—›ï¼ˆEAOï¼š63%ï¼›æ°°åŸºä¸™çƒ¯é…¸æ­£ä¸é…¯ï¼š60%ï¼‰ã€‚å»åˆå™¨ç—”ç–®å›ºå®šæœ¯ä½¿æ‰€æœ‰æ‚£è€…çš„ç—‡çŠ¶å¾—åˆ°æ”¹å–„ï¼Œä½† 4 ä¸ªæœˆå†…å¤å‘ç‡é«˜è¾¾ 25%ã€‚ä½¿ç”¨ç—”ç–®æŠ€æœ¯ï¼Œ80% çš„æ‚£è€…åœ¨ 3 ä¸ªæœˆçš„éšè®¿ä¸­è¡¨ç°å‡ºä¸´åºŠæ”¹å–„ï¼Œæ²¡æœ‰æ˜æ˜¾çš„ä¸è‰¯äº‹ä»¶ï¼Œä½†ä»£ä»·æ˜¯ 40% çš„å¤å‘ç‡ã€‚\n\n**ç»“è®ºï¼š** çº³å…¥ç ”ç©¶ä¸­è¯„ä¼°çš„æ‰€æœ‰æ²»ç–—æ–¹æ³•ä¼¼ä¹å¯¹è‚ç¡¬åŒ–æ‚£è€…æœ‰æ•ˆä¸”å®‰å…¨ã€‚è¿™ä¸€å‡è®¾æŒ‘æˆ˜äº†ä¹‹å‰å¯¹è¯¥äººç¾¤è¿›è¡Œ RBL ç­‰åŠå…¬å®¤æ‰‹æœ¯åå‡ºç°å¤§é‡å‡ºè¡€çš„æ‹…å¿§ã€‚æœªæ¥çš„ç ”ç©¶åº”ä¼˜å…ˆè€ƒè™‘éšæœºå¯¹ç…§è¯•éªŒï¼Œä»¥å½»åº•è¯„ä¼°è¿™äº›æ‚£è€…çš„ HD æ²»ç–—ï¼Œç‰¹åˆ«æ˜¯è§£å†³èšå¤šå¡é†‡æ³¡æ²«ç¡¬åŒ–ç–—æ³•ï¼Œè¿™æ˜¯ä¸€ç§å¾®åˆ›æŠ€æœ¯ï¼Œæ­¤å‰å·²è¢«è¯æ˜åœ¨æ™®é€šäººç¾¤å’Œå‡ºè¡€æ€§ç–¾ç—…æ‚£è€…ä¸­æ¯” RBL æ›´æœ‰æ•ˆã€‚", "keywords_zh": "ç—”ç–®ç–¾ç—…ï¼Œè‚ç¡¬åŒ–ï¼Œç³»ç»Ÿè¯„ä»·", "keywords_en": "Hemorrhoidal disease, Liver cirrhosis, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40171091/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 02 Apr 2025"}, {"id": "40161159", "title_en": "Hemorrhoidal Artery Ligation (HAL) vs. Rubber Band Ligation (RBL) for Second- and Third-Degree Hemorrhoids: A Systematic Review and Meta-Analysis", "title_zh": "äºŒåº¦å’Œä¸‰åº¦ç—”ç–®çš„ç—”åŠ¨è„‰ç»“æ‰ (HAL) ä¸æ©¡çš®ç­‹ç»“æ‰ (RBL)ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Ali Yasen Mohamedahmed", "abstract_en": "This systematic review investigates the outcomes of rubber band ligation (RBL) vs. hemorrhoidal artery ligation (HAL) for second and third-degree hemorrhoids. This review was designed, performed, and reported as per the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Literature databases, including PubMed, Cochrane, Science Direct, and Google Scholar, were searched for studies comparing rubber band ligation vs. hemorrhoidal artery ligation for second- and third-degree hemorrhoids. The primary outcome was the recurrence of hemorrhoids, while post-operative bleeding, post-operative pain, surgical site infection, and success rate were the secondary outcomes. The literature search and inclusion criteria identified five studies (n=953) comparing HAL (n=548) vs. RBL (n=405). The recurrence rate was higher in the RBL group (28.4%) compared to the HAL group (19.3%) (odds ratio {OR}: 0.57, p=0.001). The two groups showed comparable results regarding post-operative pain (OR: 0.77, p=0.77), post-operative bleeding (OR: 1.48, p=0.44), and surgical site infection (risk difference: 0.00, p=0.67). Moreover, the short-term success rate was 85% in HAL compared to 86% in RBL (p=0.71). Rubber band ligation and hemorrhoidal artery ligation showed comparable short-term outcomes regarding symptom treatment, post-operative bleeding, and pain. However, HAL was superior in terms of recurrence rate.", "abstract_zh": "æœ¬ç³»ç»Ÿç»¼è¿°ç ”ç©¶äº†æ©¡çš®ç­‹ç»“æ‰ (RBL) ä¸ç—”åŠ¨è„‰ç»“æ‰ (HAL) å¯¹äºäºŒåº¦å’Œä¸‰åº¦ç—”ç–®çš„ç–—æ•ˆã€‚æœ¬æ¬¡è¯„ä»·æ˜¯æ ¹æ®å¹²é¢„ç³»ç»Ÿè¯„ä»· Cochrane æ‰‹å†Œä»¥åŠç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æé¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—çš„å»ºè®®è¿›è¡Œè®¾è®¡ã€æ‰§è¡Œå’ŒæŠ¥å‘Šçš„ã€‚æ£€ç´¢äº†åŒ…æ‹¬ PubMedã€Cochraneã€Science Direct å’Œ Google Scholar åœ¨å†…çš„æ–‡çŒ®æ•°æ®åº“ï¼ŒæŸ¥æ‰¾æ¯”è¾ƒæ©¡çš®ç­‹ç»“æ‰ä¸ç—”åŠ¨è„‰ç»“æ‰æ²»ç–—äºŒåº¦å’Œä¸‰åº¦ç—”ç–®çš„ç ”ç©¶ã€‚ä¸»è¦ç»“å±€æ˜¯ç—”ç–®å¤å‘ï¼Œæ¬¡è¦ç»“å±€æ˜¯æœ¯åå‡ºè¡€ã€æœ¯åç–¼ç—›ã€æ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“å’ŒæˆåŠŸç‡ã€‚æ–‡çŒ®æ£€ç´¢å’Œçº³å…¥æ ‡å‡†ç¡®å®šäº†äº”é¡¹ç ”ç©¶ (n=953)ï¼Œæ¯”è¾ƒ HAL (n=548) ä¸ RBL (n=405)ã€‚ RBL ç»„çš„å¤å‘ç‡ (28.4%) é«˜äº HAL ç»„ (19.3%)ï¼ˆæ¯”å€¼æ¯” {OR}ï¼š0.57ï¼Œp=0.001ï¼‰ã€‚ä¸¤ç»„åœ¨æœ¯åç–¼ç—›ï¼ˆORï¼š0.77ï¼Œp=0.77ï¼‰ã€æœ¯åå‡ºè¡€ï¼ˆORï¼š1.48ï¼Œp=0.44ï¼‰å’Œæ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ï¼ˆé£é™©å·®å¼‚ï¼š0.00ï¼Œp=0.67ï¼‰æ–¹é¢æ˜¾ç¤ºå‡ºå¯æ¯”çš„ç»“æœã€‚æ­¤å¤–ï¼ŒHAL çš„çŸ­æœŸæˆåŠŸç‡ä¸º 85%ï¼Œè€Œ RBL çš„çŸ­æœŸæˆåŠŸç‡ä¸º 86% (p=0.71)ã€‚æ©¡çš®ç­‹ç»“æ‰å’Œç—”åŠ¨è„‰ç»“æ‰åœ¨ç—‡çŠ¶æ²»ç–—ã€æœ¯åå‡ºè¡€å’Œç–¼ç—›æ–¹é¢æ˜¾ç¤ºå‡ºç›¸å½“çš„çŸ­æœŸç»“æœã€‚ç„¶è€Œï¼ŒHAL åœ¨å¤å‘ç‡æ–¹é¢æ›´èƒœä¸€ç­¹ã€‚", "keywords_zh": "äºŒåº¦ã€ä¸‰åº¦ç—”ç–®ï¼ŒäºŒåº¦ï¼Œä¸‰åº¦ç—”ç–®ï¼Œç—”åŠ¨è„‰ç»“æ‰æ‰‹æœ¯ï¼ˆæ™•ï¼‰ï¼Œç—”ç–®æ‰‹æœ¯ï¼Œç›´è‚ ç§‘ï¼Œæ©¡çš®ç­‹ç»“æ‰æ‰‹æœ¯", "keywords_en": "2nd and 3rd degree hemorrhoids, 2nd degree and 3rd degree haemorrhoids, hemorrhoidal artery ligation operation (halo), hemorrhoids surgery, proctology, rubber band ligation procedure", "link": "https://pubmed.ncbi.nlm.nih.gov/40161159/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 31 Mar 2025"}, {"id": "40148836", "title_en": "Rectal prolapse as an initial presentation of colorectal cancer: a systematic review", "title_zh": "ç›´è‚ è„±å‚ä½œä¸ºç»“ç›´è‚ ç™Œçš„é¦–å‘è¡¨ç°ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Esmat Davoudi-Monfared", "abstract_en": "**Background:** Colorectal cancer rising incidence still pose a public health challenge. In the present systematic review, we aimed to study the colorectal cancer patients with initial presentation of rectal prolapse.\n\n**Method:** The study protocol was developed (PROSPERO CRD42017060473). We searched Web of Science, PubMed and Scopus to identify case reports of rectal Prolapse as a chief compliant of colorectal cancer. The Preferred Reporting Items for Systematic Reviews and Meta- Analysis (PRISMA) guidelines were used for screening and data extraction.\n\n**Results:** Thirty-one case reports were included in this review. More than half of the patients were females over 65 years old and meanâ€‰Â±â€‰SD age of the cases were 64â€‰Â±â€‰17.9 years and, the female gender were mentioned in 17 (56%) case reports. The majority (64.5%) of the identified cancer belong to rectum and recto-sigmoid origin's location. In the history retained from the cases, rectal bleeding and constipation were the most frequent reported accompanied symptoms in colorectal cancer cases with initial presentation of rectal prolapse. 67.7% of all identified cases in this review published at 2015 and later.\n\n**Conclusion:** Rectal prolapse can be an initial presentation of colorectal cancer, which is more prevalent in female more than 65 years old. The most common symptoms accompanied rectal prolapse were rectal bleeding and constipation. According to rising published case reports on colorectal cancer patients with initial presentation of rectal prolapse in recent years, further work-up is recommended for patients without predisposing factors for a concomitant tumor.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ ç™Œå‘ç—…ç‡ä¸Šå‡ä»ç„¶æ„æˆå…¬å…±å«ç”ŸæŒ‘æˆ˜ã€‚åœ¨æœ¬ç³»ç»Ÿè¯„ä»·ä¸­ï¼Œæˆ‘ä»¬æ—¨åœ¨ç ”ç©¶ä»¥ç›´è‚ è„±å‚ä¸ºé¦–å‘ç—‡çŠ¶çš„ç»“ç›´è‚ ç™Œæ‚£è€…ã€‚\n\n**Methodï¼š** åˆ¶å®šäº†ç ”ç©¶æ–¹æ¡ˆï¼ˆPROSPERO CRD42017060473ï¼‰ã€‚æˆ‘ä»¬æœç´¢äº† Web of Scienceã€PubMed å’Œ Scopusï¼Œä»¥ç¡®å®šç›´è‚ è„±å‚ä½œä¸ºç»“ç›´è‚ ç™Œä¸»è¦ç—‡çŠ¶çš„ç—…ä¾‹æŠ¥å‘Šã€‚ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æçš„é¦–é€‰æŠ¥å‘Šé¡¹ç›® (PRISMA) æŒ‡å—ç”¨äºç­›é€‰å’Œæ•°æ®æå–ã€‚\n\n**ç»“æœï¼š** æœ¬æ¬¡å®¡æŸ¥çº³å…¥äº† 31 ä»½ç—…ä¾‹æŠ¥å‘Šã€‚è¶…è¿‡ä¸€åŠçš„æ‚£è€…ä¸º65å²ä»¥ä¸Šçš„å¥³æ€§ï¼Œç—…ä¾‹çš„å¹³å‡Â±SDå¹´é¾„ä¸º64Â±17.9å²ï¼Œ17ä¾‹ï¼ˆ56%ï¼‰ç—…ä¾‹æŠ¥å‘Šä¸­æåˆ°äº†å¥³æ€§ã€‚å¤§å¤šæ•°ï¼ˆ64.5%ï¼‰å·²å‘ç°çš„ç™Œç—‡å±äºç›´è‚ å’Œç›´è‚ ä¹™çŠ¶ç»“è‚ èµ·æºä½ç½®ã€‚åœ¨ç—…ä¾‹ä¿ç•™çš„ç—…å²ä¸­ï¼Œç›´è‚ å‡ºè¡€å’Œä¾¿ç§˜æ˜¯æœ€åˆè¡¨ç°ä¸ºç›´è‚ è„±å‚çš„ç»“ç›´è‚ ç™Œç—…ä¾‹ä¸­æœ€å¸¸è§çš„ä¼´éšç—‡çŠ¶ã€‚æœ¬æ¬¡å®¡æŸ¥ä¸­å‘ç°çš„æ‰€æœ‰æ¡ˆä¾‹ä¸­ï¼Œ67.7% æ˜¯åœ¨ 2015 å¹´åŠä¹‹åå‘å¸ƒçš„ã€‚\n\n**ç»“è®ºï¼š** ç›´è‚ è„±å‚å¯èƒ½æ˜¯ç»“ç›´è‚ ç™Œçš„é¦–å‘è¡¨ç°ï¼Œç»“ç›´è‚ ç™Œåœ¨ 65 å²ä»¥ä¸Šçš„å¥³æ€§ä¸­æ›´ä¸ºå¸¸è§ã€‚ç›´è‚ è„±å‚æœ€å¸¸è§çš„ç—‡çŠ¶æ˜¯ç›´è‚ å‡ºè¡€å’Œä¾¿ç§˜ã€‚è¿‘å¹´æ¥ï¼Œå…³äºåˆæ¬¡å‡ºç°ç›´è‚ è„±å‚çš„ç»“ç›´è‚ ç™Œæ‚£è€…çš„ç—…ä¾‹æŠ¥å‘Šä¸æ–­å¢åŠ ï¼Œå»ºè®®å¯¹æ²¡æœ‰ä¼´éšè‚¿ç˜¤è¯±å‘å› ç´ çš„æ‚£è€…è¿›è¡Œè¿›ä¸€æ­¥æ£€æŸ¥ã€‚", "keywords_zh": "ç»“ç›´è‚ ç™Œ, åˆæ¬¡è¡¨ç°, ç›´è‚ è„±å‚, ç³»ç»Ÿè¯„ä»·", "keywords_en": "Colorectal cancer, Initial presentation, Rectal prolapse, Systematic review", "link": "https://pubmed.ncbi.nlm.nih.gov/40148836/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 28 Mar 2025"}, {"id": "40148672", "title_en": "Does biodegradable peri-rectal spacer mitigate treatment toxicities in radiation therapy for localised prostate cancer-a systematic review and meta-analysis", "title_zh": "å¯ç”Ÿç‰©é™è§£çš„ç›´è‚ å‘¨å›´é—´éš”ç‰©æ˜¯å¦å¯ä»¥å‡è½»å±€é™æ€§å‰åˆ—è…ºç™Œæ”¾å°„æ²»ç–—çš„æ²»ç–—æ¯’æ€§â€”â€”ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Jeremy Yuen-Chun Teoh", "abstract_en": "**Introduction:** There is an increasing use of biodegradable peri-rectal spacer prior to radiation therapy for prostate cancer to reduce treatment-associated rectal toxicity. While data from individual trials and cohorts is maturing, there is a lack of an updated quantitative analysis that includes outcomes following peri-rectal spacer. We aim to delineate the clinical impact of peri-rectal spacer in localised prostate cancer patients treated with radiotherapy.\n\n**Methods:** In March 2024, a systematic search was performed on MEDLINE, Embase, and Cochrane Central Register of controlled trials for publications since the year 2010. Prospective and retrospective studies reporting comparative outcomes of patients with and without peri-rectal spacer prior to radiotherapy were considered. Outcomes are reported in binary fashion. Random effect meta-analysis with the use of weighted mean difference was adopted. Early (â‰¤3 months) and late rectal toxicity stratified according to the Common Terminology Criteria for Adverse Events (CTCAE) criteria, early and late genitourinary toxicity, quality of life in bowel, sexual and urinary domains (in terms of minimal clinically important difference) were assessed.\n\n**Results:** The systematic review included 17 studies. There are 3 RCTs, 3 prospective cohorts, and 11 retrospective cohorts. Three thousand two hundred patients were included, with 1471 patients who received peri-rectal spacer and 1729 without. The use of spacer is associated with lower likelihood of late (1.62% vs. 9.35%, RRâ€‰=â€‰0.25, 95% CIâ€‰=â€‰0.15-0.42, Pâ€‰<â€‰0.001) and early grade 2 or above late rectal toxicity (3.07% vs. 6.05%, RRâ€‰=â€‰0.53, 95% CIâ€‰=â€‰0.33-0.86, Pâ€‰<â€‰0.001). No difference is observed in significant grade 3 or above GI (acute or late) events. There is no statistical difference in bowel-related bowel QoL (risk differenceâ€‰=â€‰-0.16, 95% CIâ€‰=â€‰-0.38-0.06, Pâ€‰=â€‰0.15). The perirectal spacer is not associated with negative impact to urinary or sexual domains of QoL either.\n\n**Conclusion:** In localised prostate cancer patients treated with radiation therapy, the use of peri-rectal spacer is associated with reduced rectal toxicities.", "abstract_zh": "**ä»‹ç»ï¼š** åœ¨å‰åˆ—è…ºç™Œæ”¾å°„æ²»ç–—ä¹‹å‰ï¼Œè¶Šæ¥è¶Šå¤šåœ°ä½¿ç”¨å¯ç”Ÿç‰©é™è§£çš„ç›´è‚ å‘¨å›´é—´éš”ç‰©ï¼Œä»¥å‡å°‘æ²»ç–—ç›¸å…³çš„ç›´è‚ æ¯’æ€§ã€‚è™½ç„¶æ¥è‡ªä¸ªåˆ«è¯•éªŒå’Œé˜Ÿåˆ—çš„æ•°æ®æ­£åœ¨æˆç†Ÿï¼Œä½†ç¼ºä¹åŒ…æ‹¬ç›´è‚ å‘¨å›´é—´éš”å™¨åç»“æœçš„æ›´æ–°çš„å®šé‡åˆ†æã€‚æˆ‘ä»¬çš„ç›®çš„æ˜¯æè¿°ç›´è‚ å‘¨å›´é—´éš”ç‰©å¯¹æ¥å—æ”¾å°„æ²»ç–—çš„å±€é™æ€§å‰åˆ—è…ºç™Œæ‚£è€…çš„ä¸´åºŠå½±å“ã€‚\n\n**æ–¹æ³•ï¼š** 2024 å¹´ 3 æœˆï¼Œå¯¹ MEDLINEã€Embase å’Œ Cochrane Central Register ä¸Šè‡ª 2010 å¹´ä»¥æ¥å‘è¡¨çš„å¯¹ç…§è¯•éªŒè¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚è€ƒè™‘äº†æŠ¥å‘Šæ”¾ç–—å‰ä½¿ç”¨å’Œä¸ä½¿ç”¨ç›´è‚ å‘¨å›´é—´éš”ç‰©çš„æ‚£è€…çš„æ¯”è¾ƒç»“æœçš„å‰ç»æ€§å’Œå›é¡¾æ€§ç ”ç©¶ã€‚ç»“æœä»¥äºŒè¿›åˆ¶æ–¹å¼æŠ¥å‘Šã€‚é‡‡ç”¨åŠ æƒå¹³å‡å·®çš„éšæœºæ•ˆåº”èŸèƒåˆ†æã€‚æ ¹æ®ä¸è‰¯äº‹ä»¶é€šç”¨æœ¯è¯­æ ‡å‡† (CTCAE) æ ‡å‡†åˆ†å±‚çš„æ—©æœŸï¼ˆâ‰¤3 ä¸ªæœˆï¼‰å’Œæ™šæœŸç›´è‚ æ¯’æ€§ã€æ—©æœŸå’Œæ™šæœŸæ³Œå°¿ç”Ÿæ®–æ¯’æ€§ã€è‚ é“ã€æ€§å’Œæ³Œå°¿é¢†åŸŸçš„ç”Ÿæ´»è´¨é‡ï¼ˆå°±æœ€å°ä¸´åºŠé‡è¦å·®å¼‚è€Œè¨€ï¼‰è¿›è¡Œäº†è¯„ä¼°ã€‚\n\n**ç»“æœï¼š** ç³»ç»Ÿè¯„ä»·åŒ…æ‹¬ 17 é¡¹ç ”ç©¶ã€‚æœ‰ 3 ä¸ªéšæœºå¯¹ç…§è¯•éªŒã€3 ä¸ªå‰ç»æ€§é˜Ÿåˆ—å’Œ 11 ä¸ªå›é¡¾æ€§é˜Ÿåˆ—ã€‚ç ”ç©¶çº³å…¥äº† 3200 åæ‚£è€…ï¼Œå…¶ä¸­ 1471 åæ‚£è€…æ¥å—äº†ç›´è‚ å‘¨å›´é—´éš”å™¨ï¼Œ1729 åæ‚£è€…æœªæ¥å—ç›´è‚ å‘¨å›´é—´éš”å™¨ã€‚ä½¿ç”¨å«ç‰‡ä¸æ™šæœŸï¼ˆ1.62% vs. 9.35%ï¼ŒRRâ€‰=â€‰0.25ï¼Œ95% CIâ€‰=â€‰0.15-0.42ï¼ŒPâ€‰<â€‰0.001ï¼‰å’Œæ—©æœŸ2çº§æˆ–ä»¥ä¸Šæ™šæœŸç›´è‚ æ¯’æ€§çš„å¯èƒ½æ€§è¾ƒä½ï¼ˆ3.07% vs. 6.05%ï¼ŒRRâ€‰=â€‰0.53ï¼Œ 95% CIâ€‰=â€‰0.33-0.86ï¼ŒPâ€‰<â€‰0.001ï¼‰ã€‚åœ¨æ˜¾ç€çš„ 3 çº§æˆ–ä»¥ä¸Š GIï¼ˆæ€¥æ€§æˆ–æ™šæœŸï¼‰äº‹ä»¶ä¸­æ²¡æœ‰è§‚å¯Ÿåˆ°å·®å¼‚ã€‚è‚ é“ç›¸å…³çš„è‚ é“QoLæ²¡æœ‰ç»Ÿè®¡å­¦å·®å¼‚ï¼ˆé£é™©å·®â€‰=â€‰-0.16ï¼Œ95% CIâ€‰=â€‰-0.38-0.06ï¼ŒPâ€‰=â€‰0.15ï¼‰ã€‚ç›´è‚ å‘¨å›´é—´éš”ç‰©ä¹Ÿä¸ä¼šå¯¹æ³Œå°¿æˆ–æ€§é¢†åŸŸçš„ç”Ÿæ´»è´¨é‡äº§ç”Ÿè´Ÿé¢å½±å“ã€‚\n\n**ç»“è®ºï¼š** åœ¨æ¥å—æ”¾å°„æ²»ç–—çš„å±€é™æ€§å‰åˆ—è…ºç™Œæ‚£è€…ä¸­ï¼Œä½¿ç”¨ç›´è‚ å‘¨å›´é—´éš”ç‰©å¯å‡å°‘ç›´è‚ æ¯’æ€§ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40148672/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 28 Mar 2025"}, {"id": "40135757", "title_en": "Author's Reply to Letter About: How to Write a Systematic Review and Meta-Analysis", "title_zh": "ä½œè€…å¯¹å…³äºä»¥ä¸‹å†…å®¹çš„ä¿¡çš„å›å¤ï¼šå¦‚ä½•æ’°å†™ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Richard L Nelson", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40135757/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 26 Mar 2025"}, {"id": "40135742", "title_en": "Striking A Balance: The Risks of Oversimplifying Systematic Review Methodology", "title_zh": "å–å¾—å¹³è¡¡ï¼šè¿‡åº¦ç®€åŒ–ç³»ç»Ÿå®¡æŸ¥æ–¹æ³•çš„é£é™©", "authors": "Rachel Riera", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/40135742/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 26 Mar 2025"}, {"id": "40102483", "title_en": "Comparative pregnancy rate after colorectal resection versus other surgical procedures for deep infiltrating rectal endometriosis: a systematic review and meta-analysis", "title_zh": "ç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸å…¶ä»–æ·±éƒ¨æµ¸æ¶¦ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡æ‰‹æœ¯åå¦Šå¨ ç‡çš„æ¯”è¾ƒï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Jean-Marc Ayoubi", "abstract_en": "The debate around colorectal surgery for endometriosis has been ongoing, but to date no meta-analysis has investigated the impact of the different surgical approaches on the pregnancy rate. The aim of this meta-analysis study was to determine in women with deep infiltrating rectal endometriosis, how does colorectal resection surgery compare to other surgical techniques (e.g., rectal shaving, disc excision) in terms of pregnancy rates. We searched PubMed, Web of Science, Cochrane library and Clinical Trials for relevant studies published from inception to December 2024. We performed a systematic review and meta-analysis of all English language full-text articles addressing colorectal resection compared with other management of deep infiltrating rectal endometriosis and presenting pregnancy outcomes. We included a study when it (i) provided data on surgical management (shaving, disc excision, and/or colorectal resection) and (ii) detailed the pregnancy outcomes in each subgroup. Four authors independently performed the initial search to evaluate the eligibility criteria. Four authors extracted the data and a fifth author checked this extraction. Of the 113 full-text articles assessed for eligibility, we included 13 in the meta-analysis. These studies represented a total of 3,248 patients. Pregnancy information was available for 2,131 patients: 1073 colorectal resection, 502 shaving, 172 disc excisions, and 384 other practices (expectant management). Colorectal resection was associated with a lower pregnancy rate compared with the other techniques (Nâ€‰=â€‰2,131, odds ratio [OR]â€‰=â€‰0.64 [95% confidence interval 0.52-0.79], pâ€‰<â€‰0.001, I2â€‰=â€‰35%). There were similar results when comparing colorectal resection with rectal shaving (Nâ€‰=â€‰952, ORâ€‰=â€‰0.51 [95% confidence interval 0.36-0.73], pâ€‰<â€‰0.001, I2â€‰=â€‰0%), but not when comparing colorectal resection with disc excision (Nâ€‰=â€‰432, ORâ€‰=â€‰0.65 [95% confidence interval 0.37-1.13], pâ€‰=â€‰0.13). Conclusions Rectal resection for endometriosis is associated with a lower pregnancy rate compared with other type of surgery, such as shaving. Trial registration: PROSPERO registration number CRD42024512328.", "abstract_zh": "å…³äºå­å®«å†…è†œå¼‚ä½ç—‡çš„ç»“ç›´è‚ æ‰‹æœ¯çš„äº‰è®ºä¸€ç›´åœ¨æŒç»­ï¼Œä½†è¿„ä»Šä¸ºæ­¢è¿˜æ²¡æœ‰èŸèƒåˆ†æè°ƒæŸ¥ä¸åŒæ‰‹æœ¯æ–¹æ³•å¯¹å¦Šå¨ ç‡çš„å½±å“ã€‚è¿™é¡¹èŸèƒåˆ†æç ”ç©¶çš„ç›®çš„æ˜¯ç¡®å®šå¯¹äºæ‚£æœ‰æ·±éƒ¨æµ¸æ¶¦ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡çš„å¥³æ€§ï¼Œç»“ç›´è‚ åˆ‡é™¤æ‰‹æœ¯ä¸å…¶ä»–æ‰‹æœ¯æŠ€æœ¯ï¼ˆä¾‹å¦‚ç›´è‚ å‰ƒé™¤æœ¯ã€æ¤é—´ç›˜åˆ‡é™¤æœ¯ï¼‰ç›¸æ¯”ï¼Œå…¶å¦Šå¨ ç‡å¦‚ä½•ã€‚æˆ‘ä»¬æ£€ç´¢äº† PubMedã€Web of Scienceã€Cochrane å›¾ä¹¦é¦†å’Œä¸´åºŠè¯•éªŒï¼ŒæŸ¥æ‰¾ä»å¼€å§‹åˆ° 2024 å¹´ 12 æœˆå‘è¡¨çš„ç›¸å…³ç ”ç©¶ã€‚æˆ‘ä»¬å¯¹æ‰€æœ‰æ¶‰åŠç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸æ·±éƒ¨æµ¸æ¶¦ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡çš„å…¶ä»–æ²»ç–—æ–¹æ³•å’Œå¦Šå¨ ç»“å±€çš„è‹±æ–‡å…¨æ–‡æ–‡ç« è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æã€‚æˆ‘ä»¬çº³å…¥äº†ä¸€é¡¹ç ”ç©¶ï¼Œå®ƒï¼ˆiï¼‰æä¾›äº†æ‰‹æœ¯æ²»ç–—ï¼ˆå‰ƒæ¯›ã€æ¤é—´ç›˜åˆ‡é™¤å’Œ/æˆ–ç»“ç›´è‚ åˆ‡é™¤ï¼‰çš„æ•°æ®ï¼Œå¹¶ä¸”ï¼ˆiiï¼‰è¯¦ç»†è¯´æ˜äº†æ¯ä¸ªäºšç»„çš„å¦Šå¨ ç»“å±€ã€‚å››ä½ä½œè€…ç‹¬ç«‹è¿›è¡Œäº†åˆæ­¥æ£€ç´¢ä»¥è¯„ä¼°èµ„æ ¼æ ‡å‡†ã€‚å››ä½ä½œè€…æå–äº†æ•°æ®ï¼Œç¬¬äº”ä½ä½œè€…æ£€æŸ¥äº†æ­¤æå–ã€‚åœ¨è¯„ä¼°èµ„æ ¼çš„ 113 ç¯‡å…¨æ–‡æ–‡ç« ä¸­ï¼Œæˆ‘ä»¬å°† 13 ç¯‡çº³å…¥èŸèƒåˆ†æã€‚è¿™äº›ç ”ç©¶æ€»å…±æ¶‰åŠ 3,248 åæ‚£è€…ã€‚æä¾›äº† 2,131 åæ‚£è€…çš„æ€€å­•ä¿¡æ¯ï¼š1073 ä¾‹ç»“ç›´è‚ åˆ‡é™¤æœ¯ã€502 ä¾‹å‰ƒæ¯›æœ¯ã€172 ä¾‹æ¤é—´ç›˜åˆ‡é™¤æœ¯å’Œ 384 ä¾‹å…¶ä»–æ‰‹æœ¯ï¼ˆæœŸå¾…æ²»ç–—ï¼‰ã€‚ä¸å…¶ä»–æŠ€æœ¯ç›¸æ¯”ï¼Œç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸è¾ƒä½çš„å¦Šå¨ ç‡ç›¸å…³ï¼ˆNâ€‰=â€‰2,131ï¼Œæ¯”å€¼æ¯”[OR]â€‰=â€‰0.64 [95%ç½®ä¿¡åŒºé—´0.52-0.79]ï¼Œpâ€‰<â€‰0.001ï¼ŒI2â€‰=â€‰35%ï¼‰ã€‚æ¯”è¾ƒç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸ç›´è‚ å‰ƒé™¤æœ¯æ—¶æœ‰ç›¸ä¼¼çš„ç»“æœï¼ˆNâ€‰=â€‰952ï¼ŒORâ€‰=â€‰0.51 [95%ç½®ä¿¡åŒºé—´0.36-0.73]ï¼Œpâ€‰<â€‰0.001ï¼ŒI2â€‰=â€‰0%ï¼‰ï¼Œä½†æ¯”è¾ƒç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸æ¤é—´ç›˜åˆ‡é™¤æœ¯æ—¶åˆ™ä¸ç„¶ï¼ˆNâ€‰=â€‰432ï¼Œ ORâ€‰=â€‰0.65 [95% ç½®ä¿¡åŒºé—´ 0.37-1.13]ï¼Œpâ€‰=â€‰0.13ï¼‰ã€‚ç»“è®º ä¸å…¶ä»–ç±»å‹çš„æ‰‹æœ¯ï¼ˆä¾‹å¦‚å‰ƒæ¯›ï¼‰ç›¸æ¯”ï¼Œç›´è‚ åˆ‡é™¤æœ¯æ²»ç–—å­å®«å†…è†œå¼‚ä½ç—‡çš„å¦Šå¨ ç‡è¾ƒä½ã€‚è¯•ç”¨æ³¨å†Œï¼šPROSPEROæ³¨å†Œå·CRD42024512328ã€‚", "keywords_zh": "ç»“ç›´è‚ åˆ‡é™¤æœ¯ã€æ¤é—´ç›˜åˆ‡é™¤æœ¯ã€å­å®«å†…è†œå¼‚ä½ç—‡ã€æ€€å­•ã€å‰ƒæ¯›", "keywords_en": "Colorectal resection, Disc excision, Endometriosis, Pregnancy, Shaving", "link": "https://pubmed.ncbi.nlm.nih.gov/40102483/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 19 Mar 2025"}, {"id": "40072118", "title_en": "Key Factors to Consider for Candida auris Screening in Healthcare Settings: A Systematic Review", "title_zh": "åŒ»ç–—æœºæ„ä¸­è€³å¿µç èŒç­›æŸ¥è¦è€ƒè™‘çš„å…³é”®å› ç´ ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Mari Molvik", "abstract_en": "**Background:** Candida auris is an emerging fungal pathogen that is often multidrug-resistant. It can persist on skin and in hospital environments, leading to outbreaks and severe infections for patients at risk. Several countries and institutions are working on establishing guidelines and recommendations for prevention. This review aims to assess the evidence on factors associated with C. auris colonisation or infection, the duration of such colonisation, possible colonisation sites, and the risk of secondary cases to inform screening recommendations.\n\n**Methods:** We systematically searched five databases for primary studies and systematic reviews of our four outcomes. We excluded studies on treatment, management, laboratory methods, drug resistance, and environmental screening. From each paper, we extracted relevant data and summarised them in tables. Main findings were described narratively.\n\n**Findings:** We selected 117 studies for inclusion. Most of the studies were observational studies. Without taking the method of testing into account, the duration of C. auris colonisation varied, with up to and beyond a year being common. The predominant sites of colonisation were the axillae and groin, with the nares and rectum being less common sites. The risk of secondary cases saw considerable variation across the studies, and the secondary cases primarily involved patients and not healthcare workers. Critical care settings, invasive medical devices, recent antimicrobial use, and comorbidities were often associated with C. auris colonisation and infection.\n\n**Conclusion:** Our review highlights that, despite relevant findings on factors influencing C. auris colonisation and infection, substantial gaps remain in the evidence supporting screening practices. Most studies were conducted reactively, in outbreak settings, and lack systematic protocols. Given these limitations, screening guidelines are likely to be more successful if grounded in medical theory and yeast microbiology rather than relying solely on current studies. Rigorous, well-designed research is urgently needed to inform future C. auris screening and control efforts.", "abstract_zh": "**èƒŒæ™¯ï¼š** è€³å¿µç èŒæ˜¯ä¸€ç§æ–°å…´çš„çœŸèŒç—…åŸä½“ï¼Œé€šå¸¸å…·æœ‰å¤šé‡è€è¯æ€§ã€‚å®ƒå¯ä»¥æŒç»­å­˜åœ¨äºçš®è‚¤å’ŒåŒ»é™¢ç¯å¢ƒä¸­ï¼Œå¯¼è‡´é«˜å±æ‚£è€…çˆ†å‘å’Œä¸¥é‡æ„ŸæŸ“ã€‚ä¸€äº›å›½å®¶å’Œæœºæ„æ­£åœ¨åŠªåŠ›åˆ¶å®šé¢„é˜²æŒ‡å—å’Œå»ºè®®ã€‚æœ¬ç»¼è¿°æ—¨åœ¨è¯„ä¼°ä¸è€³å¿µç èŒå®šæ¤æˆ–æ„ŸæŸ“ç›¸å…³çš„å› ç´ ã€å®šæ¤æŒç»­æ—¶é—´ã€å¯èƒ½çš„å®šæ¤ä½ç‚¹ä»¥åŠç»§å‘ç—…ä¾‹çš„é£é™©çš„è¯æ®ï¼Œä»¥æä¾›ç­›æŸ¥å»ºè®®ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬ç³»ç»Ÿåœ°æ£€ç´¢äº†äº”ä¸ªæ•°æ®åº“è¿›è¡Œåˆæ­¥ç ”ç©¶å¹¶å¯¹æˆ‘ä»¬çš„å››ä¸ªç»“æœè¿›è¡Œç³»ç»Ÿè¯„ä»·ã€‚æˆ‘ä»¬æ’é™¤äº†æœ‰å…³æ²»ç–—ã€ç®¡ç†ã€å®éªŒå®¤æ–¹æ³•ã€è€è¯æ€§å’Œç¯å¢ƒç­›æŸ¥çš„ç ”ç©¶ã€‚æˆ‘ä»¬ä»æ¯ç¯‡è®ºæ–‡ä¸­æå–äº†ç›¸å…³æ•°æ®å¹¶å°†å…¶æ€»ç»“åœ¨è¡¨æ ¼ä¸­ã€‚å¯¹ä¸»è¦å‘ç°è¿›è¡Œäº†å™è¿°æ€§æè¿°ã€‚\n\n**Findingsï¼š** æˆ‘ä»¬é€‰æ‹©äº† 117 é¡¹ç ”ç©¶çº³å…¥å…¶ä¸­ã€‚å¤§å¤šæ•°ç ”ç©¶éƒ½æ˜¯è§‚å¯Ÿæ€§ç ”ç©¶ã€‚å¦‚æœä¸è€ƒè™‘æµ‹è¯•æ–¹æ³•ï¼Œè€³å¿µç èŒå®šæ®–çš„æŒç»­æ—¶é—´å„ä¸ç›¸åŒï¼Œæœ€é•¿æˆ–è¶…è¿‡ä¸€å¹´çš„æƒ…å†µå¾ˆå¸¸è§ã€‚å®šæ¤çš„ä¸»è¦éƒ¨ä½æ˜¯è…‹çªå’Œè…¹è‚¡æ²Ÿï¼Œé¼»å­”å’Œç›´è‚ æ˜¯ä¸å¤ªå¸¸è§çš„éƒ¨ä½ã€‚å„ä¸ªç ”ç©¶ä¸­ç»§å‘ç—…ä¾‹çš„é£é™©å­˜åœ¨å¾ˆå¤§å·®å¼‚ï¼Œå¹¶ä¸”ç»§å‘ç—…ä¾‹ä¸»è¦æ¶‰åŠæ‚£è€…è€Œä¸æ˜¯åŒ»æŠ¤äººå‘˜ã€‚é‡ç—‡ç›‘æŠ¤ç¯å¢ƒã€ä¾µå…¥æ€§åŒ»ç–—è®¾å¤‡ã€è¿‘æœŸæŠ—èŒè¯ç‰©çš„ä½¿ç”¨ä»¥åŠåˆå¹¶ç—‡é€šå¸¸ä¸è€³å¿µç èŒå®šæ¤å’Œæ„ŸæŸ“æœ‰å…³ã€‚\n\n**ç»“è®ºï¼š** æˆ‘ä»¬çš„ç»¼è¿°å¼ºè°ƒï¼Œå°½ç®¡å¯¹å½±å“è€³å¿µç èŒå®šæ¤å’Œæ„ŸæŸ“çš„å› ç´ æœ‰ç›¸å…³å‘ç°ï¼Œä½†æ”¯æŒç­›æŸ¥å®è·µçš„è¯æ®ä»ç„¶å­˜åœ¨å¾ˆå¤§å·®è·ã€‚å¤§å¤šæ•°ç ”ç©¶éƒ½æ˜¯åœ¨ç–«æƒ…çˆ†å‘çš„æƒ…å†µä¸‹è¢«åŠ¨è¿›è¡Œçš„ï¼Œç¼ºä¹ç³»ç»Ÿçš„æ–¹æ¡ˆã€‚é‰´äºè¿™äº›é™åˆ¶ï¼Œå¦‚æœåŸºäºåŒ»å­¦ç†è®ºå’Œé…µæ¯å¾®ç”Ÿç‰©å­¦è€Œä¸æ˜¯ä»…ä»…ä¾èµ–å½“å‰çš„ç ”ç©¶ï¼Œç­›æŸ¥æŒ‡å—å¯èƒ½ä¼šæ›´æˆåŠŸã€‚è¿«åˆ‡éœ€è¦ä¸¥è°¨ã€ç²¾å¿ƒè®¾è®¡çš„ç ”ç©¶æ¥ä¸ºæœªæ¥çš„è€³å¿µç èŒç­›æŸ¥å’Œæ§åˆ¶å·¥ä½œæä¾›ä¿¡æ¯ã€‚", "keywords_zh": "è€³å¿µç èŒã€çœŸèŒæ„ŸæŸ“ã€åŒ»ç–—ä¿å¥ç›¸å…³æ„ŸæŸ“ã€æ„ŸæŸ“æ§åˆ¶ã€ç­›æŸ¥", "keywords_en": "Candida auris, fungal infections, healthcareâ€associated infections, infection control, screening", "link": "https://pubmed.ncbi.nlm.nih.gov/40072118/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 12 Mar 2025"}, {"id": "40063683", "title_en": "Evaluating the Impact of Induction and Consolidation Total Neoadjuvant Therapies Compared to Conventional Chemoradiotherapy for Locally Advanced Rectal Cancer: A Systematic Review and Network Meta-analysis", "title_zh": "è¯„ä¼°è¯±å¯¼å’Œå·©å›ºæ€»ä½“æ–°è¾…åŠ©æ²»ç–—ä¸ä¼ ç»Ÿæ”¾åŒ–ç–—å¯¹å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„å½±å“ï¼šç³»ç»Ÿè¯„ä»·å’Œç½‘ç»œèŸèƒåˆ†æ", "authors": "Jeonghyun Kang", "abstract_en": "**Background:** Total neoadjuvant therapy has been introduced to enhance oncological outcomes and minimize toxicity in locally advanced rectal cancer, but the superiority between the induction and consolidation of therapy remain unclear.\n\n**Objective:** To evaluate oncological and postoperative outcomes by comparing induction chemotherapy and consolidation chemotherapy with conventional chemoradiotherapy in patients with locally advanced rectal cancer.\n\n**Data Sources:** Systematic searches of PubMed, Embase, and Cochrane databases wereperformed for studies published from the database's inception until June 2023.\n\n**Study Selection:** The inclusion criteria were patients diagnosed with rectal cancer. Interventions included induction chemotherapy and consolidation chemotherapy, and comparisons were specified as conventional neoadjuvant chemoradiotherapy.\n\n**Main Outcome Measures:** Primary outcomes were the rates of pathologic or clinical complete response, postoperative results, chemoradiotherapy-related toxicity, and survival outcomes.\n\n**Results:** Thirty-three studies, encompassing patients from 1991 to 2021, were eligible for analysis. In network meta-analysis, a significantly increased OR for a pathologic complete response was observed in both the induction therapy group at 1.65 (95% credible interval, 1.18-2.30) and the consolidation therapy group at 1.87 (95% credible interval, 1.40-2.47) compared to conventional chemoradiotherapy. However, no difference was observed in complete response rates, postoperative results, or chemoradiotherapy-related toxicity grade 3 or higher between the groups. There were no differences among the groups in local recurrence, distant metastasis, or disease-free survival, whereas the induction group showed a nonsignificant improvement in overall survival.\n\n**Limitations:** There was significant heterogeneity among the studies, and the short follow-up period in most studies limited the assessment of long-term survival outcomes.\n\n**Conclusions:** Both induction and consolidation total neoadjuvant therapy increase the pathologic complete response rate in locally advanced rectal cancer without compromising safety or postoperative outcomes. However, total neoadjuvant therapy was not associated with a significant improvement in survival outcomes. Although total neoadjuvant therapy strategies for locally advanced rectal cancer are considered safe, additional long-term studies are needed.\n\n**Trial Registration No:** CRD42023445348.", "abstract_zh": "**èƒŒæ™¯ï¼š** å·²å¼•å…¥å…¨æ–°è¾…åŠ©æ²»ç–—æ¥å¢å¼ºå±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„è‚¿ç˜¤å­¦ç»“æœå¹¶æœ€å¤§ç¨‹åº¦åœ°å‡å°‘æ¯’æ€§ï¼Œä½†è¯±å¯¼æ²»ç–—å’Œå·©å›ºæ²»ç–—ä¹‹é—´çš„ä¼˜è¶Šæ€§ä»ä¸æ¸…æ¥šã€‚\n\n**ç›®çš„ï¼š** é€šè¿‡æ¯”è¾ƒå±€éƒ¨æ™šæœŸç›´è‚ ç™Œæ‚£è€…çš„è¯±å¯¼åŒ–ç–—å’Œå·©å›ºåŒ–ç–—ä¸å¸¸è§„æ”¾åŒ–ç–—ï¼Œè¯„ä¼°è‚¿ç˜¤å­¦å’Œæœ¯åç»“æœã€‚\n\n**Data sourcesï¼š** å¯¹ PubMedã€Embase å’Œ Cochrane æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼ŒæŸ¥æ‰¾ä»æ•°æ®åº“å»ºç«‹åˆ° 2023 å¹´ 6 æœˆæœŸé—´å‘è¡¨çš„ç ”ç©¶ã€‚\n\n**Study selectionï¼š** çº³å…¥æ ‡å‡†æ˜¯è¯Šæ–­æ‚£æœ‰ç›´è‚ ç™Œçš„æ‚£è€…ã€‚å¹²é¢„æªæ–½åŒ…æ‹¬è¯±å¯¼åŒ–ç–—å’Œå·©å›ºåŒ–ç–—ï¼Œæ¯”è¾ƒæŒ‡å®šä¸ºå¸¸è§„æ–°è¾…åŠ©æ”¾åŒ–ç–—ã€‚\n\n**Main outcome measuresï¼š** ä¸»è¦ç»“å±€æ˜¯ç—…ç†æˆ–ä¸´åºŠå®Œå…¨ç¼“è§£ç‡ã€æœ¯åç»“æœã€æ”¾åŒ–ç–—ç›¸å…³æ¯’æ€§å’Œç”Ÿå­˜ç»“æœã€‚\n\n**ç»“æœï¼š** æ¶µç›– 1991 å¹´è‡³ 2021 å¹´æ‚£è€…çš„ 33 é¡¹ç ”ç©¶ç¬¦åˆåˆ†ææ¡ä»¶ã€‚åœ¨ç½‘ç»œèŸèƒåˆ†æä¸­ï¼Œä¸ä¼ ç»Ÿæ”¾åŒ–ç–—ç›¸æ¯”ï¼Œè¯±å¯¼æ²»ç–—ç»„çš„ç—…ç†å®Œå…¨ç¼“è§£ OR æ˜¾ç€å¢åŠ ä¸º 1.65ï¼ˆ95% å¯ä¿¡åŒºé—´ï¼Œ1.18-2.30ï¼‰ï¼Œå·©å›ºæ²»ç–—ç»„ä¸º 1.87ï¼ˆ95% å¯ä¿¡åŒºé—´ï¼Œ1.40-2.47ï¼‰ã€‚ç„¶è€Œï¼Œä¸¤ç»„é—´åœ¨å®Œå…¨ç¼“è§£ç‡ã€æœ¯åç»“æœæˆ–æ”¾åŒ–ç–—ç›¸å…³æ¯’æ€§ 3 çº§æˆ–ä»¥ä¸Šæ–¹é¢æ²¡æœ‰è§‚å¯Ÿåˆ°å·®å¼‚ã€‚å„ç»„ä¹‹é—´çš„å±€éƒ¨å¤å‘ã€è¿œå¤„è½¬ç§»æˆ–æ— ç—…ç”Ÿå­˜ç‡æ²¡â€‹â€‹æœ‰å·®å¼‚ï¼Œè€Œè¯±å¯¼ç»„çš„æ€»ç”Ÿå­˜ç‡æ²¡æœ‰æ˜¾ç€æ”¹å–„ã€‚\n\n**Limitationsï¼š** ç ”ç©¶ä¹‹é—´å­˜åœ¨æ˜¾ç€çš„å¼‚è´¨æ€§ï¼Œå¹¶ä¸”å¤§å¤šæ•°ç ”ç©¶çš„çŸ­æœŸéšè®¿é™åˆ¶äº†é•¿æœŸç”Ÿå­˜ç»“æœçš„è¯„ä¼°ã€‚\n\n**ç»“è®ºï¼š** è¯±å¯¼å’Œå·©å›ºå…¨æ–°è¾…åŠ©æ²»ç–—å‡å¯æé«˜å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„ç—…ç†å®Œå…¨ç¼“è§£ç‡ï¼Œä¸”ä¸å½±å“å®‰å…¨æ€§æˆ–æœ¯åç»“æœã€‚ç„¶è€Œï¼Œæ€»ä½“æ–°è¾…åŠ©æ²»ç–—ä¸ç”Ÿå­˜ç»“æœçš„æ˜¾ç€æ”¹å–„æ— å…³ã€‚å°½ç®¡å±€éƒ¨æ™šæœŸç›´è‚ ç™Œçš„æ€»ä½“æ–°è¾…åŠ©æ²»ç–—ç­–ç•¥è¢«è®¤ä¸ºæ˜¯å®‰å…¨çš„ï¼Œä½†ä»éœ€è¦é¢å¤–çš„é•¿æœŸç ”ç©¶ã€‚\n\n**Trial registration noï¼š** CRD42023445348ã€‚", "keywords_zh": "å·©å›ºåŒ–ç–—ã€è¯±å¯¼åŒ–ç–—ã€ç›´è‚ ç™Œã€å…¨é¢æ–°è¾…åŠ©æ²»ç–—", "keywords_en": "Consolidation chemotherapy, Induction chemotherapy, Rectal cancer, Total neoadjuvant therapy", "link": "https://pubmed.ncbi.nlm.nih.gov/40063683/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 10 Mar 2025"}, {"id": "40019566", "title_en": "Quantification of indocyanine green fluorescence angiography in colorectal surgery: a systematic review of the literature", "title_zh": "ç»“ç›´è‚ æ‰‹æœ¯ä¸­å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½±çš„é‡åŒ–ï¼šæ–‡çŒ®çš„ç³»ç»Ÿå›é¡¾", "authors": "Ronan A Cahill", "abstract_en": "**Background:** Indocyanine green fluorescence angiography (ICGFA) during colorectal surgery associates with reduced post-operative anastomotic complication rates. Because its interpretation is subjective, quantification has been proposed to address inter-user variability. This study reviews the published literature regarding ICGFA quantification during colorectal surgery with a focus on impactful clinical deployment.\n\n**Methods:** A systematic review was performed of English language publications regarding clinical studies of ICGFA quantification in colorectal surgery in PubMed, Scopus, Web of Science and Cochrane Library on 29th August 2024, updated to 18th November 2024, following PRISMA guidelines. Newcastle Ottawa scale (NOS) was used to assess quality.\n\n**Results:** A total of 1428 studies were screened with 22 studies (1469 patients) selected. There was significant heterogeneity of ICGFA methodology, quantification methods and parameter selection and only three studies were NOS \"high\" quality. Extracorporeal application was most common. Four studies (154 patients) conducted real-time ICGFA analyses (others were post hoc) and four utilised artificial intelligence methods. Eleven studies only included patients undergoing left-sided resection (six focusing specifically on rectal resections). Only one study employed the quantification method to guide intra-operative decision-making regarding colonic transection. Twenty-six different perfusion parameters were assessed, with time from injection to visible fluorescence and maximum intensity the most commonly (but not only) correlated parameters regarding anastomotic complication (nâ€‰=â€‰18). Other grounding correlates were tissue oxygenation (nâ€‰=â€‰3, two with hyperspectral imagery), metabolites (nâ€‰=â€‰2) and surgeon interpretation (nâ€‰=â€‰5).\n\n**Conclusion:** Quantification of the ICGFA signal for colorectal surgery is feasible but has so far seen limited academic advancement beyond feasibility.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ æ‰‹æœ¯æœŸé—´çš„å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½±ï¼ˆICGFAï¼‰ä¸é™ä½æœ¯åå»åˆå£å¹¶å‘ç—‡å‘ç”Ÿç‡ç›¸å…³ã€‚ç”±äºå…¶è§£é‡Šæ˜¯ä¸»è§‚çš„ï¼Œå› æ­¤æå‡ºäº†é‡åŒ–æ¥è§£å†³ç”¨æˆ·é—´çš„å¯å˜æ€§ã€‚æœ¬ç ”ç©¶å›é¡¾äº†æœ‰å…³ç»“ç›´è‚ æ‰‹æœ¯æœŸé—´ ICGFA å®šé‡çš„å·²å‘è¡¨æ–‡çŒ®ï¼Œé‡ç‚¹å…³æ³¨æœ‰å½±å“åŠ›çš„ä¸´åºŠéƒ¨ç½²ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ® PRISMA æŒ‡å—ï¼Œäº 2024 å¹´ 8 æœˆ 29 æ—¥å¯¹ PubMedã€Scopusã€Web of Science å’Œ Cochrane å›¾ä¹¦é¦†ä¸­æœ‰å…³ç»“ç›´è‚ æ‰‹æœ¯ä¸­ ICGFA å®šé‡ä¸´åºŠç ”ç©¶çš„è‹±æ–‡å‡ºç‰ˆç‰©è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾ï¼Œæ›´æ–°è‡³ 2024 å¹´ 11 æœˆ 18 æ—¥ã€‚ä½¿ç”¨çº½å¡æ–¯å°”æ¸¥å¤ªåé‡è¡¨ï¼ˆNOSï¼‰æ¥è¯„ä¼°è´¨é‡ã€‚\n\n**ç»“æœï¼š** æ€»å…±ç­›é€‰äº† 1428 é¡¹ç ”ç©¶ï¼Œé€‰å‡ºäº† 22 é¡¹ç ”ç©¶ï¼ˆ1469 åæ‚£è€…ï¼‰ã€‚ ICGFA æ–¹æ³•ã€é‡åŒ–æ–¹æ³•å’Œå‚æ•°é€‰æ‹©å­˜åœ¨æ˜¾ç€å¼‚è´¨æ€§ï¼Œåªæœ‰ä¸‰é¡¹ç ”ç©¶è¾¾åˆ° NOSâ€œé«˜â€è´¨é‡ã€‚ä½“å¤–åº”ç”¨æœ€ä¸ºå¸¸è§ã€‚å››é¡¹ç ”ç©¶ï¼ˆ154 åæ‚£è€…ï¼‰è¿›è¡Œäº†å®æ—¶ ICGFA åˆ†æï¼ˆå…¶ä»–ç ”ç©¶æ˜¯äº‹ååˆ†æï¼‰ï¼Œå››é¡¹ç ”ç©¶åˆ©ç”¨äº†äººå·¥æ™ºèƒ½æ–¹æ³•ã€‚åä¸€é¡¹ç ”ç©¶ä»…çº³å…¥æ¥å—å·¦ä¾§åˆ‡é™¤æœ¯çš„æ‚£è€…ï¼ˆå…¶ä¸­å…­é¡¹ç ”ç©¶ä¸“é—¨é’ˆå¯¹ç›´è‚ åˆ‡é™¤æœ¯ï¼‰ã€‚åªæœ‰ä¸€é¡¹ç ”ç©¶é‡‡ç”¨é‡åŒ–æ–¹æ³•æ¥æŒ‡å¯¼ç»“è‚ æ¨ªæ–­æœ¯çš„æœ¯ä¸­å†³ç­–ã€‚è¯„ä¼°äº†äºŒåå…­ä¸ªä¸åŒçš„çŒæ³¨å‚æ•°ï¼Œä»æ³¨å°„åˆ°å¯è§è§å…‰çš„æ—¶é—´å’Œæœ€å¤§å¼ºåº¦æ˜¯ä¸å»åˆå¹¶å‘ç—‡æœ€å¸¸è§ï¼ˆä½†ä¸ä»…ä»…æ˜¯ï¼‰ç›¸å…³çš„å‚æ•°ï¼ˆnâ€‰=â€‰18ï¼‰ã€‚å…¶ä»–åŸºç¡€ç›¸å…³å› ç´ åŒ…æ‹¬ç»„ç»‡æ°§åˆï¼ˆnâ€‰=â€‰3ï¼Œå…¶ä¸­ä¸¤ä¸ªå…·æœ‰é«˜å…‰è°±å›¾åƒï¼‰ã€ä»£è°¢ç‰©ï¼ˆnâ€‰=â€‰2ï¼‰å’Œå¤–ç§‘åŒ»ç”Ÿè§£é‡Šï¼ˆnâ€‰=â€‰5ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ç»“ç›´è‚ æ‰‹æœ¯ä¸­ ICGFA ä¿¡å·çš„é‡åŒ–æ˜¯å¯è¡Œçš„ï¼Œä½†è¿„ä»Šä¸ºæ­¢å­¦æœ¯è¿›å±•æœ‰é™ï¼Œè¶…å‡ºäº†å¯è¡Œæ€§ã€‚", "keywords_zh": "ç»“ç›´è‚ æ‰‹æœ¯ã€è§å…‰è¡€ç®¡é€ å½±ã€å²å“šèç»¿ã€è¿‘çº¢å¤–è…¹è…”é•œæ£€æŸ¥ã€å®šé‡", "keywords_en": "Colorectal surgery, Fluorescence angiography, Indocyanine green, Near infrared laparoscopy, Quantification", "link": "https://pubmed.ncbi.nlm.nih.gov/40019566/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 28 Feb 2025"}, {"id": "39982791", "title_en": "Research Perspective on Outcome Following Surgical Treatment for Chronic Pilonidal Sinus Disease: A Systematic Review of Common Surgical Techniques", "title_zh": "æ…¢æ€§è—æ¯›çª¦ç–¾ç—…æ‰‹æœ¯æ²»ç–—ç»“æœçš„ç ”ç©¶è§†è§’ï¼šå¸¸ç”¨æ‰‹æœ¯æŠ€æœ¯çš„ç³»ç»Ÿå›é¡¾", "authors": "Arielle E Kanters", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39982791/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 21 Feb 2025"}, {"id": "39982788", "title_en": "Outcome After Surgical Treatment for Chronic Pilonidal Sinus Disease: A Systematic Review of Common Surgical Techniques", "title_zh": "æ…¢æ€§è—æ¯›çª¦ç–¾ç—…æ‰‹æœ¯æ²»ç–—åçš„ç»“æœï¼šå¸¸è§æ‰‹æœ¯æŠ€æœ¯çš„ç³»ç»Ÿå›é¡¾", "authors": "Birgitte Brandstrup", "abstract_en": "**Background:** The choice of operation for chronic pilonidal sinus disease remains controversial.\n\n**Objective:** To compare the outcomes of common operations for chronic pilonidal disease.\n\n**Data Sources:** We searched PubMed, Embase, and the Cochrane Library.\n\n**Study Selection:** We included randomized trials in English or Danish language, published 2002 to 2024 that compared outcomes of operations to treat chronic pilonidal disease in adults and teenagers.\n\n**Interventions:** We compared the outcomes of secondary healing, primary midline closure, Bascom, Limberg, and Karydakis flap operations.\n\n**Main Outcome Measures:** The primary outcome was recurrence; secondary outcomes were infection, healing time, and length of stay. We compared recurrence and infection rates in meta-analyses for all techniques. We assessed the risk of bias and the quality of all trials.\n\n**Results:** Fifty trials included a total of 5762 participants. In a meta-analysis, the flap operations had fewer recurrences than primary midline closure (OR 0.31; 95% CI, 0.19-0.51; p < 0.01). The trials comparing flap operations with secondary healing were heterogeneous and did not reach significance (OR 0.38; 95% CI, 0.13-1.13; p = 0.08). Recurrence was similar between Limberg and Karydakis operations. Infection rates were lower for the flap operations compared with primary closure (OR 0.33; 95% CI, 0.23-0.48; p < 0.01) and with secondary healing (OR 0.48; 95% CI, 0.30-0.77; p < 0.01). Two trials tested Bascom procedure against Limberg operation without significant differences. All trials found secondary healing to have significantly longer healing times than any other operation.\n\n**Limitations:** Most studies had a high or medium risk of bias, resulting in very low to low certainty of evidence. The trials generally had small numbers, short follow-ups, and no reported primary outcomes or power calculations.\n\n**Conclusions:** Primary closure and secondary healing performed poorly compared with the flap techniques. Most trials tested Limberg operation; only 2 tested Bascom operation. The literature suggests the surgeon's expertise determines the choice of flap technique.", "abstract_zh": "**èƒŒæ™¯ï¼š** æ…¢æ€§è—æ¯›çª¦ç–¾ç—…çš„æ‰‹æœ¯é€‰æ‹©ä»å­˜åœ¨äº‰è®®ã€‚\n\n**ç›®çš„ï¼š** æ¯”è¾ƒæ…¢æ€§è—æ¯›ç—…å¸¸è§æ‰‹æœ¯çš„ç»“æœã€‚\n\n**Data sourcesï¼š** æˆ‘ä»¬æ£€ç´¢äº† PubMedã€Embase å’Œ Cochrane å›¾ä¹¦é¦†ã€‚\n\n**Study selectionï¼š** æˆ‘ä»¬çº³å…¥äº† 2002 å¹´è‡³ 2024 å¹´å‘è¡¨çš„è‹±è¯­æˆ–ä¸¹éº¦è¯­éšæœºè¯•éªŒï¼Œæ¯”è¾ƒäº†æ²»ç–—æˆäººå’Œé’å°‘å¹´æ…¢æ€§è—æ¯›ç—…çš„æ‰‹æœ¯ç»“æœã€‚\n\n**Interventionsï¼š** æˆ‘ä»¬æ¯”è¾ƒäº†äºŒæ¬¡æ„ˆåˆã€åˆæ¬¡ä¸­çº¿é—­åˆã€Bascomã€Limberg å’Œ Karydakis çš®ç“£æ‰‹æœ¯çš„ç»“æœã€‚\n\n**Main outcome measuresï¼š** ä¸»è¦ç»“å±€æ˜¯å¤å‘ï¼›æ¬¡è¦ç»“å±€æ˜¯æ„ŸæŸ“ã€æ„ˆåˆæ—¶é—´å’Œä½é™¢æ—¶é—´ã€‚æˆ‘ä»¬åœ¨èŸèƒåˆ†æä¸­æ¯”è¾ƒäº†æ‰€æœ‰æŠ€æœ¯çš„å¤å‘ç‡å’Œæ„ŸæŸ“ç‡ã€‚æˆ‘ä»¬è¯„ä¼°äº†æ‰€æœ‰è¯•éªŒçš„åå€šé£é™©å’Œè´¨é‡ã€‚\n\n**ç»“æœï¼š** 50 é¡¹è¯•éªŒå…±æœ‰ 5762 åå‚ä¸è€…ã€‚åœ¨èŸèƒåˆ†æä¸­ï¼Œçš®ç“£æ‰‹æœ¯çš„å¤å‘ç‡ä½äºåˆæ¬¡ä¸­çº¿é—­åˆæœ¯ï¼ˆOR 0.31ï¼›95% CIï¼Œ0.19-0.51ï¼›p < 0.01ï¼‰ã€‚æ¯”è¾ƒçš®ç“£æ‰‹æœ¯ä¸äºŒæ¬¡æ„ˆåˆçš„è¯•éªŒå­˜åœ¨å¼‚è´¨æ€§ï¼Œæœªè¾¾åˆ°æ˜¾ç€æ€§ï¼ˆOR 0.38ï¼›95% CIï¼Œ0.13-1.13ï¼›p = 0.08ï¼‰ã€‚ Limberg å’Œ Karydakis æ‰‹æœ¯çš„å¤å‘ç‡ç›¸ä¼¼ã€‚ä¸åˆæ¬¡é—­åˆï¼ˆOR 0.33ï¼›95% CIï¼Œ0.23-0.48ï¼›p < 0.01ï¼‰å’ŒäºŒæ¬¡æ„ˆåˆï¼ˆOR 0.48ï¼›95% CIï¼Œ0.30-0.77ï¼›p < 0.01ï¼‰ç›¸æ¯”ï¼Œçš®ç“£æ‰‹æœ¯çš„æ„ŸæŸ“ç‡è¾ƒä½ã€‚ä¸¤é¡¹è¯•éªŒé’ˆå¯¹ Limberg æ‰‹æœ¯æµ‹è¯•äº† Bascom ç¨‹åºï¼Œæ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚æ‰€æœ‰è¯•éªŒéƒ½å‘ç°äºŒæ¬¡æ„ˆåˆçš„æ„ˆåˆæ—¶é—´æ¯”ä»»ä½•å…¶ä»–æ‰‹æœ¯éƒ½è¦é•¿å¾—å¤šã€‚\n\n**Limitationsï¼š** å¤§å¤šæ•°ç ”ç©¶éƒ½å­˜åœ¨é«˜æˆ–ä¸­ç­‰åå€šé£é™©ï¼Œå¯¼è‡´è¯æ®è´¨é‡æä½è‡³ä½ã€‚è¿™äº›è¯•éªŒé€šå¸¸æ•°é‡å°‘ï¼Œéšè®¿æ—¶é—´çŸ­ï¼Œå¹¶ä¸”æ²¡æœ‰æŠ¥å‘Šä¸»è¦ç»“æœæˆ–åŠŸæ•ˆè®¡ç®—ã€‚\n\n**ç»“è®ºï¼š** ä¸çš®ç“£æŠ€æœ¯ç›¸æ¯”ï¼Œåˆæ¬¡é—­åˆå’ŒäºŒæ¬¡æ„ˆåˆæ•ˆæœè¾ƒå·®ã€‚å¤§å¤šæ•°è¯•éªŒæµ‹è¯•äº†æ—ä¼¯æ ¼æ“ä½œï¼›ä»… 2 ä¸ªæµ‹è¯•äº† Bascom æ“ä½œã€‚æ–‡çŒ®è¡¨æ˜å¤–ç§‘åŒ»ç”Ÿçš„ä¸“ä¸šçŸ¥è¯†å†³å®šäº†çš®ç“£æŠ€æœ¯çš„é€‰æ‹©ã€‚", "keywords_zh": "Bascom è£‚å£æå‡æ‰‹æœ¯ã€æ…¢æ€§è—æ¯›çª¦ç–¾ç—…ã€è—æ¯›ç–¾ç—…å¹¶å‘ç—‡ã€æ—ä¼¯æ ¼æ‰‹æœ¯ã€è—æ¯›ç–¾ç—…å¤å‘ã€æ‰‹æœ¯æ²»ç–—è—æ¯›ç–¾ç—…", "keywords_en": "Bascom cleft-lift operation, Chronic pilonidal sinus disease, Complications pilonidal disease, Limberg operation, Pilonidal disease recurrence, Surgical treatment pilonidal disease", "link": "https://pubmed.ncbi.nlm.nih.gov/39982788/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 21 Feb 2025"}, {"id": "39980238", "title_en": "A quality-of-life meta-analysis comparing pre- and postoperative symptoms in women undergoing colorectal resection for deep infiltrating endometriosis", "title_zh": "æ¯”è¾ƒå› æ·±éƒ¨æµ¸æ¶¦å­å®«å†…è†œå¼‚ä½ç—‡æ¥å—ç»“ç›´è‚ åˆ‡é™¤æœ¯çš„å¥³æ€§æœ¯å‰å’Œæœ¯åç—‡çŠ¶çš„ç”Ÿæ´»è´¨é‡èŸèƒåˆ†æ", "authors": "Cillian Clancy", "abstract_en": "**Aim:** Deep infiltrating endometriosis (DIE) may involve the rectum or colon and is associated with pain, gastrointestinal dysfunction and reduced quality of life (QoL). While hormonal treatment may be effective, surgical intervention including colorectal resection can be required. Colorectal resection can result in functional changes and complications, which can also impair QoL. The aim of this study is to examine all available comparative pre- and postoperative data on QoL and symptom outcomes following colorectal resection for DIE.\n\n**Method:** An electronic database search was conducted for studies reporting pre- and postoperative QoL and symptom outcomes following colorectal resection for DIE. The study was registered with PROSPERO and followed PRISMA (Preferred Reporting Items in Systematic Reviews and Meta-analyses) guidelines. Data were combined using random-effects models.\n\n**Results:** Fourteen studies including 1142 patients were included. Colorectal resection was associated with improved outcomes for all items in the SF-36 QoL questionnaire as well as symptom outcomes including dysmenorrhoea, chronic pelvic pain and deep dyspareunia. Importantly, the gastrointestinal QoL index was significantly improved (mean difference 24.50, 95% CI 15.93-33.08, pâ€‰<â€‰0.0001) as was dyschezia (mean difference -4.1, 95% CI -4.77 to -3.42, pâ€‰<â€‰0.0001). There was no change in low anterior resection syndrome scores (mean difference -5.28, 95% CI -11.65 to 1.10, pâ€‰=â€‰0.1046).\n\n**Conclusion:** This study demonstrates a significant postoperative improvement in patient-reported QoL, pain symptoms and gastrointestinal function following colorectal resection for endometriosis.", "abstract_zh": "**Aimï¼š** æ·±éƒ¨æµ¸æ¶¦æ€§å­å®«å†…è†œå¼‚ä½ç—‡ (DIE) å¯èƒ½ç´¯åŠç›´è‚ æˆ–ç»“è‚ ï¼Œå¹¶ä¸ç–¼ç—›ã€èƒƒè‚ åŠŸèƒ½éšœç¢å’Œç”Ÿæ´»è´¨é‡ (QoL) ä¸‹é™æœ‰å…³ã€‚è™½ç„¶æ¿€ç´ æ²»ç–—å¯èƒ½æœ‰æ•ˆï¼Œä½†å¯èƒ½éœ€è¦æ‰‹æœ¯å¹²é¢„ï¼ŒåŒ…æ‹¬ç»“ç›´è‚ åˆ‡é™¤æœ¯ã€‚ç»“ç›´è‚ åˆ‡é™¤æœ¯å¯èƒ½å¯¼è‡´åŠŸèƒ½æ”¹å˜å’Œå¹¶å‘ç—‡ï¼Œè¿™ä¹Ÿä¼šæŸå®³ç”Ÿæ´»è´¨é‡ã€‚æœ¬ç ”ç©¶çš„ç›®çš„æ˜¯æ£€æŸ¥æ‰€æœ‰å¯ç”¨çš„ DIE ç»“ç›´è‚ åˆ‡é™¤æœ¯åç”Ÿæ´»è´¨é‡å’Œç—‡çŠ¶ç»“æœçš„æœ¯å‰å’Œæœ¯åæ¯”è¾ƒæ•°æ®ã€‚\n\n**Methodï¼š** å¯¹æŠ¥å‘Š DIE ç»“ç›´è‚ åˆ‡é™¤æœ¯åæœ¯å‰å’Œæœ¯å QoL ä»¥åŠç—‡çŠ¶ç»“æœçš„ç ”ç©¶è¿›è¡Œäº†ç”µå­æ•°æ®åº“æœç´¢ã€‚è¯¥ç ”ç©¶å·²åœ¨ PROSPERO æ³¨å†Œå¹¶éµå¾ª PRISMAï¼ˆç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æä¸­çš„é¦–é€‰æŠ¥å‘Šé¡¹ç›®ï¼‰æŒ‡å—ã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹ç»„åˆæ•°æ®ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 14 é¡¹ç ”ç©¶ï¼ŒåŒ…æ‹¬ 1142 åæ‚£è€…ã€‚ç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸ SF-36 ç”Ÿæ´»è´¨é‡é—®å·ä¸­æ‰€æœ‰é¡¹ç›®çš„æ”¹å–„ç»“æœä»¥åŠç—›ç»ã€æ…¢æ€§ç›†è…”ç–¼ç—›å’Œæ·±åº¦æ€§äº¤ç–¼ç—›ç­‰ç—‡çŠ¶ç»“æœç›¸å…³ã€‚é‡è¦çš„æ˜¯ï¼Œèƒƒè‚ é“ QoL æŒ‡æ•°æ˜¾ç€æ”¹å–„ï¼ˆå¹³å‡å·® 24.50ï¼Œ95% CI 15.93-33.08ï¼Œp<â€‰0.0001ï¼‰ï¼Œæ’ä¾¿å›°éš¾ä¹Ÿæ˜¾ç€æ”¹å–„ï¼ˆå¹³å‡å·® -4.1ï¼Œ95% CI -4.77 è‡³ -3.42ï¼Œp<â€‰0.0001ï¼‰ã€‚ä½å‰åˆ‡é™¤ç»¼åˆå¾è¯„åˆ†æ²¡æœ‰å˜åŒ–ï¼ˆå¹³å‡å·® -5.28ï¼Œ95% CI -11.65 è‡³ 1.10ï¼Œpâ€‰=â€‰0.1046ï¼‰ã€‚\n\n**ç»“è®ºï¼š** è¿™é¡¹ç ”ç©¶è¡¨æ˜ï¼Œå­å®«å†…è†œå¼‚ä½ç—‡ç»“ç›´è‚ åˆ‡é™¤æœ¯åæ‚£è€…æŠ¥å‘Šçš„ç”Ÿæ´»è´¨é‡ã€ç–¼ç—›ç—‡çŠ¶å’Œèƒƒè‚ åŠŸèƒ½æ˜¾ç€æ”¹å–„ã€‚", "keywords_zh": "ç»“ç›´è‚ åˆ‡é™¤æœ¯, å­å®«å†…è†œå¼‚ä½ç—‡, ç”Ÿæ´»è´¨é‡", "keywords_en": "colorectal resection, endometriosis, quality of life", "link": "https://pubmed.ncbi.nlm.nih.gov/39980238/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 21 Feb 2025"}, {"id": "39974280", "title_en": "Impact of dipeptidyl peptidase-4 inhibitors on incidence of colorectal cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis", "title_zh": "äºŒè‚½åŸºè‚½é…¶ 4 æŠ‘åˆ¶å‰‚å¯¹ 2 å‹ç³–å°¿ç—…æ‚£è€…ç»“ç›´è‚ ç™Œå‘ç—…ç‡çš„å½±å“ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Zhiyan Wang", "abstract_en": "**Background:** The association between dipeptidyl peptidase-4 inhibitors (DPP-4i) exposure and the risk of colorectal cancer (CRC) in patients with type 2 diabetes mellitus (T2DM) is unclear.\n\n**Objectives:** This meta-analysis aims to investigate the relationship between DPP-4i exposure and the incidence of CRC in patients with T2DM.\n\n**Design:** A systematic review and meta-analysis.\n\n**Methods:** A comprehensive search of electronic databases, including PubMed, Web of Science, EMBASE, and ScienceDirect, was conducted up to March 2024. The studies including randomized clinical trials (RCTs), cohort studies, and case-control studies were retrieved. The odds ratio (OR) was calculated using Stata 12.0 statistical software. The primary outcome assessed was the incidence of CRC.\n\n**Results:** This meta-analysis incorporated six retrospective cohort studies and two case-control studies. The findings indicate that the incidence of CRC in the DPP-4i exposure group was significantly higher than that in the control group (ORâ€‰=â€‰1.11, 95% CI: 1.02-1.21, <i>p</i>â€‰=â€‰0.013). Subgroup analysis revealed that both male (ORâ€‰=â€‰2.07, <i>p</i>â€‰<â€‰0.001) and female participants (ORâ€‰=â€‰1.49, <i>p</i>â€‰=â€‰0.05) in the DPP-4i exposure group exhibited a significantly higher incidence of CRC compared to the control group. Among participants younger than 65 years, the incidence of CRC was markedly elevated in the exposure group (ORâ€‰=â€‰2.81, <i>p</i>â€‰<â€‰0.001). Furthermore, when the exposure duration was less than 1â€‰year, the CRC incidence in the exposure group surpassed that of the control group (ORâ€‰=â€‰1.24, <i>p</i>â€‰=â€‰0.005). When sulfonylureas (SU) were used as control drugs, the incidence of CRC was higher in the exposure group (ORâ€‰=â€‰1.10, <i>p</i>â€‰=â€‰0.017).\n\n**Conclusion:** There is a potential correlation between DPP-4i exposure and increased incidence of CRC in T2DM patients. This association appears to be influenced by gender, age, duration of exposure, and the choice of control medications. Therefore, attention should be paid to colorectal diseases when DPP-4i is employed in the clinic.\n\n**Trial Registration:** The meta-analysis has been registered with the International Prospective Register of Systematic Reviews (PROSPERO). The registration number is CRD42024535292.", "abstract_zh": "**èƒŒæ™¯ï¼š** äºŒè‚½åŸºè‚½é…¶ 4 æŠ‘åˆ¶å‰‚ (DPP-4i) æš´éœ²ä¸ 2 å‹ç³–å°¿ç—… (T2DM) æ‚£è€…æ‚£ç»“ç›´è‚ ç™Œ (CRC) é£é™©ä¹‹é—´çš„å…³ç³»å°šä¸æ¸…æ¥šã€‚\n\n**Objectivesï¼š** æœ¬èŸèƒåˆ†ææ—¨åœ¨æ¢è®¨ T2DM æ‚£è€… DPP-4i æš´éœ²ä¸ CRC å‘ç—…ç‡ä¹‹é—´çš„å…³ç³»ã€‚\n\n**Designï¼š** ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æã€‚\n\n**æ–¹æ³•ï¼š** æˆªè‡³2024å¹´3æœˆï¼Œå¯¹PubMedã€Web of Scienceã€EMBASEå’ŒScienceDirectç­‰ç”µå­æ•°æ®åº“è¿›è¡Œäº†å…¨é¢æ£€ç´¢ï¼Œæ£€ç´¢äº†åŒ…æ‹¬éšæœºä¸´åºŠè¯•éªŒï¼ˆRCTï¼‰ã€é˜Ÿåˆ—ç ”ç©¶å’Œç—…ä¾‹å¯¹ç…§ç ”ç©¶åœ¨å†…çš„ç ”ç©¶ã€‚ä½¿ç”¨Stata 12.0ç»Ÿè®¡è½¯ä»¶è®¡ç®—ä¼˜åŠ¿æ¯”ï¼ˆORï¼‰ã€‚è¯„ä¼°çš„ä¸»è¦ç»“æœæ˜¯ CRC çš„å‘ç”Ÿç‡ã€‚\n\n**ç»“æœï¼š** è¿™é¡¹èŸèƒåˆ†æçº³å…¥äº†å…­é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶å’Œä¸¤é¡¹ç—…ä¾‹å¯¹ç…§ç ”ç©¶ã€‚ç ”ç©¶ç»“æœè¡¨æ˜ï¼ŒDPP-4iæš´éœ²ç»„CRCçš„å‘ç”Ÿç‡æ˜¾ç€é«˜äºå¯¹ç…§ç»„ï¼ˆORâ€‰=â€‰1.11ï¼Œ95% CIï¼š1.02-1.21ï¼Œ<i>p</i>â€‰=â€‰0.013ï¼‰ã€‚äºšç»„åˆ†ææ˜¾ç¤ºï¼Œä¸å¯¹ç…§ç»„ç›¸æ¯”ï¼ŒDPP-4iæš´éœ²ç»„ä¸­ç”·æ€§ï¼ˆORâ€‰=â€‰2.07ï¼Œ<i>p</i>â€‰<â€‰0.001ï¼‰å’Œå¥³æ€§å‚ä¸è€…ï¼ˆORâ€‰=â€‰1.49ï¼Œ<i>p</i>â€‰=â€‰0.05ï¼‰çš„CRCå‘ç—…ç‡å‡æ˜¾ç€é«˜äºå¯¹ç…§ç»„ã€‚åœ¨65å²ä»¥ä¸‹çš„å‚ä¸è€…ä¸­ï¼Œæš´éœ²ç»„çš„CRCå‘ç—…ç‡æ˜¾ç€å‡é«˜ï¼ˆORâ€‰=â€‰2.81ï¼Œ<i>p</i>â€‰<â€‰0.001ï¼‰ã€‚æ­¤å¤–ï¼Œå½“æš´éœ²æ—¶é—´å°äº1å¹´æ—¶ï¼Œæš´éœ²ç»„çš„CRCå‘ç—…ç‡è¶…è¿‡å¯¹ç…§ç»„ï¼ˆORâ€‰=â€‰1.24ï¼Œ<i>p</i>â€‰=â€‰0.005ï¼‰ã€‚å½“ä½¿ç”¨ç£ºè„²ç±»è¯ç‰©ï¼ˆSUï¼‰ä½œä¸ºå¯¹ç…§è¯ç‰©æ—¶ï¼Œæš´éœ²ç»„CRCçš„å‘ç”Ÿç‡è¾ƒé«˜ï¼ˆORâ€‰=â€‰1.10ï¼Œ<i>p</i>â€‰=â€‰0.017ï¼‰ã€‚\n\n**ç»“è®ºï¼š** T2DM æ‚£è€…ä¸­ DPP-4i æš´éœ²ä¸ CRC å‘ç—…ç‡å¢åŠ ä¹‹é—´å­˜åœ¨æ½œåœ¨ç›¸å…³æ€§ã€‚è¿™ç§å…³è”ä¼¼ä¹å—åˆ°æ€§åˆ«ã€å¹´é¾„ã€æš´éœ²æ—¶é—´å’Œå¯¹ç…§è¯ç‰©é€‰æ‹©çš„å½±å“ã€‚å› æ­¤ï¼Œä¸´åºŠåº”ç”¨DPP-4iæ—¶åº”æ³¨æ„ç»“ç›´è‚ ç–¾ç—…ã€‚\n\n**Trial registrationï¼š** è¯¥èŸèƒåˆ†æå·²åœ¨å›½é™…å‰ç»æ€§ç³»ç»Ÿè¯„ä»·ç™»è®°å†Œï¼ˆPROSPEROï¼‰æ³¨å†Œã€‚æ³¨å†Œå·ä¸ºCRD42024535292ã€‚", "keywords_zh": "DPP-4iã€ç»“ç›´è‚ ç™Œã€å‘ç—…ç‡ã€èŸèƒåˆ†æã€é£é™©ã€2 å‹ç³–å°¿ç—…", "keywords_en": "DPP-4i, colorectal cancer, incidence, meta-analysis, risk, type 2 diabetes mellitus", "link": "https://pubmed.ncbi.nlm.nih.gov/39974280/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Thu, 20 Feb 2025"}, {"id": "39960767", "title_en": "Is colonic J-pouch superior to other reconstructive techniques after total mesorectal excision? A systematic review with meta-analysis", "title_zh": "å…¨ç›´è‚ ç³»è†œåˆ‡é™¤åç»“è‚  J è¢‹æ˜¯å¦ä¼˜äºå…¶ä»–é‡å»ºæŠ€æœ¯ï¼ŸèŸèƒåˆ†æçš„ç³»ç»Ÿè¯„ä»·", "authors": "Mario Morino", "abstract_en": "**Background:** Different reconstruction techniques after total mesorectal excision have been described, such as straight coloanal anastomosis, colonic J-pouch, side-to-end anastomosis and transverse coloplasty pouch. Establishing which technique is the best in functional terms is essential to improving a patient's quality of life.\n\n**Methods:** We compared benefits and harms of different reconstructive techniques. The primary outcome was to compare functional results at 18â€‰months after surgery (long-term). Secondary outcomes were the same as primary but at different time intervals (short-term and medium-term) and perioperative morbidity and mortality.\n\n**Results:** Forty-one reports of 36 trials were included in the analysis. According to primary outcome, no significant difference was observed in terms of bowel frequency, while colonic J-pouch resulted in a lower incidence of faecal urgency only compared to side-to-end. Only up to 18â€‰months after bowel restoration bowel frequency, fecal urgency and the number of individuals using anti-diarrheal medications were reduced in the colonic J-pouch group. No difference in mortality/morbidity could be assessed among the techniques, but a lower rate of anastomotic leak after side-to-end compared to straight coloanal anastomosis was observed.\n\n**Conclusions:** Evidence suggests that reconstruction with colonic J-pouch offers similar long-term benefits to straight coloanal anastomosis and Transverse coloplasty pouch, while superior to side-to-end.", "abstract_zh": "**èƒŒæ™¯ï¼š** å…¨ç›´è‚ ç³»è†œåˆ‡é™¤åçš„ä¸åŒé‡å»ºæŠ€æœ¯å·²æœ‰æè¿°ï¼Œå¦‚ç»“è‚ ç›´è‚ å»åˆæœ¯ã€ç»“è‚ Jå½¢è¢‹ã€ä¾§ç«¯å»åˆæœ¯å’Œæ¨ªå‘ç»“è‚ æˆå½¢æœ¯è¢‹ã€‚ç¡®å®šå“ªç§æŠ€æœ¯åœ¨åŠŸèƒ½ä¸Šæ˜¯æœ€å¥½çš„å¯¹äºæ”¹å–„æ‚£è€…çš„ç”Ÿæ´»è´¨é‡è‡³å…³é‡è¦ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬æ¯”è¾ƒäº†ä¸åŒé‡å»ºæŠ€æœ¯çš„å¥½å¤„å’Œåå¤„ã€‚ä¸»è¦ç»“æœæ˜¯æ¯”è¾ƒæœ¯å 18 ä¸ªæœˆï¼ˆé•¿æœŸï¼‰çš„åŠŸèƒ½ç»“æœã€‚æ¬¡è¦ç»“å±€ä¸ä¸»è¦ç»“å±€ç›¸åŒï¼Œä½†æ—¶é—´é—´éš”ï¼ˆçŸ­æœŸå’Œä¸­æœŸï¼‰ä»¥åŠå›´æ‰‹æœ¯æœŸå‘ç—…ç‡å’Œæ­»äº¡ç‡ä¸åŒã€‚\n\n**ç»“æœï¼š** åˆ†æä¸­çº³å…¥äº† 36 é¡¹è¯•éªŒçš„ 41 ä»½æŠ¥å‘Šã€‚æ ¹æ®ä¸»è¦ç»“æœï¼Œåœ¨æ’ä¾¿é¢‘ç‡æ–¹é¢æ²¡æœ‰è§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ï¼Œè€Œç»“è‚  J å‹è¢‹ä»…ä¸ä¾§å¯¹ç«¯ç›¸æ¯”å¯¼è‡´æ’ä¾¿ç´§è¿«æ„Ÿçš„å‘ç”Ÿç‡è¾ƒä½ã€‚ä»…åœ¨è‚ é“æ¢å¤å 18 ä¸ªæœˆå†…ï¼Œç»“è‚  J è¢‹ç»„çš„æ’ä¾¿é¢‘ç‡ã€æ’ä¾¿ç´§è¿«æ„Ÿå’Œä½¿ç”¨æ­¢æ³»è¯ç‰©çš„äººæ•°å‡æœ‰æ‰€å‡å°‘ã€‚æ— æ³•è¯„ä¼°è¿™äº›æŠ€æœ¯ä¹‹é—´æ­»äº¡ç‡/å‘ç—…ç‡çš„å·®å¼‚ï¼Œä½†ä¸ç›´æ¥ç»“è‚ è‚›é—¨å»åˆç›¸æ¯”ï¼Œè§‚å¯Ÿåˆ°ä¾§ç«¯å»åˆæœ¯åå»åˆå£ç˜˜çš„å‘ç”Ÿç‡è¾ƒä½ã€‚\n\n**ç»“è®ºï¼š** æœ‰è¯æ®è¡¨æ˜ï¼Œç»“è‚  J å½¢è¢‹é‡å»ºä¸ç›´è‚ ç»“è‚ å»åˆæœ¯å’Œæ¨ªå‘ç»“è‚ æˆå½¢æœ¯è¢‹å…·æœ‰ç›¸ä¼¼çš„é•¿æœŸç›Šå¤„ï¼ŒåŒæ—¶ä¼˜äºä¾§ç«¯ç»“è‚ æˆå½¢æœ¯ã€‚", "keywords_zh": "ç›´è‚ ç™Œã€åŠŸèƒ½ç»“æœã€èŸèƒåˆ†æã€é‡å»ºæŠ€æœ¯ã€ç›´è‚ æ‰‹æœ¯", "keywords_en": "Rectal cancer, functional outcomes, meta-analysis, reconstructive techniques, rectal surgery", "link": "https://pubmed.ncbi.nlm.nih.gov/39960767/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 17 Feb 2025"}, {"id": "39920437", "title_en": "Voiding dysfunction after surgery for colorectal deep infiltrating endometriosis: an updated systematic review and meta-analysis", "title_zh": "ç»“ç›´è‚ æ·±éƒ¨æµ¸æ¶¦å­å®«å†…è†œå¼‚ä½ç—‡æ‰‹æœ¯åæ’å°¿åŠŸèƒ½éšœç¢ï¼šæ›´æ–°çš„ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Sofiane Bendifallah", "abstract_en": "To define the risk factors of post-operative voiding dysfunction according to the type of surgical procedure performed. A systematic review through PubMed, the Cochrane Library, and Web of Science databases was performed. The Medical Subject Headings terms aimed for English articles about colorectal endometriosis surgery and voiding dysfunction published until December 26, 2022 were used. The primary outcome was the occurrence of post-operative voiding dysfunction. Secondary outcome was the presence of a persistent voiding dysfunction at 1Â month. MeSH terms included ''deep endometriosis'', ''surgery'', or ''voiding dysfunction''. Two reviewers (AM, PE) assessed the quality of each article independently. A Study Quality Assessment Tool was used to provide rating of the quality of the included studies. 22 studies were included in the final analysis. Rectal shaving was associated with less voiding dysfunction than segmental resection (OR 0.33; 95%CI [0.20: 0.54]; I<sup>2</sup>â€‰=â€‰0%; pâ€‰<â€‰10<sup>-3</sup>). No difference was found between rectal shaving and discoid excision (OR 0.44; 95%CI [0.07: 2.84]; I<sup>2</sup>â€‰=â€‰55%; pâ€‰=â€‰0.39), nor between discoid excision and segmental resection (OR 0.44; 95%CI [0.18: 1.09]; I<sup>2</sup>â€‰=â€‰49%; pâ€‰=â€‰0.08). Conservative surgery (i.e., shaving and discoid) was associated with less voiding dysfunction than radical surgery (i.e., segmental resection) (OR 0.37; 95%CI [0.25: 0.55]; I<sup>2</sup>â€‰=â€‰0%; pâ€‰<â€‰10<sup>-3</sup>). Regarding persistent voiding dysfunction, rectal shaving and discoid excision were less associated with voiding dysfunction than segmental resection (respectively, OR 0.30; 95%CI [0.14: 0.66]; I<sup>2</sup>â€‰=â€‰0%; pâ€‰=â€‰0.003 and OR 0.13; 95%CI [0.03: 0.57]; I<sup>2</sup>â€‰=â€‰0%; pâ€‰=â€‰0.007). Conservative bowel procedures are associated with lower rates of persistent post-operative voiding dysfunction and should be considered first when possible.Trial registration: Our meta-analysis was registered under the PROSPERO number: CRD42023395356.", "abstract_zh": "æ ¹æ®æ‰€è¿›è¡Œçš„æ‰‹æœ¯ç±»å‹ç¡®å®šæœ¯åæ’å°¿åŠŸèƒ½éšœç¢çš„å±é™©å› ç´ ã€‚é€šè¿‡ PubMedã€Cochrane å›¾ä¹¦é¦†å’Œ Web of Science æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ã€‚ä½¿ç”¨çš„åŒ»å­¦ä¸»é¢˜æ ‡é¢˜æœ¯è¯­é’ˆå¯¹çš„æ˜¯æˆªè‡³ 2022 å¹´ 12 æœˆ 26 æ—¥å‘è¡¨çš„æœ‰å…³ç»“ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡æ‰‹æœ¯å’Œæ’å°¿åŠŸèƒ½éšœç¢çš„è‹±æ–‡æ–‡ç« ã€‚ä¸»è¦ç»“å±€æ˜¯æœ¯åæ’å°¿åŠŸèƒ½éšœç¢çš„å‘ç”Ÿã€‚æ¬¡è¦ç»“æœæ˜¯ 1 ä¸ªæœˆæ—¶å‡ºç°æŒç»­æ€§æ’å°¿åŠŸèƒ½éšœç¢ã€‚ MeSH æœ¯è¯­åŒ…æ‹¬â€œæ·±éƒ¨å­å®«å†…è†œå¼‚ä½ç—‡â€ã€â€œæ‰‹æœ¯â€æˆ–â€œæ’å°¿åŠŸèƒ½éšœç¢â€ã€‚ä¸¤ä½å®¡ç¨¿äººï¼ˆAMã€PEï¼‰ç‹¬ç«‹è¯„ä¼°æ¯ç¯‡æ–‡ç« çš„è´¨é‡ã€‚ç ”ç©¶è´¨é‡è¯„ä¼°å·¥å…·ç”¨äºå¯¹çº³å…¥ç ”ç©¶çš„è´¨é‡è¿›è¡Œè¯„çº§ã€‚æœ€ç»ˆåˆ†æçº³å…¥22é¡¹ç ”ç©¶ã€‚ç›´è‚ å‰ƒæ¯›ä¸èŠ‚æ®µåˆ‡é™¤ç›¸æ¯”ï¼Œæ’å°¿åŠŸèƒ½éšœç¢è¾ƒå°‘ï¼ˆOR 0.33ï¼›95%CI [0.20: 0.54]ï¼›I<sup>2</sup>â€‰=â€‰0%ï¼›pâ€‰<â€‰10<sup>-3</sup>ï¼‰ã€‚ç›´è‚ å‰ƒé™¤å’Œç›˜çŠ¶åˆ‡é™¤ä¹‹é—´æ²¡æœ‰å‘ç°å·®å¼‚ï¼ˆOR 0.44; 95%CI [0.07: 2.84]; I<sup>2</sup>â€‰=â€‰55%; pâ€‰=â€‰0.39ï¼‰ï¼Œç›˜çŠ¶åˆ‡é™¤å’ŒèŠ‚æ®µåˆ‡é™¤ä¹‹é—´ä¹Ÿæ²¡æœ‰å‘ç°å·®å¼‚ï¼ˆOR 0.44; 95%CI [0.18: 1.09]; I<sup>2</sup>â€‰=â€‰55%; pâ€‰=â€‰0.39ï¼‰ã€‚ I<sup>2</sup>â€‰=â€‰49%ï¼›pâ€‰=â€‰0.08)ã€‚ä¸æ ¹æ²»æ€§æ‰‹æœ¯ï¼ˆå³èŠ‚æ®µåˆ‡é™¤ï¼‰ç›¸æ¯”ï¼Œä¿å®ˆæ‰‹æœ¯ï¼ˆå³å‰ƒæ¯›å’Œç›˜çŠ¶æ‰‹æœ¯ï¼‰ä¸è¾ƒå°‘çš„æ’å°¿åŠŸèƒ½éšœç¢ç›¸å…³ï¼ˆOR 0.37ï¼›95%CI [0.25: 0.55]ï¼›I<sup>2</sup>â€‰=â€‰0%ï¼›pâ€‰<â€‰10<sup>-3</sup>ï¼‰ã€‚å…³äºæŒç»­æ€§æ’å°¿åŠŸèƒ½éšœç¢ï¼Œç›´è‚ å‰ƒé™¤å’Œç›˜çŠ¶åˆ‡é™¤ä¸èŠ‚æ®µæ€§åˆ‡é™¤ç›¸æ¯”ï¼Œä¸æ’å°¿åŠŸèƒ½éšœç¢çš„ç›¸å…³æ€§è¾ƒå°ï¼ˆåˆ†åˆ«ä¸º OR 0.30ï¼›95%CI [0.14: 0.66]ï¼›I<sup>2</sup>â€‰=â€‰0%ï¼›pâ€‰=â€‰0.003 å’Œ OR 0.13ï¼›95%CI [0.03: 0.57]ï¼› I<sup>2</sup>â€‰=â€‰0%ï¼›pâ€‰=â€‰0.007)ã€‚ä¿å®ˆæ€§è‚ é“æ‰‹æœ¯ä¸æœ¯åæŒç»­æ’å°¿åŠŸèƒ½éšœç¢çš„å‘ç”Ÿç‡è¾ƒä½æœ‰å…³ï¼Œå¦‚æœ‰å¯èƒ½ï¼Œåº”é¦–å…ˆè€ƒè™‘ã€‚è¯•éªŒæ³¨å†Œï¼šæˆ‘ä»¬çš„èŸèƒåˆ†æå·²åœ¨ PROSPERO ç¼–å·ä¸‹æ³¨å†Œï¼šCRD42023395356ã€‚", "keywords_zh": "ç»“ç›´è‚ å­å®«å†…è†œå¼‚ä½ç—‡ã€ç»“ç›´è‚ åˆ‡é™¤æœ¯ã€ç›˜çŠ¶åˆ‡é™¤æœ¯ã€å‰ƒæ¯›ã€æ‰‹æœ¯ã€æ’å°¿åŠŸèƒ½éšœç¢", "keywords_en": "Colorectal endometriosis, Colorectal resection, Discoid excision, Shaving, Surgery, Voiding dysfunction", "link": "https://pubmed.ncbi.nlm.nih.gov/39920437/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 07 Feb 2025"}, {"id": "39908072", "title_en": "Endovascular rectal artery embolisation (RAE) for symptomatic haemorrhoids", "title_zh": "è¡€ç®¡å†…ç›´è‚ åŠ¨è„‰æ “å¡æœ¯ï¼ˆRAEï¼‰æ²»ç–—æœ‰ç—‡çŠ¶çš„ç—”ç–®", "authors": "Ian Chetter", "abstract_en": "This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the safety and clinical effectiveness of endovascular rectal artery embolisation (RAE) for symptomatic haemorrhoids.", "abstract_zh": "è¿™æ˜¯ Cochrane ç»¼è¿°ï¼ˆå¹²é¢„ï¼‰çš„æ–¹æ¡ˆã€‚ç›®æ ‡å¦‚ä¸‹ï¼š è¯„ä¼°è¡€ç®¡å†…ç›´è‚ åŠ¨è„‰æ “å¡æœ¯ï¼ˆRAEï¼‰æ²»ç–—æœ‰ç—‡çŠ¶çš„ç—”ç–®çš„å®‰å…¨æ€§å’Œä¸´åºŠæœ‰æ•ˆæ€§ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39908072/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 05 Feb 2025"}, {"id": "39907263", "title_en": "How to Write a Systematic Review and Meta-analysis", "title_zh": "å¦‚ä½•æ’°å†™ç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Richard L Nelson", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39907263/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 05 Feb 2025"}, {"id": "39900861", "title_en": "Impact of indocyanine green fluorescence angiography on surgeon action and anastomotic leak in colorectal resections. A systematic review and meta-analysis", "title_zh": "å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½±å¯¹ç»“ç›´è‚ åˆ‡é™¤æœ¯ä¸­å¤–ç§‘åŒ»ç”Ÿè¡ŒåŠ¨å’Œå»åˆå£ç˜˜çš„å½±å“ã€‚ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æ", "authors": "Ronan A Cahill", "abstract_en": "**Background:** Indocyanine green fluorescence angiography (ICGFA) during colorectal surgery either reassures surgeons regarding intestinal perfusion sufficiency or prompts changed surgical strategy by indicating unsuspected insufficiency. This study describes existing evidence supporting ICGFA use in colorectal surgery, particularly regarding impact on intraoperative decisions.\n\n**Methods:** Searches were performed on PubMed, ScienceDirect, Scopus, Web of Science, Cochrane Collaboration databases on 5th December 2023, updated to 19th August 2024. Full English language publications of clinical studies in human patients undergoing colorectal resection with primary anastomosis with the use of ICGFA to assess bowel perfusion intraoperatively, with a control group, were included. Pooling of anastomotic leak (AL) rates was performed for primary outcome analysis with odds ratio (OR) and number-needed-to-treat (NNT) calculated regarding leak reduction.\n\n**Results:** 45 studies comprising 14,333 patients were included, with 7 randomised controlled trials (2911 patients). Overall, AL rate was 6.8%, 4.5% with ICGFA and 8.5% without (OR:0.47, pâ€‰<â€‰0.001, NNT 23), increasing to 9.5%, 7.5% and 11.6%, respectively, in randomised controlled trials (OR:0.62, pâ€‰<â€‰0.01, NNT 25). In rectal resections, AL rate was 4.7% with ICGFA vs 11.5% without (OR: 0.38, pâ€‰<â€‰0.0001). 26 studies performed ICGFA before and after anastomosis formation and 19 used ICGFA only prior to bowel transection, with no significant difference of AL rate reduction on subgroup testing. ICGFA prompted a change in surgical plan in 8.4% of thirty-four studies reporting this. Interestingly, in these studies, leak rates overall were 3.7% when ICGFA matched surgeon judgement versus 5.7% when it prompted change (OR 0.51, pâ€‰<â€‰0.0025), versus 7.7% without (OR 0.45, pâ€‰<â€‰0.0001). In rectal resections, these figures were 5%, 8.8% (OR 0.42, pâ€‰=â€‰0.01) and 12.0% (OR0.39, pâ€‰<â€‰0.0001), respectively.\n\n**Conclusions:** ICGFA colorectal perfusion assessment is associated with lower anastomotic leak rates, especially when confirming surgeons' judgement, and may so stratify patients post-operatively regarding subsequent anastomotic leak rate.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ æ‰‹æœ¯æœŸé—´çš„å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½± (ICGFA) è¦ä¹ˆå¯ä»¥è®©å¤–ç§‘åŒ»ç”Ÿæ”¾å¿ƒè‚ é“çŒæ³¨å……è¶³ï¼Œè¦ä¹ˆé€šè¿‡æŒ‡ç¤ºæ„å¤–çš„ä¸è¶³æ¥æç¤ºæ”¹å˜æ‰‹æœ¯ç­–ç•¥ã€‚æœ¬ç ”ç©¶æè¿°äº†æ”¯æŒ ICGFA åœ¨ç»“ç›´è‚ æ‰‹æœ¯ä¸­ä½¿ç”¨çš„ç°æœ‰è¯æ®ï¼Œç‰¹åˆ«æ˜¯å…³äºå¯¹æœ¯ä¸­å†³ç­–çš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** æ£€ç´¢äº 2023 å¹´ 12 æœˆ 5 æ—¥åœ¨ PubMedã€ScienceDirectã€Scopusã€Web of Scienceã€Cochrane Collaboration æ•°æ®åº“ä¸­è¿›è¡Œï¼Œæ›´æ–°è‡³ 2024 å¹´ 8 æœˆ 19 æ—¥ã€‚çº³å…¥äº†å¯¹æ¥å—ä¸€æœŸç»“ç›´è‚ åˆ‡é™¤æœ¯çš„äººç±»æ‚£è€…è¿›è¡Œä¸´åºŠç ”ç©¶çš„å®Œæ•´è‹±æ–‡å‡ºç‰ˆç‰©ï¼Œå…¶ä¸­ä½¿ç”¨ ICGFA è¯„ä¼°æœ¯ä¸­è‚ é“çŒæ³¨ï¼Œå¹¶æœ‰å¯¹ç…§ç»„ã€‚æ±‡æ€»å»åˆå£æ¼ (AL) ç‡ä»¥è¿›è¡Œä¸»è¦ç»“æœåˆ†æï¼Œå¹¶è®¡ç®—å‡ºæœ‰å…³å‡å°‘æ¼çš„æ¯”å€¼æ¯” (OR) å’Œéœ€è¦æ²»ç–—çš„äººæ•° (NNT)ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 45 é¡¹ç ”ç©¶ï¼Œæ¶‰åŠ 14,333 åæ‚£è€…ï¼Œå…¶ä¸­ 7 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼ˆ2911 åæ‚£è€…ï¼‰ã€‚æ€»ä½“è€Œè¨€ï¼Œæ¥å— ICGFA çš„ AL å‘ç”Ÿç‡ä¸º 6.8%ã€4.5%ï¼Œä¸æ¥å— ICGFA çš„ AL ç‡ä¸º 8.5%ï¼ˆORï¼š0.47ï¼Œp<0.001ï¼ŒNNT 23ï¼‰ï¼Œåœ¨éšæœºå¯¹ç…§è¯•éªŒä¸­åˆ†åˆ«å¢åŠ è‡³ 9.5%ã€7.5% å’Œ 11.6%ï¼ˆORï¼š0.62ï¼Œp<0.01ï¼ŒNNT 25ï¼‰ã€‚åœ¨ç›´è‚ åˆ‡é™¤æœ¯ä¸­ï¼Œä½¿ç”¨ ICGFA çš„ AL ç‡ä¸º 4.7%ï¼Œè€Œæœªä½¿ç”¨ ICGFA çš„ AL ç‡ä¸º 11.5%ï¼ˆORï¼š0.38ï¼Œp<â€‰0.0001ï¼‰ã€‚ 26 é¡¹ç ”ç©¶åœ¨å»åˆå½¢æˆä¹‹å‰å’Œä¹‹åè¿›è¡Œäº† ICGFAï¼Œ19 é¡¹ç ”ç©¶ä»…åœ¨è‚ æ¨ªæ–­ä¹‹å‰ä½¿ç”¨ ICGFAï¼Œäºšç»„æµ‹è¯•ä¸­ AL ç‡é™ä½æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚åœ¨æŠ¥å‘Šè¿™ä¸€æƒ…å†µçš„ 34 é¡¹ç ”ç©¶ä¸­ï¼ŒICGFA ä¿ƒä½¿ 8.4% çš„äººæ”¹å˜äº†æ‰‹æœ¯è®¡åˆ’ã€‚æœ‰è¶£çš„æ˜¯ï¼Œåœ¨è¿™äº›ç ”ç©¶ä¸­ï¼Œå½“ ICGFA ä¸å¤–ç§‘åŒ»ç”Ÿåˆ¤æ–­ç›¸åŒ¹é…æ—¶ï¼Œæ³„æ¼ç‡ä¸º 3.7%ï¼Œè€Œå½“ ICGFA ä¿ƒä½¿æ”¹å˜æ—¶ï¼Œæ³„æ¼ç‡ä¸º 5.7%ï¼ˆOR 0.51ï¼Œp<â€‰0.0025ï¼‰ï¼Œè€Œå½“ ICGFA ä¸åŒ¹é…å¤–ç§‘åŒ»ç”Ÿåˆ¤æ–­æ—¶ï¼Œæ³„æ¼ç‡ä¸º 7.7%ï¼ˆOR 0.45ï¼Œp<â€‰0.0001ï¼‰ã€‚åœ¨ç›´è‚ åˆ‡é™¤æœ¯ä¸­ï¼Œè¿™äº›æ•°å­—åˆ†åˆ«ä¸º 5%ã€8.8%ï¼ˆOR 0.42ï¼Œpâ€‰=â€‰0.01ï¼‰å’Œ 12.0%ï¼ˆOR0.39ï¼Œpâ€‰<â€‰0.0001ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ICGFAç»“ç›´è‚ çŒæ³¨è¯„ä¼°ä¸è¾ƒä½çš„å»åˆå£æ¼ç‡ç›¸å…³ï¼Œç‰¹åˆ«æ˜¯åœ¨ç¡®è®¤å¤–ç§‘åŒ»ç”Ÿçš„åˆ¤æ–­æ—¶ï¼Œå¹¶ä¸”å¯èƒ½å› æ­¤åœ¨æœ¯åå¯¹æ‚£è€…éšåçš„å»åˆå£æ¼ç‡è¿›è¡Œåˆ†å±‚ã€‚", "keywords_zh": "å»åˆå£ç˜˜ï¼Œç»“ç›´è‚ æ‰‹æœ¯ï¼Œå²å“šèç»¿ï¼Œè¿‘çº¢å¤–è…¹è…”é•œï¼Œç›´è‚ ç™Œ", "keywords_en": "Anastomotic leak, Colorectal surgery, Indocyanine green, Near-infrared laparoscopy, Rectal cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/39900861/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 03 Feb 2025"}, {"id": "39859149", "title_en": "Comprehensive Overview of Molecular, Imaging, and Therapeutic Challenges in Rectal Mucinous Adenocarcinoma", "title_zh": "ç›´è‚ ç²˜æ¶²è…ºç™Œçš„åˆ†å­ã€å½±åƒå­¦å’Œæ²»ç–—æŒ‘æˆ˜çš„å…¨é¢æ¦‚è¿°", "authors": "Florin Graur", "abstract_en": "Rectal cancer is one of the most frequent malignancies worldwide. The most common histological type is adenocarcinoma, followed by mucinous adenocarcinoma. The outcome is less favorable for the mucinous type, yet the treatment course is the same. The aim of this systematic literature review is to assess existing information in order to improve survival in rectal mucinous adenocarcinoma (RMA) and establish a starting point for future research. A systematic search of PubMed, Google Scholar, and Web of Science online libraries was performed in October 2024, evaluating studies regarding clinicopathological and genetic features in connection with targeted treatment and survival outcomes in RMA, using the terms \"rectal cancer\", \"rectum\", \"mucinous adenocarcinoma\", or a combination of the terms. We selected 23 studies, 10 of them regarding the diagnostic implications and 13 discussing the treatment strategies and prognosis of this histological subtype. There were six studies addressing the imaging aspects, highlighting the distinct features of mucinous histology in MRI. The molecular specifics were detailed in four studies, outlining the molecular footprint. The prognosis and treatment course were addressed in 12 studies. The inflammation index prognosis, complete response to neoadjuvant chemotherapy, and surgical aspects were addressed individually in each study. We encapsulated the molecular and clinicopathological characteristics of RMA, as well as diagnostic and treatment approaches, to establish a baseline of references for the benefit of daily practice and further research.", "abstract_zh": "ç›´è‚ ç™Œæ˜¯å…¨ä¸–ç•Œæœ€å¸¸è§çš„æ¶æ€§è‚¿ç˜¤ä¹‹ä¸€ã€‚æœ€å¸¸è§çš„ç»„ç»‡å­¦ç±»å‹æ˜¯è…ºç™Œï¼Œå…¶æ¬¡æ˜¯ç²˜æ¶²æ€§è…ºç™Œã€‚ç²˜æ¶²å‹çš„ç»“æœè¾ƒå·®ï¼Œä½†æ²»ç–—è¿‡ç¨‹æ˜¯ç›¸åŒçš„ã€‚æœ¬ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°çš„ç›®çš„æ˜¯è¯„ä¼°ç°æœ‰ä¿¡æ¯ï¼Œä»¥æé«˜ç›´è‚ ç²˜æ¶²è…ºç™Œ (RMA) çš„ç”Ÿå­˜ç‡ï¼Œå¹¶ä¸ºæœªæ¥çš„ç ”ç©¶å¥ å®šèµ·ç‚¹ã€‚ 2024 å¹´ 10 æœˆå¯¹ PubMedã€Google Scholar å’Œ Web of Science åœ¨çº¿å›¾ä¹¦é¦†è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ï¼Œä½¿ç”¨æœ¯è¯­â€œç›´è‚ ç™Œâ€ã€â€œç›´è‚ â€ã€â€œç²˜æ¶²è…ºç™Œâ€æˆ–è¿™äº›æœ¯è¯­çš„ç»„åˆï¼Œè¯„ä¼°äº†ä¸ RMA é¶å‘æ²»ç–—å’Œç”Ÿå­˜ç»“æœç›¸å…³çš„ä¸´åºŠç—…ç†å­¦å’Œé—ä¼ ç‰¹å¾çš„ç ”ç©¶ã€‚æˆ‘ä»¬é€‰æ‹©äº† 23 é¡¹ç ”ç©¶ï¼Œå…¶ä¸­ 10 é¡¹æ¶‰åŠè¯Šæ–­æ„ä¹‰ï¼Œ13 é¡¹è®¨è®ºè¯¥ç»„ç»‡å­¦äºšå‹çš„æ²»ç–—ç­–ç•¥å’Œé¢„åã€‚æœ‰å…­é¡¹ç ”ç©¶æ¶‰åŠæˆåƒæ–¹é¢ï¼Œçªå‡ºäº† MRI ä¸­ç²˜æ¶²ç»„ç»‡å­¦çš„ç‹¬ç‰¹ç‰¹å¾ã€‚å››é¡¹ç ”ç©¶è¯¦ç»†ä»‹ç»äº†åˆ†å­ç»†èŠ‚ï¼Œæ¦‚è¿°äº†åˆ†å­è¶³è¿¹ã€‚ 12 é¡¹ç ”ç©¶æ¢è®¨äº†é¢„åå’Œæ²»ç–—è¿‡ç¨‹ã€‚æ¯é¡¹ç ”ç©¶å‡å•ç‹¬è®¨è®ºäº†ç‚ç—‡æŒ‡æ•°é¢„åã€å¯¹æ–°è¾…åŠ©åŒ–ç–—çš„å®Œå…¨ååº”ä»¥åŠæ‰‹æœ¯æ–¹é¢çš„é—®é¢˜ã€‚æˆ‘ä»¬æ¦‚æ‹¬äº† RMA çš„åˆ†å­å’Œä¸´åºŠç—…ç†å­¦ç‰¹å¾ä»¥åŠè¯Šæ–­å’Œæ²»ç–—æ–¹æ³•ï¼Œä»¥å»ºç«‹å‚è€ƒåŸºçº¿ï¼Œä»¥åˆ©äºæ—¥å¸¸å®è·µå’Œè¿›ä¸€æ­¥ç ”ç©¶ã€‚", "keywords_zh": "åˆ†å­é€”å¾„, ç²˜æ¶²è…ºç™Œ, æ–°è¾…åŠ©æ²»ç–—, ç›´è‚ ç™Œ", "keywords_en": "molecular pathways, mucinous adenocarcinoma, neoadjuvant treatment, rectal cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/39859149/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sat, 25 Jan 2025"}, {"id": "39855400", "title_en": "The Determinants of Toxicity in the Treatment of Prostate Cancer With a Focal, Intraprostatic \"Microboost\"", "title_zh": "å±€éƒ¨å‰åˆ—è…ºå†…â€œå¾®å¢å¼ºâ€æ²»ç–—å‰åˆ—è…ºç™Œçš„æ¯’æ€§å†³å®šå› ç´ ", "authors": "Jeffrey M Ryckman", "abstract_en": "**Purpose:** A single-phase 3 trial has demonstrated that prostate radiation therapy with a focal, intraprostatic \"microboost\" can improve disease control without an overall increase in toxicity. It is unclear how these results generalize to other treatment schedules and protocols.\n\n**Methods And Materials:** A systematic search of PubMed and the Cochrane review was performed for studies published on or before September 1, 2023. A random-effects meta-analysis was used to pool the cumulative incidence of grade â‰¥2 (â‰¥G2) acute and late genitourinary (GU) and gastrointestinal (GI) toxicity. Heterogeneity was assessed, and the association of trial-level covariates with toxicity was examined via the subgroup analyses and meta-regression. Odds ratios (ORs) for dose metrics were reported per Gy equivalent dose in 2Gy per fraction (EQD2).\n\n**Results:** Thirty-eight patient cohorts were included. The pooled estimate of the cumulative incidence of â‰¥G2 acute and late GU toxicity was 25.3% (95% CI, 19.1%-32.8%) and 21.1% (95% CI, 16.7%-26.3%), respectively. Late â‰¥G2 GI toxicity was less frequent, estimated at 5.6% (95% CI, 3.5%-8.7%) and 6.9% (95% CI, 4.6%-10.1%), respectively. Subgroup factors associated with at least one â‰¥G2 toxicity category were treatment technique, imaging used for boost volume definition, intrafraction motion management, trial phase, and toxicity grading. Rectal D<sub>Max</sub> was associated with acute â‰¥G2 GI toxicity (OR, 1.05; 95% CI, 1.02-1.08; P < .001). Additionally, urethral D<sub>Max</sub> was associated with late â‰¥G2 GU toxicity (OR, 1.02; 95% CI, 1.01-1.03; P < .001), and a stronger relationship was observed with the average plan urethral D<sub>Max</sub> (OR, 1.05; 95% CI, 1.03-1.07; P < .001). No association of toxicity with any bladder dose metric examined was observed.\n\n**Conclusions:** The utilization of a microboost seems tolerable across treatment protocols; however, subgroup factors, including the use of intrafraction motion management and the type of imaging modality used, may influence the probability of toxicity. Attention to rectal D<sub>Max</sub> constraints and urethral D<sub>Max</sub> dose constraints may help to mitigate GI and GU toxicity, respectively. No association between toxicity and bladder dose constraints was observed.", "abstract_zh": "**Purposeï¼š** ä¸€é¡¹å•æœŸ 3 æœŸè¯•éªŒè¡¨æ˜ï¼Œé‡‡ç”¨å±€ç¶æ€§å‰åˆ—è…ºå†…â€œå¾®å¢å¼ºâ€çš„å‰åˆ—è…ºæ”¾å°„æ²»ç–—å¯ä»¥æ”¹å–„ç–¾ç—…æ§åˆ¶ï¼Œè€Œä¸ä¼šæ€»ä½“å¢åŠ æ¯’æ€§ã€‚ç›®å‰å°šä¸æ¸…æ¥šè¿™äº›ç»“æœå¦‚ä½•æ¨å¹¿åˆ°å…¶ä»–æ²»ç–—æ–¹æ¡ˆå’Œæ–¹æ¡ˆã€‚\n\n**Methods and materialsï¼š** å¯¹ 2023 å¹´ 9 æœˆ 1 æ—¥æˆ–ä¹‹å‰å‘è¡¨çš„ç ”ç©¶è¿›è¡Œäº† PubMed å’Œ Cochrane ç»¼è¿°çš„ç³»ç»Ÿæ£€ç´¢ã€‚ä½¿ç”¨éšæœºæ•ˆåº”èŸèƒåˆ†ææ¥æ±‡æ€» â‰¥2 çº§ (â‰¥G2) æ€¥æ€§å’Œæ™šæœŸæ³Œå°¿ç”Ÿæ®– (GU) å’Œèƒƒè‚ é“ (GI) æ¯’æ€§çš„ç´¯ç§¯å‘ç”Ÿç‡ã€‚è¯„ä¼°å¼‚è´¨æ€§ï¼Œå¹¶é€šè¿‡äºšç»„åˆ†æå’ŒèŸèƒå›å½’æ£€æŸ¥è¯•éªŒæ°´å¹³åå˜é‡ä¸æ¯’æ€§çš„å…³è”ã€‚å‰‚é‡æŒ‡æ ‡çš„æ¯”å€¼æ¯” (OR) ä»¥æ¯ Gy ç­‰æ•ˆå‰‚é‡æŠ¥å‘Šï¼Œä»¥æ¯åˆ†æ•° 2Gy (EQD2) è¡¨ç¤ºã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 38 åæ‚£è€…é˜Ÿåˆ—ã€‚ â‰¥G2 æ€¥æ€§å’Œæ™šæœŸ GU æ¯’æ€§ç´¯ç§¯å‘ç”Ÿç‡çš„æ±‡æ€»ä¼°è®¡å€¼åˆ†åˆ«ä¸º 25.3%ï¼ˆ95% CIï¼Œ19.1%-32.8%ï¼‰å’Œ 21.1%ï¼ˆ95% CIï¼Œ16.7%-26.3%ï¼‰ã€‚æ™šæœŸâ‰¥G2èƒƒè‚ é“æ¯’æ€§å‘ç”Ÿç‡è¾ƒä½ï¼Œä¼°è®¡åˆ†åˆ«ä¸º5.6%ï¼ˆ95% CIï¼Œ3.5%-8.7%ï¼‰å’Œ6.9%ï¼ˆ95% CIï¼Œ4.6%-10.1%ï¼‰ã€‚ä¸è‡³å°‘ä¸€ç§ â‰¥G2 æ¯’æ€§ç±»åˆ«ç›¸å…³çš„äºšç»„å› ç´ åŒ…æ‹¬æ²»ç–—æŠ€æœ¯ã€ç”¨äºå®šä¹‰å‡å‹é‡çš„æˆåƒã€åˆ†æ¬¡å†…è¿åŠ¨ç®¡ç†ã€è¯•éªŒé˜¶æ®µå’Œæ¯’æ€§åˆ†çº§ã€‚ç›´è‚  D<sub>Max</sub> ä¸æ€¥æ€§ â‰¥G2 èƒƒè‚ é“æ¯’æ€§ç›¸å…³ï¼ˆORï¼Œ1.05ï¼›95% CIï¼Œ1.02-1.08ï¼›P < .001ï¼‰ã€‚æ­¤å¤–ï¼Œå°¿é“ D<sub>Max</sub> ä¸æ™šæœŸ â‰¥G2 GU æ¯’æ€§ç›¸å…³ï¼ˆORï¼Œ1.02ï¼›95% CIï¼Œ1.01-1.03ï¼›P < .001ï¼‰ï¼Œå¹¶ä¸”ä¸å¹³å‡è®¡åˆ’å°¿é“ D<sub>Max</sub> ä¹‹é—´çš„å…³ç³»æ›´å¼ºï¼ˆORï¼Œ1.05ï¼›95% CIï¼Œ1.03-1.07ï¼›P < .001ï¼‰ã€‚æ²¡æœ‰è§‚å¯Ÿåˆ°æ¯’æ€§ä¸ä»»ä½•æ£€æŸ¥çš„è†€èƒ±å‰‚é‡æŒ‡æ ‡ä¹‹é—´çš„å…³è”ã€‚\n\n**ç»“è®ºï¼š** åœ¨ä¸åŒçš„æ²»ç–—æ–¹æ¡ˆä¸­ï¼Œå¾®å¢å¼ºçš„ä½¿ç”¨ä¼¼ä¹æ˜¯å¯ä»¥æ¥å—çš„ã€‚ç„¶è€Œï¼Œäºšç»„å› ç´ ï¼ŒåŒ…æ‹¬åˆ†æ¬¡å†…è¿åŠ¨ç®¡ç†çš„ä½¿ç”¨å’Œæ‰€ä½¿ç”¨çš„æˆåƒæ–¹å¼çš„ç±»å‹ï¼Œå¯èƒ½ä¼šå½±å“æ¯’æ€§çš„å¯èƒ½æ€§ã€‚æ³¨æ„ç›´è‚  D<sub>Max</sub> é™åˆ¶å’Œå°¿é“ D<sub>Max</sub> å‰‚é‡é™åˆ¶å¯èƒ½æœ‰åŠ©äºåˆ†åˆ«å‡è½» GI å’Œ GU æ¯’æ€§ã€‚æ²¡æœ‰è§‚å¯Ÿåˆ°æ¯’æ€§å’Œè†€èƒ±å‰‚é‡é™åˆ¶ä¹‹é—´çš„å…³è”ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39855400/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 24 Jan 2025"}, {"id": "39854786", "title_en": "The prevalence of incontinence after excisional hemorrhoidectomy and stapled hemorrhoidopexy: A systematic review and meta-analysis", "title_zh": "ç—”åˆ‡é™¤æœ¯å’Œå»åˆå™¨ç—”å›ºå®šæœ¯åå¤±ç¦çš„å‘ç”Ÿç‡ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Andrew G Hill", "abstract_en": "**Background:** Excisional hemorrhoidectomy and stapled hemorrhoidopexy are 2 common procedures for treating symptomatic hemorrhoids. However, concerns persist regarding the risk of postoperative complications and their unclear prevalence in the literature. This systematic review aims to evaluate andÂ compare the prevalence of incontinence after stapled hemorrhoidopexy and excisional hemorrhoidectomy.\n\n**Methods:** A systematic search of Medline, EMBASE, and CENTRAL identified studies published in the past 25Â years that reported incontinence after excisional treatments for hemorrhoids. Primary outcomes included early (<3Â months) and late (â‰¥3Â months) fecal incontinence. Secondary outcomes included postoperative bleeding, urinary retention, and recurrence. Single-arm meta-analyses of proportions were performed using R with meta-regression.\n\n**Results:** In total, 139 studies were included in the meta-analysis, including 68 randomized controlled trials with 8,445 participants and 71 observational studies with 22,687 participants. Early incontinence rates were 5.32% in randomized controlled trials (95% confidence interval, 2.74-8.51%) and 1.03% in nonrandomized controlled trials (95% confidence interval, 0.28-2.09%). Late incontinence rates were 2.48% in randomized controlled trials (95% confidence interval, 1.09-4.25%) and 1.44% in nonrandomized controlled trials (95% confidence interval, 0.71-2.37%). There was no significant difference in the risk of incontinence or other postoperative complications between stapled hemorrhoidopexy and excisional hemorrhoidectomy, both in randomized controlled trials and nonrandomized controlled trials.\n\n**Conclusion:** Incontinence after stapled hemorrhoidopexy and excisional hemorrhoidectomy is uncommon, and there appears to be no significant difference in risk between the 2 procedures. However, considerable heterogeneity was observed, likely the result of differences in assessment and reporting methods across studies. Future research should standardize definitions and methods for assessing incontinence and include preoperative assessments to more accurately define the risks of complications associated with hemorrhoid surgery.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç—”åˆ‡é™¤æœ¯å’Œå»åˆå™¨ç—”å›ºå®šæœ¯æ˜¯æ²»ç–—ç—‡çŠ¶æ€§ç—”ç–®çš„ä¸¤ç§å¸¸è§æ‰‹æœ¯ã€‚ç„¶è€Œï¼Œäººä»¬ä»ç„¶å¯¹æœ¯åå¹¶å‘ç—‡çš„é£é™©åŠå…¶æ–‡çŒ®ä¸­ä¸æ¸…æ¥šçš„å‘ç”Ÿç‡è¡¨ç¤ºæ‹…å¿§ã€‚æœ¬ç³»ç»Ÿè¯„ä»·æ—¨åœ¨è¯„ä¼°å’Œæ¯”è¾ƒå»åˆå™¨ç—”å›ºå®šæœ¯å’Œç—”åˆ‡é™¤æœ¯åå¤±ç¦çš„å‘ç”Ÿç‡ã€‚\n\n**æ–¹æ³•ï¼š** å¯¹ Medlineã€EMBASE å’Œ CENTRAL çš„ç³»ç»Ÿæ£€ç´¢å‘ç°äº†è¿‡å» 25 å¹´å‘è¡¨çš„ç ”ç©¶ï¼Œè¿™äº›ç ”ç©¶æŠ¥å‘Šäº†ç—”ç–®åˆ‡é™¤æ²»ç–—åå¤±ç¦çš„æƒ…å†µã€‚ä¸»è¦ç»“å±€åŒ…æ‹¬æ—©æœŸï¼ˆ<3 ä¸ªæœˆï¼‰å’Œæ™šæœŸï¼ˆâ‰¥3 ä¸ªæœˆï¼‰å¤§ä¾¿å¤±ç¦ã€‚æ¬¡è¦ç»“å±€åŒ…æ‹¬æœ¯åå‡ºè¡€ã€å°¿æ½´ç•™å’Œå¤å‘ã€‚ä½¿ç”¨ R å’ŒèŸèƒå›å½’å¯¹æ¯”ä¾‹è¿›è¡Œå•è‡‚èŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** èŸèƒåˆ†ææ€»å…±çº³å…¥äº† 139 é¡¹ç ”ç©¶ï¼Œå…¶ä¸­åŒ…æ‹¬ 68 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼ˆ8,445 åå—è¯•è€…ï¼‰å’Œ 71 é¡¹è§‚å¯Ÿæ€§ç ”ç©¶ï¼ˆ22,687 åå—è¯•è€…ï¼‰ã€‚éšæœºå¯¹ç…§è¯•éªŒä¸­çš„æ—©æœŸå¤±ç¦ç‡ä¸º 5.32%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼Œ2.74-8.51%ï¼‰ï¼Œééšæœºå¯¹ç…§è¯•éªŒä¸­çš„æ—©æœŸå¤±ç¦ç‡ä¸º 1.03%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼Œ0.28-2.09%ï¼‰ã€‚éšæœºå¯¹ç…§è¯•éªŒä¸­çš„æ™šæœŸå¤±ç¦ç‡ä¸º 2.48%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼Œ1.09-4.25%ï¼‰ï¼Œééšæœºå¯¹ç…§è¯•éªŒä¸­çš„æ™šæœŸå¤±ç¦ç‡ä¸º 1.44%ï¼ˆ95% ç½®ä¿¡åŒºé—´ï¼Œ0.71-2.37%ï¼‰ã€‚åœ¨éšæœºå¯¹ç…§è¯•éªŒå’Œééšæœºå¯¹ç…§è¯•éªŒä¸­ï¼Œå»åˆå™¨ç—”å›ºå®šæœ¯å’Œç—”åˆ‡é™¤æœ¯ä¹‹é—´çš„å¤±ç¦æˆ–å…¶ä»–æœ¯åå¹¶å‘ç—‡çš„é£é™©æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** å»åˆå™¨ç—”å›ºå®šæœ¯å’Œç—”åˆ‡é™¤æœ¯æœ¯åå¤±ç¦å¹¶ä¸å¸¸è§ï¼Œä¸¤ç§æ‰‹æœ¯ä¹‹é—´çš„é£é™©ä¼¼ä¹æ²¡æœ‰æ˜¾ç€å·®å¼‚ã€‚ç„¶è€Œï¼Œè§‚å¯Ÿåˆ°ç›¸å½“å¤§çš„å¼‚è´¨æ€§ï¼Œè¿™å¯èƒ½æ˜¯å„ä¸ªç ”ç©¶çš„è¯„ä¼°å’ŒæŠ¥å‘Šæ–¹æ³•å­˜åœ¨å·®å¼‚çš„ç»“æœã€‚æœªæ¥çš„ç ”ç©¶åº”è¯¥æ ‡å‡†åŒ–è¯„ä¼°å¤±ç¦çš„å®šä¹‰å’Œæ–¹æ³•ï¼Œå¹¶åŒ…æ‹¬æœ¯å‰è¯„ä¼°ï¼Œä»¥æ›´å‡†ç¡®åœ°ç¡®å®šä¸ç—”ç–®æ‰‹æœ¯ç›¸å…³çš„å¹¶å‘ç—‡çš„é£é™©ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39854786/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 24 Jan 2025"}, {"id": "39843599", "title_en": "The impact of indocyanine green fluorescence angiography (ICG-FA) on anastomotic leak rates and postoperative outcomes in colorectal anastomoses: a systematic review", "title_zh": "å²å“šèç»¿è§å…‰è¡€ç®¡é€ å½±ï¼ˆICG-FAï¼‰å¯¹ç»“ç›´è‚ å»åˆæœ¯ä¸­å»åˆå£æ¼ç‡å’Œæœ¯åç»“æœçš„å½±å“ï¼šç³»ç»Ÿè¯„ä»·", "authors": "Vinayak Rengan", "abstract_en": "**Background:** Anastomotic leak (AL) is a major complication in colorectal surgery, significantly contributing to perioperative morbidity and mortality. Among strategies to prevent AL, Indocyanine Green Fluorescence Angiography (ICG-FA) has emerged as a promising method for assessing bowel perfusion intraoperatively. This systematic review evaluates the impact of ICG-FA on AL rates and other postoperative outcomes following colorectal anastomoses.\n\n**Methods:** A systematic search was conducted in PubMed, PubMed Central, MEDLINE, and Google Scholar, following PRISMA guidelines. Eligible studies included randomized controlled trials (RCTs), prospective cohort studies, and retrospective cohort studies comparing ICG-FA to controls in adult patients undergoing colorectal resections and anastomoses. Data on AL rates, intraoperative characteristics, and postoperative outcomes were extracted. Quality assessment was performed using the Newcastle-Ottawa Scale and the Revised Cochrane Risk-of-Bias Tool.\n\n**Results:** Sixteen studies (12 retrospective, 1 prospective, and 3 RCTs) involving 3231 patients (1562 ICG-FA and 1669 controls) were included. AL rates were significantly lower in the ICG-FA group (5.18%) compared to controls (11.50%) (pâ€‰<â€‰0.01). ICG-FA influenced surgical plans in 16.31% of cases. Operative time and ileostomy formation rates were comparable between groups. Reoperation, ileus, and wound infection rates showed minimal differences. Mortality rates were low in both groups (ICG-FA: 0.55%, control: 0.51%).\n\n**Conclusion:** ICG-FA significantly reduces AL rates without increasing operative time or postoperative complications. This technique provides a reliable and safe assessment of bowel perfusion, supporting its integration into colorectal surgery protocols. Further high-quality RCTs are needed to confirm these findings and optimise its application.", "abstract_zh": "**èƒŒæ™¯ï¼š** å»åˆå£ç˜˜ï¼ˆALï¼‰æ˜¯ç»“ç›´è‚ æ‰‹æœ¯çš„ä¸»è¦å¹¶å‘ç—‡ï¼Œæ˜¾ç€å¢åŠ å›´æ‰‹æœ¯æœŸçš„å‘ç—…ç‡å’Œæ­»äº¡ç‡ã€‚åœ¨é¢„é˜² AL çš„ç­–ç•¥ä¸­ï¼Œå²å“šèç»¿è§å…‰è¡€ç®¡é€ å½± (ICG-FA) å·²æˆä¸ºè¯„ä¼°æœ¯ä¸­è‚ é“çŒæ³¨çš„ä¸€ç§æœ‰å‰æ™¯çš„æ–¹æ³•ã€‚æœ¬ç³»ç»Ÿç»¼è¿°è¯„ä¼°äº† ICG-FA å¯¹ç»“ç›´è‚ å»åˆæœ¯å AL ç‡å’Œå…¶ä»–æœ¯åç»“æœçš„å½±å“ã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ® PRISMA æŒ‡å—ï¼Œåœ¨ PubMedã€PubMed Centralã€MEDLINE å’Œ Google Scholar ä¸­è¿›è¡Œäº†ç³»ç»Ÿæ£€ç´¢ã€‚ç¬¦åˆæ¡ä»¶çš„ç ”ç©¶åŒ…æ‹¬éšæœºå¯¹ç…§è¯•éªŒ (RCT)ã€å‰ç»æ€§é˜Ÿåˆ—ç ”ç©¶å’Œå›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶ï¼Œåœ¨æ¥å—ç»“ç›´è‚ åˆ‡é™¤å’Œå»åˆçš„æˆå¹´æ‚£è€…ä¸­å°† ICG-FA ä¸å¯¹ç…§è¿›è¡Œæ¯”è¾ƒã€‚æå–äº† AL å‘ç”Ÿç‡ã€æœ¯ä¸­ç‰¹å¾å’Œæœ¯åç»“æœçš„æ•°æ®ã€‚ä½¿ç”¨çº½å¡æ–¯å°”-æ¸¥å¤ªåé‡è¡¨å’Œä¿®è®¢çš„ Cochrane åå€šé£é™©å·¥å…·è¿›è¡Œè´¨é‡è¯„ä¼°ã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 16 é¡¹ç ”ç©¶ï¼ˆ12 é¡¹å›é¡¾æ€§ç ”ç©¶ã€1 é¡¹å‰ç»æ€§ç ”ç©¶å’Œ 3 é¡¹éšæœºå¯¹ç…§è¯•éªŒï¼‰ï¼Œæ¶‰åŠ 3231 åæ‚£è€…ï¼ˆ1562 å ICG-FA å’Œ 1669 åå¯¹ç…§ï¼‰ã€‚ä¸å¯¹ç…§ç»„ (11.50%) ç›¸æ¯”ï¼ŒICG-FA ç»„ (5.18%) çš„ AL ç‡æ˜¾ç€é™ä½ (p<0.01)ã€‚ ICG-FA å½±å“äº† 16.31% ç—…ä¾‹çš„æ‰‹æœ¯è®¡åˆ’ã€‚å„ç»„ä¹‹é—´çš„æ‰‹æœ¯æ—¶é—´å’Œå›è‚ é€ å£å½¢æˆç‡ç›¸å½“ã€‚å†æ¬¡æ‰‹æœ¯ã€è‚ æ¢—é˜»å’Œä¼¤å£æ„ŸæŸ“ç‡å·®å¼‚å¾ˆå°ã€‚ä¸¤ç»„æ­»äº¡ç‡å‡è¾ƒä½ï¼ˆICG-FAï¼š0.55%ï¼Œå¯¹ç…§ç»„ï¼š0.51%ï¼‰ã€‚\n\n**ç»“è®ºï¼š** ICG-FA æ˜¾ç€é™ä½ AL ç‡ï¼Œä¸”ä¸ä¼šå¢åŠ æ‰‹æœ¯æ—¶é—´æˆ–æœ¯åå¹¶å‘ç—‡ã€‚è¯¥æŠ€æœ¯æä¾›äº†å¯é ä¸”å®‰å…¨çš„è‚ é“çŒæ³¨è¯„ä¼°ï¼Œæ”¯æŒå°†å…¶çº³å…¥ç»“ç›´è‚ æ‰‹æœ¯æ–¹æ¡ˆã€‚éœ€è¦è¿›ä¸€æ­¥çš„é«˜è´¨é‡éšæœºå¯¹ç…§è¯•éªŒæ¥è¯å®è¿™äº›å‘ç°å¹¶ä¼˜åŒ–å…¶åº”ç”¨ã€‚", "keywords_zh": "å»åˆå£æ¼ã€ç»“ç›´è‚ å»åˆæœ¯ã€ç»“ç›´è‚ åˆ‡é™¤æœ¯ã€è§å…‰è¡€ç®¡é€ å½±ã€ICGã€å²å“šèç»¿", "keywords_en": "Anastomotic leak, Colorectal anastomosis, Colorectal resection, Fluorescence angiography, ICG, Indocyanine green", "link": "https://pubmed.ncbi.nlm.nih.gov/39843599/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 22 Jan 2025"}, {"id": "39800833", "title_en": "Curative-Intended Management of Synchronous Esophageal and Rectal Cancer-A Systematic Literature Review", "title_zh": "é£Ÿç®¡ç™Œå’Œç›´è‚ ç™ŒåŒæ—¶å‘ç”Ÿçš„æ²»ç–—æ€§æ²»ç–—â€”â€”ç³»ç»Ÿæ–‡çŒ®ç»¼è¿°", "authors": "Maximilian RÃ¶mer", "abstract_en": "**Purpose:** Synchronous esophageal (EC) and rectal carcinoma (RC) is a rare and challenging condition, particularly in curative-intended treatment. Especially locally advanced tumors may not be suitable for primary resection and require individual multimodal treatment. This review examines curative-intended management of synchronous EC and RC.\n\n**Material And Methods:** A systematic literature search across five electronic databases according to the PRISMA guideline was conducted. Individual patient data was analyzed, including two additional cases from our institution.\n\n**Results:** We identified 9 relevant cases from 1552 results. Additionally, two male patients (62 and 65Â years old) from our institution were included. Both received 5-fluorouracil/cisplatin-based chemoradiotherapy (CRT) for EC. Sequential short-course radiation (SCRT) for RC was performed in one patient. After complete response (CR) in both tumors, no consecutive surgery was performed. He underwent resection for local recurrence of RC 11Â months later and is currently considered as disease-free (30Â months follow-up). The second patient underwent primary resection of RC and had early progression following resection of EC.Â We found that most patients had advanced EC (8/11), with the majority receiving neoadjuvant (5/11) or definitive treatment (3/11). Locally advanced RC was diagnosed in 5/11 patients, primarily treated with sequential resection. Pyrimidine-based systemic treatment was common. Four relapses and two deaths were reported, but median follow-up was 11 (range 1.5-30) months only.\n\n**Conclusion:** The review suggests that neoadjuvant multimodal approaches may offer curative potential for synchronous EC and RC, with individualized treatment protocols adapted from single-cancer protocols. Nevertheless, data on long-term outcome is limited.", "abstract_zh": "**Purposeï¼š** åŒæ­¥æ€§é£Ÿç®¡ç™Œ (EC) å’Œç›´è‚ ç™Œ (RC) æ˜¯ä¸€ç§ç½•è§ä¸”å…·æœ‰æŒ‘æˆ˜æ€§çš„ç–¾ç—…ï¼Œç‰¹åˆ«æ˜¯åœ¨æ²»æ„ˆæ€§æ²»ç–—ä¸­ã€‚ç‰¹åˆ«æ˜¯å±€éƒ¨æ™šæœŸè‚¿ç˜¤å¯èƒ½ä¸é€‚åˆä¸€æœŸåˆ‡é™¤ï¼Œéœ€è¦ä¸ªä½“åŒ–å¤šæ¨¡å¼æ²»ç–—ã€‚æœ¬ç»¼è¿°æ¢è®¨äº†åŒæ­¥ EC å’Œ RC çš„æ²»ç–—æ€§ç®¡ç†ã€‚\n\n**Material and methodsï¼š** æ ¹æ® PRISMA æŒ‡å—ï¼Œå¯¹äº”ä¸ªç”µå­æ•°æ®åº“è¿›è¡Œäº†ç³»ç»Ÿçš„æ–‡çŒ®æ£€ç´¢ã€‚å¯¹ä¸ªä½“æ‚£è€…æ•°æ®è¿›è¡Œäº†åˆ†æï¼ŒåŒ…æ‹¬æˆ‘ä»¬æœºæ„çš„å¦å¤–ä¸¤ä¸ªç—…ä¾‹ã€‚\n\n**ç»“æœï¼š** æˆ‘ä»¬ä» 1552 ä¸ªç»“æœä¸­è¯†åˆ«å‡º 9 ä¸ªç›¸å…³æ¡ˆä¾‹ã€‚æ­¤å¤–ï¼Œè¿˜åŒ…æ‹¬æˆ‘ä»¬æœºæ„çš„ä¸¤åç”·æ€§æ‚£è€…ï¼ˆ62 å²å’Œ 65 å²ï¼‰ã€‚ä¸¤äººå‡æ¥å—äº†åŸºäº 5-æ°Ÿå°¿å˜§å•¶/é¡ºé“‚çš„ EC æ”¾åŒ–ç–— (CRT)ã€‚å¯¹ä¸€åæ‚£è€…è¿›è¡Œäº† RC åºè´¯çŸ­ç¨‹æ”¾ç–— (SCRT)ã€‚ä¸¤ä¸ªè‚¿ç˜¤å®Œå…¨ç¼“è§£ï¼ˆCRï¼‰åï¼Œæ²¡æœ‰è¿›è¡Œè¿ç»­æ‰‹æœ¯ã€‚ 11 ä¸ªæœˆåï¼Œä»–å›  RC å±€éƒ¨å¤å‘æ¥å—äº†åˆ‡é™¤æœ¯ï¼Œç›®å‰è¢«è®¤ä¸ºæ— ç—…ï¼ˆéšè®¿ 30 ä¸ªæœˆï¼‰ã€‚ç¬¬äºŒåæ‚£è€…æ¥å—äº† RC åˆæ¬¡åˆ‡é™¤ï¼Œå¹¶åœ¨ EC åˆ‡é™¤åå‡ºç°æ—©æœŸè¿›å±•ã€‚Â æˆ‘ä»¬å‘ç°å¤§å¤šæ•°æ‚£è€…æ‚£æœ‰æ™šæœŸ EC (8/11)ï¼Œå…¶ä¸­å¤§å¤šæ•°æ¥å—æ–°è¾…åŠ©æ²»ç–— (5/11) æˆ–æ ¹æ²»æ€§æ²»ç–— (3/11)ã€‚ 5/11 çš„æ‚£è€…è¢«è¯Šæ–­ä¸ºå±€éƒ¨æ™šæœŸ RCï¼Œä¸»è¦é‡‡ç”¨åºè´¯åˆ‡é™¤æ²»ç–—ã€‚ä»¥å˜§å•¶ä¸ºåŸºç¡€çš„å…¨èº«æ²»ç–—å¾ˆå¸¸è§ã€‚æŠ¥å‘Šæœ‰ 4 ä¾‹å¤å‘å’Œ 2 ä¾‹æ­»äº¡ï¼Œä½†ä¸­ä½éšè®¿æ—¶é—´ä»…ä¸º 11ï¼ˆèŒƒå›´ 1.5-30ï¼‰ä¸ªæœˆã€‚\n\n**ç»“è®ºï¼š** è¯¥ç»¼è¿°è¡¨æ˜ï¼Œæ–°è¾…åŠ©å¤šæ¨¡å¼æ–¹æ³•å¯èƒ½ä¸ºåŒæ­¥ EC å’Œ RC æä¾›æ²»ç–—æ½œåŠ›ï¼Œå¹¶é‡‡ç”¨æ”¹ç¼–è‡ªå•ä¸€ç™Œç—‡æ–¹æ¡ˆçš„ä¸ªä½“åŒ–æ²»ç–—æ–¹æ¡ˆã€‚ç„¶è€Œï¼Œæœ‰å…³é•¿æœŸç»“æœçš„æ•°æ®æœ‰é™ã€‚", "keywords_zh": "é£Ÿç®¡ã€æ–°è¾…åŠ©æ²»ç–—ã€ç›´è‚ ã€åŒæ­¥ç™Œ", "keywords_en": "Esophagus, Neoadjuvant Treatment, Rectum, Synchronous Cancer", "link": "https://pubmed.ncbi.nlm.nih.gov/39800833/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sun, 12 Jan 2025"}, {"id": "39798047", "title_en": "Partial versus radical cystectomy in localized colorectal cancer: a systematic review and meta-analysis", "title_zh": "å±€éƒ¨ç»“ç›´è‚ ç™Œçš„éƒ¨åˆ†è†€èƒ±åˆ‡é™¤æœ¯ä¸æ ¹æ²»æ€§è†€èƒ±åˆ‡é™¤æœ¯ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Fernanda Bellotti Formiga", "abstract_en": "**Purpose:** Locally advanced colorectal tumors frequently invade adjacent organs, particularly the urinary bladder in the sigmoid colon and upper rectum, complicating multivisceral resections. This study compared postoperative outcomes of partial cystectomy (PC) and total cystectomy (TC) in patients with locally advanced colorectal cancer.\n\n**Methods:** A systematic review was conducted in PubMed, Scopus, Central Register of Clinical Trials, and Web of Science for studies published up to November 2024. Odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Heterogeneity was assessed with I<sup>2</sup> statistics. Statistical analyses were performed in R Software 4.4.1.\n\n**Results:** Nine retrospective studies including 894 patients were analyzed. Among them, 433 (48.43%) underwent PC, and 461 (51.57%) underwent TC. Compared to TC, PC was associated with significantly lower rates of surgical site infection (OR 0.33; 95% CI 0.13-0.80; pâ€‰=â€‰0.015), shorter operative time (MD - 169.7Â min; 95% CI - 214.1 to - 125.3; pâ€‰<â€‰0.01), reduced blood loss (MD - 1005.9Â ml; 95% CI - 1362.1 to - 649.8; pâ€‰<â€‰0.01), and shorter hospital stay (MD - 6.6Â days; 95% CI - 9.4 to - 3.9; pâ€‰<â€‰0.01). No significant differences were observed between groups in local or distant recurrence, urinary and intestinal leaks, pelvic abscess, ileus, urinary tract infection, or 90-day mortality.\n\n**Conclusion:** Partial cystectomy demonstrated superior postoperative outcomes, including fewer surgical site infections, reduced operative time, less blood loss, and shorter hospitalization. Oncological outcomes and other postoperative complications were comparable between PC and TC, supporting PC as a safe and effective option in selected patients.", "abstract_zh": "**Purposeï¼š** å±€éƒ¨æ™šæœŸç»“ç›´è‚ è‚¿ç˜¤ç»å¸¸ä¾µçŠ¯é‚»è¿‘å™¨å®˜ï¼Œç‰¹åˆ«æ˜¯ä¹™çŠ¶ç»“è‚ å’Œä¸Šç›´è‚ çš„è†€èƒ±ï¼Œä½¿å¤šè„å™¨åˆ‡é™¤å˜å¾—å¤æ‚ã€‚æœ¬ç ”ç©¶æ¯”è¾ƒäº†å±€éƒ¨æ™šæœŸç»“ç›´è‚ ç™Œæ‚£è€…è†€èƒ±éƒ¨åˆ†åˆ‡é™¤æœ¯ï¼ˆPCï¼‰å’Œè†€èƒ±å…¨åˆ‡é™¤æœ¯ï¼ˆTCï¼‰çš„æœ¯åç»“æœã€‚\n\n**æ–¹æ³•ï¼š** PubMedã€Scopusã€ä¸´åºŠè¯•éªŒä¸­å¤®æ³¨å†Œä¸­å¿ƒå’Œ Web of Science å¯¹æˆªè‡³ 2024 å¹´ 11 æœˆå‘è¡¨çš„ç ”ç©¶è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ã€‚ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹æ±‡æ€»äº†æ¯”å€¼æ¯” (OR) å’Œå¹³å‡å·® (MD) ä»¥åŠ 95% ç½®ä¿¡åŒºé—´ (CI)ã€‚ä½¿ç”¨ I<sup>2</sup> ç»Ÿè®¡æ•°æ®è¯„ä¼°å¼‚è´¨æ€§ã€‚ç»Ÿè®¡åˆ†æåœ¨R Software 4.4.1ä¸­è¿›è¡Œã€‚\n\n**ç»“æœï¼š** åˆ†æäº† 9 é¡¹å›é¡¾æ€§ç ”ç©¶ï¼ŒåŒ…æ‹¬ 894 åæ‚£è€…ã€‚å…¶ä¸­ï¼Œ433 ä¾‹ï¼ˆ48.43%ï¼‰æ¥å—äº† PCï¼Œ461 ä¾‹ï¼ˆ51.57%ï¼‰æ¥å—äº† TCã€‚ä¸ TC ç›¸æ¯”ï¼ŒPC ä¸æ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ç‡æ˜¾ç€é™ä½ï¼ˆOR 0.33ï¼›95% CI 0.13-0.80ï¼›pâ€‰=â€‰0.015ï¼‰ã€æ‰‹æœ¯æ—¶é—´æ›´çŸ­ï¼ˆMD - 169.7 åˆ†é’Ÿï¼›95% CI - 214.1 è‡³ - 125.3ï¼›pâ€‰<â€‰0.01ï¼‰ã€å¤±è¡€é‡å‡å°‘ï¼ˆMD - 1005.9 mlï¼›95% CI - 1362.1 è‡³ - 649.8ï¼›p<â€‰0.01ï¼‰ï¼Œä½é™¢æ—¶é—´è¾ƒçŸ­ï¼ˆMD - 6.6 å¤©ï¼›95% CI - 9.4 è‡³ - 3.9ï¼›p<â€‰0.01ï¼‰ã€‚å„ç»„ä¹‹é—´åœ¨å±€éƒ¨æˆ–è¿œå¤„å¤å‘ã€å°¿æ¼å’Œè‚ æ¼ã€ç›†è…”è„“è‚¿ã€è‚ æ¢—é˜»ã€å°¿è·¯æ„ŸæŸ“æˆ– 90 å¤©æ­»äº¡ç‡æ–¹é¢æ²¡æœ‰è§‚å¯Ÿåˆ°æ˜¾ç€å·®å¼‚ã€‚\n\n**ç»“è®ºï¼š** è†€èƒ±éƒ¨åˆ†åˆ‡é™¤æœ¯æ˜¾ç¤ºå‡ºä¼˜è¶Šçš„æœ¯åæ•ˆæœï¼ŒåŒ…æ‹¬æ›´å°‘çš„æ‰‹æœ¯éƒ¨ä½æ„ŸæŸ“ã€ç¼©çŸ­çš„æ‰‹æœ¯æ—¶é—´ã€æ›´å°‘çš„å¤±è¡€å’Œæ›´çŸ­çš„ä½é™¢æ—¶é—´ã€‚ PC å’Œ TC ä¹‹é—´çš„è‚¿ç˜¤ç»“æœå’Œå…¶ä»–æœ¯åå¹¶å‘ç—‡ç›¸å½“ï¼Œæ”¯æŒ PC ä½œä¸ºé€‰å®šæ‚£è€…çš„å®‰å…¨æœ‰æ•ˆçš„é€‰æ‹©ã€‚", "keywords_zh": "æ™šæœŸç»“ç›´è‚ ç™Œã€è†€èƒ±åˆ‡é™¤æœ¯ã€æ–°è†€èƒ±æœ¯ã€å°¿è·¯é€ å£æœ¯", "keywords_en": "Advanced colorectal cancer, Cystectomy, Neobladder, Urostomy", "link": "https://pubmed.ncbi.nlm.nih.gov/39798047/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Sat, 11 Jan 2025"}, {"id": "39774691", "title_en": "Comment on \"Risk of Postoperative Venous Thromboembolism After Benign Colorectal Surgery: Systematic Review and Meta-analysis\"", "title_zh": "å¯¹â€œè‰¯æ€§ç»“ç›´è‚ æ‰‹æœ¯åæœ¯åé™è„‰è¡€æ “æ “å¡çš„é£é™©ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æâ€çš„è¯„è®º", "authors": "Saima Syed", "abstract_en": "No abstract", "abstract_zh": "æ— æ‘˜è¦", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39774691/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Wed, 08 Jan 2025"}, {"id": "39671968", "title_en": "New alternative colorectal anastomotic devices: A systematic review and meta-analysis", "title_zh": "æ–°çš„æ›¿ä»£ç»“ç›´è‚ å»åˆè£…ç½®ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "S Wexner", "abstract_en": "**Background:** Colorectal anastomotic devices have been used for nearly a century, with stapled anastomoses being the most common despite leak rates up to 20Â â€‹%. This review aimed to evaluate newer alternative devices.\n\n**Method:** A systematic review and meta-analysis of publications from the last decade were conducted, focusing on devices forming colorectal anastomoses, excluding those facilitating sutured or stapled anastomoses or designed to prevent leaks. Data from MEDLINE, Embase, Cochrane, and ClinicalTrials.gov were analysed.\n\n**Results:** Eighteen studies (7 human, 10 animal, 1 ex-vivo) involving 955 anastomoses were included. Compression mechanisms were the most common. The pooled complication rate in human studies was 9.7Â â€‹% (95Â â€‹% CI: 4.3-15.2Â â€‹%) with significant heterogeneity (I2Â â€‹=Â â€‹81.7Â â€‹%). The leak rate after compression anastomoses was 3.3Â â€‹% (95Â â€‹% CI: 1.9-4.7Â â€‹%) with no heterogeneity (I2Â â€‹=Â â€‹0Â â€‹%). A novel device with transanal catheters allowed intraoperative and postoperative assessment.\n\n**Conclusions:** Outcomes are comparable to existing methods, with new technologies offering promising advancements.", "abstract_zh": "**èƒŒæ™¯ï¼š** ç»“ç›´è‚ å»åˆè£…ç½®å·²ç»ä½¿ç”¨äº†è¿‘ä¸€ä¸ªä¸–çºªï¼Œå…¶ä¸­å»åˆå™¨å»åˆæœ¯æ˜¯æœ€å¸¸è§çš„ï¼Œå°½ç®¡æ³„æ¼ç‡é«˜è¾¾ 20%ã€‚æœ¬æ¬¡å®¡æŸ¥æ—¨åœ¨è¯„ä¼°æ›´æ–°çš„æ›¿ä»£è®¾å¤‡ã€‚\n\n**Methodï¼š** å¯¹è¿‡å»åå¹´çš„å‡ºç‰ˆç‰©è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æï¼Œé‡ç‚¹å…³æ³¨å½¢æˆç»“ç›´è‚ å»åˆçš„è£…ç½®ï¼Œä¸åŒ…æ‹¬é‚£äº›ä¿ƒè¿›ç¼åˆæˆ–å»åˆæˆ–æ—¨åœ¨é˜²æ­¢æ³„æ¼çš„è£…ç½®ã€‚å¯¹æ¥è‡ª MEDLINEã€Embaseã€Cochrane å’Œ ClinicalTrials.gov çš„æ•°æ®è¿›è¡Œäº†åˆ†æã€‚\n\n**ç»“æœï¼š** çº³å…¥äº† 18 é¡¹ç ”ç©¶ï¼ˆ7 é¡¹äººç±»ç ”ç©¶ã€10 é¡¹åŠ¨ç‰©ç ”ç©¶ã€1 é¡¹ç¦»ä½“ç ”ç©¶ï¼‰ï¼Œæ¶‰åŠ 955 ä¾‹å»åˆæœ¯ã€‚å‹ç¼©æœºåˆ¶æ˜¯æœ€å¸¸è§çš„ã€‚äººç±»ç ”ç©¶ä¸­çš„æ±‡æ€»å¹¶å‘ç—‡ç‡ä¸º 9.7%ï¼ˆ95% CIï¼š4.3-15.2%ï¼‰ï¼Œå…·æœ‰æ˜¾ç€å¼‚è´¨æ€§ï¼ˆI2=81.7%ï¼‰ã€‚å‹ç¼©å»åˆåçš„æ¼ç‡ä¸º 3.3%ï¼ˆ95% CIï¼š1.9-4.7%ï¼‰ï¼Œæ— å¼‚è´¨æ€§ï¼ˆI2=0%ï¼‰ã€‚ä¸€ç§å¸¦æœ‰ç»è‚›é—¨å¯¼ç®¡çš„æ–°å‹è£…ç½®å¯ä»¥è¿›è¡Œæœ¯ä¸­å’Œæœ¯åè¯„ä¼°ã€‚\n\n**ç»“è®ºï¼š** ç»“æœä¸ç°æœ‰æ–¹æ³•ç›¸å½“ï¼Œæ–°æŠ€æœ¯æä¾›äº†æœ‰å¸Œæœ›çš„è¿›æ­¥ã€‚", "keywords_zh": "", "keywords_en": "", "link": "https://pubmed.ncbi.nlm.nih.gov/39671968/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Fri, 13 Dec 2024"}, {"id": "39656328", "title_en": "Systematic review of the feasibility of sparing the rectoprostatic fascia in male patients undergoing total mesorectal excision for rectal cancer", "title_zh": "ç³»ç»Ÿè¯„ä»·æ¥å—ç›´è‚ ç™Œå…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯çš„ç”·æ€§æ‚£è€…ä¿ç•™ç›´è‚ å‰åˆ—è…ºç­‹è†œçš„å¯è¡Œæ€§", "authors": "J Tsiaoussis", "abstract_en": "**Background:** The main purpose of this study was to determine the feasibility of sparing the rectoprostatic fascia (RPF) in adult male cadavers and in adult male patients who underwent total mesorectal excision (TME) for rectal cancer. A secondary objective was to evaluate urogenital function following rectal cancer surgery, pathologic, and oncologic outcomes.\n\n**Methods:** In accordance with PRISMA guidelines, we performed a systematic review with an a priori design to identify relevant studies via MESH terms and keywords. Research was conducted from March 1stÂ to JulyÂ 31st 2023Â andÂ was updated betweenÂ September 30thÂ toÂ October 10th 2024 in MEDLINE, SCOPUS, the Web of Science, Google Scholar, and reference lists. Disagreements between individual judgments were resolved by referral to a third researcher.\n\n**Results:** In total, 3693 studies were identified, 22 of which were relevant to the main research question. Overall, 785 living individuals and 25 cadavers were included in whom RPF was identified and spared (498/785 patients or 63.44%). The quality of the surgical specimen was considered good in all cases. Urogenital integrity at 6Â months after RPF-TME and the classic TME were compromised in 27.9% and 41% of patients, respectively. One study revealed that at 3Â years, local/systemic recurrence was similar between the two groups.\n\n**Conclusions:** Despite the fact that the current practice of rectal cancer surgery requires the TME to extend anteriorly to the RPF, RPF-sparing TME is not only a feasible and safe option but also important for preserving fair male urogenital function, especially for young patients whose erectile function is a priority.\n\n**Trial Registration:** CRD42020171188.", "abstract_zh": "**èƒŒæ™¯ï¼š** æœ¬ç ”ç©¶çš„ä¸»è¦ç›®çš„æ˜¯ç¡®å®šåœ¨æˆå¹´ç”·æ€§å°¸ä½“å’Œå› ç›´è‚ ç™Œæ¥å—å…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯ï¼ˆTMEï¼‰çš„æˆå¹´ç”·æ€§æ‚£è€…ä¸­ä¿ç•™ç›´è‚ å‰åˆ—è…ºç­‹è†œï¼ˆRPFï¼‰çš„å¯è¡Œæ€§ã€‚æ¬¡è¦ç›®æ ‡æ˜¯è¯„ä¼°ç›´è‚ ç™Œæ‰‹æœ¯åçš„æ³Œå°¿ç”Ÿæ®–åŠŸèƒ½ã€ç—…ç†å’Œè‚¿ç˜¤å­¦ç»“æœã€‚\n\n**æ–¹æ³•ï¼š** æ ¹æ® PRISMA æŒ‡å—ï¼Œæˆ‘ä»¬é€šè¿‡å…ˆéªŒè®¾è®¡è¿›è¡Œäº†ç³»ç»Ÿè¯„ä»·ï¼Œé€šè¿‡ MESH æœ¯è¯­å’Œå…³é”®è¯è¯†åˆ«ç›¸å…³ç ”ç©¶ã€‚ç ”ç©¶äº 2023 å¹´ 3 æœˆ 1 æ—¥è‡³ 7 æœˆ 31 æ—¥è¿›è¡Œï¼Œå¹¶äº 2024 å¹´ 9 æœˆ 30 æ—¥è‡³ 10 æœˆ 10 æ—¥åœ¨ MEDLINEã€SCOPUSã€Web of Scienceã€Google Scholar å’Œå‚è€ƒæ–‡çŒ®åˆ—è¡¨ä¸­è¿›è¡Œæ›´æ–°ã€‚ä¸ªäººåˆ¤æ–­ä¹‹é—´çš„åˆ†æ­§é€šè¿‡è½¬ä»‹ç»™ç¬¬ä¸‰ä½ç ”ç©¶äººå‘˜æ¥è§£å†³ã€‚\n\n**ç»“æœï¼š** æ€»å…±ç¡®å®šäº† 3693 é¡¹ç ”ç©¶ï¼Œå…¶ä¸­ 22 é¡¹ä¸ä¸»è¦ç ”ç©¶é—®é¢˜ç›¸å…³ã€‚æ€»ä½“è€Œè¨€ï¼Œ785 åæ´»äººå’Œ 25 å…·å°¸ä½“è¢«çº³å…¥ RPF è¯†åˆ«å¹¶å¹¸å…ï¼ˆ498/785 åæ‚£è€…æˆ– 63.44%ï¼‰ã€‚åœ¨æ‰€æœ‰æƒ…å†µä¸‹ï¼Œæ‰‹æœ¯æ ‡æœ¬çš„è´¨é‡éƒ½è¢«è®¤ä¸ºæ˜¯è‰¯å¥½çš„ã€‚ RPF-TME å’Œç»å…¸ TME å 6 ä¸ªæœˆæ—¶ï¼Œåˆ†åˆ«æœ‰ 27.9% å’Œ 41% çš„æ‚£è€…çš„æ³Œå°¿ç”Ÿæ®–å®Œæ•´æ€§å—åˆ°æŸå®³ã€‚ä¸€é¡¹ç ”ç©¶æ˜¾ç¤ºï¼Œ3 å¹´æ—¶ï¼Œä¸¤ç»„çš„å±€éƒ¨/å…¨èº«å¤å‘ç‡ç›¸ä¼¼ã€‚\n\n**ç»“è®ºï¼š** å°½ç®¡ç›®å‰çš„ç›´è‚ ç™Œæ‰‹æœ¯å®è·µè¦æ±‚ TME å‘å‰å»¶ä¼¸è‡³ RPFï¼Œä½†ä¿ç•™ RPF çš„ TME ä¸ä»…æ˜¯ä¸€ç§å¯è¡Œä¸”å®‰å…¨çš„é€‰æ‹©ï¼Œè€Œä¸”å¯¹äºä¿ç•™å…¬å¹³çš„ç”·æ€§æ³Œå°¿ç”Ÿæ®–åŠŸèƒ½ä¹Ÿå¾ˆé‡è¦ï¼Œç‰¹åˆ«æ˜¯å¯¹äºå‹ƒèµ·åŠŸèƒ½ä¸ºä¼˜å…ˆè€ƒè™‘çš„å¹´è½»æ‚£è€…ã€‚\n\n**Trial registrationï¼š** CRD42020171188ã€‚", "keywords_zh": "å‹ƒèµ·åŠŸèƒ½éšœç¢ã€ç›´è‚ ç™Œã€ä¿ç•™ç›´è‚ å‰åˆ—è…ºç­‹è†œã€ç³»ç»Ÿè¯„ä»·ã€å…¨ç›´è‚ ç³»è†œåˆ‡é™¤æœ¯", "keywords_en": "Erectile dysfunction, Rectal cancer, Spare rectoprostatic fascia, Systematic review, Total mesorectal excision", "link": "https://pubmed.ncbi.nlm.nih.gov/39656328/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Tue, 10 Dec 2024"}, {"id": "39650188", "title_en": "Statin exposure and risk of colorectal cancer in patients with inflammatory bowel disease: a systematic review and meta-analysis", "title_zh": "ç‚ç—‡æ€§è‚ ç—…æ‚£è€…çš„ä»–æ±€ç±»è¯ç‰©æš´éœ²ä¸ç»“ç›´è‚ ç™Œé£é™©ï¼šç³»ç»Ÿè¯„ä»·å’ŒèŸèƒåˆ†æ", "authors": "Yong-Hui Jia", "abstract_en": "**Background:** While epidemiological studies have linked statin use to a reduced risk of advanced colorectal adenomas, its impact on colorectal cancer (CRC) risk in patients with inflammatory bowel disease (IBD) remains unclear. To our knowledge, no meta-analysis to date has specifically examined this association. Therefore, we conducted a systematic review and meta-analysis of the available observational studies to investigate the risk of CRC associated with statin use in IBD patients.\n\n**Methods:** We searched three databases for articles published in English before September 2024, focusing on the protective effects of statins against CRC in IBD patients. We calculated multivariate odds ratios (ORs) and their 95% confidence intervals (CIs) to assess this association. A random-effects meta-analysis was conducted using the generic inverse variance method.\n\n**Results:** The meta-analysis included 4 studies encompassing 22,250 IBD patients, 6,712 of whom were statin users. The methodological quality of three of the studies was deemed high. We found a significantly lower risk of CRC in statin users compared to non-users, with a pooled relative risk of 1.88 (95% CI 1.54-2.30). Sensitivity analyses confirmed the consistency of these findings.\n\n**Conclusion:** Statin use appears to be associated with a reduced risk of CRC in patients with IBD. However, given the limited number of studies available, further prospective research with large sample size is necessary to confirm the potential chemopreventive role of statins in this population.", "abstract_zh": "**èƒŒæ™¯ï¼š** è™½ç„¶æµè¡Œç—…å­¦ç ”ç©¶è¡¨æ˜ä»–æ±€ç±»è¯ç‰©çš„ä½¿ç”¨å¯ä»¥é™ä½æ™šæœŸç»“ç›´è‚ è…ºç˜¤çš„é£é™©ï¼Œä½†å…¶å¯¹ç‚ç—‡æ€§è‚ ç—… (IBD) æ‚£è€…ç»“ç›´è‚ ç™Œ (CRC) é£é™©çš„å½±å“ä»ä¸æ¸…æ¥šã€‚æ®æˆ‘ä»¬æ‰€çŸ¥ï¼Œè¿„ä»Šä¸ºæ­¢è¿˜æ²¡æœ‰èŸèƒåˆ†æä¸“é—¨ç ”ç©¶è¿‡è¿™ç§å…³è”ã€‚å› æ­¤ï¼Œæˆ‘ä»¬å¯¹ç°æœ‰çš„è§‚å¯Ÿæ€§ç ”ç©¶è¿›è¡Œäº†ç³»ç»Ÿå›é¡¾å’ŒèŸèƒåˆ†æï¼Œä»¥è°ƒæŸ¥ IBD æ‚£è€…ä½¿ç”¨ä»–æ±€ç±»è¯ç‰©ç›¸å…³çš„ CRC é£é™©ã€‚\n\n**æ–¹æ³•ï¼š** æˆ‘ä»¬æ£€ç´¢äº†ä¸‰ä¸ªæ•°æ®åº“ï¼ŒæŸ¥æ‰¾ 2024 å¹´ 9 æœˆä¹‹å‰å‘è¡¨çš„è‹±æ–‡æ–‡ç« ï¼Œé‡ç‚¹å…³æ³¨ä»–æ±€ç±»è¯ç‰©å¯¹ IBD æ‚£è€…å¯¹ CRC çš„ä¿æŠ¤ä½œç”¨ã€‚æˆ‘ä»¬è®¡ç®—äº†å¤šå˜é‡æ¯”å€¼æ¯” (OR) åŠå…¶ 95% ç½®ä¿¡åŒºé—´ (CI) æ¥è¯„ä¼°è¿™ç§å…³è”ã€‚ä½¿ç”¨é€šç”¨é€†æ–¹å·®æ–¹æ³•è¿›è¡Œéšæœºæ•ˆåº”èŸèƒåˆ†æã€‚\n\n**ç»“æœï¼š** è¯¥èŸèƒåˆ†æåŒ…æ‹¬ 4 é¡¹ç ”ç©¶ï¼Œæ¶‰åŠ 22,250 å IBD æ‚£è€…ï¼Œå…¶ä¸­ 6,712 åæ‚£è€…æ˜¯ä»–æ±€ç±»è¯ç‰©ä½¿ç”¨è€…ã€‚å…¶ä¸­ä¸‰é¡¹ç ”ç©¶çš„æ–¹æ³•å­¦è´¨é‡è¢«è®¤ä¸ºå¾ˆé«˜ã€‚æˆ‘ä»¬å‘ç°ï¼Œä¸éä½¿ç”¨è€…ç›¸æ¯”ï¼Œä»–æ±€ç±»è¯ç‰©ä½¿ç”¨è€…æ‚£ CRC çš„é£é™©æ˜¾ç€é™ä½ï¼Œæ±‡æ€»ç›¸å¯¹é£é™©ä¸º 1.88 (95% CI 1.54-2.30)ã€‚æ•æ„Ÿæ€§åˆ†æè¯å®äº†è¿™äº›ç ”ç©¶ç»“æœçš„ä¸€è‡´æ€§ã€‚\n\n**ç»“è®ºï¼š** ä»–æ±€ç±»è¯ç‰©çš„ä½¿ç”¨ä¼¼ä¹ä¸ IBD æ‚£è€…æ‚£ CRC é£é™©é™ä½ç›¸å…³ã€‚ç„¶è€Œï¼Œé‰´äºç°æœ‰ç ”ç©¶æ•°é‡æœ‰é™ï¼Œæœ‰å¿…è¦è¿›è¡Œè¿›ä¸€æ­¥çš„å¤§æ ·æœ¬å‰ç»æ€§ç ”ç©¶ï¼Œä»¥è¯å®ä»–æ±€ç±»è¯ç‰©åœ¨è¯¥äººç¾¤ä¸­çš„æ½œåœ¨åŒ–å­¦é¢„é˜²ä½œç”¨ã€‚", "keywords_zh": "ç™Œç—‡, ç»“è‚ , é™è„‚, è‚¿ç˜¤, ç›´è‚ ", "keywords_en": "cancer, colon, lipid-lowering, neoplasm, rectum", "link": "https://pubmed.ncbi.nlm.nih.gov/39650188/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1p9j2Ia0knTignEE7vvWNCOPD-p8oHaBJk6HqSr1JJOMQoMsn2&fc=20260103012326&ff=20260124211523&v=2.18.0.post22+67771e2", "date": "Mon, 09 Dec 2024"}]}, currentFeed: '', currentPapers: [], currentPaper: null,
                    init() { const ks = Object.keys(this.feeds); if(ks.length > 0) { this.currentFeed = ks[0]; this.selectFeed(); } },
                    selectFeed() { this.currentPapers = this.feeds[this.currentFeed]; this.currentPaper = this.currentPapers.length > 0 ? this.currentPapers[0] : null; document.querySelector('aside').scrollTop = 0; }
                }
            }
        </script>
    </body>
    </html>
    